<SEC-DOCUMENT>0001178879-22-000006.txt : 20220224
<SEC-HEADER>0001178879-22-000006.hdr.sgml : 20220224
<ACCEPTANCE-DATETIME>20220224161922
ACCESSION NUMBER:		0001178879-22-000006
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220224
DATE AS OF CHANGE:		20220224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		22671259

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>fold-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:420dc514-3d5c-42ec-9084-f88f3b76faf7,g:716e386a-5032-46b5-a55b-0ba5d954afee,d:4e1826361eea43a9b8ec57ad5f93ef33--><html xmlns:fold="http://www.amicustherapeutics.com/20211231" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>fold-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM180L2ZyYWc6NTE2OWIzOTliNDE2NDIzOGFlNjViMWRhNGQ5ZDk0MjUvdGFibGU6YTkyNmVkMjkwODI3NDk3Y2JhNGUyNDQzZThiMTc1MDUvdGFibGVyYW5nZTphOTI2ZWQyOTA4Mjc0OTdjYmE0ZTI0NDNlOGIxNzUwNV8zLTEtMS0xLTEwNTYy_98534ec4-06bb-4eda-ac51-69b8672a98f9">0001178879</ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM180L2ZyYWc6NTE2OWIzOTliNDE2NDIzOGFlNjViMWRhNGQ5ZDk0MjUvdGFibGU6YTkyNmVkMjkwODI3NDk3Y2JhNGUyNDQzZThiMTc1MDUvdGFibGVyYW5nZTphOTI2ZWQyOTA4Mjc0OTdjYmE0ZTI0NDNlOGIxNzUwNV80LTEtMS0xLTEwNTYy_539f8c6f-6aed-488e-905a-41f7a3da7780">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM180L2ZyYWc6NTE2OWIzOTliNDE2NDIzOGFlNjViMWRhNGQ5ZDk0MjUvdGFibGU6YTkyNmVkMjkwODI3NDk3Y2JhNGUyNDQzZThiMTc1MDUvdGFibGVyYW5nZTphOTI2ZWQyOTA4Mjc0OTdjYmE0ZTI0NDNlOGIxNzUwNV81LTEtMS0xLTEwNTYy_a69b5516-f9f7-40b0-851f-0c66b9080342">2021</ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM180L2ZyYWc6NTE2OWIzOTliNDE2NDIzOGFlNjViMWRhNGQ5ZDk0MjUvdGFibGU6YTkyNmVkMjkwODI3NDk3Y2JhNGUyNDQzZThiMTc1MDUvdGFibGVyYW5nZTphOTI2ZWQyOTA4Mjc0OTdjYmE0ZTI0NDNlOGIxNzUwNV82LTEtMS0xLTEwNTYy_556f0b15-e9e1-4894-836a-c307277419d8">FY</ix:nonNumeric><ix:nonNumeric contextRef="ia0e62c3f34054304bc488a828183c4ef_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDYwOA_36c2035c-6429-44ec-a5ff-c15bdbc6abf6">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ia0f988918ba344f883b74b4646d25fbe_D20210101-20211231" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDMvZnJhZzpkMjlhYmNmOGYwNzM0NTg3YmYwMjRiM2U3ZTVhYWE2MS90YWJsZTpiMjE4YTRiYjA0NDg0NTE0YmM2MzgwMmYxNGMyY2RhOS90YWJsZXJhbmdlOmIyMThhNGJiMDQ0ODQ1MTRiYzYzODAyZjE0YzJjZGE5XzAtMS0xLTEtMTA1NjI_6e25d797-6680-40fb-bc70-6bbda2c48af9">0.0208</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i98061b690c584def995fd5b3650941ec_D20161201-20161231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTUvZnJhZzo4ZTBmZjI2MWZlNzA0NDQyYWY1MGViZThkYmY1ZjJhYi90YWJsZTplM2M1YmFkNzhkYWM0MTU5OTE3Y2NhM2IwN2ZlOTQ1OC90YWJsZXJhbmdlOmUzYzViYWQ3OGRhYzQxNTk5MTdjY2EzYjA3ZmU5NDU4XzEtMS0xLTEtMTA1NjI_486be392-9c7b-4d27-80f0-fd24ecc87bb6">0.1633987</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="fold-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1e363eba974f6ea7542b9e4c4333c1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2e067fbb488e4a8480dd4ccdf00e2d6e_I20220215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iecb1de42def1452da99c0b437348ff0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65709436b74a491bb3674af00ed88b22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59b0f5748c0040d4ba044c170c4498a5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eaeeea22e1c450bb0f3ef7f208d55da_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e06cd88eed94c93bd863d9d2fa7e86a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fde1813dc7d44159942aa86b1104baf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4b02a7b929749bcbb33c5ac89bfc395_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id112dec781f849479a5fea1933c18841_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d174a7fea084bb889559168de083956_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b1ffa344ad4c46a05f2baded3c95de_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c2736e1c5f4bbdbe8ee555092181b6_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d9f0aae1dd4a489dc1c015715214d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec7f88d07a8f4a3196f84540950c1ba1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i295c47ed72d64074b5f32eeaad26a5cd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f87ef3b9001442e9d1783fa4ab6164a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idebd74e031ad4aa8847d48abfeb2cb4c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a49ef645774a039703edbf41d99de6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0283e0a778b241b69b7dc2f9f44b0620_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb03c87cbb644915a36d8589d01d130f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31157945f1834f739f2eb29aa5b1c152_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0925432d607c491d8c8762f88a8343ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife0397e8e64147d183a31226e47071e0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d67ba7a78d4493685eb33d08eab6fe3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1caab1a891c34d6db105ce12805fe47d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59667a8b6b6e402abb2689a16193a16e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f392c0af90404aa7ba763120f8093c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9abca8aab34fa6938b4176b42afcca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a2dd5b7af4a40d8b104a56e99abd5c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8631b1d954a432cab195334e4ab3c22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fc96de0a30247109dd0e367a5fda28e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib685c8f6567a444dafe12c28724621c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4be7fadcd724e6e96874c8bdf5adad5_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b570f4240774f97a85fc8f243de27b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i640ccbc1c3154c0080c449287054612e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf5bb75d47341398ad73aa8e894bf9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07df4fa1308d4f84a4aa5160e8a69ceb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9f9159fe2d74c02899336811f098a03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68cc19d3396498d82b2a8b900bcb129_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e1512bc26b649368f7c7a1f80c153cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia89d77f8f61e4f3997ffe7f4c43ce4bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cac20d40d594fdb84c482f1f832ea26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7acdfb076641c09f78a07d2ad0884d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida79dc6999b2473ca1d1e66873b93aae_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i526b094eedf24604a14d40a8149d2578_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0e62c3f34054304bc488a828183c4ef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016a712198df44609ada40ce0ec6040e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5f7d12a2e74e94b84af411c94b825f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id98a23a12f314c0399ddc82d07f167d9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d0ef6f58f21490982734d184ffa708c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a13db14f0fd48d7b5bae936a24df08c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd944574f2a423983b2d669ba0a005a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i141786068eaa494eabbae0eed4ca91ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3697f78d277b440cb2fdcf968fe349c8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73069b90118447438bdbc91aa2291082_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1211cdc53247450f9cf2280aa82ab844_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e29c1f134e24ca6a71a18a5867402ee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>fold:plan</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>fold:segment</xbrli:measure></xbrli:unit><xbrli:unit id="unit"><xbrli:measure>fold:unit</xbrli:measure></xbrli:unit><xbrli:context id="i9e86b2f8a2ae449789640b3a74210938_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de1351a52bd4f60a456ac8231b36fa1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4951a0821e7472faa395694373f197f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c9330e046a4e39b05065c516da655f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bac4dce92ae48faa8415719eeb29418_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9989c222dbf4f51a1e18465f25d9679_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i790f73964a7348a8861ffaa0cd855ce6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c294134d0304a859adb3c48427afe95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9043474a4a1d4089aaaa1c119c5ded63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i506e380918854e4287cf7b8f4aec8307_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i961d1290b5bb44a89495cd0f93b4d7c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16cd09ac01f449a786ec0c0e00df7434_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9f1194f778c47b687d90861adf8f887_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66e8c7b22d7744d49e714d729f4a3155_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18b897fa4f7e47f09f12e76a909b949f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a56fb4793d42e9983d44923f0ea779_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie154cc033bab496a99fb346732f0a456_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i582c365c59c5453c936ce8bba128fd1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe3018b481564885813a6100e4a32e2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50bd891b09b1476badb04c23c7939da3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc60489656e8435486f90d2cf2907e4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79912bf414894f7c880e3b24a7d15884_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e5b99eaef547c5b606f006be101008_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b21949c52d343ef9e73e3897f897333_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>fold:vote</xbrli:measure></xbrli:unit><xbrli:context id="i5d2bcc60d5354077b1fcf38386ec3c2e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id196c02fecfc4cba9917670db7d5c97a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ead177e0cc4421928422190e6ada54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba81fbdcb57c4b63b3261c40099c722f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a9bcf319bae47bdbd01835594ec4441_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b8a5ba609f4354b35e10b27be3ff0f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d2bc422365419a845cd1b651b3a636_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b32bb1228f4457281ae01a46fc12e65_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90c6ab2b0ea94811b533075e4f2a87ff_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c032683abb24387a73c8bc636880d41_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74af5a78ba0e4e39b3e7266e28299ef6_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f3536bcc2ae4952bcd1f4f308635ac0_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482c3a76c4274a0e899e18ce88699cb5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f988918ba344f883b74b4646d25fbe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f26112489e84068b2efcf3e81829b41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf65e4e37b3456d95b9a66cf49959fa_D20181221-20181221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-21</xbrli:startDate><xbrli:endDate>2018-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7512772b097432b956535d96e9b7951_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia272441483a740d6812f2646381f7580_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia576c72c43a84ff6b63f05447685167d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ab772d198ff45af9c40e229d45fba03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c9e518216b4905aab06b70874e18f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35de6676f38491e98b8f52cc5c3919b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971ea6dc71dd40bfbe43d1b72669ed21_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056c458b470c4579b84a162e7b90dbda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96486b3a389847dea0287bfe980e800b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a1701b3e114ced8682f3b8ad409f43_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62afedf6cc6c4e2faa6b8366f3d4d566_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d2388394104afb8de4248ba2dcc24a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54f245a14704edc868849226467c804_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c7b7702b4a40ddb250ad6a54dbfb5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66fbce7b1254986b68bdecf5d3984a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a5acb325e646a18e6704ab00914755_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162893650e38441e88ef4089246a0337_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559389e21f1d4d0d9353f0f940507a03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica7968ff22354a119a411677a353c84c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ddce89a114b41f59eb1562989c82baf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia17c20a9953e4a9cafbd1c6bf678b365_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa6cf6f33a74c329c64fa2645338266_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e5b1225df74406a3b71f72661e0aa3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i209e1f50b3fd43be91783671c328accb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66d2efb30f714078b268efed578feb16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e0e4ee9e39849208ef9727b7981c2e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48fbd33b6e4d4c73ac985cc9959e7635_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib485fdd881d140c3ade6dc51f9633b29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6966889240c4972b480adb57c32195c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e3e42521364090aa637b816999865a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b67daeb3434490faa14ce758326fde1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8216eb3ec03f429fae6e1e74d98807b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69b50b330c64830b70c78bcaaeb37d6_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33fc42c9674f4e879bc61864ba60a261_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>fold:day</xbrli:measure></xbrli:unit><xbrli:context id="ib3f9db4f690745eda3163dd56d581246_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3d9dd50f724a0da7d1eefc3d5f135e_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7600524d0cbe42d4b2f4532af786aeb3_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice065bd0045f4f5f9e31f898f0f63b1f_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cdaaf76680246429703216e122dbd6c_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9778c3d9e7be42298274edd0168bd81d_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98061b690c584def995fd5b3650941ec_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie195a0454be34ff68a307be34a84c86c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib94c7a79d6b04897ba7c2cd123307880_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b24aa516c24be2963d03b2a2fe67c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacb244f94b724eb4939e9350be861b33_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8c034a30ff14ec285bf6a0f3a25e67a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie25229baab7b448a94693d9550e33f9e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i110a74da32da49fd9b6d03056e710aca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia902df35c10346d3815341846f96d4a9_D20171222-20171222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-22</xbrli:startDate><xbrli:endDate>2017-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37d238be9634e70925be89cb7453666_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd581809cdbc4334985e5a98f01fe250_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3afe69e33524b46a12ea4a1d4d0b740_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee21a641b74a48e686ea400e8e04484c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fold:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i322b8d6caffd45d09d34af4c5317a66d_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie02d2bc95ee4441cafb8448b58435d04_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812c13b023674c2a8bf3fe358c45cc8e_I20131130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice787d3f9d9b45d5ac985f96cbc7cab8_D20131101-20131130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-11-01</xbrli:startDate><xbrli:endDate>2013-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="market"><xbrli:measure>fold:market</xbrli:measure></xbrli:unit><xbrli:context id="ib092d444dccf4d32aa8a33c7b683e7f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b66068ec6445888b7a4f287f32fe7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1a09fdb4bb4d548e2ccf3315079cb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie569617484754b05a11d764873af2392_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fd1ccf9f8ab4f1c93b7b88a953bacde_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17b033bab30245779ca01d44c1085c54_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf1bdab05104ab9b9570bc2365d7aba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7c7aceb760548b4b27547de88d2a4c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e30b656f4141acbe98c23e31bd8683_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dc30a51972343fbbfeeb2ead881ceef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d605eafe9c435eabdcab7621bec3fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie53bbf1d49be45c8b6aeb0307b4fcf08_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e11e6d8d67c45cb824db13d53516217_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i953f7cedc14842d1ba60adb562f671c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63e57c6c2cd049289478bad341710825_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjY5_56427cee-2273-45c7-8ee1-d2cbaec687bd">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjcw_337e3735-f57a-45a8-9937-3a106ee01099">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zMjk4NTM0ODg3MTMz_99c27a1a-b9a7-4240-af03-4a1031061bab"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zMjk4NTM0ODg3MTMz_1b871c8c-b85b-4fd6-9bfc-d11ab4f0f691">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjcy_33e7e208-83ba-44f9-aabc-16128cc6c996">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjYy_a1249539-1f1d-4c59-8977-6b7b935c2703">001-33497</ix:nonNumeric> </span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjY0_9d8becc2-e740-4f33-b4da-f63d0e0326af">Amicus Therapeutics,&#160;Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:22.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.722%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl8wLTAtMS0xLTEwNTYy_c11d1a7b-4be4-4d36-92a1-136bf59681a8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl8wLTQtMS0xLTEwNTYy_6381aec3-145d-4745-b0d0-398c4a8d712a">71-0869350</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl80LTAtMS0xLTEwNTYy_ff9165d8-386b-4a88-bf1a-c041cff0ca5b">3675 Market Street,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl80LTEtMS0xLTEwNTYy_e96be47b-af8e-4726-bffc-85d7d64c0f45">Philadelphia,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl80LTItMS0xLTEwNTYy_28aa2462-ef3d-4057-81bc-62a4a6461784">PA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl80LTQtMS0xLTEwNTYy_21028228-2e56-4846-8dfc-6694742ff6be">19104</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr style="height:5pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl83LTAtMS0xLTEwNTYy_4ed1d959-bc8b-4a10-871f-390be40b8b41">(215)</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl83LTMtMS0xLTEwNTYy_6429b96b-30f1-4e2e-a1dc-db2e58ccdc08">921-7600</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant's Telephone Number,&#160;Including Area Code)</span></div></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6YTQ4ZDM2MGZkMDJmNDIxZTgyZDkzNjg4NGI0YzkxMGMvdGFibGVyYW5nZTphNDhkMzYwZmQwMmY0MjFlODJkOTM2ODg0YjRjOTEwY18xLTAtMS0xLTEwNTYy_9685e92f-aa67-4369-8f0f-024a9eec2757">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6YTQ4ZDM2MGZkMDJmNDIxZTgyZDkzNjg4NGI0YzkxMGMvdGFibGVyYW5nZTphNDhkMzYwZmQwMmY0MjFlODJkOTM2ODg0YjRjOTEwY18xLTEtMS0xLTEwNTYy_cedf17f7-129a-46bb-a722-bd5a6989a6c7">FOLD</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6YTQ4ZDM2MGZkMDJmNDIxZTgyZDkzNjg4NGI0YzkxMGMvdGFibGVyYW5nZTphNDhkMzYwZmQwMmY0MjFlODJkOTM2ODg0YjRjOTEwY18xLTItMS0xLTEwNTYy_7de80f87-dd9a-4c4c-a998-3245f9a504a4">NASDAQ Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjc0_1729829d-1c22-4407-9c8f-61e3ccdfa66f">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjc1_07cd4a05-8906-4ee0-a5d9-885cb5e30504">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;  <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjY1_d8314e6a-ccd2-4d11-8c31-4b79e3aa2e2b">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;  <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjcz_9b15d250-b3cb-4176-8c5f-56eaa6c5e217">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:28.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MGQzZTRlYTJlY2M3NGE5NGJiZTM4NDg2ZTJhYzFkNjgvdGFibGVyYW5nZTowZDNlNGVhMmVjYzc0YTk0YmJlMzg0ODZlMmFjMWQ2OF8wLTAtMS0xLTEwNTYy_46ff1324-d57f-4d7d-9290-416951d761e9">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MGQzZTRlYTJlY2M3NGE5NGJiZTM4NDg2ZTJhYzFkNjgvdGFibGVyYW5nZTowZDNlNGVhMmVjYzc0YTk0YmJlMzg0ODZlMmFjMWQ2OF8xLTQtMS0xLTEwNTYy_8eb55442-c75f-489c-b700-e1a82a76f01d">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MGQzZTRlYTJlY2M3NGE5NGJiZTM4NDg2ZTJhYzFkNjgvdGFibGVyYW5nZTowZDNlNGVhMmVjYzc0YTk0YmJlMzg0ODZlMmFjMWQ2OF8yLTQtMS0xLTEwNTYy_ec28fc9a-8593-4e53-b85f-503fb7188a3f">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report  .<ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjYx_63ef3d42-72b7-4800-9522-184030ffbe01">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).  Yes <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjcx_5edd76d1-fc8a-4881-80ab-7a49355fe948">&#9744;</ix:nonNumeric>  No &#9746;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the 263,549,335 shares of voting common equity held by non-affiliates of the registrant, computed by reference to the closing price as reported on The NASDAQ Global Market, as of the last business day of the registrant's most recently completed second fiscal quarter (June 30, 2021) was $<ix:nonFraction unitRef="usd" contextRef="i3b1e363eba974f6ea7542b9e4c4333c1_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV85ODk1NjA0NjUzODQ2_355fc9d3-09f5-4a6e-a771-d706c660a7b7">2,540,615,589</ix:nonFraction>. Shares of voting and non-voting stock held by executive officers, directors, and holders of more than 10% of the outstanding stock have been excluded from this calculation because such persons or institutions may be deemed affiliates. This determination of affiliate status is not a conclusive determination for other purposes.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant's common stock, $0.01 par value per share, as of February&#160;15, 2022 was <ix:nonFraction unitRef="shares" contextRef="i2e067fbb488e4a8480dd4ccdf00e2d6e_I20220215" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV80Mzk4MDQ2NTE0ODkz_00230286-2a21-4fdf-b420-9fbfd53e803a">280,029,345</ix:nonFraction> shares.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE: <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjY4_a1fe2218-ad90-41c9-a09c-b9d19abb15d9" escape="true">Portions of the Proxy Statement for the registrant's 2021 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_19">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_19">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_22">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_22">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_22">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_25">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_25">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_25">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_28">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_28">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_28">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_31">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_31">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_31">70</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_37">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_37">MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_37">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_40">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_40">[RESERVED]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_40">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_43">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_43">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_43">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_46">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_46">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_46">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_49">Item&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_49">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_49">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_133">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_133">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_133">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_136">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_136">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_136">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_139">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_139">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_139">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_1099511629554">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_1099511629554">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_1099511629554">118</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_145">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_145">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_145">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_148">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_148">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_148">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_151">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_151">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_151">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_154">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_154">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_154">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_157">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_157">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_157">119</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_163">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_163">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_163">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_166">Item 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_166">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_166">124</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_169">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_169">125</a></span></div></td></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have filed applications to register certain trademarks in the United States and abroad, including AMICUS THERAPEUTICS and design, AMICUS ASSIST and design, CHART and design, AT THE FOREFRONT OF THERAPIES FOR RARE AND ORPHAN DISEASES, HEALING BEYOND DISEASE, OUR GOOD STUFF, and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and design. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Annual Report on Form&#160;10-K contains forward-looking statements that involve risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "can," "could," "estimate," "expect," "forecast," "intend," "likely," "may," "outlook," "plan," "potential," "predict," "project," "seek," "should," "will," "would," the negatives or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our clinical trials of our drug candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing drug supply for our commercial, clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200" or "cipaglucosidase alfa");</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future results of preclinical research and subsequent clinical trials for pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize these therapies and obtain market acceptance for such therapies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in regulatory standards relating to the review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we pursue;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat HCl") and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain reimbursement for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, if approved and applicable, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims, including Hatch-Waxman litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of litigation that has been or may be brought against us or of litigation that we are pursuing or may pursue against others;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate our acquired products and technologies into our business, or successfully divest or license existing products and technologies from our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish licensing agreements, collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-1-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our business could be adversely impacted by the effects of the novel coronavirus ("COVID-19") outbreak, including due to actions by us, governments, our customers, our suppliers, or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with, and our ability to comply with, emerging environmental, social and governance standards;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to accurately forecast revenue, operating expenditures, or other metrics impacting profitability;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these risks and uncertainties, we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in Part I, Item 1A "&#8212; Risk Factors", a summary of which may be found below, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Those factors and the other risk factors described herein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. Our forward-looking statements do not reflect the potential impact of any future collaborations, alliances, business combinations, partnerships, strategic out-licensing of certain assets, the acquisition of preclinical-stage, clinical-stage, marketed products or platform technologies or other investments we may make. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we incorporate by reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements speak only as of the date of this report. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face and is qualified in its entirety by reference to the more detailed descriptions included in Part I, Item 1A "&#8212; Risk Factors". This summary should be read together with those more detailed descriptions, along with our other SEC filings before making an investment decision.</span></div><div style="margin-bottom:2pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We depend heavily on sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe, the U.S. and Japan. If we are delayed or unable to commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> successfully, our business could be materially harmed.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are not able to obtain, or delayed in obtaining, required regulatory approvals, we will not be able to commercialize our product or product candidates, materially impairing our ability to generate revenue.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are unable to establish and maintain sales and marketing capabilities, or relationships, to market and sell our product or, if approved, product candidates, their commercialization may suffer.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If the market opportunities for our product or product candidates are smaller than we believe they are, then our revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our product candidates that receive regulatory approval may fail to achieve the degree of market acceptance necessary for commercial success.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">A variety of risks associated with international operations could adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our product or any product candidates receiving approval may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are found to have promoted off-label uses by regulatory authorities, we may become subject to significant liability.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If applicable regulatory authorities approve generic or biosimilar products with claims that compete with our product or any of our product candidates, it could reduce our sales.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may expend our limited resources to pursue a particular product, product candidate or indication and fail to capitalize on an alternative for which there is a greater likelihood of success.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our product or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Any product or product candidate we obtain marketing approval for could be subject to restrictions or withdrawal from the market and we may be subject to penalties or enforcement actions if we fail to comply with regulatory requirements.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Certain relationships will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and corruption and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If clinical trials of our product candidates do not produce results satisfactory to regulatory authorities, the development and commercialization of our product candidates may not be completed.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we experience unforeseen events in connection with our clinical trials, potential regulatory approval or commercialization of our product candidates could be delayed or prevented.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initial results from a clinical trial do not ensure that the trial will be successful and success in preclinical or early stage clinical trials does not ensure success in later-stage clinical trials.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If our competitors obtain orphan drug exclusivity for their products and we do not, we may not unable to have competing products approved in the applicable jurisdiction for a significant period of time.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Failure to obtain or maintain regulatory approval outside the U.S. would prevent us from marketing our products abroad.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our business activities involve the use of hazardous materials which could subject us to significant adverse consequences if we fail to comply with the applicable laws regulating their use.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are unable to obtain marketing approval, or if approved unable to successfully commercialize AT-GAA, our business could be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our gene therapy product candidates are based on novel technologies, which makes it difficult to predict the time and cost of their development and subsequently obtaining regulatory approval.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Use of third parties to manufacture our product or product candidates may increase the risk that we will not have sufficient quantities of our product or product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We rely on third parties to conduct certain preclinical development activities and our clinical trials, and those third parties may not perform satisfactorily.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may not be successful in maintaining or establishing collaborations, which could adversely affect our ability to develop and, particularly in international markets, commercialize products.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Materials necessary to manufacture our product or product candidates may not be available on commercially reasonable terms, which may delay their development and commercialization.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Manufacturing issues may arise that could increase costs or delay commercialization.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We have incurred significant losses and anticipate that we will continue to incur losses in the future.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may never become profitable even though we currently generate revenue from the sale of products.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we require, and fail to obtain, additional necessary financing, we may be unable to complete the development and commercialization of our product and product candidates.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or product candidates.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may not have sufficient cash flow from our business to pay our substantial debt.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Foreign currency exchange rate fluctuations could harm our financial results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our executive officers, directors and principal stockholders maintain the ability to exert significant influence and control over matters submitted to our stockholders for approval.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Because we do not anticipate paying any cash dividends on our capital in the foreseeable future, capital appreciation, if any, will be our stockholders sole source of gain.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are unable to obtain and maintain sufficiently broad patent protection, our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may become involved in lawsuits to protect or enforce our patents or other intellectual property.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights which could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Failure to secure trademark registrations could adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our rights to develop and commercialize our gene therapy product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The novel coronavirus ("COVID-19") pandemic may negatively impact our business and operations.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our employees, independent contractors, principal investigators, consultants and vendors may engage in misconduct or improper activities which could lead to significant liability and harm our reputation.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If our enterprise risk program, global risk committee and other compliance methods are not effective, our business, financial condition and operating results may be adversely affected.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our business and reputation may be adversely affected by environmental, social and governance matters. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio of product opportunities including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). We are committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of our portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of our pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, we announced, with ARYA Sciences Acquisition Corp IV ("ARYA"), a special purpose acquisition company (or "SPAC"), sponsored by Perceptive Advisors, we have agreed to mutually terminate the previously announced definitive business combination agreement, originally executed in September 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in September 2021, we entered into securities purchase agreements with certain investors for the private placement of an aggregate of 11,296,660 shares of our common stock, at a purchase price of $10.18 per share and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. The net proceeds from these private placements were approximately $199.8 million. We expect to use the net proceeds to further fund initiatives in the global commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the anticipated global launch of AT-GAA and to further support our discovery work on next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to create, manufacture, test, and deliver the highest quality medicines for people living with rare diseases through internally developed, jointly developed, acquired, or in-licensed products and product candidates that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. We are leveraging our global capabilities to develop and broaden our lead franchises in Fabry and Pompe disease, with focused discovery work on next generation therapies and novel platform technologies. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have not been significantly impacted by the novel coronavirus (&#8220;COVID-19&#8221;) pandemic thus far. However, we continued to observe a periodic increase in lag times between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiation due to the resurgence of COVID-19 in 2021. We have maintained operations in all geographies, secured our global supply chain for our commercial and clinical products, as well as maintained the operational integrity of our clinical trials, with minimum disruptions. Our ability to continue to operate without any significant disruptions will depend on the continued health of our employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the continued operation of our global supply chain. We have continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of our global workforce. However, our results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights of our progress include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial and regulatory success in Fabry disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the year ended December 31, 2021, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue totaled $305.5 million, an increase of $44.6 million compared to the prior year. We continue to see strong commercial momentum and expansion into additional geographies. In countries where we have been operating the longest, we see an increasing proportion of previously untreated patients come onto Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the U.S., we continue to see a significant increase in patients from a growing and very wide prescriber base. Across all markets, we see a high rate of compliance and adherence to this oral treatment option. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pompe disease clinical program milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In December 2020, we completed last patient, last visit in our global Phase 3 pivotal study of AT-GAA (ATB200-03, also known as "PROPEL") with 123 patients at 62 sites in 24 countries. In February 2021, we subsequently reported topline results for the PROPEL study. In June 2021, the MHRA granted AT-GAA a positive scientific opinion through the Early Access to Medicines Scheme ("EAMS") which permits eligible adults living with late-onset Pompe disease ("LOPD") who have received alglucosidase alfa for at least 2 years to switch to AT-GAA prior to marketing authorization in the U.K. We completed the submission of the rolling BLA and NDA to the FDA, which was accepted for review in September 2021 and in the fourth quarter of 2021, the MAA was submitted and validated by the EMA.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pipeline advancement and growth.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are leveraging our global capabilities to develop and broaden our lead franchises in Fabry and Pompe disease, with focused discovery work on next generation therapies and novel platform technologies. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have managed our clinical and commercial supply chains during the COVID-19 pandemic such that as of the date hereof we have not experienced supply impacts. We have been able to continue to meet required commercial demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as supply our ongoing Pompe disease clinical studies without interruption. We have secured supply for our continued needs for the Pompe disease program through a long-term supply agreement with Wuxi Biologics. The agreement allows for the continuous manufacture of our biologic to support future clinical needs and our anticipated commercial requirements should we garner regulatory approvals as planned. We have contracts in place to supply miglustat, our small molecule component of ATGAA, to support both clinical and future commercial requirements. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Financial strength. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents, and marketable securities as of December 31, 2021 was $482.5 million. Based on the current operating model, we believe that the current cash position, which includes expected revenues, and net proceeds from the September 2021 private placement of securities, is sufficient to fund our operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Product and Product Candidates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Migalastat HCl) for Fabry Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our oral precision medicine Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was granted accelerated approval by the FDA in August 2018 under the brand name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ("GLA") variant based on in vitro assay data. The FDA has approved Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for 350 amenable GLA variants. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the E.U. and U.K. in May 2016 as a first-line therapy for long-term treatment of adults and adolescents, aged 16 years and older, with a confirmed diagnosis of Fabry disease and who have an amenable mutation (variant). The approved E.U. and U.K. labels include 1,384 mutations amenable to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment, which represent up to half of all patients with Fabry disease. In countries where mutations are provided only on the amenability website, these 1,384 amenable mutations are now available. Marketing authorization approvals have been granted in over 40 countries around the world, including the U.S., E.U., U.K., Japan, and others. In July 2021, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the E.U. for adolescents aged 12 years and older weighing 45 kg or more. We plan to continue to launch Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in additional countries during 2022, including for adolescents aged 12 years and older. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an orally administered monotherapy, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to bind to and stabilize an endogenous alpha-galactosidase A ("alpha-Gal A") enzyme in those patients with genetic variants identified as amenable in a GLP cell-based amenability assay. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral precision medicine intended to treat Fabry disease in patients who have amenable genetic variants, and at this time, it is not intended for concomitant use with ERT. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Next Generation for Fabry Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to continued innovation for all people living with Fabry disease. Our pipeline includes a Fabry gene therapy. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2021, we presented initial preclinical data from our investigational AAV gene therapy program. This initial preclinical study assessed a range of single doses of AAV in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> knockout mice with either wild-type hGLA (&#8220;unmodified hGLA&#8221;) or an Amicus/University of Pennsylvania ("Penn") engineered hGLA transgenes (&#8220;engineered hGLA&#8221; or &#8220;AT-GTX-701&#8221;). The engineered hGLA AAV gene therapy demonstrated stable homodimer formation, enhanced temperature, plasma and neutral ph stability compared to the unmodified hGLA AAV gene therapy. In the lowest tested dose of AT-GTX-701, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">la knockout mice showed partial substrate reduction, while the mid and highest tested doses resulted in near complete substrate reduction. Additionally, AT-GTX-701 demonstrated significantly greater lyso-Gb3/GL-3 substrate reduction across all Fabry disease relevant tissues including the dorsal root ganglia (&#8220;DRG&#8221;), kidney, and heart, with reductions at low dose being equal to or greater than the reductions observed at higher doses with wildtype transgene and provided the first evidence for DRG storage reduction in a Fabry mouse model treated with an AAV gene therapy.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fabry Disease Background</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with Fabry disease have an inherited deficiency of the alpha-Gal A enzyme that would normally degrade the lipid substrate globotriaosylceramide in the lysosome. Genetic variants that cause changes in the amino acid sequence of alpha-Gal A result in an unstable enzyme that does not efficiently fold into its correct three-dimensional shape and cannot be trafficked properly in the cell, even if it has the potential for biological activity. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral small molecule pharmacological chaperone that is designed to bind to and stabilize a patient&#8217;s own endogenous target protein. This is considered a precision medicine because Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> targets only patients with GLA variants amenable to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fabry disease is an X-linked disease caused by mutations in the GLA gene, which encodes the alpha-Gal A enzyme. These mutations can cause alpha-Gal A to be either absent or deficient. When alpha-Gal A is absent or deficient the substrates, GL-3 and lyso-Gb3 accumulate, leading to damage of cells within affected parts of the individual's body and causing the various pathologies seen in Fabry disease. Fabry disease leads to progressive, irreversible organ damage, typically involving the nervous, cardiac, and renal systems, as well as multiple other tissues. The symptoms can be severe, differ from patient to patient, and begin at an early age, resulting in significant clinical, humanistic, and healthcare costs. Fabry disease requires lifelong medical intervention to manage the complications of this devastating disease across multiple organ systems.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fabry disease is a relatively rare disorder. The annual incidence of Fabry disease in newborn males has been historically estimated to be 1:40,000-1:60,000 (Journal of the American Medical Association January 1999 and The Metabolic and Molecular Bases of Inherited Disease 8th&#160;edition 2001). However, more recent newborn screening studies in Italy, Taiwan, Austria, Spain and the U.S., which collectively screened more than 500,000 male and female newborns, found the incidence of GLA mutations to be between 1:2,445 to 1:8,454, more than ten times higher than previous estimates for classic patients (American Journal of Human Genetics 2006, Human Mutation 2009, the Lancet 2011, Journal of Pediatrics 2017, and JAMA Pediatrics 2018). When looking at only male newborns within these studies, the incidence of Fabry disease mutations is as high as 1:1,316 &#8211; 1:7,575 (Circulation in Cardiovascular Genetics 2009, American Journal of Human Genetics 2006, European Journal of Pediatrics 2017).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that approximately 35-50% of the Fabry disease patient population may benefit from treatment with Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy. Additionally, we expect that as awareness of late-onset symptoms of Fabry disease grows, the number of patients diagnosed with the disease will increase. Increased awareness of Fabry disease, particularly for specialists not accustomed to treating Fabry disease patients, may lead to increased testing and diagnosis of patients with the disease.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, two other products, both ERTs, are approved for the treatment of Fabry disease: agalsidase beta by Sanofi Aventis and agalsidase alfa by Takeda, the latter of which is not approved in the U.S. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel ERT for Pompe Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our biologics capabilities to develop AT-GAA, a novel treatment paradigm for Pompe disease. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221, or miglustat, that functions as an enzyme stabilizer. Miglustat binds to and stabilizes ATB200, or cipaglucosidase alfa, preventing inactivation of rhGAA in circulation to improve the uptake of active enzyme in key disease-relevant tissues, resulting in increased clearance of accumulated substrate, glycogen. Miglustat is not an active ingredient that contributes directly to substrate reduction ("glycogen"). </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated ATB200-03 (or "PROPEL"), a global Phase 3 clinical study of AT-GAA in adult patients with late onset Pompe disease in December 2018 and completed last patient, last visit in December 2020. In February 2021, we reported topline results from the Phase 3 PROPEL study. Patients in PROPEL were randomized 2:1 so that for every two patients randomized to be treated with AT-GAA, one was randomized to be treated with alglucosidase alfa. Of the Pompe disease patients enrolled, 77% were being treated with alglucosidase alfa (n=95) immediately prior to enrollment (&#8220;Switch&#8221;) and 23% had never been treated with any ERT (n=28) (&#8220;Na&#239;ve&#8221;). 117 patients completed the PROPEL study and all 117 voluntarily enrolled in the long-term extension study. The primary endpoint of the study was the mean change in 6-minute walk distance as compared with baseline measurements at 52 weeks across the combined ERT Switch and ERT Na&#239;ve patient populations. In this combined population patients taking AT-GAA (n=85) walked on average 21 meters farther at 52 weeks compared to 7 meters with those treated with alglucosidase alfa (n=37). This primary endpoint in the combined population was assessed for superiority and while numerically greater, statistical significance for superiority on this combined population was not achieved for the AT-GAA arm as compared to the alglucosidase alfa arm (p=0.072).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the hierarchy of the statistical analysis plan, the first key secondary endpoint of the study was the mean change in percent-predicted Forced Vital Capacity (&#8220;FVC&#8221;) at 52 weeks across the combined population. In this combined population patients taking AT-GAA demonstrated a nominally statistically significant and clinically meaningful difference for superiority over those treated with alglucosidase alfa. AT-GAA significantly slowed the rate of respiratory decline in patients after 52 weeks. Patients treated with AT-GAA showed a 0.9% absolute decline in percent-predicted FVC, compared to a 4.0% absolute decline in the alglucosidase alfa arm (p=0.023). Patients within the combined study population demonstrated statistically significant improvements on the GSGC (&#8220;Gait, Stairs, Gower&#8217;s Chair&#8221;) key secondary endpoint, which captures strength, coordination and mobility, compared to a worsening for alglucosidase alfa treated patients in the overall population (p&lt;0.05). Additionally, lower MMT (Manual Muscle Testing), Patient-Reported Outcomes Measurement Information System (&#8220;PROMIS&#8221;) physical function and PROMIS fatigue secondary endpoints favored AT-GAA treated patients over alglucosidase alfa treated patients. Results also showed improvements in the two important biomarker endpoints of Pompe disease (Hex-4 and CK), which significantly favored AT-GAA compared to alglucosidase alfa (p&lt;0.001). AT-GAA demonstrated a similar safety profile to alglucosidase alfa. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PROPEL Switch patients entered the study having been treated with alglucosidase alfa for a minimum of two years. More than two thirds (67%+) of those patients had been on ERT treatment for more than five years prior to entering the PROPEL study (mean of 7.4 years). A pre-specified analysis of the patients switching from alglucosidase alfa on 6-minute walk distance showed that after 52 weeks from switching, AT-GAA treated patients (n=65) walked 16.9 meters farther than their baseline, compared to 0.0 meters for those patients who were randomized to remain on alglucosidase alfa (n=30) (p=0.046). A pre-specified analysis of the patients switching from alglucosidase alfa on percent-predicted FVC showed that AT-GAA treated patients stabilized and slightly improved their respiratory function on this important measure while those patients remaining on alglucosidase alfa continued to significantly decline in respiratory muscle function. AT-GAA patients showed a 0.1% absolute increase in percent-predicted FVC while the alglucosidase alfa patients showed a 4.0% absolute decline over the course of the year (p=0.006).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PROPEL Na&#239;ve patients treated with AT-GAA for 52 weeks (n=20) walked 33 meters farther than their baseline, on the 6-minute walk distance endpoint. The Na&#239;ve patients treated with alglucosidase alfa (n=7) walked 38 meters further than their baseline. The difference between the two groups was not statistically significant (p=0.60). Additionally, patients never previously treated with any ERT showed similar declines in percent-predicted FVC at 52 weeks of &#8211;4.1% for AT-GAA treated patients and &#8211;3.6% for alglucosidase alpha treated patients. The difference between the two groups was not statistically significant (p=0.57). </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are conducting ongoing clinical studies in pediatric patients for both LOPD and infantile-onset Pompe disease ("IOPD") populations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-8-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Next Generation for Pompe Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our long-term commitment to provide multiple solutions to address the significant unmet needs of the Pompe disease community, we are also continuing discovery for next-generation genetic medicines for Pompe disease. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pompe Disease Background</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like Fabry disease, Pompe disease is a lysosomal disorder ("LD") that results from a deficiency in an enzyme, GAA. Signs and symptoms of Pompe disease can be severe and debilitating and include progressive muscle weakness throughout the body, particularly the heart and skeletal muscles. GAA deficiency causes accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. Pompe disease ranges from a rapidly fatal infantile form with severe cardiac involvement to a more slowly progressive, late-onset form primarily affecting skeletal muscle. All forms are characterized by severe muscle weakness that worsens over time. In the early-onset form, patients are usually diagnosed shortly after birth and often experience enlargement of the heart and severe muscle weakness. In late-onset Pompe disease, symptoms may not appear until late childhood or adulthood and patients often experience progressive muscle weakness.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to reported estimates of the Acid Maltase Deficiency Association, the United Pompe Foundation, and the Lysosomal Disease Program at Massachusetts General Hospital, there are 5,000-10,000 patients with Pompe disease worldwide.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, two products, both ERTs, are approved for the treatment of Pompe disease: alglucosidase alfa and avalglucosidase alfa-ngpt by Sanofi Aventis.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CDKL5 Deficiency Disorder </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are researching a potential first-in-class genetic medicine for CDKL5 deficiency disorder ("CDD") consisting of a CDKL5 protein engineered for cross correction, delivered as either a protein replacement or as a gene therapy through our collaboration with Penn. We are collaborating with the LouLou Foundation to assess the natural history of the disease to identify endpoints for potential use in future studies. CDKL5 is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development. Genetic mutations in the CDKL5 gene result in CDKL5 protein deficiency and CDD. This disorder manifests clinically as persistent seizures starting in infancy, followed by severe impairment in neurological development. Most children affected by CDD cannot walk or care for themselves and may also suffer from scoliosis, visual impairment, sensory issues, and gastrointestinal complications. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Next Generation Programs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of additional gene therapies in clinical and preclinical development, including potential gene therapies in multiple forms of Batten disease. Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses ("NCLs"). In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell's ability to recycle certain molecules. Each gene is called ceroid lipofuscinosis, neuronal ("CLN") and given a different number designation as its subtype. There are 13 known forms of Batten disease often referred to as CLN1-8; 10-14. The various types of Batten disease have similar features and symptoms but vary in severity and age of onset.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most forms of Batten disease/NCLs usually begin during childhood. The clinical course often involves progressive loss of independent adaptive skills such as mobility, feeding, and communication. Patients may also experience vision loss, personality changes, behavioral problems, learning impairment, and seizures. Patients typically experience progressive loss of motor function and eventually those affected become wheelchair-bound, are then bedridden, and die prematurely.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-9-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing Phase 1/2 clinical study for CLN3 to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3. In February 2021, we announced initial safety for the first four patients up to 15 months post-administration of AT-GTX-502 and preliminary efficacy data for the first three patients in the low-dose cohort for up 15 months post-administration of AT-GTX-502, as well as one patient in the high-dose cohort for up to 3 months post-administration of AT-GTX-502. Initial results of the study suggest that AT-GTX-502 was well tolerated and demonstrated potential early signs of disease stabilization compared to a natural history dataset. CLN3 impacts approximately 5,000 patients across our commercial landscape today and there are no approved therapies for this disorder.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we discontinued development of our CLN6 Batten disease gene therapy program following review of long-term extension study data. It was recently determined that any initial stabilization of disease progression at the two-year time point was not maintained through the long-term extension study.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Alliances and Arrangements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to evaluate business development opportunities as appropriate to build stockholder value and provide us with access to the financial, technical, clinical, and commercial resources necessary to develop and market technologies or products with a focus on rare and orphan diseases. We are exploring potential collaborations, alliances, and other business development opportunities on a regular basis. These opportunities may include business combinations, partnerships, the strategic out-licensing of certain assets, or the acquisition of preclinical-stage, clinical-stage, or marketed products or platform technologies consistent with our strategic plan to develop and provide therapies to patients living with rare and orphan diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Celenex,&#160;Inc.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we expanded our pipeline by acquiring the rights and related intellectual property of ten gene therapy programs through the acquisition of Celenex, Inc. ("Celenex"). Celenex is a private, clinical stage gene therapy company whose lead programs are ten gene therapy programs including CLN3, which is in clinical stage, and several programs in pre-clinical stage. Pursuant to the terms of the agreement, we agreed to pay up to an additional $10 million in connection with the achievement of certain development milestones, $220 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments. Celenex has an exclusive license agreement with Nationwide Children&#8217;s Hospital ("Nationwide Children&#8217;s"). Under this license agreement, Nationwide Children&#8217;s is eligible to receive development and sales-based milestones of up to $7.8 million for each product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MiaMed,&#160;Inc.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, we acquired MiaMed,&#160;Inc., ("MiaMed"), which is a pre-clinical biotechnology company focused on developing protein replacement therapy for CDD and related diseases. As part of the transaction, we may be obligated to pay up to an additional $83.0&#160;million in connection with the achievement of certain clinical, regulatory, and commercial milestones, for a potential aggregate deal value of $89.5&#160;million. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Callidus Biopharma,&#160;Inc.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Callidus Biopharma, Inc. ("Callidus"), we may be obligated to make additional payments to the former stockholders of Callidus upon the achievement of certain clinical milestones of up to $35&#160;million and regulatory milestones of up to $80&#160;million set forth in the merger agreement, provided that the aggregate merger consideration shall not exceed $130&#160;million. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents and Trade Secrets</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to maintain proprietary protection surrounding our product candidates, technology, and know-how, to operate without infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by filing U.S. and foreign patent applications related to our proprietary technology, including both new inventions and improvements of existing technology, that are important to the development of our business, unless this proprietary position would be better protected using trade secrets. Our patent strategy includes obtaining patent protection, where possible, on compositions of matter, methods of manufacture, methods of use, combination therapies, dosing and administration regimens, formulations, therapeutic monitoring, screening methods, and assays. We also rely on trade secrets, know-how, continuing technological innovation, in-licensing, and partnership opportunities to develop and maintain our proprietary position. Lastly, we monitor third parties for activities that may infringe our proprietary rights, as well as the progression of third-party patent applications that may have the potential to create blocks to our products or otherwise interfere with the development of our business. We are aware, for example, of U.S. patents, and corresponding international counterparts, owned by third parties that contain claims related to ERTs, and small molecules for stabilizing enzymes. If any of these patents were to be asserted against us, there is no assurance that a court would find in our favor or that, if we choose or are required to seek a license, a license to any of these patents would be available to us on acceptable terms or at all.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or hold license rights to several issued patents and numerous pending and issued applications, filed in the U.S., Europe, Japan, and other jurisdictions that are related to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our ongoing clinical programs:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We own issued U.S. patents that cover the use of migalastat, the active pharmaceutical ingredients in Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the treatment of Fabry disease, which expire in 2027, 2028, 2029, 2037 or 2038 and are listed in the FDA Orange Book. Foreign counterparts of the U.S. patents are pending or issued in Europe, Japan, and certain other jurisdictions. Further, we have pending U.S. patent applications covering various aspects of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including composition-of-matter methods of treating a patient diagnosed with Fabry disease with migalastat and their foreign counterparts. Any patents issuing from these applications will expire in 2036, 2038, 2039, 2040, or 2041.and we anticipate listing these patents in the FDA Orange Book if issued.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We own several issued U.S. patents that cover various aspects of our investigational new treatment for Pompe disease, AT-GAA (ATB200/AT2221, an ERT/pharmacological chaperone combination) as well as foreign counterparts to the issued patents, most of which are still pending. Issued U.S. patents cover ATB200 compositions-of-matter, formulations, methods of manufacturing and methods of treatment and will expire in 2033, 2035 or 2037. We also have pending U.S. patent applications covering compositions, methods of treatment, methods of manufacture, and formulations with anticipated expiry in 2033, 2035, 2036, 2037, 2038, 2040, or 2042.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">From the Celenex acquisition, we acquired an exclusive license to composition-of-matter and intrathecal method of treatment patent applications covering the gene therapy for treating Batten disease that are pending in the U.S., Europe, Japan, and other jurisdictions. Any patents issued from these applications will expire in 2033 or 2040. The patent covering an intrathecal method of treatment, which expires in 2033, has issued in Europe and Japan.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">From our agreement with Penn, we have license to Penn&#8217;s patent portfolio pertaining to vector and other platform technologies for treating Pompe disease, Fabry disease, CDD, CLN1, Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). Any patents issued from these applications will expire in 2039.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent term extensions and adjustments, supplementary protection certificates, and pediatric exclusivity periods are not reflected in the expiration dates listed above and may extend protection. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical programs, we actively monitor and file patent applications in the U.S. and in foreign countries on relevant technologies and pre-clinical programs. For example, we own or hold license rights to U.S. and foreign patents or patent applications covering the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gene therapy protein engineering technology;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-11-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gene therapy (e.g., Pompe, Fabry, CDLK5, MPSIIIB and next generation MPSIIIA) and ERT (e.g., CDKL5) programs and the use to treat specified diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain, however, that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Individual patents extend for varying periods depending on the effective date of filing of the patent application or the date of patent issuance, and the legal term of the patents in the countries in which they are obtained. Generally, patents issued in the U.S. are effective for 20&#160;years from the earliest nonprovisional filing date. This period may be shortened by terminal disclaimer or further extended by patent term adjustment or extension. The term of foreign patents varies in accordance with provisions of applicable local law, but typically is 20&#160;years from the earliest nonprovisional filing date.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Drug Price Competition and Patent Term Restoration Act of 1984, and amendments thereto, more commonly known as the Hatch-Waxman Act, provides for an extension of one patent, known as a Hatch-Waxman statutory extension, for each New Chemical Entity ("NCE") to compensate for a portion of the time spent in clinical development and regulatory review. However, the maximum extension is five years and the extension cannot extend the patent beyond 14&#160;years from the new drug application ("NDA") approval. Similar extensions are available in European countries, known as Supplemental Protection Certificate ("SPC") extensions, Japan, and other countries. However, in the U.S. we will not know what, if any, extensions are available until a drug is approved. In addition, in the U.S., under provisions of the Best Pharmaceuticals for Children Act, we may be entitled to an additional six-month period of patent protection or market exclusivity for completing pediatric clinical studies in response to an FDA issued Pediatric Written Request before said exclusivities expire.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies like ours are generally uncertain and involve complex legal, technical, scientific, and factual questions. Our ability to maintain and solidify our proprietary position for our technology will depend on our success in promptly filing patent applications on new discoveries, and in obtaining effective claims and enforcing those claims once granted. We focus special attention on filing patent applications for formulations and delivery regimens for our products in development to further enhance our patent exclusivity for those products. We seek to protect our proprietary technology and processes, in part, by contracting with our employees, collaborators, scientific advisors, and our commercial consultants to ensure that any inventions resulting from the relationship are disclosed promptly, maintained in confidence until a patent application is filed, and preferably until publication of the patent application, and assigned to us or subject to a right to obtain a license. We do not know whether any of our owned patent applications or those patent applications that are licensed to us will result in the issuance of any patents. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed, invalidated, circumvented, or be found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products and reduce the term of patent protection that we may have for our products. Neither we nor our licensors can be certain that we were the first to invent the inventions claimed in our owned or licensed patents or patent applications. In addition, our competitors may independently develop similar technologies or duplicate any technology developed by us and the rights granted under any issued patents may not provide us with any meaningful competitive advantages against these competitors. Furthermore, because of the extensive time required for development, testing, and regulatory review of a potential product, it is possible that any related patent may expire prior to or shortly after commencing commercialization, thereby reducing the advantage of the patent to our business and products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets are difficult to protect. We seek to protect our trade secret technology and processes, in part, by entering into confidentiality agreements with commercial partners, collaborators, employees, consultants, scientific advisors, and other contractors, and by contracting with our employees and some of our commercial consultants to ensure that any trade secrets resulting from such employment or consulting are owned by us. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be discovered independently by others. To the extent that our consultants, contractors, or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-12-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired rights to develop and commercialize our product candidates through licenses granted by various parties. The following summarizes our material rights and obligations under those licenses:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nationwide Children's Hospital</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we expanded our pipeline by acquiring the rights and related intellectual property of ten gene therapy programs through our acquisition of Celenex. Celenex has an exclusive license agreement with Nationwide Children&#8217;s. Under this license agreement, Nationwide Children&#8217;s is eligible to receive development and sales-based milestones of up to $7.8 million for each product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">University of Pennsylvania</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, as amended, we entered into a collaboration agreement with Penn to pursue research and development of novel gene therapies. Our gene therapy portfolio pipeline expanded to include Pompe disease, Fabry disease, CDD, CLN1, MPSIIIB, as well as a next generation program in MPSIIIA. This expanded collaboration with Penn also provides us with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of other rare diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $88.0 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country- by-country basis. We will provide $10.0 million each year during the five-year agreement to fund the discovery research program. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, as amended in November 2013, we entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease (&#8220;Collaboration Agreement&#8221;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to rely on contract manufacturers to supply the active biopharmaceutical ingredients and final drug product for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, other pharmacological chaperones, our next-generation ERT product candidates, and our gene therapy product candidates. The active biopharmaceutical ingredients and final formulations for these products are manufactured under current Good Manufacturing Practice ("cGMP"). The components in the final formulation for each product are commonly used in other biopharmaceutical products and are well characterized ingredients. Although we rely on contract manufacturers, we have personnel with extensive manufacturing and quality experience to oversee our contract manufacturers. We have implemented appropriate controls for assuring the quality of both active biopharmaceutical ingredients and final drug products. Product specifications will be established in concurrence with regulatory bodies at the time of product registration. Our current arrangement with third-party manufacturers provide sufficient quantities of our program materials to meet anticipated clinical trial demands.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-13-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. In addition, several large pharmaceutical companies are increasingly focused on developing therapies for the treatment of rare diseases through organic growth, acquisitions, and partnerships. While we believe that our technologies, knowledge, experience, and scientific resources, provide us with competitive advantages, we face potential competition from many different sources, including commercial enterprises, academic institutions, government agencies, and private and public research institutions. Any product candidates that we successfully develop and commercialize will compete with both existing and new therapies that may become available in the future.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors may have significantly greater financial resources and expertise associated with research and development, regulatory approvals, and marketing approved products. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient, and/or are less expensive than products that we may develop. In addition, our ability to compete may be affected because in some cases insurers or other third-party payors seek to encourage the use of generic products. This may have the effect of making branded products less attractive to buyers.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major Competitors</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for LDs. Other competitors are pharmaceutical and biotechnology companies that have approved therapies or therapies in development for rare diseases for which pharmacological chaperone technology, or next-generation ERT may be applicable. Additionally, we are aware of several early-stage, niche pharmaceutical, and biotechnology companies whose core business revolves around protein misfolding; however, we are not aware that any of these companies are currently working to develop products that would directly compete with ours. We are also aware of several pharmaceutical and biotechnology companies who are developing various treatments for novel ERTs and gene therapy. The key competitive factors affecting the success of our product candidates are likely to be their efficacy, safety, convenience, and price.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-14-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The following table lists our principal competitors and publicly available information on the status of their clinical-stage product offerings:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Competitor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class of Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Sales</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sanofi Aventis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fabrazyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Myozyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">/ Lumizyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Venglustat</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oral GCS Inhibitor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase&#160;3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nexviazyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Takeda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Replagal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#165;52,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Idorsia </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lucerastat</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oral Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase&#160;3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Protalix Biotherapeutics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PRX-102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Freeline</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLT-190</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase&#160;1/2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sangamo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ST-920</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase&#160;1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4DMT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4D-310</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AskBio (Bayer)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACTUS-101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase&#160;1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Audentes (Astellas)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AT-845</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase&#160;1/2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Roche (Spark)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPK-3006</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase&#160;1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reflects commercial products and product candidates for which IND has been filed or are in clinical development.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reflects running 12 month revenue as of December 31, 2021, as Takeda's fiscal year ends on March 31, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., biopharmaceutical products, including gene therapies, are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, Public Health Services Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biopharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to file&#160;a marketing application, to issue complete response letters or to not approve pending NDAs or biologic product license applications ("BLAs"), or to issue warning letters, untitled letters, Form 483s, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, litigation, government investigation, and criminal prosecution.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical product development in the U.S. typically involves nonclinical laboratory and animal tests, the submission to the FDA of an Investigational New Drug application ("IND"), which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required varies substantially based upon the type, complexity, and novelty of the product or disease. Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal studies to assess the characteristics, potential safety, and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including Good Laboratory Practice ("GLP"). The results of preclinical testing are submitted to the FDA as part of an IND along with other information including information about product chemistry, manufacturing and controls, and at least one proposed clinical trial protocol. Long-term preclinical safety evaluations, such as animal tests of reproductive toxicity and carcinogenicity, continue during the IND phase of development. Reproductive toxicity studies are required to allow inclusion of women of childbearing potential in clinical trials, whereas carcinogenicity studies are required for registration. The results of these long-term studies would eventually be described in product labeling.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 30-day review period after the submission and receipt of an IND is required prior to the commencement of clinical testing in humans. The IND becomes effective 30&#160;days after its receipt by the FDA, and trials may begin at that point unless the FDA notifies the sponsor that the investigations are subject to a clinical hold.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-15-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials usually involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted in compliance with applicable government regulations, Good Clinical Practice ("GCP"), as well as under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to an Institutional Review Board ("IRB"), for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support an NDA or BLA for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase&#160;1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence on pharmacodynamics effects and effectiveness.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase&#160;2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication or indications, dosage tolerance, and optimum dosage, and identify common adverse effects and safety risks. If a compound demonstrates evidence of efficacy and an acceptable safety profile in Phase&#160;2 evaluations, Phase&#160;3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients over longer treatment periods, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has established the Office of Tissue and Advanced Therapies within the Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving gene therapies. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors that the FDA will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire. NIH and the FDA have a publicly accessible database, the Genetic Modification Clinical Research Information System, which includes information on gene therapy trials and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these trials. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an NDA or BLA is prepared and submitted to the FDA for the determination of efficacy and safety. FDA approval of the NDA or BLA is required before marketing of the product may begin in the U.S. The NDA or BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product's pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA or BLA is substantial. Under federal law, the submission of most NDAs and BLAs is additionally subject to a substantial application user fee; although for orphan drugs these fees are waived, and the holder of an approved NDA or BLA may also be subject to annual product and establishment user fees. These fees are typically increased annually.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-16-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60&#160;days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs and BLAs. Marketing applications are assigned review status during the filing period. Review status could be either standard or priority. Most such applications for standard review are reviewed within 12&#160;months under PDUFA V (two months for filing plus ten months for review). The FDA attempts to review a drug candidate that is eligible for priority review within six months, as discussed below. The review process may be extended by the FDA for three additional months to evaluate major amendments submitted during the pre-specified PDUFA V review clock. The FDA may also refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee for public review, typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA may also undertake an audit of nonclinical and clinical trial sites. The FDA will not approve the product candidate unless compliance with cGMP is satisfactory and the NDA or BLA contains data that provide substantial evidence that the drug is safe and effective in the indication studied and to be marketed. During the product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the product candidate. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA or BLA and the manufacturing facilities, it issues an approval letter or a complete response letter. Complete response letters outline the deficiencies in the submission that prevent approval and may require substantial additional testing or information for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in an amendment submitted to the NDA or BLA, the FDA will then issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type and extent of information included.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA or BLA approval, the FDA may require substantial post-approval commitments or requirements to conduct additional testing and/or surveillance to monitor the drug's safety or efficacy and may impose other conditions, including distribution and labeling restrictions which can materially affect the potential market and profitability of the drug. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained, problems are identified following initial marketing, or post-marketing commitments are not met.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hatch-Waxman Act</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patent(s) with claims that cover the applicant's product or approved method of use. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an Abbreviated New Drug Application ("ANDA"). An ANDA provides for marketing of a drug product that has the same route of administration, active ingredients strength, and dosage form as the listed drug and has been shown through bioequivalence testing to be, in most cases, therapeutically equivalent to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as "generic equivalents" to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed "innovator" drug.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-17-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA's Orange Book. Specifically, the applicant must certify that: (i)&#160;the required patent information has not been filed; (ii)&#160;the listed patent has expired; (iii)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patent is invalid or will not be infringed by the new product. A certification that the new product will not infringe the already approved product's listed patents or that such patents are invalid is called a Paragraph&#160;4 certification. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the ANDA applicant submits a Paragraph&#160;4 certification to the FDA, the applicant must also send notice of the Paragraph&#160;4 certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;4 certification. The filing of a patent infringement lawsuit within 45&#160;days of the receipt of a Paragraph&#160;4 certification automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent term and data exclusivity run in parallel. An ANDA application also will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of an NCE, listed in the Orange Book for the referenced product has expired ("New Chemical Entity Market Exclusivity"). Federal law provides a period of five years following approval of a drug containing no previously approved active ingredients, during which ANDAs for generic versions of those drugs cannot be submitted unless the submission contains a Paragraph&#160;4 certification that challenges a listed patent, in which case the submission may be made four years following the original product approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law provides for a period of three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use, the approval of which was required to be supported by new clinical trials conducted by or for the sponsor, during which the FDA cannot grant effective approval of an ANDA based on that listed drug for the same new dosage form, route of administration or combination, or new use.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA or BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, communications regarding unindicated uses, industry-sponsored scientific and educational activities, and promotional activities involving the internet. Products approved under Subpart H or Subpart E carry additional post-marketing considerations and requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs may be promoted only for approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, new safety information, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA, NDA supplement, BLA, or BLA supplement before the change can be implemented. New efficacy claims require submission and approval of an NDA supplement and BLA supplement for each new indication.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The efficacy claims typically require new clinical data similar to those included in the original application. The FDA uses the same procedures and actions in reviewing NDA and BLA supplements as it does in reviewing NDAs and BLAs. Additional exclusivity may be granted for new efficacy claims. Generic ANDAs cannot be labeled for these types of claims until the new exclusivity period expires.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-18-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA or BLA. The FDA also may require post-marketing testing, known as Phase&#160;4 testing, risk evaluation and mitigation strategies, and surveillance to monitor the effects of an approved product, or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as drug manufacture, packaging, and labeling procedures must continue to conform to cGMP, after approval. Drug manufacturers and certain subcontractors are required to register their establishments with FDA and certain state agencies and are subject to routine inspections by the FDA during which the agency inspects manufacturing facilities to access compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drugs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. The first NDA or BLA applicant with FDA orphan drug designation for a particular active ingredient to receive FDA approval of the designated drug for the disease indication for which it has such designation, is entitled to a seven-year exclusive marketing period ("Orphan Drug Exclusivity") in the U.S. for that product, for that indication. During the seven-year period, the FDA may not finally approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the license holder cannot supply sufficient quantities of the product. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition, provided that the sponsor has conducted appropriate clinical trials required for approval. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application user fee for the orphan indication.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2007 ("PREA"), NDAs or supplements to NDAs and BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track Designation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Fast Track program, the sponsor of an IND may request the FDA to designate the drug candidate as a Fast Track drug if it is intended to treat a serious condition and fulfill an unmet medical need. The FDA must determine if the drug candidate qualifies for Fast Track designation within 60&#160;days of receipt of the sponsor's request. Once the FDA designates a drug as a Fast Track candidate, it is required to facilitate the development and expedite the review of that drug by providing more frequent communication with and guidance to the sponsor.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to other benefits such as greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track drug's NDA or BLA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA's review period as specified under PDUFA V for filing and reviewing an application does not begin until the last section of the NDA or BLA has been submitted. Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-19-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough Therapy Designation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A Breakthrough Therapy designation conveys all of the Fast Track program features, as well as more intensive FDA guidance on an efficient drug development program. The FDA also has an organizational commitment to involve senior management in such guidance.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Priority Review</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under FDA policies, a drug candidate is eligible for priority review, or review within six months from filing for a new molecular entity ("NME") or six months from submission for a non-NME if the drug candidate provides a significant improvement compared to marketed drugs in the treatment, diagnosis, or prevention of a disease, rather than the standard review of ten months under current PDUFA guidelines. A Fast Track designated drug candidate would ordinarily meet the FDA's criteria for priority review. The FDA makes its determination of priority or standard review during the 60-day filing period after an initial NDA or BLA submission.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated Approval</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDA's accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit. This approval mechanism is provided for under 21CRF314 Subpart&#160;H and Subpart&#160;E. In this case, clinical trials are conducted in which a surrogate endpoint is used as the primary outcome for approval. A surrogate endpoint is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. This surrogate endpoint substitutes for a direct measurement of how a patient feels, functions, or survives and is considered reasonably likely to predict clinical benefit. Such surrogate endpoints may be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. When the Phase&#160;4 commitment is successfully completed, the biomarker is deemed to be a surrogate endpoint. Failure to conduct required post-approval studies or confirm a clinical benefit during post-marketing studies, could lead the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section&#160;505(b) (2)&#160;New Drug Applications</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most drug products obtain FDA marketing approval pursuant to an NDA, an ANDA, or a BLA. A fourth alternative is a special type of NDA, commonly referred to as a Section&#160;505(b) (2)&#160;NDA, which enables the applicant to rely, in part, on the safety and efficacy data of an existing product, or published literature, in support of its application.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505(b) (2)&#160;NDAs often provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section&#160;505(b)(2) permits the submission of an NDA for which at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely upon certain preclinical or clinical studies conducted for an approved product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section&#160;505(b) (2)&#160;applicant.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the Section&#160;505(b) (2)&#160;applicant is relying on studies conducted for an already-approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent as an ANDA applicant. Thus approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of an NCE, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph&#160;4 certification and subsequent patent infringement suit, until the earlier of 30&#160;months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section&#160;505(b)(2) applicant.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-20-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics Price Competition and Innovation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Act </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which was enacted as part of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 ("PPACA") created an abbreviated approval pathway for biological products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-licensed reference biological product via an approved BLA. Biosimilarity to an approved reference product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity is demonstrated in steps beginning with rigorous analytical studies or "fingerprinting", in vitro studies, in vivo animal studies, and generally at least one clinical study, absent a waiver from the Secretary of Health and Human Services. The biosimilarity exercise tests the hypothesis that the investigational product and the reference product are the same. If at any point in the stepwise biosimilarity process a significant difference is observed, then the products are not biosimilar, and the development of a stand-alone NDA or BLA is necessary. In order to meet the higher hurdle of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being evaluated by the FDA. Under the BPCIA, a reference biologic is granted 12&#160;years of exclusivity from the time of first licensure of the reference product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Kickback, False Claims Laws,&#160;the Prescription Drug Marketing Act and Other Regulations</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. civil False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government), prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-21-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to certain payments made in the preceding calendar year and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; beginning in 2022, applicable manufacturers are required to report such information regarding payments and transfers of value provided, as well as ownership and investment interests held, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical and medical device companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Drug Samples</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug Marketing Act (the "PDMA") imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include minimum standards for storage, handling, and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside the U.S.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we are subject to a variety of regulations in other jurisdictions governing clinical studies, commercial sales, and distribution of our products. Most countries outside the U.S. require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In addition, whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of countries outside the U.S. before we can commence clinical studies or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-22-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain regulatory approval of an orphan drug under the E.U. regulatory system, we are mandated to submit a marketing authorization application ("MAA") to be assessed in the centralized procedure. The centralized procedure, which came into operation in 1995, allows applicants to obtain a marketing authorization that is valid throughout the E.U. It is compulsory for medicinal products manufactured using biotechnological processes, for orphan medicinal products and for human products containing a new active substance which was not authorized in the community before 20&#160;May 2004 (date of entry into force of Regulation (EC) No 726/2004) and which are intended for the treatment of AIDS, cancer, neurodegenerative disorder or diabetes. The centralized procedure is optional for any other products containing new active substances not authorized in the community before 20&#160;May 2004 or for products which constitute a significant therapeutic, scientific or technical innovation or for which a community authorization is in the interests of patients at community level. When a company wishes to place on the market a medicinal product that is eligible for the centralized procedure, it sends an application directly to the European Medicines Agency ("EMA"), to be assessed by the Committee for Medicinal Products for Human Use ("CHMP"). The procedure results in a commission decision, which is valid in all E.U. member states. Centrally-authorized products may be marketed in all member states. Under the centralized procedure, full copies of the MAA are sent to a rapporteur and a co-rapporteur designated by the competent EMA scientific committee. They coordinate the EMA's scientific assessment of the medicinal product and prepare draft reports. Once the draft reports are prepared (other experts might be called upon for this purpose), they are sent to the CHMP, whose comments or objections are communicated to the applicant. The rapporteur is therefore the privileged interlocutor of the applicant and continues to play this role, even after the MAA has been granted approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapporteur and co-rapporteur then assess the applicant's replies, submit them for discussion to the CHMP and, taking into account the conclusions of this debate, prepare a final assessment report. Once the evaluation is completed, the CHMP gives a favorable or unfavorable opinion as to whether to grant the authorization. When the opinion is favorable, it shall include the draft summary of the product's characteristics, the package leaflet and the texts proposed for the various packaging materials. The time limit for the evaluation procedure is 210&#160;days. The EMA then has fifteen days to forward its opinion to the commission. This is the start of the second phase of the procedure: the decision-making process. The Agency sends to the commission its opinion and assessment report, together with annexes containing: the SmPC ("Annex&#160;1"); the particulars of the MAH responsible for batch release, the particulars of the manufacturer of the active substance and the conditions of the marketing authorization ("Annex&#160;2"); and the labelling and the package leaflet ("Annex&#160;3"). The annexes are translated into the 22 other official languages of the E.U. During the decision-making process, the commission services verify that the marketing authorization complies with Union law. The commission has fifteen days to prepare a draft decision. The medicinal product is assigned a community registration number, which will be placed on its packaging if the marketing authorization is granted. During this period, various commission directorates-general are consulted on the draft marketing authorization decision.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The draft decision is then sent to the Standing Committee on Medicinal Products for Human Use, (member states have one representative each in both of these committees) for their opinions. The centralized procedure provides for the grant of a single marketing authorization that is valid for all E.U. member states. The "decentralized procedure" provides for approval by one or more other, or concerned, member states of an assessment of an application performed by one member state, known as the reference member state. Under this procedure, an applicant submits an application, or dossier, and related materials including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120&#160;days after receipt of a valid application. Within 90&#160;days of receiving the reference member state's assessment report, each concerned member state must decide whether to approve the assessment report and related materials. If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to the public health, the disputed points may eventually be referred to the European Commission, whose decision is binding on all member states.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained an orphan medicinal product designation in the E.U. from the EMA for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease and the combination product, ATB200/AT2221, for the treatment of Pompe disease. Applications from persons or companies seeking "orphan medicinal product designation" for products they intend to develop for the diagnosis, prevention, or treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 persons in the E.U. are reviewed by the Committee for Orphan Medicinal Products ("COMP"). In addition, orphan drug designation can be granted if the drug is intended for a life threatening, seriously debilitating, or serious and chronic condition in the E.U. and that without incentives it is unlikely that sales of the drug in the E.U. would be sufficient to justify developing the drug. Orphan drug designation is only available if there is no other satisfactory method approved in the E.U. of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-23-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation provides opportunities for fee reductions, protocol assistance and access to the centralized procedure before and during the first year after marketing approval. Fee reductions are not limited to the first year after marketing approval for small and medium enterprises. In addition, if a product which has an orphan drug designation subsequently receives EMA marketing approval for the indication for which it has such designation, the product is entitled to orphan market exclusivity, which means the EMA may not approve any other application to market a similar drug for the same indication for a period of 10&#160;years. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Competitors may receive marketing approval of different drugs or biologics for the indications for which the orphan product has exclusivity. In order to do so, however, they must demonstrate that the new drugs or biologics are clinically superior over the existing orphan product. This demonstration of clinical superiority may be done at the time of initial approval or in post-approval studies, depending on the type of marketing authorization granted.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative, the Priority Medicines (&#8220;PRIME&#8221;) scheme, to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIME scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, AT-GTX-501 was granted PRIME designation.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained a positive opinion for our pediatric investigation plan ("PIP") in the E.U. for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease as well. A PIP is a development plan aimed at ensuring that the necessary data are obtained to support the authorization of a medicine for children, through studies in children. All applications for marketing authorization for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral or waiver. This requirement also applies when a marketing-authorization holder wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized and covered by intellectual property rights. Several rewards and incentives for the development of pediatric medicines for children are available in the E.U. Medicines authorized across the E.U. with the results of studies from a PIP included in the product information are eligible for an extension of their supplementary protection certificate by six months. This is the case even when the studies' results are negative. For orphan medicines, the incentive is an additional two years of market exclusivity. Scientific advice and protocol assistance at the agency are free of charge for questions relating to the development of pediatric medicines. Medicines developed specifically for children that are already authorized but are not protected by a patent or supplementary protection certificate are eligible for a pediatric-use marketing authorization ("PUMA"). If a PUMA is granted, the product will benefit from 10&#160;years of market protection as an incentive.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.K. left the E.U. on January 31, 2020 following which, existing E.U. medicinal product legislation continued to apply in the U.K. during the transition period under the terms of the E.U.-U.K. Withdrawal Agreement. A transition period, which ended on December 31, 2020, maintained access to the E.U. single market and to the global trade deals negotiated by the E.U. on behalf of its members. The transition period provided time for the U.K. and E.U. to negotiate a framework for partnership for the future, which was then crystallized in the Trade and Cooperation Agreement ("TCA") and became effective on January 1, 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2021, the Medicines and Healthcare products Regulatory Agency ("MHRA") will be the U.K.&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales and Scotland (together Great Britain, "GB"); broadly, Northern Ireland will continue to follow the E.U. regulatory regime, but its national competent authority will remain the MHRA. The MHRA has published a draft guidance on how various aspects of the U.K. regulatory regime for medicines will operate in GB and in Northern Ireland following the expiry of the Brexit transition period on December 31, 2020. The guidance includes clinical trials, marketing authorizations, importing, exporting and pharmacovigilance and is relevant to any business involved in the research, development or commercialization of medicines in the U.K. The new guidance will be given effect via the Human Medicines Regulations ("Amendment etc.") ("E.U. Exit") Regulations 2019 (the "Exit Regulations"). The U.K. regulatory regime largely mirrors that of the E.U. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-24-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, an accelerated assessment procedure and new routes of evaluation for novel products and biotechnological products. All existing E.U. marketing authorizations ("MAs") for centrally authorized products were automatically converted ("grand fathered") into U.K. MAs free-of-charge on January 1, 2021. Amicus has completed the necessary baseline submission for conversion and was granted Marketing Authorization on August 4, 2021 with an effective date of January 1, 2021. Amicus has completed the necessary baseline submission for conversion and was granted MA on August 4, 2021 with an effective date of January 1, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There will be no pre-marketing authorization orphan designation. Instead, the MHRA will review applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the GB market, e.g. the prevalence of the condition in GB (rather than the E.U.) must not be more than 5 in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in GB or E.U./European Economic Area, wherever is earliest.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PIP application process for applicants is simplified by offering an expedited assessment where possible, and by mirroring the submission format, content and terminology of the E.U.-PIP system. The MHRA is taking decisions on PIP and waiver opinions, modifications and compliance statements to support pediatric market authorization decisions, while acknowledging that Northern Ireland continues to be part of the E.U.&#8217;s system for pediatric medicines development including agreement of E.U. PIPs or waivers.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MHRA has maintained the Early Access to Medicine Scheme ("EAMS"). EAMS is designed to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorization when there is a clear unmet medical need. It is anticipated that medicines with a positive EAMS opinion could be made available to patients 12-18 months ahead of formal marketing authorization. As the initial step in this process, the applicant must apply for and be granted a Promising Innovative Medicine (&#8220;PIM&#8221;) designation. The designation is issued after an MHRA scientific designation meeting on the basis of non-clinical and clinical data available on the product, in a defined disease area. Following designation, the applicant is expected to complete a clinical development program within a reasonable time period, in order to continue with an application under the EAMS. In January 2020, the MHRA issued a PIM designation for AT-GAA for the treatment of late-onset Pompe disease and subsequently granted a positive opinion under  EAMS in June 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained orphan drug designation in Japan for migalastat for the treatment of Fabry Disease. We also have other Orphan Drug applications approved in other world markets including Switzerland, Australia, South Korea and Taiwan. The Ministry of Health, Labor, and Welfare, based on the opinion of the Pharmaceutical Affairs and Food Sanitation Council, grants orphan status to drugs intended to address serious illnesses with high unmet medical need that affect fewer than 50,000 patients in Japan. In 2020, orphan drug designation was granted in Japan for AT-GAA for the treatment of Pompe disease. Orphan designation provides certain benefits and incentives, including priority review for marketing authorization and a period of 10&#160;years of market exclusivity if the drug candidate is approved for the designated indication.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Foreign Corrupt Practices Act</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act, or the FCPA, generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our industry is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. Violations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Enforcement actions may be brought by the Department of Justice or the Securities and Exchanges Commission (&#8220;SEC&#8221;), and recent enacted legislation has expanded the SEC&#8217;s power to seek disgorgement in all FCPA cases filed in federal court and extended the statute of limitations in SEC enforcement actions in intent-based claims such as those under the FCPA from five years to ten years.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-25-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> United States Healthcare Reform</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act, was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the provisions of the Affordable Care Act that have been implemented since enactment and are of importance to the commercialization of our product and product candidates, if approved, are the following: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an annual, nondeductible fee on any entity that manufactures, or imports specified branded prescription drugs or biologic agents; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expansion of healthcare fraud and abuse laws, including the U.S. civil False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expansion of eligibility criteria for Medicaid programs; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">requirements to report certain financial arrangements with physicians and teaching hospitals; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-26-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been significant ongoing judicial, administrative, executive and legislative efforts to modify or eliminate the Affordable Care Act. For example, the Tax Act enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code, commonly referred to as the individual mandate. Other legislative changes have been proposed and adopted since passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. Subsequent litigation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, which was designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 to December 31, 2021. The sequester will remain in place through 2030. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act has also been subject to challenges in the courts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An appeal was taken to the U.S. Supreme Court. On June 17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs, changes allowing the federal government to directly negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that the Affordable Care Act, as well as other healthcare reform measures that have and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for our product and product candidates, if approved.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in payments from private payers. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Amicus, one of our founding principles is that we believe in each other to foster teamwork and respect for each individuals' contribution. Our passion for making a difference unites us. Supporting our globally diverse employees is an essential part of the core values and culture at Amicus. Tied to these values and culture, we believe our success and our ability to help patients depends on our capability to attract, develop and retain key personnel. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-27-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe that diversity of experience and thought is essential. At Amicus, we are committed to the advancement of diversity and inclusion in the workplace. Diversity is the representation of all our varied identities and differences (race, ethnicity, gender, disability, sexual orientation, gender identity, national origin, tribe, socio-economic status, thinking and communication styles, etc.), collectively and as individuals. Equity seeks to ensure fair treatment, equality of opportunity, and fairness in access to information and resources for all. Inclusion means that all individuals feel respected, accepted, and valued. Inclusion builds a culture of belonging, by actively inviting the contribution and participation of all people. Combined, Diversity, Equity and Inclusion ("DEI") creates a work environment where every voice is heard and valued, resulting in a dimensional way of thinking that is used when meeting company goals. This ensures that every employee feels they are treated fairly regardless of identities and differences.  This is referred to as &#8216;Justice&#8217; in the Great Place to Work Engagement survey we participate in annually, where we come within 2% of the World&#8217;s Best Top 25 Companies in &#8216;Justice&#8217; with a 90% positive response compared to the global benchmark of 92%. DEI at Amicus is about creating an environment that supports bringing the authentic employee to the workplace. Our unique experiences, cultures, and backgrounds are what make us so great at putting patients at the forefront of what we do and pushing ideas as far and fast as possible. As of December 31, 2021, we had 496 full-time employees. Currently, 50% of our executive management team are women and 27% of our board of directors are women</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe it is critical that our employees are informed and engaged. In our Great Place to Work engagement survey results, Amicus surpassed the global benchmark of 84% positive response of the World&#8217;s Best Top 25 Companies in the category of employee &#8216;Pride&#8217; with 92% positive response where employees say they feel &#8220;their work has special meaning: it is not just a job.&#8221;  Our Mission to &#8216;Always Put Patients First&#8217; helps keep our employees engaged with this sense of purpose. We support engagement through communicating frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings, round tables, employee pulse surveys, company intranet, and acknowledge individual contributions through a number of reward and recognition programs. We believe these engagement efforts keep employees informed about our strategy, culture and purpose and motivated to do their best work. As a result of the COVID-19 pandemic, we also further strengthened our digital communication and social networking platforms. Our communications during the pandemic have kept our employees informed on critical priorities, important actions being taken by management in response to the pandemic, and continued efforts to protect employee&#8217;s health, safety and well-being.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support and develop our employees through global training and development programs that build and strengthen employees&#8217; leadership and professional skills. These are further emphasized through our engagement on employee career paths through the annual goal process, a tuition reimbursement program, providing the ability to attend industry conferences and trainings, and holding patient-mission focused Lunch and Learns. Additionally, we strive to attract and retain the most talented employees in the industry and across the globe by offering competitive compensation and benefits that support their health, financial and emotional well-being. Our compensation philosophy is based on rewarding each employee&#8217;s individual contributions and striving to achieve equal pay for equal work regardless of gender, race or ethnicity. We use a combination of fixed and variable pay including base salary, bonuses, and share based compensation. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware on February&#160;4, 2002. The address of our global headquarters is 3675 Market Street, Philadelphia, PA 19104 and our telephone number is 215-921-7600. Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.amicusrx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make available free of charge on our website our annual, quarterly, and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the U.S. Securities and Exchange Commission.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our corporate governance, including our Code of Business Conduct for Employees, Executive Officers and Directors (the "Code of Conduct"), Corporate Governance Guidelines, and information concerning our senior management team, Board of Directors, including Board Committees and Committee charters, and transactions in our securities by directors and executive officers, is available free of charge on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.amicusrx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the "Investors&#160;&#8212; Corporate Governance" caption and in print to any stockholder upon written request to our Chief Legal Officer at the address set forth on the cover of this Annual Report. Any waivers or material amendments to the Code will be posted promptly on our website.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-28-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.  &#160;RISK FACTORS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider these risk factors, together with all of the other information included in this Annual Report on Form 10-K, including our Consolidated Financial Statements and the related notes thereto, before you decide whether to make an investment in our securities. The risks set forth below are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, prospects, financial condition, cash flows, liquidity, funds from operations, results of operations, stock price and ability to service our indebtedness. In such case, the value of our common stock and the trading price of our securities could decline, and you may lose all or a significant part of your investment. Some statements in the following risk factors constitute forward looking statements. Please refer to the explanation of the qualifications and limitations on forward-looking statements under &#8220;Forward-Looking Statements&#8221; of this Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Ability to Generate and Sustain Revenue</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on sales of our first product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, in Europe, the U.S., Japan, and other geographies. Moreover, if we are unable to commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> successfully, or experience significant delays in doing so, our business could be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested a significant portion of our efforts and financial resources in the development of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease and rely upon sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily in Europe and growing sales in the U.S., Japan, and other geographies. Our ability to generate material product revenues will depend heavily on the successful development, regulatory approval, and commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We began the commercial launch of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the E.U. and U.K. in May 2016, in Japan in June 2018 and in the U.S. in August 2018 and continue to seek commercial approval in additional foreign jurisdictions. Approvals have been granted in over 40 countries around the world. We will continue to study Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a confirmatory Phase 4 program and other supportive Phase 4 studies. If the results of the Phase 4 studies negatively change the benefit/risk profile of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the commercial success of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may be substantially diminished. Any adverse market event with respect to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including failure to obtain sufficient market acceptance, could have a material adverse effect on our business, financial condition and results of operations. If our sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were to decrease, or such sales were substantially or completely displaced in the market, or if we are unable to achieve sufficient market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by physicians, patients, third-party payors and others in the medical community, or if we fail to receive commercial approval in any additional jurisdictions, it could have a material adverse effect on our business, financial condition and results of operations. In addition, if Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or similar products from our competitors were to become the subject of litigation and/or an adverse governmental action requiring us or such competitors, as applicable, to cease sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, such an event could have a material adverse effect on our business, financial condition and results of operations. In addition, the entry into the market of competitors with new or generic treatments, including oral, ERT and gene therapies, may erode the market for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and have a material impact on our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or impediment in our ability to obtain regulatory approval in any region to commercialize, or, when approved, obtain coverage and adequate reimbursement from third parties, including government payors, for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may cause us to be unable to meet our revenue guidance or to generate the revenues necessary to continue our research and development pipeline activities, thereby adversely affecting our business and our prospects for future growth.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the success of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will depend on a number of factors, including the following:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining a sufficiently broad label in each territory that would not unduly restrict patient access;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining additional foreign approvals for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continuing to build and maintain an infrastructure capable of supporting product sales, marketing, and distribution of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., Europe, Japan and other territories where we pursue commercialization directly;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining commercial manufacturing arrangements with third-party manufacturers;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining commercial distribution agreements with third-party distributors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">launching commercial sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, where approved, whether alone or in collaboration with others;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, where approved, by patients, the medical community and third-party payors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-29-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">effectively competing with other therapies, including potential generics and potential gene therapies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a continued acceptable safety profile of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">protecting and enforcing our rights in our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining and maintaining a commercially viable price for our products; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continuing to successfully mitigate the impact of the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which would materially harm our business.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product or product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product and product candidates, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AT-GAA and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, commercialization and reimbursement are subject to comprehensive regulation by the European Medicines Agency (&#8220;EMA&#8221;), the Pharmaceutical and Medical Devices Agency (&#8220;PMDA&#8221;), the Food and Drug Administration (&#8220;FDA&#8221;), and other regulatory agencies in the U.S. and by comparable authorities in other countries. Failure to obtain regulatory approval for our product and product candidates will prevent us from commercializing our product in jurisdictions beyond those in which we have obtained regulatory approval for our product or in any jurisdictions for our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval for all our product candidates, including AT-GAA, requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy. We will continue to rely on third parties to assist us with filing and supporting the applications necessary to obtain marketing approvals for product candidates in this process. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Regulatory authorities may determine that any of our products or product candidates are not effective or only moderately effective, or have undesirable or unintended side effects, toxicities, safety profiles or other characteristics that preclude us from obtaining marketing approval or that prevent or limit commercial use.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining approval for all of our product candidates, including AT-GAA, is highly uncertain and we may fail to obtain regulatory approval in any or all jurisdictions. The review processes and the processes of regulatory authorities, including the FDA, EMA and PMDA, are extensive, lengthy, expensive, and uncertain, and such regulatory authorities may delay, limit, or deny approval of any of our product candidates for many reasons, including, but not limited to:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our failure to demonstrate to the satisfaction of the applicable regulatory authorities that any of our product candidates, including AT-GAA are safe and effective for a particular indication;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the results of clinical trials may not meet the level of statistical significance or other efficacy or safety parameters required by the applicable regulatory authorities for approval;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may disagree with the number, design, size, conduct, or implementation of our clinical trials or conclude that the data fail to meet statistical or clinical significance;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may not find the data from preclinical studies and clinical trials sufficient to demonstrate that the product candidate's clinical and other benefits outweigh its safety risks;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may disagree with our interpretation of data from preclinical studies or clinical trials, and may reject conclusions from preclinical studies or clinical trials, or determine that primary or secondary endpoints from clinical trials were not met, or reject safety conclusions from such studies or trials;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may not accept data generated at one or more of our clinical trial sites;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may determine that we did not properly oversee our clinical trials or follow the regulatory authority's advice or recommendations in designing and conducting our clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-30-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product candidate;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may only approve a limited label for less than the full indicated population, as a second line or rescue therapy, or impose other label restrictions; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may identify deficiencies in the chemistry, manufacturing, and control sections of our application, our manufacturing processes, facilities, or analytical methods or those of our third-party contract manufacturers, and this may lead to significant delays in the approval of our product candidates or to the rejection of our applications altogether.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain sales and marketing capabilities or enter into agreements with third parties to market and sell our product or product candidates, we may not be successful in commercializing Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, or any product candidate, including AT-GAA, if and when they are approved.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve commercial success for any approved product, we must continue to develop and maintain a sales and marketing organization or outsource commercialization to third parties. We have established our own sales and marketing capabilities to promote Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe, Japan, the U.S. and other foreign jurisdictions with a targeted sales force. We have also entered into distribution agreements with third parties to market our products in jurisdictions in which we do not have our own sales and marketing capabilities. There are risks involved with establishing and maintaining our own sales and marketing capabilities and entering into arrangements with third parties to perform these services for any of our products or product candidates. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Similarly, if we enter into agreements with third parties, including the out licensing of our product or product candidates, we may choose to reduce or eliminate our sales and marketing operations and thereby lose our commercialization investment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or our product candidates, including AT-GAA, if and when they are approved by regulatory authorities, including the FDA, PMDA and EMA, on our own include:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability of sales personnel to obtain access to adequate numbers of physicians to prescribe any future products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">efforts by our competitors to commercialize products at or about the time when our product candidates would be coming to market.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-31-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also co-promote or out license our product or product candidates in various markets with pharmaceutical and biotechnology companies in instances where we believe that a larger sales and marketing presence will expand the market or accelerate penetration. If we do enter into co-promote or out licensing arrangements with third parties, our product revenues will be lower than if we directly sold and marketed our products and any revenues received under such arrangements will depend on the skills and efforts of others.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in entering into distribution arrangements and marketing alliances with third parties. Our failure to enter into these arrangements on favorable terms could delay or impair our ability to commercialize our product and product candidates and could increase our costs of commercialization. Dependence on distribution arrangements and marketing alliances to commercialize our products and product candidates will subject us to a number of risks, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not be able to control the amount and timing of resources that our distributors may devote to the commercialization of our product or product candidates;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our distributors may experience financial difficulties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our distributors may experience compliance related issues and associated government investigations;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our distributors may require transfer of the marketing authorization for our products and may refuse to relinquish them at the end of the distribution relationship;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our distributors may be out of compliance with applicable Anti-bribery and Corruption laws with an adverse effect on operations and expose us to liability;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business combinations or significant changes in a distributor's business strategy may also adversely affect a distributor's willingness or ability to complete its obligations under any arrangement; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">these arrangements are often terminated or allowed to expire, which could interrupt the marketing and sales of a product and decrease our revenue.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish and maintain adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue at our current guidance and may not ever become profitable.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our product or product candidates are smaller than we believe they are, then our revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the diseases that our product and most advanced product candidates are being developed to address is rare. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product and product candidates, are based on estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, most reported estimates of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which are then extrapolated to estimate the prevalence of the diseases in the broader world population. In addition, as new studies are performed the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Fabry disease, Pompe disease, or other rare diseases in the study populations, particularly in these newer studies, accurately reflects the prevalence of these diseases in the broader world population. If our estimates of the prevalence of Fabry disease, Pompe disease, or other rare diseases or of the number of patients who may benefit from treatment with our product or product candidates prove to be incorrect, the market opportunities for our product and product candidates may be smaller than we believe they are, our prospects for generating revenue at our guidance levels may be adversely affected and our business may suffer.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any of our product candidates that receive regulatory approval may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any of our other products or product candidates that receive regulatory approval may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-32-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy and potential advantages compared to competitive or alternative treatments, including generics and gene therapies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability to offer our product and product candidates for sale at competitive prices;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">publicity concerning our products or competing products and treatments; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sufficient third-party coverage or reimbursement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to negotiate, secure and maintain third-party coverage and reimbursement may be affected by political, economic and regulatory developments in the U.S., E.U., U.K. and other jurisdictions. Governments continue to impose cost containment measures, and third-party payors are increasingly challenging prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any of our product candidates that receive marketing approval and we may fail to meet our revenue targets.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and product candidates, including AT-GAA, and any products we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology and gene therapy companies worldwide. For example, several large pharmaceutical and biotechnology companies currently market and sell products for the treatment of lysosomal storage disorders, including Fabry disease. These products include Sanofi Aventis' Fabrazyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Takeda&#8217;s Replagal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as other Fabry treatment products in development. In addition, Sanofi markets and sells Myozyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumizyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Nexviazyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Pompe disease. We are also aware of other enzyme replacement and substrate reduction therapies in development by third parties for Fabry and Pompe, as well as potential gene therapies for both Fabry and Pompe and our other product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or noncompetitive. Our competitors may also obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours, could achieve regulatory exclusivity and block us from approval and marketing our products for a significant period of time. We may also face competition from off-label use of other approved therapies. There can be no assurance that developments by others will not render our product candidates or any acquired products obsolete or noncompetitive either during the research phase or once the products reach commercialization.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, prosecuting intellectual property rights and marketing approved products than we do. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to or necessary for our programs or advantageous to our business. In addition, if we obtain regulatory approvals for our product candidates, manufacturing efficiency and marketing capabilities are likely to be significant competitive factors. We currently rely on third-party manufacturers for our product and all of our product candidates including our gene therapies. Further, many of our competitors have substantial resources and expertise in conducting collaborative arrangements, sourcing in-licensing arrangements, manufacturing and acquiring new business lines or businesses that are greater than our own.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-33-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and any of our other product candidates, including AT-GAA, that may be approved in the future for commercialization in the E.U., U.K. or in other foreign countries are or will be subject to additional risks related to international operations or entering into international business relationships, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">different regulatory requirements for maintaining approval of drugs in foreign countries;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced protection for contractual and intellectual property rights in some countries;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anti-corruption laws in other jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">tighter restrictions on privacy and the collection and use of patient data; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business interruptions resulting from geopolitical actions (including war and terrorism), pandemic diseases (such as the recent spread of COVID-19 &#8220;coronavirus&#8221;), or natural disasters (including earthquakes, typhoons, floods and fires).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are complex regulatory, tax, labor and other legal requirements imposed by the E.U., U.K., and many of the individual countries in Europe, Asia and Latin America with which we will need to comply. Many U.S.-based biopharmaceutical companies have found the process of marketing their own products in Europe and other international geographies to be very challenging.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Following the receipt of marketing approval of our product or any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations and practices that govern marketing approvals, pricing, commercialization, coverage and reimbursement for new drug products vary widely from country to country and product to product. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries, including almost all of the member states of the European Economic Area, require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, including the European market, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted and approved products are subject to re-reviews, class reviews and other governmental controls which can negatively impact pricing originally approved. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact any revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. This is particularly true in the case of gene therapies for which payors and manufacturers must develop different pricing models for this growing area. Current pricing for gene therapies may not be sustainable in the future which would have a negative impact on our revenues and business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-34-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any product candidate, including AT-GAA, successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the European and U.S. healthcare industries and elsewhere is cost containment. It is currently unknown what impact, if any proposed changes by the federal and state governments in the U.S. and similar changes in foreign countries may have on pricing and reimbursement, particularly with respect to government programs such as Medicare and Medicaid and Pharmacy Benefit Managers for commercial plans, and including reimportation, reference pricing and limitations on manufacturer price increases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices at which we or our customers seek reimbursement for our products can be subject to challenge, reduction or denial by the government and other payers. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for pharmaceutical products. We cannot be sure that coverage and reimbursement will continue to be available for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any product that we commercialize, and in particular gene therapies, and, if coverage and reimbursement are available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any product candidate for which we obtain marketing approval. Obtaining reimbursement for our product candidates when approved may be particularly difficult because of the higher prices typically associated with drugs directed at smaller orphan populations of patients and the pricing and reimbursement of competitive products. In addition, third-party payors are likely to impose strict requirements for reimbursement of a higher priced drug. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product for which we obtain marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that may affect our ability to profitably sell our product and product candidates, if approved. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. The Affordable Care Act was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been significant ongoing judicial, administrative, executive and legislative efforts to modify or eliminate the Affordable Care Act. For example, the Tax Act enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code (the &#8220;Code&#8221;), commonly referred to as the individual mandate. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. Subsequent litigation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, the 2% Medicare sequester reductions have been suspended from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act has also been subject to challenges in the courts. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the "individual mandate" was repealed by Congress. On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act. On June 17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-35-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs, changes allowing the federal government to directly negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.  We also expect that the Affordable Care Act, as well as other healthcare reform measures that have and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for our product and product candidates, if approved. Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in payments from private payers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have promoted off-label uses, we may become subject to significant liability. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription drug products. In particular, a product may not be promoted in the U.S. for uses that are not approved by the FDA as reflected in the product's approved labeling or prior to regulatory approval. Further, any labeling approved by the FDA for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our other product candidates, including AT-GAA, may include restrictions on use, or other limitations. The FDA may impose further requirements or restrictions on the distribution or use of any of our other product candidates as part of a REMS plan. Physicians may nevertheless prescribe such products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. Similarly, the FDA strictly regulates the promotion of investigational products prior to approval, known as pre-approval promotion. The federal government has levied large civil and criminal fines and / or other penalties against companies for alleged improper promotion and has investigated and / or prosecuted several companies in relation to off-label and/or pre-approval promotion. The FDA has also requested that certain companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed, curtailed or prohibited or have delayed approval of investigational products due to pre-approval conduct. </span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk when we commercially sell any products that we develop, including those which may arise from misuse or malfunction of, or design flaws in, such products, whether or not such problems directly relate to the products and services we have provided. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced resources of our management to pursue our business strategy;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory investigations, prosecutions or enforcement actions that could require costly recalls or product modifications;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities placing ongoing clinical trials on clinical hold;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant costs to defend the related litigation;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increased insurance costs, or an inability to maintain appropriate insurance coverage;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial monetary awards to trial participants or patients, including awards that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available, and would damage our ability to obtain liability insurance at reasonable costs, or at all, in the future;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of revenue; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability to commercialize any products that we may develop.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-36-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. We have increased our insurance coverage for the commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and may increase insurance coverage when, and if, we begin commercializing any other product candidate that receives marketing approval. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or a series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our available cash and adversely affect our business.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA or other applicable regulatory authorities approve generic or biosimilar products with claims that compete with our product or any of our product candidates, it could reduce our sales of our product or those product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., after an NDA is approved, such as Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the product covered thereby becomes a "listed drug" which can, in turn, be cited by potential competitors in support of approval of an abbreviated NDA, or ANDA. The Federal Food, Drug, and Cosmetic Act, or the FD&amp;C Act, FDA regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product has the same active ingredients, dosage form, strength, route of administration, and conditions of use, or product labeling, as our product or product candidate and that the generic product is absorbed in the body at the same rate and to the same extent as, or is bioequivalent to, our product or product candidate. These generic equivalents would be significantly less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product are typically lost to the generic product. Accordingly, competition from generic equivalents to our product or product candidates, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, would substantially limit our ability to generate revenues or achieve profitability with a negative impact on continued operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act of 2010, or the ACA, Pub. L. No. 111-148 (2010). The BPCIA authorizes the FDA to approve "abbreviated" BLAs for products whose sponsors demonstrate they are "biosimilar" to reference products previously approved under BLAs, including AT-GAA, if approved. The FDA may also separately determine whether "biosimilar" products are "interchangeable" with their reference products. However, the FDA may not approve an "abbreviated" BLA for a biosimilar product until at least twelve years after the date on which the BLA for the reference product was approved. FDA approval of abbreviated BLAs could be further delayed if the reference products are subject to unexpired and otherwise valid patents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the enactment of the BPCIA, information in approved BLAs could not be relied upon by other manufacturers to establish the safety and efficacy of their products for which they were seeking FDA approval. Accordingly, if our products such as AT-GAA are approved under a BLA, other manufacturers potentially could develop and seek FDA approval of "biosimilar" products at some point in the future, including a biosimilar of AT-GAA.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product, product candidate or indication and fail to capitalize on a product, product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-37-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically been focused on the development and commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a small molecule for Fabry disease and in a next generation ERT treatment for Pompe disease, AT-GAA. In 2018, we also made a significant investment in potential gene therapies for Fabry, Pompe, CDD, Batten&#8217;s disease and other LDs. Notwithstanding our large investment in gene therapies and Pompe ERT to date and anticipated future expenditures in related proprietary technologies, we have not yet developed, and may never successfully develop, any marketed drugs using ERT and gene therapy approaches. As a result of pursuing the development and commercialization of our product and product candidates using our proprietary and licensed technologies, we may fail to develop products or product candidates, or address indications based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success. Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product candidates yet fail to yield product candidates for clinical development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Products and the Regulatory Approval and Clinical Development of our Product Candidates</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or product candidates including AT-GAA, could interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA, EMA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing our product or product candidates and generating revenues from their sale. In addition, if we or others identify undesirable side effects caused by our products or product candidates after receipt of marketing approval:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may require the addition of restrictive labeling statements;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may withdraw their approval of the product; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to change the way the product is administered, or additional clinical trials are conducted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or product candidate or could substantially increase the costs and expenses of commercializing the product or product candidate, which in turn could delay or prevent us from generating significant revenues from its sale or adversely affect our reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-38-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product or product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to penalties or other enforcement actions if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product or our product candidates, when and if any of them are approved.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product or product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA, EMA, PMDA and other regulatory authorities. For example, the FDA's requirements include submissions of safety and other post-marketing information and reports, registration requirements, Current Good Manufacturing Practices, or cGMP, requirements relating to manufacturing, quality control, quality assurance and complaints and corresponding maintenance of records and documents, requirements regarding the distribution of samples to healthcare professionals and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or may be subject to significant conditions of approval, including the requirement of a REMS. The FDA also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The labeling, advertising, promotion, marketing and distribution of a drug, biologic, or gene therapy product also must be in compliance with FDA requirements which include, among others, promotional activities, standards and regulations for direct-to-consumer advertising, promotional activities involving the internet, and industry sponsored scientific and educational activities. In general, all product promotion must be consistent with the labeling approved by the FDA for such product, contain a balanced presentation of information on the product's uses, benefits, risks, and important safety information and limitations on use, and otherwise not be false or misleading. The FDA has very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing a company to correct deviations from regulatory standards and enforcement actions that can include seizures, injunctions and criminal prosecution. Failure to comply with applicable FDA requirements and restrictions also may subject a company to adverse publicity and enforcement action by the FDA, the U.S. Department of Justice ("DOJ") or the Office of the Inspector General of the U.S. Department of Health and Human Services ("HHS") as well as state authorities. This could subject us to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes its products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes to or restrictions on the labeling or marketing of a product;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on product distribution or use;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requirements to implement a REMS;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">warning or untitled letters;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of the products from the market;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">recall of products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal to permit the import or export of our products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product seizure;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injunctions; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the imposition of civil or criminal penalties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-39-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance with E.U. and U.K. requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the E.U.'s and U.K.'s requirements regarding the protection of personal information, which are effective as of May&#160;25, 2018, can also lead to significant penalties and sanctions and business restrictions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or our suppliers, third-party contractors, clinical investigators or collaborators are slow to adapt, or are unable to adapt, to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, we or our collaborators may lose marketing approval for our products when and if any of them are approved, resulting in decreased revenue from milestones, product sales or royalties.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, healthcare providers, patients, patient organizations, charitable foundations and third-party payors will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and corruption and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Increasingly, patients, patient organizations and charitable foundations also can influence selection of and payment for therapies. Our future arrangements with payors, healthcare providers, patient organizations, charitable foundations and patients may expose us to broadly applicable fraud and abuse, anti-bribery and corruption, and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal, state and foreign healthcare laws and regulations pertaining to fraud and abuse, anti-bribery and corruption, interaction with patient organizations, charitable foundations, and patients' rights are and will be applicable to our business. Restrictions under applicable federal, state and foreign healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Several other countries, including the U.K., have enacted similar anti-kickback, fraud and abuse, and healthcare laws and regulations;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. In addition, charitable contributions to foundations for use in supporting patients may expose those foundations and us to additional penalties and prosecution under the False Claims Act. There is also a separate false claims provision imposing criminal penalties. Applicable regulations of both the EMA and E.U. member states also impose liability for failing to comply with fraud and abuse laws or improperly using information obtained in in the course of clinical trials with the EMA or other regulatory authorities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-40-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The U.S. federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a violation. This statute also may impose monetary penalties on any offers or transfers of remuneration to Medicare or Medicaid beneficiaries (patients) which is likely to influence the beneficiary's selection of particular supplier of government payable items. States, such as California have enacted their own privacy regulations and others may enact similar legislation. Similarly, the collection and use of personal health data in the E.U. is governed by the E.U. General Data Protection Regulation (the "GDPR"), with many requirements mandated by the GDPR for the consent of the individuals to whom the personal data relates, the information provided to the individuals, transfer of personal data within and outside of the E.U. and the security and confidentiality of the personal data. Enforcement of the GDPR began on May&#160;25, 2018, and failure to comply with the requirements of the GDPR may result in substantial fines and other administrative penalties. The GDPR increases our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and adversely affect our business, financial condition, results of operations and prospects;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">U.S. federal laws requiring drug manufacturers to report annually information related to certain payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities and requiring manufacturers to report marketing expenditures, payments and other transfers of value to physicians and other healthcare providers. Similarly, payments made to physicians in certain E.U. member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician's employer, his or her competent professional organization and/or the regulatory authorities of the individual E.U. member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the E.U. member states. In addition, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the E.U. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">U.S. federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs. Participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, potential liability for the failure to report such prices in an accurate and timely manner, and potentially limit our ability to offer certain marketplace discounts;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">U.S. Foreign Corrupt Practices Act, which prohibit us and third parties working on our behalf from making payments to foreign government officials to assist in obtaining or retaining business. Specifically, the anti-bribery provisions of the FCPA prohibit the willful use of the mails or any means of instrumentality of interstate commerce corruptly in furtherance of any offer, payment, promise to pay, or authorization of the payment of money or anything of value to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to influence the foreign official in his or her official capacity, induce the foreign official to do or omit to do an act in violation of his or her lawful duty, or to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business to, any person; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-41-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state and foreign equivalents of each of the above laws, including foreign anti-bribery and corruption laws and state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not submit claims and our customers will make the ultimate decision on how to submit claims, in the U.S. we may provide reimbursement guidance and support regarding Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our other product candidates for which we receive regulatory approval, to our customers and patients. If a government authority were to conclude that we provided improper advice to our customers and patients and/or encouraged the submission of false claims for reimbursement, we could face action by government authorities. Similarly, if a government authority were to conclude that our patient support efforts or interactions with charitable foundations were improper, we could face action by government authorities. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, EMA, PMDA or other foreign regulatory authorities, or do not otherwise produce favorable results, we may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with seeking marketing approval from regulatory authorities for the sale of any product candidate, including AT-GAA, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. This is particularly the case with AT-GAA, as there can be no assurance that the Phase 3 PROPEL study results will meet regulatory standards for approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the regulatory pathways for gene therapies are evolving. In some cases, the FDA will approve gene therapies based on Phase 2 clinical trial data. If, however, the FDA decides we need to complete Phase&#160;3 clinical trial(s), we may need to expend significantly more capital to pursue FDA approval of gene therapies. If we are required to conduct additional clinical trials or other testing of our product candidates, including AT-GAA, or any gene therapies, that we develop beyond those tests and trials that we contemplate; if we are unable to successfully complete our clinical trials or other testing; if the results of these trials or tests are not positive or are only modestly positive; or if there are safety concerns, we may:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">choose not to seek regulatory approval in the U.S., E.U., U.K. or other key jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">not obtain marketing approval at all;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-42-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be subject to additional post-marketing testing requirements, safety strategies or restrictions, such as a requirement of a risk evaluation and mitigation strategy, or REMS; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">have the product removed from the market after obtaining regulatory approval.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential regulatory approval or commercialization of our product candidates could be delayed or prevented.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials including ongoing clinical trials of AT-GAA in additional study populations that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or patients may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be unable to enroll a sufficient number of patients in our trials to ensure adequate statistical power to detect any statistically significant treatment effects;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulators, institutional review boards, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulators, institutional review boards, or independent ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, institutional review boards or independent ethics committees to suspend or terminate the trials.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in testing or regulatory approvals. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, allow our competitors to bring products to market before we do, or impair our ability to successfully commercialize our product candidates, and so may harm our business and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-43-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials. Each of the diseases that our lead product candidates are intended to treat are characterized by small patient populations, which could result in slow enrollment of clinical trial participants. In addition, our competitors have ongoing clinical trials for product candidates that could be competitive with our product candidates. As a result, potential clinical trial sites may elect to dedicate their limited resources to participation in our competitors' clinical trials and not ours, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors' product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is affected by other factors including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">severity of the disease under investigation;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">eligibility criteria for the clinical trial in question;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patient referral practices of physicians;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the Company to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients in any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial results from a clinical trial do not ensure that the trial will be successful and success in preclinical or early stage clinical trials does not ensure success in later-stage clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will only obtain regulatory approval to commercialize a product candidate if we can demonstrate to the satisfaction of the FDA or the applicable non-U.S. regulatory authority, in well-designed and conducted clinical trials, that the product candidate is safe and effective and otherwise meets the appropriate standards required for approval for a particular indication. Clinical trials are lengthy, complex and extremely expensive processes with uncertain duration and results. A failure of one or more of our clinical trials may occur at any stage of testing.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful. Our product candidates may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials or preliminary stages of clinical trials. For some of our product candidates, we have no safety or efficacy data in humans. There can be no assurance that the results seen in preclinical studies for any product candidates will result in success in clinical trials. When administered in humans, the product candidates may perform differently than in preclinical studies. Product candidates may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies or animal studies, and may interact with human biological systems in unforeseen, ineffective or harmful ways. We may be unable to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-44-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial results from a clinical trial do not necessarily predict final results. We cannot be assured that these trials will ultimately be successful. In addition, patients may not be compliant with their dosing regimen or trial protocols or they may withdraw from the clinical trial at any time for any reason. In addition, while the clinical trials of our product candidates are designed based on the available relevant information, in view of the uncertainties inherent in drug development, such clinical trials may not be designed with focus on indications, patient populations, dosing regimens, safety or efficacy parameters or other variables that will provide the necessary safety or efficacy data to support regulatory approval to commercialize the resulting product candidates. This is particularly the case for emerging gene therapies where we do not yet have a defined regulatory pathway and there can be no assurance that regulators in the U.S., E.U., U.K., Japan or other jurisdictions will accept any gene therapy clinical data sets for approval and without additional clinical trials or that future trials will support approvals. In addition, individual patient responses to the dose administered of a product candidate may vary in a manner that is difficult to predict. Also, the methods we select to assess particular safety or efficacy parameters may not yield statistical precision in estimating our product candidates' effects on study participants. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Preclinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our product candidates may be based on emerging gene therapy technologies. The FDA may require different endpoints than the endpoints we anticipate using or have used in our clinical trials, or a different analysis of those endpoints, it may be more difficult for us to obtain, or we may be delayed in obtaining, FDA approval of our product candidates. If we are not successful in commercializing any of our products or product candidates, or are significantly delayed in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain or maintain orphan drug exclusivity for our product or product candidates. If our competitors are able to obtain orphan drug exclusivity for their products, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the E.U., U.K., and the U.S., may designate drugs for relatively small patient populations as orphan drugs. We obtained orphan drug designations from the FDA for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease in February 2004. We also obtained orphan medicinal product designation in the E.U. and U.K. for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in May 2006. AT-GAA has also received this designation from the FDA, EMA, and, in 2020, from PMDA. Our competitors have also received orphan designations. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity, which, subject to certain exceptions, precludes the EMA from approving another marketing application for a similar medicinal product or the FDA from approving another marketing application for the same drug for the same indication for that time period. The FDA defines &#8220;same drug&#8221; as a drug or biologic that contains the same active moiety and is intended for the same use. The applicable market exclusivity period for orphan drugs is ten years in the E.U. and U.K. and seven years in the U.S. The E.U. and U.K. exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation, including if the drug is sufficiently profitable so that market exclusivity is no longer justified.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the E.U. and U.K., a "similar medicinal product" is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. Obtaining orphan drug exclusivity for our product candidates, in the E.U., U.K. and U.S., may be important to the product candidate's success. If a competitor to AT-GAA or our other product candidates obtains orphan drug exclusivity for and approval of a product with the same indications as our product candidates as before we do and if the competitor's product is the same drug or a similar medicinal product as ours, we could be excluded from the market for a certain period of time.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain orphan drug exclusivity for other product candidates in these indications, we may not be able to maintain it. For example, if a competitive product that is the same drug or a similar medicinal product as our product or product candidate is shown to be clinically superior to our product or product candidate, as applicable, any orphan drug exclusivity we have obtained will not block the approval of such competitive product. In addition, orphan drug exclusivity will not prevent the approval of a product that is the same drug as our product or product candidate if the FDA finds that we cannot assure the availability of sufficient quantities of the drug to meet the needs of the persons with the disease or condition for which the drug was designated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-45-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA Reauthorization Act, signed into law in August 2017, authorizes the FDA to impose additional clinical trial requirements on manufacturers seeking orphan drug designation and/or pediatric indications. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AT-GAA have obtained orphan drug designations from the FDA. The impact, however, of future regulations on other product candidates is uncertain and could result in the need for additional clinical trials.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain or maintain regulatory approval in foreign jurisdictions would prevent us from marketing our products abroad.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in Europe and many other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, some countries outside the U.S. require approval of the sales price of a drug before it can be marketed. In many countries, separate procedures must be followed to obtain reimbursement. We may not obtain marketing, pricing or reimbursement approvals outside the U.S. on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the U.S. does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. Regulatory approvals in countries outside the U.S. do not ensure pricing approvals in those countries or in any other countries, and regulatory approvals and pricing approvals do not ensure that reimbursement will be obtained.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities involve the use of hazardous materials, which require compliance with environmental and occupational safety laws regulating the use of such materials. If we violate these laws, we could be subject to significant fines, liabilities or other adverse consequences.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development programs involve the controlled use of hazardous materials, including microbial agents, corrosive, explosive and flammable chemicals and other hazardous compounds in addition to certain biological hazardous waste. Additionally, the activities of our third-party product manufacturers of our product, and of our product candidates if and when they reach commercialization, will also require the use of hazardous materials. Accordingly, we are subject to federal, state and local laws governing the use, handling and disposal of these materials. Although we believe that our safety procedures for handling and disposing of these materials comply in all material respects with the standards prescribed by local, state and federal regulations, we cannot completely eliminate the risk of accidental contamination or injury from these materials. In addition, although our collaborators have environmental compliance processes in place, and we include oversight of these processes in our business reviews, they may not ultimately comply with these laws. In the event of an accident or failure to comply with environmental laws, we could be held liable for damages that result, and any such liability could exceed our assets and resources or we could be subject to limitations or stoppages related to our use of these materials which may lead to an interruption of our business operations or those of our third-party contractors. While we believe that our existing insurance coverage is generally adequate for our normal handling of these hazardous materials, it may not be sufficient to cover pollution conditions or other extraordinary or unanticipated events. Furthermore, an accident could damage or force us to shut down our operations. Changes in environmental laws may impose costly compliance requirements on us or otherwise subject us to future liabilities and additional laws relating to the management, handling, generation, manufacture, transportation, storage, use and disposal of materials used in or generated by the manufacture of our products or related to our clinical trials. In addition, we cannot predict the effect that these potential requirements may have on us, our suppliers and contractors or our customers.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-46-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain marketing approval for AT-GAA, or if it is approved and the label does not support reimbursement and we are unable to successfully commercialize AT-GAA, our business could be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we announced topline data results from the AT-GAA Phase 3 Propel Study and our intention to both complete the rolling BLA submission to the FDA and seek additional approvals worldwide. While we believe the results of the trial will permit successful regulatory submissions, and labels to support broad use and favorable pricing and reimbursement, there is no guarantee that the FDA or any other regulatory authority will grant AT-GAA marketing approval, or if approved will receive favorable pricing or reimbursement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy. Regulatory authorities may determine that AT-GAA is not effective or only moderately effective, have effect in only a limited population, or have undesirable or unintended side effects, toxicities, safety profiles or other characteristics that preclude us from obtaining marketing approval or that prevent or limit commercial use. If AT-GAA fails to receive marketing approval, is significantly delayed in receiving marketing approval or if the approved labeling is not as expected, AT-GAA may fail to receive market acceptance, receive reimbursement or be able to generate material revenue, any of which could substantially harm our future business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Preclinical Product Candidates</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our gene therapy product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a few gene therapy products have been approved in the U.S., E.U., and U.K. We have acquired the rights to many potential gene therapies and have focused a substantial amount of our research and development efforts on these gene therapy platforms. There can be no assurance that any development problems we experience in the future related to our gene therapies will not cause significant delays or unanticipated costs, or that such development problems can be solved. In addition, the clinical study requirements of the FDA, the EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as our gene therapies can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. There is no guarantee that our potential gene therapies will ever receive regulatory approval, that we will have the resources to develop these therapies, that we will recoup our investments made in gene therapies or that we will meet any projected timelines for development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Manufacture of our Product and Product Candidates and our Dependence on Third Parties</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties manufacturing our gene therapy which could impact timing and availability of clinical and commercial supply.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in developing a sustainable, reproducible and commercial-scale manufacturing process or transferring that process to commercial partners for our gene therapy product candidates. There is intense competition for limited commercial manufacturing capacity in gene therapy and for base materials, such as plasmids, necessary to the manufacturing of gene therapy products. We do not currently have our own gene therapy manufacturing capacity and rely instead on commercial manufacturing partners. These commercial manufacturing partners are expanding rapidly and there can be no assurance that needed capacity will be available or that these partners will continue to meet evolving regulatory standards. Any delay in securing supply of these materials and the manufacturing slots with commercial partners may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, FDA and other regulatory bodies are continuing to evolve their guidance for gene therapy manufacturing and could impose rigorous requirements relating to the manufacturing and testing of clinical and commercial products that could add time, complexity and the risk that we or our manufacturing partners will be unable to meet these requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-47-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of third parties to manufacture Galafold or AT-GAA may increase the risk that we will not have sufficient quantities of Galafold or product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate manufacturing facilities for clinical or commercial production of Galafold or AT-GAA. We currently lack the resources and the capabilities to manufacture ourselves on a clinical or commercial scale. If we choose in the future to manufacture ourselves, we would face all of the risks and uncertainties of third-party manufacture of our products. We currently outsource all manufacturing and packaging of our product and preclinical and clinical product candidates to third parties. The manufacture of pharmaceutical and gene therapy products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. In particular, the manufacture of our biologic product candidate ATB200 for Pompe, is highly complex and we may encounter difficulties in production. These problems include difficulties with production costs and yields and quality control, including stability of the product or product candidate. The occurrence of any of these problems could significantly delay our clinical trials or the commercial availability of our product or product candidates.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to enter into agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable terms. Even if we enter into these agreements, the manufacturers of each product candidate will be single source suppliers to us for a significant period of time.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limitations on supply availability resulting from capacity and scheduling constraints of the third parties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to manufacture product that meets the regulatory requirements for product approval;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to manufacture batches that meet specifications and quality standards; </span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to hire and retain the skilled workers necessary to manufacture our products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to meet environmental sustainability requirements;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">impact on our reputation in the marketplace if manufacturers of our products, once commercialized, fail to meet the demands of our customers;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure of any of our contract manufacturers to maintain high manufacturing standards could result in injury or death of clinical trial participants or patients using products. Such failure could also result in product liability claims, product recalls, product seizures or withdrawals, delays or failures in testing or delivery, cost overruns or other problems that could seriously harm our business or profitability.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and regulatory authorities in other jurisdictions require our contract manufacturers to comply with cGMP regulations. These regulations cover all aspects of the manufacturing, testing, quality control and recordkeeping relating to our product candidates and any products that we may commercialize, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,AT-GAA, and our gene therapy product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the U.S. Our failure or the failure of our third-party manufacturers, to comply with applicable regulations could significantly and adversely affect regulatory approval and supplies of our product candidates. Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-48-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the third parties that we engage to manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, we likely would experience delays in advancing these trials while we identify and qualify replacement suppliers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the drug substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive regulatory approval on a timely and competitive basis.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct certain preclinical development activities and our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not independently conduct clinical trials for our product candidates or certain preclinical development activities of our product candidates. We rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators and collaboration partners, to perform these functions. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for certain preclinical and clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, or GCP, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register certain ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within particular timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Similar GCP and transparency requirements apply in the E.U. and U.K. Failure to comply with such requirements, including with respect to clinical trials conducted outside the E.U., U.K. and U.S., can also lead regulatory authorities to refuse to take into account clinical trial data submitted as part of an MAA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, third parties that we rely on for our clinical development activities may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Our product development costs will increase if we experience delays in testing or obtaining marketing approvals.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on other third parties to obtain, store and distribute drug supplies for our preclinical development activities and clinical trials. In addition, in some instances we are required to purchase clinical supplies from our competitors, who may refuse to allow this purchase or do so at prohibitively high prices. Any performance failure on the part of our distributors or inability to secure supply from our competitors could delay preclinical and clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensions, delays, suspensions or terminations of our preclinical development activities or our clinical trials as a result of the performance of our independent clinical investigators and CROs will delay, and make more costly, regulatory approval for any product candidates that we may develop. Any change in a CRO during an ongoing preclinical development activity or clinical trial could seriously delay that trial and potentially compromise the results of the activity or trial.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-49-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in maintaining or establishing collaborations, which could adversely affect our ability to develop and, particularly in international markets, commercialize products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with physicians, academic institutions, hospitals, patient advocacy groups, foundations and government agencies in order to assist with the development of our products and each of our product candidates. We plan to pursue similar activities in future programs and plan to evaluate the merits of retaining commercialization rights for ourselves or entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies. We also may seek to establish collaborations for the sales, marketing and distribution of our products in all or select geographies. If we elect to seek collaborators in the future but are unable to reach agreements with suitable collaborators, we may fail to meet our business objectives for the affected product or program. We face, and will continue to face, significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts, if any, to establish and implement collaborations or other alternative arrangements. The terms of any collaboration or other arrangements that we establish, if any, may not be favorable to us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any collaboration that we enter into may not be successful. The success of our collaboration arrangements, if any, will depend heavily on the efforts and activities of our collaborators. It is likely that any collaborators of ours will have significant discretion in determining the efforts and resources that they will apply to these collaborations. The risks that we may be subject to in possible future collaborations include the following:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may not pursue development and commercialization of our product or product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise between the collaborator and us as to the ownership of intellectual property arising during the collaboration;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may grant rights to our collaborators to be the holder of any marketing authorizations in a jurisdiction;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may grant exclusive rights to our collaborators, which would prevent us from collaborating with others;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-50-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations with pharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Such terminations or expirations may adversely affect us financially and could harm our business reputation in the event we elect to pursue collaborations that ultimately expire or are terminated.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Materials necessary to manufacture our product or product candidates may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our product or product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on the manufacturers of our product and product candidates to purchase from third-party suppliers the materials necessary to produce the compounds for our preclinical studies, clinical trials, and commercial supply and we rely, or will rely, on these other manufacturers for commercial distribution of our product and, if and when we obtain marketing approval, for any of our product candidates. Suppliers may not sell these materials to our manufacturers at the time we need them or on commercially reasonable terms and all such prices are susceptible to fluctuations in price and availability due to transportation costs, government regulations, price controls, geopolitical risk and changes in economic climate or other foreseen circumstances. We do not have any control over the process or timing of the acquisition of these materials by our manufacturers. We may enter into agreements to purchase certain materials and provide them to our manufacturers, with all the risks and uncertainties of supply associated with those purchases. If we or our manufacturers are unable to obtain these materials for our preclinical studies and clinical trials, product testing and potential regulatory approval of our product candidates would be delayed, significantly impacting our ability to develop and commercialize our product candidates. If our manufacturers or we are unable to purchase these materials for commercial distribution of our product or, after regulatory approval has been obtained, our product candidates, the commercial launch of our product and product candidates would be delayed or there would be a shortage in supply, which would materially affect our ability to generate revenues from the sale of our product or product candidates.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing of our product and product candidates requires us or our manufacturing partners to conduct required stability and comparability testing. We or our partners may encounter product, packaging, equipment and process-related issues that may require refinement or resolution in order to successfully commercialize our product and proceed with our planned clinical trials and obtain regulatory approval for commercial marketing of our product candidates. In the future, we may identify impurities, which could result in increased scrutiny by regulatory authorities, delays in our clinical programs and regulatory approval, increases in our operating expenses or failure to obtain or maintain approval for our product or product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on WuXi App Tec Biopharmaceuticals, a company based in the People's Republic of China (the "PRC"), as the sole supplier of our biologic product, ATB200. Accordingly, there is a risk that supplies of our product may be significantly delayed by or may become unavailable as a result of manufacturing, equipment, process, regulatory or business-related issues affecting that company. We may also face additional manufacturing and supply-chain risks due to the regulatory and political structure of the PRC, or as a result of the international relationship between the PRC and the U.S. or any of the other countries in which our products are marketed. In addition, the out-breaks of SARS, COVID-19 &#8220;coronavirus&#8221; or other similar illnesses in PRC could impact operations at Wuxi. Although currently there has been no impact on operations and we and Wuxi have robust mitigation plans in place, there can be no assurance that operations would not be impacted in the future with a negative impact on supply of our product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-51-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Position</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the future.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have focused on developing and commercializing our first product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our pipeline product AT-GAA as well as our gene therapies. Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. Although the European Commission, PMDA and FDA have granted approval for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of adults with a confirmed diagnosis of Fabry disease and who have an amenable genetic variant, and we are generating product sales, we continue to incur significant research, development, commercialization and other expenses related to our ongoing operations. As a result, we are not profitable, have incurred losses in each period since our inception, and may never be profitable on a non-GAAP or GAAP basis. For the year ended December 31, 2021, we have a net loss of $250.5 million, and we have an accumulated deficit of $2.3 billion at December 31, 2021.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our development and commercialization of, and seek regulatory approvals for, product candidates, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AT-GAA in the U.S., the E.U., U.K., Japan and other foreign countries, as applicable;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">conduct additional clinical trials to support the full approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and post-approval commitments or trials;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue communicating with the EMA, as necessary, regarding post-marketing requirements and clinical trials for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue to or initiate the regulatory submission process for marketing approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of the U.S. and E.U. and other foreign jurisdictions where approved, as applicable;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">build and maintain our commercial infrastructure so that it is capable of supporting product sales, marketing and distribution of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our other product candidates in Europe, Japan and the U.S. or other territories in which we have received or may receive regulatory approval;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prepare for launch of AT-GAA in the U.S., E.U., U.K. and other jurisdictions if approved by regulators;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our gene transfer discovery and next generation product research; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our preclinical studies of and potentially conduct clinical studies of ERT and gene therapy for CDD.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. The size of our future losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If any of our product candidates fails in clinical trials or does not gain regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders' equity and working capital.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may never become profitable even though we currently generate revenue from the sale of products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began the commercial launch of our first product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in May 2016, with the U.S. and Japan commercial launches in 2018 and are now approved in over 40 countries. Our ability to generate material revenue and become profitable depends upon our ability to successfully commercialize our existing product and product candidates, or product candidates that we may in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for our product candidates, including AT-GAA, we do not know when any of these product candidates will generate revenue for us, if at all and we may not meet our current revenue, operating expense and profitability guidance. Our ability to generate revenue from our current or future product and product candidates depends on a number of factors, including our ability to:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successfully complete development activities and obtain additional regulatory and pricing and reimbursement approvals for, and continue to successfully commercialize, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-52-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">develop and maintain a commercial organization capable of sales, marketing, and distribution for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any product candidates we intend to market, in the countries where we have chosen to commercialize the product candidates ourselves including the U.S. and Japan;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacture commercial quantities of our products at acceptable cost levels;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain a commercially viable price for our products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain coverage and adequate reimbursement from third parties, including government payors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successfully satisfy post-marketing requirements that the FDA, EMA, or other foreign regulatory authorities may impose for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any of our other product candidates that may receive regulatory approval, including pediatric trials and patient registries;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successfully complete development activities, including the necessary preclinical studies and clinical trials, with respect to product candidates;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">complete and submit regulatory submissions to the FDA, EMA, MHRA, PDMA and others and obtain regulatory approval for our product candidates including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities for AT-GAA; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue to navigate any adverse impacts of the COVID-19 outbreak, including due to actions by us, governments, our customers, our suppliers or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because of the numerous risks and uncertainties associated with product development, including that our product candidates may not advance through development or achieve the safety and efficacy endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. Furthermore, we anticipate incurring significant costs associated with commercializing these products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to generate significant revenues from the sale of our products, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we require substantial additional capital to fund our operations and we fail to obtain necessary financing, we may be unable to complete the development and commercialization of our product and development and commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash. We expect to continue to spend substantial amounts to advance the preclinical and clinical development of our product candidates, and launch and commercialize our product and product candidates for which we may receive regulatory approval, including continuing to build our own commercial organization. We believe that our current cash position, including expected Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, is sufficient to fund ongoing Fabry and Pompe, operations to achieve self-sustainability without the need for future dilutive financing. Potential future business development collaborations, restructurings, pipeline expansion, in-licensing or out-licensing activities could impact our future capital requirements. However, we may require substantial additional capital for the development and commercialization of our product and further development and commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on acceptable terms, we could also be required to:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significantly delay, scale back, or discontinue the development or the commercialization of our product or product candidates or one or more of our other research and development initiatives;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek collaborators for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AT-GAA or one or more of our current or future product candidates at an earlier stage than otherwise would be desirable, or on terms that are less favorable than might otherwise be available;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">relinquish or license on unfavorable terms our rights to our technologies, product or product candidates that we otherwise would seek to develop or commercialize ourselves;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-53-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significantly curtail operations; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">enter into strategic partnerships on unfavorable terms, including sale of our assets for less than full value.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this "Risk Factors" section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of commercialization activities, including maintaining sales, marketing, and distribution capabilities for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope, progress, results, and costs of preclinical development, laboratory testing, and clinical trials for our product candidates and any other product candidates that we may in-license or acquire;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of manufacturing drug supply for our preclinical studies, clinical trials, and commercial supply, including the significant cost of manufacturing AT-GAA and our gene therapies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome, timing, and cost of the regulatory approval process by the FDA, EMA, PMDA and other foreign regulatory authorities, including the potential for regulatory authorities to require that we perform more studies than those that we currently anticipate for our product and product candidates including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights; </span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost and timing of completion of existing or expanded commercial-scale outsourced manufacturing activities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of defending any claims asserted against us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which we acquire or invest in additional businesses, products, and technologies.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of private and public equity offerings, debt financings, receivables or royalty financings, strategic collaborations and alliances, restructuring and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt, receivables, and royalty financings may be coupled with an equity component, such as warrants to purchase stock, which could also result in dilution of our existing stockholders' ownership. The incurrence of additional indebtedness beyond our existing indebtedness with the Senior Secured Term Loan due 2026 could also result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur further debt, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could have a material adverse effect on our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to default on any of our indebtedness, we could lose such assets and intellectual property. If we raise additional funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AT-GAA or our other product candidates, or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market our technologies that we would otherwise prefer to develop and market ourselves.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-54-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into the Senior Secured Term Loan due 2026 for a $400 million credit facility with Hayfin Capital Management, with an interest rate equal to 3-month LIBOR, subject to a 1% floor, plus 6.5% per annum that requires interest-only payments until mid-2024 and matures in six years in 2026. We received net proceeds of $385.9 million in July 2020, after deducting fees and expenses. There were no warrants or equity conversion features associated with the Senior Secured Term Loan due 2026. The Senior Secured Term Loan due 2026 contains a minimum liquidity covenant of $75 million, tested monthly and in effect at all times, and an incremental minimum consolidated revenue covenant, measured as of the previous four consecutive fiscal quarters. The minimum consolidated revenue covenant ranges from $140 million, beginning March 31, 2021, and peaks at $225 million by June 30, 2023, continuing at that level until the loan is repaid.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our cash and cash equivalents, together with funds generated by our operations and any future financings, will be sufficient to satisfy our debt payment obligations or that we will have sufficient equity to satisfy these obligations. Our inability to generate funds obtain financing sufficient to satisfy our debt payment obligations or remain in compliance with the debt covenants may result in such obligations being accelerated by our lenders, which would likely have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency exchange rate fluctuations could harm our financial results.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct operations in many countries involving transactions denominated in a variety of currencies other than the U.S. dollar. The majority of our current Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue is derived from outside the U.S. Accordingly, changes in the value of currencies relative to the U.S. dollar may impact our consolidated revenues and operating results due to transactional and translational remeasurement that is reflected in our earnings. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, and net product sales denominated in foreign currencies. Fluctuations in currency exchange rates have had, and will continue to have, an impact on our results as expressed in U.S. dollars. We are not currently engaged in any foreign currency hedging activities and there can be no assurance that currency exchange rate fluctuations will not adversely affect our results of operations, financial condition and cash flows. In addition, our outlooks do not assume fluctuations in currency exchange rates. Adverse fluctuations in currency exchange rates from the date of our outlooks could cause our actual results to differ materially from those anticipated in our outlooks and adversely impact our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks arising from the imposition of exchange controls and currency devaluations. Exchange controls may limit our ability to convert foreign currencies into U.S. dollars or to make payments by our foreign subsidiaries or businesses located in or conducted within a country imposing controls. Currency devaluations result in a diminished value of funds denominated in the currency of the country instituting the devaluation.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had federal and state net operating loss carry forwards ("NOLs") of approximately $1,292 million and $1,000&#160;million respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the 2017 Tax Act. Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through 2020 will expire in 2029 through 2040. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended, as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past, and could occur again in the future Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section 382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership some of which are outside our control. We completed a detailed study of our NOLs and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on our ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-55-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders maintain the ability to exert significant influence and control over matters submitted to our stockholders for approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and affiliated stockholders beneficially own shares representing approximately 51% of our common stock as of December 31, 2021. As a result, if these stockholders were to choose to act together, they would be able to exert significant influence and control over matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could influence the election of directors and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination or reorganization. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire. The interests of this group of stockholders may not always coincide with the interests of other stockholders, and they may act, whether by meeting or written consent of stockholders, in a manner that advances their best interests and not necessarily those of other stockholders, including obtaining a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital in the foreseeable future, capital appreciation, if any, will be our stockholders sole source of gain.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the development and growth of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be our stockholders sole source of gain for the foreseeable future. </span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations reflect the reality that judgments can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Intellectual Property</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the U.S. and in certain foreign jurisdictions related to our novel technologies, product and product candidates that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, if we license technology or product candidates from third parties in the future, these license agreements may not permit us to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering this intellectual property. These agreements could also give our licensors the right to enforce the licensed patents without our involvement, or to decide not to enforce the patents at all. Therefore, in these circumstances, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-56-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, including U.S. Hatch-Waxman litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors were the first to make the inventions covered by each of our pending patent applications;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors were the first to file patent applications for these inventions;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any patents issued to us or our licensors will provide a basis for commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">licenses from other third parties will not be required to commercialize patented products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we will develop additional proprietary technologies that are patentable;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we will file patent applications for new proprietary technologies promptly or at all;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our patents will not expire prior to or shortly after commencing commercialization of a product;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the patents of others will not have a negative effect on our ability to do business;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patent authorities will not identify deficiencies in our patent applications and refuse to grant our patents; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">outcome of any patent litigation, including Hatch-Waxman litigation involving Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or AT-GAA, will demonstrate that our patents are valid and enforceable. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot be assured that any of our pending patent applications will result in issued patents. In particular, we have filed patent applications in the U.S., the European Patent Office and other countries outside the U.S. that have not been issued as patents. These pending applications include, among others, some of the patent applications for ATB200, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our gene therapy platforms and product candidates. If patents are not issued in respect of our pending patent applications, we may not be able to stop competitors from marketing similar products in Europe and other countries in which we do not have issued patents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection outside of the U.S., we intend to seek orphan medicinal product designation of our product candidates and to rely on statutory data exclusivity provisions in jurisdictions outside the U.S. where such protections are available, including Europe. The patent rights that we own or have licensed relating to our product candidates are limited in ways that may affect our ability to exclude third parties from competing against us if we obtain regulatory approval to market these product candidates. In particular:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We now hold a composition of matter patent covering Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and we have multiple method of treatment patents issued and listed. We have composition of matter patents, method of manufacture and other patents issued for ATB200. We also have several pending applications covering Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ATB200 and gene therapy. There can be no assurance that these applications will be allowed or that allowed applications will be issued or that the scope of such patents, if they issue, will be sufficient to protect our product. Composition of matter patents can provide protection for pharmaceutical products to the extent that the specifically covered compositions are important. For our product candidates for which we do not hold composition of matter patents, competitors who obtain the requisite regulatory approval can offer products with the same composition as our products so long as the competitors do not infringe any method of use patents that we may hold.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-57-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">For some of our product candidates the principal patent protection that covers or those we expect will cover our product candidate is a method of use patent. This type of patent only protects the product when used or sold for the specified method. However, this type of patent does not limit a competitor from making and marketing a product that is identical to our product that is labeled for an indication that is outside of the patented method, or for which there is a substantial use in commerce outside the patented method.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, physicians may prescribe such a competitive identical product for indications other than the one for which the product has been approved, or off-label indications, that are covered by the applicable patents. Although such off-label prescriptions may infringe or induce infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Certain foreign jurisdictions may not recognize or enforce any patents granted or patent applications filed in those jurisdictions. In addition, we may not pursue or obtain patent protection in all major markets. Assuming the other requirements for patentability are met, currently, the first to file&#160;a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the U.S., the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office or become involved in opposition, derivation, reexamination, inter partes review, post grant review, interference proceedings or other patent office proceedings or litigation, in the U.S. or elsewhere, challenging our patent rights or the patent rights of others, including U.S. Hatch-Waxman litigation. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. In addition, other companies may attempt to circumvent any regulatory data protection or market exclusivity that we obtain under applicable legislation, which may require us to allocate significant resources to preventing such circumvention. Legal and regulatory developments in the E.U. and elsewhere may also result in clinical trial data submitted as part of an MAA becoming publicly available. Such developments could enable other companies to circumvent our intellectual property rights and use our clinical trial data to obtain marketing authorizations in the E.U. and in other jurisdictions. Such developments may also require us to allocate significant resources to prevent other companies from circumventing or violating our intellectual property rights. Our attempts to prevent third parties from circumventing our intellectual property and other rights may ultimately be unsuccessful. We may also fail to take the required actions or pay the necessary fees to maintain our patents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-58-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, litigation, interferences, oppositions, inter partes reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity. Litigation, interference, oppositions, inter partes reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our products, or&#160;the technologies or processes used to formulate or manufacture those products may now, or in the future, infringe the patent rights of third parties. It is also possible that third parties will obtain patent or other proprietary rights that might be necessary or useful for the development, manufacture or sale of our products. We may need to obtain licenses for intellectual property rights from others and may not be able to&#160;obtain these licenses on commercially reasonable terms, if at all.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent's claims narrowly or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question with a detrimental impact on our business and future revenue.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and commercialization activities, as well as any product candidates or products resulting from these activities, including Galafold or AT-GAA, may infringe or be accused of infringing one or more claims of an issued patent or may fall within the scope of one or more claims in a published patent application that may subsequently issue and to which we do not hold a license or other rights. Third parties may own or control these patents or patent applications in the U.S. and abroad. These third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we or they could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No assurance can be given that patents do not exist, have not been filed, or could not be filed or issued, which contain claims covering our product candidates, technology or methods. Because of the number of patents issued and patent applications filed in our field, we believe there is a risk that third parties may allege they have patent rights encompassing our product candidates, technology or methods.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-59-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these patents were to be asserted against us, while we do not believe that our product candidates would be found to infringe any valid claim of such patents, there is no assurance that a court would find in our favor. If we were to challenge the validity of any issued U.S. patent in court, we would need to overcome a presumption of validity that attaches to every patent. This burden is high and would require us to present clear and convincing evidence as to the invalidity of the patent's claims. There is no assurance that a court would find in our favor on infringement or validity. Furthermore, during the course of litigation, confidential information may be disclosed in the form of documents or testimony in connection with discovery requests, depositions or trial testimony. Disclosure of our confidential information and our involvement in intellectual property litigation could materially adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to avoid or settle potential claims with respect to any patent rights of third parties, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our collaborators were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. This could harm our business significantly. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference proceedings declared by the U.S. Patent and Trademark Office and opposition proceedings in the European Patent Office, regarding intellectual property rights with respect to our products and technology. Even if we prevail, the cost to us of any patent litigation or other proceeding could be substantial.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from any litigation could significantly limit our ability to continue our operations. Patent litigation and other proceedings may also absorb significant management time.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee's former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we typically require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements with Nationwide Children&#8217;s Hospital ("Nationwide Children&#8217;s") and University of Pennsylvania ("Penn") pursuant to which we license key intellectual property relating to our gene therapy product candidates. We expect to enter into additional licenses in the future. Our existing licenses impose, and we expect that future licenses will impose, various diligences, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license, in which event we might not be able to market any product that is covered by the licensed patents.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-60-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our gene therapy product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries, especially in the gene therapy field, are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions. We are aware of companies focused on developing gene therapies in various indications as well as several companies addressing other methods for delivering or modifying genes and regulating gene expression. Any advances in gene therapy technology made by a competitor may be used to develop therapies that could compete against any of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our own patents, we have acquired licenses to certain patent rights and proprietary technology from third parties, including our current partners at Nationwide Children&#8217;s and Penn, that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product and product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-61-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The novel coronavirus ("COVID-19") pandemic and efforts to reduce its spread may negatively impact our business and operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has substantially burdened healthcare systems worldwide which may impact progression of our clinical trials, development and manufacturing of our product and product candidates and continued commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Required inspections and reviews by regulatory agencies may also be delayed due to the focus of resources on COVID-19 as well as travel and other restrictions. Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize some assets in our product pipeline. Lack of normal access by patients to the healthcare system, along with concern about the continued supply of medications, may result in changes in buying patterns throughout the supply chain, including by patients, which could increase or decrease demand for our products. Similarly, we have temporarily halted in-person interactions by our employees with healthcare providers, which may decrease demand for our products. COVID-19 could also have an adverse impact on our supply chain and distribution systems, which could impact our ability to distribute our products and the ability of third parties on which we rely to fulfill their obligations to us, increase our expenses and have a material adverse effect on our ability to generate revenue. In addition, the conditions created by the pandemic may intensify other risks inherent in our business, including, among other things, risks related to drug pricing and access, intellectual property protection, product safety and efficacy concerns, product liability and other litigation, and the impact of adverse global and local economic conditions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, while the financial impact on us has not been material to date, given the rapid and evolving nature of the virus, COVID-19 could negatively affect our results of operations, financial condition, liquidity and cash flows in future periods, perhaps materially. The degree to which COVID-19 affects us will depend on developments that are highly uncertain and beyond our knowledge or control, including, but not limited to, the duration and severity of the pandemic, the actions taken to reduce its transmission, and the speed with which, and extent to which, more stable economic and operating conditions resume. Should the COVID-19 pandemic and any associated mitigation measures, recession or depression continue for a prolonged period, our results of operations, financial condition, liquidity, and cash flows could be materially impacted by lower revenues and profitability and a lower likelihood of effectively and efficiently developing and launching new products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employment, Environmental, Social and Governance Matters</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on John F. Crowley, our Chairman and Chief Executive Officer, Bradley&#160;L. Campbell, our President and Chief Operating Officer, and Daphne Quimi, our Chief Financial Officer. These executives each have significant pharmaceutical industry experience. The loss of the services of any of these executives might impede the achievement of our research, development and commercialization objectives and materially adversely affect our business and we may not be able to replace these executives with candidates with similar background and experience in the event of the loss of their services. We do not maintain "key person" insurance on Mr.&#160;Crowley or on any of our other executive officers.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical and sales and marketing personnel will also be critical to our success, including for our Global Headquarters in Philadelphia. In addition, maintaining a qualified finance and legal department is key to our ability to meet our regulatory obligations as a public company and important in any potential capital raising activities. Our industry has experienced a high rate of turnover in recent years. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel, particularly in New Jersey and Philadelphia and their surrounding areas. Although we believe we offer competitive salaries and benefits, we may have to increase spending in order to retain personnel. If we fail to retain our remaining qualified personnel or replace them when they leave, we may be unable to recruit replacements nor continue our development and commercialization activities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-62-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had 496 full-time employees. As our development and commercialization strategies develop, we will need additional managerial, operational, sales, marketing, financial, technical operations and other resources. Our management, personnel and systems currently in place may not be adequate to support this future growth. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our existing or future product candidates and we may not be able to replace key personnel in the event of turnover. Future growth would impose significant added responsibilities on members of management, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing the development and commercialization of any product candidates approved for marketing;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">overseeing our ongoing preclinical studies and clinical trials effectively;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">identifying, recruiting, maintaining, motivating and integrating additional employees, including any sales and marketing personnel engaged in connection with the commercialization of any approved product;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing our collaboration partners and associated joint steering committees;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing any clinical or commercial collaborations with third parties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">improving our managerial, development, operational and financial systems and procedures;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">monitoring and improving diversity, inclusion and pay-equity initiatives;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developing our compliance infrastructure and processes to ensure compliance with regulations applicable to public companies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developing biologics and gene therapy manufacturing expertise; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expanding our facilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in fraudulent conduct, harassment or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">FDA or similar regulations of foreign regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacturing standards;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal and state healthcare fraud and abuse laws and regulations, anti-bribery and corruption laws, anti-discrimination and harassment laws, privacy and similar laws and regulations established and enforced by foreign regulatory authorities; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">laws that require the reporting of financial information or data accurately.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-63-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, bribery and corruption and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, a robust Enterprise Risk Management Program, and conduct comprehensive training, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our enterprise risk program, global risk committee and other compliance methods are not effective, our business, financial condition and operating results may be adversely affected</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to identify, manage and respond to the various risks related to our business is largely dependent on our established and maintained compliance, risk, audit and reporting systems and procedures. The Board of Directors has ultimate responsibility for risk oversight of the Company and carries out this duty through its Committees. Our Audit and Compliance Committee, Nominating and Corporate Governance Committee, Compensation and Leadership Development Committee and Science and Technology Committee have each been delegated oversight authority by the Board of Directors with respect to issues in their applicable areas of expertise. These committees are responsible for identifying, monitoring and reporting areas of concern to the full Board of Directors. At the Company level, our senior management team similarly monitors risk through the Global Risk Committee, which is co-chaired by our Chief Compliance Officer and President and Chief Operating Officer. Membership of the Global Risk Committee consists primarily of key department heads who are asked to bring to such committee relevant items for discussion that they or their teams have identified at the numerous sub-committees these individuals chair or attend. The Global Risk Committee then uses this information to develop an Enterprise Risk Management Program, which identifies key risks and mitigation strategies and which is reported directly to the Audit and Compliance Committee on a quarterly basis, and to the full Board of Directors on a yearly basis. Our international business segment also has its own companion committee which operates in substantially the same way as the Global Risk Committee and reports key risks to the Global Risk Committee for inclusion in the Enterprise Risk Management Program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our policies, procedures, and compliance systems, including our Enterprise Risk Management Program and the Global Risk Committee are not effective, or if we are not successful in monitoring or evaluating the risks to which we are or may be exposed, our business, reputation, financial condition and operating results could be materially adversely affected. We cannot provide assurance that our policies and procedures will always be effective, or that our management, the Enterprise Risk Management Program or the Global Risk Committee would be able to identify any such ineffectiveness. If our compliance and risk management strategies are not effective, our business, financial condition and operating results may be adversely affected.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and reputation may be adversely affected by environmental, social and governance matters.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies are being increasingly judged by not just their financial performance, but also by their performance on a variety of environmental, social and governance (&#8220;ESG&#8221;) matters. These matters include, among others, (i) the company&#8217;s efforts and contributions to or impacts on climate change and human rights matters, (ii) ethics and compliance with law, (iii) diversity and inclusion, and (iv) the role of the company&#8217;s board of directors in supervising various sustainability issues. Additionally, in the healthcare, pharmaceutical and life sciences industries, the public&#8217;s ability to access our medicines is of particular importance.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in funds that specialize in companies that perform well in ESG assessments are increasingly popular, and major institutional investors and advisors have publicly emphasized the importance of ESG measures to their investment decisions and recommendations. Investors who are focused on ESG matters may seek enhanced ESG disclosures or to implement policies adverse to our business, and there can be no assurances that stockholders will not advocate, via proxy contests, media campaigns or other public or private means, for us to make corporate governance changes or engage in certain corporate actions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-64-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there can be no certainty that we will successfully navigate or manage ESG issues or that we will successfully meet society&#8217;s expectations as to our proper role in the economy at large or as a global citizen. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation with governments, customers, employees, other third parties and the communities and industries in which we operate and on our business, share price, financial condition, access to capital or results of operations, including the sustainability of our business over time.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of computer system failures or security breaches.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems, and those of our CROs, contract manufacturing organizations and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, security breaches, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations and could result in a material disruption of our clinical activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our commercialization of our product and our product candidate development programs. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruptions or security breach were to result in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur significant unexpected losses, expenses and liabilities, we could face litigation or suffer reputational harm and the further development of our product candidates could be delayed.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire or divest assets or businesses, or form collaborations or make investments in other companies or technologies that could harm our operating results, dilute our stockholders' ownership, increase our debt, or cause us to incur significant expense.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may continue to pursue acquisitions or licenses of assets or businesses, or strategic alliances and collaborations, to expand our existing technologies and operations, such as our acquisition of Celenex in 2018 and the research collaboration with Penn to develop gene therapies in 2018 and expanded in 2019. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any such transaction, any of which could have a detrimental effect on our financial condition, results of operations, and cash flows. We may not be able to find suitable acquisition or licensing candidates, and if we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business and we may incur additional debt or assume unknown or contingent liabilities in connection therewith. Integration of an acquired company or assets may also disrupt ongoing operations, require the hiring of additional personnel and the implementation of additional internal systems and infrastructure, especially the acquisition of commercial assets, and require management resources that would otherwise focus on developing our existing business. We may not be able to find suitable collaboration partners or identify other investment opportunities, and we may experience losses related to any such investments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions, licenses or collaborations, we may choose to issue debt or shares of our common stock as consideration. Any such issuance of shares would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other assets or companies or fund a transaction using our stock as consideration. Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may divest or license all or a portion of certain businesses and/or facilities, joint venture or minority equity investment interests, subsidiaries, distributorships, or product categories, which could cause a decline in revenue or profitability and may make our financial results more volatile. We may be unable to complete any such divestiture or license on terms favorable to us, within the expected timeframes, or at all. We may have continued financial exposure to divested or licensed businesses following the completion of any such transaction, including increased costs due to potential litigation, contingent liabilities and indemnification of the buyer or licensee related to, among other things, lawsuits, regulatory matters or tax liabilities. Such divestitures or licenses may also divert management&#8217;s attention from our core businesses and lead to potential issues with employees, customers or suppliers.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-65-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish a classified board of directors, and, as a result, not all directors are elected at one time;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit the manner in which stockholders can remove directors from our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit who may call stockholder meetings;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize our board of directors to issue preferred stock, without stockholder approval, which could be used to institute a "poison pill" that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require the approval of the holders of at least 67% of the outstanding voting stock to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is highly volatile and may be subject to wide fluctuations in response to numerous factors, some of which are beyond our control. In addition to the factors discussed in this Annual Report on Form&#160;10-K, these factors include:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory actions with respect to our product or product candidates or our competitors' products or product candidates;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome of any patent infringement or other litigation that may be brought against us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results of clinical trials of our product candidates or those of our competitors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory or legal developments in the E.U., U.K., U.S. and other countries;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-66-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of expenses related to our product or any of our product candidates or clinical development programs;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated variations in our quarterly operating results;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and characteristics of our efforts to in-license or acquire additional product candidates or products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">introduction of new products or services by us or our competitors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of our common stock by us, our insiders or our other stockholders;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in accounting practices;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lawsuits and other claims asserted against us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic, industry and market conditions;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">publication of research reports about us, our competitors or our industry, or positive or negative recommendations or withdrawal of research coverage by securities or industry analysts;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">other events or factors, many of which are beyond our control; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the other factors described in this "Risk Factors" section.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks stated above could have a material adverse effect on the market price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we operate in the pharmaceutical and biotechnology industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-67-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares may be sold into the market. This could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain holders of our common stock have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also have registered on a Form&#160;S-8 registration statement all shares of common stock that we may issue under our equity compensation plans. As a result, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. In addition, certain of our employees, executive officers and directors have entered into, or may enter into, Rule&#160;10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule&#160;10b5-1 plan, a broker executes trades pursuant to parameters established by the employee, director or officer when entering into the plan, without further direction from the employee, officer or director. A Rule&#160;10b5-1 plan may be amended or terminated in some circumstances. Our employees, executive officers and directors may also buy or sell additional shares outside of a Rule&#160;10b5-1 plan when they are not in possession of material, nonpublic information. Finally, in September 2021, we entered into a securities purchase agreement an investor for the private placement of, among other things, pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. Each pre-funded warrant has an initial exercise price of $0.01 per share and is exercisable at any time after its original issuance at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds of the initial exercise price for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to qualify for continued listing on The NASDAQ Global Market which could make it more difficult for investors to sell their shares.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on The NASDAQ Global Market, or NASDAQ. As a NASDAQ listed company, we are required to satisfy the continued listing requirements of NASDAQ for inclusion in the Global Market to maintain such listing, including, among other things, the maintenance of a minimum closing bid price of $1.00 per share and stockholders' equity of at least $10.0&#160;million. There can be no assurance that we will be able to maintain compliance with the continued listing requirements or that our common stock will not be delisted from NASDAQ in the future. If our common stock is delisted by NASDAQ, we could face significant material adverse consequences, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a limited availability of market quotations for our securities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced liquidity with respect to our securities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a determination that our shares are a "penny stock," which will require brokers trading in our shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a limited amount of news and analyst coverage for our company; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a decreased ability to issue additional securities or obtain additional financing in the future.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports or publish unfavorable research about our business, the price of our common stock and trading volume could decline.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If securities or industry analysts do not initiate or continue coverage of us, the trading price for our common stock would be negatively affected. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our common stock, the price of our common stock would likely decline. If one or more of these analysts ceases to cover us or fails to publish regular reports on us, interest in the purchase of our common stock could decrease, which could cause the price of our common stock or trading volume to decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-68-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have broad discretion in the use of our cash and cash equivalents, and investors must rely on the judgment of our management regarding the use of our cash and cash equivalents. Our management may not use cash and cash equivalents in ways that ultimately increase the value of your investment. Our failure to use our cash and cash equivalents effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product and product candidates. Pending their use, we may invest our cash and cash equivalents in short-term or long-term, investment-grade, interest-bearing securities. These investments may not yield favorable returns. If we do not invest or apply our cash and cash equivalents in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause the price of our common stock to decline.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be obtained or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation may adversely affect our business, financial condition, results of operations or liquidity.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to the risk of litigation by employees, consumers, vendors, competitors, intellectual property rights holders, shareholders, government agencies and others through private actions, class actions, administrative proceedings, regulatory actions, Hatch-Waxman or other litigation. For example, we and certain of our current and former officers have previously been parties to securities class action lawsuits against us, all of which have been settled or dismissed. The outcome of litigation, particularly class action lawsuits, regulatory actions and intellectual property claims, is difficult to assess or quantify. Plaintiffs in these types of lawsuits may seek recovery of very large or indeterminate amounts, and the magnitude of the potential loss relating to these lawsuits may remain unknown for substantial periods of time. In addition, certain of these lawsuits, if decided against us or settled by us, may result in liability material to our Consolidated Financial Statements as a whole or may negatively affect our operating results if changes to our business operation are required. The cost to defend litigation may be significant. There also may be adverse publicity associated with litigation that could negatively affect customer perception of our business, regardless of whether the allegations are valid or whether we are ultimately found liable. As a result, litigation may adversely affect our business, financial condition, results of operations or liquidity.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be exposed to employment-related claims and losses which could have an adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to increase the size of our workforce, the risk of potential employment-related claims will also increase. As such, we may be subject to claims, allegations or legal proceedings related to employment matters including, but not limited to, discrimination, harassment (sexual or otherwise), wrongful termination or retaliation, local, state or federal labor law violations, injury, and wage violations. In the event we are subject to one or more employment-related claims, allegations or legal proceedings, we may incur substantial costs, losses or other liabilities in the defense, investigation, settlement or other disposition of such claims. In addition to the economic impact, we may also suffer reputational harm as a result of such claims, allegations and legal proceedings and the investigation, defense and prosecution of such claims, allegations and legal proceedings could cause substantial disruption in our business and operations. While we do have policies and procedures in place to reduce our exposure to these risks, there can be no assurance that such policies and procedures will be effective or that we will not be exposed to such claims, allegations or legal proceedings.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-69-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_25"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains information about our current significant leased properties as of December 31, 2021. </span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"></td><td style="width:38.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Square Feet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Use</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease expiry date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philadelphia, Pennsylvania, U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2044</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marlow, United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Princeton, New Jersey, U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2022</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;margin-top:1pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Includes renewal options on leases which we are reasonably certain to exercise.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, we also maintain offices in other U.S. and international jurisdictions in which we operate. We believe that our current office and laboratory facilities are adequate and suitable for our current and anticipated needs. We believe that, to the extent required, we will be able to lease or buy additional facilities at commercially reasonable rates.</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_28"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_31"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-70-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_37"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market for Our Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been traded on the NASDAQ Global Market under the symbol "FOLD" since May&#160;31, 2007. Prior to that time, there was no public market for our common stock. The closing price for our common stock as reported by the NASDAQ Global Market on February&#160;15, 2022 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.56</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share. As of February&#160;15, 2022, there were 20 holders of record of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our capital stock. We currently intend to retain any future earnings to finance the development and growth of our business. We do not intend to declare or pay cash dividends to our stockholders in the foreseeable future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph compares the cumulative total return on our common stock during the last five fiscal years with the NASDAQ Composite Index (U.S.) and the NASDAQ Biotechnology Index during the same period. The graph shows the value at the end of each of the last five fiscal years, of $100 invested in our common stock. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><img src="fold-20211231_g1.jpg" alt="fold-20211231_g1.jpg" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:654px"/></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:24.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amicus Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$290</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$193</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$196</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$465</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$232</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NASDAQ Composite</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$123</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$167</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$239</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$291</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NASDAQ Biotechnology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$121</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$137</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$172</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$171</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-71-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information with respect to purchase of our common stock during the three months ended December 31, 2021:</span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 1, 2021 through October 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 1, 2021 through November 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1, 2021 through December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock awards.</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_40"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;[RESERVED]</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_43"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio of product opportunities including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). We are committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of our portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of our pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, clinical-stage, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, we announced, with ARYA Sciences Acquisition Corp IV ("ARYA"), a special purpose acquisition company (or "SPAC"), sponsored by Perceptive Advisors, we have agreed to mutually terminate the previously announced definitive business combination agreement, originally executed in September 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in September 2021, we entered into securities purchase agreements with certain investors for the private placement of an aggregate of 11,296,660 shares of our common stock, at a purchase price of $10.18 per share, and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. The net proceeds from these private placements were approximately $199.8 million. We expect to use the net proceeds to further fund initiatives in the global commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the anticipated global launch of AT-GAA and to further support our discovery work on next generation therapies in Fabry and Pompe diseases.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-72-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have not been significantly impacted from the novel coronavirus (&#8220;COVID-19&#8221;) pandemic to date. However, we observed increased lag times between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiation due to the resurgence of COVID-19 in 2021. We have maintained operations in all geographies, secured our global supply chain for our commercial and clinical products, as well as maintained the operational integrity of our clinical trials, with minimum disruptions. Our ability to continue to operate without any significant disruptions will depend on the continued health of our employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the continued operation of our global supply chain. We have continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of our global workforce. However, our results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-73-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Results of Operations</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with the Consolidated Financial Statements and related notes included elsewhere in this report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following section generally discusses 2021 and 2020 items and year-to-year comparisons between 2021 and 2020. Discussions of 2019 items and year-to-year comparisons between 2020 and 2019 that are not included in this Form 10-K can be found in Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which comparisons are hereby incorporated by reference.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December 31, 2021 Compared to Year Ended December 31, 2020 </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected financial information for the Company:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:57.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of goods sold as a percentage of net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(36,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,637)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(10,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(781)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,598)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,460)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,852)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,392&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales increased $44.6 million during the year ended December 31, 2021 compared to the prior year. The increase was primarily due to continued growth in the Europe, U.S. and Japan markets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-74-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal product development programs for each product candidate in development, and the out-of-pocket, third-party expenses incurred with respect to each product candidate:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:66.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Projects</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party direct project expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Fabry Disease)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AT-GAA (Pompe Disease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gene therapy programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical and other programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total third-party direct project expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other project costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other project costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,697&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,096&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $36.4 million decrease in research and development costs was primarily due to the decrease in gene therapy programs driven by timing of spend for manufacturing costs, a decrease in personnel costs primarily due to realignment with strategic priorities and the timing of clinical research and manufacturing costs associated with the advancement in the Pompe disease program.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expense increased $36.3 million, mainly driven by increased personnel costs and third-party professional fees.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Fair Value of Contingent Consideration Payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Changes in fair value of contingent consideration payable increased $3.4&#160;million during the year ended December 31, 2021.  The increase was primarily due to achievement of two regulatory milestones during the year ended December 31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense increased $10.0 million during the year ended December 31, 2021. The increase was driven by the $400 million Senior Secured Loan due 2026 entered in July 2020. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Extinguishment of Debt. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July of 2020, the Company voluntarily settled the principal amount, accrued interest, and early settlement premiums of the Senior Secured Term Loan with BioPharma Credit PLC. As a result of this early extinguishment, a loss on extinguishment of debt of $7.3 million was recognized in the Consolidated Statements of Operations, compared to a loss of $0.3 million associated with the voluntary full settlement of the 2023 Convertible Debt in August 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the year ended December 31, 2021 was $8.9 million. We are subject to income taxes in various jurisdictions. Our tax liabilities are largely dependent on the distributions of pre-tax earnings among the many jurisdictions in which we operate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-75-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP"). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the following discussion represents our critical accounting policies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of Fabry disease. We have recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are generally received from distributors and pharmacies with the ultimate payor often a government authority.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when our performance obligation with our customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in our customer contracts and is recorded net of estimates for variable consideration, which are third-party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is recognized. We recognize revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. We evaluate these estimates each reporting period to reflect known changes.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our Consolidated Financial Statements, we are required to estimate and accrue our research and development expenses, including those related to clinical studies and drug manufacturing. This process involves reviewing contracts and purchase orders, identifying services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for preclinical studies, clinical studies and manufacturing activities are recognized based on an evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as clinical site activations, clinical site maintenance, clinical site close out, patient out of pocket cost reimbursements, or information provided to us by our vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed. We determine accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-76-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="text-align:justify;text-indent:27.8pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Grants</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the applicable accounting guidance, we estimate the fair value of each equity award granted. We chose the "straight-line" attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007. We determine the average expected life using our actual historical data. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on historical analysis of actual option forfeitures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the plan are generally subject to graded vesting and are contingent on an employee's continued service on such date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We expense the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. In addition, certain of our share-based awards are market- and performance-based and dependent upon achieving certain goals. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized on a straight-line basis over the vesting term. With respect to performance-based awards, we estimate the probability that the performance conditions will be achieved. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased in-process research and development ("IPR&amp;D") is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. A goodwill impairment loss, if any, is measured as the amount by which our single reporting unit's carrying value, including goodwill, exceeds its fair value.  An IPR&amp;D impairment loss, if any, is measured as the amount by which the carrying amount of the asset exceeds its fair value.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event. For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved, and the consideration is paid or becomes payable.  Contingent consideration obligations in business acquisitions are rerecorded at fair value on the acquisition date. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of contingent consideration obligations through a probability weighted discounted cash flow valuation approach based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Each period we reassess the fair value of the contingent consideration payable and recognize changes within the Consolidated Statements of Operations. Changes in the fair value of the contingent consideration payable can result from changes in estimated probability adjustments with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Significant judgment is employed in determining the appropriateness of these assumptions each period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described in the accounting for business combinations above can materially impact the amount of contingent consideration expense that we record and, therefore, our results of operations in any given period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-77-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our significant research and development expenditures, as well as expenditures to build a commercial organization to support the launch of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have not been profitable and have generated operating losses since we were incorporated in 2002. We have historically funded our operations through stock offerings, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, debt issuance, collaborations, and other financing arrangements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into securities purchase agreements with certain investors for the private placement of an aggregate of 11,296,660 shares of our common stock, at a purchase price of $10.18 per share, and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. The net proceeds from these private placements were approximately $199.8 million. We expect to use the net proceeds to further fund initiatives in the global commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the anticipated global launch of AT-GAA and to further support our discovery work on next generation therapies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into the Senior Secured Term Loan due 2026. This transaction resulted in net proceeds of $385.9 million, after deducting fees and expenses. There were no warrants or equity conversion features associated with the Senior Secured Term Loan due 2026. Additionally, we used $156.3 million of the proceeds to voluntarily settle the principal amount, accrued interest, and early settlement premiums of the Senior Secured Term Loan with BioPharma Credit PLC. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow Discussion</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had cash, cash equivalents, and marketable securities of $482.5 million. We invest cash in excess of our immediate requirements in regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such cash balances. For more details on the cash, cash equivalents, and marketable securities, refer to "&#8212; Note 4.&#160;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash," in our Notes to Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations for the year ended December 31, 2021 was $202.5 million. The components of net cash used in operations included the net loss for the year ended December 31, 2021 of $250.5 million and the net change in operating assets and liabilities of $28.9 million. The change in operating assets was primarily due to increases in accounts receivable by $8.2 million due to increased commercial sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an increase in inventory of $7.8 million, and increase in prepaid and other current assets of $5.9 million to support commercial activities for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The net cash used in operations was also impacted by an </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in accounts payable and accrued expenses of $7.4 million, mainly related to program expenses and support for the commercial activities of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, decrease due to payment of contingent consideration of $10.4 million associated with meeting certain regulatory milestones during the year, and a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in deferred reimbursement of $1.5 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations for the year ended December 31, 2020 was $233.3 million. The components of net cash used in operations included the net loss for the year ended December 31, 2020 of $276.9 million, and the net change in operating assets and liabilities of $32.1 million. The change in operating assets was primarily due to increases in accounts receivable by $11.2 million due to increased commercial sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an increase in inventory of $4.6 million, and increase in prepaid and other current assets of $8.8 million to support commercial activities for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> launch. The net cash used in operations was also impacted by a decrease in accounts payable and accrued expenses of $10.6 million, mainly related to program expenses and support for the commercial launch of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and decrease in deferred reimbursement of $1.3 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-78-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by (Used in) Investing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December 31, 2021 was $78.8 million. Our investing activities have consisted primarily of purchases, sales, and maturities of investments and capital expenditures. Net cash provided by investing activities reflects $424 million for the sale and redemption of marketable securities, partially offset by $341.4 million for the purchase of marketable securities and $3.9 million for capital expenditures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December 31, 2020 was $13.6 million. Our investing activities have consisted primarily of purchases, sales, and maturities of investments and capital expenditures. Net cash used in investing activities reflects $365.2 million for the purchase of marketable securities and $3.2 million for capital expenditures, partially offset by $354.8 million for the sale and redemption of marketable securities </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2021 was $212.1 million. Net cash provided by financing activities primarily reflects $199.8 million in net proceeds from the September 2021 private placement of securities, $19.2 million from the exercise of warrants and $10.2 million from the exercise of stock options, partially offset by $15 million from payments of employee withholding taxes related to restricted stock unit vesting.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2020 was $262.9 million. Net cash provided by financing activities primarily reflects $385.9 million in proceeds from the Senior Secured Term Loan due 2026, net of issuance costs, and $42.3 million from the exercise of stock options. This was partially offset by $155.2 million for the voluntary settlement of the Senior Secured Term Loan with BioPharma Credit PLC, and $10.0 million from the purchase of vested restricted stock units.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur losses from operations for the foreseeable future primarily due to research and development expenses, including expenses related to conducting clinical trials.&#160;Our future capital requirements will depend on a number of factors, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our clinical trials of our drug candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing drug supply for our commercial, clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200" or "cipaglucosidase alfa");</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future results of preclinical research and subsequent clinical trials for pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize these therapies and obtain market acceptance for such therapies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in regulatory standards relating to the review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we pursue;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat HCl") and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain reimbursement for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, if approved and applicable, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-79-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims, including Hatch-Waxman litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of litigation that has been or may be brought against us or of litigation that we are pursuing or may pursue against others;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate our acquired products and technologies into our business, or successfully divest or license existing products and technologies from our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish licensing agreements, collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our business could be adversely impacted by the effects of the novel coronavirus ("COVID-19") outbreak, including due to actions by us, governments, our customers, our suppliers, or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with, and our ability to comply with, emerging environmental, social and governance standards;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to accurately forecast revenue, operating expenditures, or other metrics impacting profitability;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to generate revenue from product sales, in the absence of additional funding, we expect our continuing operating losses to result in increases in our cash used in operations over the next several quarters and years. We may seek additional funding through public or private financings of debt or equity. Based on our current operating model, we believe that the current cash position, which includes expected revenues, and net proceeds from the September 2021 private placement of securities, is sufficient to fund our operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, remaining maturities, including interest, on our Senior Secured Term Loan due 2026 was $509.0 million. Refer to "&#8212; Note 11. Debt," to the Consolidated Financial Statements for more information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are lessees to various operating leases for facilities and equipment. As of December 31, 2021, our undiscounted cash liabilities for operating leases were $188.2 million, with maturities ranging up through fiscal 2044. Refer to &#8220;&#8212; Note 12. Leases,&#8221; to the Consolidated Financial Statements for more information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of binding minimum purchase and manufacturing commitments due to our third-party manufacturers. As of December 31, 2021, these purchase and manufacturing obligations totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$49.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Contracts for which our commitment is variable, based on volumes, with no fixed minimum quantities, and contracts that can be canceled without payment penalties have been excluded. These purchase obligations are in addition to amounts recorded on our December 31, 2021 consolidated balance sheet.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements as of December 31, 2021 and 2020. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milestone Payments / Royalties</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Callidus - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Callidus in 2013, we agreed to pay up to an additional $35 million in connection with the achievement of certain clinical milestones and up to $80 million in connection with the achievement of certain regulatory approval milestones. As of December 31, 2021, $20 million and $68 million remain outstanding, respectively. Refer to &#8220;&#8212; Note 10. Assets and Liabilities Measured at Fair Value,&#8221; to the Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-80-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celenex - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Celenex in 2018, we agreed to pay up to an additional $10 million in connection with the achievement of certain development milestones, $220 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nationwide Children&#8217;s Hospital -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Celenex has an exclusive license agreement with Nationwide Children's Hospital ("Nationwide Children&#8217;s"). Under this license agreement, Nationwide Children&#8217;s is eligible to receive development and sales-based milestones of up to $7.8 million from us for each product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">University of Pennsylvania</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Under our collaboration agreement with the University of Pennsylvania ("Penn"), Penn is eligible to receive certain milestone, royalty, and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $88.0 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis. We provide $10.0 million each year during the five-year agreement to fund the discovery research program, of which two years of payments remain outstanding.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In July 2012, as amended in November 2013, we entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease (&#8220;Collaboration Agreement&#8221;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to "&#8212; Note&#160;2. Summary of Significant Accounting Policies," in our Notes to Consolidated Financial Statements.</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_46"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, creditworthiness, financing, exchange rates or other factors. Our primary market risk exposure relates to changes in interest rates in our cash, cash equivalents, and marketable securities. We place our investments in high-quality financial instruments, primarily money market funds, corporate debt securities, asset backed securities, and U.S. government agency notes with maturities of less than one year, which we believe are subject to limited interest rate and credit risk. The securities in our investment portfolio are not leveraged, are classified as available-for-sale and, due to the short-term nature, are subject to minimal interest rate risk. We believe that a 1% (100 basis points) change in average interest rates would either increase or decrease the market value of our investment portfolio by $0.8&#160;million as of December 31, 2021. We currently do not hedge interest rate exposure and consistent with our investment policy, we do not use derivative financial instruments in our investment portfolio. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk with respect to variable rate debt. At December 31, 2021, we had a $400 million Senior Secured Term Loan due 2026 that bears interest at a rate equal to the 3-month LIBOR, subject to a 1% floor, plus 6.5% per year. We do not currently hedge our variable interest rate debt. The annual average variable interest rate for our variable rate debt as of December 31, 2021 was 7.5%. A hypothetical 100 basis point increase or decrease in the average interest rate on our variable rate debt would result in $4.1 million change in the interest expense as of December 31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Conduct Authority has announced the intent to phase out the use of LIBOR by mid-2023. If LIBOR is discontinued, we may need to renegotiate the terms of the Senior Secured Term Loan due 2026 in order to replace LIBOR with an alternative standard. As a result, we may incur incremental costs in transitioning to a new standard, and interest rates on our current or future indebtedness may be adversely affected by the new standard. The potential effect of any such event on our cost of capital cannot yet be determined, but we do not expect it to have a material impact on our consolidated financial condition, results of operations, or cash flows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-81-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. We are not currently engaged in any foreign currency hedging activities. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, and net product sales denominated in foreign currencies. Both positive and negative impacts to our international product sales from movements in foreign currency exchange rates may be partially mitigated by the natural, opposite impact that foreign currency exchange rates have on our international operating expenses. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-82-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Consolidated Financial Statements and</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of Amicus Therapeutics,&#160;Inc. has prepared, and is responsible for the Company's Consolidated Financial Statements and related footnotes. These Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S.&#160;GAAP").</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule&#160;13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of the Company's principal executive and principal financial officers and effected by the Company's board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S.&#160;GAAP and includes those policies and procedures that:</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of Amicus Therapeutics,&#160;Inc.;</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of Amicus therapeutics,&#160;Inc. are being made only in accordance with authorizations of management and directors of Amicus therapeutics,&#160;Inc.; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of Amicus Therapeutics,&#160;Inc. that could have a material effect on the financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) ("COSO") in Internal Control&#160;&#8212; Integrated Framework. Based on our assessment we believe that, as of December 31, 2021, our internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company's internal control over financial reporting as of December 31, 2021 has been audited by Ernst&#160;&amp; Young&#160;LLP, an independent registered public accounting firm, as stated in their report. This report appears on the following page.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated February&#160;24, 2022 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.064%"><tr><td style="width:1.0%"></td><td style="width:37.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JOHN F. CROWLEY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;DAPHNE QUIMI</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-83-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_52"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:0.05pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Amicus Therapeutics,&#160;Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, Amicus Therapeutics,&#160;Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February&#160;24, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Consolidated Financial Statements and Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.953%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  Ernst&#160;&amp; Young&#160;LLP</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iselin, New Jersey</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2022 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-84-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Amicus Therapeutics,&#160;Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February&#160;24, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-85-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the Consolidated Financial Statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:15.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement of the Contingent Consideration</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As described in Note 10 to the consolidated financial statements, the Company has a $20.3 million contingent consideration liability recorded as of December 31, 2021 representing the fair value of additional amounts that management believes are likely to be paid to the former stockholders of Callidus Biopharma, Inc. The determination of the recorded amount of the contingent consideration liabilities requires the Company to make significant estimates and assumptions.</span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We identified the measurement of the contingent consideration liability as a critical audit matter because auditing the Company&#8217;s valuation of the contingent consideration liability involved complex and challenging auditor judgment as the inputs to such valuation, such as the estimated probability of achieving milestones, the assumed timing of milestones and the discount rates, are largely unobservable. </span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To test the estimated fair value of the contingent consideration liability, we performed audit procedures that included testing the operating effectiveness of internal controls relating to management&#8217;s fair value measurement of the contingent consideration liability including controls over the Company&#8217;s model, significant assumptions, and data. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our procedures also included, among others, assessing the terms of the arrangement, evaluating the methodology used, testing the significant assumptions discussed above and the completeness, accuracy and relevance of the underlying data used by management in its analysis. We also performed analyses of certain assumptions to assess the impact of changes in certain assumptions on the Company&#8217;s determination of the fair value of the contingent consideration liability. Evaluating the assumptions also involved evaluating whether the assumptions used by management were consistent with external market data and evidence obtained in other areas of the audit.</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:0.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.953%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181NS9mcmFnOjQ0NzJjYjI0Y2I2NDQ3NDZhYmEyM2NhYWY3NTUyNTcyL3RhYmxlOjg2MWJkZjc2MWYzMjQzZTU5MTVlNTM4ZWNjNWQ1ZGQxL3RhYmxlcmFuZ2U6ODYxYmRmNzYxZjMyNDNlNTkxNWU1MzhlY2M1ZDVkZDFfMC0wLTEtMS0xOTg3Ni90ZXh0cmVnaW9uOjlhZTk0YjNlY2UzZTQ3OGNiNTczMjc2MThmZTYxOWMwXzI3NDg3NzkwNjk0ODM_bbb820ed-06db-478f-8357-dca623b103ee">Ernst&#160;&amp; Young&#160;LLP</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2003.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181NS9mcmFnOjQ0NzJjYjI0Y2I2NDQ3NDZhYmEyM2NhYWY3NTUyNTcyL3RleHRyZWdpb246NDQ3MmNiMjRjYjY0NDc0NmFiYTIzY2FhZjc1NTI1NzJfMjc0ODc3OTA3MjkzOA_ee40e853-f906-42e3-a3a9-d20c70064450">Iselin, New Jersey</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2022 </span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-86-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNC0xLTEtMS0xMDU2Mg_9ad745cb-f9b9-4a50-8d76-abbff256186b">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNC0zLTEtMS0xMDU2Mg_9625d06c-521f-42af-8f56-a127dd5d420c">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNS0xLTEtMS0xMDU2Mg_2831069d-5fae-4a8d-a41b-7f755cb99da8">237,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNS0zLTEtMS0xMDU2Mg_04ad8165-a432-4d7f-8208-96629c2faf2c">320,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNi0xLTEtMS0xMDU2Mg_df52aa41-5f4e-4ec2-a1ea-0a45d04cb2bb">52,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNi0zLTEtMS0xMDU2Mg_c75c372d-1ea0-40a8-8786-a0f83d109316">46,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNy0xLTEtMS0xMDU2Mg_bde58b82-2b2a-4bb2-be44-03cb42301646">26,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNy0zLTEtMS0xMDU2Mg_62b03aa3-1c0f-459f-bb9f-1ef01f02ebe7">19,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfOC0xLTEtMS0xMDU2Mg_7c60d2f6-3aa3-4c63-8b08-8c496c72d7f3">34,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfOC0zLTEtMS0xMDU2Mg_fb664c3b-3d7d-4b18-8c5b-13ab60a87bcd">29,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfOS0xLTEtMS0xMDU2Mg_e7b67df8-12b5-4b66-bcff-38503cc008b2">596,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfOS0zLTEtMS0xMDU2Mg_07c5ad09-59df-44f3-bddc-b0af8f02dd9b">579,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTAtMS0xLTEtMTA1NjI_13e12317-e294-4cfa-b21b-788d73fb9f50">20,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTAtMy0xLTEtMTA1NjI_393accc8-4bea-432f-ad34-f790cba7460b">23,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, less accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTEtMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjowNzliZTJjYTNjNWE0MzkyODJhNjhlMTNmMzQ3MmM2NF82MQ_d95ca163-b68c-4a26-bc3e-b02545454532">19,882</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTEtMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjowNzliZTJjYTNjNWE0MzkyODJhNjhlMTNmMzQ3MmM2NF82OA_39442663-7419-4900-aeb5-285950e86603">14,487</ix:nonFraction> at December 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTEtMS0xLTEtMTA1NjI_bccee835-d78a-4b66-945c-8a8c1635ba3b">42,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTEtMy0xLTEtMTA1NjI_33332037-40f9-47b3-8960-3e4269b98aec">43,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research&#160;&amp; development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTItMS0xLTEtMTA1NjI_c246838e-ab96-459f-9428-d88d09806542">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTItMy0xLTEtMTA1NjI_88e788f3-f1e9-4c19-aee0-9d978cb0fd95">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTMtMS0xLTEtMTA1NjI_61f9f4da-075a-4907-8341-9627aad7e34f">197,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTMtMy0xLTEtMTA1NjI_9a3ac179-082b-4dc1-9e98-9e33430a3862">197,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTQtMS0xLTEtMTA1NjI_ecf74a80-66c2-45b9-a39d-56d383727ee1">24,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTQtMy0xLTEtMTA1NjI_0de0db0f-43a8-4a8b-97bb-3c0333fae35c">19,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTUtMS0xLTEtMTA1NjI_94772685-9bf9-4af6-aaf9-8bbdccf9e96c">905,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTUtMy0xLTEtMTA1NjI_030d4b25-c13e-4ba9-92e0-5cacdb4a618c">886,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTgtMS0xLTEtMTA1NjI_ce844bcf-2433-4cbd-a735-e23c9641f1a2">21,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTgtMy0xLTEtMTA1NjI_83d1dec0-0806-43dc-a16c-50ebc6ac3981">17,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTktMS0xLTEtMTA1NjI_3bfa70fe-a366-4629-ae61-b524ce57a43d">98,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTktMy0xLTEtMTA1NjI_d3d704a9-9f73-4006-8658-accd3756671d">96,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjAtMS0xLTEtMTA1NjI_6fafe1e7-fe4e-4160-9bbd-ff537e9fdfaf">18,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjAtMy0xLTEtMTA1NjI_7b742119-5f7d-4f06-9200-6aa6c0cd3f0f">8,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjEtMS0xLTEtMTA1NjI_62c3f504-62ad-4846-9d9b-c3a7e239b124">7,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjEtMy0xLTEtMTA1NjI_a292de8e-64df-45c7-8ae2-6c30d29b3f0b">6,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjItMS0xLTEtMTA1NjI_ee0eacae-b130-45cc-ab6d-d3d5cc28578d">145,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjItMy0xLTEtMTA1NjI_1845c4dd-b844-49e5-84ad-df1922b3c586">129,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjMtMS0xLTEtMTA1NjI_7d72b251-7678-4a2f-89e7-39f95fffdcfe">5,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjMtMy0xLTEtMTA1NjI_884e2eab-e871-4493-97dc-126bad16793d">7,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjQtMS0xLTEtMTA1NjI_e5d9553a-9800-417c-8ad9-1c1e8e8d2866">389,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjQtMy0xLTEtMTA1NjI_02e682be-4f7b-4299-aa9b-800b2698bc87">389,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjUtMS0xLTEtMTA1NjI_66f0ce7b-6832-41e8-8b56-c55a88033b24">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjUtMy0xLTEtMTA1NjI_51e199f3-cafc-401b-9866-9b658cb1316e">16,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjYtMS0xLTEtMTA1NjI_9f4cec08-f0ae-4e72-b283-c31522b40d49">4,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjYtMy0xLTEtMTA1NjI_6187859e-a02a-45de-a972-cf7fc3ad600c">4,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjctMS0xLTEtMTA1NjI_0181a129-a787-4259-9dd5-b72c6447bd3f">43,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjctMy0xLTEtMTA1NjI_7ab834b0-de1d-436c-8500-d9c226e287b8">45,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjgtMS0xLTEtMTA1NjI_c1d1d931-f03d-45b2-b462-a965bb25ef63">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjgtMy0xLTEtMTA1NjI_2de2d22c-34b5-4582-8b47-3f78b1b1d57c">6,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjktMS0xLTEtMTA1NjI_9c78ac48-385e-4442-b16f-c7fac8c3cb71">597,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjktMy0xLTEtMTA1NjI_fd26a9d5-e1ec-48e7-8b3a-0f5b8080b66f">600,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzAtMS0xLTEtMTA1NjI_e0f9dd99-4193-417f-9b66-eb92ea06b1da"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzAtMy0xLTEtMTA1NjI_4ebda449-fad2-4fc4-a4d6-03d6816e3c34"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV8xOA_15b4ac42-f940-4903-9fb1-01ddd0746a01"><ix:nonFraction unitRef="usdPerShare" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV8xOA_7743eea2-d485-4568-982a-b661e4bf067a">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV8zMg_9c01dfc1-04ac-47f8-8560-a19aa48bbb48"><ix:nonFraction unitRef="shares" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV8zMg_c39cb335-c91f-4dd3-be89-024fea7ae547">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV81NA_7263a9b6-44e8-4fb2-9f50-0e32da92eba3"><ix:nonFraction unitRef="shares" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV81NA_971b0da3-87b6-4a68-87f7-d301794ebd08">278,912,800</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV82MQ_5d789d12-4034-41a1-b410-272f638b1ce8"><ix:nonFraction unitRef="shares" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV82MQ_60529c14-000b-4a65-84c9-5e11a586f3ca">262,063,461</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMS0xLTEtMTA1NjI_f5bede04-7d54-4e81-851c-a439d46b42d9">2,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMy0xLTEtMTA1NjI_91b2f44d-a291-47ba-bdb4-a515996bccaf">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzMtMS0xLTEtMTA1NjI_b8a4b9cd-a4c9-46a7-bfdd-e5b7373f8d88">2,595,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzMtMy0xLTEtMTA1NjI_18a82038-3e1b-4a00-8107-186c9e75557d">2,308,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive gain (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzUtMS0xLTEtMTA1NjI_aa1722ce-efb7-44ee-b244-f66608aa6433">5,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzUtMy0xLTEtMTA1NjI_bc8b7b5f-7be3-4748-b7a5-f9bc539a6508">8,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on available-for securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzYtMS0xLTEtMTA1NjI_1db42aaa-76b8-476e-b7a7-4561aaf1b303">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzYtMy0xLTEtMTA1NjI_c023e9be-bb35-4a53-8c65-2c0b4fc1e6d3">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzctMS0xLTEtMTA1NjI_47684e79-640e-4764-8559-1f536e0cad0e">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzctMy0xLTEtMTA1NjI_03ea7f95-9a4a-4179-8678-99febf9d8770">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzgtMS0xLTEtMTA1NjI_47b5e7ed-4bcd-495c-aacd-ca4f2e0cd9af">2,295,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzgtMy0xLTEtMTA1NjI_635bc4b5-272a-41ca-8a0f-be2036fb09b8">2,045,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzktMS0xLTEtMTA1NjI_27544176-c980-4a0b-83dc-76e493893f3a">307,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzktMy0xLTEtMTA1NjI_81e0771c-b639-40c9-97b8-2cbef9adc3e9">286,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities and Stockholders' Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNDAtMS0xLTEtMTA1NjI_2e9cccfc-3278-42f7-a57c-f237101058ee">905,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNDAtMy0xLTEtMTA1NjI_ef17f285-27db-4b55-b0bb-586a8dadb1ea">886,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-87-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMi0xLTEtMS0xMDU2Mg_ef16f3cd-3fb3-4082-b734-4a80c751f8ff">305,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMi0zLTEtMS0xMDU2Mg_1cbc33c5-2b52-44ba-951d-f9d0488d8b53">260,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMi01LTEtMS0xMDU2Mg_65e7d822-d534-4291-ba9e-ab38335cba29">182,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMy0xLTEtMS0xMDU2Mg_a09da487-d708-412e-bb76-4ac469d745e7">34,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMy0zLTEtMS0xMDU2Mg_61dd5305-837a-41dd-b4d1-1a0a7d3d4f9b">31,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMy01LTEtMS0xMDU2Mg_ce9001d8-9623-47b6-a9d5-9cf1793d3cda">21,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNC0xLTEtMS0xMDU2Mg_74a2b0e0-6609-4c04-a35c-f7f56d676f0c">271,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNC0zLTEtMS0xMDU2Mg_c7f20b5b-c8a3-4d1a-8f3a-83601332dd68">229,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNC01LTEtMS0xMDU2Mg_a2ee0b30-6eee-4419-abf9-01b16755f928">160,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNi0xLTEtMS0xMDU2Mg_f2f1f776-e4d8-496d-ac7e-1e52ff13bb49">272,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNi0zLTEtMS0xMDU2Mg_5eaf89d4-0582-46b7-85d3-aa6b22e6d563">308,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNi01LTEtMS0xMDU2Mg_309f810c-2ea4-4e6f-a995-36c77ce3f82e">286,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNy0xLTEtMS0xMDU2Mg_f277fc5a-eaa1-4e48-b48c-a5b732f5fb97">192,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNy0zLTEtMS0xMDU2Mg_1d2f0c22-7e48-4d2e-b708-1b6a91822d9e">156,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNy01LTEtMS0xMDU2Mg_bb997386-f1bf-4643-90cd-b93fa02fcdc9">169,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOC0xLTEtMS0xMDU2Mg_e3a83433-cc11-446a-9cdc-0a175007083c">6,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOC0zLTEtMS0xMDU2Mg_324e5309-4df6-4a51-ae72-22f8fbfd1be5">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOC01LTEtMS0xMDU2Mg_c52b1f7f-a7e0-4cff-99e4-f1641d6d9e13">3,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOS0xLTEtMS0xMDU2Mg_7cd21738-3511-49b5-9353-922124a070f7">6,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOS0zLTEtMS0xMDU2Mg_06f5df84-7c02-4aa0-ac45-25e0065fe4ff">8,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOS01LTEtMS0xMDU2Mg_5ba19e07-e4a2-4099-bd20-f1e95feb1d21">4,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTAtMS0xLTEtMTA1NjI_bc8ae2a2-ba28-42ae-8c0d-c21e58bf7592">477,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTAtMy0xLTEtMTA1NjI_c947045c-3e00-42b4-a6a0-6594c2b95dd8">476,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTAtNS0xLTEtMTA1NjI_1c92e66d-3cfe-4c47-9799-0583840b4211">464,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTEtMS0xLTEtMTA1NjI_d53cc99c-1728-47a5-838b-a7323faf6f05">206,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTEtMy0xLTEtMTA1NjI_8c125a04-bc5c-4818-8e2b-9211c23ebfda">246,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTEtNS0xLTEtMTA1NjI_c306948d-c5d0-4714-adcd-082a04f9202e">304,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTMtMS0xLTEtMTA1NjI_4d3e88e6-fed6-414e-9920-ed058351a458">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTMtMy0xLTEtMTA1NjI_74723a17-6a12-4186-9786-8410251b2efd">3,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTMtNS0xLTEtMTA1NjI_46b2b147-b8f2-49e7-b880-2557686d1905">10,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTQtMS0xLTEtMTA1NjI_a8174f3c-1350-4337-9236-b2ceabc3bedc">32,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTQtMy0xLTEtMTA1NjI_2f0b6ac2-6432-4c1d-bb6a-38d933f6afe8">22,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTQtNS0xLTEtMTA1NjI_84002f13-24ac-4527-8f2c-5f863c99027e">18,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on exchange of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="fold:GainLossOnExchangeOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTUtMS0xLTEtMTA1NjI_a6d5ebae-1cb2-44b6-9db2-86382c040a12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="fold:GainLossOnExchangeOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTUtMy0xLTEtMTA1NjI_709e6744-ba2f-4f35-a07e-1c51a38eb6a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="fold:GainLossOnExchangeOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTUtNS0xLTEtMTA1NjI_aacee89e-b51c-4ed4-9989-cd05ea06de8e">40,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTYtMS0xLTEtMTA1NjI_ca95a2c8-fbc1-4494-858b-8ac3ae4b9f4b">257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTYtMy0xLTEtMTA1NjI_269aed97-dc48-4610-a90b-0127db92954d">7,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTYtNS0xLTEtMTA1NjI_04398041-7eac-462a-a70e-63367367042e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTgtMS0xLTEtMTA1NjI_2744d1bf-0133-47d1-8e4c-c637865ea134">2,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTgtMy0xLTEtMTA1NjI_71e6f9ec-b001-4c54-af0c-d72e8f99a7be">781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTgtNS0xLTEtMTA1NjI_f2b90097-a4ee-4d56-80e0-e3ba1ded2b87">2,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTktMS0xLTEtMTA1NjI_ded1a9df-d032-4353-ab41-de3578c57e6d">241,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTktMy0xLTEtMTA1NjI_58b8c412-f413-4a02-937b-5dbebe56cbd7">274,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTktNS0xLTEtMTA1NjI_1c7a9853-e56f-4b66-8f86-05c61473edbb">355,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjAtMS0xLTEtMTA1NjI_4994ec6b-df6d-422d-bc0f-5f0675e464f6">8,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjAtMy0xLTEtMTA1NjI_64e8ddb6-8d0d-42fc-810a-8ca09c414c4b">2,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjAtNS0xLTEtMTA1NjI_ed65873b-d004-4c52-8b2c-173f460662e4">478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjEtMS0xLTEtMTA1NjI_f431c726-9191-4225-92ea-a7b018de1b2a">250,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjEtMy0xLTEtMTA1NjI_1d484c12-893a-4877-ad12-67b366f2eaca">276,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjEtNS0xLTEtMTA1NjI_12893a33-8114-4250-aaf8-0a0c00df15e4">356,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders per common share&#160;&#8212; basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItMS0xLTEtMTA1NjI_5ece9cad-7d75-4ab5-8160-1d004ef5aba9"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItMS0xLTEtMTA1NjI_dcb39d0f-4ae9-4c0b-8ceb-07a99d078163">0.92</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItMy0xLTEtMTA1NjI_ce055133-2374-43e8-b87b-7affcde74783"><ix:nonFraction unitRef="usdPerShare" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItMy0xLTEtMTA1NjI_eb44722a-9fb3-4143-a11b-75197d6fa094">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItNS0xLTEtMTA1NjI_1d911fbb-bb7e-4082-8cd1-d5a1bd00d742"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItNS0xLTEtMTA1NjI_b6eec001-7479-4fe0-9773-75c0d7fa235a">1.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtMS0xLTEtMTA1NjI_c4f03da6-fd79-4db6-9d8c-3181219a12cc"><ix:nonFraction unitRef="shares" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtMS0xLTEtMTA1NjI_cf3fc10d-ff35-4d59-a8fe-ca65e1e7dea1">271,421,986</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtMy0xLTEtMTA1NjI_a1e2eeb4-dd4b-4f1e-9f70-ea1e71cfbe50"><ix:nonFraction unitRef="shares" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtMy0xLTEtMTA1NjI_c9884a9f-0689-4695-a881-952166d78014">258,867,380</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtNS0xLTEtMTA1NjI_3e7e2bbe-450a-407d-b664-c3d5c9fdbef8"><ix:nonFraction unitRef="shares" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtNS0xLTEtMTA1NjI_7dc4de5f-46bb-48db-9fbe-caaadd5d30df">240,421,001</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-88-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfMi0xLTEtMS0xMDU2Mg_5e10d2b1-349f-4bd1-a326-9b96f5e5d58e">250,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfMi0zLTEtMS0xMDU2Mg_0639bd5c-5b3f-4828-8c08-8ef02764a29e">276,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfMi01LTEtMS0xMDU2Mg_a4e79d91-cc39-4b0a-85e1-26f83f7bfe8a">356,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment (loss) gain, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOmQzMjBlZDkzZGI4ZjQ4ODViZjk3NWMzMzI0ZmQ0MWNjXzcx_8c5c33d1-9664-4de4-8b86-9ad8b22af674">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOmQzMjBlZDkzZGI4ZjQ4ODViZjk3NWMzMzI0ZmQ0MWNjXzc1_4d04ca20-f3b4-473d-9888-225515015ff1">1,552</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOmQzMjBlZDkzZGI4ZjQ4ODViZjk3NWMzMzI0ZmQ0MWNjXzgz_8adc9c9a-19c6-4d33-96c4-9c42e0643ed1">889</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0xLTEtMS0xMDU2Mg_d37c76dd-79f3-4ef0-b209-3281cb85fc2e">3,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0zLTEtMS0xMDU2Mg_361a3252-4402-4e60-94e8-d222ce469247">5,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC01LTEtMS0xMDU2Mg_a014537f-da6e-4ea3-bb96-20fb154d7e8c">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on available-for-sale securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOjNiZjg3NzljYjk0YzQzMmE4MzkyNWJhZTUxNDk2NDgyXzgy_8fae8d13-db4d-4b38-8965-bd4735601fb4">0</ix:nonFraction>, $(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOjNiZjg3NzljYjk0YzQzMmE4MzkyNWJhZTUxNDk2NDgyXzg2_a86ad2bd-0335-499e-a92e-f945a6d024b6">50</ix:nonFraction>), and $<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOjNiZjg3NzljYjk0YzQzMmE4MzkyNWJhZTUxNDk2NDgyXzk0_31d09a62-2865-4492-a464-ace759c1c8aa">182</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0xLTEtMS0xMDU2Mg_f4c30434-49bc-45b6-9630-0388ade22e75">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0zLTEtMS0xMDU2Mg_d34700a0-41f9-4ae8-b5a4-56e3a5bdeb0a">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS01LTEtMS0xMDU2Mg_65ef39c2-83d8-409f-b7e4-850fb2648034">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNi0xLTEtMS0xMDU2Mg_66d5b8f2-718d-46a9-8653-ac0550065433">3,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNi0zLTEtMS0xMDU2Mg_fd240db3-84d4-4eea-b103-d48db4916067">5,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNi01LTEtMS0xMDU2Mg_b6ae41ef-5b9e-4bac-8ddb-9725bbd47b29">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNy0xLTEtMS0xMDU2Mg_82a45857-f451-4792-8b3b-e9f9e28b00b7">253,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNy0zLTEtMS0xMDU2Mg_307b9a44-139c-4f03-99a4-ada35f979088">271,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNy01LTEtMS0xMDU2Mg_44b597a1-f163-41a2-989e-18d57e20380b">353,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-89-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.288%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59b0f5748c0040d4ba044c170c4498a5_I20181231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi0xLTEtMS0xMDU2Mg_18aeb0cf-80ac-4123-9d70-9fa13f6a864e">189,383,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59b0f5748c0040d4ba044c170c4498a5_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi0zLTEtMS0xMDU2Mg_78912207-21ed-40b7-a16d-e8a3c504a441">1,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eaeeea22e1c450bb0f3ef7f208d55da_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi01LTEtMS0xMDU2Mg_3a2f1cb6-3e79-4f1d-8d88-355de248caa2">1,740,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e06cd88eed94c93bd863d9d2fa7e86a_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi03LTEtMS0xMDU2Mg_cd866b41-4ca2-4e30-b749-13e683655b54">13,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fde1813dc7d44159942aa86b1104baf_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi05LTEtMS0xMDU2Mg_5a04a25b-6901-438f-8452-ba47aa5552e1">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4b02a7b929749bcbb33c5ac89bfc395_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi0xMS0xLTEtMTA1NjI_da2118f3-b138-450a-8633-2a204ef9e610">1,412,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id112dec781f849479a5fea1933c18841_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi0xMy0xLTEtMTA1NjI_c4027a32-17f5-4440-9f8f-9f75b24a6139">342,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMy0xLTEtMS0xMDU2Mg_499fbf7e-1ba1-4c19-b7ba-321916efc860">1,967,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMy0zLTEtMS0xMDU2Mg_18ef7b26-6ad5-41ec-aa94-5367752e6d9a">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMy01LTEtMS0xMDU2Mg_2f983a19-7b6b-4cb5-ab47-3a196dc1b63c">11,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMy0xMy0xLTEtMTA1NjI_ecef27b4-b71f-4069-b725-6b6d705cbc57">11,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock issued from equity financing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNC0xLTEtMS0xMDU2Mg_3b760959-8aa5-4bc3-b0f6-5c796d11c487">18,720,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNC0zLTEtMS0xMDU2Mg_0a964463-854b-4448-9b69-ac13e5cceeef">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNC01LTEtMS0xMDU2Mg_596e9b96-368d-4f51-b726-f62d459d16a7">188,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNC0xMy0xLTEtMTA1NjI_6ee0aef4-cbf8-43ff-9b88-4a90d250a3e3">188,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee withholding taxes related to restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNS0xLTEtMS0xMDU2Mg_96d40b0c-1640-408d-b33c-118bf4f83b94">477,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNS01LTEtMS0xMDU2Mg_efe5bfde-de0b-414b-b7ad-e88fa61a069d">3,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNS0xMy0xLTEtMTA1NjI_35dfa79f-c877-45a2-acd9-7ac0b5f5ab50">3,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock issued for contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231" decimals="INF" name="fold:StockIssuedDuringPeriodSharesContingentConsideration" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNi0xLTEtMS0xMDU2Mg_6f00c51d-dc09-4a3b-b573-57e2f2249b87">771,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b1ffa344ad4c46a05f2baded3c95de_D20190101-20190331" decimals="-3" name="fold:StockIssuedDuringPeriodValueContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNi0zLTEtMS0xMDU2Mg_d36d9b8e-0753-40fa-bd5e-217ce7b361f8">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c2736e1c5f4bbdbe8ee555092181b6_D20190101-20190331" decimals="-3" name="fold:StockIssuedDuringPeriodValueContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNi01LTEtMS0xMDU2Mg_c2a67281-7eff-4394-9ac1-3adfeb5bbb26">9,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="fold:StockIssuedDuringPeriodValueContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNi0xMy0xLTEtMTA1NjI_fc3fabe7-396c-41af-abcf-91414b2ecf2e">9,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNy01LTEtMS0xMDU2Mg_256693bb-7d0e-461f-9f70-b1421c0e93e6">44,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNy0xMy0xLTEtMTA1NjI_4b48c063-52ca-4cf4-908b-5b329aa4560c">44,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231" decimals="INF" name="fold:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC0xLTEtMS0xMDU2Mg_c75cd793-a148-4365-98b4-249fb54e73eb">101,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC0zLTEtMS0xMDU2Mg_703131d9-fe4a-47de-9656-bec869c4ccd0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC01LTEtMS0xMDU2Mg_d0f98460-be4d-499b-83a1-79747bf7785b">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d9f0aae1dd4a489dc1c015715214d8_D20190101-20191231" decimals="-3" sign="-" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC03LTEtMS0xMDU2Mg_b79535e7-e510-42b4-9c62-ca8ff783fa79">676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC0xMy0xLTEtMTA1NjI_350909c7-2ba6-4c89-acbf-db1f4c7c9d44">812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of the convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOS0xLTEtMS0xMDU2Mg_da217097-2b60-47f4-8275-626baed5b01d">43,995,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7f88d07a8f4a3196f84540950c1ba1_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOS0zLTEtMS0xMDU2Mg_7e848fd7-af46-4801-aa8a-73df6f7177ea">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295c47ed72d64074b5f32eeaad26a5cd_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOS01LTEtMS0xMDU2Mg_4bc8024f-33d5-42e2-9cb7-90e8377d1e0e">215,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOS0xMy0xLTEtMTA1NjI_9c8094b1-ce5e-46c4-9efc-5c4129a185b0">215,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination of capped call confirmations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231" decimals="-3" name="fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTAtNS0xLTEtMTA1NjI_a213b349-877e-4ac9-a50b-5e75aed985ed">19,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTAtMTMtMS0xLTEwNTYy_1dc11d7a-0610-4e37-8acf-776d0b0552c0">19,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f87ef3b9001442e9d1783fa4ab6164a_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTEtOS0xLTEtMTA1NjI_78cc2146-de12-4480-bcaa-a82922b837e2">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTEtMTMtMS0xLTEwNTYy_f727a34d-58ff-4bdb-b107-2a3069c8fb3b">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f87ef3b9001442e9d1783fa4ab6164a_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTItOS0xLTEtMTA1NjI_5a5ab19f-d8c3-4e9d-91f8-4a163f7a99d5">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTItMTMtMS0xLTEwNTYy_d74561a6-ec2c-4edb-b8c8-fc1908cd2a40">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idebd74e031ad4aa8847d48abfeb2cb4c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTMtMTEtMS0xLTEwNTYy_b9ddbe65-c10f-42f1-a3b6-944432eb7198">356,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTMtMTMtMS0xLTEwNTYy_c170a285-ce99-4785-bee2-b04e4f71ea84">356,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1a49ef645774a039703edbf41d99de6_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtMS0xLTEtMTA1NjI_7a618142-89b3-4dfb-bf80-a54b6e62781d">255,417,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a49ef645774a039703edbf41d99de6_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtMy0xLTEtMTA1NjI_e68c3012-0474-44ea-b340-fc63b9080516">2,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0283e0a778b241b69b7dc2f9f44b0620_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtNS0xLTEtMTA1NjI_5d573f91-344e-4e8b-a5ea-7cec0d4cedc3">2,227,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb03c87cbb644915a36d8589d01d130f_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtNy0xLTEtMTA1NjI_129902b4-8c42-4328-a4a5-e14b99205585">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31157945f1834f739f2eb29aa5b1c152_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtOS0xLTEtMTA1NjI_64e15a16-c571-40f4-93ef-e2c61e5f0e1c">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0925432d607c491d8c8762f88a8343ca_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtMTEtMS0xLTEwNTYy_fb2a8803-87d1-48eb-8b77-b64427e8a43a">1,768,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtMTMtMS0xLTEwNTYy_7d691f8d-36e7-4cf8-87e6-1b410427cec6">476,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d67ba7a78d4493685eb33d08eab6fe3_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTUtMS0xLTEtMTA1NjI_603e00f6-e17e-4de4-ab74-660047a105b0">5,233,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d67ba7a78d4493685eb33d08eab6fe3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTUtMy0xLTEtMTA1NjI_f0399ea7-c469-4e65-843d-78843c2b4cb9">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1caab1a891c34d6db105ce12805fe47d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTUtNS0xLTEtMTA1NjI_6c3d9152-acbf-45db-8a89-fb9cb5cfeae6">42,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTUtMTMtMS0xLTEwNTYy_bd6ba483-abc7-40a1-80ac-7409adb2be52">42,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee withholding taxes related to restricted stock unit vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d67ba7a78d4493685eb33d08eab6fe3_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTYtMS0xLTEtMTA1NjI_f1c25a77-c244-4b30-b2ed-a835295a8d9b">1,411,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1caab1a891c34d6db105ce12805fe47d_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTYtNS0xLTEtMTA1NjI_c2ddd70e-3f2c-4b06-a88a-20dc219f95fb">10,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTYtMTMtMS0xLTEwNTYy_fbd2c6f4-384b-4774-91da-d2719cdb4c1e">10,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1caab1a891c34d6db105ce12805fe47d_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTctNS0xLTEtMTA1NjI_4888da19-cf59-4a53-b301-a708c4c46b12">49,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTctMTMtMS0xLTEwNTYy_f214f82b-6d58-463d-88b3-2b273aa01d63">49,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59667a8b6b6e402abb2689a16193a16e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTgtOS0xLTEtMTA1NjI_99fab089-2692-435f-b36d-99219bf619f7">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTgtMTMtMS0xLTEwNTYy_33d3b483-e95f-4961-9af5-02c3dbe70ba1">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59667a8b6b6e402abb2689a16193a16e_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTktOS0xLTEtMTA1NjI_38817806-bbec-4daa-b15b-97351ff07b62">5,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTktMTMtMS0xLTEwNTYy_9dd4224d-9382-4475-843a-259ab15d100f">5,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f392c0af90404aa7ba763120f8093c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjAtMTEtMS0xLTEwNTYy_1fa27334-0297-44ba-bdc9-5e7550c16411">276,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjAtMTMtMS0xLTEwNTYy_356be1c0-8ee1-4b89-a66c-a4d8bffd975b">276,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a9abca8aab34fa6938b4176b42afcca_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtMS0xLTEtMTA1NjI_59ffade5-a071-426a-b5bb-d740323faac4">262,063,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9abca8aab34fa6938b4176b42afcca_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtMy0xLTEtMTA1NjI_17efd813-fce6-4598-bc20-512885ea4ff3">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a2dd5b7af4a40d8b104a56e99abd5c7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtNS0xLTEtMTA1NjI_e0f0ef39-941b-4e85-839f-747b82cd8588">2,308,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8631b1d954a432cab195334e4ab3c22_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtNy0xLTEtMTA1NjI_321a998b-0c30-436d-a6a0-2d1ed6ca16c5">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc96de0a30247109dd0e367a5fda28e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtOS0xLTEtMTA1NjI_61208550-560d-442a-9c55-0fdc22bb4749">8,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib685c8f6567a444dafe12c28724621c6_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtMTEtMS0xLTEwNTYy_3a23a618-df20-4132-bf80-54de398b1605">2,045,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtMTMtMS0xLTEwNTYy_20feceac-fcdb-4f7f-9e5f-7f015f6dd8f7">286,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjItMS0xLTEtMTA1NjI_426bc2af-a8f2-422a-b480-ec2a472d81d4">1,461,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjItMy0xLTEtMTA1NjI_54363327-2d68-451b-a271-ed55b2617a7d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjItNS0xLTEtMTA1NjI_541cdae9-70c2-499b-9155-594e63773266">10,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjItMTMtMS0xLTEwNTYy_ec6687bc-f471-498e-94ec-6e704de4b6cf">10,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued from equity financing and pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4be7fadcd724e6e96874c8bdf5adad5_D20210901-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMS0xLTEtMTUyODI_bd8d7f1a-0866-43f5-8fb5-e8d137eee530">11,296,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMy0xLTEtMTUyODI_72ce679a-f5d2-41cf-b55e-a66eacc20b49">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtNS0xLTEtMTUyODI_789bdde8-58ba-4fdf-bae8-0a5327e562ee">199,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b570f4240774f97a85fc8f243de27b6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtNy0xLTEtMTUyODI_9d8767e2-738b-4372-a547-ab1b4df5bbc8">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMTMtMS0xLTE1Mjgy_c23f11b3-746b-48e4-a713-2eaeead43bf8">199,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee withholding taxes related to restricted stock unit vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMS0xLTEtMTA1NjI_39788ce0-1319-4b5e-9b8c-8688f8e5f3c5">1,064,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtNS0xLTEtMTA1NjI_62e166ca-65d2-4e4b-9914-4272366fde23">15,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMTMtMS0xLTEwNTYy_4b5c575a-5b46-40ad-89cf-cdcd5baa62d4">15,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjQtNS0xLTEtMTA1NjI_18c6ee5b-ddad-48f3-9825-18cc12403000">57,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjQtMTMtMS0xLTEwNTYy_08230c45-d07a-4fa4-ad42-97334b4ed5a8">57,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231" decimals="INF" name="fold:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtMS0xLTEtMTA1NjI_2411d500-004f-440f-bb13-3208c0792d73">2,554,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtMy0xLTEtMTA1NjI_30c5b944-fc2f-48ca-97ce-14a4cf1d69e5">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtNS0xLTEtMTA1NjI_56194a31-b908-4ac3-8923-c9338ed5c6a2">31,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b570f4240774f97a85fc8f243de27b6_D20210101-20211231" decimals="-3" sign="-" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtNy0xLTEtMTA1NjI_d2a37808-024d-429e-9e4f-b2e60f6d6733">12,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtMTMtMS0xLTEwNTYy_5223f8b5-79dc-48e2-a2d1-d4d77d4274c6">19,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of the convertible notes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjYtMS0xLTEtMTA1NjI_50375b84-f793-4cff-b91d-084c499b76df">472,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjYtMy0xLTEtMTA1NjI_8e26d893-e883-42e0-94f8-665a7a161439">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i640ccbc1c3154c0080c449287054612e_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjYtNS0xLTEtMTA1NjI_f5871155-f236-49b5-bc39-2d764c62e74a">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjYtMTMtMS0xLTEwNTYy_ae4e83f1-9830-4e23-a1c2-2e758f85249c">2,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf5bb75d47341398ad73aa8e894bf9f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjgtOS0xLTEtMTA1NjI_de92fe16-5045-4a55-b25b-dedd3ff34f6e">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjgtMTMtMS0xLTEwNTYy_6de672b6-8535-461e-a580-6c9be7d0fb58">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation Adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf5bb75d47341398ad73aa8e894bf9f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjktOS0xLTEtMTA1NjI_25951cf0-36aa-49af-9f4b-e1ee3f5382a9">3,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjktMTMtMS0xLTEwNTYy_b78358b4-1fcb-4286-8357-d8eee2171109">3,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07df4fa1308d4f84a4aa5160e8a69ceb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzAtMTEtMS0xLTEwNTYy_0b801a07-2de7-455a-b4ca-1ffe713b080e">250,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzAtMTMtMS0xLTEwNTYy_06531270-9a89-48e9-af56-e633741a7c8c">250,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9f9159fe2d74c02899336811f098a03_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtMS0xLTEtMTA1NjI_5b7af8d0-aad0-46c0-9aac-b77e28a46f82">278,912,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9f9159fe2d74c02899336811f098a03_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtMy0xLTEtMTA1NjI_c1dcad91-706d-4ded-9f39-55ed5fdc7749">2,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68cc19d3396498d82b2a8b900bcb129_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtNS0xLTEtMTA1NjI_ee41f4cc-d7ac-428d-9115-771f806f4d76">2,595,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1512bc26b649368f7c7a1f80c153cc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtNy0xLTEtMTA1NjI_35b4e0e7-f731-4405-9828-1347ccf88135">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89d77f8f61e4f3997ffe7f4c43ce4bc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtOS0xLTEtMTA1NjI_1c9e32b8-e000-4e05-a0fa-737703bc0693">4,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cac20d40d594fdb84c482f1f832ea26_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtMTEtMS0xLTEwNTYy_4a554f48-8a43-4b8c-93b8-23b55d6df8db">2,295,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtMTMtMS0xLTEwNTYy_2ce4ce71-6994-4898-b19d-59adc0852a6b">307,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-90-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMy0xLTEtMS0xMDU2Mg_11ab8732-8499-4da3-a911-bac1eebc627d">250,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMy0zLTEtMS0xMDU2Mg_a86e9a34-e280-43a8-93fd-79584a7239a8">276,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMy01LTEtMS0xMDU2Mg_fceac09e-80b3-4732-88fc-a12090b5f835">356,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and deferred financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNS0xLTEtMS0xMDU2Mg_855064a6-172a-4119-b150-2678a4f7d9e2">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNS0zLTEtMS0xMDU2Mg_2925fc62-23f2-4a2d-aece-dbdd6286e6c6">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNS01LTEtMS0xMDU2Mg_2b68402a-cd47-468c-a121-9da9fb94c9bc">2,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNi0xLTEtMS0xMDU2Mg_98562624-fa17-41c1-8b63-08c806e70463">6,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNi0zLTEtMS0xMDU2Mg_54b25cdb-6986-4c26-8da5-37f9d2226f47">8,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNi01LTEtMS0xMDU2Mg_b9f93e5a-1d36-4e25-b168-d4ebef3d0679">4,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNy0xLTEtMS0xMDU2Mg_918c411b-66d7-48e3-8ad6-544076b22150">57,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNy0zLTEtMS0xMDU2Mg_1ce64edf-d8ad-4f77-a8f3-9b2d870d651c">49,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNy01LTEtMS0xMDU2Mg_fa9729d4-2247-4d30-9ba8-d62edc859d95">44,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on exchange of convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="fold:GainLossOnExchangeOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOC0xLTEtMS0xMDU2Mg_62fa0fb7-963b-4677-8f80-82f4d9bace58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="fold:GainLossOnExchangeOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOC0zLTEtMS0xMDU2Mg_5abb8ec7-1302-465c-b8e5-0315f4677bda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="fold:GainLossOnExchangeOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOC01LTEtMS0xMDU2Mg_685362ee-bb9f-42f9-b51c-efba4e3a13de">40,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOS0xLTEtMS0xMDU2Mg_42fce7fd-3db6-463a-ba14-48b14e70aa81">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOS0zLTEtMS0xMDU2Mg_a86ec58d-90af-4464-b3ed-b9b0b6b82cab">7,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOS01LTEtMS0xMDU2Mg_ce9ec704-359f-40cd-86c4-084e89f6039e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash changes in the fair value of contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTEtMS0xLTEtMTA1NjI_159bc39c-7f37-4e36-980a-1e6eb2f33393">6,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTEtMy0xLTEtMTA1NjI_c4bd0aa2-fab7-449a-8f0f-ed71d739abb1">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTEtNS0xLTEtMTA1NjI_07e4b8d7-5cf7-48c7-a115-36902040bb9c">3,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency remeasurement loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTItMS0xLTEtMTA1NjI_5ccb0cc3-b9c7-406e-b5bc-03c322eb9ae1">3,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTItMy0xLTEtMTA1NjI_58fde154-0c76-4e66-bcab-1b8652ab7c28">5,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTItNS0xLTEtMTA1NjI_9a4eea00-10a4-40d9-b971-1bdaaddc9a34">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTMtMS0xLTEtMTA1NjI_09c98504-8e4f-46d4-ab3f-3a94e9259974">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTMtMy0xLTEtMTA1NjI_de180773-8d84-4c6d-b01b-d2133ea44e17">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTMtNS0xLTEtMTA1NjI_37610c68-ff27-469a-80e5-5a348f5da9ce">1,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTQtMS0xLTEtMTA1NjI_da8c13be-6204-4ed3-ba8b-4695b3233d21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTQtMy0xLTEtMTA1NjI_90d7d9df-b91d-4657-8183-c694b4abe298">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTQtNS0xLTEtMTA1NjI_c268305d-1fc3-48f2-8448-3d13048b5421">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTYtMS0xLTEtMTA1NjI_ab10031c-1b2e-4329-a9dc-9ffa336e4845">8,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTYtMy0xLTEtMTA1NjI_46c934c2-ddc8-40ee-980e-8d032d43d185">11,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTYtNS0xLTEtMTA1NjI_f4534ed4-8cee-4ad4-9c60-cad3f8aafac0">11,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTctMS0xLTEtMTA1NjI_7bf39791-3b2b-4bc1-aefc-59989a9f1167">7,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTctMy0xLTEtMTA1NjI_f95b9194-b24a-46df-bf81-a29e75ab2571">4,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTctNS0xLTEtMTA1NjI_046b5836-29fe-4bdd-b36f-0f4614c58099">5,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTgtMS0xLTEtMTA1NjI_63d81193-534c-4e33-bcfe-a49dfe309670">5,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTgtMy0xLTEtMTA1NjI_5815c8f1-6e48-4a54-a9f9-7f44cbe79e1b">8,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTgtNS0xLTEtMTA1NjI_a95c0e8f-f8ac-4218-8748-8f23507ccad8">3,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses, and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTktMS0xLTEtMTA1NjI_2fe14888-1e05-459f-b356-0b1980661eac">7,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTktMy0xLTEtMTA1NjI_0989c167-3d48-40e7-8f5c-8674be3953ef">10,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTktNS0xLTEtMTA1NjI_25a0bafe-9f29-4438-9ea4-de2c48f4d354">46,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjAtMS0xLTEtMTA1NjI_0b716f7d-28c7-417d-b9e8-b1e77d92e684">2,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjAtMy0xLTEtMTA1NjI_e4d37dc3-ef86-4db1-8903-2f2ebc9f8e66">4,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjAtNS0xLTEtMTA1NjI_45787fd0-3fab-43df-bcee-d6cd9b5bdea6">10,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred reimbursements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="fold:IncreaseDecreaseInDeferredReimbursements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjEtMS0xLTEtMTA1NjI_bf24869c-3d32-4a2c-a61a-daf4600e9e7e">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="fold:IncreaseDecreaseInDeferredReimbursements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjEtMy0xLTEtMTA1NjI_392757a5-33b8-4c6d-9c06-f2aa7d14ac1e">1,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="fold:IncreaseDecreaseInDeferredReimbursements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjEtNS0xLTEtMTA1NjI_5b9c8618-3639-4612-ab24-c0fdd4b643ea">5,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItMS0xLTEtMTM3MjA_0b4d1d04-c2a5-433e-8100-b1be7493ce3d">10,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItMy0xLTEtMTM3Mjg_ccc9c438-ad61-46ab-9213-8d7cffc795b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItNS0xLTEtMTM3MzU_454871aa-5802-42be-9db5-2ba061ad6ecf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItMS0xLTEtMTA1NjI_5ba35a71-1265-40ae-ba80-918e9b4c44c5">202,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItMy0xLTEtMTA1NjI_9f728bbd-c056-4474-8907-fb92ae37b529">233,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItNS0xLTEtMTA1NjI_f5a4660e-f9cc-47b2-be24-f17ebf0d5c31">250,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale and redemption of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjQtMS0xLTEtMTA1NjI_de68cf57-6587-45b0-9915-b38789a8c7a9">424,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjQtMy0xLTEtMTA1NjI_64512ed0-45fb-4f73-a1c7-e4bec9c2dd97">354,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjQtNS0xLTEtMTA1NjI_796f007b-9eef-46da-8ec2-346ec16d7b80">499,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjUtMS0xLTEtMTA1NjI_8e2c05da-1839-407b-ae18-996303b2030e">341,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjUtMy0xLTEtMTA1NjI_2760913e-b4a9-475b-af65-9914bcaead7f">365,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjUtNS0xLTEtMTA1NjI_dd0a6762-71ec-47dd-bb97-a90dc601ad67">383,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjYtMS0xLTEtMTA1NjI_273c07ee-6ee5-405f-935f-bbdc8dbde53f">3,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjYtMy0xLTEtMTA1NjI_3ef47115-2f5d-4565-96dd-84f93d47b389">3,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjYtNS0xLTEtMTA1NjI_66afe7fe-27c7-4675-a3a4-bd38a75bb6dc">20,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjctMS0xLTEtMTA1NjI_ca6b6846-fa5d-4e78-af56-544ecef19e0a">78,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjctMy0xLTEtMTA1NjI_e8fefadd-00d7-4a8d-ac32-10ba599e365e">13,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjctNS0xLTEtMTA1NjI_b9869a85-ff2e-4821-ad7a-d09fe23d7901">95,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from  issuance of common stock from equity financing and pre-funded warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjktMS0xLTEtMTA1NjI_b624ff62-9f4c-478d-b011-324ac6ad3056">199,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjktMy0xLTEtMTA1NjI_059c962a-45a7-4c32-acda-25803c016749">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjktNS0xLTEtMTA1NjI_5923d42c-5e3d-4cae-afc8-c4a6e828cad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtMS0xLTEtMTU2NzU_d17c9ff8-2909-4be2-b6fe-cb2f9bcfb487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtMy0xLTEtMTU2ODE_fef23e1a-5cbb-4009-ad86-9d7722cd28f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtNS0xLTEtMTU2ODc_53eec8ea-7441-4a7f-88c1-b6f073a56aeb">188,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzAtMS0xLTEtMTA1NjI_02ae450a-c639-478b-8d99-b1a2bafa63bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzAtMy0xLTEtMTA1NjI_b52e29c0-8205-4bc4-9519-e676feec3014">155,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzAtNS0xLTEtMTA1NjI_c33d075b-5c73-4b96-a0fb-1ed480193ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtMS0xLTEtMTA1NjI_f29a0075-c4d8-460f-8c94-bfd60b477b8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtMy0xLTEtMTA1NjI_3eb4703f-b2eb-484a-890b-f0655c6440ec">385,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtNS0xLTEtMTA1NjI_252d528c-3ab9-47c4-bcd1-12ed3819b9f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzItMS0xLTEtMTA1NjI_ca988eb9-e839-48a7-a9c1-a9438a562bad">479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzItMy0xLTEtMTA1NjI_b47cdaca-d98c-4fb3-8aac-026b734ce589">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzItNS0xLTEtMTA1NjI_dbd8040e-5f18-4d7c-8c37-6bb2522154c5">420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of employee withholding taxes related to restricted stock unit vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzMtMS0xLTEtMTA1NjI_851aa74b-b3d1-4341-b93b-0b993931f5ed">15,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzMtMy0xLTEtMTA1NjI_69f37d3b-9bde-4f31-8a0e-c2ae9e961724">10,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzMtNS0xLTEtMTA1NjI_d55f6afe-abd8-4258-9d6c-4059971c007b">3,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from termination of capped call confirmations </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzQtMS0xLTEtMTA1NjI_45f3190a-d43d-4638-ae32-17131f3fe643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzQtMy0xLTEtMTA1NjI_7273cd8c-f1c6-46ce-bea5-cafc83cf651d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzQtNS0xLTEtMTA1NjI_f8afee67-2b71-47e3-adbd-ec8949cf1038">19,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from stock options exercised, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzUtMS0xLTEtMTA1NjI_f370d769-6287-4454-87ac-73d0f6c8bb8d">10,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzUtMy0xLTEtMTA1NjI_62652a69-8988-4bad-ba03-1cd3dcd5c540">42,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzUtNS0xLTEtMTA1NjI_788a8d01-8252-4e8c-aa27-41c44800b7f8">11,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from warrants exercised, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzYtMS0xLTEtMTA1NjI_a3a7442c-ab14-49a9-93cb-39bac2ced38a">19,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzYtMy0xLTEtMTA1NjI_097562da-7eaf-4f09-adfb-2a87471f32c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzYtNS0xLTEtMTA1NjI_cb76f6d7-14e7-4104-bf48-78654e4c912c">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtMS0xLTEtMTM4MTU_ccf4bc23-57c4-4a68-a1e2-4b78f2c55f7a">1,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtMy0xLTEtMTM4MTU_b07eed40-6796-4530-9c34-278379637baf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtNS0xLTEtMTM4MTU_1fb60fe7-3641-4aa0-825b-3a530915ceed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzctMS0xLTEtMTA1NjI_508626b7-0991-4df2-b54d-7f1ebf481c7b">212,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzctMy0xLTEtMTA1NjI_70cbbb75-aaf2-46b4-a159-0b140880dce3">262,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzctNS0xLTEtMTA1NjI_90bc60c3-fce5-42ef-9e59-fe8e33ed6edd">217,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtMS0xLTEtMTA1NjI_c3e3d679-d2ed-4e5b-9c1b-3b91406d9781">5,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtMy0xLTEtMTA1NjI_53c5e8b7-8eb7-42c2-8b1c-39a31f866096">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtNS0xLTEtMTA1NjI_d95b8ccf-7855-4136-b3ec-acd7bd635e6f">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzktMS0xLTEtMTA1NjI_0e171812-d3f7-4891-9f74-17a4edf9cd2f">83,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzktMy0xLTEtMTA1NjI_27fced79-af33-4c27-b3f0-7f383d09089f">19,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzktNS0xLTEtMTA1NjI_607a5d62-cb7e-46ad-9b24-dca84b935e47">63,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-91-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_7">s</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at the beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDAtMS0xLTEtMTA1NjI_86f1cdf2-a298-4886-8269-19aa82414b06">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDAtMy0xLTEtMTA1NjI_2b9255cd-e2a5-47f6-a56a-892149886815">146,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id112dec781f849479a5fea1933c18841_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDAtNS0xLTEtMTA1NjI_ad663dde-2678-4122-9b90-a308f7c0947f">82,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at the end of the year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDEtMS0xLTEtMTA1NjI_0aa4b8fb-d7ac-47c5-8bdd-5ac9d594bf62">249,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDEtMy0xLTEtMTA1NjI_38708e89-8609-42c9-b013-002a2e43f50d">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDEtNS0xLTEtMTA1NjI_4fa23a2b-5389-4fa5-af92-0eb9fdeedd11">146,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements paid through lease incentive</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDQtMS0xLTEtMTA1NjI_d5fc7d20-f689-4490-b71f-1b6f16a5875d">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDQtMy0xLTEtMTA1NjI_507b53be-6ae4-46ca-a2f2-4825705be823">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDQtNS0xLTEtMTA1NjI_68b6c107-fd1a-4792-aeab-f1dc82cba21f">19,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the period for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDUtMS0xLTEtMTA1NjI_608f4ce3-deff-4cb1-a551-2754e7fa99bf">30,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDUtMy0xLTEtMTA1NjI_009ad721-cfb9-4716-a107-346062a2e6c0">24,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDUtNS0xLTEtMTA1NjI_06b1af51-5be1-4c0a-9f61-a7423e156d8c">16,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration paid in shares</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="fold:ContingentConsiderationPaidInStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDYtMS0xLTEtMTA1NjI_20755f14-5610-45f8-a5bf-1bb5effb0f86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="fold:ContingentConsiderationPaidInStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDYtMy0xLTEtMTA1NjI_d08cb89c-39a3-4fd8-969d-799b5a7efd2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="fold:ContingentConsiderationPaidInStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDYtNS0xLTEtMTA1NjI_db4bbf8a-03c8-4890-9180-2b8c79532f49">9,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures unpaid at the end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDctMS0xLTEtMTA1NjI_c47ebe86-0a75-4f2b-ab7a-fb2dd1f25df7">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDctMy0xLTEtMTA1NjI_63eaf7f8-5f01-40b9-84e8-d15ef713c803">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDctNS0xLTEtMTA1NjI_e9ff6e07-1358-4fb8-bb33-98fbf68f6925">1,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDgtMS0xLTEtMTA1NjI_c25e2834-6d47-440f-a570-002f8d1da0e9">20,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDgtMy0xLTEtMTA1NjI_6442cf1c-a3a8-4150-851d-de8309dccd9a">10,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDgtNS0xLTEtMTA1NjI_e1e8a8ec-66da-4133-b3d7-78d6c4a5fb77">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-92-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:36pt"><span><br/></span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_76"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfNTYzNg_3f5b689c-9acb-450e-acbb-fc515c8c4264" continuedAt="i691d8652001a444a80115d00a735612c" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i691d8652001a444a80115d00a735612c"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). We are committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of the Company's portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, the Company announced, with ARYA Sciences Acquisition Corp IV ("ARYA"), a special purpose acquisition company (or "SPAC"), sponsored by Perceptive Advisors, it has agreed to mutually terminate the previously announced definitive business combination agreement, originally executed in September 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in September 2021, the Company entered into securities purchase agreements with certain investors for the private placement of an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib4be7fadcd724e6e96874c8bdf5adad5_D20210901-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU1Ng_bd8d7f1a-0866-43f5-8fb5-e8d137eee530">11,296,660</ix:nonFraction> shares of the Company's common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU2OQ_22512cc7-d765-421d-ad7b-73a347e9694e">10.18</ix:nonFraction> per share, and pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU4NQ_54ae2f10-b288-4e94-8e7e-2c242bcff12e">8,349,705</ix:nonFraction> shares of common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ida79dc6999b2473ca1d1e66873b93aae_I20210930" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU3Nw_efa68023-eda4-497c-b453-ed2df159d2fd">10.17</ix:nonFraction> per pre-funded warrant. The net proceeds from these private placements were approximately $<ix:nonFraction unitRef="usd" contextRef="i526b094eedf24604a14d40a8149d2578_D20210901-20210930" decimals="-3" name="fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU5Ng_7859fb1c-b64c-446b-ab05-9813eb29c151">199.8</ix:nonFraction> million. The Company expects to use the net proceeds to further fund initiatives in the global commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the anticipated global launch of AT-GAA and to further support the Company's discovery work on next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations have not been significantly impacted by the novel coronavirus (&#8220;COVID-19&#8221;) pandemic to date. However, the Company observed increased lag times between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation due to the resurgence of COVID-19 in 2021. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimal disruptions. Whether the Company will continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfNDg3MQ_e000025a-2d2d-40be-9c1d-ea2cfefdcd33">2.3</ix:nonFraction> billion as of December 31, 2021 and anticipates incurring losses through the fiscal year ending December&#160;31, 2022 and beyond. The Company has historically funded its operations through stock offerings, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, debt issuances, collaborations, and other financing arrangements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, and net proceeds from the September 2021 private placement of securities, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-93-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MTI_f8a7c77f-d792-454b-a2d3-3be1ac6a2fcf" continuedAt="iaea413c302d64ab087ba27f88c067ef4" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="iaea413c302d64ab087ba27f88c067ef4" continuedAt="i1b55f718a81742c990f4395b8572ed40"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3Mzg_119c5da4-7054-4f3b-942c-71030234caa9" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MjQ_47b6401c-c171-41d1-b04e-ecc81c52bf03" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MTU_e8d5c12f-d8ad-42e6-b59c-9361f5640baf" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjY_f71e9a8b-d117-4124-b92e-49c7b85ef377" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of December 31, 2021 and through the issuance of these financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MTY_695114b3-f447-4661-bd95-c987c0210354" continuedAt="if9e57a7889e446808afcd3107f73d680" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if9e57a7889e446808afcd3107f73d680">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-94-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="i1b55f718a81742c990f4395b8572ed40" continuedAt="i76f69a50167c46bab84e1ececc309d77"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3Mzk_d84777f3-8a27-4e2d-9044-c1826577bf6f" continuedAt="i7ae85580af9d4913b4fceadf0db2f289" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="i7ae85580af9d4913b4fceadf0db2f289" continuedAt="i5ceb738a118648208b44712fe32dfd18"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ceb738a118648208b44712fe32dfd18">. The Company's accounts receivable at December 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</ix:continuation> As of December 31, 2021, the Company recorded an allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDQwNQ_dbccf7f1-669d-447a-a293-65fa4e7e4226">0.2</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MDQ_b568b26f-6468-49c5-abc1-7a8215052d63" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDYwOA_36c2035c-6429-44ec-a5ff-c15bdbc6abf6">three</span> to <ix:nonNumeric contextRef="i016a712198df44609ada40ce0ec6040e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDYxNA_6ca1d88f-3c1b-447f-9fb8-4b47a8262882">five years</ix:nonNumeric>, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NTg_731fb34b-da22-44f5-ae68-98006ce753e3" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2021, one customer accounted for <ix:nonFraction unitRef="number" contextRef="icb5f7d12a2e74e94b84af411c94b825f_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTA5OTUxMTY2MjMwNA_64679d3e-3186-4bf1-8223-227e3ef4e93c">24</ix:nonFraction>% of net product sales and <ix:nonFraction unitRef="number" contextRef="id98a23a12f314c0399ddc82d07f167d9_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTA5OTUxMTY2MjMwOA_ff57d371-c3ff-41f9-b5ce-4a583f5e74a1">14</ix:nonFraction>% of accounts receivable from product sales. In 2020, one customer accounted for <ix:nonFraction unitRef="number" contextRef="i8d0ef6f58f21490982734d184ffa708c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTA5OTUxMTY1MzU4NQ_b4110db2-b837-44f3-85e6-d2cb2b0f01a4">25</ix:nonFraction>% of net product sales and <ix:nonFraction unitRef="number" contextRef="i3a13db14f0fd48d7b5bae936a24df08c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTA5OTUxMTY1MzU5NA_ebcacfed-89f6-486c-aab1-99f5aabeb8d8">12</ix:nonFraction>% of accounts receivable from product sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDI_19032961-6aa7-42dd-a19f-348b3b3200b5" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by geographic area:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"></td><td style="width:53.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd944574f2a423983b2d669ba0a005a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMi0yLTEtMS0xMDU2Mg_f6cd196e-3a5e-41b4-9773-4258f6e4914f">95,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141786068eaa494eabbae0eed4ca91ec_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMi00LTEtMS0xMDU2Mg_f685a48f-7018-4f65-8e95-a75cf6b2adcb">80,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3697f78d277b440cb2fdcf968fe349c8_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMi02LTEtMS0xMDU2Mg_3afa01ab-db68-4fdf-9a55-80e1f3f0f029">52,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73069b90118447438bdbc91aa2291082_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMy0yLTEtMS0xMDU2Mg_5b559663-df3b-4afa-b854-2041d66ebc1e">210,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1211cdc53247450f9cf2280aa82ab844_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMy00LTEtMS0xMDU2Mg_5c895113-7d85-4768-8c75-7064da3151a7">180,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e29c1f134e24ca6a71a18a5867402ee_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMy02LTEtMS0xMDU2Mg_c23ba2af-6225-4171-b5f0-cc02021eef1a">129,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfNC0yLTEtMS0xMDU2Mg_f0ab6e1c-c0f7-4285-ad66-4bc543e785bd">305,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfNC00LTEtMS0xMDU2Mg_f1e83ebd-5148-4076-9681-e21a89340de9">260,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfNC02LTEtMS0xMDU2Mg_25de01cc-cda0-4a16-adf3-9c07a225a8a9">182,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-95-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="i76f69a50167c46bab84e1ececc309d77" continuedAt="ib9c237970bf8483a9e63caef1cc511b6"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NTk_599acc63-171e-4485-ae63-adf47cfbdd54" continuedAt="i6f0427992c81480d8ac8dec781cef183" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6f0427992c81480d8ac8dec781cef183">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU2OTQ_71146110-7fad-4cc9-9732-e293b8c8f704" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ContingentLiabilityReserveEstimatePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MTk_8f504944-6fc6-4c47-acfc-dabaae9dfb62" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-96-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="ib9c237970bf8483a9e63caef1cc511b6" continuedAt="i9dcf855b6494439f8f45cce3d1489a10"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDA_b3e82d68-1752-44a3-9aea-12a4c5a5e414" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="fold:InterestIncomeAndInterestExpensePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NTU_de4108c9-b2fe-4f9b-b119-71239e4525a9" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Interest Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjI_608c509c-472f-4e3f-b1d6-33e813ea3d12" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="fold:OtherComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NTE_2e50a905-ebc5-405f-9b67-0a50df754f2d" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3Njk_9a8177aa-4cd1-43f8-adbf-d86015f4fdb6" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-97-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="i9dcf855b6494439f8f45cce3d1489a10" continuedAt="iaa54de9e8282425197f24c175e52f054"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="fold:NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MzU_2eff3779-addf-4db4-938d-d3f80cf70c68" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjA_81daae62-0094-41ac-8f72-82a7626251e3" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company had <ix:nonFraction unitRef="plan" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="INF" name="fold:ShareBasedCompensationNumberOfPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTU5MTA_2c19bf31-69a4-4b58-b295-5af035e3c924">one</ix:nonFraction> equity-based employee compensation plan, which is described more fully in "&#8212;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDQ_79d6297a-9496-44bd-9e40-bcc21872083a" continuedAt="i06354419f1d045b1828b2b1a6246d304" escape="true">Loss per Common Share</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i06354419f1d045b1828b2b1a6246d304">The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same.</ix:continuation> See "&#8212;&#160;Note&#160;15. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.</span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDU_07a84854-7f3a-441e-b2b9-3d3c470297fd" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTY5MzM_35e3b1c2-0250-4dcb-a97a-675de8603c84">one</ix:nonFraction> business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is <ix:nonFraction unitRef="unit" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTc1NTI_8522e65d-4408-4425-b0ef-f8f19ea48e6d">one</ix:nonFraction> reporting unit.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDc_74b067de-0323-4c73-b05b-48c97a758f96" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjE_b4acb720-919a-451f-8bcd-11e84adad43d" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-98-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="iaa54de9e8282425197f24c175e52f054"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDE_7d795497-09ba-487d-a406-e1ce17c7e046" continuedAt="if198557899fe4a9181073e4377ea7ffa" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if198557899fe4a9181073e4377ea7ffa">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.</ix:continuation> If it is determined the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value, an impairment loss is recorded for the difference. No indicators of impairment were noted during the years ended December 31, 2021 and December 31, 2020.</span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjU_44275227-5f72-475f-9ff9-56ca5590e2ac" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2019-12 - In December 2019, the FASB issued Accounting Standard Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i4e1826361eea43a9b8ec57ad5f93ef33_85"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTMzOA_708ab278-be4a-46c6-bc84-4750193c2d87" continuedAt="i366308c5d0ac400f9205c7db674e510c" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i366308c5d0ac400f9205c7db674e510c" continuedAt="i3b816fb7f0dd41009c60ab14377c1824"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, in connection with the acquisitions, the Company had goodwill of $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTI5_648bebaa-7f3c-488a-b9f3-85c4b9545dfe">197.8</ix:nonFraction> million </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTQ1_e10a8085-9f88-4699-bf40-19c151f0c84a">23.0</ix:nonFraction> million, which are reported at fair value on the Company's Consolidated Balance Sheets. Intangible assets related to IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D assets below their respective carrying amounts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. A goodwill impairment loss, if any, is measured as the amount by which the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value.   An IPR&amp;D impairment loss, if any, is measured as the amount by which the carrying amount of the asset exceeds its fair value. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-99-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="i3b816fb7f0dd41009c60ab14377c1824"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTM0MA_69b5e782-640a-4f3c-82ec-4f8115b30287" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in IPR&amp;D for the years ended December 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:85.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfMS0yLTEtMS0xMDU2Mg_3ec055f1-1968-49fb-97f2-c0b1d51208f6">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfMi0yLTEtMS0xMDU2Mg_a2a2dd72-905a-4305-a52e-7481037b9d29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfMy0yLTEtMS0xMDU2Mg_64b5a3f7-8066-482e-a8da-20e1552168a1">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfNC0yLTEtMS0xMDU2Mg_fb62b521-65fb-46b0-972e-07583a90c3ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfNS0yLTEtMS0xMDU2Mg_e897b667-904f-4dcd-87f7-90dd91ecefe7">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTMzNg_906ce590-d29b-42df-8723-92e0d6843155" escape="true"><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in Goodwill for the years ended December 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:85.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfMS0yLTEtMS0xMDU2Mg_5c6fc1d0-7391-4763-bf5f-a25f4c463986">197.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfMi0yLTEtMS0xMDU2Mg_bfc71f45-3cf9-41e0-8c3d-6c5ae1664c19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfMy0yLTEtMS0xMDU2Mg_f38a336a-9cae-49e3-91c7-178e427c17ee">197.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfNC0yLTEtMS0xMDU2Mg_0a7c9217-1554-4168-9798-a436f5093006">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfNS0yLTEtMS0xMDU2Mg_43d04e3c-3836-4c6d-810a-bd8551b1bc7c">197.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_88"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjk3OA_765fa047-18ab-4311-a816-0ef554bde660" continuedAt="i3c1704c6bd0a4e7f86141b6626d8ca02" escape="true">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="i3c1704c6bd0a4e7f86141b6626d8ca02" continuedAt="ief2d004139f54fe1bd228a03e71b3111"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company held $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMTAy_f9f155f4-49e0-411b-9589-f5bb4f50684c">245.2</ix:nonFraction> million in cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMTM4_01f57765-3f38-41e0-a866-707d20f74ac7">237.3</ix:nonFraction> million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-100-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="ief2d004139f54fe1bd228a03e71b3111" continuedAt="i11fa0031081e42139ec7d854bd41efe5"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjk4MA_54a81824-d20c-4589-a825-2004e607db86" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:46.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMi0yLTEtMS0xMDU2Mg_24d74a75-ee9e-4540-a01b-10bf1eb73b62">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMi04LTEtMS0xMDU2Mg_e364620a-1204-4fda-b811-adb54432594b">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMy0yLTEtMS0xMDU2Mg_0c1ef0bf-b2f9-458d-890a-1b40f6145c53">174,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMy00LTEtMS0xMDU2Mg_d785de7f-8171-4996-b068-7184d04081fb">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMy02LTEtMS0xMDU2Mg_f50626fb-fb6e-4c12-b8bf-693f340340f1">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMy04LTEtMS0xMDU2Mg_f37dafc6-66ca-4347-8aaa-f7cfca11e9d4">174,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de1351a52bd4f60a456ac8231b36fa1_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNC0yLTEtMS0xMDU2Mg_970712c8-d9c4-46c0-8717-01f2792dc6d4">32,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de1351a52bd4f60a456ac8231b36fa1_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNC00LTEtMS0xMDU2Mg_068f8fd6-58ff-4ec3-be5b-cd54b85e73f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9de1351a52bd4f60a456ac8231b36fa1_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNC02LTEtMS0xMDU2Mg_34157c17-6c30-4006-b26b-7157e3a6ffd6">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de1351a52bd4f60a456ac8231b36fa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNC04LTEtMS0xMDU2Mg_28a54fb6-7676-414c-a177-f03043f2e281">32,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4951a0821e7472faa395694373f197f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNS0yLTEtMS0xMDU2Mg_3b774dea-7580-416f-9372-476c1aa5d898">30,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4951a0821e7472faa395694373f197f_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNS00LTEtMS0xMDU2Mg_a6f3dc32-5cdb-484e-9be4-ff49593b6d7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4951a0821e7472faa395694373f197f_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNS02LTEtMS0xMDU2Mg_b1727da0-89c8-4635-a944-7b9c32e18503">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4951a0821e7472faa395694373f197f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNS04LTEtMS0xMDU2Mg_53503166-1831-45f8-8f13-9051f69e7884">30,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c9330e046a4e39b05065c516da655f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNy0yLTEtMS0xMDU2Mg_d7392f91-02ab-4371-8bd5-2dca52d11652">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c9330e046a4e39b05065c516da655f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNy00LTEtMS0xMDU2Mg_b10aa3be-37c1-4170-9609-d3d5151cf5b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c9330e046a4e39b05065c516da655f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNy02LTEtMS0xMDU2Mg_cd5d6660-192f-4365-b504-60573e1e54dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c9330e046a4e39b05065c516da655f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNy04LTEtMS0xMDU2Mg_01d94dcf-ced8-42c7-ba5d-b44a16020096">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bac4dce92ae48faa8415719eeb29418_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOC0yLTEtMS0xMDU2Mg_5f42d1ac-e91e-4976-b182-27ca7ae72451">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bac4dce92ae48faa8415719eeb29418_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOC00LTEtMS0xMDU2Mg_016b6c1b-c506-4107-839d-eb38cdb01b92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bac4dce92ae48faa8415719eeb29418_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOC02LTEtMS0xMDU2Mg_714fbb23-79e9-4af8-9d31-cc91b01343b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bac4dce92ae48faa8415719eeb29418_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOC04LTEtMS0xMDU2Mg_8c5f3b2b-a81c-4354-a29d-2f7ac843be4e">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOS0yLTEtMS0xMDU2Mg_8d9116c2-fe69-4745-9a3e-4ca412087314">482,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOS00LTEtMS0xMDU2Mg_15f6b72a-b016-4394-8de4-c8b84e6ee014">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOS02LTEtMS0xMDU2Mg_fa547f61-675e-4425-b265-3abd1a1cfad5">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOS04LTEtMS0xMDU2Mg_4bfdac9f-69ca-47ca-be43-a43450f573b8">482,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTAtMi0xLTEtMTA1NjI_cf64dccb-6cac-4b23-839d-8e4173214efb">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTAtOC0xLTEtMTA1NjI_acdd7d6e-3ca6-4752-8c2c-62120a1ed3a2">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTEtMi0xLTEtMTA1NjI_9d12d390-ed45-4b0a-a3a1-b9164a5aa4f5">237,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTEtNC0xLTEtMTA1NjI_0db8d7ae-1231-4ab4-883b-6b07a09fe099">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTEtNi0xLTEtMTA1NjI_30d1f1b4-92e8-44fe-afaf-908e62ed7651">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTEtOC0xLTEtMTA1NjI_8c9c35c4-e3db-4800-be7a-a5b358e1ad1c">237,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTItMi0xLTEtMTA1NjI_9cb04255-7755-42c0-bccd-23bc2fdd265a">482,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTItNC0xLTEtMTA1NjI_3f2a05f0-5e1e-4f06-878c-ada8b17d9790">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTItNi0xLTEtMTA1NjI_c5afc037-5a15-4dc3-b5fb-355e90166d57">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTItOC0xLTEtMTA1NjI_d8ce9780-8da0-415b-afd3-861ca8a8b97c">482,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:46.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMi0yLTEtMS0xMDU2Mg_c30ab330-b7a7-49cb-a9da-9780be2c2aff">217,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMi00LTEtMS0xMDU2Mg_6a08a8e5-c7fd-4511-9e2b-77b1204dac7b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMi02LTEtMS0xMDU2Mg_469fa6c5-9e4d-4396-9222-9122a4210bf8">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMi04LTEtMS0xMDU2Mg_ec81d4f4-38af-4092-955b-50324ee66355">217,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMy0yLTEtMS0xMDU2Mg_c262ab9e-e98f-408e-a9d9-82198e638acf">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMy04LTEtMS0xMDU2Mg_8e9b6e1e-12ea-463b-9a69-7435ab39c15a">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNC0yLTEtMS0xMDU2Mg_3f7f7b0f-251f-4ecb-a15f-c85056ce3e12">53,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNC00LTEtMS0xMDU2Mg_9f35046d-4b82-4c7a-9b46-ba335b3e8fca">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNC02LTEtMS0xMDU2Mg_2cff54b2-99b8-493b-afbb-fb8ae947707f">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNC04LTEtMS0xMDU2Mg_d933e4ac-1322-41fc-ba96-32e9bd22fd15">53,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9989c222dbf4f51a1e18465f25d9679_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNS0yLTEtMS0xMDU2Mg_67ff605b-6d16-454a-a07e-a10bf611405d">39,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9989c222dbf4f51a1e18465f25d9679_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNS00LTEtMS0xMDU2Mg_b98ebf55-0d8f-4cb5-9f49-08ef1d292c40">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9989c222dbf4f51a1e18465f25d9679_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNS02LTEtMS0xMDU2Mg_de53a5a5-2c5f-47cf-b43c-ae40e9681962">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9989c222dbf4f51a1e18465f25d9679_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNS04LTEtMS0xMDU2Mg_7459f0dd-58fb-4270-899b-8b292e956d61">39,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNi0yLTEtMS0xMDU2Mg_289bdbf3-b335-46b8-ad42-478886117863">9,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNi00LTEtMS0xMDU2Mg_6e18a581-c133-4cf6-a407-c2273447ad28">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNi02LTEtMS0xMDU2Mg_2c1e3878-abff-41ec-a0e7-b517683860b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNi04LTEtMS0xMDU2Mg_409083ca-ffd8-490e-b41d-e77ac19db365">9,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNy0yLTEtMS0xMDU2Mg_a63aa18b-6dd8-4185-9caf-ccd631457d60">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNy00LTEtMS0xMDU2Mg_186966e1-0315-48dc-b16d-b4fb3bb4a451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNy02LTEtMS0xMDU2Mg_927ebf89-6d75-4eb7-b391-0b5d626e11b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNy04LTEtMS0xMDU2Mg_786b50b2-e9d4-43cf-aeb8-4dc532137b0b">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c294134d0304a859adb3c48427afe95_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOC0yLTEtMS0xMDU2Mg_7dce6af2-ac48-4845-a0c7-446926bcaf14">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c294134d0304a859adb3c48427afe95_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOC00LTEtMS0xMDU2Mg_4aa026a4-30ef-49a5-b530-8933f58c9dc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c294134d0304a859adb3c48427afe95_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOC02LTEtMS0xMDU2Mg_b9b2ae9d-dae1-49f5-9344-1f501bfe159a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c294134d0304a859adb3c48427afe95_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOC04LTEtMS0xMDU2Mg_feb1ca18-abee-4848-b004-f8a6efd48cdf">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOS0yLTEtMS0xMDU2Mg_32b2d660-f8b3-4a97-b1fb-a582523da740">483,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOS00LTEtMS0xMDU2Mg_3c5b22f5-671a-42ee-b3d0-5eed4aa327db">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOS02LTEtMS0xMDU2Mg_75c619f8-a253-41e8-9c38-e9229fd3506a">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOS04LTEtMS0xMDU2Mg_b44769ad-854f-4439-96c5-90b48780a515">483,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTAtMi0xLTEtMTA1NjI_3cab3b96-238d-4206-959a-0ded1d2c5d33">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTAtOC0xLTEtMTA1NjI_90c89626-5adf-4fbc-84f3-cd4f5e9f4b23">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTEtMi0xLTEtMTA1NjI_7a5cec10-df97-4cc7-8a5c-9887a66c8f41">320,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTEtNC0xLTEtMTA1NjI_b239e42f-fc11-4cd3-827e-5f9940230ecb">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTEtNi0xLTEtMTA1NjI_ca82c0e7-0853-460e-857a-5a9061e92ae6">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTEtOC0xLTEtMTA1NjI_49e5cf25-9759-4b49-8642-51eddb411e91">320,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTItMi0xLTEtMTA1NjI_e1d1c12c-c1cb-412a-aac4-d637518081e8">483,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTItNC0xLTEtMTA1NjI_45803ea0-2c7e-4442-9ecd-00bbc58c722b">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTItNi0xLTEtMTA1NjI_bbede4b6-6936-4bc6-90d4-2f94f8f88c71">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTItOC0xLTEtMTA1NjI_f2cd38c3-2481-4065-82e8-8caebecde6d7">483,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021 there were <ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjA4Mw_361d3b5f-a1f9-4888-a6b9-8da692df4afb">no</ix:nonFraction> realized gains or losses. For the fiscal year ended December 31, 2020, there were <ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjE0OA_f2f706ec-186b-445b-9062-52e7caaf3849">no</ix:nonFraction>minal realized gains. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss positions in the marketable securities as of December 31, 2021 and 2020 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjY5Ng_3bb81c4a-2b7f-44ea-8ee2-ca017a776391">173.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjcwMw_bc1e3d8b-1bc5-4d64-b9d7-cb073bdbcf85">124.9</ix:nonFraction> million as of December 31, 2021 and December 31, 2020, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-101-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="i11fa0031081e42139ec7d854bd41efe5"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjk4Mw_abdd9a24-e98c-48f6-84a4-13eb2c5ab9d0" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:44.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMS0yLTEtMS0xMDU2Mg_03206182-aea3-496c-80e9-59f51fcd6ad2">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMS00LTEtMS0xMDU2Mg_d2f8b072-911d-476c-9032-c9d66ee64ee5">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMS02LTEtMS0xMDU2Mg_fc4090c1-136d-46f8-b73b-b8ac7ebec17a">142,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMi0yLTEtMS0xMDU2Mg_b0750c08-d5cb-4449-8f4a-4ea8a4b9b6ad">4,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMi00LTEtMS0xMDU2Mg_52d99417-81f4-4c91-a4e6-115e870d0bcb">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMi02LTEtMS0xMDU2Mg_a7963acd-3091-4a73-9e51-0128d846093a">3,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMy0yLTEtMS0xMDU2Mg_808de7ed-ae92-4a2b-b305-32fd49865f28">249,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMy00LTEtMS0xMDU2Mg_6c4c7d59-88ff-42f6-bc6c-f85c4ca4f506">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMy02LTEtMS0xMDU2Mg_db3cff77-b044-48a8-9a6d-8dfa682cd27b">146,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4e1826361eea43a9b8ec57ad5f93ef33_91"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RleHRyZWdpb246ZDE0MTA4MzQwNDA5NDdkMTliZTM4MTk0Yjg0NDAxZDBfMjg4_faa91466-2103-4a7f-bd5c-f26a9f62880f" continuedAt="i8c9a6f17f0414dc58acef1b25401281f" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i8c9a6f17f0414dc58acef1b25401281f"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of raw materials, work in process, and finished goods related to the manufacture of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RleHRyZWdpb246ZDE0MTA4MzQwNDA5NDdkMTliZTM4MTk0Yjg0NDAxZDBfMjg2_3f0712b6-b8f1-4bc5-81f6-9a9c7239bf65" continuedAt="idbdd4b191b204e2892723fa02ecb5c4e" escape="true">The following table summarizes the components of inventories: </ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="idbdd4b191b204e2892723fa02ecb5c4e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:66.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMS0yLTEtMS0xMDU2Mg_9680a38e-b4e0-407e-b66b-2c8d93adcd4d">12,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMS00LTEtMS0xMDU2Mg_80aa6284-8388-484a-91b9-a96c189b984a">5,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMi0yLTEtMS0xMDU2Mg_1bda04e2-3693-4818-9a05-29d876955a24">10,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMi00LTEtMS0xMDU2Mg_459ee99c-8e19-46f6-9a88-95fe946552ae">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMy0yLTEtMS0xMDU2Mg_56ffe7e1-407b-44e5-8911-02528cf59db1">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMy00LTEtMS0xMDU2Mg_b681fde3-7a4a-46ee-b668-80b1a1117915">6,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfNC0yLTEtMS0xMDU2Mg_9304cbf5-2988-43bb-8262-d1da24c76a87">26,818</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfNC00LTEtMS0xMDU2Mg_35b1e5f0-7ebd-4344-9979-e392626b5b28">19,556</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a reserve for inventory of $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RleHRyZWdpb246ZDE0MTA4MzQwNDA5NDdkMTliZTM4MTk0Yjg0NDAxZDBfMjQ3_aba45824-6d47-4f82-8998-1e2ed7501eae">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RleHRyZWdpb246ZDE0MTA4MzQwNDA5NDdkMTliZTM4MTk0Yjg0NDAxZDBfMjU0_de8f2a7b-23a2-4781-9e2e-be266aaef9f8">0.1</ix:nonFraction> million as of December 31, 2021 and December 31, 2020, respectively.</span></div></ix:continuation><div id="i4e1826361eea43a9b8ec57ad5f93ef33_94"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RleHRyZWdpb246OGFjOGJjY2E2NzUxNGQzMmIwNGMwYTk1NzM3MmE5YjJfMTYw_ed4a9cef-6ec5-49f1-a5c9-f79dc4ce33c2" continuedAt="i6d0674a90f464b1494fc6d536c8704f5" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i6d0674a90f464b1494fc6d536c8704f5"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RleHRyZWdpb246OGFjOGJjY2E2NzUxNGQzMmIwNGMwYTk1NzM3MmE5YjJfMTY0_9c936e62-8d21-4e83-87bc-5be18ce3cb6c" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:72.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9043474a4a1d4089aaaa1c119c5ded63_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMy0yLTEtMS0xMDU2Mg_ca195921-6172-4497-b4a6-5b809db8ab8b">24,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i506e380918854e4287cf7b8f4aec8307_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMy00LTEtMS0xMDU2Mg_78966031-8f53-4193-acc0-ec1f989aac5f">24,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961d1290b5bb44a89495cd0f93b4d7c7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNC0yLTEtMS0xMDU2Mg_5866d74a-f885-496b-8c52-30175dbbecc3">16,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cd09ac01f449a786ec0c0e00df7434_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNC00LTEtMS0xMDU2Mg_1b4e3442-5b4f-4b56-a29f-7bc97563f52c">15,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f1194f778c47b687d90861adf8f887_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNS0yLTEtMS0xMDU2Mg_41d9e597-b053-4d0d-bf73-b8ac46fc0b42">8,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e8c7b22d7744d49e714d729f4a3155_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNS00LTEtMS0xMDU2Mg_ce7073cf-9ad0-400b-ac0a-7689d7a6ac88">5,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b897fa4f7e47f09f12e76a909b949f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNi0yLTEtMS0xMDU2Mg_521440c5-c393-43ef-a18a-d521e1eb03db">5,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a56fb4793d42e9983d44923f0ea779_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNi00LTEtMS0xMDU2Mg_c9a94e73-c39e-442d-9f5a-c31619012efa">5,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie154cc033bab496a99fb346732f0a456_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNy0yLTEtMS0xMDU2Mg_ff6e089e-33ae-465c-9704-c2ad2be44946">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582c365c59c5453c936ce8bba128fd1d_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNy00LTEtMS0xMDU2Mg_2663a6ec-6037-40c0-9a62-0d8a0d99d70b">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3018b481564885813a6100e4a32e2f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfOC0yLTEtMS0xMDU2Mg_9594922a-d22c-41ba-951d-f48cc7da3001">3,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50bd891b09b1476badb04c23c7939da3_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfOC00LTEtMS0xMDU2Mg_0981234c-fccb-4fef-8af7-bd70c7aed41e">2,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc60489656e8435486f90d2cf2907e4e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfOS0yLTEtMS0xMDU2Mg_f0ec6595-2f90-4432-b1ef-e6241c2e7bb4">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79912bf414894f7c880e3b24a7d15884_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfOS00LTEtMS0xMDU2Mg_af086139-7f7e-4d9d-b43f-0fa399064579">1,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e5b99eaef547c5b606f006be101008_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTAtMi0xLTEtMTA1NjI_b01945b3-29e0-4cba-af0d-1ffc213886ef">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b21949c52d343ef9e73e3897f897333_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTAtNC0xLTEtMTA1NjI_6b98ba1f-c805-4a48-bcc9-6b206720ab7e">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTEtMi0xLTEtMTA1NjI_27187a4b-dcff-42c0-ad15-6ddcdd0164ec">62,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTEtNC0xLTEtMTA1NjI_534ad63f-16bc-4682-bff5-a84d5b3577be">58,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTItMi0xLTEtMTA1NjI_a6a403c8-0fe5-40f3-ac7b-b6f59e4ccbaa">19,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTItNC0xLTEtMTA1NjI_921e56bf-0ce5-4cb7-8738-0e771ea1fd4f">14,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTMtMi0xLTEtMTA1NjI_1eb8c681-3712-459b-ba22-e81c75da9479">42,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTMtNC0xLTEtMTA1NjI_0b9d586b-d0fa-4028-9f65-969a3347c6c0">43,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RleHRyZWdpb246OGFjOGJjY2E2NzUxNGQzMmIwNGMwYTk1NzM3MmE5YjJfMTA2_fce7eed7-d8ed-4e3d-8360-e365e6012803">5.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RleHRyZWdpb246OGFjOGJjY2E2NzUxNGQzMmIwNGMwYTk1NzM3MmE5YjJfMTEz_c1e2fa00-c1a1-4cfa-813b-95aa9c233fec">8.4</ix:nonFraction> million for the years ended December 31, 2021 and December 31, 2020, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-102-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RleHRyZWdpb246ODE1ODY1YTFmYWUxNDAwMjhlM2M3MDcxZGQ3Zjk1OTNfMTMw_117aaff7-c8d6-49be-9dfc-c3f37aa3d867" continuedAt="iba623f0eda1841c5b5f997daea0e56dd" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="iba623f0eda1841c5b5f997daea0e56dd"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RleHRyZWdpb246ODE1ODY1YTFmYWUxNDAwMjhlM2M3MDcxZGQ3Zjk1OTNfMTMy_ad148642-b447-42ad-9442-259017da7f7b" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of the following: </span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:72.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMi0yLTEtMS0xMDU2Mg_dde9148f-f59b-486e-832f-1f1e8fe2509d">24,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMi00LTEtMS0xMDU2Mg_6c0d38a8-fefb-4b58-a309-f24dc0f021b2">23,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing&#160;&amp; contract research costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:AccruedContractManufacturingAndContractResearchCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMy0yLTEtMS0xMDU2Mg_1356a849-08a0-4679-9dd1-47a41f7d41e6">20,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:AccruedContractManufacturingAndContractResearchCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMy00LTEtMS0xMDU2Mg_0dd8dc4b-b8d3-4e9f-861a-e68641f88d8a">19,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales rebates and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:AccruedSalesRebatesAndChargebacksCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNC0yLTEtMS0xMDU2Mg_c852dca0-54d1-43ff-8afa-ce366bd8477e">15,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:AccruedSalesRebatesAndChargebacksCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNC00LTEtMS0xMDU2Mg_f6bd1767-5896-4002-a123-a507e85358d3">12,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued program fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:AccruedProgramFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNS0yLTEtMS0xMDU2Mg_cddaf89e-1e37-4722-9644-e9b1a8598e44">13,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:AccruedProgramFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNS00LTEtMS0xMDU2Mg_affc156e-2480-48aa-8f64-1fe3378d0597">16,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNi0yLTEtMS0xMDU2Mg_7f45118a-3c44-4771-bb75-0c500d45c785">9,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNi00LTEtMS0xMDU2Mg_d6d74136-7124-4c74-b7e7-9cc25d7bee48">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfOS0yLTEtMS0xMDU2Mg_259ca495-d6a6-44b9-8175-b48bf5573b5f">6,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfOS00LTEtMS0xMDU2Mg_99a89314-defb-48da-ab50-c9ef4f84940b">11,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTAtMi0xLTEtMTA1NjI_0290bd5c-9fea-4593-a7ef-671c9856249a">4,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTAtNC0xLTEtMTA1NjI_3c7b3ff6-4956-4ad1-b704-731fcace9fa4">6,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTEtMi0xLTEtMTA1NjI_3ccbccfd-01d3-45c9-96d4-c37ca31f10c4">4,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTEtNC0xLTEtMTA1NjI_b3699b6c-f1e6-44b0-987b-067680d15fd1">4,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTMtMi0xLTEtMTA1NjI_7ed08490-5c83-41ca-87b4-75afffd71f2c">98,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTMtNC0xLTEtMTA1NjI_f10d8797-8f27-462d-a97a-fc6413b85182">96,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4e1826361eea43a9b8ec57ad5f93ef33_100"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQ3NjU_171dab99-d11f-425f-b0f5-7f310027765c" continuedAt="i174d50a84c46415b822d085ca5c6b180" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i174d50a84c46415b822d085ca5c6b180" continuedAt="i5a2866e5eec14ea08ad3f5158982923a"><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Warrants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company was authorized to issue <ix:nonFraction unitRef="shares" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwMQ_e7f6581c-d822-4e13-8c0b-fc3ab5482d0b">500</ix:nonFraction> million shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to <ix:nonFraction unitRef="vote" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="INF" name="fold:CommonStockVotingRightsForEachShareHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzM0Mw_688f2869-29a9-47f9-a654-47bebea6afe0">one</ix:nonFraction> vote for each share held.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a securities purchase agreement with certain entities, the (&#8220;Purchase Agreements&#8221;) for the private placement of an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib4be7fadcd724e6e96874c8bdf5adad5_D20210901-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwODM_bd8d7f1a-0866-43f5-8fb5-e8d137eee530">11,296,660</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwNzU_33753c57-b7a1-4fa5-915b-5132a5071ba4">10.18</ix:nonFraction> per share, and pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwMjk_12e5ba1f-81ab-40ff-bbd1-0522b6cd77bd">8,349,705</ix:nonFraction> shares of common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ida79dc6999b2473ca1d1e66873b93aae_I20210930" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwNjA_7e679356-0225-4ba3-8116-885755a8b294">10.17</ix:nonFraction> per pre-funded warrant. Proceeds from the private placement, net of offering costs, were $<ix:nonFraction unitRef="usd" contextRef="i526b094eedf24604a14d40a8149d2578_D20210901-20210930" decimals="-3" name="fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwOTI_7859fb1c-b64c-446b-ab05-9813eb29c151">199.8</ix:nonFraction>&#160;million. Each pre-funded warrant has an initial exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwNDY_9a07b43d-87da-4243-8e9a-798be7d8932f">0.01</ix:nonFraction> per share and is exercisable at any time after its original issuance, subject generally to the lock-up period, at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds of the initial exercise price for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. Certain of the Purchase Agreements provide for a lock-up period of either 60 days or nine months based on the individual agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first quarter of 2021, <ix:nonFraction unitRef="shares" contextRef="i5d2bcc60d5354077b1fcf38386ec3c2e_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjQzNzE_9a96ae43-0e97-4eb2-b3a0-8f0fcf90fdb6">1,294,999</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id196c02fecfc4cba9917670db7d5c97a_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzUwMDk_4c3314ad-427a-45a4-ac1e-fc75b0a5e4da">1,260,000</ix:nonFraction> warrants were exercised at $<ix:nonFraction unitRef="usdPerShare" contextRef="if6ead177e0cc4421928422190e6ada54_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjQzODI_1e102f73-ca48-4ed2-875a-1368caa9b030">7.98</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iba81fbdcb57c4b63b3261c40099c722f_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzUwMzE_5df7a3c9-0d63-4e78-a104-ab0acf391633">7.06</ix:nonFraction> per share of common stock, respectively, resulting in gross cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9a9bcf319bae47bdbd01835594ec4441_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyOTg1MzQ4OTcyOTM_1e2e2cd7-7b58-4cfa-ae96-26f787fe5080">19.2</ix:nonFraction>&#160;million. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As discussed in ''&#8212; Note 11. Debt'', during the first and third quarters of 2021, the Company entered into separate, privately negotiated exchange agreements with the holders of the Convertible Notes (the "Holders"). Under the terms of the exchange agreements, the Holders agreed to exchange the remaining aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ia8b8a5ba609f4354b35e10b27be3ff0f_D20210701-20210930" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzU3NjQ_70b04105-6fbc-4dc4-8c5f-ce98ed6ec132">2.8</ix:nonFraction>&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzU3NTk_50375b84-f793-4cff-b91d-084c499b76df">472,356</ix:nonFraction> shares of Company common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzU3Nzc_65dde109-9348-4168-a56b-b384d76733d4">0.01</ix:nonFraction> per share. This transaction resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i640ccbc1c3154c0080c449287054612e_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyOTg1MzQ4OTczMDI_f99bf60a-28f9-45df-a4a7-6f246461efca">2.7</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyOTg1MzQ4OTczNDg_e02507e4-307e-4a49-90f3-9aae7836b96a">five</ix:nonFraction> thousand dollars to additional paid-in-capital and common stock, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As discussed in ''&#8212; Note 11. Debt'', during the first and second quarters of 2019, the Company entered into separate, privately negotiated exchange agreements with a limited number of Holders. Under the terms of the exchange agreements, the Holders agreed to exchange an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i10d2bc422365419a845cd1b651b3a636_D20190701-20190930" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjYxODI_23b6ce7f-f5f8-4600-ad21-5528bdd5e359">247.2</ix:nonFraction>&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="iec7f88d07a8f4a3196f84540950c1ba1_D20190701-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjYxOTg_a1273226-b82b-4417-b106-4858109cbf99">44.0</ix:nonFraction>&#160;million shares of Company's common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjYxNzU_8b00d149-902e-4c2d-8b12-1c60227bb92f">0.01</ix:nonFraction> per share. These transactions resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i295c47ed72d64074b5f32eeaad26a5cd_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2NDE4MTY_90450925-f698-4075-9910-1ff78c21b620">215.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="iec7f88d07a8f4a3196f84540950c1ba1_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjYyNjM_7e848fd7-af46-4801-aa8a-73df6f7177ea">four hundred forty</ix:nonFraction> thousand dollars to additional paid-in-capital and common stock, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-103-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5a2866e5eec14ea08ad3f5158982923a"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2019, the Company completed an underwritten equity offering and issued <ix:nonFraction unitRef="shares" contextRef="i1b32bb1228f4457281ae01a46fc12e65_D20190401-20190630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzU5MA_2183b1df-63f9-44e8-9012-d8263cefbb7b">18.7</ix:nonFraction> million shares of its common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i90c6ab2b0ea94811b533075e4f2a87ff_I20190630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzYyMw_435aa4bc-b0ab-4b8a-9441-52009a76e636">10.75</ix:nonFraction> per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1b32bb1228f4457281ae01a46fc12e65_D20190401-20190630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzc3OQ_4e08703c-195b-433e-8e9b-4df21ebc7e92">189.0</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2019, <ix:nonFraction unitRef="shares" contextRef="i3c032683abb24387a73c8bc636880d41_D20190301-20190331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzg3Nw_50465457-04c3-403a-9146-48eb37d285c7">101,787</ix:nonFraction> warrants were exercised at $<ix:nonFraction unitRef="usdPerShare" contextRef="i74af5a78ba0e4e39b3e7266e28299ef6_I20190331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzkwNw_6300f421-98dc-4a0c-af60-6ff2c4f2cfb2">7.98</ix:nonFraction> per share of common stock resulting in gross cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7f3536bcc2ae4952bcd1f4f308635ac0_D20190301-20190331" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzk3Mg_977b709c-ba7d-4793-aaa1-a99d46524e76">0.8</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2018, the Company reached a clinical milestone, which was the dosing of the first patient in a Phase 3 study, related to the contingent consideration from the acquisition of Callidus Biopharma, Inc. ("Callidus"). The milestone for this event was $<ix:nonFraction unitRef="usd" contextRef="i482c3a76c4274a0e899e18ce88699cb5_D20190101-20190331" decimals="-5" name="fold:ContingentConsiderationMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEzMjc_df9a4434-124c-48d8-93a4-26e12ef431d3">9.0</ix:nonFraction> million, which was paid by issuance of <ix:nonFraction unitRef="usd" contextRef="i482c3a76c4274a0e899e18ce88699cb5_D20190101-20190331" decimals="INF" name="fold:MilestonePaymentStockIssuedAsConsideration" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzU5NDU_e23ba845-de80-4baa-97b5-a746d11c60bf">771,804</ix:nonFraction> shares of Company common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzYwMDQ_65dde109-9348-4168-a56b-b384d76733d4">0.01</ix:nonFraction> per share, in the first quarter of 2019.  This transaction resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="ie7c2736e1c5f4bbdbe8ee555092181b6_D20190101-20190331" decimals="-5" name="fold:StockIssuedDuringPeriodValueContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyOTg1MzQ4OTczNTk_b80490af-86fd-46c3-99a8-9cc8017d26a2">9.3</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i20b1ffa344ad4c46a05f2baded3c95de_D20190101-20190331" decimals="-3" name="fold:StockIssuedDuringPeriodValueContingentConsideration" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2NDE4MjY_7974077e-9f05-416b-b2b4-afa4af261762">eight</ix:nonFraction> thousand dollars to additional paid-in-capital and common stock, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Deferral Plan, (the "Deferral Plan") provides certain key employees and members of the Board of Directors as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code of 1986 as amended.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a deferred compensation investment balance of $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyMDY_affe5e0e-3986-4b89-96ad-ab549ceb626a">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-5" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyMTM_13178e5a-da26-42d2-9b1f-e2d576322c1f">4.1</ix:nonFraction> million as of December 31, 2021 and December 31, 2020, respectively, with corresponding approximate amounts of liability. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral Plan investment assets are classified as trading securities and are recorded at fair value with changes in the investments' fair value recognized in accumulate other comprehensive gain (loss) in the period they occur. Deferred compensation liability amounts under the Deferral Plan are included in other long-term liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plan </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. Under the provisions of the Plan, no option will have a term in excess of <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQxODQ_e0827b78-9964-4726-81ce-1d0a9992d3f3">10</ix:nonNumeric> years. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest <ix:nonFraction unitRef="number" contextRef="ia0f988918ba344f883b74b4646d25fbe_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQ0Nzg_3cec992d-056f-4df6-9b1a-d3a381f58c00">25</ix:nonFraction>% on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for <ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQ2MjI_a978cbe7-f1af-45b3-9e28-a866b8abac1e">100</ix:nonFraction>% of the shares vested at any time after the date of grant. As of December 31, 2021, the Company has reserved up to <ix:nonFraction unitRef="shares" contextRef="i4f26112489e84068b2efcf3e81829b41_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQ3MjQ_8e6c85f8-ca2e-4ee1-930b-f98801544986">18,322,154</ix:nonFraction> shares for issuance under the Plan.</span></div></ix:continuation><div id="i4e1826361eea43a9b8ec57ad5f93ef33_106"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMTA_a795f554-24ae-4ada-a388-ac636dddfa4d" continuedAt="i9d6f61a866bf450d87020ce2abd1c87e" escape="true">Share based Compensation </ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9d6f61a866bf450d87020ce2abd1c87e" continuedAt="i94afcbf58d0a40c6a43cd0f990aa9b76">The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors. advisors, and consultants at a price to be determined by the Company&#8217;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-104-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i94afcbf58d0a40c6a43cd0f990aa9b76" continuedAt="i0280cb6f2dae4b43a0eabc53e5a8e323"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan provides for certain benefits to qualifying Plan participants who separate from service with the Company due to death, disability or "retirement" (as such term is defined under the Plan) ("Qualified Participants"). Options granted under the Plan ("Options") to a Qualified Participant shall continue to vest until the 2nd anniversary of the Qualified Participant&#8217;s separation and all vested Options held by such Qualified Participant shall remain exercisable until the earlier of the 4th anniversary of the Qualified Participant&#8217;s separation or the original expiration date of the Option. Options that are not exercised during this exercise period shall be forfeited. Time-based restricted stock units and restricted stock granted to a Qualified Participant under the Plan that was scheduled to vest within the <ix:nonNumeric contextRef="i3bf65e4e37b3456d95b9a66cf49959fa_D20181221-20181221" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzI3NDg3NzkwNzQ3NTQ_200d4f06-6280-46e2-95a5-cfcfc162bbe3">two year</ix:nonNumeric> period following the Qualified Participant's separation shall accelerate and be delivered upon such separation. Any time-based restricted stock units or restricted stock that would have vested after such <ix:nonNumeric contextRef="i3bf65e4e37b3456d95b9a66cf49959fa_D20181221-20181221" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzI3NDg3NzkwNzQ3NTU_58c05e55-37b8-46fb-af1f-b9273ebc75a9">two year</ix:nonNumeric> period will be forfeited upon the Qualified Participant's separation. Also, per the Amendment, any performance-based restricted stock units under the Plan ("PRSUs") received by the Qualified Participant, shall remain eligible to vest after the Qualified Participant&#8217;s separation based on the actual performance of the Company through the end of the performance period applicable to any such PRSUs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the fair value method of measuring stock-based compensation, using the fair value of each equity award granted. The Company chose the &#8216;&#8216;straight-line&#8217;&#8217; attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007. The average expected life is determined using our actual historical data. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.</span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMTE_8605bc20-8425-4b9c-be5f-79f4563261e0" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzItMi0xLTEtMTA1NjI_aeb35af7-e712-46da-9615-345670a7d18e">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia272441483a740d6812f2646381f7580_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzItNC0xLTEtMTA1NjI_9039c02f-b50e-4772-baf2-b8cc66141711">75.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzItNi0xLTEtMTA1NjI_27d2be83-61f1-44dc-a870-765eb5061f06">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzMtMi0xLTEtMTA1NjI_9e1d218c-34de-41a4-98da-a863bce3a9d6">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia272441483a740d6812f2646381f7580_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzMtNC0xLTEtMTA1NjI_aff098e9-305a-42c1-bef6-7a744c5a21d6">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzMtNi0xLTEtMTA1NjI_080aab89-ffc6-46db-94bc-1ca5a99de036">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life of options (years) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzQtMi0xLTEtMTA1NjI_9a687b44-828e-478e-8ca9-c79d46084b8c">5.40</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia272441483a740d6812f2646381f7580_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzQtNC0xLTEtMTA1NjI_f9df2818-0178-4e7d-bad1-d37228fc9c1e">5.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzQtNi0xLTEtMTA1NjI_fa2e9948-d1dc-4f85-9bf5-2f4da913e6b1">5.68</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzUtMi0xLTEtMTA1NjI_4fc43062-95cd-4e82-967a-08d0c27ac3fc">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia272441483a740d6812f2646381f7580_D20200101-20201231" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzUtNC0xLTEtMTA1NjI_07299ed4-c5f2-4c8d-9af8-b916ddae9d26">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzUtNi0xLTEtMTA1NjI_8c17ac28-d3da-4284-a80d-86862cea7af9">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value per share of options granted during 2021, 2020, and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM2MDY_46e445ce-031b-466e-9faa-b7bfba9e453c">9.08</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM2MTA_48cf72b1-b4e2-4bc0-9305-1445dfc5891c">6.40</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM2MTg_9cedfc8b-6a95-4e75-ae1c-03b9b5c13622">6.67</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-105-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0280cb6f2dae4b43a0eabc53e5a8e323" continuedAt="i0282f3efb86943b5b47de38f23a905c8"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMDk_8f37f9d2-c4f5-44ae-b4da-bd324ed14c0e" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock options for the year ended December 31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id112dec781f849479a5fea1933c18841_I20181231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzItMS0xLTEtMTA1NjI_5e651ecd-3c1c-4e39-9e24-70a3dc525f0e">15,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id112dec781f849479a5fea1933c18841_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzItMy0xLTEtMTA1NjI_3ceab119-9877-484a-b951-d217c539e536">8.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzMtMS0xLTEtMTA1NjI_b4b769e1-0718-46fd-b57c-182e536ed82d">4,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzMtMy0xLTEtMTA1NjI_d58d9726-23b2-4ebb-adbd-9685bdbdbfd9">10.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzQtMS0xLTEtMTA1NjI_eda85862-e228-4ae6-8c2f-5bc86a6b3a6f">1,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzQtMy0xLTEtMTA1NjI_426afee6-edce-4acd-bb96-760f744573bc">5.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzUtMS0xLTEtMTA1NjI_cdc8e33d-84e0-4322-abf5-87f9f2a85808">879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzUtMy0xLTEtMTA1NjI_9b1ce0f6-b369-4dfa-b57f-187d72a368b6">11.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzYtMS0xLTEtMTA1NjI_01d32d6b-6086-490c-98d2-4be5cbbe0e88">331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzYtMy0xLTEtMTA1NjI_605a25f1-0f23-442f-b7c1-43626aa73f96">13.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzctMS0xLTEtMTA1NjI_9831f281-4cf5-415d-abc6-a65144daea21">16,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzctMy0xLTEtMTA1NjI_e807e011-3c50-4aa2-ab9a-43867082d25a">9.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzgtMS0xLTEtMTA1NjI_aa547438-7d25-4482-9ca0-9b792c478770">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzgtMy0xLTEtMTA1NjI_b3dcb525-642c-4e19-b27b-747d98fe0371">9.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzktMS0xLTEtMTA1NjI_a0b6e191-3837-4094-971e-ba529d909154">5,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzktMy0xLTEtMTA1NjI_18848584-3520-4356-9e1c-03e43fe230b1">8.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEwLTEtMS0xLTEwNTYy_04ed8ff6-3ea1-4903-b9cb-3ba07a4c451c">1,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEwLTMtMS0xLTEwNTYy_e6fb31f0-2afb-417d-b399-b77341055738">10.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzExLTEtMS0xLTEwNTYy_cce7c45b-c7d9-4dd8-8fb0-1e44d9d871a2">435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzExLTMtMS0xLTEwNTYy_c66c4490-6a7e-4e37-94d6-887a25fde5ae">13.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEyLTEtMS0xLTEwNTYy_e826443b-0292-4fbb-92b6-83ea5f2103e4">14,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEyLTMtMS0xLTEwNTYy_63bce7bf-1932-4177-9107-c77bbb25d1d3">9.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEzLTEtMS0xLTEwNTYy_c89c6de7-114d-42d1-86fe-9fb3d194fb42">3,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEzLTMtMS0xLTEwNTYy_1b86f45f-bf56-4192-aa9d-ebaed4947a63">16.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE0LTEtMS0xLTEwNTYy_4e5fe010-e4dc-4ab8-9b7c-3a4f5bb854b8">1,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE0LTMtMS0xLTEwNTYy_b5fc58ef-8311-4afa-a8b0-089d0125487e">7.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE1LTEtMS0xLTEwNTYy_b4033652-5e85-4ea7-bc79-cb106d861543">844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE1LTMtMS0xLTEwNTYy_a21fa33a-b2ef-470f-9d0e-21c4007e6d25">12.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE2LTEtMS0xLTEwNTYy_9cd4a5a8-bc7b-4d73-9eb7-bb0dc47a495a">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE2LTMtMS0xLTEwNTYy_36bb0c8e-9d01-479e-971a-d9d9d14fd807">13.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE3LTEtMS0xLTEwNTYy_6339a789-c491-4c52-951e-5bb35243079e">14,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE3LTMtMS0xLTEwNTYy_d8684cf3-2a77-4b96-ab3d-6561b784ed5b">11.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE3LTUtMS0xLTEwNTYy_2d3e18c6-66e2-4d36-aa40-d9c3da508685">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE3LTctMS0xLTEwNTYy_2a72adc8-a8ea-470d-8578-25925b9b50b9">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE4LTEtMS0xLTEwNTYy_38aadd05-8a08-43a0-b73b-235d4724c8f4">13,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE4LTMtMS0xLTEwNTYy_ac94e5c2-a2bc-487c-961e-e5489a2bec16">10.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE4LTUtMS0xLTEwNTYy_4b0ecdff-53a6-4d33-bdc4-d39d0c0c0d71">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE4LTctMS0xLTEwNTYy_0dcf2e0e-6a2c-46ce-92c3-66719c0df60b">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE5LTEtMS0xLTEwNTYy_dfd18171-8e1b-4df3-a62b-ca1d686982ce">9,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE5LTMtMS0xLTEwNTYy_cf4f2778-8ceb-442a-ad97-652ebb2e379f">9.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE5LTUtMS0xLTEwNTYy_2577ad32-d7da-4326-b874-3394643b833d">5.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE5LTctMS0xLTEwNTYy_68a2be16-bd1f-4cc6-864c-fb4ae0b2574d">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM4MDk_e741c7c9-1389-4108-90ed-06757b4fb7db">8.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM4MTM_9e666315-c687-449c-ac8c-16325a758170">40.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM4MjE_4e3301ac-6f4f-4d94-b05d-0fa5cd60c1a1">11.8</ix:nonFraction> million respectively. Cash proceeds from stock options exercised during the years ended December 31, 2021, 2020, and 2019 were $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM5MjQ_974d083c-39ef-47e2-a44c-0281f42d1b6d">10.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM5Mjg_23de9ff9-c16b-45f1-9a04-cec50ea592b7">42.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM5MzY_4656315a-4106-4637-89c5-d4b7df88f338">11.5</ix:nonFraction> million, respectively. As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock options granted was $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzQwNTM_cd8e64b4-17ab-4c30-bcfe-2f18af7023f8">28.9</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzQxMjM_459a4d44-729d-410d-9c2b-061d2d85e716">three years</ix:nonNumeric>.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-106-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0282f3efb86943b5b47de38f23a905c8"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMDQ_6b63f35b-acfa-4d18-b463-016c8eacb408" continuedAt="iab2bf9314f054133b69e3e61165cdda7" escape="true">A summary of non-vested RSU activity under the Plan for the year ended December 31, 2021 is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><ix:continuation id="iab2bf9314f054133b69e3e61165cdda7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia576c72c43a84ff6b63f05447685167d_I20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzItMS0xLTEtMTA1NjI_ebd6c588-df35-4dc7-bd11-57b94fa84efe">3,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia576c72c43a84ff6b63f05447685167d_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzItMy0xLTEtMTA1NjI_bf422e2e-1870-455f-a71e-b95c7e5f7150">10.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzMtMS0xLTEtMTA1NjI_969a0691-92a5-4f04-bb86-6820d10e6351">3,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzMtMy0xLTEtMTA1NjI_5c57682a-68d9-49f3-83a4-5275585faa3c">10.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzQtMS0xLTEtMTA1NjI_2e293e1a-5ed1-4c12-8875-46234436c581">921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzQtMy0xLTEtMTA1NjI_7e1dec01-5813-4a90-a484-a9027be066c8">8.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzUtMS0xLTEtMTA1NjI_29a461a0-1609-4efd-bf82-f3eeb9c999e4">525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzUtMy0xLTEtMTA1NjI_a7de2252-21f8-485c-ad41-9a7fee922110">10.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ab772d198ff45af9c40e229d45fba03_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzYtMS0xLTEtMTA1NjI_0365b459-49b1-47f3-ab3e-ed802193940a">5,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ab772d198ff45af9c40e229d45fba03_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzYtMy0xLTEtMTA1NjI_6478294d-72b4-455a-a632-d5c119a15da1">11.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzctMS0xLTEtMTA1NjI_e9deede7-3b42-4d1c-be35-4fdcc0ac7b3b">4,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzctMy0xLTEtMTA1NjI_240b2934-c5ca-4233-acd7-9f1ab75ab614">11.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzgtMS0xLTEtMTA1NjI_6dc6d989-19bc-4ec3-abae-77eacf3f7d76">2,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzgtMy0xLTEtMTA1NjI_3a93f813-8cb7-4050-ba43-7dda211ffb32">10.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzktMS0xLTEtMTA1NjI_3eb19cfa-8e06-45ec-a818-190b779656ed">1,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzktMy0xLTEtMTA1NjI_0bd5c6aa-4e87-44eb-ab29-f15cc0c0c3df">11.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03c9e518216b4905aab06b70874e18f0_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEwLTEtMS0xLTEwNTYy_210c4b6e-e219-4533-be8a-fe75d119b6d7">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03c9e518216b4905aab06b70874e18f0_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEwLTMtMS0xLTEwNTYy_0a8786e3-b214-496e-aa09-dcbf99254a14">11.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzExLTEtMS0xLTEwNTYy_79c381bf-ae6f-441b-9ab4-db1d81dbd0a3">3,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzExLTMtMS0xLTEwNTYy_b4e367f9-400e-47ec-92e7-d028d5d2ef72">16.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEyLTEtMS0xLTEwNTYy_ba4d6ead-d0d9-42ec-b337-bad7f862e0ae">1,863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEyLTMtMS0xLTEwNTYy_610eaf2f-6fd7-4de6-a7ce-703b22400012">15.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEzLTEtMS0xLTEwNTYy_54e164b2-3760-4ecc-b1f5-63838215c8da">1,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEzLTMtMS0xLTEwNTYy_05f86df2-4d90-4c46-a2c6-6d58705b5ab8">12.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie35de6676f38491e98b8f52cc5c3919b_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzE0LTEtMS0xLTEwNTYy_a8d66cba-875d-4f13-aa01-6ef11780a494">7,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie35de6676f38491e98b8f52cc5c3919b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzE0LTMtMS0xLTEwNTYy_52733e02-7fdf-40f7-a0c2-fdb77377c462">13.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzE0LTUtMS0xLTEwNTYy_7d58712d-4781-4589-a04f-f681aa691a5e">2.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35de6676f38491e98b8f52cc5c3919b_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzE0LTctMS0xLTEwNTYy_deef1e35-b081-4d01-8de8-ff7144f98fa7">84.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzQ3OTk_cecb693c-59be-4ed4-8108-250e8e2a7984">1,863,436</ix:nonFraction> RSUs have vested and all non-vested units are expected to vest over their normal term. As of December 31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ie35de6676f38491e98b8f52cc5c3919b_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzQ5MDk_763448f5-8fc4-4c49-89a7-15c8aa3db6cf">47.6</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUwOTI_0476ee9a-9c9c-4f2d-b258-b4da101344a4">two years</ix:nonNumeric>.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense Related to Equity Awards</span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMTM_63ac1059-7df1-40a2-950e-2ae32f9ecbe9" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971ea6dc71dd40bfbe43d1b72669ed21_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzMtMi0xLTEtMTA1NjI_2dbd8210-ce50-4e4b-8205-0427adb13d9b">17,340</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056c458b470c4579b84a162e7b90dbda_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzMtNC0xLTEtMTA1NjI_690a3909-b434-4e9f-ba34-9f17b50c3df3">20,817</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96486b3a389847dea0287bfe980e800b_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzMtNi0xLTEtMTA1NjI_fa699b60-5c18-473e-b6f5-d4ed4a019390">17,575</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a1701b3e114ced8682f3b8ad409f43_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzQtMi0xLTEtMTA1NjI_02c46181-f5a1-4325-a737-dd9a879381ba">40,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62afedf6cc6c4e2faa6b8366f3d4d566_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzQtNC0xLTEtMTA1NjI_72db1638-6776-4dd1-8839-dbf83616baac">28,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d2388394104afb8de4248ba2dcc24a_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzQtNi0xLTEtMTA1NjI_9129311e-724a-47b4-b386-d5403c311a59">26,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzUtMi0xLTEtMTA1NjI_369b2bdd-4ff9-4cd1-9214-96ed3a86b6c2">57,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzUtNC0xLTEtMTA1NjI_70e862be-e154-4b64-b1e8-f0c755c5791c">49,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzUtNi0xLTEtMTA1NjI_683133c4-92ab-42fc-98fe-621b0e83c18e">44,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4e1826361eea43a9b8ec57ad5f93ef33_109"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzQ1MzA_2779f615-8ed9-4fa0-876c-8946a80a4eca" continuedAt="ie3dd4fccef774071b0dac3804a2a843f" escape="true">Assets and Liabilities Measured at Fair Value</ix:nonNumeric></span></div><ix:continuation id="ie3dd4fccef774071b0dac3804a2a843f" continuedAt="id4cb614dd431496e8fcdec3b9021c77b"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-107-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id4cb614dd431496e8fcdec3b9021c77b" continuedAt="ic1814f0882b84e90b8a875d0e58a69a6"><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs that are unobservable for the asset or liability.</span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzQ1MjU_01ebfbd6-6b0a-41ff-a9ab-48c062adbc4f" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:72.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54f245a14704edc868849226467c804_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzItMi0xLTEtMTA1NjI_4aa8fb2a-1e2f-403a-935a-298fd15ef721">174,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzItNC0xLTEtMTA1NjI_a0e1d06a-a726-4cdb-8c0c-635ff9b6526e">174,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c7b7702b4a40ddb250ad6a54dbfb5f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzMtMi0xLTEtMTA1NjI_ade147ef-e17d-4881-90e2-ee6bbcca0702">32,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66fbce7b1254986b68bdecf5d3984a5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzMtNC0xLTEtMTA1NjI_e89cf1d7-c8a6-4aed-a8aa-db7f07853d6a">32,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a5acb325e646a18e6704ab00914755_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzQtMi0xLTEtMTA1NjI_1cae2a6f-e7ff-4dbf-984b-1b65da2c92db">30,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4951a0821e7472faa395694373f197f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzQtNC0xLTEtMTA1NjI_b6a42a88-f089-4055-8fa0-0314630e0e69">30,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162893650e38441e88ef4089246a0337_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzYtMi0xLTEtMTA1NjI_eea009f8-a533-43fd-ae39-d93ee1733bb9">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c9330e046a4e39b05065c516da655f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzYtNC0xLTEtMTA1NjI_76f9bf4d-c7d6-4b48-9f3e-0d46ccf96ee8">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzctMi0xLTEtMTA1NjI_5141fae9-7880-4987-b6a3-c7b593e414f9">242,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzctNC0xLTEtMTA1NjI_bfa83d28-4e04-4479-b77d-1fabde53145b">242,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzItMi0xLTEtMTA1NjI_f738c1cd-623a-45ad-a536-8827f44a66f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559389e21f1d4d0d9353f0f940507a03_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzItNC0xLTEtMTA1NjI_67d5df85-cfe2-41a3-af26-05ae90576980">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzItNi0xLTEtMTA1NjI_9899b803-0550-4a59-8c50-99f73b51e66b">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzMtMi0xLTEtMTA1NjI_7c1bb98f-7777-4304-ada8-5b1748d7e41b">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559389e21f1d4d0d9353f0f940507a03_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzMtNC0xLTEtMTA1NjI_6d3dac31-cc15-4b84-8242-44ea85f2b501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzMtNi0xLTEtMTA1NjI_2681809c-4fa0-48bc-b019-4cc0231aba1d">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzQtMi0xLTEtMTA1NjI_3740a9df-7234-402e-9216-ee7e7bfca0cf">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559389e21f1d4d0d9353f0f940507a03_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzQtNC0xLTEtMTA1NjI_3e48c34d-47ff-48e0-a5a9-10dd24a5449b">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzQtNi0xLTEtMTA1NjI_639e63bc-ab4d-4916-9cd6-9360635eb3d2">25,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"></td><td style="width:72.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7968ff22354a119a411677a353c84c_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzItMi0xLTEtMTA1NjI_85e2a11e-777a-46cb-ac5c-b0adc0155a54">217,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzItNC0xLTEtMTA1NjI_07da0f57-1667-419d-b16c-3f4a4852deea">217,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ddce89a114b41f59eb1562989c82baf_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzMtMi0xLTEtMTA1NjI_bb4290e6-7419-4bc1-a99c-192cd07fefe7">53,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzMtNC0xLTEtMTA1NjI_0daf4830-af21-49f0-8d61-241b3b06adde">53,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17c20a9953e4a9cafbd1c6bf678b365_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzQtMi0xLTEtMTA1NjI_ea8ce179-6dd8-44fe-92bb-96b40b9211c6">39,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa6cf6f33a74c329c64fa2645338266_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzQtNC0xLTEtMTA1NjI_4bb6635d-d074-4398-abdf-6bcd2c63b691">39,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e5b1225df74406a3b71f72661e0aa3_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzUtMi0xLTEtMTA1NjI_8d54b321-75f3-4ef5-af02-a765ea114cd5">9,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzUtNC0xLTEtMTA1NjI_4c8a46fb-d77e-414e-bc36-ddbfa942f063">9,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209e1f50b3fd43be91783671c328accb_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzYtMi0xLTEtMTA1NjI_80deeb21-4723-4c6d-9714-b0ff897ab019">4,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzYtNC0xLTEtMTA1NjI_38cc0d06-4b4d-4fff-80bf-a8ff94901a2d">4,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d2efb30f714078b268efed578feb16_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzctMi0xLTEtMTA1NjI_185289d7-03c6-46ff-ad22-88fcf17169e8">324,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzctNC0xLTEtMTA1NjI_b36de926-9bd7-4a4f-93d1-1acf9d2bbc7e">324,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d2efb30f714078b268efed578feb16_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzItMi0xLTEtMTA1NjI_66d2db84-7960-4601-9820-b528d852d380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0e4ee9e39849208ef9727b7981c2e8_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzItNC0xLTEtMTA1NjI_b75df211-00a0-4ac2-8126-557946d07447">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzItNi0xLTEtMTA1NjI_693372ce-1903-4ec3-a837-96682f329b21">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d2efb30f714078b268efed578feb16_I20201231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzMtMi0xLTEtMTA1NjI_4a6ade36-0057-4c56-8b85-112cb19fe905">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0e4ee9e39849208ef9727b7981c2e8_I20201231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzMtNC0xLTEtMTA1NjI_b6180548-7d63-4edb-914c-f7d7596cf41f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzMtNi0xLTEtMTA1NjI_a1491866-5792-4f43-beef-9b784607e50e">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d2efb30f714078b268efed578feb16_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzQtMi0xLTEtMTA1NjI_663bbc1d-9f60-487a-b935-f16cc7ea8aaf">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0e4ee9e39849208ef9727b7981c2e8_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzQtNC0xLTEtMTA1NjI_ee285f96-52cb-406c-8bf8-e91df6940d43">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzQtNi0xLTEtMTA1NjI_cbdf1feb-1ddb-422a-8070-d50c15add130">29,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, the Company's Convertible Notes fell into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. As noted in ''&#8212; Note 11. Debt," the Convertible Notes were fully settled during the third quarter of 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-108-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic1814f0882b84e90b8a875d0e58a69a6" continuedAt="i8b8458668ca243ed816183a38a61d827"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets as of December 31, 2021 or December 31, 2020.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Money Market Funds and Marketable Securities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended December 31, 2021. No transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the year ended December 31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable resulted from the acquisition of Callidus. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable for Callidus has been classified as a Level&#160;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzQ1MjY_725379c6-9221-41bd-a389-baa7571216cb" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe disease program:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i48fbd33b6e4d4c73ac985cc9959e7635_I20211231" decimals="3" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZToyMmZlOWUwYmFiNjE0NDc5YjY1MzA4YmNmMmQzY2E5MC90YWJsZXJhbmdlOjIyZmU5ZTBiYWI2MTQ0NzliNjUzMDhiY2YyZDNjYTkwXzItOC0xLTEtMTA1NjI_1e042542-d081-4b07-89a9-e69cbbbdec29">7.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib485fdd881d140c3ade6dc51f9633b29_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZToyMmZlOWUwYmFiNjE0NDc5YjY1MzA4YmNmMmQzY2E5MC90YWJsZXJhbmdlOjIyZmU5ZTBiYWI2MTQ0NzliNjUzMDhiY2YyZDNjYTkwXzMtMi0xLTEtMTA1NjI_182608c4-70cd-4ab5-afdb-48891498980c">18,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6966889240c4972b480adb57c32195c_I20211231" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZToyMmZlOWUwYmFiNjE0NDc5YjY1MzA4YmNmMmQzY2E5MC90YWJsZXJhbmdlOjIyZmU5ZTBiYWI2MTQ0NzliNjUzMDhiY2YyZDNjYTkwXzMtOC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjpiNzhjOWUyOWU0MzA0ZjFmYTYwZTFhNDMzNGEyODFlNF80_f06f3d10-58ac-4afc-bc41-222f4f2b6aaf">75</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i20e3e42521364090aa637b816999865a_I20211231" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZToyMmZlOWUwYmFiNjE0NDc5YjY1MzA4YmNmMmQzY2E5MC90YWJsZXJhbmdlOjIyZmU5ZTBiYWI2MTQ0NzliNjUzMDhiY2YyZDNjYTkwXzMtOC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjpiNzhjOWUyOWU0MzA0ZjFmYTYwZTFhNDMzNGEyODFlNF83_5e3b763d-d78f-44e3-ae37-f465ff60c448">88</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reached regulatory milestone in September 2021 associated with FDA approval of the first BLA and in November 2021 associated with EMA validation of the MAA, both related to the contingent consideration of Callidus for the ATB-200 Pompe disease program. The satisfaction of these milestones resulted in  the collective milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="fold:ContingentConsiderationPaidInStockAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzMyOTg1MzQ4OTAzNzA_df4c1d59-22d9-4748-bc81-85daf7fa0cec">12.0</ix:nonFraction> million, which was payable in cash, resulting in a decrease in the current portion of the contingent consideration liability on the Consolidated Balance Sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-109-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8b8458668ca243ed816183a38a61d827"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzQ1MjM_b07586e8-15e3-498e-bd87-4bc03a1c69cf" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2021 and December 31, 2020, respectively:  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:71.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzItMi0xLTEtMTA1NjI_4c515590-425f-41f7-82bc-84e7266c23a2">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0397e8e64147d183a31226e47071e0_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzItNC0xLTEtMTA1NjI_5f0fbf94-09d0-478a-8667-9e0d0e030162">22,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzMtMi0xLTEtMTA1NjI_39df2e1c-7b8d-4a54-9a40-b5a577208987">6,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzMtNC0xLTEtMTA1NjI_4d5258f4-6700-43f7-97d5-d6f3e02c6d8b">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration  in cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="fold:ContingentConsiderationPaidInStockAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzQtMi0xLTEtMTA1NjI_df4c1d59-22d9-4748-bc81-85daf7fa0cec">12,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="fold:ContingentConsiderationPaidInStockAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzQtNC0xLTEtMTA1NjI_e96a4e0e-c7f9-4d85-97fa-2f07747cecd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzUtMi0xLTEtMTA1NjI_d478f9fa-fd98-4b83-a9c1-cf953efc189d">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzUtNC0xLTEtMTA1NjI_975f0cae-05ef-40a9-948d-2a02d52efdb1">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4e1826361eea43a9b8ec57ad5f93ef33_112"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMzE3_1caef82f-16b8-468b-a20f-21a428a5b82b" continuedAt="ie85033b37b9047d88f0d25268a9deb94" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="ie85033b37b9047d88f0d25268a9deb94" continuedAt="i417b9afa89484c25b1efc9f3e0e067b9"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMzE5_1c853ec4-92e3-4425-b53a-caa73bb24ed7" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b67daeb3434490faa14ce758326fde1_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzItMi0xLTEtMTA1NjI_152be20f-7fd0-4cb0-a80c-b4f29c73316b">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzItNC0xLTEtMTA1NjI_6406e99b-9c7d-40b4-b22c-3d147368bc24">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b67daeb3434490faa14ce758326fde1_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzMtMi0xLTEtMTA1NjI_076ecbdf-d68c-48fe-b16e-76bcfaa34fbb">6,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzMtNC0xLTEtMTA1NjI_86eea45a-4d7e-4385-bda6-8e347ca8a389">7,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b67daeb3434490faa14ce758326fde1_I20211231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzQtMi0xLTEtMTA1NjI_2a4f299e-0fd2-4b0f-93fd-1ea51f628691">4,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzQtNC0xLTEtMTA1NjI_c8cfaedd-2b27-44fc-9cd3-664a785d8559">5,592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Senior Secured Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b67daeb3434490faa14ce758326fde1_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzUtMi0xLTEtMTA1NjI_8cd428a7-5d4a-447b-91e4-a95e9cd8b024">389,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzUtNC0xLTEtMTA1NjI_9ccf4f22-3b74-405f-b3a8-36d44de5304c">386,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE0LTItMS0xLTEwNTYy_570bf20c-ddcd-40f6-8199-fe0d58328799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE0LTQtMS0xLTEwNTYy_b81b2dfc-40ac-4434-90d3-3479a18e05f3">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE1LTItMS0xLTEwNTYy_60f956c9-63df-4901-8bda-fb57867e9df2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE1LTQtMS0xLTEwNTYy_bcf5eb17-5114-45b0-b731-3cc4f90f0a49">518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE2LTItMS0xLTEwNTYy_24c3be61-aeef-46df-af55-65746360fe24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE2LTQtMS0xLTEwNTYy_2b279b05-4e1a-405f-88c3-863aabd0dba3">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE3LTItMS0xLTEwNTYy_fceb5ba5-dce2-494e-b5a8-e4fe58848453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE3LTQtMS0xLTEwNTYy_38c94c40-971d-4b8f-9400-6a5a51173d4c">2,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE5LTItMS0xLTEwNTYy_811be4b7-8971-4329-9603-977b8df5429b">389,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE5LTQtMS0xLTEwNTYy_26744b1c-0ee0-47fe-80a4-a951fb537d35">389,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Term Loan due 2026</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a definitive agreement for a $<ix:nonFraction unitRef="usd" contextRef="ie69b50b330c64830b70c78bcaaeb37d6_I20200731" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzg1Mw_5335be1c-6d06-4392-993b-28b719e1fa26">400</ix:nonFraction>&#160;million credit facility with Hayfin Capital Management (&#8220;Senior Secured Term Loan due 2026&#8221;) with an interest rate equal to 3-month LIBOR, subject to a <ix:nonFraction unitRef="number" contextRef="i33fc42c9674f4e879bc61864ba60a261_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMDA_23001580-4443-4d0a-9327-195a9f0e7a6e">1</ix:nonFraction>% floor, plus <ix:nonFraction unitRef="number" contextRef="i33fc42c9674f4e879bc61864ba60a261_D20200701-20200731" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMTU_503854cd-4324-4d25-ac2a-f677076a89fc">6.5</ix:nonFraction>% per annum and requires interest-only payments until mid-2024. The Senior Secured Term Loan due 2026 will be repaid in <ix:nonFraction unitRef="day" contextRef="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentPeriodicPaymentNumberOfPayments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzExMzY_a8118734-cdf2-4bd3-b7bc-57838f739a23">nine</ix:nonFraction> quarterly payments of $<ix:nonFraction unitRef="usd" contextRef="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzExNjE_e01e49d4-d8fc-40a0-be2f-009cbb4262f0">44.4</ix:nonFraction>&#160;million, starting on July 2024 with the final balance due on the maturity date in July 2026. This transaction resulted in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731" decimals="-5" name="us-gaap:ProceedsFromSecuredLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEyOTQ_cb6acf94-cda0-4766-a547-39a2c96c395b">385.9</ix:nonFraction>&#160;million, after deducting fees and expenses. There were no warrants or equity conversion features associated with the Senior Secured Term Loan due 2026. The Company used the proceeds to voluntarily settle the Senior Secured Term Loan with BioPharma Credit PLC, which included the $<ix:nonFraction unitRef="usd" contextRef="ib3f9db4f690745eda3163dd56d581246_I20180930" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY2MzU_23949d5e-f2d3-4f19-bb11-1bb1f2736f5f">150</ix:nonFraction>&#160;million principal, $<ix:nonFraction unitRef="usd" contextRef="i7c3d9dd50f724a0da7d1eefc3d5f135e_D20200701-20200731" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY2NDk_491c111c-d408-436c-a3ce-0163dbda9dd4">1.1</ix:nonFraction>&#160;million accrued interest, and $<ix:nonFraction unitRef="usd" contextRef="i7c3d9dd50f724a0da7d1eefc3d5f135e_D20200701-20200731" decimals="-5" name="fold:EarlySettlementPremiums" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY2NjM_4d2b5af9-730e-48d2-912b-c48c61864934">5.2</ix:nonFraction>&#160;million in early settlement premiums. As a result of this early extinguishment, the Company recognized a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i7c3d9dd50f724a0da7d1eefc3d5f135e_D20200701-20200731" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY2Nzc_295d6db4-af35-4e79-8f79-2dd84b8d9ca4">7.3</ix:nonFraction>&#160;million in the Consolidated Statements of Operations.</span></div></ix:continuation><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-110-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i417b9afa89484c25b1efc9f3e0e067b9" continuedAt="i62d53f333bcd47d1bb36a9bf2814cffe"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Term Loan due 2026 is subject to mandatory prepayment provisions that require prepayment upon a change of control, the incurrence of certain additional indebtedness, asset sale, or an event of loss, subject to certain conditions set forth in the Senior Secured Term Loan due 2026. The Company may prepay the Senior Secured Term Loan due 2026 in whole, at its option at any time. Any prepayment of the Senior Secured Term Loan due 2026 is subject to certain make-whole premiums and prepayment premiums, the latter of which decrease until the fourth anniversary of the transaction date at which point no prepayment penalty shall exist. The obligations under the Senior Secured Term Loan due 2026 are secured by a first lien security interest in certain assets of the Company. The Senior Secured Term Loan due 2026 contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company. The Senior Secured Term Loan due 2026 also contains a minimum liquidity covenant of $<ix:nonFraction unitRef="usd" contextRef="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentLiquidityCovenantMinimumAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI2Njc_f5d30453-86f2-4043-85f6-f154a5f97aa6">75</ix:nonFraction>&#160;million, and an incremental minimum consolidated revenue covenant, measured as of the previous four consecutive fiscal quarters. The minimum consolidated revenue covenant ranges from $<ix:nonFraction unitRef="usd" contextRef="i7600524d0cbe42d4b2f4532af786aeb3_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentConsolidatedRevenueCovenantAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI4NDU_e5c35e8f-b975-4ef7-80a4-bcf2f848bb61">140</ix:nonFraction>&#160;million, beginning March 31, 2021, and peaks at $<ix:nonFraction unitRef="usd" contextRef="ice065bd0045f4f5f9e31f898f0f63b1f_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentConsolidatedRevenueCovenantAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI4ODg_bfb7c08b-2a4e-4505-bd58-8be4f59237f3">225</ix:nonFraction>&#160;million by June 30, 2023, continuing at that level until the Senior Secured Term Loan due 2026 is repaid. If an event of default occurs and is continuing, Hayfin Capital Management may declare all amounts outstanding under the Senior Secured Term Loan due 2026 to be immediately due and payable.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued at par value $<ix:nonFraction unitRef="usd" contextRef="i3cdaaf76680246429703216e122dbd6c_I20161231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzQ4MTg_7ce93222-9667-4305-ad5c-f5e96cbb8f83">250</ix:nonFraction> million aggregate principal amount of Convertible Notes, which included the exercise in full of the $<ix:nonFraction unitRef="usd" contextRef="i9778c3d9e7be42298274edd0168bd81d_I20161231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzQ5MTM_163a7e6b-a7a2-432d-b1e2-2ffc5be32886">25</ix:nonFraction> million over-allotment option granted to the initial purchasers of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act (the "Note Offering"). Interest was payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes would mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Convertible Notes were convertible at the option of the Holders, under certain circumstances and during certain periods, into cash, shares of the Company&#8217;s common stock or a combination thereof. The net proceeds from the Note Offering were $<ix:nonFraction unitRef="usd" contextRef="i98061b690c584def995fd5b3650941ec_D20161201-20161231" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzU2NDg_b5ce1ae9-8195-4766-8778-e0bd6686d140">243.0</ix:nonFraction> million, after deducting fees and expenses. In addition, the Company used approximately $<ix:nonFraction unitRef="usd" contextRef="i98061b690c584def995fd5b3650941ec_D20161201-20161231" decimals="-5" name="fold:PremiumsPaidForCappedCallConfirmations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzU3MzE_550682cc-a31e-4046-ad54-4c90e4e2eb29">13.5</ix:nonFraction> million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The Convertible Notes were initially convertible into approximately <ix:nonFraction unitRef="shares" contextRef="i98061b690c584def995fd5b3650941ec_D20161201-20161231" decimals="INF" name="fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzYyMDE_15a6da9e-40dd-4d7a-8286-1ba2c6c02899">40.8</ix:nonFraction> million shares of the Company&#8217;s common stock under certain circumstances prior to maturity at a conversion rate of 163.3987 shares per $1,000 principal amount of Convertible Notes, which represented a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3cdaaf76680246429703216e122dbd6c_I20161231" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzY0MjQ_37b1643f-db9e-41a2-94de-a2c677408422">6.12</ix:nonFraction> per share of common stock, subject to adjustment under certain conditions. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with a limited number of Holders. Under the terms of the Exchange Agreements, the limited number of Holders agreed to exchange an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ie195a0454be34ff68a307be34a84c86c_I20190630" decimals="-5" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzkxNzQ_5f4f4db1-d8c2-42fb-b03a-6f17ec00873b">247.2</ix:nonFraction>&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="ie195a0454be34ff68a307be34a84c86c_I20190630" decimals="-5" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzkyNTc_6e2782af-dd95-444d-bbef-1c9498d7f704">44.0</ix:nonFraction>&#160;million shares of Company common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ie195a0454be34ff68a307be34a84c86c_I20190630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzkzMDI_3dd232e3-6475-4e03-9502-7cba05ec9a8a">0.01</ix:nonFraction> per share. In addition, pursuant to the Exchange Agreements, the Company made aggregate cash payments of $<ix:nonFraction unitRef="usd" contextRef="ib94c7a79d6b04897ba7c2cd123307880_D20190101-20190630" decimals="-5" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzk0MTA_40b8f669-25fd-46d4-be00-4b73fc31a878">1.3</ix:nonFraction>&#160;million to the limited number of Holders to satisfy accrued and unpaid interest to the closing date of the transactions, along with cash in lieu of fractional shares. These transactions resulted in $<ix:nonFraction unitRef="usd" contextRef="i49b24aa516c24be2963d03b2a2fe67c4_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzk2MDM_9fa1179e-49fe-4a45-be87-250ba7334bcc">215.0</ix:nonFraction>&#160;million in additional paid-in-capital and common stock of $<ix:nonFraction unitRef="usd" contextRef="iacb244f94b724eb4939e9350be861b33_D20190101-20191231" decimals="-5" name="fold:GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzk2NTY_1a498bc1-ce96-4009-b459-7f7ec6927eff">0.4</ix:nonFraction>&#160;million on the Consolidated Balance Sheets as of December 31, 2019. Additionally, the Company recognized a loss on the exchange of debt of $<ix:nonFraction unitRef="usd" contextRef="iacb244f94b724eb4939e9350be861b33_D20190101-20191231" decimals="-5" sign="-" name="fold:GainLossOnExchangeOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzk3OTA_601ef007-54ac-422e-a4d7-4234a32c63a8">40.6</ix:nonFraction>&#160;million on the Consolidated Statements of Operations during the year ended December 31, 2019. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first and second quarter of 2019, the Company terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib94c7a79d6b04897ba7c2cd123307880_D20190101-20190630" decimals="-5" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMTU5_67c12c6d-ce07-410d-a90a-6ceaca3346c8">19.9</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first and third quarters of 2021, the Company entered into separate, privately negotiated exchange agreements with a limited number of Holders. Under the terms of the Exchange Agreements, the Holders agreed to exchange the remaining aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ia8b8a5ba609f4354b35e10b27be3ff0f_D20210701-20210930" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwOTk1MTE2Mzk1Nzg_32ff7061-4f66-47b9-80b2-b0e8e9b6735d">2.8</ix:nonFraction>&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwOTk1MTE2Mzk1NjE_50375b84-f793-4cff-b91d-084c499b76df">472,356</ix:nonFraction> shares of Company common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwOTk1MTE2Mzk1NzE_ff7d750c-e52a-4a45-9aef-5d410890bcc8">0.01</ix:nonFraction> per share. This transaction resulted in $<ix:nonFraction unitRef="usd" contextRef="i640ccbc1c3154c0080c449287054612e_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwOTk1MTE2NDUxMTI_f99bf60a-28f9-45df-a4a7-6f246461efca">2.7</ix:nonFraction>&#160;million in additional paid-in-capital and common stock of <ix:nonFraction unitRef="usd" contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY3ODg_96e848cc-598e-44bb-b273-c44fc057d5b1">five thousand</ix:nonFraction> dollars on the Consolidated Balance Sheets as of December 31, 2021. Additionally, the Company recognized a net loss from extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzMyOTg1MzQ5MDA1ODI_0c3bb682-d97e-4a85-b5e9-acaf55a662a2">0.3</ix:nonFraction>&#160;million in the Consolidated Statements of Operations for the year ended December 31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-111-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i62d53f333bcd47d1bb36a9bf2814cffe"><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMzEz_05313dc3-1062-4b52-9871-66f7f029dde2" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2021 and 2020 respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:73.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except interest rate amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzEtMi0xLTEtMTA1NjI_f2e867c6-4361-4e42-9628-fdc8ba42fa29">30,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c034a30ff14ec285bf6a0f3a25e67a_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzEtNC0xLTEtMTA1NjI_29f10b2b-d915-4543-82f5-43de8a263682">20,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzItMi0xLTEtMTA1NjI_cbf7dfb1-64c0-4038-b326-2b7ed0c3f0ea">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c034a30ff14ec285bf6a0f3a25e67a_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzItNC0xLTEtMTA1NjI_9f4c9675-d869-48f8-b980-5425ebc22a38">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzMtMi0xLTEtMTA1NjI_b8ec88f0-34ec-43ad-adb6-10b408628d75">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c034a30ff14ec285bf6a0f3a25e67a_D20200101-20201231" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzMtNC0xLTEtMTA1NjI_4fafe5f0-cc06-4892-b350-3c9dfc0543c0">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate of the liability component, Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzQtMi0xLTEtMTA1NjI_5d9a0a6e-9f91-4607-a222-a65e55482947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzQtNC0xLTEtMTA1NjI_b789b263-250e-4191-9acd-178404219ddd">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate of the liability component, Senior Secured Term Loan due 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie25229baab7b448a94693d9550e33f9e_I20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzUtMi0xLTEtMTA1NjI_ed6d179b-ddf2-48e4-9e2a-00c1b48a6cea">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i110a74da32da49fd9b6d03056e710aca_I20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzUtNC0xLTEtMTA1NjI_3e586d9f-7400-4731-91ca-16ba79620193">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4e1826361eea43a9b8ec57ad5f93ef33_118"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzExNTI_29ed5cef-4787-4620-a1d0-659f6db1cca2" continuedAt="ia19e38addf5f4dcf9911c0e84b8d3983" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ia19e38addf5f4dcf9911c0e84b8d3983" continuedAt="if1cd1dd0933143719779bc085bcfebaf"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has operating leases for office and research laboratory space, equipment, and vehicles under agreements expiring at various dates through 2044, which include renewal options on leases which the Company is reasonably certain to exercise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, and 2020, operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzM0MQ_a2d9a9db-adb6-4e8f-9e7d-0c606dc8c805">10.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzM0OA_53902f2c-9925-439d-9422-ccbb9d127a1d">11.1</ix:nonFraction>&#160;million and variable lease expense was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzEwOTk1MTE2MzAyMTQ_9de0666e-053d-4819-8414-bf3248a75c76">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzEwOTk1MTE2MzAyMjI_ef248c19-a0ec-49cb-bede-466564c81825">1.8</ix:nonFraction> million, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the years ended December 31, 2021, and 2020, the Company paid $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzQxNw_55ecf719-0446-4d9e-8656-20c488327709">8.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzQyNA_04a835c5-16f7-48ed-95e4-c6c0dc589d63">9.6</ix:nonFraction>&#160;million, respectively, for amounts included in the measurement of operating lease liabilities and recorded $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzUyNg_41b77d7f-abdd-4893-8575-17685b61a75e">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzUzMw_7cd964e9-08bd-4bea-979c-7f67af4a89aa">1.7</ix:nonFraction>&#160;million, respectively, of&#160;right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForTenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzU3OA_12a41509-b666-4c7f-929b-020f45fa8ac8">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForTenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzU4NQ_f257d36b-ef37-4d32-a7bf-f099a9d33c2f">0.5</ix:nonFraction>&#160;million, respectively, of tenant improvements paid through lease incentives in exchange for new operating lease liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments under finance leases are not significant for the year ended December 31, 2021.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-112-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if1cd1dd0933143719779bc085bcfebaf"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzExNDg_f9829233-1c22-45e7-9d1a-7a432677660c" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except year and discount rate amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzEtMi0xLTEtMTA1NjI_4f3f5a32-b48e-4a4b-9182-32ef2f52c0bd">20,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzEtNC0xLTEtMTA1NjI_7810b2a3-0825-425b-901f-e372067842ab">23,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzMtMi0xLTEtMTA1NjI_52c50cbf-421f-4f20-9f36-2acc8126f724">7,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzMtNC0xLTEtMTA1NjI_d739b03f-ef1e-4962-bc7c-ec8bb843742c">6,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzQtMi0xLTEtMTA1NjI_e653d119-ac9d-43b7-b94e-cc35cd12d26d">43,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzQtNC0xLTEtMTA1NjI_654ddea3-2c75-4578-87df-77665ed07c31">45,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzUtMi0xLTEtMTA1NjI_2724b7ff-d188-4f5c-be6c-b8023c1c1cbb">50,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzUtNC0xLTEtMTA1NjI_e85f1cf0-f09d-4fc8-b253-126e32d45d1e">52,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzctMi0xLTEtMTA1NjI_08c008b5-0536-44ab-b2c9-9ede11bcec20">19.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzctNC0xLTEtMTA1NjI_98cf3ea8-3562-4498-8a34-f146d0092f59">19.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzgtMi0xLTEtMTA1NjI_fb66270a-835e-4dd1-9ec2-2cb43c4b5c1b">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzgtNC0xLTEtMTA1NjI_84ca0293-6876-4a6f-be7d-7a324288bdd0">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzExNDc_b4ec8ddb-9f21-4017-bc98-667bd11d54d9" escape="true"><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the future minimum operating lease payments were as follows:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:83.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzEtMi0xLTEtMTA1NjI_fd7eece1-db57-4b99-b42f-24bc7b052c6b">8,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzItMi0xLTEtMTA1NjI_2978ca9f-106a-46d4-ab79-57b73cad5040">8,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzMtMi0xLTEtMTA1NjI_6b5cc704-7568-4749-93d5-60f57a7ef2be">8,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzQtMi0xLTEtMTA1NjI_10396213-b154-4acc-9b42-59550b0aba53">8,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzUtMi0xLTEtMTA1NjI_243adc5a-e4ac-4f1a-8506-c28550909c2f">8,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzYtMi0xLTEtMTA1NjI_3df4e656-abe3-4bfa-b7eb-0976bd093710">145,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzctMi0xLTEtMTA1NjI_29355d60-fbc2-44ab-bc2c-15266ed8f46b">188,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less lease incentives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:LesseeOperatingLeaseLiabilityTenantIncentives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzgtMi0xLTEtMTA1NjI_96753417-b105-43de-92e0-4354436d7bb7">28,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzktMi0xLTEtMTA1NjI_663ff462-54d1-4bcc-810d-eb2a547acb27">108,478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzEwLTItMS0xLTEwNTYy_94256e15-50ce-41f8-8477-3cf7dde309db">50,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company has an additional operating lease for office space that has not yet commenced, with minimum lease payments of $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="fold:LesseeOperatingLeaseLeaseNotYetCommencedLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzEwOTk1MTE2Mjk2OTg_b92bd0cf-2a41-4096-9c88-5019e01ae564">15.1</ix:nonFraction> million.  This operating lease commenced during the first quarter of 2022 with a lease term of <ix:nonNumeric contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzI3NDg3NzkwNzIwNzY_b9622ffe-6e5e-41cf-8ac3-bd2d48077d67">ten years</ix:nonNumeric>.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-113-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzQ5OTY_c82e1e4b-f53d-4f51-bedb-d0ed26e3480f" continuedAt="i71aafd24a4424d30a8006e01bba3bc34" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i71aafd24a4424d30a8006e01bba3bc34" continuedAt="i8bcce88b089a440f9ad4bf2884c089b8"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzUwMDY_5c478a1b-383a-48de-9d8c-95b1987030ce" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, income (loss) before income taxes includes the following components:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzItMi0xLTEtMTA1NjI_21d57f84-18b4-4553-9a9f-5b9295ce7f9a">333,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzItNC0xLTEtMTA1NjI_aa208732-a271-46cc-b5b4-4631ad582964">365,332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzItNi0xLTEtMTA1NjI_181ab1b2-f3b9-44d9-82bc-b6ca8780e6f8">393,955</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzMtMi0xLTEtMTA1NjI_ab32a698-cc05-4a3e-8f93-38a6012e52bb">92,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzMtNC0xLTEtMTA1NjI_fdc6229e-e7de-4a7c-adde-590fc074e503">91,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzMtNi0xLTEtMTA1NjI_f7bc2c3c-2140-4536-819e-e66b4bc225ff">38,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzQtMi0xLTEtMTA1NjI_683a0587-0b38-4acb-a0cb-b3aa44d3e749">241,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzQtNC0xLTEtMTA1NjI_fd8de9e7-5392-47c2-b63d-8ac3620222d8">274,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzQtNi0xLTEtMTA1NjI_255a0780-3cb2-4d38-a043-0535b5017349">355,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzUwMDk_0f607c6d-3eba-4ab0-8cde-9b7da7a825e4" escape="true"><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following were the components of income tax expense (benefit) for the years ended December 31, 2021, 2020, and 2019:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzItMi0xLTEtMTA1NjI_1747b65f-4b47-43b1-b54b-e70767439f10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzItNC0xLTEtMTA1NjI_69b6cc73-cec1-47be-83f5-229438a45bea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzItNi0xLTEtMTA1NjI_cc5b7b37-bfb5-4be9-8939-48f5d9c57838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzMtMi0xLTEtMTA1NjI_8af884d7-09e5-49fc-885c-52167a1b48cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzMtNC0xLTEtMTA1NjI_21a1c93b-c941-49b3-b3b4-33cdf8976bec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzMtNi0xLTEtMTA1NjI_7b7c568f-ba6f-478e-b299-098a8de99331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzQtMi0xLTEtMTA1NjI_d11151ce-9b29-4b1a-9957-e8e847af5235">8,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzQtNC0xLTEtMTA1NjI_93497493-d828-44b0-af57-623b8f0f166e">4,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzQtNi0xLTEtMTA1NjI_8ed0ebd9-8fb4-4247-b418-4debbe994b93">2,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzYtMi0xLTEtMTA1NjI_968e6464-c932-4549-9fec-3a09cfc02a54">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzYtNC0xLTEtMTA1NjI_f3225341-26ec-4363-897d-e4ff99760792">1,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzYtNi0xLTEtMTA1NjI_c21d9c3e-00b4-4560-a43f-a8442eb7a32b">984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzctMi0xLTEtMTA1NjI_60690a0f-d76c-42e0-a85d-2153f4ee3025">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzctNC0xLTEtMTA1NjI_556b1fc9-5904-494c-af16-f6e87dff9418">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzctNi0xLTEtMTA1NjI_7bbad955-27f2-4ffd-b376-a11d665ed5a4">1,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzgtMi0xLTEtMTA1NjI_eedb7145-830e-47bc-892c-ed149f617693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzgtNC0xLTEtMTA1NjI_412a1dd7-9b1d-42c4-bc4b-0027a7ed8fae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzgtNi0xLTEtMTA1NjI_f7a9e566-10f4-41e2-8032-15fec5c2746c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzktMi0xLTEtMTA1NjI_730dc6f5-c7c6-41d6-994b-9b53141bea2c">8,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzktNC0xLTEtMTA1NjI_2e83eb06-95c9-4376-9b55-15beaaf495f0">2,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzktNi0xLTEtMTA1NjI_223a662f-39a1-44c1-84fb-55a5b7a81f70">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzQ5OTk_7fe434b8-f133-401d-a533-351d1e977dfd" escape="true"><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2021, 2020, and 2019 are as follows:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzItMi0xLTEtMTA1NjI_dba07ad3-f150-4c66-8e3d-cfb76e36278a">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzItNC0xLTEtMTA1NjI_c5127792-ef02-4b35-b16a-9d32b9b2b14f">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzItNi0xLTEtMTA1NjI_2ac93d11-2b2f-440a-be04-9ee54a29dbf1">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzMtMi0xLTEtMTA1NjI_e688025b-7a40-4765-9253-aded42fc9ad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzMtNC0xLTEtMTA1NjI_f5bd2b1f-89fd-4e42-86ea-73465571e4b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzMtNi0xLTEtMTA1NjI_5e64b4c7-b845-4c7b-a46e-411012976b57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzQtMi0xLTEtMTA1NjI_1a34146a-0833-49a3-ac41-ae44d0fb8e32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzQtNC0xLTEtMTA1NjI_018de4b2-5b22-44a8-8bb8-8182a80a71dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzQtNi0xLTEtMTA1NjI_f6881cce-107d-47ba-a743-d1ff876d4a29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" name="fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzUtMi0xLTEtMTA1NjI_c2a603f9-92a1-4618-9c05-ed0692faf2dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzUtNC0xLTEtMTA1NjI_6dda0275-763a-4d62-aa60-a75a91e80f87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzUtNi0xLTEtMTA1NjI_bc55cd00-6fd2-4761-a331-017e41b0a152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzYtMi0xLTEtMTA1NjI_383c4d9e-4804-4629-b26b-2e1cc3805f55">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzYtNC0xLTEtMTA1NjI_b23fedd9-3367-4628-8e13-7fe31599ed91">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzYtNi0xLTEtMTA1NjI_ffff1bc1-b67d-425c-923c-0f53803761de">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzctMi0xLTEtMTA1NjI_b83eec86-ebdc-4941-9db0-7519c409d39a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzctNC0xLTEtMTA1NjI_3f9a7515-7a2f-469f-bdfd-b0d3020a128f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzctNi0xLTEtMTA1NjI_330b6c3d-87f6-4aa9-b0e8-ab69586004f3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzgtMi0xLTEtMTA1NjI_6f4330df-44fb-42e0-a46b-2ec8ca094651">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzgtNC0xLTEtMTA1NjI_f24e4c6b-4768-4d9d-a941-50f50a2e912e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzgtNi0xLTEtMTA1NjI_0ba5100a-8546-4d1c-b15e-303bafe31ae6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible debt conversion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" name="fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzktMi0xLTEtMTA1NjI_25cfa47a-a27a-4b0e-b752-d9a805f9892f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzktNC0xLTEtMTA1NjI_e4dc2f60-1f2c-428c-b6ad-796e5846d2c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzktNi0xLTEtMTA1NjI_5178f5d0-ce5b-49a5-bd56-289b77099fd0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEwLTItMS0xLTEwNTYy_e743c89e-12c0-4f51-b52e-8d85455512ed">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEwLTQtMS0xLTEwNTYy_7e9a3469-2dcd-4ba6-a6f1-61415c1636b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEwLTYtMS0xLTEwNTYy_7d1515b4-c592-47ba-ac3e-6b1910f3ebc0">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzExLTItMS0xLTEwNTYy_74ae4a3f-3d11-42f3-9d13-ae9cb72b2ccb">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzExLTQtMS0xLTEwNTYy_8b6f201c-6ac7-4c68-842f-49d6d810a268">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzExLTYtMS0xLTEwNTYy_b6dfffb8-dfc3-4077-8e65-6b675fef90c6">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEyLTItMS0xLTEwNTYy_ac39e366-d858-47ff-8102-7ab6b11e8eb5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEyLTQtMS0xLTEwNTYy_e2b76090-f521-48cd-bcd0-12a54020ef79">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEyLTYtMS0xLTEwNTYy_e49ca9cc-e895-42c5-9255-6b365aec7628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to <ix:nonFraction unitRef="number" contextRef="ia902df35c10346d3815341846f96d4a9_D20171222-20171222" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzU1OQ_15a86e38-e778-4b55-b981-2de94e3baae6">21</ix:nonFraction>%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Tax Act also introduced an additional U.S. tax on certain non-U.S. subsidiaries&#8217; earnings which are considered to be Global Intangible Low Taxed Income (referred to as "GILTI"). After consideration of the relevant guidance and completing the accounting for the tax effects of the Tax Act, the Company has elected to treat GILTI as a period cost. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-114-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8bcce88b089a440f9ad4bf2884c089b8" continuedAt="i526326efe8824aa3818c37a4a61c75b2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzExMDU_23dca4ff-f265-4444-b6e0-807f95ed62f4">8.9</ix:nonFraction> million in 2021 for taxes in foreign jurisdictions. Due to the loss position and full valuation allowance, there is nominal tax expense in  2021 for taxes in U.S. federal and state jurisdictions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had minimal interest or penalties related to UK corporate taxes during the period ended  December 31, 2021 and did <ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzEzMzY_1549b89d-1ca9-4498-88c9-65f84c991bc9">no</ix:nonFraction>t accrue for any interest or penalties as of December 31, 2021. The Company had a nominal accrual for uncertain tax positions as of  December 31, 2021. Tax returns for years 2016 through 2020 are open to examination by tax authorities. The Company is also subject to examination in any period for which it has net operating losses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzUwMDM_9088fb20-9d4c-4263-95ab-d87e9066ddfe" continuedAt="ia898c4ae366442a4b567de67d98a1f96" escape="true">The significant components of the deferred tax assets and liabilities are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="ia898c4ae366442a4b567de67d98a1f96"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:72.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:DeferredTaxAssetsIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzMtMi0xLTEtMTA1NjI_6ef01ea7-0476-4b31-8db8-6bc6c9a39606">105,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:DeferredTaxAssetsIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzMtNC0xLTEtMTA1NjI_4dcbcd62-ee4f-4043-9475-ac356847b384">68,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization/depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzQtMi0xLTEtMTA1NjI_950e70ce-dc1b-4360-b6a4-44d3e1ab3e7f">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzQtNC0xLTEtMTA1NjI_df0c7d8d-1961-49e6-82dc-c31e7bc45d8d">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzUtMi0xLTEtMTA1NjI_e1d642cc-316e-4312-9b61-8e5d93ef514d">205,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzUtNC0xLTEtMTA1NjI_84d4c6b3-e039-4963-a251-6808aa26101f">182,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry forwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzYtMi0xLTEtMTA1NjI_f42f6ac4-923d-4212-b3c4-2f0248c521db">334,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzYtNC0xLTEtMTA1NjI_a76890b5-bfae-4109-996f-ff1db0fd006b">305,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzctMi0xLTEtMTA1NjI_fb8676c9-d8ab-4821-a81f-5f8e650aa0ac">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzctNC0xLTEtMTA1NjI_85a596da-4373-4d29-bf98-5d005ab40a5c">1,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock issue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:DeferredTaxAssetsNonCashStockIssueNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzgtMi0xLTEtMTA1NjI_40f2fdd2-1473-4301-bd78-9f7ae9045830">11,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:DeferredTaxAssetsNonCashStockIssueNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzgtNC0xLTEtMTA1NjI_117df6d4-99db-4e2c-9243-1203f4554f50">17,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest carry forward limitation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:DeferredTaxAssetsInterestCarryforwardLimitation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzktMi0xLTEtMTA1NjI_f907c882-9eae-4514-81e6-9c8fd287ce20">8,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:DeferredTaxAssetsInterestCarryforwardLimitation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzktNC0xLTEtMTA1NjI_7d396299-035c-44da-8f7c-4a0588ad48bf">5,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzEwLTItMS0xLTEwNTYy_a64bbc27-8c7e-419c-87b4-4312c8adbe39">9,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzEwLTQtMS0xLTEwNTYy_f3f1bdf5-36a1-426f-9bca-8872135a0aec">9,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzExLTItMS0xLTEwNTYy_b1d2372d-f0bd-4a74-8985-0ba4284f7cc7">15,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzExLTQtMS0xLTEwNTYy_30f895d6-0ec9-4860-8681-2ce2af42521c">10,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzEyLTItMS0xLTEwNTYy_82190673-5604-46d3-9150-ea9db9fd8dd6">692,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzEyLTQtMS0xLTEwNTYy_f5783f4e-ca80-4dc1-ab27-53c1f8d6a9b9">602,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:DeferredTaxLiabilitiesBusinessAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE0LTItMS0xLTEwNTYy_1b8bf22d-1119-4c33-8d07-0a524ef480d9">4,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:DeferredTaxLiabilitiesBusinessAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE0LTQtMS0xLTEwNTYy_cfbb2f6e-3545-4c52-b8f7-c74406d700fd">4,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:DeferredTaxLiabilitiesRoyaltyPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE1LTItMS0xLTEwNTYy_014d0f35-96f7-4bc3-9c65-6e07feba8d01">105,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:DeferredTaxLiabilitiesRoyaltyPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE1LTQtMS0xLTEwNTYy_f7f3453d-8ae1-42ff-9eb0-2f80758e8af7">68,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:DeferredTaxLiabilitiesConvertibleNotes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE2LTItMS0xLTEwNTYy_9714a2b4-e88c-44d4-9a3c-6e6e4152c1fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:DeferredTaxLiabilitiesConvertibleNotes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE2LTQtMS0xLTEwNTYy_cfba82fb-eb13-4d77-a859-857904d4cb91">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced R&amp;D payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE3LTItMS0xLTEwNTYy_b55134c4-8b78-42f6-b1eb-da6fcb5d3f92">1,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE3LTQtMS0xLTEwNTYy_f07a11ac-bfa0-4b73-a9c9-fc7d10079b0e">1,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE4LTItMS0xLTEwNTYy_68a48ab3-c75f-484a-9e22-ba8a4dfc7b5a">3,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE4LTQtMS0xLTEwNTYy_78d23f54-3964-4f48-9782-ae25503f30ff">3,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="fold:DeferredTaxAssetsLiabilitiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE5LTItMS0xLTEwNTYy_a285c1c4-90ac-4679-af1a-bbc3c5c6115a">576,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="fold:DeferredTaxAssetsLiabilitiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE5LTQtMS0xLTEwNTYy_93be33fc-31ab-4520-87fb-56ca7cbf88a4">523,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzIwLTItMS0xLTEwNTYy_35e509d6-f82e-4360-85eb-8ac50e667939">581,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzIwLTQtMS0xLTEwNTYy_712a1eb1-a7d4-468a-8e17-97310378b39a">528,895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzIxLTItMS0xLTEwNTYy_efc86d98-27e4-4a20-88f4-098abb256fc9">4,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzIxLTQtMS0xLTEwNTYy_e38dd389-3ed2-42bf-8c22-7aa15c042663">4,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2021 and 2020, the Company recorded valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzIxNDc_a5c3b1b0-e1b2-41eb-82ff-f3c04bb93b94">581.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i65709436b74a491bb3674af00ed88b22_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzIxNTQ_cc985447-0355-4b27-8927-fa119c6a3d36">528.9</ix:nonFraction> million, respectively, representing an increase in the valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzIyMjc_9606e5de-8ff0-4538-bd4c-054cf095cdb3">52.9</ix:nonFraction> million in 2021, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D that may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-115-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i526326efe8824aa3818c37a4a61c75b2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had federal and state net operating loss carry forwards ("NOLs") of approximately $<ix:nonFraction unitRef="usd" contextRef="id37d238be9634e70925be89cb7453666_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzI5MTU_45d6b3ef-377c-4ff6-b5e1-62d75f7d08d7">1,292</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd581809cdbc4334985e5a98f01fe250_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzI5MjI_a1bad3a4-3c9e-4e7c-8300-b30c1f411f0c">1,000</ix:nonFraction> million, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the 2017 Tax Act.&#160;Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through 2021 will expire in 2029 through 2040. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. The Company may experience ownership changes in the future as a result of shifts in the stock ownership some of which are outside the Company's control. The Company completed a detailed study of the NOLs and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on the Company's ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently decrease the amount of state attributes and increase state taxes owed. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has research and experimentation and orphan drug credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ie3afe69e33524b46a12ea4a1d4d0b740_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzQ4MzY_9ce09dfd-a835-43f2-bf53-eb0f15deff52">30.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iee21a641b74a48e686ea400e8e04484c_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzQ4NDM_215eb801-22ff-4fba-af4b-d8b35f5988d7">165.2</ix:nonFraction> million, respectively, which will expire in the years 2021 through 2040. Deferred tax assets for these carryforwards are subject to a full valuation allowance.</span></div></ix:continuation><div id="i4e1826361eea43a9b8ec57ad5f93ef33_124"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI3NjE_2938a659-543e-44ac-b744-22b6a48b43b2" continuedAt="i942c316fcdda4ed3b94a02852d2a8f97" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="i942c316fcdda4ed3b94a02852d2a8f97"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">University of Pennsylvania</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, as amended, the Company entered into a collaboration agreement with the University of Pennsylvania ("Penn") to pursue research and development of novel gene therapies. The Company's gene therapy portfolio pipeline expanded to include Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), ceroid lipofuscinosis, neuronal ("CLN1"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of other rare diseases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i322b8d6caffd45d09d34af4c5317a66d_I20181031" decimals="-5" name="fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzEwOTQ_b872b6b4-34e1-4609-a38e-4d2ed01ea6e2">88.0</ix:nonFraction>&#160;million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country- by-country basis. The Company will provide $<ix:nonFraction unitRef="usd" contextRef="i322b8d6caffd45d09d34af4c5317a66d_I20181031" decimals="-5" name="fold:CollaborationAgreementAnnualContributionByCompany" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzEyNzI_19c7878c-a57b-4443-ba3a-530d39e1e455">10.0</ix:nonFraction> million each year during the <ix:nonNumeric contextRef="ie02d2bc95ee4441cafb8448b58435d04_D20181001-20181031" name="fold:CollaborativeAgreementTermOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI3NDg3NzkwODA1MDY_bc3ba75a-ac74-45f3-909a-76e267864f32">five-year</ix:nonNumeric> agreement to fund the discovery research program. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, as amended in November 2013, the Company entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease (&#8220;Collaboration Agreement&#8221;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $<ix:nonFraction unitRef="usd" contextRef="i812c13b023674c2a8bf3fe358c45cc8e_I20131130" decimals="-6" name="fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzE5OTc_c244206f-00d7-4659-9aa7-68c4fda62d17">40</ix:nonFraction> million, as well as tiered royalties in the mid-teens in <ix:nonFraction unitRef="market" contextRef="ice787d3f9d9b45d5ac985f96cbc7cab8_D20131101-20131130" decimals="INF" name="fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzIwNDk_4a422318-fe15-4e85-a892-f8b1a4710099">eight</ix:nonFraction> major markets outside the U.S. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent milestone payments due to GSK are recorded within the short term and long term deferred reimbursements accounts on the Consolidated Balance Sheets. Sales based tiered royalties due to GSK are recorded within the cost of goods sold within the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, under the GSK collaboration agreements, the Company paid $<ix:nonFraction unitRef="usd" contextRef="ib092d444dccf4d32aa8a33c7b683e7f0_D20210101-20211231" decimals="-5" name="fold:PaymentsForCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI0NjA_563bf2f6-37e3-4f39-95aa-cb64a02b8740">1.5</ix:nonFraction> million in sales-based milestones and the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i86b66068ec6445888b7a4f287f32fe7c_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI1Mjg_fd4dd098-7208-4b17-b3d3-ec49cd0684c2">25.4</ix:nonFraction> million of royalty expenses. As of December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ice1a09fdb4bb4d548e2ccf3315079cb4_I20211231" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI1NjI_6db669da-42d1-48ff-8044-24754d67e24b">7.4</ix:nonFraction> million was recorded as deferred reimbursements and the Company recognized a liability of $<ix:nonFraction unitRef="usd" contextRef="ice1a09fdb4bb4d548e2ccf3315079cb4_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI2NDc_64a31649-c437-4b23-8ecd-0ff2b6dbd1a2">4.5</ix:nonFraction> million related to royalties payable to GSK in accounts payable and accrued expenses in the Consolidated Balance Sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-116-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90ZXh0cmVnaW9uOmQ4MDc1NjRhOTMxMTRhMDE4YTkzMTQxNTI2Y2MwYjQ3XzcxOQ_548ece3c-5e84-45ba-97da-0fa9291dbe70" continuedAt="i462dc5aa87b94458b7e168c4e634b0b4" escape="true">Basic and Diluted Net Loss per Common Share</ix:nonNumeric></span></div><ix:continuation id="i462dc5aa87b94458b7e168c4e634b0b4"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90ZXh0cmVnaW9uOmQ4MDc1NjRhOTMxMTRhMDE4YTkzMTQxNTI2Y2MwYjQ3XzcyMQ_04bd3a3d-e817-4f0b-b554-f4b02fbd359a" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:56.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzMtMi0xLTEtMTA1NjI_68d22838-7a4f-454a-8139-d2a31155fc27">250,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzMtNC0xLTEtMTA1NjI_17690ddd-de4c-43b5-a4d0-0313253436b5">276,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzMtNi0xLTEtMTA1NjI_2d2dbac9-4dbe-4149-8d27-41216b61e3dd">356,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtMi0xLTEtMTA1NjI_9862d1cf-8584-4dc7-921a-9a22cfbf270c"><ix:nonFraction unitRef="shares" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtMi0xLTEtMTA1NjI_b091edd9-efb0-4745-a3cc-3761fffb705e">271,421,986</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtNC0xLTEtMTA1NjI_1d58ebc3-2039-410b-8df5-802c4e628712"><ix:nonFraction unitRef="shares" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtNC0xLTEtMTA1NjI_fe186b35-e1e5-4a0e-a9bb-d18c1301807a">258,867,380</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtNi0xLTEtMTA1NjI_a87a84f8-6678-4735-8088-5d3dc40ed6cf"><ix:nonFraction unitRef="shares" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtNi0xLTEtMTA1NjI_fe17d8ef-d79f-44cc-b67e-23e055b8de85">240,421,001</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. </span></div><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90ZXh0cmVnaW9uOmQ4MDc1NjRhOTMxMTRhMDE4YTkzMTQxNTI2Y2MwYjQ3XzcyNA_30d59e84-92fd-429e-ade2-f943d84b34ac" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie569617484754b05a11d764873af2392_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzItMi0xLTEtMTA1NjI_36ce5cb3-8730-4117-85a9-b57be9b4e405">14,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fd1ccf9f8ab4f1c93b7b88a953bacde_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzItNC0xLTEtMTA1NjI_b63a48ec-051d-48b4-bd58-f2311fb416ad">14,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17b033bab30245779ca01d44c1085c54_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzItNi0xLTEtMTA1NjI_8f6cc605-cd79-4b27-8ed3-e293f6e2a583">16,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf1bdab05104ab9b9570bc2365d7aba_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzMtMi0xLTEtMTA1NjI_f1f0329b-9786-43d8-94f0-0f56eabc050b">7,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7c7aceb760548b4b27547de88d2a4c7_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzMtNC0xLTEtMTA1NjI_456c8153-4f00-448a-99e2-69138243f0cd">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13e30b656f4141acbe98c23e31bd8683_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzMtNi0xLTEtMTA1NjI_75a4793f-5fcd-4674-9962-d148dfe5c6de">5,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dc30a51972343fbbfeeb2ead881ceef_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzQtMi0xLTEtMTA1NjI_dccd52a3-0801-4932-a8d2-5f92ed39051c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65d605eafe9c435eabdcab7621bec3fa_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzQtNC0xLTEtMTA1NjI_4837d6a3-675e-4c4b-8ee9-af9cc10c7458">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie53bbf1d49be45c8b6aeb0307b4fcf08_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzQtNi0xLTEtMTA1NjI_da6e5fa8-06d1-40be-8d7e-0f870d3bceda">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e11e6d8d67c45cb824db13d53516217_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzUtMi0xLTEtMTA1NjI_2488a93f-d4fe-49ff-a755-00366380039d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i953f7cedc14842d1ba60adb562f671c4_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzUtNC0xLTEtMTA1NjI_cc84ec24-a22a-4fad-a605-b8b95fec78e9">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63e57c6c2cd049289478bad341710825_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzUtNi0xLTEtMTA1NjI_2d5e8406-c756-4dbe-86dd-13e9d1896b2e">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzYtMi0xLTEtMTA1NjI_4e682518-7bdb-4713-86b4-9a6e5258a43c">22,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzYtNC0xLTEtMTA1NjI_3ac15066-8fdc-4e52-afb1-426b18a7923f">24,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzYtNi0xLTEtMTA1NjI_51696287-a187-40eb-b21c-354d919816e9">25,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_133"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_136"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term "disclosure controls and procedures," as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-117-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal controls over financial reporting during the fourth quarter of the year ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this section which includes the "Management's Report on Consolidated Financial Statements and Internal Control over Financial Reporting" and the "Report of Independent Registered Public Accounting Firm" are incorporated by reference from "Item&#160;8. Financial Statements and Supplementary Data."</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_139"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OTHER INFORMATION.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_1099511629554"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-118-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information required by Part&#160;III is omitted from this Annual Report on Form&#160;10-K as we intend to file our definitive proxy statement for our 2022 annual meeting of stockholders, pursuant to Regulation&#160;14A of the Securities Exchange Act, not later than 120&#160;days after the end of the fiscal year covered by this Annual Report on Form&#160;10-K, and certain information to be included in the proxy statement is incorporated herein by reference.</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_145"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DIRECTORS, EXECUTIVE OFFICERS OF THE REGISTRANT AND CORPORATE GOVERNANCE.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the caption "Management," "Section&#160;16(a) Beneficial Ownership Reporting Compliance," and "Proposal No.&#160;1&#160;&#8212; Election of Directors"</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Ethics and Conduct for Employees, Executive Officers and Directors that applies to our employees, officers and directors, including the principal executive officer, principal financial officer, and principal accounting officer, and incorporates guidelines designed to deter wrongdoing and to promote the honest and ethical conduct and compliance with applicable laws and regulations. In addition, the code of ethics incorporates our guidelines pertaining to topics such as conflicts of interest and workplace behavior. We have posted the text of our code on our website, where it is accessible for free, at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.amicusrx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in connection with "Investors/Corporate Governance" materials. In addition, we intend to promptly disclose (1)&#160;the nature of any amendment to our code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions and (2)&#160;the nature of any waiver, including an implicit waiver, from provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date the waiver on our website in the future.</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_148"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the caption "Compensation Discussion and Analysis."</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_151"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the captions "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" and "Equity Compensation Plan Information."</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_154"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the captions "Certain Relationships and Related Transactions," "Director Independence," "Committee Compensation and Meetings of the Board of Directors," and "Compensation Committee Interlock and Insider Participation."</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_157"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTING FEES AND SERVICES.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-119-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_163"></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EXHIBITS, FINANCIAL STATEMENT SCHEDULE</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Index to Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Consolidated Financial Statements are filed as part of this report:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_49">Management's Report on Consolidated Financial Statements and Internal Control over Financial Reporting</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_49">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_52">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xNjMvZnJhZzo5MWZkNDNlOWJiZDk0NGQxYTM4YTM0OWFkODcyZWJlZC90YWJsZTowOWM4N2M5MjNhZmE0MzNlOTY1YmRlMjM0YjlhMWFlMC90YWJsZXJhbmdlOjA5Yzg3YzkyM2FmYTQzM2U5NjViZGUyMzRiOWExYWUwXzEtMC0xLTEtMTk4NDMvdGV4dHJlZ2lvbjpmMzIwNDE3N2NmZTA0NTIxYWJjZmJhZWY4OTc3ODczNl8yNzQ4Nzc5MDY5NTg3_187e05b8-47f3-43f3-8f2f-6487e83b6d3e">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_52">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_52">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_58">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_58">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_61">Consolidated Statements of Operations for the years ended December 31, 2021, 2020, and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_61">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_64">Consolidated Statements of Comprehensive Loss for the years ended December 31, 2021, 2020, and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_64">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_67">Consolidated Statements of Changes in Stockholders' Equity</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_67"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_67">for the years ended December 31, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_67">2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_67">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_67">2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_67">, and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_67">2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_67">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_70">Consolidated Statements of Cash Flows for the years ended December 31, 2021, 2020, and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_70">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_73">Notes To Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4e1826361eea43a9b8ec57ad5f93ef33_73">93</a></span></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2. Consolidated Financial Statement Schedules</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not required or because the required information is included in the Consolidated Financial Statements or notes thereto.</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3. Exhibits </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference<br/>to SEC Filing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Form&#160;10-K</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465914009064/a14-5772_1ex2d1.htm">Agreement and Plan of Merger, dated November&#160;19, 2013, by and among Amicus Therapeutics,&#160;Inc., CB Acquisition Corp., Callidus BioPharma,&#160;Inc., and Cuong&#160;Do</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/12/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915068317/a15-20301_1ex2d2.htm">Amendment to Agreement and Plan of Merger, dated September&#160;30, 2015, by and among the Registrant, Titan Merger Sub Corp. and Scioderm,&#160;Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916131264/a16-14342_2ex2d1.htm">Agreement and Plan of Merger, dated July&#160;5, 2016, by and among MiaMed,&#160;Inc., the Registrant and Minervas Merger Sub,&#160;Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/6/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465918058298/a18-35026_1ex2d1.htm#Exhibit2_1_042023">Agreement and Plan of Merger, dated as of September 19, 2018, by and among Amicus Therapeutics, Inc., Columbus Merger Sub Corp., Celenex, Inc. and Shareholder Representative Services LLC, solely in its capacity as the Shareholders&#8217; Representative</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/25/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000119312512085717/d299897dex31.htm">Restated Certificate of Incorporation of the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2012</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv3w4.htm">Restated By-laws of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A (333-141700)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/27/2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915044580/a15-13880_1ex3d1.htm">Certificate of Amendment to the Registrant's Restated Certificate of Incorporation, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/10/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465918039068/a18-15070_1ex3d1.htm#Exhibit3_1_045312">Certificate of Amendment to the Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307007596/y32191a2exv4w1.txt">Specimen Stock Certificate evidencing shares of common stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1 (333-141700)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916116168/a16-9905_1ex4d7.htm">Form of Indenture</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;S-3ASR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/24/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit48descriptionof.htm">Description of the Registrant's securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-120-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference<br/>to SEC Filing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Form&#160;10-K</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-3.htm">Securities Purchase Agreement, dated September 29, 2021, by and between the Company and Redmile Group LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-4.htm">Securities Purchase Agreement, dated September 29, 2021, by and between the Company and Perceptive Life Sciences Master Fund, Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-5.htm">Securities Purchase Agreement, dated September 29, 2021, by and among the Company and the Purchasers identified on the signature pages thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv10w1.txt">2002 Equity Incentive Plan, as amended, and forms of option agreements thereunder</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A (333-141700)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/27/2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000095012307004755/y32191exv10w17.txt">Form of Director and Officer Indemnification Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1 (333-141700)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000095012310059110/c02571exv10w2.htm">Amended and Restated 2007 Director Option Plan and form of option agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/18/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465913086132/a13-24764_2ex10d1.htm">Securities Purchase Agreement, dated November&#160;20, 2013 by and among the Company and the purchasers identified therein</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/20/2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000104746914001702/a2218555zex-10_46.htm">Second Restated Agreement, dated November&#160;19, 2013 by and between the Registrant and Glaxo Group Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/3/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465917075420/a17-29011_1ex10d1.htm">Amicus Amicus Therapeutics, Inc. Amended and Restated Restricted Stock Unit Deferral Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/28/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465914030658/a14-11143_1ex10d1.htm">Employment Agreement dated April&#160;23, 2014, between the Registrant and John&#160;F. Crowley</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/25/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000114036121014545/nc10021408x1_def14a.htm">Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEF 14A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/27/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465916152935/a16-20656_1ex10d1.htm">Amicus Therapeutics,&#160;Inc. Cash Deferral Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/28/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916164572/a16-23950_1ex10d1.htm">Form of Performance-Based Restricted Stock Unit Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/30/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000117887919000063/a102pennamicus.htm">Amended and Restated Research, Collaboration &amp; License Agreement, dated May 28, 2019, by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/8/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465914071932/a14-22497_1ex10d1.htm">Amendment #1 to the Amicus Therapeutics, Inc. Cash Deferral Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/26/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887919000072/exhibit101.htm">Amendment #2 to the Amicus Therapeutics, Inc. Cash Deferral Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit1044jfcamendagr.htm">Amendment No. 1 to Employment Agreement dated April 23, 2014 between the Registrant and John F. Crowley</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit1045ellenrosenb.htm">Employment Agreement dated February 18, 2020 between the Registrant and Ellen S. Rosenberg </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit1046bradleycamp.htm">Employment Agreement dated February 18, 2020, between the Registrant and Bradley L. Campbell</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.17 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit1048daphnequimi.htm">Employment Agreement dated February 18, 2020, between the Registrant and Daphne Quimi</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-121-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference<br/>to SEC Filing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Form&#160;10-K</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit1049hungdo-empl.htm">Employment Agreement dated February 18, 2020 between the Registrant and Hung Do</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">++10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000023/exhibit101.htm">First Amendment to the Amended and Restated Research, Collaboration &amp; License Agreement dated December 20, 2019 by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/7/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">++10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000023/exhibit102.htm">Second Amendment to the Amended and Restated Research, Collaboration &amp; License Agreement dated March 26, 2020 by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/7/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000033/amicus-xloanagreemente.htm">Loan Agreement, dated as of July 17, 2020, by and among Amicus Therapeutics International Holding Ltd, as Borrower, Amicus Therapeutics, Inc. as Parent and a Guarantor, certain subsidiaries of Parent as additional Guarantors, and Hayfin Services LLP as Agent for certain lenders</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/10/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001178879/000117887921000004/formofboardrestrictedstock.htm">Form of Board Restricted Stock Unit Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001178879/000117887921000004/formofboardstockoptionawar.htm">Form of Board Stock Option Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001178879/000117887921000004/formofstockoptionawardagre.htm">Form of Stock Option Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fold-12312021xex1025.htm">Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">++10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="fold-12312021xex1026.htm">Third Amendment to the Amended and Restated Research, Collaboration &amp; License Agreement dated December 3, 2020 by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">++10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fold-12312021xex1027.htm">Fourth Amendment to the Amended and Restated Research, Collaboration &amp; License Agreement dated December 23, 2020 by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">++10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="fold-12312021xex1028.htm">Fifth Amendment to the Amended and Restated Research, Collaboration &amp; License Agreement dated April 6, 2021 by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">++10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="fold-12312021xex1029.htm">Sixth Amendment to the Amended and Restated Research, Collaboration &amp; License Agreement dated August 1, 2021 by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-122-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference<br/>to SEC Filing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Form&#160;10-K</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">++10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="fold-12312021xex1030.htm">Seventh Amendment to the Amended and Restated Research, Collaboration &amp; License Agreement dated September 28, 2021 by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21_2021.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231_2021.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311_2021.htm">Certification of Principal Executive Officer Pursuant to Rule&#160;13a-14(a) of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312_2021.htm">Certification of Principal Financial Officer Pursuant to Rule&#160;13a-14(a) of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321_2021.htm">Certificate of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350 and Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322_2021.htm">Certificate of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350 and Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information from this Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021, formatted in Inline XBRL (Extensible Business Reporting Language) and filed electronically herewith: (i)&#160;the Consolidated Balance Sheets; (ii)&#160;the Consolidated Statements of Operations; (iii)&#160;the Consolidated Statements of Comprehensive Loss; (iv)&#160;the Consolidated Statements of Cash Flows; (v)&#160;and the Notes to the Consolidated Financial Statements.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Annual Report on Form 10-K for the year ended December 31, 2021 formatted in Inline XBRL (included in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________________________________________</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Confidential treatment has been granted as to certain portions of the document, which portions have been omitted and filed separately with the Securities and Exchange Commission.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Subject to confidential treatment request.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the captions "Certain Relationships and Related Transactions," "Director Independence," "Committee Compensation and Meetings of the Board of Directors," and "Compensation Committee Interlock and Insider Participation."</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-123-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FORM 10-K SUMMARY.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-124-</span></div></div></div><div id="i4e1826361eea43a9b8ec57ad5f93ef33_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on February&#160;24, 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.508%"><tr><td style="width:1.0%"></td><td style="width:13.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMICUS THERAPEUTICS,&#160;INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ &#160;&#160;&#160;John F. Crowley</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John F. Crowley</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Date</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ &#160;&#160;&#160;John F. Crowley</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman and Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(John F. Crowley)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ &#160;&#160;&#160;Bradley L. Campbell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director and President and Chief Operating Officer<br/>(Director)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Bradley L. Campbell)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;Daphne Quimi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principle Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Daphne Quimi)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;Robert Essner</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Robert Essner)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;Margaret G. McGlynn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Margaret G. McGlynn)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael G. Raab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Michael G. Raab)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Glenn Sblendorio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Glenn Sblendorio)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Craig Wheeler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Craig Wheeler)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-125-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Date</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; Lynn&#160;Bleil</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Lynn Bleil)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Burke Whitman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Burke Whitman)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael A. Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Michael A. Kelly)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Eiry W. Roberts, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Eiry W. Roberts, M.D.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-126-</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>2
<FILENAME>fold-12312021xex1025.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4f0e10d33431474ca84ca326c5641591_1"></div><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.85pt;padding-left:97.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:49.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is</font></div><div style="padding-left:5.95pt;padding-right:27.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">made by and between Amicus Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and &#91;   &#93; (the &#8220;Participant&#8221;) as of the &#91;   &#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Capitalized terms used herein without definition shall have the meaning ascribed to such terms in the Company's Amended and Restated 2007 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), a copy of which is available in the Participant&#8217;s on-line account. </font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:28.45pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.15pt;text-decoration:underline">Award of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company hereby awards the Participant &#91;   &#93; Restricted Stock Units, subject to the restrictions and on the terms and conditions set forth in this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The terms of the Plan are hereby incorporated into this Agreement by this reference, as though fully set forth herein.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:28.45pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.15pt;text-decoration:underline">Vesting of Restricted Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Restricted Units are subject to a Restriction Period until they become vested in accordance with this Section 2. </font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:24.7pt;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.98pt">&#91;Insert Description of Vesting&#93;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:25.85pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.98pt">Additionally, if, during the Participant&#8217;s continuous service with the Company there occurs a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as such term is defined in the Plan, then the Restricted Units shall become fully vested.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:23.75pt;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.6pt">Upon a Separation of the Participant from the Company or its Affiliates for any reason other than death, Disability or Retirement (as defined in the Plan), any Restricted Units which then remain subject to a Restriction Period will immediately and automatically, without any action on the part of the Company, be forfeited, and the Participant will have no further rights with respect to those shares.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:23.75pt;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.98pt">In the event of a Separation by the Participant from the Company or its Affiliates due to death, Disability or Retirement, all outstanding Restricted Units that would have become vested between the Separation and the second anniversary of such Separation shall immediately become fully vested. Restricted Units that would vest after this two-year period will be immediately forfeited upon such Separation with no further compensation due to the Participant unless otherwise determined by the Committee. </font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:41.35pt;text-indent:-13.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.5pt;text-decoration:underline">Distribution of Shares.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:28.45pt;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.6pt">Upon the lapse of the Restricted Period applicable to the Restricted Units (and provided that appropriate arrangements have been made with the Company for the withholding or payment of any taxes that may be due with respect to such share), the Company will issue shares of Common Stock to the Participant with respect to the Restricted Units that vest. Such shares may be issued in the Participant&#8217;s name by issuance of a stock certificate or certificates.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:27.25pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.98pt">The Company may also condition delivery of certificates underlying the Restricted Units upon receipt from the Participant of any undertakings that it may determine are appropriate to facilitate compliance with federal and state securities laws.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:27.25pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.6pt">Notwithstanding any provision in this Agreement to the contrary, if, as of the date of the Participant&#8217;s Separation, the Participant is a &#8220;specified employee&#8221; (within the meaning of Section 409A of the Code) and the Participant could become eligible for Retirement at any time during the Restricted Period, then, to the extent required under Section 409A of the Code, shares of Common Stock with respect to the Restricted Units that vest upon such Separation, if any, will not be issued to such Participant until the date that is six months and one day after such Separation (or, if earlier, the Participant&#8217;s death).</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:38pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.15pt;text-decoration:underline">Transfer of Restricted Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Other than as expressly permitted by Section 7.3(e) of the Plan, the Restricted Units may not be transferred unless, to the extent not otherwise prohibited under Section 409A of the Code, such transfer is pursuant to a bona fide divorce agreement or settlement delineating the division of assets between a divorcing Participant and Participant&#8217;s spouse.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:1.902%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:111%">1</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:27.6pt;padding-right:38pt;text-align:right"><font><br></font></div><div style="padding-left:6pt;padding-right:38pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.15pt;text-decoration:underline">Substitute Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If, while any of the Restricted Units remain subject to a Restricted Period, there occurs a merger, reclassification, recapitalization, stock split, stock dividend or other similar event or transaction resulting in new, substituted or additional securities being issued or delivered to the Participant by reason of the Participant&#8217;s ownership of the Restricted Units, such securities will constitute &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; for all purposes of this Agreement.</font></div><div style="padding-left:27.6pt;padding-right:38pt;text-align:right"><font><br></font></div><div style="margin-top:2.85pt;padding-left:6pt;padding-right:28.45pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.15pt;text-decoration:underline">Rights of Participant During Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Participant will not have any right to vote the Restricted Units during the Restricted Period. The Participant will have the right to receive dividends and distributions with respect to the Restricted Units&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that any cash dividends or distributions paid in respect of the Restricted Units while those units remain subject to a Restricted Period will be delivered to the Participant (without interest) only if and when the Restricted Units giving rise to such dividends or distributions become vested.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:41.85pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.15pt;text-decoration:underline">Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Committee may from time to time impose any conditions on the Restricted Units as it deems necessary or advisable to ensure that the Restricted Units or any shares of Common Stock issued with respect to the Restricted Units are issued and sold in compliance with the requirements of any stock exchange or quotation system upon which the shares are then listed or quoted, the Securities Act of 1933 and all other applicable laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:28.45pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.15pt;text-decoration:underline">Tax Consequences</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Participant acknowledges that the Company has not advised the Participant regarding the Participant&#8217;s income tax liability in connection with the grant or vesting of the Restricted Units. The Participant has had the opportunity to review with his or her own tax advisors the federal, state and local tax consequences of the transactions contemplated by this Agreement. The Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#8217;s own tax liability that may arise as a result of the transactions contemplated by this Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:29.9pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:0.15pt;text-decoration:underline">The Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Award of Restricted Units is subject to, and the Participant agrees to be bound by, all of the terms and conditions of the Plan, a copy of which has been provided to the Participant. Pursuant to the Plan, the Committee is authorized to adopt rules and regulations not inconsistent with the Plan as it shall deem appropriate and proper. All questions of interpretation and application of the Plan shall be determined by the Committee and any such determination shall be final, binding and conclusive.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:23.15pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:30.65pt;text-decoration:underline">Consent to Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Participant hereby authorizes the Company to deliver electronically any prospectuses or other documentation related to this Agreement, the Plan and any other compensation or benefit plan or arrangement in effect from time to time (including, without limitation, reports, proxy statements or other documents that are required to be delivered to participants in such plans or arrangements pursuant to federal or state laws, rules or regulations).  For this purpose, electronic delivery will include, without limitation, delivery by means of e-mail or e-mail notification that such documentation is available on the Company&#8217;s intranet site. Upon written request, the Company will provide to the Participant a paper copy of any document also delivered to the Participant electronically. The authorization described in this paragraph may be revoked by the Participant at any time by written notice to the Company.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:23.15pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:30.65pt;text-decoration:underline">Deemed Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Participant hereby acknowledges that all Restricted Units granted under this Agreement are subject to and bound by the terms of this Agreement. A failure to affirmatively reject this award prior to &#91;   &#93; shall result in the automatic acceptance of the Restricted Units under the terms of this Agreement. </font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:6pt;padding-right:38pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:30.65pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement together with the Plan, represents the entire agreement between the parties hereto relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt;padding-right:38pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:30.65pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement will be construed in accordance with the laws of the State of New Jersey, without regard to the application of the principles of conflicts of laws.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:1.902%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:111%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:64.5pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:30.65pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the provisions of the Plan, this Agreement may only be amended by a writing signed by each of the parties hereto.</font></div><div style="padding-right:64.5pt"><font><br></font></div><div style="padding-left:206.5pt"><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:1.902%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:111%">3</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>3
<FILENAME>fold-12312021xex1026.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i36fedcf359b041798bc09418ec7b67a2_1"></div><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div style="margin-top:3.15pt;padding-left:413.25pt"><font><br></font></div><div style="margin-top:3.15pt;padding-left:413.25pt"><font><br></font></div><div style="margin-top:3.15pt;padding-left:413.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">CONFIDENTIAL</font></div><div style="padding-left:411.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Execution Version</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:220.55pt;padding-right:220.55pt;text-align:center;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIRD AMENDMENT TO AMENDED AND RESTATED</font></div><div style="padding-left:82.9pt;padding-right:82.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RESEARCH, COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78pt;padding-right:89.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This THIRD AMENDMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated December 23, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Penn and Licensee may be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or, collectively, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78pt;padding-right:89.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties entered into a Research, Collaboration &#38; License Agreement dated October 8, 2018, which was later amended pursuant to the Amended and Restated Research, Collaboration &#38; License Agreement dated May 28, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which was amended by the First Amendment dated December 20, 2019 and the Second Amendment dated March 26, 2020, pursuant to which, among other things, Penn and Licensee are conducting a research program for the pre- clinical development of certain gene therapy products intended to treat certain specified indications&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78pt;padding-right:89.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties now wish to amend certain provisions of the Collaboration Agreement as set forth in this Amendment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78pt;padding-right:89.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78pt;padding-right:89.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The Research Plan and timeline contained in Exhibit B of the Collaboration Agreement for the &#91;***&#93; programs is hereby amended to include the additional work and timeline outlined in the updated Schedule B to this Third Amendment.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78pt;padding-right:89.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The Research Program Budget contained in Exhibit C of the Collaboration Agreement for the &#91;***&#93; programs is hereby amended to include the new Research Program Budget contained in Schedule C to this Third Amendment. The payment schedule contained in Schedule C of the Agreement is amended and restated in its entirety as set forth in Exhibit C to this Third Amendment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78pt;padding-right:89.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">A complete and amended patent schedule for Penn Patent Rights A of the Collaboration Agreement is attached as Exhibit A, a complete and amended patent schedule for Funded Discovery Patent Rights Exceptions &#91;***&#93; is attached as Exhibit G, and a complete and amended patent schedule for DRG Patent Rights is attached as Exhibit Y.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78pt;padding-right:89.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">This Third Amendment and the Collaboration Agreement contains the entire understanding between the Parties and supersedes any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect </font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:78pt;padding-right:89.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the matters contained in the Agreement and this Third Amendment. No amendments, changes, modifications or alterations of the terms and conditions of this Third Amendment shall be binding upon any Party, unless in writing and signed by an authorized representative of each Party.</font></div><div style="padding-right:89.95pt"><font><br></font></div><div style="padding-left:72pt;padding-right:89.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;All terms and conditions of the Agreement not changed by this Third Amendment shall remain in full force and effect.</font></div><div style="padding-right:89.95pt"><font><br></font></div><div style="padding-left:72pt;padding-right:89.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Signatures on this Third Amendment may be communicated by facsimile or e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by facsimile or e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment shall be effective as if simultaneously executed.</font></div><div style="padding-right:89.95pt"><font><br></font></div><div style="padding-right:89.95pt"><font><br></font></div><div style="padding-left:14.25pt;padding-right:14.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of the page intentionally left blank&#59; signature page follows.&#93;</font></div><div><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:14.25pt;padding-right:14.25pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:77.95pt;padding-right:89.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:128%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:128%">duly authorized representatives of the Parties have executed this Amendment as of the Amendment Date.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:81.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.529%"><tr><td style="width:1.0%"></td><td style="width:54.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt;padding-right:25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.8pt;padding-right:2.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMICUS&#160;&#160;&#160;&#160;THERAPEUTICS, INC.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%">By&#58;          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;text-decoration:underline">&#47;s&#47;John S. Swartley</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%">By&#58;      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;text-decoration:underline">&#47;s&#47; Jeff Castelli</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Name&#58;     John S. Swartley, PhD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:26.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Name&#58; Jeff Castelli, PhD</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.05pt;padding-right:20.75pt;text-indent:-45.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Associate Vice Provost for Research and Managing Director, Penn Center</font></div><div style="padding-left:48.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">for Innovation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:26.55pt;padding-right:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   Chief Development  </font></div><div style="padding-left:26.55pt;padding-right:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.5pt;padding-left:78pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Read and Acknowledged&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.6pt;padding-left:78pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;James Wilson</font></div><div style="margin-top:1.8pt;padding-left:78pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Dr. James M. Wilson</font></div><div style="margin-top:1.8pt;padding-left:78pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Director, Gene Therapy Program</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36fedcf359b041798bc09418ec7b67a2_4"></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i36fedcf359b041798bc09418ec7b67a2_7"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:267.7pt;padding-right:267.7pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">Exhibit A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Patent Rights</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:265.85pt;padding-right:265.85pt;text-align:center;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Exhibit B </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;text-decoration:underline">Research Plan</font></div><div style="margin-top:4.5pt;padding-left:265.85pt;padding-right:265.85pt;text-align:center;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:82.9pt;padding-right:82.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit C</font></div><div><font><br></font></div><div style="padding-left:82.97pt;padding-right:82.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Research Program Budget and Payment Schedule</font></div><div style="margin-top:0.1pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:265.85pt;padding-right:265.85pt;text-align:center;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:82.92pt;padding-right:82.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit G</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:193.92pt;padding-right:193.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Funded Discovery Patent Rights Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:4.5pt;padding-right:199.95pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:265.85pt;padding-right:265.85pt;text-align:center;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">&#91;***&#93;</font></div><div style="margin-top:4.5pt;padding-left:193.92pt;padding-right:193.92pt;text-align:center"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:193.92pt;padding-right:193.92pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:82.92pt;padding-right:82.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit Y</font></div><div><font><br></font></div><div style="padding-left:246.8pt;padding-right:246.8pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DRG Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:246.8pt;padding-right:246.8pt;text-align:center;text-indent:-0.05pt"><font><br></font></div><div style="padding-left:246.8pt;padding-right:246.8pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>4
<FILENAME>fold-12312021xex1027.htm
<DESCRIPTION>EX-10.27
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9c20bf6cbf844e4fa6c073ca21ff0b2e_1"></div><div style="min-height:38.88pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div style="margin-top:4pt;padding-left:341.25pt"><font><br></font></div><div style="margin-top:4pt;padding-left:341.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">CONFIDENTIAL</font></div><div style="padding-left:339.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Execution Version</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:173.05pt;padding-right:173.05pt;text-align:center;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOURTH AMENDMENT TO AMENDED AND RESTATED</font></div><div style="padding-left:78.35pt;padding-right:78.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RESEARCH, COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:66.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This FOURTH AMENDMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated December 23, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Penn and Licensee may be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or, collectively, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:66.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties entered into a Research, Collaboration &#38; License Agreement dated October 8, 2018, which was later amended pursuant to the Amended and Restated Research, Collaboration &#38; License Agreement dated May 28, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which was amended by the First Amendment dated December 20, 2019, the Second Amendment dated March 26, 2020, and the Third Amendment dated December 23, 2020, pursuant to which, among other things, Penn and Licensee are conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:66.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties now wish to amend certain provisions of the Collaboration Agreement as set forth in this Amendment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:66.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:66.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Licensee has exercised its Exploratory Indication Option to start a Research Program for &#91;***&#93; and the parties have agreed on a Research Plan and a Research Plan Budget. The Research Plan and timeline for the &#91;***&#93; program is contained in the updated Exhibit B to this Fourth Amendment. The Research Program Budget for the &#91;***&#93; program is contained in the updated Exhibit C to this Fourth Amendment. The payment schedule set forth in Exhibit C is incremental to the payment schedule contained in the Third Amendment of the Collaboration Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:66.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Within &#91;***&#93; business days following the Amendment Date, Licensee will pay to Penn a non-refundable, non-creditable payment in the amount of &#91;***&#93; by wire transfer of immediately available funds (&#8220;New Indication Option Fee&#8221;) pursuant to Section 6.6 of the Collaboration Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:66.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">This Fourth Amendment and the Collaboration Agreement contains the entire understanding between the Parties and supersedes any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Collaboration Agreement and this Fourth Amendment. No amendments, changes, modifications or alterations of the terms and conditions of this</font></div><div style="height:56.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9c20bf6cbf844e4fa6c073ca21ff0b2e_4"></div><hr style="page-break-after:always"><div style="min-height:38.88pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:18.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fourth Amendment shall be binding upon any Party, unless in writing and signed by an authorized representative of each Party.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:66.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">All terms and conditions of the Collaboration Agreement not changed by this Fourth Amendment shall remain in full force and effect.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:66.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt">Signatures on this Fourth Amendment may be communicated by facsimile or e- mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by facsimile or e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment shall be effective as if simultaneously executed.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.9pt;padding-left:48.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of the page intentionally left blank&#59; signature page follows.&#93;</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9c20bf6cbf844e4fa6c073ca21ff0b2e_7"></div><hr style="page-break-after:always"><div style="min-height:38.88pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:29.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:128%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:128%">duly authorized representatives of the Parties have executed this Amendment as of the Amendment Date.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9c20bf6cbf844e4fa6c073ca21ff0b2e_10"></div><hr style="page-break-after:always"><div style="min-height:38.88pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.702%"><div style="margin-top:4.5pt;padding-left:11.4pt;padding-right:1.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</font></div><div style="margin-top:4.5pt;padding-left:11.35pt;padding-right:63.75pt"><font><br></font></div></div><div style="display:inline-block;max-width:6.595%;min-width:5.595%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.703%"><div style="padding-left:11.35pt;padding-right:63.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMICUS&#160;&#160;&#160;&#160;THERAPEUTICS, INC.</font></div></div></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:11.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John S. Swartley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jeff Castelli</font></div><div style="padding-left:11.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; John S. Swartley, PhD&#160;&#160;&#160;&#160;Name&#58; Jeff Castelli, PhD</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.627%"><div style="padding-left:57pt;padding-right:1.9pt;text-align:justify;text-indent:-45.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Associate Vice Provost for Research and Managing Director, Penn Center for Innovation</font></div><div style="padding-left:11.35pt;padding-right:99.35pt"><font><br></font></div></div><div style="display:inline-block;max-width:6.744%;min-width:5.744%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.629%"><div style="padding-left:11.35pt;padding-right:99.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Development Officer</font></div></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Read and Acknowledged&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James Wilson</font></div><div style="margin-top:1.8pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Dr. James M. Wilson</font></div><div style="margin-top:1.85pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Director, Gene Therapy Program</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9c20bf6cbf844e4fa6c073ca21ff0b2e_13"></div><hr style="page-break-after:always"><div style="min-height:38.88pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:218.35pt;padding-right:218.35pt;text-align:center;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit B </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Research Plan</font></div><div style="margin-top:0.5pt;text-align:center"><font><br></font></div><div style="margin-top:0.5pt;padding-left:27.5pt;padding-right:27.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:81.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:38.88pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:218.35pt;padding-right:218.35pt;text-align:center;text-indent:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:218.35pt;padding-right:218.35pt;text-align:center;text-indent:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:148.37pt;padding-right:148.37pt;text-align:center;text-indent:-115.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit C </font></div><div style="margin-top:4.5pt;padding-left:148.37pt;padding-right:148.37pt;text-align:center;text-indent:-115.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Research Program Budget and Payment Schedule</font></div><div style="margin-top:0.5pt;text-align:center"><font><br></font></div><div style="margin-top:0.5pt;padding-left:27.5pt;padding-right:27.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-top:0.5pt;padding-left:27.5pt;padding-right:27.5pt;text-align:center"><font><br></font></div><div style="height:81.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>5
<FILENAME>fold-12312021xex1028.htm
<DESCRIPTION>EX-10.28
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6bb1c800c73c403180b84b1132e0908e_1"></div><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div style="margin-top:3.15pt;padding-right:46.85pt;text-align:right"><font><br></font></div><div style="margin-top:3.15pt;padding-right:46.85pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">CONFIDENTIAL</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:160.05pt;padding-right:160.05pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FIFTH AMENDMENT TO AMENDED AND RESTATED</font></div><div style="padding-left:65.35pt;padding-right:65.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RESEARCH, COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:40.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This FIFTH AMENDMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated April 6, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fifth Amendment Effective  Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Penn and Licensee may be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or, collectively, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:40.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties entered into a Research, Collaboration &#38; License Agreement dated October 8, 2018, which was later amended pursuant to the Amended and Restated Research, Collaboration &#38; License Agreement dated May 28, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which was amended by the First Amendment dated December 20, 2019, the Second Amendment dated March 26, 2020, the Third Amendment</font></div><div style="padding-left:6pt;padding-right:41pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dated December 23, 2020, and the Fourth Amendment also dated December 23, 2021 pursuant to which, among other things, Penn and Licensee are conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:40.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties now wish to amend certain provisions of the Collaboration Agreement as set forth in this Amendment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:40.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:40.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Pursuant to Section 2.5.1, Licensee and Penn have agreed to initiate a Pilot Study for &#91;***&#93;. The Research Plan and timeline for the &#91;***&#93; Pilot Study is contained in the updated Exhibit B to this Fifth Amendment. The Research Program Budget for the &#91;***&#93; Pilot Study program is contained in the updated Exhibit C to this Fifth Amendment. The full amount of the Program Budget will be paid by Licensee within &#91;***&#93; days of the Fifth Amendment Effective Date.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">If, at the conclusion of the &#91;***&#93; Pilot Study, Licensee elects not to move forward with an &#91;***&#93; Research Program, &#91;***&#93; shall be deleted from the definition of Exclusive DRG Indications in Section 1.105 of the Collaboration Agreement, and &#91;***&#93; will thereafter be considered an  Exploratory DRG Technology Indication.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Licensee acknowledges that pursuant to Section 2.5.5, Penn has granted a license for &#91;***&#93; under Patent Rights Controlled by Penn and conceived and reduced to practice by the Wilson Lab to an entity controlled by &#91;***&#93; and Penn is not able to collaborate with Licensee on &#91;***&#93;, and the &#91;***&#93; is deleted from the definition of Exploratory Indications.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:82.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.95pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt">This Fifth Amendment and the Collaboration Agreement contains the entire understanding between the Parties and supersedes any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Collaboration Agreement and this Fifth Amendment. No amendments, changes, modifications or alterations of the terms and conditions of this Fifth Amendment shall be binding upon any Party, unless in writing and signed by an authorized representative of each Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:40.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">All terms and conditions of the Collaboration Agreement not changed by this Fifth Amendment shall remain in full force and effect.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:40.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt">Signatures on this Fifth Amendment may be communicated by facsimile or e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by facsimile or e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment shall be effective as if simultaneously executed.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.9pt;padding-left:48.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of the page intentionally left blank&#59; signature page follows.&#93;</font></div><div style="height:82.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6bb1c800c73c403180b84b1132e0908e_4"></div><hr style="page-break-after:always"><div style="min-height:38.88pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:29.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:128%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:128%">duly authorized representatives of the Parties have executed this Amendment as of the Amendment Date.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6bb1c800c73c403180b84b1132e0908e_7"></div><hr style="page-break-after:always"><div style="min-height:38.88pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.702%"><div style="margin-top:4.5pt;padding-left:11.4pt;padding-right:1.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</font></div><div style="margin-top:4.5pt;padding-left:11.35pt;padding-right:63.75pt"><font><br></font></div></div><div style="display:inline-block;max-width:6.595%;min-width:5.595%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.703%"><div style="padding-left:11.35pt;padding-right:63.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMICUS&#160;&#160;&#160;&#160;THERAPEUTICS, INC.</font></div></div></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:11.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;John S. Swartley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;Jeff Castelli</font></div><div style="padding-left:11.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; John S. Swartley, PhD&#160;&#160;&#160;&#160;Name&#58; Jeff Castelli, PhD</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.627%"><div style="padding-left:57pt;padding-right:1.9pt;text-align:justify;text-indent:-45.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Associate Vice Provost for Research and Managing Director, Penn Center for Innovation</font></div><div style="margin-top:4.5pt;padding-left:6pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Read and Acknowledged&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James Wilson</font></div><div style="margin-top:1.8pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Dr. James M. Wilson</font></div><div style="margin-top:1.85pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Director, Gene Therapy Program</font></div><div style="padding-left:11.35pt;padding-right:99.35pt"><font><br></font></div></div><div style="display:inline-block;max-width:6.744%;min-width:5.744%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.629%"><div style="padding-left:11.35pt;padding-right:99.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Development Officer</font></div></div></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6bb1c800c73c403180b84b1132e0908e_10"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:217.2pt;padding-right:217.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B</font></div><div><font><br></font></div><div style="padding-left:65.3pt;padding-right:65.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pilot Study and Timeline</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:46.72pt;padding-right:46.72pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-bottom:1.2pt;padding-left:218.1pt;padding-right:218.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:232%">Exhibit C </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:232%;text-decoration:underline">Budget</font></div><div style="margin-bottom:1.2pt;padding-left:218.1pt;padding-right:218.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:232%">&#91;***&#93;</font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>6
<FILENAME>fold-12312021xex1029.htm
<DESCRIPTION>EX-10.29
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iecba2b7698c247dd86d4b3e407104192_1"></div><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div></div><div style="margin-top:0.1pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div><div style="margin-top:4.5pt;padding-left:170.75pt;padding-right:170.75pt;text-align:center;text-indent:-0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:170.75pt;padding-right:170.75pt;text-align:center;text-indent:-0.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SIXTH AMENDMENT TO AMENDED AND RESTATED</font></div><div style="margin-top:0.05pt;padding-left:75.57pt;padding-right:75.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RESEARCH, COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:6pt;padding-right:61.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This SIXTH AMENDMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated August 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sixth Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Penn and Licensee may be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or, collectively, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:61.45pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties entered into a Research, Collaboration &#38; License Agreement dated October 8, 2018, which was later amended pursuant to the Amended and Restated Research, Collaboration &#38; License Agreement dated May 28, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which was amended by the First Amendment dated December 20, 2019, the Second Amendment dated March 26, 2020, the Third Amendment dated December 23, 2020, the Fourth Amendment also dated December 23, 2021 and the Fifth Amendment dated April 6, 2021 pursuant to which, among other things, Penn and Licensee are conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications&#59; and</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:6pt;padding-right:61.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">WHEREAS, the Parties now wish to amend certain provisions of the Collaboration Agreement as set forth in this Amendment.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:6pt;padding-right:61.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6pt;padding-right:61.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Pursuant to Section 2.5.1, Licensee and Penn have agreed to initiate a Pilot Study for &#91;***&#93;. The Research Plan and timeline for the &#91;***&#93; Pilot Study is contained in the updated Exhibit B to this Sixth Amendment. The Research Program Budget for the &#91;***&#93; Pilot Study program is contained in the updated Exhibit C to this Sixth Amendment. The full amount of the Program Budget will be paid by Licensee within &#91;***&#93; days of the Sixth Amendment Effective Date.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:61.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">This Sixth Amendment and the Collaboration Agreement contains the entire understanding between the Parties and supersedes any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Collaboration Agreement and this Sixth Amendment. No amendments, changes, modifications or alterations of the terms and conditions of this Sixth Amendment shall be binding upon any Party, unless in writing and signed by an authorized representative of each Party.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:27.97pt;padding-right:27.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iecba2b7698c247dd86d4b3e407104192_4"></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:61.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">All terms and conditions of the Collaboration Agreement not changed by this Sixth Amendment shall remain in full force and effect. The Parties agree that the this Sixth Amendment is affective retroactively as of the Sixth Amendment Effective Date.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6pt;padding-right:61.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Signatures on this Sixth Amendment may be communicated by facsimile or e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by facsimile or e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment shall be effective as if simultaneously executed.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.05pt;padding-left:49pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of the page intentionally left blank&#59; signature page follows.&#93;</font></div><div><font><br></font></div><div style="height:87.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:61.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:128%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:128%">duly authorized representatives of the Parties have executed this Amendment as of the Amendment Date.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:9.19pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.205%"><tr><td style="width:1.0%"></td><td style="width:55.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt;padding-right:25.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;padding-right:2.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">AMICUS&#160;&#160;&#160;&#160;THERAPEUTICS, INC.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%">By&#58;         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;text-decoration:underline">&#47;s&#47; John S. Swartley</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:26.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%">By&#58;     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;text-decoration:underline">&#47;s&#47; Jeff Castelli</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Name&#58;  John S. Swartley, PhD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:26.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Name&#58; Jeff Castelli, PhD</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.1pt;text-indent:-45.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Title&#58;&#160;&#160;&#160;&#160;Associate Vice Provost for Research</font></div><div style="padding-left:48.1pt;padding-right:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">and Managing Director, Penn Center for Innovation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:26.75pt;padding-right:37.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Title&#58; Chief Development Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Read and Acknowledged&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James Wilson</font></div><div style="margin-top:1.8pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Dr. James M. Wilson</font></div><div style="margin-top:1.8pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Director, Gene Therapy Program</font></div><div><font><br></font></div><div style="height:87.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:218.35pt;padding-right:218.35pt;text-align:center;text-indent:0.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Research Plan</font></div><div style="margin-top:0.5pt;text-align:center"><font><br></font></div><div style="margin-top:0.5pt;padding-left:27.5pt;padding-right:27.5pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:87.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:218.35pt;padding-right:218.35pt;text-align:center;text-indent:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:218.35pt;padding-right:218.35pt;text-align:center;text-indent:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:148.37pt;padding-right:148.37pt;text-align:center;text-indent:-115.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C </font></div><div style="margin-top:4.5pt;padding-left:148.37pt;padding-right:148.37pt;text-align:center;text-indent:-115.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Research Program Budget </font></div><div style="margin-top:0.5pt;text-align:center"><font><br></font></div><div style="margin-top:0.5pt;padding-left:27.5pt;padding-right:27.5pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-top:0.5pt;padding-left:27.5pt;padding-right:27.5pt;text-align:center"><font><br></font></div><div style="margin-top:10.45pt;padding-left:75.45pt;padding-right:75.45pt;text-align:center"><font><br></font></div><div style="height:87.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>7
<FILENAME>fold-12312021xex1030.htm
<DESCRIPTION>EX-10.30
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ida04b7a4275e443ab1e40fa20907fda3_1"></div><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div style="margin-top:3.35pt;padding-left:376.75pt;padding-right:11.8pt;text-align:right;text-indent:-12.85pt"><font><br></font></div><div style="margin-top:3.35pt;padding-left:376.75pt;padding-right:11.8pt;text-align:right;text-indent:-12.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">EXECUTION COPY CONFIDENTIAL</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:158.82pt;padding-right:158.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SEVENTH AMENDMENT TO AMENDED AND RESTATED</font></div><div style="padding-left:65.62pt;padding-right:65.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:113%">RESEARCH, COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.05pt;padding-right:5.75pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This SEVENTH AMENDMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), effective as of September 28, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amicus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Penn and Amicus may be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or, collectively, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.05pt;padding-right:6.05pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties entered into that certain Amended and Restated Research, Collaboration &#38; License Agreement dated May 28, 2019, as amended through a first amendment dated December 20, 2019, a second amendment dated March 26, 2020, a third amendment dated December 3, 2020, a fourth amendment dated December 23, 2020, a fifth amendment dated April 6, 2021 and a sixth amendment dated August 1, 2021 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to which, among other things, Penn and Amicus are conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.05pt;padding-right:6.45pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">WHEREAS, the Parties entered in to that certain Process Development Research &#38; License Agreement dated March 26, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">PD Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">&#8221;), pursuant to which, among other things, Penn and Amicus are conducting a research program for the development and&#47;or optimization of manufacturing technology for gene therapy products&#59;</font></div><div style="margin-top:11.6pt;padding-left:5.05pt;padding-right:6.2pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">WHEREAS, in conjunction with this Amendment, the Parties are entering into a letter agreement with respect to certain matters dated as of September 28, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Letter Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.05pt;padding-right:6.7pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">WHEREAS, the Parties now wish to further amend certain provisions of the Collaboration Agreement as set forth in this Amendment.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.05pt;padding-right:7.25pt;text-align:justify;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:11.55pt;padding-left:23.5pt;padding-right:7.3pt;text-align:justify;text-indent:-18.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9.45pt">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Capitalized terms used in this Amendment and not defined herein shall have the meaning given to such terms in the Collaboration Agreement, unless otherwise specified herein.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:23.5pt;padding-right:6.15pt;text-align:justify;text-indent:-18.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9.45pt">Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">. The Parties agree to amend the Collaboration Agreement by the following revisions&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45.95pt;padding-right:7.15pt;text-indent:-18.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.13pt">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Section 1.25 of the Collaboration Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:45.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;1.25 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Discovery Program Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the period beginning &#91;***&#93; and ending on &#91;***&#93;.&#8221;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ida04b7a4275e443ab1e40fa20907fda3_4"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.15pt;padding-left:45.95pt;padding-right:6.95pt;text-indent:-18.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9.45pt">The first sentence of Section 3.1.1 of the Collaboration Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:45.95pt;padding-right:6.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">&#8220;During the period beginning on the New Effective Date and thereafter for the remainder of the Discovery Program Period, subject to the terms and conditions of this Agreement, Licensee shall pay &#91;***&#93; in research and development funding to Penn to fund the Discovery Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%">Discovery Support Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">&#8221;).&#8221;</font></div><div style="margin-top:11.5pt;padding-left:23.5pt;padding-right:6.25pt;text-align:justify;text-indent:-18.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:9.45pt">Effectiveness&#59; Termination. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">This Amendment shall automatically terminate without any notice or further action by either Party, and shall be deemed null and void in its entirety, if all of the Transactions described in the second paragraph of the Letter Agreement are not executed and fully consummated on or before &#91;***&#93;.</font></div><div style="margin-top:11.5pt;padding-left:23.5pt;padding-right:6.85pt;text-align:justify;text-indent:-18.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:117%;padding-left:9.45pt">No Other Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">. Except as specifically set forth in this Amendment, the terms and conditions of the Collaboration Agreement shall continue in full force and effect and shall apply to this Amendment. This Amendment constitutes the complete and exclusive statement of agreement between the Parties with respect to the subject matter of this Amendment, and supersedes all prior agreements and understandings, and all prior and contemporaneous (oral or written) proposals, understanding, representations, conditions, warranties, covenants and all other communications between the Parties respecting the subject matter hereof. No waiver, modification or amendment of any provision of this Amendment shall be valid or effective unless made in a writing referencing this Amendment and signed by a duly authorized officer of each Party.</font></div><div style="margin-top:11.2pt;padding-left:23.5pt;padding-right:6.4pt;text-align:justify;text-indent:-18.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.45pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Amendment, including the signature pages, will be deemed an original. This Amendment shall be governed by and interpreted in accordance with the laws of the Commonwealth of Pennsylvania, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the Commonwealth of Pennsylvania.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:64.22pt;padding-right:64.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of the page intentionally left blank&#59; signature page follows.&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.05pt;padding-left:5.05pt;text-indent:36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:128%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:128%">duly authorized representatives of the Parties have executed this Agreement as of the Amendment Date.</font></div><div style="margin-bottom:0.05pt;margin-top:0.45pt"><font><br></font></div><div style="padding-left:8.55pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.735%"><tr><td style="width:1.0%"></td><td style="width:55.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt;padding-right:25.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;padding-right:18.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AMICUS THERAPEUTICS, INC.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">&#47;s&#47; John S. Swartley</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:25.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline">&#47;s&#47; John F. Crowley</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">Name&#58; John S. Swartley, PhD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:25.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">Name&#58; John Crowley</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58;&#160;&#160;&#160;&#160;Associate Vice Provost for Research</font></div><div style="padding-left:48.1pt;padding-right:19.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">and Managing Director, Penn Center for Innovation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:25.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Chairman and CEO</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:5.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Read and Acknowledged&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.55pt;padding-left:5.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James M. Wilson</font></div><div style="margin-top:2.2pt;padding-left:5.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Dr. James M. Wilson</font></div><div style="margin-top:1.45pt;padding-left:5.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Director, Gene Therapy Program</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>8
<FILENAME>exhibit21_2021.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ieb7847cef83a4852b0725810667aac6e_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 21</font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">List of Subsidiaries of the Registrant&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Callidus Biopharma,&#160;Inc. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Celenex, Inc. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Scioderm,&#160;Inc. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">MiaMed,&#160;Inc. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics International Holding Limited (UK)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics UK Limited (UK)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics UK Operations Limited (UK)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics SAS (France)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics&#160;B.V. (Netherlands)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics&#160;GmbH (Germany)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics S.L.U. (Spain)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics&#160;S.r.l. (Italy)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics K.K. (Japan)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics Canada&#160;Inc. (Canada)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics PTY&#160;LTD (Australia)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics US, LLC. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Biologics, Inc. (Florida)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics ApS (Denmark)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics Europe Limited (Ireland)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics Switzerland GmbH (Switzerland)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus GT Holdings, LLC (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Caritas Therapeutics, LLC (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics France Services SAS (France)</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>exhibit231_2021.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ief6b10b86bc843eb89b10a656eaa79aa_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 23.1&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-260924) pertaining to the issuance of common stock and warrants in 2021</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-257289) pertaining to the Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-252646) pertaining to the issuance of warrants in 2016</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-243779) pertaining to the&#58; 1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. Amended and Restated 2007 Director Option Plan</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-233153) pertaining to the Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3ASR No. 333-231017) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3ASR No. 333-212414), pertaining to the acquisition of MiaMed, Inc.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3ASR No. 333-207210), pertaining to the acquisition of Scioderm, Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-197202) pertaining to the Amicus Therapeutics, Inc. Cash Deferral Plan</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-195194) pertaining to the Amicus Therapeutics, Inc. Restricted Stock Unit Deferral Plan</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-3 No. 333-192876), pertaining to the issuance of warrants</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-3 No. 333-192747), pertaining to the acquisition of Callidus Biopharma, Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-174900) pertaining to the&#58; 1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. Amended and Restated 2007 Director Option Plan</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-157219) pertaining to the&#58;  1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. 2007 Director Option Plan</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-145305) pertaining to the&#58; 1) Amicus Therapeutics, Inc. 2002 Equity Incentive Plan, as Amended, 2) Amicus Therapeutics, Inc. 2007 Equity Incentive Plan, 3) Amicus Therapeutics, Inc. 2007 Director Option Plan, 4) Amicus Therapeutics, Inc. 2007 Employee Stock Purchase Plan</font></div><div style="text-indent:-18pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;24, 2022 with respect to the consolidated financial statements of Amicus Therapeutics,&#160;Inc., and the effectiveness of internal control over financial reporting of Amicus Therapeutics,&#160;Inc. included in this Annual Report (Form&#160;10-K) of Amicus Therapeutics,&#160;Inc. for the year ended December 31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young&#160;LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iselin, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2022 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>exhibit311_2021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ieec260594d6a4791ab0e772ab95bd597_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John F. Crowley, certify that&#58;</font></div><div style="margin-bottom:12pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form&#160;10-K of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;24, 2022 </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John F. Crowley</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Crowley</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>exhibit312_2021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id7e545758ecb4d4abc82f7f41ba0edc4_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daphne Quimi, certify that&#58;</font></div><div style="margin-bottom:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form&#160;10-K of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;24, 2022</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>exhibit321_2021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2f37edd967cc49259e00b2a4ca72088a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Principal Executive Officer Pursuant to 18 U. S. C. Section&#160;1350, as</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U. S. C. Section&#160;1350, I, John F. Crowley, hereby certify that, to the best of my knowledge, Amicus Therapeutics&#160;Inc., (the &#34;Company&#34;) Annual Report on Form&#160;10-K for the year ended December 31, 2021 (the &#34;Report&#34;), as filed with the Securities and Exchange Commission on February&#160;24, 2022, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John F. Crowley</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Crowley<br>Chairman and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>13
<FILENAME>exhibit322_2021.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4a6d6cce957f4638ac5087ce7bbf9b36_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Principal Financial Officer Pursuant to 18 U. S. C. Section&#160;1350, as</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U. S. C. Section&#160;1350, I, Daphne Quimi, hereby certify that, to the best of my knowledge, the Amicus Therapeutics&#160;Inc. (the &#34;Company&#34;) Annual Report on Form&#160;10-K for the year ended December 31, 2021 (the &#34;Report&#34;), as filed with the Securities and Exchange Commission on February&#160;24, 2022, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi<br>Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2022</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>fold-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:420dc514-3d5c-42ec-9084-f88f3b76faf7,g:716e386a-5032-46b5-a55b-0ba5d954afee-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fold="http://www.amicustherapeutics.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amicustherapeutics.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.amicustherapeutics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.amicustherapeutics.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical">
        <link:definition>1005007 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>1006008 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets">
        <link:definition>2111103 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2312302 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2413407 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsChangesinIPRDDetails" roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails">
        <link:definition>2414408 - Disclosure - Goodwill and Intangible Assets - Changes in IPR&amp;D (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCash" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash">
        <link:definition>2115104 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables">
        <link:definition>2316303 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails">
        <link:definition>2417409 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails">
        <link:definition>2418410 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1">
        <link:definition>2418410 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails">
        <link:definition>2419411 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amicustherapeutics.com/role/Inventories">
        <link:definition>2120105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amicustherapeutics.com/role/InventoriesTables">
        <link:definition>2321304 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails">
        <link:definition>2422412 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipment">
        <link:definition>2123106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentTables">
        <link:definition>2324305 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails">
        <link:definition>2425413 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>2126107 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>2327306 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>2428414 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity">
        <link:definition>2129108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockandWarrantsDetails" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails">
        <link:definition>2430415 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails">
        <link:definition>2431416 - Disclosure - Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensation" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensation">
        <link:definition>2132109 - Disclosure - Share based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationTables" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationTables">
        <link:definition>2333307 - Disclosure - Share based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails">
        <link:definition>2434417 - Disclosure - Share based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationWeightedaverageAssumptionsDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails">
        <link:definition>2435418 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationStockOptionActivityDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails">
        <link:definition>2436419 - Disclosure - Share based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationRSUsandPBRSUsSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails">
        <link:definition>2437420 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationExpenseSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails">
        <link:definition>2438421 - Disclosure - Share based Compensation - Expense Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValue" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue">
        <link:definition>2139110 - Disclosure - Assets and Liabilities Measured at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueTables" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables">
        <link:definition>2340308 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails">
        <link:definition>2441422 - Disclosure - Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails">
        <link:definition>2442423 - Disclosure - Assets and Liabilities Measured at Fair Value - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails">
        <link:definition>2443424 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.amicustherapeutics.com/role/Debt">
        <link:definition>2144111 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.amicustherapeutics.com/role/DebtTables">
        <link:definition>2345309 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofLongTermDebtDetails" roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails">
        <link:definition>2446425 - Disclosure - Debt - Summary of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails">
        <link:definition>2447426 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails">
        <link:definition>2448427 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.amicustherapeutics.com/role/Leases">
        <link:definition>2149112 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.amicustherapeutics.com/role/LeasesTables">
        <link:definition>2350310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.amicustherapeutics.com/role/LeasesDetails">
        <link:definition>2451428 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails_1" roleURI="http://www.amicustherapeutics.com/role/LeasesDetails_1">
        <link:definition>2451428 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxes">
        <link:definition>2152113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesTables">
        <link:definition>2353311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesStatutoryRateDetails" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails">
        <link:definition>2454429 - Disclosure - Income Taxes - Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredandValuationDetails" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails">
        <link:definition>2455430 - Disclosure - Income Taxes - Deferred and Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossCarryforwardsDetails" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails">
        <link:definition>2456431 - Disclosure - Income Taxes - Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreements">
        <link:definition>2157114 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails">
        <link:definition>2458432 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShare" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare">
        <link:definition>2159115 - Disclosure - Basic and Diluted Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareTables" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables">
        <link:definition>2360312 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareDetails" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails">
        <link:definition>2461433 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="fold_AccruedProgramFees" abstract="false" name="AccruedProgramFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" abstract="false" name="CollaborativeAgreementConditionalAggregatePaymentsPerIndication" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtInstrumentPeriodicPaymentNumberOfPayments" abstract="false" name="DebtInstrumentPeriodicPaymentNumberOfPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fold_ProbabilityWeightedDiscountedCashFlowMember" abstract="true" name="ProbabilityWeightedDiscountedCashFlowMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_DebtInstrumentConsolidatedRevenueCovenantAmount" abstract="false" name="DebtInstrumentConsolidatedRevenueCovenantAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DeferredTaxAssetsIntellectualProperty" abstract="false" name="DeferredTaxAssetsIntellectualProperty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DeferredTaxLiabilitiesRoyaltyPayable" abstract="false" name="DeferredTaxLiabilitiesRoyaltyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fold_OrphanDrugTaxCreditCarryforwardMember" abstract="true" name="OrphanDrugTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_InterestIncomeAndInterestExpensePolicyTextBlock" abstract="false" name="InterestIncomeAndInterestExpensePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_StockExercisesAt798Member" abstract="true" name="StockExercisesAt798Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_PrivatePlacementPurchaseAgreementMember" abstract="true" name="PrivatePlacementPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_DeferredTaxAssetsInterestCarryforwardLimitation" abstract="false" name="DeferredTaxAssetsInterestCarryforwardLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" abstract="false" name="DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="fold_DebtInstrumentVariableRate" abstract="false" name="DebtInstrumentVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fold_DeferredTaxAssetsLiabilitiesGross" abstract="false" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_OtherComprehensiveIncomePolicyPolicyTextBlock" abstract="false" name="OtherComprehensiveIncomePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_GainLossOnExchangeOfDebt" abstract="false" name="GainLossOnExchangeOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" abstract="false" name="CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_SeniorSecuredTermLoanDue2026Member" abstract="true" name="SeniorSecuredTermLoanDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ContingentConsiderationPaidInStock" abstract="false" name="ContingentConsiderationPaidInStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShareBasedCompensationNumberOfPlans" abstract="false" name="ShareBasedCompensationNumberOfPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fold_CollaborationAgreementAnnualContributionByCompany" abstract="false" name="CollaborationAgreementAnnualContributionByCompany" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_RevisedCollaborationAgreementMember" abstract="true" name="RevisedCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ContingentConsiderationPaidInStockAdjustment" abstract="false" name="ContingentConsiderationPaidInStockAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" abstract="false" name="DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_PaymentsForCollaborativeArrangement" abstract="false" name="PaymentsForCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_TB200PompeProgramMember" abstract="true" name="TB200PompeProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" abstract="false" name="DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_ContingentConsiderationMilestonePayment" abstract="false" name="ContingentConsiderationMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CollaborativeAgreementTermOfAgreement" abstract="false" name="CollaborativeAgreementTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInNoncurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentConsiderationMeasurementInput" abstract="false" name="ContingentConsiderationMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_MilestonePaymentStockIssuedAsConsideration" abstract="false" name="MilestonePaymentStockIssuedAsConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodSharesContingentConsideration" abstract="false" name="StockIssuedDuringPeriodSharesContingentConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_AccruedContractManufacturingAndContractResearchCostsCurrent" abstract="false" name="AccruedContractManufacturingAndContractResearchCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="fold_UnderwrittenOfferingMember" abstract="true" name="UnderwrittenOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" abstract="false" name="DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_PremiumsPaidForCappedCallConfirmations" abstract="false" name="PremiumsPaidForCappedCallConfirmations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShortTermCorporateDebtSecuritiesMember" abstract="true" name="ShortTermCorporateDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_AccruedSalesRebatesAndChargebacksCurrent" abstract="false" name="AccruedSalesRebatesAndChargebacksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" abstract="false" name="NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" abstract="false" name="ContingentAcquisitionConsiderationPayablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_EarlySettlementPremiums" abstract="false" name="EarlySettlementPremiums" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_DebtInstrumentLiquidityCovenantMinimumAmount" abstract="false" name="DebtInstrumentLiquidityCovenantMinimumAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DeferredTaxLiabilitiesBusinessAcquisition" abstract="false" name="DeferredTaxLiabilitiesBusinessAcquisition" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" abstract="false" name="NumberOfSharesIssuedPerIncrementOfConvertibleDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" abstract="false" name="EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fold_GlaxoSmithKlinePLCMember" abstract="true" name="GlaxoSmithKlinePLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" abstract="false" name="ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_PaymentsForRepurchaseOfRestrictedStockUnits" abstract="false" name="PaymentsForRepurchaseOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DeferredTaxAssetsLeasingArrangements" abstract="false" name="DeferredTaxAssetsLeasingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ConvertibleSeniorNotes2016Due2023Member" abstract="true" name="ConvertibleSeniorNotes2016Due2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_AmortizationDeferredFinancingCosts" abstract="false" name="AmortizationDeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" abstract="true" name="ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ForeignCurrencyRemeasurementGainLossBeforeTax" abstract="false" name="ForeignCurrencyRemeasurementGainLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_MeasurementInputProbabilityOfMilestoneAchievementMember" abstract="true" name="MeasurementInputProbabilityOfMilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_IncreaseDecreaseInDeferredReimbursements" abstract="false" name="IncreaseDecreaseInDeferredReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" abstract="false" name="ProceedsFromIssuanceOfWarrantsAndEquityFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" abstract="false" name="NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" abstract="false" name="CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_StockExercisesAt706Member" abstract="true" name="StockExercisesAt706Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ResearchEquipmentMember" abstract="true" name="ResearchEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_LesseeOperatingLeaseLiabilityTenantIncentives" abstract="false" name="LesseeOperatingLeaseLiabilityTenantIncentives" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CommonStockVotingRightsForEachShareHeld" abstract="false" name="CommonStockVotingRightsForEachShareHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" abstract="false" name="DeferredTaxAssetsNonCashStockIssueNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodValueContingentConsideration" abstract="false" name="StockIssuedDuringPeriodValueContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CollaborativeArrangementDisclosureAbstract" abstract="true" name="CollaborativeArrangementDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="fold_DeferredTaxLiabilitiesConvertibleNotes" abstract="false" name="DeferredTaxLiabilitiesConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" abstract="false" name="GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CallidusBiopharmaIncMember" abstract="true" name="CallidusBiopharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>fold-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:420dc514-3d5c-42ec-9084-f88f3b76faf7,g:716e386a-5032-46b5-a55b-0ba5d954afee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0a105749-7da5-408b-b1d7-27220dd00929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5326c1d8-e1de-44b7-bdaf-af87a668c2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a105749-7da5-408b-b1d7-27220dd00929" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5326c1d8-e1de-44b7-bdaf-af87a668c2c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d4b3aae4-e3c4-4572-b47b-52980afda263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a105749-7da5-408b-b1d7-27220dd00929" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d4b3aae4-e3c4-4572-b47b-52980afda263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3227b556-970c-4b5e-8613-ae7a5b931f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a105749-7da5-408b-b1d7-27220dd00929" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3227b556-970c-4b5e-8613-ae7a5b931f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_24990799-2b5b-45c6-8e58-4df4b3d60b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a105749-7da5-408b-b1d7-27220dd00929" xlink:to="loc_us-gaap_InventoryNet_24990799-2b5b-45c6-8e58-4df4b3d60b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7cc58e0-7868-48fc-8d5c-3a3c6b3b2299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a105749-7da5-408b-b1d7-27220dd00929" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7cc58e0-7868-48fc-8d5c-3a3c6b3b2299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fc89188-b65b-45d3-964f-392bd5fd9f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a15e07ea-0868-45d1-b016-6f5574cadc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9fc89188-b65b-45d3-964f-392bd5fd9f9b" xlink:to="loc_us-gaap_CommonStockValue_a15e07ea-0868-45d1-b016-6f5574cadc5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_04e48200-b37e-41f2-94ba-15681b3f3c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9fc89188-b65b-45d3-964f-392bd5fd9f9b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_04e48200-b37e-41f2-94ba-15681b3f3c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_96504f2c-0e75-4b8c-98ff-e155e5c674ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9fc89188-b65b-45d3-964f-392bd5fd9f9b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_96504f2c-0e75-4b8c-98ff-e155e5c674ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4bb1e7fd-4204-4149-a368-5973558ab1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9fc89188-b65b-45d3-964f-392bd5fd9f9b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4bb1e7fd-4204-4149-a368-5973558ab1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_2d27c94f-d647-43c1-8804-4d065270b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9fc89188-b65b-45d3-964f-392bd5fd9f9b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_2d27c94f-d647-43c1-8804-4d065270b1a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c99c6bea-bf4e-467d-97e9-fcc924d54415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9fc89188-b65b-45d3-964f-392bd5fd9f9b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c99c6bea-bf4e-467d-97e9-fcc924d54415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6c8ef606-8208-4644-80ff-ecbcacd2379e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b4e98115-fe85-4cc0-bbc6-7f7fcdca6b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6c8ef606-8208-4644-80ff-ecbcacd2379e" xlink:to="loc_us-gaap_AccountsPayableCurrent_b4e98115-fe85-4cc0-bbc6-7f7fcdca6b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_ca1546a0-67f6-44ea-8bc4-6d8f1bd4961f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6c8ef606-8208-4644-80ff-ecbcacd2379e" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_ca1546a0-67f6-44ea-8bc4-6d8f1bd4961f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c6eb4689-46ed-44e3-b368-90e10ebcab3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6c8ef606-8208-4644-80ff-ecbcacd2379e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c6eb4689-46ed-44e3-b368-90e10ebcab3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b3bd157a-927e-4eb1-bb5d-c63ad4593a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6c8ef606-8208-4644-80ff-ecbcacd2379e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b3bd157a-927e-4eb1-bb5d-c63ad4593a16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_290e4123-6531-46a6-869c-aa0529406222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d9953f76-379b-4052-b0b0-1caa431cf7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_290e4123-6531-46a6-869c-aa0529406222" xlink:to="loc_us-gaap_AssetsCurrent_d9953f76-379b-4052-b0b0-1caa431cf7e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_89eeee96-dfe1-411a-844c-9b19cddb51b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_290e4123-6531-46a6-869c-aa0529406222" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_89eeee96-dfe1-411a-844c-9b19cddb51b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_613f4bcb-0dbf-418a-b41e-b116119c1ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_290e4123-6531-46a6-869c-aa0529406222" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_613f4bcb-0dbf-418a-b41e-b116119c1ab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ab1ce43-7939-4029-8ab8-3255a00a20c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_290e4123-6531-46a6-869c-aa0529406222" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ab1ce43-7939-4029-8ab8-3255a00a20c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6e55bf33-7c02-4765-9933-24cfa6b73cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_290e4123-6531-46a6-869c-aa0529406222" xlink:to="loc_us-gaap_Goodwill_6e55bf33-7c02-4765-9933-24cfa6b73cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7da1d36e-260b-46cf-ae59-e44c4637a8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_290e4123-6531-46a6-869c-aa0529406222" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7da1d36e-260b-46cf-ae59-e44c4637a8cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa1bf7e0-4b3a-48bb-bc66-639ae00e2a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dcc582d5-70c6-43f1-bb79-66860bb82dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa1bf7e0-4b3a-48bb-bc66-639ae00e2a94" xlink:to="loc_us-gaap_Liabilities_dcc582d5-70c6-43f1-bb79-66860bb82dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a18f6987-0ca7-4733-982f-0067aa81fe2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa1bf7e0-4b3a-48bb-bc66-639ae00e2a94" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a18f6987-0ca7-4733-982f-0067aa81fe2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f3fca9b8-d5b1-44e4-8bb6-2b04d9d4e141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa1bf7e0-4b3a-48bb-bc66-639ae00e2a94" xlink:to="loc_us-gaap_StockholdersEquity_f3fca9b8-d5b1-44e4-8bb6-2b04d9d4e141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1494f3f2-ef64-4451-a21d-bd2d919fade9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_38e32248-7f36-490f-98c6-c5cbfd290791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1494f3f2-ef64-4451-a21d-bd2d919fade9" xlink:to="loc_us-gaap_LiabilitiesCurrent_38e32248-7f36-490f-98c6-c5cbfd290791" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_28f61207-7770-40d5-bec1-26259a826038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1494f3f2-ef64-4451-a21d-bd2d919fade9" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_28f61207-7770-40d5-bec1-26259a826038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0b79fd04-ae68-4876-83c2-3c881def2f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1494f3f2-ef64-4451-a21d-bd2d919fade9" xlink:to="loc_us-gaap_LongTermDebt_0b79fd04-ae68-4876-83c2-3c881def2f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_192a42b9-362b-4e19-b281-62a03abf8371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1494f3f2-ef64-4451-a21d-bd2d919fade9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_192a42b9-362b-4e19-b281-62a03abf8371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b6b214f7-24c5-48f8-839f-ed63294baa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1494f3f2-ef64-4451-a21d-bd2d919fade9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b6b214f7-24c5-48f8-839f-ed63294baa1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9fc9b5f-e653-4d6c-a15c-2f6156257b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1494f3f2-ef64-4451-a21d-bd2d919fade9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9fc9b5f-e653-4d6c-a15c-2f6156257b9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_168c0571-e008-466b-ac27-5db77852d41c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1494f3f2-ef64-4451-a21d-bd2d919fade9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_168c0571-e008-466b-ac27-5db77852d41c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c9f02e3b-9afc-4e18-997a-bb2bad726943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ce327da3-7607-43f4-a627-6a797d8ab8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c9f02e3b-9afc-4e18-997a-bb2bad726943" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ce327da3-7607-43f4-a627-6a797d8ab8b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_07d31c0f-97db-4065-a7ea-437e4b78f389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c9f02e3b-9afc-4e18-997a-bb2bad726943" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_07d31c0f-97db-4065-a7ea-437e4b78f389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_fc44c197-058e-45ca-8ee8-60300f0f2b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6b7e2475-6c6c-4d3d-acba-21d8c149bc87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fc44c197-058e-45ca-8ee8-60300f0f2b6b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6b7e2475-6c6c-4d3d-acba-21d8c149bc87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e2f48471-a4bb-4523-b84b-a216636a1a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fc44c197-058e-45ca-8ee8-60300f0f2b6b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e2f48471-a4bb-4523-b84b-a216636a1a56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66535c2-35cc-415b-b6a8-98236937df72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ba90f80-91f9-491d-9c9d-4d385ce85b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66535c2-35cc-415b-b6a8-98236937df72" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ba90f80-91f9-491d-9c9d-4d385ce85b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1b52a858-bafd-46e4-9de5-e47b2094bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66535c2-35cc-415b-b6a8-98236937df72" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1b52a858-bafd-46e4-9de5-e47b2094bcfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3adc9620-c539-4abb-8d70-994a35c10f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66535c2-35cc-415b-b6a8-98236937df72" xlink:to="loc_us-gaap_InterestExpense_3adc9620-c539-4abb-8d70-994a35c10f54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExchangeOfDebt_f5d29564-94fa-4e1e-945a-36c2c840bf72" xlink:href="fold-20211231.xsd#fold_GainLossOnExchangeOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66535c2-35cc-415b-b6a8-98236937df72" xlink:to="loc_fold_GainLossOnExchangeOfDebt_f5d29564-94fa-4e1e-945a-36c2c840bf72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_109a7833-d066-4798-980b-5ab68da42479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66535c2-35cc-415b-b6a8-98236937df72" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_109a7833-d066-4798-980b-5ab68da42479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9b5947fc-381b-4d88-a796-fff10ab43a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66535c2-35cc-415b-b6a8-98236937df72" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9b5947fc-381b-4d88-a796-fff10ab43a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5fc6153d-6d9b-42d7-82ab-8d9871296b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_2c7cb671-0f02-43d3-a753-70e62bf6792d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5fc6153d-6d9b-42d7-82ab-8d9871296b7d" xlink:to="loc_us-gaap_GrossProfit_2c7cb671-0f02-43d3-a753-70e62bf6792d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3e73dd18-30b9-42d9-aef4-26d4ac2d8825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5fc6153d-6d9b-42d7-82ab-8d9871296b7d" xlink:to="loc_us-gaap_OperatingExpenses_3e73dd18-30b9-42d9-aef4-26d4ac2d8825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_23a5a055-0fb1-4d9d-9b24-f8cb6a87123e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7042d0bc-390e-4b98-a2b0-61e2251c8f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a5a055-0fb1-4d9d-9b24-f8cb6a87123e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7042d0bc-390e-4b98-a2b0-61e2251c8f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a2226366-3b50-4afc-b0af-3a966bf4fbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a5a055-0fb1-4d9d-9b24-f8cb6a87123e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a2226366-3b50-4afc-b0af-3a966bf4fbfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_01e3517b-3067-45fc-9411-61c122efe92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a5a055-0fb1-4d9d-9b24-f8cb6a87123e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_01e3517b-3067-45fc-9411-61c122efe92d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5b5f8bbc-c1c4-4160-b5bd-9b15897031fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a5a055-0fb1-4d9d-9b24-f8cb6a87123e" xlink:to="loc_us-gaap_DepreciationAndAmortization_5b5f8bbc-c1c4-4160-b5bd-9b15897031fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3d839ad7-333b-4682-ab78-c02e58c756d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_47f8d97d-2146-47ee-8d02-d452040fe2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3d839ad7-333b-4682-ab78-c02e58c756d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_47f8d97d-2146-47ee-8d02-d452040fe2a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b31db13b-c3d0-447f-b0d7-e29c28e88aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3d839ad7-333b-4682-ab78-c02e58c756d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b31db13b-c3d0-447f-b0d7-e29c28e88aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_262126c3-4bc5-4152-8378-1cf9dc2d4551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1726e412-6ae0-4bc7-999e-4b9e70e50eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_262126c3-4bc5-4152-8378-1cf9dc2d4551" xlink:to="loc_us-gaap_NetIncomeLoss_1726e412-6ae0-4bc7-999e-4b9e70e50eb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d6d84e76-1d91-4518-a107-722afaebf692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_262126c3-4bc5-4152-8378-1cf9dc2d4551" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d6d84e76-1d91-4518-a107-722afaebf692" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21863ffd-7036-4f23-be44-944359e5c37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21863ffd-7036-4f23-be44-944359e5c37a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d60ae10b-faad-4e8e-b5e0-00c8099e6c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d60ae10b-faad-4e8e-b5e0-00c8099e6c79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_eb28c76c-4a8b-4c08-98e3-0feae3b708c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_eb28c76c-4a8b-4c08-98e3-0feae3b708c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_8dd7ea54-d61a-450c-9286-65e615e51829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_8dd7ea54-d61a-450c-9286-65e615e51829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_a48b0608-c129-438a-aefa-bf7897c13be5" xlink:href="fold-20211231.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_a48b0608-c129-438a-aefa-bf7897c13be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6293089f-c4c9-4724-be87-ae5e616b7ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6293089f-c4c9-4724-be87-ae5e616b7ad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_9d75f0ef-7367-4b24-a545-e68d36eb3c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_9d75f0ef-7367-4b24-a545-e68d36eb3c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_0ac59f6f-ed46-4cd0-97c6-4bc9a5691078" xlink:href="fold-20211231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_0ac59f6f-ed46-4cd0-97c6-4bc9a5691078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_97b3c684-33b5-4e0e-8794-2f7d4f2bcd05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_97b3c684-33b5-4e0e-8794-2f7d4f2bcd05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_b02c55dd-26a9-4f45-b169-052f9d512035" xlink:href="fold-20211231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eff6c6c9-01ae-430f-b8a7-f5ddc4cfb16d" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_b02c55dd-26a9-4f45-b169-052f9d512035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e563b4b-0b3f-4294-a163-b7cce98d139d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_40560f6b-7eda-4032-a131-8edd7cc4fe02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e563b4b-0b3f-4294-a163-b7cce98d139d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_40560f6b-7eda-4032-a131-8edd7cc4fe02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_23f15b2d-a3ba-4aaa-a851-e56ae117c9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e563b4b-0b3f-4294-a163-b7cce98d139d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_23f15b2d-a3ba-4aaa-a851-e56ae117c9d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87a56fdb-e565-4ee5-a233-df636eea68a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e563b4b-0b3f-4294-a163-b7cce98d139d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87a56fdb-e565-4ee5-a233-df636eea68a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8835ff68-ea8b-4fe1-9e87-287d86494ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_ProfitLoss_8835ff68-ea8b-4fe1-9e87-287d86494ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b2e4127a-12c4-4ed4-8da9-9ea739cb2c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b2e4127a-12c4-4ed4-8da9-9ea739cb2c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b8f66fbd-7bde-4e00-a717-972f50410c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b8f66fbd-7bde-4e00-a717-972f50410c30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_07607fea-6ad8-40f0-85b2-720902583c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_ShareBasedCompensation_07607fea-6ad8-40f0-85b2-720902583c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExchangeOfDebt_56b67eb1-3cdb-453e-a7e3-31c259710551" xlink:href="fold-20211231.xsd#fold_GainLossOnExchangeOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_fold_GainLossOnExchangeOfDebt_56b67eb1-3cdb-453e-a7e3-31c259710551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a30de895-b139-4b95-abe3-3a2725c158bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a30de895-b139-4b95-abe3-3a2725c158bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f73aa16f-105d-4e03-857e-8e96c97f2663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f73aa16f-105d-4e03-857e-8e96c97f2663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_6bfc9232-b48b-4f67-882b-0ebbfaca687e" xlink:href="fold-20211231.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_6bfc9232-b48b-4f67-882b-0ebbfaca687e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f6848749-b96e-4cac-a4cc-27229c497df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f6848749-b96e-4cac-a4cc-27229c497df5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e4466935-5da3-4661-aba8-667b3bd3470a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e4466935-5da3-4661-aba8-667b3bd3470a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d2126211-b404-4d06-bb04-169ac2c7c87c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d2126211-b404-4d06-bb04-169ac2c7c87c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f900f816-7f51-4c4e-ac14-35d7f6df2565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f900f816-7f51-4c4e-ac14-35d7f6df2565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0486831a-3e70-44bb-8d8c-560a4616b2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0486831a-3e70-44bb-8d8c-560a4616b2b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e5918055-315c-4117-8fc6-27b34a1bab05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e5918055-315c-4117-8fc6-27b34a1bab05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_915baa2c-37f9-4d29-882f-fa390e25f5c0" xlink:href="fold-20211231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_915baa2c-37f9-4d29-882f-fa390e25f5c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInDeferredReimbursements_607b5eb9-8b81-4e36-91de-08dadb587e33" xlink:href="fold-20211231.xsd#fold_IncreaseDecreaseInDeferredReimbursements"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_fold_IncreaseDecreaseInDeferredReimbursements_607b5eb9-8b81-4e36-91de-08dadb587e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_d45367e0-17b1-4aa2-99b0-92a70f98b0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a812e28c-0f71-4425-9a48-f33220bdddf9" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_d45367e0-17b1-4aa2-99b0-92a70f98b0c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7bdc693b-9875-4e93-b1d1-df90de4bfb48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4dd0bcfe-2c19-45d5-8173-937cf57d96de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7bdc693b-9875-4e93-b1d1-df90de4bfb48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4dd0bcfe-2c19-45d5-8173-937cf57d96de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13dde9c8-947c-413d-b7cf-a352de851268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7bdc693b-9875-4e93-b1d1-df90de4bfb48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13dde9c8-947c-413d-b7cf-a352de851268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8871d2f0-7688-4636-be1f-f24a00191f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7bdc693b-9875-4e93-b1d1-df90de4bfb48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8871d2f0-7688-4636-be1f-f24a00191f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed59ff5d-1f2c-4107-a61b-24589a2a6927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7bdc693b-9875-4e93-b1d1-df90de4bfb48" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed59ff5d-1f2c-4107-a61b-24589a2a6927" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1e1cb5bb-0c24-44a2-9d7b-eb00d3a5cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_21aa24c8-93dc-4b4c-8e51-2496599aafdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1e1cb5bb-0c24-44a2-9d7b-eb00d3a5cda8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_21aa24c8-93dc-4b4c-8e51-2496599aafdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_66246f82-b7be-487a-8ae0-59a9dad389c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1e1cb5bb-0c24-44a2-9d7b-eb00d3a5cda8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_66246f82-b7be-487a-8ae0-59a9dad389c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe3e4167-8f3a-47d4-923c-a3c26dddb5af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1e1cb5bb-0c24-44a2-9d7b-eb00d3a5cda8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe3e4167-8f3a-47d4-923c-a3c26dddb5af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e106a74a-4dc5-4a10-94ab-6b9b21e72fba" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f074c20-f0e3-4491-9fe3-b0253e69cf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e106a74a-4dc5-4a10-94ab-6b9b21e72fba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f074c20-f0e3-4491-9fe3-b0253e69cf3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8d5e539c-52ff-47e5-af2d-b4b675ff5af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e106a74a-4dc5-4a10-94ab-6b9b21e72fba" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8d5e539c-52ff-47e5-af2d-b4b675ff5af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34ef4cba-412d-49da-8edb-d987e7740bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0ad861a5-7a45-43ed-aa26-6f2c8c0fd56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34ef4cba-412d-49da-8edb-d987e7740bef" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0ad861a5-7a45-43ed-aa26-6f2c8c0fd56b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_056d8322-8e43-4130-b8a3-ac97b5b0cf31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_89a7e0db-c9f6-45d1-89cb-ff17e224b515" xlink:href="fold-20211231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_056d8322-8e43-4130-b8a3-ac97b5b0cf31" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_89a7e0db-c9f6-45d1-89cb-ff17e224b515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d89a9a9d-6f21-4cbc-9391-ba23a93f2f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_056d8322-8e43-4130-b8a3-ac97b5b0cf31" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d89a9a9d-6f21-4cbc-9391-ba23a93f2f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_9f2db212-0248-47ad-b678-6aa266d0a5a8" xlink:href="fold-20211231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_056d8322-8e43-4130-b8a3-ac97b5b0cf31" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_9f2db212-0248-47ad-b678-6aa266d0a5a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_432be6db-9c0c-42b6-aaf8-2ac695edac21" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bbcf27a1-118e-4600-b529-8ce0d0bf0b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_432be6db-9c0c-42b6-aaf8-2ac695edac21" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bbcf27a1-118e-4600-b529-8ce0d0bf0b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f526397-0b93-4e8d-a7fe-58fef04b42df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_432be6db-9c0c-42b6-aaf8-2ac695edac21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f526397-0b93-4e8d-a7fe-58fef04b42df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_3497e6b1-3252-4250-90ab-03c67a0ceed9" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48aec63e-92ca-44da-bb8b-42935b5f0508" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_3497e6b1-3252-4250-90ab-03c67a0ceed9" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48aec63e-92ca-44da-bb8b-42935b5f0508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_77a8266d-f0c1-4668-8e8d-b6a81a097464" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_3497e6b1-3252-4250-90ab-03c67a0ceed9" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_77a8266d-f0c1-4668-8e8d-b6a81a097464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2dc81eb4-6432-47de-8dca-510010ef8c0e" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_3497e6b1-3252-4250-90ab-03c67a0ceed9" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2dc81eb4-6432-47de-8dca-510010ef8c0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a3e5271-ee4a-49d2-b1e3-ca635b739a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_084b395a-115d-48ea-ac50-8a62343360ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a3e5271-ee4a-49d2-b1e3-ca635b739a96" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_084b395a-115d-48ea-ac50-8a62343360ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_190fe574-009c-4214-94ef-30227961580b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a3e5271-ee4a-49d2-b1e3-ca635b739a96" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_190fe574-009c-4214-94ef-30227961580b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_34796be1-53b9-4682-8efc-d88a53e072b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4ad1628b-f0c4-4d7a-8525-13e9c1ed4eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_34796be1-53b9-4682-8efc-d88a53e072b8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4ad1628b-f0c4-4d7a-8525-13e9c1ed4eeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_35c91e2f-670e-4628-ac52-01322cf43ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_34796be1-53b9-4682-8efc-d88a53e072b8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_35c91e2f-670e-4628-ac52-01322cf43ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c7239a02-23b6-4ff5-9c00-cd82b22fc986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_34796be1-53b9-4682-8efc-d88a53e072b8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c7239a02-23b6-4ff5-9c00-cd82b22fc986" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6dec757a-8fd5-4502-a3f4-25f547d243dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_17034036-41fd-4acd-b297-dd13b0aa061e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6dec757a-8fd5-4502-a3f4-25f547d243dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_17034036-41fd-4acd-b297-dd13b0aa061e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d6d142e1-4c22-469c-86fc-25a752d7d3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6dec757a-8fd5-4502-a3f4-25f547d243dd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d6d142e1-4c22-469c-86fc-25a752d7d3ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_36fa05ef-aada-47a2-80f3-c0f0f33fbe30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_5339cdad-4e8a-4867-a470-1b1ef3572772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_36fa05ef-aada-47a2-80f3-c0f0f33fbe30" xlink:to="loc_us-gaap_TaxesPayableCurrent_5339cdad-4e8a-4867-a470-1b1ef3572772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_68214c19-084b-4594-9a4a-6a3af15bb948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_36fa05ef-aada-47a2-80f3-c0f0f33fbe30" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_68214c19-084b-4594-9a4a-6a3af15bb948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_20325156-4a37-415d-afdf-e54db3c32578" xlink:href="fold-20211231.xsd#fold_AccruedSalesRebatesAndChargebacksCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_36fa05ef-aada-47a2-80f3-c0f0f33fbe30" xlink:to="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_20325156-4a37-415d-afdf-e54db3c32578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedProgramFees_d31f6879-84cf-4446-979d-c6cd9d3d96e7" xlink:href="fold-20211231.xsd#fold_AccruedProgramFees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_36fa05ef-aada-47a2-80f3-c0f0f33fbe30" xlink:to="loc_fold_AccruedProgramFees_d31f6879-84cf-4446-979d-c6cd9d3d96e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_79a5cc34-6e17-4ac1-bb21-6fc919ab647c" xlink:href="fold-20211231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_36fa05ef-aada-47a2-80f3-c0f0f33fbe30" xlink:to="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_79a5cc34-6e17-4ac1-bb21-6fc919ab647c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_758c85b3-96f0-44c3-bc17-b68defc074cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_36fa05ef-aada-47a2-80f3-c0f0f33fbe30" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_758c85b3-96f0-44c3-bc17-b68defc074cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ed5ad88f-7e59-4f7c-b7ca-112c12b2dab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_36fa05ef-aada-47a2-80f3-c0f0f33fbe30" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ed5ad88f-7e59-4f7c-b7ca-112c12b2dab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9e7e2632-f054-4d95-8087-25ade9ed6fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_36fa05ef-aada-47a2-80f3-c0f0f33fbe30" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9e7e2632-f054-4d95-8087-25ade9ed6fa5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b0f38ae1-f0e0-4760-b428-9ced09f4af27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2a5b4c78-5d1f-42fe-a3ff-1633f33c00af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_b0f38ae1-f0e0-4760-b428-9ced09f4af27" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2a5b4c78-5d1f-42fe-a3ff-1633f33c00af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_6f019af9-c3c0-4dbf-ba65-5aba8c5c536b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_b0f38ae1-f0e0-4760-b428-9ced09f4af27" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_6f019af9-c3c0-4dbf-ba65-5aba8c5c536b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_12d34f33-0073-4bf4-87ee-8797a4d05996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8029f966-3547-4910-8e70-4cf1bde8bdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_12d34f33-0073-4bf4-87ee-8797a4d05996" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8029f966-3547-4910-8e70-4cf1bde8bdd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0b895324-8f14-41b9-97c7-ae3875a5de23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_12d34f33-0073-4bf4-87ee-8797a4d05996" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0b895324-8f14-41b9-97c7-ae3875a5de23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_e07efe72-f46d-47a8-a1fc-f911218550ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_12d34f33-0073-4bf4-87ee-8797a4d05996" xlink:to="loc_us-gaap_DeferredOfferingCosts_e07efe72-f46d-47a8-a1fc-f911218550ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#LeasesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3c9bac6-3172-4707-8950-3ec79d8e12a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_913e2958-f4fb-4142-8193-ab0cd2a9b920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3c9bac6-3172-4707-8950-3ec79d8e12a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_913e2958-f4fb-4142-8193-ab0cd2a9b920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e97bbb69-2ccb-44d9-9798-8568304187ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3c9bac6-3172-4707-8950-3ec79d8e12a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e97bbb69-2ccb-44d9-9798-8568304187ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d4175a00-68d5-4c3e-a9af-272a0183d191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3c9bac6-3172-4707-8950-3ec79d8e12a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d4175a00-68d5-4c3e-a9af-272a0183d191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2c52087a-5f25-496f-9819-27ea6e5a05f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3c9bac6-3172-4707-8950-3ec79d8e12a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2c52087a-5f25-496f-9819-27ea6e5a05f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_faa3cd23-1ea2-4e2b-ae14-ad6da0ca4ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3c9bac6-3172-4707-8950-3ec79d8e12a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_faa3cd23-1ea2-4e2b-ae14-ad6da0ca4ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d7eab0df-d4e9-48ec-bb67-2c9b75f9002c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3c9bac6-3172-4707-8950-3ec79d8e12a5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d7eab0df-d4e9-48ec-bb67-2c9b75f9002c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesDetails_1" xlink:type="simple" xlink:href="fold-20211231.xsd#LeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe237c44-2f08-4fbf-b9d1-d88da84115c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_976f323c-d356-4ed2-a9fb-4f45277cbc5b" xlink:href="fold-20211231.xsd#fold_LesseeOperatingLeaseLiabilityTenantIncentives"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe237c44-2f08-4fbf-b9d1-d88da84115c7" xlink:to="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_976f323c-d356-4ed2-a9fb-4f45277cbc5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c9d98edc-929a-4e42-addb-24df49a7f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe237c44-2f08-4fbf-b9d1-d88da84115c7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c9d98edc-929a-4e42-addb-24df49a7f91d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4fdcba22-dfcf-4d45-a816-15956cfa63e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe237c44-2f08-4fbf-b9d1-d88da84115c7" xlink:to="loc_us-gaap_OperatingLeaseLiability_4fdcba22-dfcf-4d45-a816-15956cfa63e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#IncomeTaxesStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ea4502aa-ff44-48b3-a562-0b7c4fdf88c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5831fd6c-844a-42c2-82bc-f176b2b0e549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea4502aa-ff44-48b3-a562-0b7c4fdf88c8" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5831fd6c-844a-42c2-82bc-f176b2b0e549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b59663e3-9f2f-4159-844c-0a4af8c1cc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea4502aa-ff44-48b3-a562-0b7c4fdf88c8" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b59663e3-9f2f-4159-844c-0a4af8c1cc64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_8573de1d-f365-4f27-af34-3af317f43a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea4502aa-ff44-48b3-a562-0b7c4fdf88c8" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_8573de1d-f365-4f27-af34-3af317f43a5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a5e1e1df-e77f-460b-8da5-dc0753ba9619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea4502aa-ff44-48b3-a562-0b7c4fdf88c8" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a5e1e1df-e77f-460b-8da5-dc0753ba9619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0142c782-b493-4f92-a885-3db339ec2515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea4502aa-ff44-48b3-a562-0b7c4fdf88c8" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0142c782-b493-4f92-a885-3db339ec2515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_348a8510-0f3d-43b1-96d1-e27146152811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ea4502aa-ff44-48b3-a562-0b7c4fdf88c8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_348a8510-0f3d-43b1-96d1-e27146152811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f2440950-7b04-421c-9a55-4d583ae424e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_59a8df65-558c-468e-8fac-ee22299dc693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f2440950-7b04-421c-9a55-4d583ae424e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_59a8df65-558c-468e-8fac-ee22299dc693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b3416c27-8410-4d2d-abfd-c05020eefec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f2440950-7b04-421c-9a55-4d583ae424e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b3416c27-8410-4d2d-abfd-c05020eefec4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b6cb1570-25a4-41bf-92a5-5576242c6f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b6cb1570-25a4-41bf-92a5-5576242c6f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7781b89e-95ae-4072-9e20-377cd57048dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7781b89e-95ae-4072-9e20-377cd57048dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_b7cddc65-eacd-4076-9339-8df19dea1ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_b7cddc65-eacd-4076-9339-8df19dea1ad8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_d548b412-01cb-4121-9a06-50831a591dde" xlink:href="fold-20211231.xsd#fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_d548b412-01cb-4121-9a06-50831a591dde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_fae753eb-e9eb-4a95-819c-5e9e55d04aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_fae753eb-e9eb-4a95-819c-5e9e55d04aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_36d3f3f8-978b-4936-87d4-28de053c17fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_36d3f3f8-978b-4936-87d4-28de053c17fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5979acd3-80da-4f5e-ba98-d3227fdc9370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5979acd3-80da-4f5e-ba98-d3227fdc9370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_48d26ab9-5e92-416a-a804-c184a1c2b5e3" xlink:href="fold-20211231.xsd#fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_48d26ab9-5e92-416a-a804-c184a1c2b5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4618df88-d0e5-4cf3-934d-e60f187dd6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4618df88-d0e5-4cf3-934d-e60f187dd6f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_002411bc-f0db-4c33-869f-203b33e647ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_11727f43-7c44-4a57-8bfa-dfe5d62510bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_002411bc-f0db-4c33-869f-203b33e647ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#IncomeTaxesDeferredandValuationDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_78cb841c-b69b-4c9b-afad-0af14ab9f1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross_8453d8d1-590a-48d8-9608-c331b7ca3ac4" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsLiabilitiesGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_78cb841c-b69b-4c9b-afad-0af14ab9f1bd" xlink:to="loc_fold_DeferredTaxAssetsLiabilitiesGross_8453d8d1-590a-48d8-9608-c331b7ca3ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21f81739-3421-486a-972c-cb7b363fd148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_78cb841c-b69b-4c9b-afad-0af14ab9f1bd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21f81739-3421-486a-972c-cb7b363fd148" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross_e605bc7f-f30f-4d2b-b970-394001a17a78" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5ee2142c-477f-490b-86af-2cfebc021365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_e605bc7f-f30f-4d2b-b970-394001a17a78" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5ee2142c-477f-490b-86af-2cfebc021365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_542a5f62-7046-46a8-8628-2a0076338a03" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesBusinessAcquisition"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_e605bc7f-f30f-4d2b-b970-394001a17a78" xlink:to="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_542a5f62-7046-46a8-8628-2a0076338a03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_0d9d170b-0dfb-499c-9a98-d8ddf17440ea" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_e605bc7f-f30f-4d2b-b970-394001a17a78" xlink:to="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_0d9d170b-0dfb-499c-9a98-d8ddf17440ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_af9d8737-6975-4251-be43-541d5e7f2322" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_e605bc7f-f30f-4d2b-b970-394001a17a78" xlink:to="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_af9d8737-6975-4251-be43-541d5e7f2322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_5b602192-a079-43f6-85f9-c981ccdf5638" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_e605bc7f-f30f-4d2b-b970-394001a17a78" xlink:to="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_5b602192-a079-43f6-85f9-c981ccdf5638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bfab6b53-51ac-4e12-ae92-16284339e625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_e605bc7f-f30f-4d2b-b970-394001a17a78" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bfab6b53-51ac-4e12-ae92-16284339e625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsIntellectualProperty_56c550bf-1957-47ba-834c-34f7b254b234" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsIntellectualProperty"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:to="loc_fold_DeferredTaxAssetsIntellectualProperty_56c550bf-1957-47ba-834c-34f7b254b234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_3bbf7745-4619-476f-969b-873fe43dad95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_3bbf7745-4619-476f-969b-873fe43dad95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_105ab807-422f-4b3d-bc23-6fb3ba6a6691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_105ab807-422f-4b3d-bc23-6fb3ba6a6691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3219830c-a543-4acd-8ab5-f971b2077df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3219830c-a543-4acd-8ab5-f971b2077df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8c6f4cc7-44e8-493b-a222-338af272b5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8c6f4cc7-44e8-493b-a222-338af272b5fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_258d114b-5946-4e99-9052-1b31ca345d49" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:to="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_258d114b-5946-4e99-9052-1b31ca345d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_39ade347-2a3b-4300-8ab9-2bbc8cd81d9b" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsInterestCarryforwardLimitation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:to="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_39ade347-2a3b-4300-8ab9-2bbc8cd81d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLeasingArrangements_882859cc-0004-4ec0-b232-029fdf5478ef" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsLeasingArrangements"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:to="loc_fold_DeferredTaxAssetsLeasingArrangements_882859cc-0004-4ec0-b232-029fdf5478ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5a6db7af-742a-4b32-b6f8-b448abd97725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6300630f-f9d3-4014-9b3c-7cde473172bf" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_5a6db7af-742a-4b32-b6f8-b448abd97725" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>fold-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:420dc514-3d5c-42ec-9084-f88f3b76faf7,g:716e386a-5032-46b5-a55b-0ba5d954afee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended" id="ia117629b29c140839dfad115b1e29336_ConsolidatedStatementsofChangesinStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0e89e5e7-c21c-46e4-9ec3-af4af513fd39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e89e5e7-c21c-46e4-9ec3-af4af513fd39" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e96c792e-5a25-4e31-9730-9221b1bfcebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e96c792e-5a25-4e31-9730-9221b1bfcebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_048cf5dd-3eab-44dd-9412-e70178a9f682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockholdersEquity_048cf5dd-3eab-44dd-9412-e70178a9f682" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de615cb9-7207-4fa4-89ec-e37457520f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de615cb9-7207-4fa4-89ec-e37457520f85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ce063b1d-985b-4db9-8c38-8809817cde8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ce063b1d-985b-4db9-8c38-8809817cde8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d6c308ba-69fb-4d11-a310-897096a9913f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d6c308ba-69fb-4d11-a310-897096a9913f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34cfac69-d846-42af-8f6a-a2683972a993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34cfac69-d846-42af-8f6a-a2683972a993" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f061ccaa-e0d0-4075-8e43-28cd53d26e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f061ccaa-e0d0-4075-8e43-28cd53d26e4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_71693e70-0755-46f0-ada5-1f964b0b7073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_71693e70-0755-46f0-ada5-1f964b0b7073" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_45874c26-36a4-473b-9d77-34149a1c320f" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_45874c26-36a4-473b-9d77-34149a1c320f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_d9eb733a-16b7-4320-8a3a-f073e257abfb" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_d9eb733a-16b7-4320-8a3a-f073e257abfb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_35f453b6-edca-40a3-b695-a2c30c7c2e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_35f453b6-edca-40a3-b695-a2c30c7c2e10" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_424f16ce-88f8-4f68-9f9b-0ce63c204022" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_424f16ce-88f8-4f68-9f9b-0ce63c204022" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_24d935eb-9f42-4442-bd3b-417f3f6c8161" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_24d935eb-9f42-4442-bd3b-417f3f6c8161" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f85cb269-55ae-436c-aaa7-7e5bd70b9e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f85cb269-55ae-436c-aaa7-7e5bd70b9e91" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_b51377ff-7685-447b-907d-95c42884cf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_b51377ff-7685-447b-907d-95c42884cf5e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_d0da5d07-b846-406a-894a-1aebcd5ceb35" xlink:href="fold-20211231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_d0da5d07-b846-406a-894a-1aebcd5ceb35" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f087df51-3f1c-4beb-8198-76e30d31b498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f087df51-3f1c-4beb-8198-76e30d31b498" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d729eec0-c361-4f9a-a93e-b4d07938f0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d729eec0-c361-4f9a-a93e-b4d07938f0c5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_44fccc7d-94ee-4c84-9881-fc5e22f2c4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_NetIncomeLoss_44fccc7d-94ee-4c84-9881-fc5e22f2c4c9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bdb6174e-cedb-462b-a6e5-97cd0fdda3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a13ccd37-ec63-40ff-9531-de25d972ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a14287f4-ccae-4dd6-87c8-e757a4afe167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0e89e5e7-c21c-46e4-9ec3-af4af513fd39" xlink:to="loc_us-gaap_StatementTable_a14287f4-ccae-4dd6-87c8-e757a4afe167" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cda0f192-630a-4fc0-a698-49ea49601dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a14287f4-ccae-4dd6-87c8-e757a4afe167" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cda0f192-630a-4fc0-a698-49ea49601dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cda0f192-630a-4fc0-a698-49ea49601dab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cda0f192-630a-4fc0-a698-49ea49601dab" xlink:to="loc_us-gaap_EquityComponentDomain_cda0f192-630a-4fc0-a698-49ea49601dab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cda0f192-630a-4fc0-a698-49ea49601dab" xlink:to="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4bc82576-9e97-4567-94cd-e703dd097141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_CommonStockMember_4bc82576-9e97-4567-94cd-e703dd097141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_96fa6ba6-c5de-4d20-845a-c5723c481485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_96fa6ba6-c5de-4d20-845a-c5723c481485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a958f909-4dc4-4a94-b0ad-7ca0bd75e72f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_WarrantMember_a958f909-4dc4-4a94-b0ad-7ca0bd75e72f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_3e7395d8-8aa7-4278-a527-3a9b3bdb8c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_3e7395d8-8aa7-4278-a527-3a9b3bdb8c59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3a966af8-5378-40b3-96af-1bb2374d6a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_RetainedEarningsMember_3a966af8-5378-40b3-96af-1bb2374d6a4d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="i8fa7f44e3fcf4b07877a077b7bd6a20f_DescriptionofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19e57a46-99dd-4740-8711-cbdce3231f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19e57a46-99dd-4740-8711-cbdce3231f1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2c13250d-6bd1-467b-bbe1-723b8b906a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2c13250d-6bd1-467b-bbe1-723b8b906a8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_816cb4af-1e40-4f0d-81df-bec47892edcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_816cb4af-1e40-4f0d-81df-bec47892edcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_72c9c3c9-dee2-4409-acc3-e2d9b946c6ec" xlink:href="fold-20211231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_72c9c3c9-dee2-4409-acc3-e2d9b946c6ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a9a295b-f385-42da-9ff2-63e696e8c9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a9a295b-f385-42da-9ff2-63e696e8c9ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c11dc9cd-fd4f-4265-b53f-846e15a504c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c11dc9cd-fd4f-4265-b53f-846e15a504c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c11dc9cd-fd4f-4265-b53f-846e15a504c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c11dc9cd-fd4f-4265-b53f-846e15a504c2" xlink:to="loc_us-gaap_EquityComponentDomain_c11dc9cd-fd4f-4265-b53f-846e15a504c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_efe1d72d-ca29-4082-b64b-fbe402af8e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c11dc9cd-fd4f-4265-b53f-846e15a504c2" xlink:to="loc_us-gaap_EquityComponentDomain_efe1d72d-ca29-4082-b64b-fbe402af8e6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_db3edfc4-2a7f-4249-aa08-a9aa026682a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_efe1d72d-ca29-4082-b64b-fbe402af8e6b" xlink:to="loc_us-gaap_CommonStockMember_db3edfc4-2a7f-4249-aa08-a9aa026682a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6dd43bf6-3c68-4ceb-9882-1dcb87401481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6dd43bf6-3c68-4ceb-9882-1dcb87401481" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6dd43bf6-3c68-4ceb-9882-1dcb87401481_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6dd43bf6-3c68-4ceb-9882-1dcb87401481" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6dd43bf6-3c68-4ceb-9882-1dcb87401481_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_709bf2e3-6ef2-49bf-a393-d0c1f7b94f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6dd43bf6-3c68-4ceb-9882-1dcb87401481" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_709bf2e3-6ef2-49bf-a393-d0c1f7b94f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_cb61d493-c5e4-4ba1-9299-0240e59c433e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_709bf2e3-6ef2-49bf-a393-d0c1f7b94f5a" xlink:to="loc_us-gaap_PrivatePlacementMember_cb61d493-c5e4-4ba1-9299-0240e59c433e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_28dfae38-b144-4475-a600-2e8b88974d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_28dfae38-b144-4475-a600-2e8b88974d1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_28dfae38-b144-4475-a600-2e8b88974d1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_28dfae38-b144-4475-a600-2e8b88974d1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_28dfae38-b144-4475-a600-2e8b88974d1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_98b969f3-40be-474b-8b23-321e418acc44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_28dfae38-b144-4475-a600-2e8b88974d1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_98b969f3-40be-474b-8b23-321e418acc44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9d7383c8-b31a-4698-bc02-2888ff8aa548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_98b969f3-40be-474b-8b23-321e418acc44" xlink:to="loc_us-gaap_WarrantMember_9d7383c8-b31a-4698-bc02-2888ff8aa548" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="extended" id="i41bceb48abda4d7c8b057bd219799265_SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8634ba6d-05ef-4e5d-872d-64206e3c0207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_123bb4d4-241e-48cf-9a09-686e887f4003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8634ba6d-05ef-4e5d-872d-64206e3c0207" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_123bb4d4-241e-48cf-9a09-686e887f4003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b635bdd0-5096-40ec-aa04-b21aa1445794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8634ba6d-05ef-4e5d-872d-64206e3c0207" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b635bdd0-5096-40ec-aa04-b21aa1445794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8634ba6d-05ef-4e5d-872d-64206e3c0207" xlink:to="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_08b52a19-8bcc-4fbe-ab12-56fc535bde04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_08b52a19-8bcc-4fbe-ab12-56fc535bde04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08b52a19-8bcc-4fbe-ab12-56fc535bde04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_08b52a19-8bcc-4fbe-ab12-56fc535bde04" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08b52a19-8bcc-4fbe-ab12-56fc535bde04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91a93519-03fc-4b38-8664-5b7bf4f5711c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_08b52a19-8bcc-4fbe-ab12-56fc535bde04" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91a93519-03fc-4b38-8664-5b7bf4f5711c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_e2e91820-6f39-4cf6-9276-ab9e2908f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91a93519-03fc-4b38-8664-5b7bf4f5711c" xlink:to="loc_us-gaap_SalesRevenueNetMember_e2e91820-6f39-4cf6-9276-ab9e2908f3a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2d920c31-1da8-415f-a78a-2de686f60631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91a93519-03fc-4b38-8664-5b7bf4f5711c" xlink:to="loc_us-gaap_AccountsReceivableMember_2d920c31-1da8-415f-a78a-2de686f60631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_95099f33-8e0a-4cd0-9358-9b70e6b60956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_95099f33-8e0a-4cd0-9358-9b70e6b60956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_95099f33-8e0a-4cd0-9358-9b70e6b60956_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_95099f33-8e0a-4cd0-9358-9b70e6b60956" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_95099f33-8e0a-4cd0-9358-9b70e6b60956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9822d020-abda-4393-83c2-468649635f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_95099f33-8e0a-4cd0-9358-9b70e6b60956" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9822d020-abda-4393-83c2-468649635f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_94f97acb-7ede-43e7-b380-b82519b355ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9822d020-abda-4393-83c2-468649635f4f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_94f97acb-7ede-43e7-b380-b82519b355ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_81caa96f-7af9-403f-8276-9d35d8ff2465" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:to="loc_srt_MajorCustomersAxis_81caa96f-7af9-403f-8276-9d35d8ff2465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_81caa96f-7af9-403f-8276-9d35d8ff2465_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_81caa96f-7af9-403f-8276-9d35d8ff2465" xlink:to="loc_srt_NameOfMajorCustomerDomain_81caa96f-7af9-403f-8276-9d35d8ff2465_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_60a9f57f-cf8b-4c3c-b07d-89dcfb89e861" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_81caa96f-7af9-403f-8276-9d35d8ff2465" xlink:to="loc_srt_NameOfMajorCustomerDomain_60a9f57f-cf8b-4c3c-b07d-89dcfb89e861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CustomerOneMember_a856c68b-9e63-4c8f-8bb4-22d75885ff30" xlink:href="fold-20211231.xsd#fold_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_60a9f57f-cf8b-4c3c-b07d-89dcfb89e861" xlink:to="loc_fold_CustomerOneMember_a856c68b-9e63-4c8f-8bb4-22d75885ff30" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="ia93dbf7e7dd3488f8afea8122d1dfdb8_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc223c61-c42a-4542-9612-1d3d0e408e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2b852aae-a11a-4222-a3eb-f5390003af13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc223c61-c42a-4542-9612-1d3d0e408e21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2b852aae-a11a-4222-a3eb-f5390003af13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cea0a26b-c603-4dbf-b31e-2ee227b7b169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc223c61-c42a-4542-9612-1d3d0e408e21" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cea0a26b-c603-4dbf-b31e-2ee227b7b169" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_715ce987-10f8-4d28-80f2-521d63ab1a76" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cea0a26b-c603-4dbf-b31e-2ee227b7b169" xlink:to="loc_srt_RangeAxis_715ce987-10f8-4d28-80f2-521d63ab1a76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_715ce987-10f8-4d28-80f2-521d63ab1a76_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_715ce987-10f8-4d28-80f2-521d63ab1a76" xlink:to="loc_srt_RangeMember_715ce987-10f8-4d28-80f2-521d63ab1a76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ea14473-e4a9-4efa-81e0-5e2649d838e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_715ce987-10f8-4d28-80f2-521d63ab1a76" xlink:to="loc_srt_RangeMember_4ea14473-e4a9-4efa-81e0-5e2649d838e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4012d23-dee9-46ac-9971-cd8b509a3d63" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4ea14473-e4a9-4efa-81e0-5e2649d838e0" xlink:to="loc_srt_MinimumMember_d4012d23-dee9-46ac-9971-cd8b509a3d63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_793849b5-0c21-4a9e-85ef-ab3d445847a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4ea14473-e4a9-4efa-81e0-5e2649d838e0" xlink:to="loc_srt_MaximumMember_793849b5-0c21-4a9e-85ef-ab3d445847a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" xlink:type="extended" id="ic04d51f4021d484cbbed7fb7aa74302b_SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c179c26f-0f72-400a-876c-f59916bb92cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93f4bcf5-fd42-4204-be52-7e0208b049ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c179c26f-0f72-400a-876c-f59916bb92cc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93f4bcf5-fd42-4204-be52-7e0208b049ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0ef02c23-f7c4-4fe4-a70b-c62213f8d2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c179c26f-0f72-400a-876c-f59916bb92cc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0ef02c23-f7c4-4fe4-a70b-c62213f8d2af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a789105b-a341-4195-8678-6d0787411942" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0ef02c23-f7c4-4fe4-a70b-c62213f8d2af" xlink:to="loc_srt_StatementGeographicalAxis_a789105b-a341-4195-8678-6d0787411942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a789105b-a341-4195-8678-6d0787411942_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a789105b-a341-4195-8678-6d0787411942" xlink:to="loc_srt_SegmentGeographicalDomain_a789105b-a341-4195-8678-6d0787411942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2ce26c65-3282-4ca2-9140-8fd6917ecefb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a789105b-a341-4195-8678-6d0787411942" xlink:to="loc_srt_SegmentGeographicalDomain_2ce26c65-3282-4ca2-9140-8fd6917ecefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_332dcac2-6ac5-4cc7-aa8d-04249961e82d" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2ce26c65-3282-4ca2-9140-8fd6917ecefb" xlink:to="loc_country_US_332dcac2-6ac5-4cc7-aa8d-04249961e82d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a13a4595-26ee-4d1c-b385-a2897d7db4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2ce26c65-3282-4ca2-9140-8fd6917ecefb" xlink:to="loc_us-gaap_NonUsMember_a13a4595-26ee-4d1c-b385-a2897d7db4d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i596b754e14dd45c8b559c19496fa4acf_CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_270cb8c0-1211-4722-9c11-e49e2722b2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_270cb8c0-1211-4722-9c11-e49e2722b2ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8cb5d486-1e22-4db3-8b07-681c7ce3bba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8cb5d486-1e22-4db3-8b07-681c7ce3bba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_3a509206-320f-4131-a7fc-6867d8b6a356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_3a509206-320f-4131-a7fc-6867d8b6a356" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1d4e729e-72a9-49af-add0-20913d6c429d" xlink:href="fold-20211231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1d4e729e-72a9-49af-add0-20913d6c429d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_71fc3ba5-2a7b-4bce-a0a8-3ff49b5fe887" xlink:href="fold-20211231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_71fc3ba5-2a7b-4bce-a0a8-3ff49b5fe887" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3c20787-3166-48f2-b95b-a4818d018386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3c20787-3166-48f2-b95b-a4818d018386" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c2fc676-f283-4b00-9363-0ffbad080afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c2fc676-f283-4b00-9363-0ffbad080afd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_faf05738-9149-40fd-afaa-72d1ae02c985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_faf05738-9149-40fd-afaa-72d1ae02c985" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a8db1566-6241-4921-a1d4-29a87dc297aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a8db1566-6241-4921-a1d4-29a87dc297aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fc60f9e0-c60e-43ee-81a1-d6916ca4705e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fc60f9e0-c60e-43ee-81a1-d6916ca4705e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_fe27ddf8-80bf-432c-b57f-18062f0ccfab" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_fe27ddf8-80bf-432c-b57f-18062f0ccfab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3dd91d6-83c9-4b11-b310-cee13a7e5228" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3dd91d6-83c9-4b11-b310-cee13a7e5228" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_389ab8a1-6d43-425c-8720-e60ca76d5c01" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_389ab8a1-6d43-425c-8720-e60ca76d5c01" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_bf5214e5-0cfe-40c0-8e4a-7a29a9b2d5d6" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_bf5214e5-0cfe-40c0-8e4a-7a29a9b2d5d6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0f084f7d-4ad8-4d67-9267-d11a2a9f652a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0f084f7d-4ad8-4d67-9267-d11a2a9f652a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1cb529c5-c2b9-4251-a575-ff2bb14f3507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0f084f7d-4ad8-4d67-9267-d11a2a9f652a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1cb529c5-c2b9-4251-a575-ff2bb14f3507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1cb529c5-c2b9-4251-a575-ff2bb14f3507_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1cb529c5-c2b9-4251-a575-ff2bb14f3507" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1cb529c5-c2b9-4251-a575-ff2bb14f3507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1cb529c5-c2b9-4251-a575-ff2bb14f3507" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_8ddcd683-6c1e-4bca-9ee8-e4427d8577f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_8ddcd683-6c1e-4bca-9ee8-e4427d8577f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_a77fee62-099f-4672-9f76-024379ccc115" xlink:href="fold-20211231.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_a77fee62-099f-4672-9f76-024379ccc115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c1edbf3c-2da1-4870-9e6a-f894dbfd3633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c1edbf3c-2da1-4870-9e6a-f894dbfd3633" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_92bdbd1d-ca05-45d1-97c4-948051026379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_92bdbd1d-ca05-45d1-97c4-948051026379" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f7190033-fdf7-4117-a54f-59b5c3912439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f7190033-fdf7-4117-a54f-59b5c3912439" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_598ea547-4221-4522-8598-8759cc854e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_598ea547-4221-4522-8598-8759cc854e62" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="i5dbeb5d93f5d498ba26c3fec318c5350_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1ca8a13e-96a7-4851-a30c-90b43fa54a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1ca8a13e-96a7-4851-a30c-90b43fa54a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_982633b9-7dbc-4f29-b55b-dc7d0510e191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_982633b9-7dbc-4f29-b55b-dc7d0510e191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d29f382f-4f49-4b56-b502-d25646026b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d29f382f-4f49-4b56-b502-d25646026b24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5eb48aa6-50f1-4fa7-a62a-977c4ef587d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:to="loc_us-gaap_Depreciation_5eb48aa6-50f1-4fa7-a62a-977c4ef587d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8eb42f6-4ad2-4417-a5bc-bf30590657c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8eb42f6-4ad2-4417-a5bc-bf30590657c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_234da121-ad0c-4d0c-a345-ff9396602638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8eb42f6-4ad2-4417-a5bc-bf30590657c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_234da121-ad0c-4d0c-a345-ff9396602638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_234da121-ad0c-4d0c-a345-ff9396602638_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_234da121-ad0c-4d0c-a345-ff9396602638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_234da121-ad0c-4d0c-a345-ff9396602638_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_234da121-ad0c-4d0c-a345-ff9396602638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bbcf8fb7-e30a-4a80-b2db-cc06ebf0182c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bbcf8fb7-e30a-4a80-b2db-cc06ebf0182c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ResearchEquipmentMember_b23c0aa1-16b4-4c9a-8fe2-df9dd40d6606" xlink:href="fold-20211231.xsd#fold_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_fold_ResearchEquipmentMember_b23c0aa1-16b4-4c9a-8fe2-df9dd40d6606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_21050389-635a-4b4b-90c9-296a23882476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_ConstructionInProgressMember_21050389-635a-4b4b-90c9-296a23882476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_72039f24-ddfd-4002-815e-31c9c9fb4527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_ComputerEquipmentMember_72039f24-ddfd-4002-815e-31c9c9fb4527" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_099432e6-3e51-4ee8-b0ef-f56758299a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_LandMember_099432e6-3e51-4ee8-b0ef-f56758299a86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2e3ba070-5232-4f7e-ba7f-efafcb9fa674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2e3ba070-5232-4f7e-ba7f-efafcb9fa674" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_30cd2ce2-b2d2-4b2b-86ad-001edb9f51a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_30cd2ce2-b2d2-4b2b-86ad-001edb9f51a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_84f9715b-3223-4b6c-bffe-f5ea94acc072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_VehiclesMember_84f9715b-3223-4b6c-bffe-f5ea94acc072" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#StockholdersEquityCommonStockandWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="extended" id="ic97b8e460d024b2cb418aefa510ca73c_StockholdersEquityCommonStockandWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76f8bd9c-773c-4005-a640-80f2cb48b6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76f8bd9c-773c-4005-a640-80f2cb48b6bc" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a5476a0c-1344-41fa-9eb8-d1d8d399fbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a5476a0c-1344-41fa-9eb8-d1d8d399fbed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CommonStockVotingRightsForEachShareHeld_f62a75bb-38d2-44b5-9005-d0bf0fde3b81" xlink:href="fold-20211231.xsd#fold_CommonStockVotingRightsForEachShareHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_fold_CommonStockVotingRightsForEachShareHeld_f62a75bb-38d2-44b5-9005-d0bf0fde3b81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7719a698-578f-4ddb-aa54-a0eb0bcced7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7719a698-578f-4ddb-aa54-a0eb0bcced7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3e531e25-f129-46b0-97bf-c5ed122d971b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3e531e25-f129-46b0-97bf-c5ed122d971b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2a2b5c1d-b02b-4ca9-abfd-380f0830297a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2a2b5c1d-b02b-4ca9-abfd-380f0830297a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_925fc73a-8d22-460d-8018-405ebd82a0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_925fc73a-8d22-460d-8018-405ebd82a0cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_447f115a-37d2-4118-bb26-644122c8b176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_447f115a-37d2-4118-bb26-644122c8b176" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f3f9c73c-f8cb-45e2-80e7-45d5f81b7376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f3f9c73c-f8cb-45e2-80e7-45d5f81b7376" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b513ef3a-c3e4-448d-ac15-cf806c91bf52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b513ef3a-c3e4-448d-ac15-cf806c91bf52" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1f2ce139-f800-420c-b53e-6a2d7bd1f9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1f2ce139-f800-420c-b53e-6a2d7bd1f9e1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6f479775-b2a0-4113-b35a-e2dfefedc28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6f479775-b2a0-4113-b35a-e2dfefedc28e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bca1a079-71c3-4920-9694-ac6f7c705eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bca1a079-71c3-4920-9694-ac6f7c705eb2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMilestonePayment_707468ab-598a-489f-9007-bad24b2b4a20" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_fold_ContingentConsiderationMilestonePayment_707468ab-598a-489f-9007-bad24b2b4a20" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration_99a6f2d1-03be-424c-b734-4d4e8e42da61" xlink:href="fold-20211231.xsd#fold_MilestonePaymentStockIssuedAsConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_fold_MilestonePaymentStockIssuedAsConsideration_99a6f2d1-03be-424c-b734-4d4e8e42da61" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_c89be902-8db9-4eb0-a7dc-a76985e8e165" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_c89be902-8db9-4eb0-a7dc-a76985e8e165" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_5c566922-1b3e-400f-97f4-2bffb1b605c0" xlink:href="fold-20211231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76f8bd9c-773c-4005-a640-80f2cb48b6bc" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_5c566922-1b3e-400f-97f4-2bffb1b605c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76f8bd9c-773c-4005-a640-80f2cb48b6bc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_68b9dacf-f24d-4b09-8d46-77e689995672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_68b9dacf-f24d-4b09-8d46-77e689995672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_68b9dacf-f24d-4b09-8d46-77e689995672_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_68b9dacf-f24d-4b09-8d46-77e689995672" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_68b9dacf-f24d-4b09-8d46-77e689995672_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e3169bc4-db50-4bdc-8b40-ca547a10e69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_68b9dacf-f24d-4b09-8d46-77e689995672" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e3169bc4-db50-4bdc-8b40-ca547a10e69b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4cd0bc97-7a92-4dff-88b2-8870c13fb9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e3169bc4-db50-4bdc-8b40-ca547a10e69b" xlink:to="loc_us-gaap_WarrantMember_4cd0bc97-7a92-4dff-88b2-8870c13fb9f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1546c849-8034-4f87-ab59-f710da337b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1546c849-8034-4f87-ab59-f710da337b6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1546c849-8034-4f87-ab59-f710da337b6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1546c849-8034-4f87-ab59-f710da337b6f" xlink:to="loc_us-gaap_ClassOfStockDomain_1546c849-8034-4f87-ab59-f710da337b6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_57ff24d4-489c-49d3-8adf-ceb73178c1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1546c849-8034-4f87-ab59-f710da337b6f" xlink:to="loc_us-gaap_ClassOfStockDomain_57ff24d4-489c-49d3-8adf-ceb73178c1cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_afc84bf2-d465-4591-b66e-0437a89c8c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_57ff24d4-489c-49d3-8adf-ceb73178c1cf" xlink:to="loc_us-gaap_CommonStockMember_afc84bf2-d465-4591-b66e-0437a89c8c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1395d12d-d96e-4d6d-8abc-96976fe704ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1395d12d-d96e-4d6d-8abc-96976fe704ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1395d12d-d96e-4d6d-8abc-96976fe704ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1395d12d-d96e-4d6d-8abc-96976fe704ba" xlink:to="loc_us-gaap_EquityComponentDomain_1395d12d-d96e-4d6d-8abc-96976fe704ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ce87e81-6d42-489c-b736-74589567777f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1395d12d-d96e-4d6d-8abc-96976fe704ba" xlink:to="loc_us-gaap_EquityComponentDomain_6ce87e81-6d42-489c-b736-74589567777f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fd63546a-a71f-4941-82f3-9b85d87be70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ce87e81-6d42-489c-b736-74589567777f" xlink:to="loc_us-gaap_CommonStockMember_fd63546a-a71f-4941-82f3-9b85d87be70a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e0c4665d-36da-4730-b0e7-09e42035c4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ce87e81-6d42-489c-b736-74589567777f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e0c4665d-36da-4730-b0e7-09e42035c4f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9bdb3805-8683-47d2-86c9-bb879a51fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9bdb3805-8683-47d2-86c9-bb879a51fcc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bdb3805-8683-47d2-86c9-bb879a51fcc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9bdb3805-8683-47d2-86c9-bb879a51fcc7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bdb3805-8683-47d2-86c9-bb879a51fcc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9bdb3805-8683-47d2-86c9-bb879a51fcc7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_UnderwrittenOfferingMember_28520d35-7646-4e89-888d-81650975c413" xlink:href="fold-20211231.xsd#fold_UnderwrittenOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:to="loc_fold_UnderwrittenOfferingMember_28520d35-7646-4e89-888d-81650975c413" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_8f5cab07-0a12-4da4-bbf2-4ba3360d35e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:to="loc_us-gaap_PrivatePlacementMember_8f5cab07-0a12-4da4-bbf2-4ba3360d35e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt798Member_eae313f6-c91e-4594-952d-2be91151fedd" xlink:href="fold-20211231.xsd#fold_StockExercisesAt798Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:to="loc_fold_StockExercisesAt798Member_eae313f6-c91e-4594-952d-2be91151fedd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt706Member_79269870-8c82-4ca4-9fb2-f9ced16321e7" xlink:href="fold-20211231.xsd#fold_StockExercisesAt706Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:to="loc_fold_StockExercisesAt706Member_79269870-8c82-4ca4-9fb2-f9ced16321e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf92acf8-b802-4114-931a-500457cff004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf92acf8-b802-4114-931a-500457cff004" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf92acf8-b802-4114-931a-500457cff004_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf92acf8-b802-4114-931a-500457cff004" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf92acf8-b802-4114-931a-500457cff004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d383e81a-c460-4e4c-a471-cad46184b30a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf92acf8-b802-4114-931a-500457cff004" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d383e81a-c460-4e4c-a471-cad46184b30a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_22af94a4-2ce8-488a-bd50-2c199f84ce41" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d383e81a-c460-4e4c-a471-cad46184b30a" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_22af94a4-2ce8-488a-bd50-2c199f84ce41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e55f458f-e48d-45ab-a8f4-00b99c0a3020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e55f458f-e48d-45ab-a8f4-00b99c0a3020" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e55f458f-e48d-45ab-a8f4-00b99c0a3020_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e55f458f-e48d-45ab-a8f4-00b99c0a3020" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e55f458f-e48d-45ab-a8f4-00b99c0a3020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2110bca4-9952-4c69-baa7-a30d0b38c10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e55f458f-e48d-45ab-a8f4-00b99c0a3020" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2110bca4-9952-4c69-baa7-a30d0b38c10a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a5c2450d-1f5e-4562-bea4-3600cd2c03fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2110bca4-9952-4c69-baa7-a30d0b38c10a" xlink:to="loc_us-gaap_ConvertibleDebtMember_a5c2450d-1f5e-4562-bea4-3600cd2c03fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" xlink:type="extended" id="ia3bc8d653fd946009f35fe113e31b988_StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_38d53ff7-7ba6-4958-ac88-5687efcc8650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_us-gaap_TradingSecurities_38d53ff7-7ba6-4958-ac88-5687efcc8650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_357a425a-4a7b-4dcf-8196-1c5ac273e64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_357a425a-4a7b-4dcf-8196-1c5ac273e64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_43389596-3409-4a4b-9dbf-82ba206c04bc" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_43389596-3409-4a4b-9dbf-82ba206c04bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7fa48849-e5dc-4723-9bb3-07533a29e8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7fa48849-e5dc-4723-9bb3-07533a29e8ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0d72474f-1627-4a1b-a5f4-8f84d525c0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0d72474f-1627-4a1b-a5f4-8f84d525c0e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_30e48a45-9adc-4db7-bdbd-5b0955935cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:to="loc_us-gaap_VestingAxis_30e48a45-9adc-4db7-bdbd-5b0955935cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_30e48a45-9adc-4db7-bdbd-5b0955935cd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_30e48a45-9adc-4db7-bdbd-5b0955935cd9" xlink:to="loc_us-gaap_VestingDomain_30e48a45-9adc-4db7-bdbd-5b0955935cd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a69ab10e-eaa1-410c-95d4-0dba6e48d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_30e48a45-9adc-4db7-bdbd-5b0955935cd9" xlink:to="loc_us-gaap_VestingDomain_a69ab10e-eaa1-410c-95d4-0dba6e48d5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d9016901-d9bb-41a5-a190-a44a0e310ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a69ab10e-eaa1-410c-95d4-0dba6e48d5ea" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d9016901-d9bb-41a5-a190-a44a0e310ffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_63141b5d-7df9-48f2-b7a3-661331a36411" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:to="loc_srt_RangeAxis_63141b5d-7df9-48f2-b7a3-661331a36411" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63141b5d-7df9-48f2-b7a3-661331a36411_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_63141b5d-7df9-48f2-b7a3-661331a36411" xlink:to="loc_srt_RangeMember_63141b5d-7df9-48f2-b7a3-661331a36411_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_027a3baa-087f-4bce-9bfe-bc7d7808a897" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_63141b5d-7df9-48f2-b7a3-661331a36411" xlink:to="loc_srt_RangeMember_027a3baa-087f-4bce-9bfe-bc7d7808a897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7ef595b-9041-4613-b151-272a6cce3588" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_027a3baa-087f-4bce-9bfe-bc7d7808a897" xlink:to="loc_srt_MaximumMember_f7ef595b-9041-4613-b151-272a6cce3588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fac5edef-70a7-4659-9519-9881d3152c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:to="loc_us-gaap_AwardTypeAxis_fac5edef-70a7-4659-9519-9881d3152c8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fac5edef-70a7-4659-9519-9881d3152c8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fac5edef-70a7-4659-9519-9881d3152c8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fac5edef-70a7-4659-9519-9881d3152c8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6883f4f-7e51-4ad6-997c-40be5589f3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fac5edef-70a7-4659-9519-9881d3152c8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6883f4f-7e51-4ad6-997c-40be5589f3a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_784bf682-a15c-4b96-a448-971d710a2654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6883f4f-7e51-4ad6-997c-40be5589f3a8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_784bf682-a15c-4b96-a448-971d710a2654" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended" id="i9582248c816b4a6aa049a5bb453ad296_SharebasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_10ee4558-5955-4e3a-b480-19caf291088f" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_10ee4558-5955-4e3a-b480-19caf291088f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_096185a3-6b3e-412a-b4db-0eba3cfc22fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_096185a3-6b3e-412a-b4db-0eba3cfc22fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ced26c5-2f89-4c56-be69-a52aa08a3e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ced26c5-2f89-4c56-be69-a52aa08a3e8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3b3088cd-2317-4fc3-be68-04619ce20d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3b3088cd-2317-4fc3-be68-04619ce20d29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64a92d77-bae9-4a15-adf7-446a9ee923fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64a92d77-bae9-4a15-adf7-446a9ee923fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c2402371-3f3a-4bb9-8d6b-c023aa9825ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c2402371-3f3a-4bb9-8d6b-c023aa9825ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5d616cb3-be30-48de-a380-dd8c60a24d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5d616cb3-be30-48de-a380-dd8c60a24d0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9a51de15-3332-44d7-a553-0adf9a3e5823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9a51de15-3332-44d7-a553-0adf9a3e5823" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e69ae40-e008-451e-bf6e-16c756b1cd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e69ae40-e008-451e-bf6e-16c756b1cd98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a5f6e206-0a7b-478f-820e-d92cbbfd298f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e69ae40-e008-451e-bf6e-16c756b1cd98" xlink:to="loc_us-gaap_AwardTypeAxis_a5f6e206-0a7b-478f-820e-d92cbbfd298f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f6e206-0a7b-478f-820e-d92cbbfd298f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a5f6e206-0a7b-478f-820e-d92cbbfd298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5f6e206-0a7b-478f-820e-d92cbbfd298f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02331ea9-02ee-452c-b066-f24f4b539f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a5f6e206-0a7b-478f-820e-d92cbbfd298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02331ea9-02ee-452c-b066-f24f4b539f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_93eba05c-6d0e-4134-9451-fdec22bb47f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02331ea9-02ee-452c-b066-f24f4b539f82" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_93eba05c-6d0e-4134-9451-fdec22bb47f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_900bc49f-a2c5-4f5b-a16e-40c3bd350ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02331ea9-02ee-452c-b066-f24f4b539f82" xlink:to="loc_us-gaap_EmployeeStockOptionMember_900bc49f-a2c5-4f5b-a16e-40c3bd350ca3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended" id="i45dd7760b9304b7f92d6f4fce6e4ff90_SharebasedCompensationWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c148b504-c5e9-4811-b6e8-652c4f7a68d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c148b504-c5e9-4811-b6e8-652c4f7a68d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ea5f7142-c331-45bd-b4ed-8d41e1b28f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ea5f7142-c331-45bd-b4ed-8d41e1b28f38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1838c93c-bda4-4480-a420-40e889243a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1838c93c-bda4-4480-a420-40e889243a9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_72c53db1-1e21-44a0-8842-b6c996655124" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_72c53db1-1e21-44a0-8842-b6c996655124" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faf6c96c-b020-4f6b-ac85-7d43c3053fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faf6c96c-b020-4f6b-ac85-7d43c3053fdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cada5dc8-0a0a-42b2-8a30-275c3b6e4048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faf6c96c-b020-4f6b-ac85-7d43c3053fdc" xlink:to="loc_us-gaap_AwardTypeAxis_cada5dc8-0a0a-42b2-8a30-275c3b6e4048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cada5dc8-0a0a-42b2-8a30-275c3b6e4048_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cada5dc8-0a0a-42b2-8a30-275c3b6e4048" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cada5dc8-0a0a-42b2-8a30-275c3b6e4048_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62788b72-eb1d-43d2-babf-09817157766a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cada5dc8-0a0a-42b2-8a30-275c3b6e4048" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62788b72-eb1d-43d2-babf-09817157766a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ceac35b-c134-46e8-b485-aee8c2ec4f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62788b72-eb1d-43d2-babf-09817157766a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ceac35b-c134-46e8-b485-aee8c2ec4f60" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended" id="ibca1a15682be4b61b0d18c0a31cd8330_SharebasedCompensationRSUsandPBRSUsSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9c0c4195-7082-4339-b0be-14fd67459a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9c0c4195-7082-4339-b0be-14fd67459a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_25f186bf-a5a9-466a-bb19-b92d6520a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_25f186bf-a5a9-466a-bb19-b92d6520a1af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_38f0d728-fc85-4b21-b071-a4f1305283de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_38f0d728-fc85-4b21-b071-a4f1305283de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c02bfe41-0d8a-4f1c-bdfc-a67dafd177be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c02bfe41-0d8a-4f1c-bdfc-a67dafd177be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24e0719a-1ca0-450a-87fd-8b69bc10c7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9430d8be-7dad-4add-bcec-145de820cee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9430d8be-7dad-4add-bcec-145de820cee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93d57436-26a5-4209-8d29-d66385a3a551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93d57436-26a5-4209-8d29-d66385a3a551" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1ebd131e-c694-4188-a1f8-8df215c83090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1ebd131e-c694-4188-a1f8-8df215c83090" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ae7abb7d-9f4c-4584-8412-e89e0e820307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ae7abb7d-9f4c-4584-8412-e89e0e820307" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9a58684b-a141-4cef-935f-925b852ae5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_5d42053f-1dfd-49fa-a673-bb9356916c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_5d42053f-1dfd-49fa-a673-bb9356916c6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_44e349e0-9319-4c49-9d11-6e498a322346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_5d42053f-1dfd-49fa-a673-bb9356916c6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_44e349e0-9319-4c49-9d11-6e498a322346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_ddb5e9aa-7be8-4e34-9315-51dc0f97ceb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_5d42053f-1dfd-49fa-a673-bb9356916c6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_ddb5e9aa-7be8-4e34-9315-51dc0f97ceb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a952005d-b567-4a27-a27d-f62dbc552da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a952005d-b567-4a27-a27d-f62dbc552da9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_66f5faa0-4a5d-4600-a80c-ecbf77b1019e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a952005d-b567-4a27-a27d-f62dbc552da9" xlink:to="loc_us-gaap_AwardTypeAxis_66f5faa0-4a5d-4600-a80c-ecbf77b1019e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66f5faa0-4a5d-4600-a80c-ecbf77b1019e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_66f5faa0-4a5d-4600-a80c-ecbf77b1019e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66f5faa0-4a5d-4600-a80c-ecbf77b1019e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24037dc-45c2-4aca-b6e8-4fc9e0b2f0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_66f5faa0-4a5d-4600-a80c-ecbf77b1019e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24037dc-45c2-4aca-b6e8-4fc9e0b2f0d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e64c39fb-7360-4aac-a87d-cc2d5dc29b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24037dc-45c2-4aca-b6e8-4fc9e0b2f0d4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e64c39fb-7360-4aac-a87d-cc2d5dc29b3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationExpenseSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails" xlink:type="extended" id="idc95561012104a36a3fee6c929edb274_SharebasedCompensationExpenseSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c14de78-0994-4dfb-8756-35cb1ec82c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c145629d-5f9e-4b32-82ae-49dbff3942f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c14de78-0994-4dfb-8756-35cb1ec82c1d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c145629d-5f9e-4b32-82ae-49dbff3942f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00e34c6d-fae6-487b-b2de-e73642df4462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c14de78-0994-4dfb-8756-35cb1ec82c1d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00e34c6d-fae6-487b-b2de-e73642df4462" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_23405601-311a-44bc-a23f-bfa6f2677525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00e34c6d-fae6-487b-b2de-e73642df4462" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_23405601-311a-44bc-a23f-bfa6f2677525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_23405601-311a-44bc-a23f-bfa6f2677525_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_23405601-311a-44bc-a23f-bfa6f2677525" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_23405601-311a-44bc-a23f-bfa6f2677525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6f1f247a-5da4-4f5a-9667-e4e2e590b742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_23405601-311a-44bc-a23f-bfa6f2677525" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6f1f247a-5da4-4f5a-9667-e4e2e590b742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5abca7b2-95e1-47cc-868d-8cfdaeffc92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f1f247a-5da4-4f5a-9667-e4e2e590b742" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5abca7b2-95e1-47cc-868d-8cfdaeffc92e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a0b502ee-d3dc-4670-b64c-214b4f38e50f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f1f247a-5da4-4f5a-9667-e4e2e590b742" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a0b502ee-d3dc-4670-b64c-214b4f38e50f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="extended" id="i62fb69afc28c483bbfe32d7f6d0e3c7d_AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ce5de60-d107-4914-bf4f-14b4be75e501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_355e627e-1c2f-4c60-87f2-bd2c0513f2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ce5de60-d107-4914-bf4f-14b4be75e501" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_355e627e-1c2f-4c60-87f2-bd2c0513f2ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b2e6e49d-cb24-4701-b34e-e8f4fed4be0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_355e627e-1c2f-4c60-87f2-bd2c0513f2ce" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b2e6e49d-cb24-4701-b34e-e8f4fed4be0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ce5de60-d107-4914-bf4f-14b4be75e501" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_367fc516-184a-4ddb-9bcc-f97da3eef890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_367fc516-184a-4ddb-9bcc-f97da3eef890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_3558e4a7-b91d-4c92-a980-8952f3c34073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_3558e4a7-b91d-4c92-a980-8952f3c34073" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5f748e48-0ab4-4f14-8950-20cfe9614ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5f748e48-0ab4-4f14-8950-20cfe9614ea7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b7db52e-d721-46bc-ac2e-36e057a14777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ce5de60-d107-4914-bf4f-14b4be75e501" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b7db52e-d721-46bc-ac2e-36e057a14777" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a563891-2b82-4678-8be5-95bd535d8dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b7db52e-d721-46bc-ac2e-36e057a14777" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a563891-2b82-4678-8be5-95bd535d8dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a563891-2b82-4678-8be5-95bd535d8dfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a563891-2b82-4678-8be5-95bd535d8dfa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a563891-2b82-4678-8be5-95bd535d8dfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f4c12f3-aaa3-40d5-81d3-d0fe64656f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a563891-2b82-4678-8be5-95bd535d8dfa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f4c12f3-aaa3-40d5-81d3-d0fe64656f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3fe2b7fc-0025-4cd5-a4d5-dbc9c0fd4ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f4c12f3-aaa3-40d5-81d3-d0fe64656f72" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3fe2b7fc-0025-4cd5-a4d5-dbc9c0fd4ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b27c0c22-3040-40ee-a8e3-2bdec9e0e4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f4c12f3-aaa3-40d5-81d3-d0fe64656f72" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b27c0c22-3040-40ee-a8e3-2bdec9e0e4f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_69a4a489-415f-49cb-ad2a-c0c351a74318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b7db52e-d721-46bc-ac2e-36e057a14777" xlink:to="loc_us-gaap_FinancialInstrumentAxis_69a4a489-415f-49cb-ad2a-c0c351a74318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69a4a489-415f-49cb-ad2a-c0c351a74318_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69a4a489-415f-49cb-ad2a-c0c351a74318" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69a4a489-415f-49cb-ad2a-c0c351a74318_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69a4a489-415f-49cb-ad2a-c0c351a74318" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_909992f0-28f8-4e63-a6ae-9efad7673ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_909992f0-28f8-4e63-a6ae-9efad7673ac3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ac3f3b64-4d91-41f7-a68e-0cdc725368a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ac3f3b64-4d91-41f7-a68e-0cdc725368a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2960af89-8bb5-4341-b1b9-df8209c407b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2960af89-8bb5-4341-b1b9-df8209c407b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7faab34e-7d33-4f87-bb9f-3ba11aa03bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7faab34e-7d33-4f87-bb9f-3ba11aa03bb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_57097d89-1025-4a19-8d49-3de17a3a2c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_57097d89-1025-4a19-8d49-3de17a3a2c87" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails" xlink:type="extended" id="if331188cfdfb411288c1b0159f5b48a6_AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_7c1dfad2-5e02-4c74-928e-57eb81ba23d3" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_7c1dfad2-5e02-4c74-928e-57eb81ba23d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c9119442-955f-4d18-9c0b-c1b2d0394730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c9119442-955f-4d18-9c0b-c1b2d0394730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration_c0b9cdf9-1120-4e34-a6e7-d2bf63eb29c0" xlink:href="fold-20211231.xsd#fold_MilestonePaymentStockIssuedAsConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:to="loc_fold_MilestonePaymentStockIssuedAsConsideration_c0b9cdf9-1120-4e34-a6e7-d2bf63eb29c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_185cd271-9935-46ca-90d9-4a512521ce39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_DebtInstrumentAxis_185cd271-9935-46ca-90d9-4a512521ce39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_185cd271-9935-46ca-90d9-4a512521ce39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_185cd271-9935-46ca-90d9-4a512521ce39" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_185cd271-9935-46ca-90d9-4a512521ce39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e1424c91-98db-4874-8e74-076a85140feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_185cd271-9935-46ca-90d9-4a512521ce39" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e1424c91-98db-4874-8e74-076a85140feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_63e11f6e-f3a3-4442-b621-03212cf3e618" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1424c91-98db-4874-8e74-076a85140feb" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_63e11f6e-f3a3-4442-b621-03212cf3e618" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f027788a-4147-4981-ab39-5e68ec7de84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f027788a-4147-4981-ab39-5e68ec7de84b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f027788a-4147-4981-ab39-5e68ec7de84b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f027788a-4147-4981-ab39-5e68ec7de84b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f027788a-4147-4981-ab39-5e68ec7de84b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_93cbf623-1d9b-486d-b9fd-bd278e25fa2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f027788a-4147-4981-ab39-5e68ec7de84b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_93cbf623-1d9b-486d-b9fd-bd278e25fa2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_6da9d8cc-2199-4f60-8c3e-399e9d667ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_93cbf623-1d9b-486d-b9fd-bd278e25fa2d" xlink:to="loc_us-gaap_ConvertibleDebtMember_6da9d8cc-2199-4f60-8c3e-399e9d667ac2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e82a37da-cffa-4aa7-807b-0ce4eaa392ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e82a37da-cffa-4aa7-807b-0ce4eaa392ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e82a37da-cffa-4aa7-807b-0ce4eaa392ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e82a37da-cffa-4aa7-807b-0ce4eaa392ec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e82a37da-cffa-4aa7-807b-0ce4eaa392ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e03e0413-a92c-4bba-b3b1-0d820402db5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e82a37da-cffa-4aa7-807b-0ce4eaa392ec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e03e0413-a92c-4bba-b3b1-0d820402db5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_bd5956e5-e4df-49d4-9ba2-4cfd51965645" xlink:href="fold-20211231.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e03e0413-a92c-4bba-b3b1-0d820402db5f" xlink:to="loc_fold_CallidusBiopharmaIncMember_bd5956e5-e4df-49d4-9ba2-4cfd51965645" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_8b466cd5-6df9-4592-ad87-e572f29f28b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_8b466cd5-6df9-4592-ad87-e572f29f28b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8b466cd5-6df9-4592-ad87-e572f29f28b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_8b466cd5-6df9-4592-ad87-e572f29f28b1" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8b466cd5-6df9-4592-ad87-e572f29f28b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_321e8ead-2f24-406d-a163-8e3cf1ab91f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_8b466cd5-6df9-4592-ad87-e572f29f28b1" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_321e8ead-2f24-406d-a163-8e3cf1ab91f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_35dafcec-4b09-48f5-8d0f-7e367edd9db2" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_321e8ead-2f24-406d-a163-8e3cf1ab91f4" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_35dafcec-4b09-48f5-8d0f-7e367edd9db2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a103758-bc11-41d1-8e06-e6fd6ceb6ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a103758-bc11-41d1-8e06-e6fd6ceb6ca6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a103758-bc11-41d1-8e06-e6fd6ceb6ca6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a103758-bc11-41d1-8e06-e6fd6ceb6ca6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a103758-bc11-41d1-8e06-e6fd6ceb6ca6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb31b658-0f9b-46eb-833d-42dcc81fad3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a103758-bc11-41d1-8e06-e6fd6ceb6ca6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb31b658-0f9b-46eb-833d-42dcc81fad3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_eeef30a7-1c40-4bb2-ae0f-b04654b101bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb31b658-0f9b-46eb-833d-42dcc81fad3b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_eeef30a7-1c40-4bb2-ae0f-b04654b101bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_39b81976-5f99-4b15-a835-f4bd0453bbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_39b81976-5f99-4b15-a835-f4bd0453bbe0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_39b81976-5f99-4b15-a835-f4bd0453bbe0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_39b81976-5f99-4b15-a835-f4bd0453bbe0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_39b81976-5f99-4b15-a835-f4bd0453bbe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_96fd4f0f-cbc0-47c6-a5fe-eaf0abfcc9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_39b81976-5f99-4b15-a835-f4bd0453bbe0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_96fd4f0f-cbc0-47c6-a5fe-eaf0abfcc9eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b4e2b4b7-e3ad-4aac-8c2d-0176b422cdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96fd4f0f-cbc0-47c6-a5fe-eaf0abfcc9eb" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b4e2b4b7-e3ad-4aac-8c2d-0176b422cdf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_ba4ef51c-b31c-4212-bfa9-f38bfd39c50c" xlink:href="fold-20211231.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96fd4f0f-cbc0-47c6-a5fe-eaf0abfcc9eb" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_ba4ef51c-b31c-4212-bfa9-f38bfd39c50c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_413ea636-5ddd-4eaf-93dd-4aa1bd574d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_413ea636-5ddd-4eaf-93dd-4aa1bd574d84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_413ea636-5ddd-4eaf-93dd-4aa1bd574d84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_413ea636-5ddd-4eaf-93dd-4aa1bd574d84" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_413ea636-5ddd-4eaf-93dd-4aa1bd574d84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02e1e522-8484-4c65-8aa1-c3bfdee49fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_413ea636-5ddd-4eaf-93dd-4aa1bd574d84" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02e1e522-8484-4c65-8aa1-c3bfdee49fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_TB200PompeProgramMember_87181b46-489a-4baa-96e1-b034e049624b" xlink:href="fold-20211231.xsd#fold_TB200PompeProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02e1e522-8484-4c65-8aa1-c3bfdee49fbe" xlink:to="loc_fold_TB200PompeProgramMember_87181b46-489a-4baa-96e1-b034e049624b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a811a44f-4215-4808-bdb2-0a639e4f8eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a811a44f-4215-4808-bdb2-0a639e4f8eea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a811a44f-4215-4808-bdb2-0a639e4f8eea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a811a44f-4215-4808-bdb2-0a639e4f8eea" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a811a44f-4215-4808-bdb2-0a639e4f8eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f200d9a3-5141-4274-ab85-cf57eaf1a13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a811a44f-4215-4808-bdb2-0a639e4f8eea" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f200d9a3-5141-4274-ab85-cf57eaf1a13a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_faf6fb76-6279-4c99-a8d1-4a3da968bdc6" xlink:href="fold-20211231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f200d9a3-5141-4274-ab85-cf57eaf1a13a" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_faf6fb76-6279-4c99-a8d1-4a3da968bdc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dc882962-c28c-4f24-8152-9dba6f9e59c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_srt_RangeAxis_dc882962-c28c-4f24-8152-9dba6f9e59c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dc882962-c28c-4f24-8152-9dba6f9e59c9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dc882962-c28c-4f24-8152-9dba6f9e59c9" xlink:to="loc_srt_RangeMember_dc882962-c28c-4f24-8152-9dba6f9e59c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a44aa53b-be73-40b3-8d5a-94d0cb997533" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dc882962-c28c-4f24-8152-9dba6f9e59c9" xlink:to="loc_srt_RangeMember_a44aa53b-be73-40b3-8d5a-94d0cb997533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9e91cfdc-6cc5-4b4d-b760-2cf013ee322d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a44aa53b-be73-40b3-8d5a-94d0cb997533" xlink:to="loc_srt_MinimumMember_9e91cfdc-6cc5-4b4d-b760-2cf013ee322d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d38d319-067c-45d5-ac7c-963e86bd233f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a44aa53b-be73-40b3-8d5a-94d0cb997533" xlink:to="loc_srt_MaximumMember_2d38d319-067c-45d5-ac7c-963e86bd233f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ddc6ffa8-384e-4fad-b560-1330a4e12e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ddc6ffa8-384e-4fad-b560-1330a4e12e53" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ddc6ffa8-384e-4fad-b560-1330a4e12e53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ddc6ffa8-384e-4fad-b560-1330a4e12e53" xlink:to="loc_us-gaap_EquityComponentDomain_ddc6ffa8-384e-4fad-b560-1330a4e12e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a42b5240-aab7-4f1f-9d02-a8a98b5d8008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ddc6ffa8-384e-4fad-b560-1330a4e12e53" xlink:to="loc_us-gaap_EquityComponentDomain_a42b5240-aab7-4f1f-9d02-a8a98b5d8008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_660eef35-0076-4c38-9eed-9da00b5f44f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a42b5240-aab7-4f1f-9d02-a8a98b5d8008" xlink:to="loc_us-gaap_CommonStockMember_660eef35-0076-4c38-9eed-9da00b5f44f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended" id="i79ff665832674e8e8fee3180749fa9e0_DebtSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5f712b5b-f41c-4af9-ba7b-a5b2db665766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f712b5b-f41c-4af9-ba7b-a5b2db665766" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_36aa876f-586c-42db-a559-6ac4c2344031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_36aa876f-586c-42db-a559-6ac4c2344031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9790652c-1753-4200-b06d-c980f04714e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9790652c-1753-4200-b06d-c980f04714e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_ea24152f-5573-4c39-a5cf-5fbe2cc8cbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:to="loc_us-gaap_DeferredOfferingCosts_ea24152f-5573-4c39-a5cf-5fbe2cc8cbaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_546a1e85-a09f-4d6b-9886-b3140e758dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:to="loc_us-gaap_LongTermDebt_546a1e85-a09f-4d6b-9886-b3140e758dfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_07ff7296-bce7-47d7-9bd4-0c5067da6186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f712b5b-f41c-4af9-ba7b-a5b2db665766" xlink:to="loc_us-gaap_DebtInstrumentTable_07ff7296-bce7-47d7-9bd4-0c5067da6186" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f1149d18-b170-4dce-90f9-213d0a8bbb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07ff7296-bce7-47d7-9bd4-0c5067da6186" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f1149d18-b170-4dce-90f9-213d0a8bbb7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f1149d18-b170-4dce-90f9-213d0a8bbb7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1149d18-b170-4dce-90f9-213d0a8bbb7c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f1149d18-b170-4dce-90f9-213d0a8bbb7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_edf5ada1-c226-4885-b70a-c053536490ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1149d18-b170-4dce-90f9-213d0a8bbb7c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_edf5ada1-c226-4885-b70a-c053536490ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_37a8fea4-a03e-478e-b4d5-b6579d56e05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_edf5ada1-c226-4885-b70a-c053536490ff" xlink:to="loc_us-gaap_ConvertibleDebtMember_37a8fea4-a03e-478e-b4d5-b6579d56e05e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e84431cf-b2ad-4546-b6db-b3e1dc505015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07ff7296-bce7-47d7-9bd4-0c5067da6186" xlink:to="loc_us-gaap_DebtInstrumentAxis_e84431cf-b2ad-4546-b6db-b3e1dc505015" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e84431cf-b2ad-4546-b6db-b3e1dc505015_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e84431cf-b2ad-4546-b6db-b3e1dc505015" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e84431cf-b2ad-4546-b6db-b3e1dc505015_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ae7ce6b9-a52e-459b-b51e-3e10a8fbac73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e84431cf-b2ad-4546-b6db-b3e1dc505015" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ae7ce6b9-a52e-459b-b51e-3e10a8fbac73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_17c3b93d-7772-4a3b-8c78-6ad64ca190b3" xlink:href="fold-20211231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ae7ce6b9-a52e-459b-b51e-3e10a8fbac73" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_17c3b93d-7772-4a3b-8c78-6ad64ca190b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_53f261e7-1860-414a-a6a5-37004759a2fd" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ae7ce6b9-a52e-459b-b51e-3e10a8fbac73" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_53f261e7-1860-414a-a6a5-37004759a2fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended" id="i465d56c756724d50bbac713acf43932a_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0e17bf2c-b777-49b3-a7b3-1c9fcd10ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e17bf2c-b777-49b3-a7b3-1c9fcd10ef8b" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4cba314b-65c3-4141-ad9b-5b4367cba43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4cba314b-65c3-4141-ad9b-5b4367cba43a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentVariableRate_fd43ab0b-8013-4d81-8e91-29aaaa366fd1" xlink:href="fold-20211231.xsd#fold_DebtInstrumentVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentVariableRate_fd43ab0b-8013-4d81-8e91-29aaaa366fd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_af1b767e-82ce-477e-b4c8-57e45a0bb90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_af1b767e-82ce-477e-b4c8-57e45a0bb90d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_d048b8ca-400f-4650-9ca3-a84f8d24a026" xlink:href="fold-20211231.xsd#fold_DebtInstrumentPeriodicPaymentNumberOfPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_d048b8ca-400f-4650-9ca3-a84f8d24a026" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_2aff818d-3c9f-4bd5-88cd-909bcf8d5c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_2aff818d-3c9f-4bd5-88cd-909bcf8d5c89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_56ef99fe-e3bf-43dc-90d6-27ccaa6116ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSecuredLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_56ef99fe-e3bf-43dc-90d6-27ccaa6116ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_59d134d3-ee17-4bec-9047-b8805f9978d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_InterestExpenseDebt_59d134d3-ee17-4bec-9047-b8805f9978d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EarlySettlementPremiums_9bff61e9-984b-462f-aa0d-8fa0ed25eb7e" xlink:href="fold-20211231.xsd#fold_EarlySettlementPremiums"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_EarlySettlementPremiums_9bff61e9-984b-462f-aa0d-8fa0ed25eb7e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_656658d2-d339-4a46-bc35-b99a3e3c1b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_656658d2-d339-4a46-bc35-b99a3e3c1b72" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount_4a31ff89-19ff-4224-80dc-952d0a5105a2" xlink:href="fold-20211231.xsd#fold_DebtInstrumentLiquidityCovenantMinimumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount_4a31ff89-19ff-4224-80dc-952d0a5105a2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_49dbbead-59c7-4b51-8cb4-a444b7ae272f" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConsolidatedRevenueCovenantAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_49dbbead-59c7-4b51-8cb4-a444b7ae272f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5aeb3645-4169-4b2e-879b-ff3342aaa6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5aeb3645-4169-4b2e-879b-ff3342aaa6a5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1593cb4f-b66f-44f0-a71e-d486e1cbf88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1593cb4f-b66f-44f0-a71e-d486e1cbf88c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PremiumsPaidForCappedCallConfirmations_1c8e44f8-add3-42ec-a670-18337ba3ab81" xlink:href="fold-20211231.xsd#fold_PremiumsPaidForCappedCallConfirmations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_PremiumsPaidForCappedCallConfirmations_1c8e44f8-add3-42ec-a670-18337ba3ab81" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_9b54dee7-4694-4e52-afcc-5a7e50533c58" xlink:href="fold-20211231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_9b54dee7-4694-4e52-afcc-5a7e50533c58" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_de167f9d-3905-46a3-85d4-6860846c94d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_de167f9d-3905-46a3-85d4-6860846c94d8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7285ecab-58c2-4c48-a7f6-e950654744c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7285ecab-58c2-4c48-a7f6-e950654744c5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_a89cb4b5-7e30-48c0-a644-b3659676ed64" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_a89cb4b5-7e30-48c0-a644-b3659676ed64" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_ce0e07e5-b15f-43ba-ba39-0b2943b1f405" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_ce0e07e5-b15f-43ba-ba39-0b2943b1f405" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b52f2e0e-3b55-418c-8b1a-5a70720a4329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b52f2e0e-3b55-418c-8b1a-5a70720a4329" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_814ac992-dbb2-4a72-a713-f59e63e36cb6" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_814ac992-dbb2-4a72-a713-f59e63e36cb6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ed4c8743-abe2-4fd3-b150-16c01965f2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ed4c8743-abe2-4fd3-b150-16c01965f2cd" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_0a155dfe-390d-4727-a67b-f51d6ea0d1c8" xlink:href="fold-20211231.xsd#fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_0a155dfe-390d-4727-a67b-f51d6ea0d1c8" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExchangeOfDebt_3f439835-35c5-4c33-9e7b-8b36780ba114" xlink:href="fold-20211231.xsd#fold_GainLossOnExchangeOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_GainLossOnExchangeOfDebt_3f439835-35c5-4c33-9e7b-8b36780ba114" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_b747fc27-0463-4c86-b191-40b49e5d7ec5" xlink:href="fold-20211231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_b747fc27-0463-4c86-b191-40b49e5d7ec5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4236958c-5996-46df-b5ea-a9d4f5c70249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4236958c-5996-46df-b5ea-a9d4f5c70249" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_eedb5cfa-66d9-4066-bc38-71de6bbd5927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_eedb5cfa-66d9-4066-bc38-71de6bbd5927" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e17bf2c-b777-49b3-a7b3-1c9fcd10ef8b" xlink:to="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bc43726d-aedc-4ab6-b363-80dc3271bb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_CreditFacilityAxis_bc43726d-aedc-4ab6-b363-80dc3271bb8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bc43726d-aedc-4ab6-b363-80dc3271bb8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_bc43726d-aedc-4ab6-b363-80dc3271bb8b" xlink:to="loc_us-gaap_CreditFacilityDomain_bc43726d-aedc-4ab6-b363-80dc3271bb8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8b0709db-6ad3-4d08-9d7f-229588ff59e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_bc43726d-aedc-4ab6-b363-80dc3271bb8b" xlink:to="loc_us-gaap_CreditFacilityDomain_8b0709db-6ad3-4d08-9d7f-229588ff59e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2dd2fc71-4a9f-4edb-97ba-c097cfbcdc30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8b0709db-6ad3-4d08-9d7f-229588ff59e5" xlink:to="loc_us-gaap_SecuredDebtMember_2dd2fc71-4a9f-4edb-97ba-c097cfbcdc30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_64c7c6c2-6f61-43e9-8c8b-d51b8117dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8b0709db-6ad3-4d08-9d7f-229588ff59e5" xlink:to="loc_us-gaap_LineOfCreditMember_64c7c6c2-6f61-43e9-8c8b-d51b8117dd22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_969e864c-6d60-4f94-a43e-42dab6ff76c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_969e864c-6d60-4f94-a43e-42dab6ff76c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_969e864c-6d60-4f94-a43e-42dab6ff76c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_969e864c-6d60-4f94-a43e-42dab6ff76c8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_969e864c-6d60-4f94-a43e-42dab6ff76c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a1cfb399-08a8-4af8-9313-cd3ca7fa6125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_969e864c-6d60-4f94-a43e-42dab6ff76c8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a1cfb399-08a8-4af8-9313-cd3ca7fa6125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_25b00e2c-d5a7-455c-ae85-a2c9dee6b184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a1cfb399-08a8-4af8-9313-cd3ca7fa6125" xlink:to="loc_us-gaap_SeniorLoansMember_25b00e2c-d5a7-455c-ae85-a2c9dee6b184" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_16f8bf6c-fbcc-4797-8660-03e2ee01be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a1cfb399-08a8-4af8-9313-cd3ca7fa6125" xlink:to="loc_us-gaap_ConvertibleDebtMember_16f8bf6c-fbcc-4797-8660-03e2ee01be4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_71b94789-9261-414e-96e4-cc505f88a509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_VariableRateAxis_71b94789-9261-414e-96e4-cc505f88a509" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_71b94789-9261-414e-96e4-cc505f88a509_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_71b94789-9261-414e-96e4-cc505f88a509" xlink:to="loc_us-gaap_VariableRateDomain_71b94789-9261-414e-96e4-cc505f88a509_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_253847c8-f891-4760-a2e3-2e26ca0af639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_71b94789-9261-414e-96e4-cc505f88a509" xlink:to="loc_us-gaap_VariableRateDomain_253847c8-f891-4760-a2e3-2e26ca0af639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a26d3b28-d1fe-4cc2-bb32-b749c1e321b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_253847c8-f891-4760-a2e3-2e26ca0af639" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a26d3b28-d1fe-4cc2-bb32-b749c1e321b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_432917f4-3c0b-4fca-a115-4e9ef206d501" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_srt_RangeAxis_432917f4-3c0b-4fca-a115-4e9ef206d501" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_432917f4-3c0b-4fca-a115-4e9ef206d501_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_432917f4-3c0b-4fca-a115-4e9ef206d501" xlink:to="loc_srt_RangeMember_432917f4-3c0b-4fca-a115-4e9ef206d501_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dea5cf4b-22a0-4e6e-ba9d-8875293ab3ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_432917f4-3c0b-4fca-a115-4e9ef206d501" xlink:to="loc_srt_RangeMember_dea5cf4b-22a0-4e6e-ba9d-8875293ab3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6cf24f05-2364-41fc-8ee3-212515b31db1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dea5cf4b-22a0-4e6e-ba9d-8875293ab3ea" xlink:to="loc_srt_MinimumMember_6cf24f05-2364-41fc-8ee3-212515b31db1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d34f7f31-7086-476f-8377-9d9b1861698b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dea5cf4b-22a0-4e6e-ba9d-8875293ab3ea" xlink:to="loc_srt_MaximumMember_d34f7f31-7086-476f-8377-9d9b1861698b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2302ccee-b71e-42e4-aa3f-3cc51ab3e132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_DebtInstrumentAxis_2302ccee-b71e-42e4-aa3f-3cc51ab3e132" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2302ccee-b71e-42e4-aa3f-3cc51ab3e132_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2302ccee-b71e-42e4-aa3f-3cc51ab3e132" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2302ccee-b71e-42e4-aa3f-3cc51ab3e132_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0873abd7-76bb-4faf-b1c5-79a838332bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2302ccee-b71e-42e4-aa3f-3cc51ab3e132" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0873abd7-76bb-4faf-b1c5-79a838332bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_e31f94f8-f222-4e0f-8ac3-5a4090284b47" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0873abd7-76bb-4faf-b1c5-79a838332bf1" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_e31f94f8-f222-4e0f-8ac3-5a4090284b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_1ce3ceb5-2166-431c-9f4a-93aa3e0a4c38" xlink:href="fold-20211231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0873abd7-76bb-4faf-b1c5-79a838332bf1" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_1ce3ceb5-2166-431c-9f4a-93aa3e0a4c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ba55e2ad-ed4a-4319-9167-e9a5a690fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ba55e2ad-ed4a-4319-9167-e9a5a690fc6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba55e2ad-ed4a-4319-9167-e9a5a690fc6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ba55e2ad-ed4a-4319-9167-e9a5a690fc6e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba55e2ad-ed4a-4319-9167-e9a5a690fc6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8593ede4-9f74-4baa-ad34-25e45674144a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ba55e2ad-ed4a-4319-9167-e9a5a690fc6e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8593ede4-9f74-4baa-ad34-25e45674144a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PrivatePlacementPurchaseAgreementMember_6a650f04-e001-4ab1-8e07-afd1e0ed81e1" xlink:href="fold-20211231.xsd#fold_PrivatePlacementPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8593ede4-9f74-4baa-ad34-25e45674144a" xlink:to="loc_fold_PrivatePlacementPurchaseAgreementMember_6a650f04-e001-4ab1-8e07-afd1e0ed81e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f99db92f-1f04-49db-9b2d-6e1bfd1b3bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f99db92f-1f04-49db-9b2d-6e1bfd1b3bdb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f99db92f-1f04-49db-9b2d-6e1bfd1b3bdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f99db92f-1f04-49db-9b2d-6e1bfd1b3bdb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f99db92f-1f04-49db-9b2d-6e1bfd1b3bdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa0201ca-fd45-473b-8e06-ded107fc6d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f99db92f-1f04-49db-9b2d-6e1bfd1b3bdb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa0201ca-fd45-473b-8e06-ded107fc6d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_94531bb4-898f-47d8-a508-9ffb6f608bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa0201ca-fd45-473b-8e06-ded107fc6d39" xlink:to="loc_us-gaap_OverAllotmentOptionMember_94531bb4-898f-47d8-a508-9ffb6f608bac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c9dc6a51-6844-4d5a-b9df-49d919da59ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c9dc6a51-6844-4d5a-b9df-49d919da59ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c9dc6a51-6844-4d5a-b9df-49d919da59ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c9dc6a51-6844-4d5a-b9df-49d919da59ab" xlink:to="loc_us-gaap_EquityComponentDomain_c9dc6a51-6844-4d5a-b9df-49d919da59ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_739772ed-e7e7-4045-8b93-030c50221d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c9dc6a51-6844-4d5a-b9df-49d919da59ab" xlink:to="loc_us-gaap_EquityComponentDomain_739772ed-e7e7-4045-8b93-030c50221d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4762b261-a380-4979-ad0d-8e20a8c9abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_739772ed-e7e7-4045-8b93-030c50221d23" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4762b261-a380-4979-ad0d-8e20a8c9abbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2df357c3-3d06-407b-86f7-a0d6f6e12875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_739772ed-e7e7-4045-8b93-030c50221d23" xlink:to="loc_us-gaap_CommonStockMember_2df357c3-3d06-407b-86f7-a0d6f6e12875" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#DebtInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended" id="i260585135ad24bbebe8129c1ffbbd430_DebtInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_265583d4-52bb-4c1f-a361-483d723b5742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_265583d4-52bb-4c1f-a361-483d723b5742" xlink:to="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_93b4207d-053d-4e77-a186-932cbf88dd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_93b4207d-053d-4e77-a186-932cbf88dd9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_3f38161e-0c8e-45fc-8865-b7eb3d3b18b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_3f38161e-0c8e-45fc-8865-b7eb3d3b18b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_a341acbc-88b9-4828-8352-ca2cf64ea395" xlink:href="fold-20211231.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:to="loc_fold_AmortizationDeferredFinancingCosts_a341acbc-88b9-4828-8352-ca2cf64ea395" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_044fef09-24c6-4926-9926-50dee94352e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_044fef09-24c6-4926-9926-50dee94352e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_87f2ad2f-2e74-408b-a872-b30547888b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_265583d4-52bb-4c1f-a361-483d723b5742" xlink:to="loc_us-gaap_DebtInstrumentTable_87f2ad2f-2e74-408b-a872-b30547888b95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3af95d70-9b85-4c9a-b990-27061533ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87f2ad2f-2e74-408b-a872-b30547888b95" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3af95d70-9b85-4c9a-b990-27061533ceca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3af95d70-9b85-4c9a-b990-27061533ceca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3af95d70-9b85-4c9a-b990-27061533ceca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3af95d70-9b85-4c9a-b990-27061533ceca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a9e8616b-4a06-4deb-bc6b-ab7584218be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3af95d70-9b85-4c9a-b990-27061533ceca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a9e8616b-4a06-4deb-bc6b-ab7584218be9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_20da0da8-5e3e-4be5-8bc2-b1d0c688c902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a9e8616b-4a06-4deb-bc6b-ab7584218be9" xlink:to="loc_us-gaap_ConvertibleDebtMember_20da0da8-5e3e-4be5-8bc2-b1d0c688c902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fe981fa8-804c-4ed8-98a9-b72f96b7be71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a9e8616b-4a06-4deb-bc6b-ab7584218be9" xlink:to="loc_us-gaap_SeniorNotesMember_fe981fa8-804c-4ed8-98a9-b72f96b7be71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5af2caa2-3cf7-4922-81d6-4d557e25d638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87f2ad2f-2e74-408b-a872-b30547888b95" xlink:to="loc_us-gaap_DebtInstrumentAxis_5af2caa2-3cf7-4922-81d6-4d557e25d638" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5af2caa2-3cf7-4922-81d6-4d557e25d638_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5af2caa2-3cf7-4922-81d6-4d557e25d638" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5af2caa2-3cf7-4922-81d6-4d557e25d638_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d37a1c53-d865-498a-8122-eff3d3429095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5af2caa2-3cf7-4922-81d6-4d557e25d638" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d37a1c53-d865-498a-8122-eff3d3429095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_abe1201a-9ca5-4ab4-9e52-2dfcf3b16668" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d37a1c53-d865-498a-8122-eff3d3429095" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_abe1201a-9ca5-4ab4-9e52-2dfcf3b16668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_df502923-c034-4675-8653-58b62bcc5e2b" xlink:href="fold-20211231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d37a1c53-d865-498a-8122-eff3d3429095" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_df502923-c034-4675-8653-58b62bcc5e2b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#IncomeTaxesLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="extended" id="i75c557c8ea834eaea6ed4c3f11ed8743_IncomeTaxesLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_754873b7-723c-4207-9f3a-499ce11535ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_fd579987-237b-440b-911b-6a4157337d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_754873b7-723c-4207-9f3a-499ce11535ec" xlink:to="loc_us-gaap_OperatingLossCarryforwards_fd579987-237b-440b-911b-6a4157337d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_25efeb6d-6ecb-4987-aeca-eadf287284e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_754873b7-723c-4207-9f3a-499ce11535ec" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_25efeb6d-6ecb-4987-aeca-eadf287284e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_fd9080eb-5d18-4036-abf0-801256ff18b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_754873b7-723c-4207-9f3a-499ce11535ec" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_fd9080eb-5d18-4036-abf0-801256ff18b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_bf14403d-d1e8-4c68-9c28-8d9e5a0817c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fd9080eb-5d18-4036-abf0-801256ff18b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_bf14403d-d1e8-4c68-9c28-8d9e5a0817c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bf14403d-d1e8-4c68-9c28-8d9e5a0817c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_bf14403d-d1e8-4c68-9c28-8d9e5a0817c6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bf14403d-d1e8-4c68-9c28-8d9e5a0817c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d5fb7b57-562e-4bf6-b8a7-aa5f449d6fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_bf14403d-d1e8-4c68-9c28-8d9e5a0817c6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d5fb7b57-562e-4bf6-b8a7-aa5f449d6fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a7cd6fb3-6b95-4093-bc93-d6927f224609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d5fb7b57-562e-4bf6-b8a7-aa5f449d6fb3" xlink:to="loc_us-gaap_DomesticCountryMember_a7cd6fb3-6b95-4093-bc93-d6927f224609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_77d7bd8d-55e0-49d7-9cdf-2c644ea68097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d5fb7b57-562e-4bf6-b8a7-aa5f449d6fb3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_77d7bd8d-55e0-49d7-9cdf-2c644ea68097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5a9dd8fb-0f16-41e6-9523-7c5081b17cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fd9080eb-5d18-4036-abf0-801256ff18b3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_5a9dd8fb-0f16-41e6-9523-7c5081b17cac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_5a9dd8fb-0f16-41e6-9523-7c5081b17cac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5a9dd8fb-0f16-41e6-9523-7c5081b17cac" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_5a9dd8fb-0f16-41e6-9523-7c5081b17cac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0d6f5f6-d356-4cce-9949-a5553eea217b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5a9dd8fb-0f16-41e6-9523-7c5081b17cac" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0d6f5f6-d356-4cce-9949-a5553eea217b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_69a79a7f-2efd-4118-b452-78d1b5a9167b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0d6f5f6-d356-4cce-9949-a5553eea217b" xlink:to="loc_us-gaap_ResearchMember_69a79a7f-2efd-4118-b452-78d1b5a9167b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OrphanDrugTaxCreditCarryforwardMember_616415c1-af83-466d-b5e3-6c57038ec138" xlink:href="fold-20211231.xsd#fold_OrphanDrugTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0d6f5f6-d356-4cce-9949-a5553eea217b" xlink:to="loc_fold_OrphanDrugTaxCreditCarryforwardMember_616415c1-af83-466d-b5e3-6c57038ec138" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="i38a76f3cbffc4d33afd4ef91ae07aa15_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_39e1dc84-5d8a-4cf1-beb3-af982459cc24" xlink:href="fold-20211231.xsd#fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_39e1dc84-5d8a-4cf1-beb3-af982459cc24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborationAgreementAnnualContributionByCompany_fc828ec8-5c42-4c7e-af2e-27e575645f8c" xlink:href="fold-20211231.xsd#fold_CollaborationAgreementAnnualContributionByCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_CollaborationAgreementAnnualContributionByCompany_fc828ec8-5c42-4c7e-af2e-27e575645f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeAgreementTermOfAgreement_2d57d501-dd78-4190-a6cd-0d6b5849ba35" xlink:href="fold-20211231.xsd#fold_CollaborativeAgreementTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_CollaborativeAgreementTermOfAgreement_2d57d501-dd78-4190-a6cd-0d6b5849ba35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForCollaborativeArrangement_af4d7118-b1e4-4538-9e22-200d904b18f4" xlink:href="fold-20211231.xsd#fold_PaymentsForCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_PaymentsForCollaborativeArrangement_af4d7118-b1e4-4538-9e22-200d904b18f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_03cac6b5-d63e-412f-a2d9-aa95646ec757" xlink:href="fold-20211231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_03cac6b5-d63e-412f-a2d9-aa95646ec757" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_8e8c7dbe-3a83-4ef1-b9d1-ff3e2c4c9eca" xlink:href="fold-20211231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_8e8c7dbe-3a83-4ef1-b9d1-ff3e2c4c9eca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7c0dbfa7-8899-4ca0-99ed-42fa80135786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7c0dbfa7-8899-4ca0-99ed-42fa80135786" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_3fe64d46-d581-4ae9-ad47-fe626efdae89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_3fe64d46-d581-4ae9-ad47-fe626efdae89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_09f9cbaa-52f1-4b14-aec7-f4af085499a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_09f9cbaa-52f1-4b14-aec7-f4af085499a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c7e0f71-12eb-43c2-882b-e64c75a9de1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c7e0f71-12eb-43c2-882b-e64c75a9de1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ed57c30e-9bd0-481e-89e6-bb6608e74db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c7e0f71-12eb-43c2-882b-e64c75a9de1c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ed57c30e-9bd0-481e-89e6-bb6608e74db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed57c30e-9bd0-481e-89e6-bb6608e74db6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ed57c30e-9bd0-481e-89e6-bb6608e74db6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed57c30e-9bd0-481e-89e6-bb6608e74db6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0955a609-a5f6-40f4-b088-fcec2091d8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ed57c30e-9bd0-481e-89e6-bb6608e74db6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0955a609-a5f6-40f4-b088-fcec2091d8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5d440c5f-0764-4e29-8903-916213bd4ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0955a609-a5f6-40f4-b088-fcec2091d8f5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5d440c5f-0764-4e29-8903-916213bd4ed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_RevisedCollaborationAgreementMember_9640ea74-691c-4ae7-b59c-81877d82698d" xlink:href="fold-20211231.xsd#fold_RevisedCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0955a609-a5f6-40f4-b088-fcec2091d8f5" xlink:to="loc_fold_RevisedCollaborationAgreementMember_9640ea74-691c-4ae7-b59c-81877d82698d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f57440f0-662d-434a-b5b9-142c055629ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c7e0f71-12eb-43c2-882b-e64c75a9de1c" xlink:to="loc_srt_CounterpartyNameAxis_f57440f0-662d-434a-b5b9-142c055629ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f57440f0-662d-434a-b5b9-142c055629ba_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f57440f0-662d-434a-b5b9-142c055629ba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f57440f0-662d-434a-b5b9-142c055629ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0e9f214-0645-4849-8042-ef6344513ed2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f57440f0-662d-434a-b5b9-142c055629ba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0e9f214-0645-4849-8042-ef6344513ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GlaxoSmithKlinePLCMember_a8032f94-f657-436e-9a25-2d35dc51f954" xlink:href="fold-20211231.xsd#fold_GlaxoSmithKlinePLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0e9f214-0645-4849-8042-ef6344513ed2" xlink:to="loc_fold_GlaxoSmithKlinePLCMember_a8032f94-f657-436e-9a25-2d35dc51f954" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended" id="i418e24d1882744b5977ca41b60520ae2_BasicandDilutedNetLossperCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f96240ad-9eb3-4053-9292-7989e8dcf193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_458bbe12-8d94-4f30-8304-763562db9501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f96240ad-9eb3-4053-9292-7989e8dcf193" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_458bbe12-8d94-4f30-8304-763562db9501" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ba536fe5-ced7-4c8e-82d4-0ff828d64787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f96240ad-9eb3-4053-9292-7989e8dcf193" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ba536fe5-ced7-4c8e-82d4-0ff828d64787" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbd3567b-0113-4a70-b96d-fa607cbdeb83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ba536fe5-ced7-4c8e-82d4-0ff828d64787" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbd3567b-0113-4a70-b96d-fa607cbdeb83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fbd3567b-0113-4a70-b96d-fa607cbdeb83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbd3567b-0113-4a70-b96d-fa607cbdeb83" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fbd3567b-0113-4a70-b96d-fa607cbdeb83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbd3567b-0113-4a70-b96d-fa607cbdeb83" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b8833a02-d6de-454e-8344-888556cc8292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b8833a02-d6de-454e-8344-888556cc8292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a81f284d-f2b8-44ab-9d77-45513df45820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a81f284d-f2b8-44ab-9d77-45513df45820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_199ca76f-a239-4d8b-bc20-867b1beda2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:to="loc_us-gaap_WarrantMember_199ca76f-a239-4d8b-bc20-867b1beda2db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_82799194-2d47-43b4-b799-4237071c57a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_82799194-2d47-43b4-b799-4237071c57a5" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>fold-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:420dc514-3d5c-42ec-9084-f88f3b76faf7,g:716e386a-5032-46b5-a55b-0ba5d954afee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_ae1d1724-e40f-4264-ba44-a477944d4d53_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_8c20a560-6b3b-4112-a823-6a0d4fcbde88_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross cash proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_d97d7db3-9db1-47ab-a3c5-3222f2c764ee_terseLabel_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2026:</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_label_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Due2026 [Member]</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_documentation_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Due2026 Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member" xlink:href="fold-20211231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_SeniorSecuredTermLoanDue2026Member" xlink:to="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_22800625-0325-4c02-8026-890a8a02f356_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8402a708-a17f-4882-a73e-8e150713426e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_227cc062-9ade-4857-bf34-51e2cd7b52c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_32d01d05-7eff-442d-8d43-97b6983e8ff7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_438c4242-016f-4a5d-8c13-de594019bc8e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7710f050-8f21-4685-8466-249bc90cf190_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4017bdef-c24b-4923-aa09-a91946ab290f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested and non-vested units expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8a359528-c94c-4264-b765-b49504a85739_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59a1c7d4-0a6d-4aec-95ca-da8b3c2f4d19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2a721d3b-7916-4383-8d81-4c110815c0e6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4d34455a-992b-4066-9b02-cf9b426da82d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4167a67f-2406-4e10-8c39-67f09c17827f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a76dedba-fb46-435c-9ae3-6097a283453b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_bd1a1269-e1f5-4b92-907d-1e5b6511db58_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2a3b24e3-51b4-47ee-8912-033473977fcf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_24eff42f-3837-4533-9d8c-eebb5de4ad55_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_813a2db9-1cf5-45f4-bf17-4b2d244b41e6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_679ee995-021f-4489-9279-569213b2dc4e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_738bb8b1-4941-446d-8a5a-4b2753ef7abc_terseLabel_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_documentation_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:href="fold-20211231.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:to="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_36008fc4-b35a-43d7-bbc4-970ecdf2b421_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: deferred financing</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bd265431-d646-4b50-a229-4e2bfbfc4260_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_623de10d-c84d-4817-a7b9-a3dcc85a1bd2_terseLabel_en-US" xlink:label="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing&#160;&amp; contract research costs</link:label>
    <link:label id="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_label_en-US" xlink:label="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Manufacturing and Contract Research Costs Current</link:label>
    <link:label id="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_documentation_en-US" xlink:label="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:href="fold-20211231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:to="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c896dc15-433f-43f4-9d9b-32e530c044a3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_26a3e93e-2885-4363-a6c6-b4eda175b8a5_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_label_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationMeasurementInput" xlink:to="lab_fold_ContingentConsiderationMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_4bbf8de0-8fb4-4d34-a7b9-6b9b2975f38d_terseLabel_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability weighted discounted cash flow</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_label_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability Weighted Discounted Cash Flow [Member]</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_documentation_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to valuation technique of probability weighted discounted cash flow.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:href="fold-20211231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:to="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b032500c-0995-430b-aca7-a481709a496c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6719e960-5b41-47b4-943f-cbf2ac12759f_negatedTerseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_54033103-b44c-4fb7-9be9-abe7056a8f1e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cfe110d6-8565-4135-b954-53120c1f6f3f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ea392247-fcf0-4ce0-bdf5-492555b429f9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_c78d1b81-8efd-4632-b2e8-84bf3c3140a2_terseLabel_en-US" xlink:label="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones</link:label>
    <link:label id="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_label_en-US" xlink:label="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Major Markets Outside United States from Whom Parties to Contractual Arrangement is Eligible to Receive Post Approval and Sales Based Milestones</link:label>
    <link:label id="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_documentation_en-US" xlink:label="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:href="fold-20211231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:to="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_aa243c35-45bb-4a10-a1e7-5d93e518aa07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_b44ec381-9a88-41d6-97a3-5f9843c39261_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange agreement, aggregate principal amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:to="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46d3414c-853d-4e16-8d84-65c4093840fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ee779b61-0baf-4632-877b-5da3b2bd8abb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_fedaed51-c99c-43d5-8e33-604f46c40544_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2077dd8f-1f16-4eb7-8a0b-41a5fdb1509a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_da98a77b-e0ae-43c5-8563-f923d4672254_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease terms (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e53b9322-5b5f-40e8-9fdf-6f78f0de0196_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9174eadc-1e93-4f5f-832f-e0fc99a62117_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d884c0d4-2430-4356-9eee-1ee9c4299d84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_36c76c8a-5c00-47e4-b452-96892c5e04cd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_88df19b8-b10a-440c-a77c-8639e24870d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ba51d5af-87f3-4733-9e71-4afac5bfbe4c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_305f2941-f186-4cc9-995a-5bee82619c34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_18307454-5783-42b0-a3eb-b0f83ca160f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7d90ae8e-e39c-43a2-8139-5cd8881a3ad3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ab5b6972-759e-43dc-8c5f-fce93382ec9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_83234d8e-8217-4195-b7ad-7061a883fb1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_720cbfb7-30dc-4b8d-8a78-472a8d27ac5d_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value during the period, included in the Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_MilestonePaymentStockIssuedAsConsideration_42e5945a-a707-4b12-9390-43fd7ab3fe97_terseLabel_en-US" xlink:label="lab_fold_MilestonePaymentStockIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment, stock issued as consideration</link:label>
    <link:label id="lab_fold_MilestonePaymentStockIssuedAsConsideration_label_en-US" xlink:label="lab_fold_MilestonePaymentStockIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment, Stock Issued As Consideration</link:label>
    <link:label id="lab_fold_MilestonePaymentStockIssuedAsConsideration_documentation_en-US" xlink:label="lab_fold_MilestonePaymentStockIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment, Stock Issued As Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration" xlink:href="fold-20211231.xsd#fold_MilestonePaymentStockIssuedAsConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MilestonePaymentStockIssuedAsConsideration" xlink:to="lab_fold_MilestonePaymentStockIssuedAsConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_49d8132f-8f65-4b49-933f-0d5ad2d14327_terseLabel_en-US" xlink:label="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense</link:label>
    <link:label id="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_label_en-US" xlink:label="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense [Policy Text Block]</link:label>
    <link:label id="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_documentation_en-US" xlink:label="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for interest income and interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:href="fold-20211231.xsd#fold_InterestIncomeAndInterestExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:to="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_782da86e-a314-4340-b323-543d22d96827_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_74846726-6a41-4f92-8108-88cd005e3ec9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive gain (loss):</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_530e9019-d3e0-4eac-8812-450db13680ca_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_593fe13e-e0ad-4bdf-aae3-6f11f197cdc9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_da993c82-6c78-4333-9e7e-0329ae0eaa9a_terseLabel_en-US" xlink:label="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Policy [Policy Text Block]</link:label>
    <link:label id="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:href="fold-20211231.xsd#fold_OtherComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f288ac0b-3553-4130-bc47-58c1bf69f7af_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7a2bfe4a-029b-493a-9042-5737e8708f33_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_13a68439-4a97-4a63-9f3d-c2affd813468_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_97879048-c474-45a1-a046-e661da33a99c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories for the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a6d9f552-84c7-463c-8486-386b02d321e5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8e147ffc-a89b-42ec-ad76-00ee01f1f5c2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_9a59d906-bc74-4d56-ac5e-2f2f2f82aab7_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_188ec62e-d29a-49e7-98f7-07861203da2c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59fa0bb7-6de8-4ccf-9abe-eff313609608_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_089defa1-0c31-483a-9836-2e2ea68cbae0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract" xlink:to="lab_us-gaap_DebtInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_RevisedCollaborationAgreementMember_05c38aa0-4b25-4a51-81de-a1bc3c1f11fd_terseLabel_en-US" xlink:label="lab_fold_RevisedCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revised Agreement</link:label>
    <link:label id="lab_fold_RevisedCollaborationAgreementMember_label_en-US" xlink:label="lab_fold_RevisedCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revised Collaboration Agreement [Member]</link:label>
    <link:label id="lab_fold_RevisedCollaborationAgreementMember_documentation_en-US" xlink:label="lab_fold_RevisedCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the License and Collaboration Agreement entered into by the entity on November 19, 2013.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_RevisedCollaborationAgreementMember" xlink:href="fold-20211231.xsd#fold_RevisedCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_RevisedCollaborationAgreementMember" xlink:to="lab_fold_RevisedCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_3bb8f715-4d6d-4871-8823-f03f0d42ee42_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_9d93bdf4-4c8d-4a0f-a539-07aafd5b0977_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1fe7b52-a8ca-4f4c-b29e-b4f2d0bf3f8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_7f87606b-5e03-43e1-9ef3-bc5af2327499_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability Components of the Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_85dc84e8-98a5-432b-b8e2-29bf5e0c22b4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_643e622e-352e-4a45-bc8e-41378b0e2611_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_b8f8d363-6efc-477b-88df-baf89a1a7acc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contingent Consideration Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f35c1cb7-0b67-4a74-979a-3dbdc2c9834b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_47704857-3a23-46e7-852f-befa34692a00_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payable</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Royalty Payable</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from royalty payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:to="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8c2ce030-5709-45c2-bb52-b179c8a60258_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_07982247-f941-4b70-a917-5481d4b35a35_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_557392b3-64f5-46e6-a0a3-b79465636e28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_96c3d8f1-a6fa-4042-a4e8-a45846851af8_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a2a163ae-6341-4cad-a7d5-e82917db1ae0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest as of the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_eb6cc767-401e-42d1-b24d-5fdeba78f28a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationMilestonePayment_c0a41f86-c091-4211-af0a-906be636f2b7_verboseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, milestone payment</link:label>
    <link:label id="lab_fold_ContingentConsiderationMilestonePayment_label_en-US" xlink:label="lab_fold_ContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Milestone Payment</link:label>
    <link:label id="lab_fold_ContingentConsiderationMilestonePayment_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMilestonePayment" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationMilestonePayment" xlink:to="lab_fold_ContingentConsiderationMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_274df13f-3ace-4716-b577-1d8c6a04c268_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_39f51f09-6b8b-4ca7-83f0-1bab578373ec_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_87d0ed77-9cf2-4950-8316-8c50dfec69b4_negatedTerseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, gross unrealized loss</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="fold-20211231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_88425ed1-853a-4c03-a893-dfa988b20852_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_b44a5e1e-16e5-4052-a5ef-c4fb49d5b132_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b099e27f-9913-4d72-8302-75d6e3bb74f2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03f77607-d6af-4337-9919-8f96ee05dc35_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e3a9233d-0631-40af-9d5d-050221d5b3ca_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_51be183c-42b1-425d-9fa5-e88c3d5f6410_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_38ea2241-b069-44ca-afeb-c6f9ef65f272_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5a98a218-fae3-4548-a109-fd85fcc0a19c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_c13afb03-96c9-4d24-9e75-ca382e015170_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8bd26295-cb75-4953-ac0c-454b02e01762_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_62e33973-2052-4517-a633-489691294a44_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9a13b7fd-81d4-4d0d-b64a-30ab3a6b505b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_5067dc6d-f08e-46fa-b750-962a8741ca25_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and unpaid interest on exchange agreement</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:to="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_ecabf7e0-ff1e-4676-8ad0-04998a63ded5_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ebc2dfec-c833-4d39-87a0-5d65b2a87c34_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtAbstract_9d66f370-980c-4683-a202-574c946ec3b1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtAbstract_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract" xlink:to="lab_us-gaap_InterestExpenseDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a7edbfee-310d-4317-94d0-cccb797aabe5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures unpaid at the end of period</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_4948dc44-536b-4baf-86af-5b529d8db4af_terseLabel_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets and liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_label_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Operating Liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_documentation_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:href="fold-20211231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:to="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2a9fe35f-297f-4eb0-83a2-b0915e386302_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_dbcf4c69-8314-4da7-9c3b-5f6dc4f76796_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly vesting percentage</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_86613882-9fc6-4c04-b744-6301f2eaebcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of the Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d451e5d1-b712-4ea0-a7f7-281d1d5ac952_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4abaa4f6-f947-4b58-b1a7-a5d2d1de4de0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_81a56567-bd9d-482b-ba5a-80701020d3c6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_94de2626-6f30-4c34-9b7f-b9d611d5c688_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_30365e0c-8e0b-45b4-a102-e80b3ab3bbba_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_40072803-58df-4070-9ccf-032a4e9be6a0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0b270f57-3060-4934-ae85-a8530d49e367_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_ca4fdb01-f22f-4d23-ba85-bc7f36ee801b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_48cc3795-16a1-4611-b714-7682e2543bf6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_f265c769-56de-4d94-9364-7521e19b714b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d03f8aba-d22e-4465-a88b-1c9b8e5855f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ed0c7b08-e2c5-4b53-a61f-778025bfeab7_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d3d9e3b-9c15-42cf-9966-d0a532f3bf4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units as of the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_92dda916-8d0c-4ecd-973e-9bc2ef5f7b67_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units as of the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_1caba439-862b-47cd-9bdf-09c60e0bc9a4_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced R&amp;D payments</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Advanced Research and Development Payments</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from advanced Research and Development payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" xlink:to="lab_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_5059d659-2181-4607-bc33-73ef0765eb67_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_a35c2e3e-b5f1-4de4-bb4a-e1e44436f429_terseLabel_en-US" xlink:label="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued per increment of convertible debt (in shares)</link:label>
    <link:label id="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_label_en-US" xlink:label="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued Per Increment Of Convertible Debt</link:label>
    <link:label id="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_documentation_en-US" xlink:label="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:href="fold-20211231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:to="lab_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_54bae8f6-12a9-48c7-ad4a-2677f978d34a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_5ac8b3c7-a142-48cd-9697-7cfcbb72ea9a_terseLabel_en-US" xlink:label="lab_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales rebates and discounts</link:label>
    <link:label id="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_label_en-US" xlink:label="lab_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Rebates And Chargebacks, Current</link:label>
    <link:label id="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_documentation_en-US" xlink:label="lab_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Rebates And Chargebacks, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:href="fold-20211231.xsd#fold_AccruedSalesRebatesAndChargebacksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:to="lab_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_PremiumsPaidForCappedCallConfirmations_121476c3-6b4d-4a7e-8eba-77418fd347e9_terseLabel_en-US" xlink:label="lab_fold_PremiumsPaidForCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds for capped call confirmations</link:label>
    <link:label id="lab_fold_PremiumsPaidForCappedCallConfirmations_label_en-US" xlink:label="lab_fold_PremiumsPaidForCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Paid for Capped Call Confirmations</link:label>
    <link:label id="lab_fold_PremiumsPaidForCappedCallConfirmations_documentation_en-US" xlink:label="lab_fold_PremiumsPaidForCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow for premiums paid for capped call confirmations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PremiumsPaidForCappedCallConfirmations" xlink:href="fold-20211231.xsd#fold_PremiumsPaidForCappedCallConfirmations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PremiumsPaidForCappedCallConfirmations" xlink:to="lab_fold_PremiumsPaidForCappedCallConfirmations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c9bac33a-b402-4d41-8a25-b66108794223_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee withholding taxes related to restricted stock unit vesting</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_0634183c-5700-4527-8f56-8293daf13d70_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ae6b8c5e-a3f6-4425-b85c-e885ab3c2d73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_d0b794c9-5255-40b7-b4ef-b0cfc0290873_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_1a2a085d-0705-4b44-b451-23abeab1a7d3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_bb5f2425-d1fe-458a-a823-58dd45f7a617_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_edc84e13-e695-4f5b-bbc8-0899ea1d6a74_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation investment</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e404ec89-6cad-47cf-86e7-9d29bbe36b1b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_8ecade59-283c-41ff-95f8-f585dae6d7a7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_575ffb94-0131-4573-b9a2-8b1e7991d8f5_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_b4e585cc-1255-4e3b-8f4e-9a0dce9c7962_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a120cfef-4138-49b5-9b6e-a8cedf518c13_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_1baefc50-9f56-4cf6-a736-0d3189676fff_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value of Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6d04d890-7b34-4814-b13a-463d2ea8a71e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c936fb8-6632-4587-8ec2-b2a0e0b2949e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7e7cff11-5735-48e3-9e3b-d98219ef599d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_04d0f3d2-de41-4adf-8706-6c49e1949d44_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24923540-180b-4273-9b1d-f884dcc48510_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_196e5f53-13a8-479e-8428-a0e454a1b6f7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2f8fc1ad-9292-46a7-84fa-89d7457863e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_53815654-d157-4b81-87e5-e03700bff09a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_cc8dcba7-8dfb-4128-9e35-f02b2fe3f6c3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0f6d5576-6957-4e82-bf23-84dc118b6a24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Anniversary</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2123f1e3-b689-46c5-9d0e-234915b81763_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e4c59a82-64bc-4bdb-9d9c-a77594c02e2e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and redemption of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4c00cf23-7eaa-4a35-be04-920c0b9dcfc5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_2abeb085-a4f6-431c-a82f-4652d65ec776_terseLabel_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Convertible Notes</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_label_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes2016 Due2023 [Member]</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_documentation_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:to="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fae04f7b-8566-4dba-9a73-190224be1669_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_aa8cbd50-5983-4dba-aff4-32ae37b5d2df_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements paid through lease incentive</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements" xlink:to="lab_us-gaap_PaymentsForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_783333ce-2b24-40da-ac85-c760453749df_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_a565cfc3-dcdb-40a1-acc5-c12d44522d27_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b24457fd-a404-4f13-bd55-9423684806c3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_d72d7364-8351-4569-9c0f-7337309d78f8_terseLabel_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from termination of capped call confirmations</link:label>
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_label_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</link:label>
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_documentation_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:href="fold-20211231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:to="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_GainLossOnExchangeOfDebt_0ff02fb0-c3bd-4252-b5aa-a40dd517d633_terseLabel_en-US" xlink:label="lab_fold_GainLossOnExchangeOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on exchange of convertible notes</link:label>
    <link:label id="lab_fold_GainLossOnExchangeOfDebt_e5232062-93b1-4422-a855-c6253a678f22_negatedTerseLabel_en-US" xlink:label="lab_fold_GainLossOnExchangeOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on exchange of convertible notes</link:label>
    <link:label id="lab_fold_GainLossOnExchangeOfDebt_label_en-US" xlink:label="lab_fold_GainLossOnExchangeOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Exchange Of Debt</link:label>
    <link:label id="lab_fold_GainLossOnExchangeOfDebt_documentation_en-US" xlink:label="lab_fold_GainLossOnExchangeOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Exchange Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExchangeOfDebt" xlink:href="fold-20211231.xsd#fold_GainLossOnExchangeOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GainLossOnExchangeOfDebt" xlink:to="lab_fold_GainLossOnExchangeOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2cb7ca9e-08dc-4a2d-84e8-23fc4a5c37be_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7dcf3c88-c5b5-431e-9339-ba5aee336f6d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d2f83af5-8dff-48d9-91b6-77ee2302e980_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_dbd00847-42ad-44db-92ae-5b63ee7fec62_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_45c58440-409d-4c81-a7ac-de319e9209a9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5d473806-1a97-48af-b2d2-c648c30761be_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6504c2e7-0e1e-457d-b0dd-b942a8b40c2c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_2e9d8937-959a-4d38-8980-c4ae55455739_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation gain (loss), tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b7c1b134-3976-4044-ae4f-831ade33118f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_26af8a70-d621-41ba-91ac-9644ed861042_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash changes in the fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_29673fef-5f9b-4863-b99b-64a40aeeb217_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_45d14831-73f6-43c5-b577-acdb35448b0b_negatedLabel_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of employee withholding taxes related to restricted stock unit vesting</link:label>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_label_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Repurchase Of Restricted Stock Units</link:label>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_documentation_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow to reacquire restricted stock units during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:href="fold-20211231.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:to="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_98f7d544-11d5-4384-b292-80da82a0dec8_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9d0f86a8-fa0e-4a43-88fe-f679a6424a77_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84b7f922-c946-471e-882f-0daab8f304f3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_bcba161b-5f74-4952-a04b-4458fff94adc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion ratio (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_993420ad-5abf-4110-92cf-2d573ef3cfc6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4fb56c41-f71e-4a71-8d4f-743b0fdfab3e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6d56165a-4793-4c36-bc02-f33b70ed128f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) gain:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_403a8cba-b8ba-421b-b5cf-7c119d424876_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_a8fd1cb7-c983-41ff-9e6a-2f359f4d215d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_cea3b72c-4673-4300-8836-31073f383311_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_682708f1-91c8-4c8e-9004-cbd3b52a5255_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3a0547f1-2365-49c6-b862-799d3ec1a462_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_901cca9c-b1a0-444f-8eec-5f01869c9d8f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4fe37059-2e18-4491-aae2-13e0bd14f3aa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a1da2bee-af80-4fa6-910d-f3840b39a7a0_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_98df16c9-d9d8-4aa4-80d0-73c69e269a43_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued from equity financing</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_834c1720-bb08-4002-a674-e29605362fd4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_9d13d504-8fbe-4b9c-a2c9-387e711566d0_terseLabel_en-US" xlink:label="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_label_en-US" xlink:label="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Warrants And Equity Financing</link:label>
    <link:label id="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_documentation_en-US" xlink:label="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Warrants And Equity Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:href="fold-20211231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:to="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_40c76376-3fbc-41b6-b49e-5a3973f2deb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b29ab991-95e7-4090-8165-92dfbd57d64e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_f30601c2-3f4f-42bc-b6c9-eedee77227a2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d627ec6b-5ce8-4c59-ab62-d74b7062ace0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_ff2ab13d-1c72-4623-abd1-e030e34882e0_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4758f252-ca72-43bf-9f58-d0fdb807d265_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_ceba2c6f-76b9-46b6-9860-a2e4b94e1224_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_1dd44d26-cfd0-4973-a234-26a9681f364b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockExercisesAt798Member_bd771f25-24f3-4d65-824d-5411708f87a1_terseLabel_en-US" xlink:label="lab_fold_StockExercisesAt798Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.98</link:label>
    <link:label id="lab_fold_StockExercisesAt798Member_label_en-US" xlink:label="lab_fold_StockExercisesAt798Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.98 [Member]</link:label>
    <link:label id="lab_fold_StockExercisesAt798Member_documentation_en-US" xlink:label="lab_fold_StockExercisesAt798Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.98</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt798Member" xlink:href="fold-20211231.xsd#fold_StockExercisesAt798Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockExercisesAt798Member" xlink:to="lab_fold_StockExercisesAt798Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_7ba38783-6f89-4881-a026-e2fce2a47fd7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_bcba51bf-8570-477a-ab96-e90c35c1c29f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9a1a4ae2-395f-4b23-8052-7512761c5baa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4619112e-796a-4d80-a22a-36b4c83380ed_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bc055423-38a0-4495-9bab-16fb59ed4da9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c357b2ff-49f5-4fc1-860d-0d3a2bb0375a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued from equity financing (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_f0c4bf50-0c42-479c-a6dd-b5798a88cb20_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AuditInformationAbstract_label_en-US" xlink:label="lab_fold_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_fold_AuditInformationAbstract_documentation_en-US" xlink:label="lab_fold_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AuditInformationAbstract" xlink:href="fold-20211231.xsd#fold_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AuditInformationAbstract" xlink:to="lab_fold_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_848664c9-4f50-47dc-bd6e-b39dfe22c54b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_620e69c9-8c1c-4a79-817f-a04283748891_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4b60c090-7092-47f3-87de-3d8009e72179_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_912ffcec-63cc-4e8e-b295-7568f84abff2_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock issue</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Non Cash Stock Issue Non Current</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carry forwards expected to be realized or consumed within one year or operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:to="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4b0b62e7-1a17-4b7f-8769-a8cceb3936d8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_5a07611c-71cf-4402-ab33-fa1916be723c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Total Interest Expense Recognized Related to the Convertible Notes</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e1cf08c6-1fac-42f9-986f-6c7aa7bda26c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 500,000,000 shares authorized, 278,912,800 and 262,063,461 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_df1b2cf5-41c9-4c5a-8148-869048d9af2b_terseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, gross unrealized gain</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="fold-20211231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_27f73c00-0ac2-4199-bd8d-d99225241aa1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7a2edc43-e7dc-40a5-9909-9fe17c784375_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f303bb63-4bbf-4926-90ca-b705ea1c6ff1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units as of the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_92b9da53-9c70-433c-9355-0d9fd8bc52e5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units as of the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_36df4dc1-6bab-4f4a-9df1-b3250dbce6dc_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2b9e9a08-a795-44fd-963e-577591d9159b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_fd322d0b-547d-4a02-b807-3b8961f00afd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_64533f79-a4ec-41d4-8e85-e6151c4281b8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_UnderwrittenOfferingMember_4a979b7d-aad2-4931-b092-94c63dbc1c83_terseLabel_en-US" xlink:label="lab_fold_UnderwrittenOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Offering</link:label>
    <link:label id="lab_fold_UnderwrittenOfferingMember_label_en-US" xlink:label="lab_fold_UnderwrittenOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Offering [Member]</link:label>
    <link:label id="lab_fold_UnderwrittenOfferingMember_documentation_en-US" xlink:label="lab_fold_UnderwrittenOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_UnderwrittenOfferingMember" xlink:href="fold-20211231.xsd#fold_UnderwrittenOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_UnderwrittenOfferingMember" xlink:to="lab_fold_UnderwrittenOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d176b881-37dc-413d-ad41-67108b79f47d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_a23cb610-f719-47aa-8bb0-7560a678b9c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_eb35777e-d142-412b-bd45-1e6fb5c3b976_terseLabel_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt, fair value of common shares issued</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_label_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_documentation_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:href="fold-20211231.xsd#fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:to="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_fb7b4f8c-0d98-408d-b2e0-134fd1145815_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1682b70a-badd-4595-9df3-3e2d25fbc19b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_81db8e7d-4fee-4aa5-9966-70a56ce1e9aa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_67da87b9-cd51-4b63-beba-94d885fc0ed5_terseLabel_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of capped call confirmations</link:label>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_label_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations</link:label>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_documentation_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from Termination of Capped Call Confirmations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:href="fold-20211231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:to="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_16820e4e-196f-41c5-8149-6923b324ecaa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_39277550-5ac7-4c5b-96a5-543a9b0a4ecc_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_cb96c4eb-90f9-48ce-8c76-2b1d9a5b67e2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3422bc15-fb00-4d2a-9b07-6a4ae3d0cc28_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_3f9fb776-8778-4ea4-b06f-fbc8b55d48e4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Disaggregated by Geographical Area</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1a52eb57-4e4a-4392-bf27-3492a85635ea_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f117cbc8-ecfb-4621-a33a-9fa6fcf62782_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_228584b2-7ecb-4f69-9c18-b8031071709b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_e6480300-f995-474e-945e-1098eede9c14_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_3b36e3f3-62c4-438a-b9df-f655c0521fc6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_21150172-5460-419d-bd30-125e4eb4bb66_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_766c4f86-910f-445d-9a08-223594c5ae57_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4d20b7ed-5bf3-4de6-9990-c19f56dc7a18_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a5935004-21e9-4ec3-9216-1d792c5b12aa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSecuredLinesOfCredit_f93dd285-e728-4f94-be3f-005a5b6c5b7e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from secured lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSecuredLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Secured Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSecuredLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_fb9c721a-de7f-43ab-a4bd-2c3037744c97_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbf31693-2544-41c5-aca5-c1792116d5d7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f4ba5ee3-6ea8-4a33-b093-6fae1a5b603e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6838ba66-fb24-4592-8e45-e85fe69d9bf7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_39f56800-f309-415c-9152-1d05ba68faba_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_928a7e5b-6765-4d70-b67f-490a17162534_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_3d0729be-20b9-4559-9cb7-eecd0a393e15_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_111ea667-1161-44aa-ac9d-7f1fceb22731_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_97d7d81f-48e6-4e10-a2a5-072a03031fc3_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual dividend per share (in dollars per share)</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_ae42ff0b-46fe-46ca-9ee6-6a0572795b37_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_22233b0a-52b9-4381-9386-d20f7fefb267_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c2267858-7ca1-43a2-865a-85de28baf158_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_77fb8152-9146-4fb1-8f03-17fbe99193e4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8a9eaeeb-7ff8-4961-b8fe-f1d5381b46e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_68666d1b-dc71-4ffe-abd1-94ddc5c8d5b8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0774608f-f32f-468c-8a8f-8a4332e6ad0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_50652dbc-b8ab-4435-851b-aa73776e14c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c98f7008-b900-4aa5-aa87-89f76067cd02_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_1b36aa98-ce76-46ab-becc-8c855605f0f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of the operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2de8afd9-60a8-4512-b8a8-a02022f6b7dd_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e4101f4f-a502-4ba3-bec2-073024d1e27e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_TB200PompeProgramMember_b970cd9e-3d51-4d1d-8c66-0c7f6ee33d0d_terseLabel_en-US" xlink:label="lab_fold_TB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATB-200 Pompe Program</link:label>
    <link:label id="lab_fold_TB200PompeProgramMember_label_en-US" xlink:label="lab_fold_TB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">T B200 Pompe Program [Member]</link:label>
    <link:label id="lab_fold_TB200PompeProgramMember_documentation_en-US" xlink:label="lab_fold_TB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to ATB-200 Pompe program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_TB200PompeProgramMember" xlink:href="fold-20211231.xsd#fold_TB200PompeProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_TB200PompeProgramMember" xlink:to="lab_fold_TB200PompeProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9b3f305d-07c6-408b-b1e6-5e3a022c257c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8e4bfd77-c7a0-400c-807f-02da7e91dc4a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_2893efbe-3bd9-4066-ac53-ae5802bb019c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_65af87fc-97f1-4196-ad86-8f37b8fc9bc7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_15a048ac-058c-4e4b-a712-3e4e3816e5f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d34f0c4f-0097-428d-a3ee-e88b41f7c6cf_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d663d645-0e15-47fe-af64-e952521218f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_06299f25-d967-43c4-bf26-ff8f3fc2d508_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3171de7c-1a49-41eb-a56c-b8bf4a0ca8a4_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_2484de60-9843-4434-ba80-f40ef15294ef_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_50f2d9ca-9d77-4b3e-907b-2fd83ce51197_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44ff11c0-a858-4eac-80ba-c945fd3755c1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6c5c7fe2-8133-407d-ba04-cc7aad31739d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_36823fc2-27e5-4b0c-8338-744bf4fec5f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_b6770270-17a9-41e1-a571-20ad50b91878_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21d600e0-587c-4500-80a3-271e7041c4db_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_6c75d458-b3cc-492e-b377-787a1a0a6c84_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_4aba2ff1-b7e1-4c26-8bc0-ebc8b9de7b8d_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_021940c7-0519-4459-ada5-30e10c345c4c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_dfd4f14a-31ea-4d35-b63b-90062dd35d11_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_4eb5af08-d77c-4166-b06b-85f893ecc951_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the statutory tax rates and the effective tax rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_559c5ce0-1716-4977-bb7b-d8e5135c68e9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_240b89bd-bc37-4993-b15c-4082246c9efa_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_daa3c3ee-1ce6-4266-81eb-3ab0403802be_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_efc758f5-a127-41fb-9dfd-949e127b0ed4_terseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities [Policy Text Block]</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_b00a2f29-f0b7-4667-b552-98eb28de6909_terseLabel_en-US" xlink:label="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional aggregate payments per indication</link:label>
    <link:label id="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_label_en-US" xlink:label="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Conditional Aggregate Payments Per Indication</link:label>
    <link:label id="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_documentation_en-US" xlink:label="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Conditional Aggregate Payments Per Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:href="fold-20211231.xsd#fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:to="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_dd5c5a32-44f8-4353-98d4-ea850c1445ac_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b531e1c1-ec3e-4df8-a4a1-672bbd46dd61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1be59ebf-c1b8-45ce-b99b-7cab0ede6021_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_846c7d0a-62ca-4928-9834-d82d026a2255_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7e52fb31-97ad-4d4d-93d9-4a5abedb375d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_de88c9bf-28c9-42a9-8f89-320c90085311_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_4bea8589-f0c5-4216-9c00-9bb589871707_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_13d6309d-1657-4313-b682-0f3192416f92_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_82edd0a2-fa30-4538-8f77-1a0ae2ad2223_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7556ef4f-04e8-4875-aae7-d31b58864326_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CollaborationAgreementAnnualContributionByCompany_c030ccf9-9b38-4562-b376-42d6c454e5cb_terseLabel_en-US" xlink:label="lab_fold_CollaborationAgreementAnnualContributionByCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery program fee</link:label>
    <link:label id="lab_fold_CollaborationAgreementAnnualContributionByCompany_label_en-US" xlink:label="lab_fold_CollaborationAgreementAnnualContributionByCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Contribution By Company</link:label>
    <link:label id="lab_fold_CollaborationAgreementAnnualContributionByCompany_documentation_en-US" xlink:label="lab_fold_CollaborationAgreementAnnualContributionByCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Contribution By Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborationAgreementAnnualContributionByCompany" xlink:href="fold-20211231.xsd#fold_CollaborationAgreementAnnualContributionByCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborationAgreementAnnualContributionByCompany" xlink:to="lab_fold_CollaborationAgreementAnnualContributionByCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_fc849ad1-472b-467b-870a-8625f18b53b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_de6bbec9-e9a7-4df2-8492-e934a0849089_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_44cafa52-a4c7-4227-b155-514fec9b55d9_negatedLabel_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency remeasurement loss</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_label_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_documentation_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:href="fold-20211231.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:to="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b90c835d-2ac3-4cad-a149-efefd522a3c5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8c3798aa-313e-4a1e-9fb6-1152f75ff3d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses, and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_55868cc4-13db-495c-9ebc-a6d7c788aa18_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9f6ded4d-1915-43f9-b988-fa9e9744f57f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_f435cbe9-16bd-4be5-8eff-e74135ac0781_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_e5fc850a-7302-4a7d-a854-a9b494b7e975_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_396d4127-e6f9-44f7-b2f2-4e55fbd91f53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_08f4b85a-c22e-4c09-99ec-42d1649ecaa5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_1adcf33e-9e04-4b74-902a-07c6f354df29_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange agreement, authorized (in shares)</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:to="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d54f1179-1bc0-4165-b11f-df113c104d56_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_PrivatePlacementPurchaseAgreementMember_d3b62f21-006d-43f5-abea-d235ec451b96_terseLabel_en-US" xlink:label="lab_fold_PrivatePlacementPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Purchase Agreement</link:label>
    <link:label id="lab_fold_PrivatePlacementPurchaseAgreementMember_label_en-US" xlink:label="lab_fold_PrivatePlacementPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Purchase Agreement [Member]</link:label>
    <link:label id="lab_fold_PrivatePlacementPurchaseAgreementMember_documentation_en-US" xlink:label="lab_fold_PrivatePlacementPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information related to private placement purchase agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PrivatePlacementPurchaseAgreementMember" xlink:href="fold-20211231.xsd#fold_PrivatePlacementPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PrivatePlacementPurchaseAgreementMember" xlink:to="lab_fold_PrivatePlacementPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_0697ee02-be0b-48bc-8052-2cd6de5062d4_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_5fad37b9-b6bb-4f4e-9e97-27be90f9aafe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2aa6fff2-9911-49c7-8176-fd027f15080c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a915df70-4992-4334-8572-1ba6fd8d11c7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_38e23630-dde6-49d4-8be8-495c5c5157e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of the operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_ca759d4e-429c-473b-9be4-28ff8fb29974_negatedTerseLabel_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_label_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_documentation_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" xlink:href="fold-20211231.xsd#fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" xlink:to="lab_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_011bfcb4-c5d7-48bc-9558-a239182046f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d5386c7e-3768-49da-bc1f-c77915d54f52_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0ce1edfe-7af6-4941-b69f-9bd45cffc4dd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_90bb447e-0b96-44dc-b787-a7762a004789_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_3833a391-e770-439b-a7bf-c8f7944cd7c4_negatedTerseLabel_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible debt conversion</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_label_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion</link:label>
    <link:label id="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_documentation_en-US" xlink:label="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" xlink:href="fold-20211231.xsd#fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" xlink:to="lab_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_9e2d08b3-3a23-4876-82d8-fd87a3bfcac8_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b757e57c-1292-41fb-9b4b-93f0b7d8d5fa_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_80fa1564-6abf-4796-a5d1-5befcc1d7879_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2fe7b5a8-88f1-468c-b5b5-3398fdfbe57c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f048f75d-851f-4df6-bd6a-11a8fe6330db_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d7734af0-ec1c-4400-8933-b9acfb210014_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e1c946da-bcc6-4667-938a-3892060b2750_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_IncreaseDecreaseInDeferredReimbursements_981ce3e7-231e-4381-9bbb-a8ffbbf7b50d_terseLabel_en-US" xlink:label="lab_fold_IncreaseDecreaseInDeferredReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInDeferredReimbursements_label_en-US" xlink:label="lab_fold_IncreaseDecreaseInDeferredReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Reimbursements</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInDeferredReimbursements_documentation_en-US" xlink:label="lab_fold_IncreaseDecreaseInDeferredReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of deferred reimbursements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInDeferredReimbursements" xlink:href="fold-20211231.xsd#fold_IncreaseDecreaseInDeferredReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncreaseDecreaseInDeferredReimbursements" xlink:to="lab_fold_IncreaseDecreaseInDeferredReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08204909-f14c-482d-8ddf-567a92fc3cbd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationPaidInStockAdjustment_c155e0c3-cb74-44bb-9865-b2189828095e_negatedLabel_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStockAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration in cash</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStockAdjustment_label_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStockAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Paid In Stock, Adjustment</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStockAdjustment_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStockAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Paid In Stock, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationPaidInStockAdjustment" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationPaidInStockAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationPaidInStockAdjustment" xlink:to="lab_fold_ContingentConsiderationPaidInStockAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_7cf19a7d-39ed-4bd6-b681-a5c399590b71_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period following separation for accelerated vesting</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0aff3c47-6af0-4222-89ad-f4b0b6f86b8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6b6120cf-5206-418b-9d93-f5c15895dbc6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_b23b08bf-d006-42a8-b6e3-60c01cfac613_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_4e57ed2e-023b-4118-9a93-eb1405398196_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for contingent consideration</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Contingent Consideration</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:to="lab_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3adee5b5-34b4-4ffd-93b5-6cb5afe3c0d4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_58aca067-7329-45ed-b898-8c99fa915057_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_4bac9114-2543-4773-8d3c-a8c51a605ea4_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant components of the deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_b8486d61-0d3e-49b4-af76-e743b500caa8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b2f215c8-5a86-4653-ba7f-9f8f1128e805_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_798f457d-fe16-42a1-bf7b-86b8b14cf753_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_80d990b5-f13a-40dc-9ad3-d77ffbb330ec_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_20cf04d3-a0b8-430f-af6d-3c162f58a5f0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_87fafe91-ea85-498e-a8bc-84544d2f463f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6c7b7ab3-328e-46ed-8dd8-2cb43e2f6192_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_60701ba9-de82-45d4-bc92-63851ab0f052_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5ba59249-5c24-435b-9691-dbc1b95e8e13_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6fcf8eca-b3d2-494c-8da8-981a42240a1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a480ff25-036a-4c38-8736-a0e8b011b6f5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b288b11b-25b8-4379-a8e9-baa59793dc54_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b0366278-c206-49be-bed8-76785197ce0d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_c909c8e4-2ce2-428c-99d7-124514998021_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_255b6e62-63cc-4226-808b-1c87500c17a3_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_cda3a0fa-dd43-4294-91e1-a95d1cf6c1c2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_66f13b48-4582-406b-a0b0-602d8bc74ec8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_adae85f3-d08f-49b6-859b-67a23fdb1ce2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_63c69109-17bc-4972-a3ac-360a87805bd9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_1df33e61-91fa-4cb5-a356-484bfe3c7708_terseLabel_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_label_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Deferred Financing Costs</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_documentation_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts" xlink:href="fold-20211231.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AmortizationDeferredFinancingCosts" xlink:to="lab_fold_AmortizationDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_874c7f1a-689b-48e4-a7f0-fa53a42c6b8a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_7f7e0f09-2b60-4dd4-b65c-546d7727f0f6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d51bd9ae-c5b0-4859-a1fe-bc6d795d0d26_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_959ffedf-4c70-4033-bd52-69976f62903a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c57bf3cd-d708-4abb-b964-1916a2462cd8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6093f7ab-190b-4e49-b55f-806a85de2021_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c3f1a5ec-4d39-4bc6-a861-d2d1716be047_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_26d31a2c-3e6f-4194-abd7-47a9e75ba9e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1c4cac84-3da2-4554-9cf8-e2648890a5d3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_977af627-e204-4163-b517-094e6c0bfb08_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in the valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c4ef27d8-14a0-4071-93ce-c621335e2fa1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_08ec73a0-f832-4f55-a1f4-1c807ff09c74_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_fc613a2f-703f-43e1-b34a-eb0e936795f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2dc7d3cb-9f31-4020-bdd8-a3e0d5da7bf1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a74050f0-340c-4601-aba0-f6e86465f66c_terseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_bad10f6d-aba4-44e8-a680-a4768390ca4b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_844524f2-850d-4030-bee2-abfdb0409213_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_6699c022-a70c-4604-bb1d-e03e10fe079e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible executive compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_07149227-86a5-4ece-bea1-40ebc015ced4_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_69ae9b56-40e5-45af-a92d-990ac33e28c9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_OrphanDrugTaxCreditCarryforwardMember_5dfc6cbc-97b8-4f3a-9673-2a88b244b97a_terseLabel_en-US" xlink:label="lab_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug tax credit carryforwards</link:label>
    <link:label id="lab_fold_OrphanDrugTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_fold_OrphanDrugTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represent the information pertaining to orphan drug tax credit carryforward.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:href="fold-20211231.xsd#fold_OrphanDrugTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:to="lab_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_64c13665-ea40-4927-afa1-4d0274d5b749_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_85aa0a6f-19e0-4a11-81c7-795b1023d251_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_047c3a01-0ce8-4230-955a-cf86304e8df3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_a89585e4-2508-4157-87c9-a85cebb26d09_terseLabel_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of achievement of milestones</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_label_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_documentation_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:href="fold-20211231.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:to="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_41036d4d-5eb5-472b-9992-8ff718fcd24c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_a49abc57-08c7-4b9a-8a97-f76ba66d487a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_4e837352-3d7d-461f-bdf1-6fa69db4cd33_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a41b5b27-0abe-4274-bcc5-cdcda0de0529_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorLoansMember_fb6ab1d9-3420-46e9-9ae5-eb734281df62_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans</link:label>
    <link:label id="lab_us-gaap_SeniorLoansMember_label_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLoansMember" xlink:to="lab_us-gaap_SeniorLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_10cd8907-4818-458e-8b32-5067cda852b1_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and Regulatory Approval Milestones</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to clinical and regulatory contingent consideration milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:to="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8235ebf2-706e-446a-b8b1-800ec0561019_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_5960e973-a154-4773-ab60-e953187ceba8_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest carry forward limitation</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Carryforward Limitation</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Carryforward Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsInterestCarryforwardLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:to="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_fe07d48b-2835-4933-afd1-396bb7905acd_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_247671b1-a99a-4235-bba6-74705be1ca9a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ae8df26-bf5b-4623-b06b-e3bfc25f23df_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_82de7752-8c29-497a-ad1b-beb566df9644_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e4f6cedb-9f62-4786-90d9-509917cbe40f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b1b40323-40ad-4828-a593-0cef0537005d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4d6bb2f9-230f-46d4-992a-98b814660623_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0be1fc10-a2b8-46f5-9beb-a16e0227c7ec_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsLiabilitiesGross_608604b2-c148-4619-8761-9530fa428c05_totalLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLiabilitiesGross_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Liabilities Gross</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLiabilitiesGross_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carry forwards, net of deferred tax liability attributable to taxable temporary differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsLiabilitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross" xlink:to="lab_fold_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1c9f097-1f0e-406a-b2bf-7e14c6037a0e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6f91e3ff-1121-41bb-a4d9-a9b6da313f69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_93da3f31-5cf0-4c31-81b8-462373449776_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e3d9d503-630f-4697-b3f5-7c78fb1724db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_363d7ed2-485e-445c-a094-9be12923f4f6_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_96043ddc-f8f3-4e07-a9d2-13c286e92f8d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_542253c2-7077-45a3-a4c9-499310bb52c0_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_9a69c351-93e8-4e28-a87a-0330579337da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of available-for-sale debt securities in unrealized loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_cecc27ae-ae56-4a3e-ad0f-7beb8a7e3186_terseLabel_en-US" xlink:label="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments upon achievement of post-approval and sales-based milestones</link:label>
    <link:label id="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_label_en-US" xlink:label="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Achievement of Post Approval and Sales Based Milestones Potential Payments</link:label>
    <link:label id="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_documentation_en-US" xlink:label="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:href="fold-20211231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:to="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a0113953-2c23-436f-8fe8-a16a79f15791_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_73526fdf-f418-48d4-98ff-7bf6341ac318_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_4d1fee00-eae2-4c37-a45d-f6aee176dbf0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_90de2f19-ce00-49b3-895d-663290295941_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e065ce3f-20f6-4b9f-8fd5-390f64d05dfa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_6a3b531c-4f0c-411a-893d-106d9eb6af47_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_50cf85c8-591e-41a9-b097-0bd5a07d5243_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b35af190-1732-41a8-8915-80cc60a26d40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c6224d95-b702-4e6b-984e-8c2e4e4ccd57_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_88cc2c0d-e2d5-418b-8b0f-9c8133290053_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ResearchEquipmentMember_7de05d8a-6b15-47f2-972f-ce4f5d5bcc2d_terseLabel_en-US" xlink:label="lab_fold_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_fold_ResearchEquipmentMember_label_en-US" xlink:label="lab_fold_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_fold_ResearchEquipmentMember_documentation_en-US" xlink:label="lab_fold_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents tangible property used for research.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ResearchEquipmentMember" xlink:href="fold-20211231.xsd#fold_ResearchEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ResearchEquipmentMember" xlink:to="lab_fold_ResearchEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9b12dff0-1a09-449c-ab2b-c669ff0c9926_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_798c6ec0-abee-49c1-958d-65a0a651d832_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from the issuance of common stock after deducting underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_600d4e30-3bd0-41ed-8f2a-a7f9bbb1260b_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants (in shares).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e2a7ba88-9e74-4859-9a48-bea310b30b8f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount_84222584-538c-4b54-bc5c-b179e0eb98c1_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum liquidity covenant</link:label>
    <link:label id="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount_label_en-US" xlink:label="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Liquidity Covenant, Minimum Amount</link:label>
    <link:label id="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount_documentation_en-US" xlink:label="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Liquidity Covenant, Minimum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:href="fold-20211231.xsd#fold_DebtInstrumentLiquidityCovenantMinimumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:to="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1502d5dc-5fa9-4cb3-a08c-579bb8f6d798_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0ef60927-eb48-4380-b39b-07467d880ac5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_7cfd6789-4e10-4a67-96e0-8e4125f17b20_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_662b6fe2-1a4b-4636-ac7b-7896c9182ec8_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_afc7a984-d747-4be0-90f1-0f5b9f9ec96e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_GlaxoSmithKlinePLCMember_03521fc8-ece7-4b63-8276-022ce732b2aa_terseLabel_en-US" xlink:label="lab_fold_GlaxoSmithKlinePLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_fold_GlaxoSmithKlinePLCMember_label_en-US" xlink:label="lab_fold_GlaxoSmithKlinePLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline P L C [Member]</link:label>
    <link:label id="lab_fold_GlaxoSmithKlinePLCMember_documentation_en-US" xlink:label="lab_fold_GlaxoSmithKlinePLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Glaxo Group Limited, an affiliate of GlaxoSmithKline PLC (GSK).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GlaxoSmithKlinePLCMember" xlink:href="fold-20211231.xsd#fold_GlaxoSmithKlinePLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GlaxoSmithKlinePLCMember" xlink:to="lab_fold_GlaxoSmithKlinePLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_ee08a75d-e0a4-45cd-aa6b-50c94b0fc5e5_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_3cfb4ea4-5da5-4cbf-a5f5-e4df9edd09e2_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payments</link:label>
    <link:label id="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_label_en-US" xlink:label="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Number Of Payments</link:label>
    <link:label id="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_documentation_en-US" xlink:label="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Number Of Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:href="fold-20211231.xsd#fold_DebtInstrumentPeriodicPaymentNumberOfPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:to="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_edc7f0c8-508f-48d5-bd04-75b49feb2ad6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_30d42816-0c35-4c4e-b9cb-3bd9b7366761_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb884a1d-2b0f-4dc5-81dc-87e43038667f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationPaidInStock_d1928439-7d7e-45df-97d3-23d0fea64d85_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid in shares</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStock_label_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Paid In Stock</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStock_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration liability in stock during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationPaidInStock" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationPaidInStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationPaidInStock" xlink:to="lab_fold_ContingentConsiderationPaidInStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c4bc0746-cfe5-42a1-b166-6ec210ee25d0_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_132df741-3dd9-4fc3-8394-3b981003a28e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_6ded6b88-c144-4d78-b724-4a4db860abad_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b15af318-9d65-4f50-ab89-7cfb5f10b0a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_cff69c54-08fc-4d07-921e-55186d514687_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_0e299b9a-2ab3-4c42-a423-913f1c736fd8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1da7d050-9e1f-46fc-b107-7d871db65401_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_ab6f71dd-72c7-4fb3-90de-9dc66e8484ac_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_507aaab9-740b-4d04-85e2-cf372e8cb25a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_224477da-8d6f-4711-9a7b-2dc242d7a05c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_672af26c-7a4e-4542-8baf-43f41de40219_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_37d6dd45-219e-4ac5-95df-280b9c6349c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_93fa3708-68d4-4aec-82d3-0b922215d6f5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d6ebe752-4091-4dff-bdec-2cf88c88e958_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_33b21b16-9f3c-4225-b066-025d81571d81_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_66be26e9-34e3-4c6e-a1c6-945f34fca7fd_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and deferred financing</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_f0a8e954-8fd1-4b0b-875b-138e7b7cbc13_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsIntellectualProperty_791fbf40-1950-4b78-a404-6342eff7bf1e_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsIntellectualProperty_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Intellectual Property</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsIntellectualProperty_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsIntellectualProperty" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsIntellectualProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsIntellectualProperty" xlink:to="lab_fold_DeferredTaxAssetsIntellectualProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability_55273d91-ed26-4f89-9c31-f316c185c4d8_terseLabel_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, liability</link:label>
    <link:label id="lab_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability_label_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Liability</link:label>
    <link:label id="lab_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability_documentation_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability" xlink:href="fold-20211231.xsd#fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability" xlink:to="lab_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_a206ff5b-f116-4a52-8e35-8a97f2227e6b_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_f59738fd-3664-4bbe-b965-d4ecf5efcc57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_a1805c3a-5b9c-473f-9890-e32eeb87a686_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ex-U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_b66791f7-7ce0-4239-acc5-f59c26f80bb2_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Business Acquisition</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Business Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesBusinessAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:to="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ef7013c7-7918-43d6-a000-7871b231eefd_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c76d40e8-9657-4ec3-b60f-d9af07d5728c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research&#160;&amp; development</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f1a84b49-8c1f-4ada-8e87-7467efca91ef_periodStartLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4e13147b-e34b-4d77-a6b7-1420b44284f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_14607930-d884-4d47-a38c-7013db66845b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_09210d06-2df6-4de5-90c3-c33bc9742395_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_7edba2c7-6eae-4170-bb95-a7c54d70d154_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_930a9b90-c02f-4877-8044-9d5087dcd5ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, weighted average remaining years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_bf9a958e-5641-4ba6-8fb6-da739bbb69c9_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for contingent consideration (in shares)</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Contingent Consideration</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:to="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a04b4333-8870-4798-a118-6e971e97279a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_fc14be40-1fa1-4ee4-a030-11097f02b042_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_8e86ca82-18d0-450b-ae55-227b28a292fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested RSU Activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_8f9d3169-470f-4f46-b6ab-a0524d7d2b15_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_826c771b-b952-4150-9a57-85e08bec37fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of the Statutory Tax Rates and the Effective Tax Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d099fa5d-3c6d-49c9-b95f-233db0685cd6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d31bab12-0c57-462e-9613-efe79c23ec7c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_ead03bf8-1bed-459c-8ff9-601e512297a7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_391da9e0-c099-4b3a-9f75-5a2341d43eef_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CollaborativeAgreementTermOfAgreement_d8545210-3b7a-4078-bd5b-8fbc878f6c9b_terseLabel_en-US" xlink:label="lab_fold_CollaborativeAgreementTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_fold_CollaborativeAgreementTermOfAgreement_label_en-US" xlink:label="lab_fold_CollaborativeAgreementTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Term of Agreement</link:label>
    <link:label id="lab_fold_CollaborativeAgreementTermOfAgreement_documentation_en-US" xlink:label="lab_fold_CollaborativeAgreementTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Term of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeAgreementTermOfAgreement" xlink:href="fold-20211231.xsd#fold_CollaborativeAgreementTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeAgreementTermOfAgreement" xlink:to="lab_fold_CollaborativeAgreementTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_2806a939-9dbe-4246-abb9-7698875790bb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_952af3f9-b848-474b-b5ef-c613c305c25d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1b3fd1b6-2c11-4264-9a8f-64c6f5a3a0f0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_9d2a1b90-02b9-4891-afe2-8cfbf8eb7254_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_29910edc-2b3f-4295-9518-f0e16a30ac9d_terseLabel_en-US" xlink:label="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Payable</link:label>
    <link:label id="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_label_en-US" xlink:label="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Acquisition Consideration Payable [Policy Text Block]</link:label>
    <link:label id="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_documentation_en-US" xlink:label="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:href="fold-20211231.xsd#fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:to="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d5111154-6a1c-411e-9a95-3d827d9e4367_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5be1e3cd-519b-4e5d-95c5-5578eb077f42_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ef492008-b225-4045-b60a-0ea2641b08d7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CollaborativeArrangementDisclosureAbstract_9a0e17d7-66b9-4c37-9815-2595b1a08231_terseLabel_en-US" xlink:label="lab_fold_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_fold_CollaborativeArrangementDisclosureAbstract_label_en-US" xlink:label="lab_fold_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementDisclosureAbstract" xlink:href="fold-20211231.xsd#fold_CollaborativeArrangementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeArrangementDisclosureAbstract" xlink:to="lab_fold_CollaborativeArrangementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd49c718-cb88-4747-bcb9-e3e872d3fc1c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_0f5489d6-d777-4334-a749-b5249aa591fd_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3c97bb83-bc65-4f9f-b48e-fcce62b74629_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsLeasingArrangements_0b12130c-a1a2-4efd-9ac6-c98e17aa846e_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLeasingArrangements_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLeasingArrangements_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLeasingArrangements" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_fold_DeferredTaxAssetsLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_45581cd2-171e-485b-9fa9-fd196dff8b75_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ccba7c37-71a7-46d6-ad88-743f55532b0f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock tax vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_d41ba0a6-6e37-4720-8ae8-b26094075506_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b07955af-79b3-48f4-976f-2922b0aab213_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_4ffd61fd-7169-4876-9906-5e701f2b642c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dbeb88dc-867b-422c-ac23-937caee6bbb1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_EarlySettlementPremiums_95e968a9-08ff-422d-a7b4-1da9413f9134_terseLabel_en-US" xlink:label="lab_fold_EarlySettlementPremiums" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early settlement premiums</link:label>
    <link:label id="lab_fold_EarlySettlementPremiums_label_en-US" xlink:label="lab_fold_EarlySettlementPremiums" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Settlement Premiums</link:label>
    <link:label id="lab_fold_EarlySettlementPremiums_documentation_en-US" xlink:label="lab_fold_EarlySettlementPremiums" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Settlement Premiums</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EarlySettlementPremiums" xlink:href="fold-20211231.xsd#fold_EarlySettlementPremiums"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EarlySettlementPremiums" xlink:to="lab_fold_EarlySettlementPremiums" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2b6f4a63-b406-4fdb-8c43-dcc3415d5a6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_bdaf496f-d8aa-4d59-8970-32aa2951c4d2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_def4e086-ca42-4deb-9fce-ff880d00b2f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c36bc83b-2650-4cf7-ad10-1fc7ac36fc20_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b0b72d5e-9723-4833-bb9a-a8908c05292a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_af9fa42b-52a1-4c2f-9a87-d795faf0e8b4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a31fd987-99e6-44ea-b6d6-b973921b3598_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_12c2bf3b-0916-483b-97ae-efca1e5e23e7_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeMember" xlink:to="lab_us-gaap_ComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_103637ae-57f6-4fcb-a74a-1b17e64d9bab_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_35899203-6ee9-43d0-adc8-265aa37ff6dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_67fb21c0-dd70-4ff9-bc86-7af73995e3b0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, less accumulated depreciation of $19,882 and $14,487 at December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3cd1fcb4-abdb-4886-a978-3914f0f1b27f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a216ae7c-e72d-4a94-90f6-d756af0e4538_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_6e017dda-3a37-4a13-968e-de167d01724c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CommonStockVotingRightsForEachShareHeld_4dd779d5-2647-4a24-8daf-72c0118b880d_terseLabel_en-US" xlink:label="lab_fold_CommonStockVotingRightsForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting right for each share held, number</link:label>
    <link:label id="lab_fold_CommonStockVotingRightsForEachShareHeld_label_en-US" xlink:label="lab_fold_CommonStockVotingRightsForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Voting Rights for Each Share Held</link:label>
    <link:label id="lab_fold_CommonStockVotingRightsForEachShareHeld_documentation_en-US" xlink:label="lab_fold_CommonStockVotingRightsForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of votes entitled for each share held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CommonStockVotingRightsForEachShareHeld" xlink:href="fold-20211231.xsd#fold_CommonStockVotingRightsForEachShareHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CommonStockVotingRightsForEachShareHeld" xlink:to="lab_fold_CommonStockVotingRightsForEachShareHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7a64c212-e36c-474a-99f2-126bd76bd842_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_74d8c985-6206-4989-b9c5-dc7ccd80d85f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_91545fa1-ee17-49c4-a850-333efdabc33b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_7f1420f2-9a72-4e87-9fa1-1a74ae1456a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_60acfdfd-1d60-4af0-9933-43fca0f6a349_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_78667a26-a735-4c91-84a8-e9a4a9691d45_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_09d83313-e740-495f-a127-7fb6adc249b5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentVariableRate_28152cb3-9216-4968-aa78-768ce1811e53_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_fold_DebtInstrumentVariableRate_label_en-US" xlink:label="lab_fold_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate</link:label>
    <link:label id="lab_fold_DebtInstrumentVariableRate_documentation_en-US" xlink:label="lab_fold_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentVariableRate" xlink:href="fold-20211231.xsd#fold_DebtInstrumentVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentVariableRate" xlink:to="lab_fold_DebtInstrumentVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_3b12ed08-f4ff-4841-a59f-6335237e976b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_c181868d-4cf0-418a-b38e-3d1035e7337f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_a2050a26-8601-4f3d-9b68-af59013e9cd3_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_7d8a1870-d120-485a-a7c8-efa65507f748_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d21eada7-aeae-42eb-9882-d8267be86328_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment (loss) gain, net of tax impact of $0, $1,552, and $889, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d3d73353-dbe7-4f6a-a8a6-ed9d88ae7ed1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_52e173ab-a3f5-4e50-a99a-d24eb52a7920_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_a4f141e7-5fe7-4136-bf08-589b8aae51dd_negatedTerseLabel_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less lease incentives</link:label>
    <link:label id="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_label_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Incentives</link:label>
    <link:label id="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_documentation_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Incentives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:href="fold-20211231.xsd#fold_LesseeOperatingLeaseLiabilityTenantIncentives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:to="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_06f70b5b-e19c-4d54-a2bd-a7807d803bf4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest as of the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b8110971-bd23-49ed-b8e5-9a5b0416b901_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_72db9d7d-d817-4012-90eb-45c64658fc64_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_7ad94747-eecb-44f2-9049-575ede47bd40_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_f1698c02-0786-430c-9038-ea4d32d4687b_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding warrants, convertible to common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_f2673d67-486b-4d3a-a980-acc330a99c95_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liabilities</link:label>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_abb34a10-9f30-4ced-b2d0-e938a253d73c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4268141b-77b2-443c-960c-453d2be8d58e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_9b0cff25-b1d9-45f2-ad45-5a50d30267b4_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f81da461-cff9-4669-904b-2231f55e9b61_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_acff9582-0af9-4f06-a1f0-f0897e8e1b8b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and experimentation tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d047d78e-a326-478f-b181-34e746756fdf_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5a334954-6e7c-46b2-9901-f1985976f336_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockExercisesAt706Member_d163b6f0-9167-4ec9-95cf-6e8c38a9bcfd_terseLabel_en-US" xlink:label="lab_fold_StockExercisesAt706Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.06</link:label>
    <link:label id="lab_fold_StockExercisesAt706Member_label_en-US" xlink:label="lab_fold_StockExercisesAt706Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.06 [Member]</link:label>
    <link:label id="lab_fold_StockExercisesAt706Member_documentation_en-US" xlink:label="lab_fold_StockExercisesAt706Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.06</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt706Member" xlink:href="fold-20211231.xsd#fold_StockExercisesAt706Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockExercisesAt706Member" xlink:to="lab_fold_StockExercisesAt706Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c47f8f0a-3322-448a-a8a0-6515f8d0eccc_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_fcdeeb2a-9567-4501-ac7a-4897616f75d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a54cad21-14bb-406c-8e1e-6987fa4b6327_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_d263d19a-b8d7-4fad-830d-867936055987_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_f28fe3e4-cc11-4d16-89a7-ab143b5731f1_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_de1502fc-e7a3-430d-a33b-b58d1571150b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9fea626b-f736-4ce1-954e-41d090290ffb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of loss before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_d3d51b89-dcea-4869-a895-08db07ba0b02_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_de2d5e59-b202-4852-b50e-b1ae2a45d214_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d8a8505-fab9-4773-8382-b88381760fd3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c02b9eff-e288-44af-941e-972a54ab7358_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40ad410d-f0b5-4a53-a34c-86a3f6dc93ae_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_f042eb7b-08e3-485f-a800-983d37648e9c_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated revenue covenant, amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_label_en-US" xlink:label="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Consolidated Revenue Covenant, Amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Consolidated Revenue Covenant, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConsolidatedRevenueCovenantAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:to="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_45a33fb3-17b0-4b71-869b-b020d9456e20_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f58d0b3c-9c73-4c7b-a344-21b8931bf34e_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_59d2b95c-58be-43a1-a6f7-e515d61163b3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_da865da5-b0d2-42a7-9b2f-f0079023da3b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_4c3e726c-f9f0-433a-9afe-a2b063b0edfa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_c99447be-2772-4517-b533-c4b32f3c74f9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_52a49a1b-a1af-4d78-a09f-5f0bda3217c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3a939d01-6571-4746-bca2-6092470957ba_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_06df11a0-0f98-440e-bfc9-f98acf65a262_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_f8951cdf-c61b-4386-ab4a-7635b4150dc6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_f620b829-de3b-407f-9a7e-30cf46dd364f_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6f5443d7-d8c3-4ca5-9045-23cf7f8bbb24_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, cash balances</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cc1cf4e6-6883-4e93-8a6b-ba113567ebc2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_c93184a9-a5b3-4fa6-8785-4f7f9c2a2177_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8cc14568-4706-4daf-a688-71e5164cf58c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b69302ed-ea4a-4571-a425-10ddec000717_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e42d8fb1-6e55-45e7-bf4f-fb9722bbdd77_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_1d1b4b83-45db-4ec4-af21-e12659a0ad51_terseLabel_en-US" xlink:label="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Cash Deferral Plan</link:label>
    <link:label id="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_label_en-US" xlink:label="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Cash Deferral Plans Policy [Policy Text Block]</link:label>
    <link:label id="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:href="fold-20211231.xsd#fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:to="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_846ded0c-fad3-4bcc-96d1-a12202b1e5bb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_006fc837-2928-4ee2-baac-ac9635107af6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_ece00ee6-50d6-4e03-93bb-217c9ecc4122_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CustomerOneMember_6e97cfea-36f1-4cbf-aadb-dd544f1302bd_terseLabel_en-US" xlink:label="lab_fold_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_fold_CustomerOneMember_label_en-US" xlink:label="lab_fold_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_fold_CustomerOneMember_documentation_en-US" xlink:label="lab_fold_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CustomerOneMember" xlink:href="fold-20211231.xsd#fold_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CustomerOneMember" xlink:to="lab_fold_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_73774ff0-2442-49c3-be8a-cdc2e87db10c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_e7a0ccb2-e50f-4d52-958c-7b8138333c07_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d85e6911-5f5b-407b-8433-86236d40cb47_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_aec63545-4724-4e05-9c97-6a9c53c02051_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_deafdd3d-d41f-43d9-8dc4-b565c6de4762_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a5c43c62-d9fa-4a7a-9eea-2a11db7df60d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e4617834-1ac7-4190-811b-0c59a137268d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_98281ce0-2735-480e-8398-5d20a26aaebc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2bbf9c6e-2bd7-482f-b45b-dcd8f4e0d49d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_cead8bbe-6e4c-4ffc-9982-4bfd9fed3856_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_c92bb42c-fb8d-4e0c-a346-4f983ee2614c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4096fde0-a528-4f3f-98ef-841f454c27df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3e5be9b-9dff-4794-a6fb-3f9d3b1f9e24_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_daf99149-c52e-491e-a1f4-a43457542ecd_terseLabel_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_label_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus Biopharma Inc [Member]</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_documentation_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Callidus Biopharma, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember" xlink:href="fold-20211231.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CallidusBiopharmaIncMember" xlink:to="lab_fold_CallidusBiopharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1d326aad-ad9d-4a11-b988-50f5cf3e9349_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_67c939a0-fd7b-42ef-9f78-b77d8f88d98e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_163db806-4109-4f2d-b9f8-cb56b3cb852c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationNumberOfPlans_ff912e0e-721f-4211-941d-6f4e10ceb0e6_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity-based employee compensation plans</link:label>
    <link:label id="lab_fold_ShareBasedCompensationNumberOfPlans_label_en-US" xlink:label="lab_fold_ShareBasedCompensationNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Number of Plans</link:label>
    <link:label id="lab_fold_ShareBasedCompensationNumberOfPlans_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of plans under the equity-based arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationNumberOfPlans" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationNumberOfPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationNumberOfPlans" xlink:to="lab_fold_ShareBasedCompensationNumberOfPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_935e9b1e-28ad-4fcb-ac48-219d53dd8093_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities, net of tax impact of $0, $(50), and $182, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0d6d597d-b879-44f1-95b2-6e9a77e278e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_4c164158-31ce-4db5-b196-1af92e79d8ed_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_34e08c3b-6ea7-40c9-8cc3-cb61c0e8b688_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3ac88cf7-b90c-4b30-825d-b9094f37d104_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_783303c1-2c5b-45a3-a5d0-43b8582470df_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_86d91fc6-5b96-4aa7-884f-1b5add8df723_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e059bf03-e27f-4d14-a5b2-5f4ddd5ecee4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8d546b10-b061-42d3-a5ac-965fa4ab9b43_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_5cd3528f-99e7-4877-a9d0-f875ada2976e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AccruedProgramFees_6ab7c8e3-db0a-4e88-8252-2968e419292a_terseLabel_en-US" xlink:label="lab_fold_AccruedProgramFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Program Fees</link:label>
    <link:label id="lab_fold_AccruedProgramFees_label_en-US" xlink:label="lab_fold_AccruedProgramFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Program Fees</link:label>
    <link:label id="lab_fold_AccruedProgramFees_documentation_en-US" xlink:label="lab_fold_AccruedProgramFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable related to a pharmaceutical program, including but not limited to clinical studies or commercial preparation activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedProgramFees" xlink:href="fold-20211231.xsd#fold_AccruedProgramFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedProgramFees" xlink:to="lab_fold_AccruedProgramFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a93fdfa2-b57f-4a92-aff9-2988816ae727_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ff3e3a98-4cae-4939-b92e-0b30471dfcf6_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d2113c9f-3ed2-4676-90d5-a15175dd56df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options vested and unvested expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a162ebfb-6cbc-4262-8038-c9852f891813_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f9c5682d-c3f2-46a4-bed5-cb68307c8628_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_db945e6f-7b0f-4dfe-a637-43315f526fd9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Subject to Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_a30cd370-aede-4dbb-9083-3300869da200_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Convertible Notes</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesConvertibleNotes_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax consequences attributable to taxable temporary differences derived from convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:to="lab_fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fd6c734e-a654-4679-a4a6-bdf2f821ea35_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fd2f9ff7-2362-4dda-a745-adf079a93797_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_bf36eb45-9a3e-4110-8075-6082b9d4b973_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_87eb5f03-d834-4e88-915c-272fa06db1d3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Developments</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_f9068b1e-861c-468e-911e-1bb212ab45d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_386c637b-6eee-4401-9915-86753cda004f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d1849ac8-1d8e-45fd-bf13-bf61fce51033_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_f9a3c4fc-4d1a-4dd6-a4aa-f2910a60fe4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_a2a16d42-23e7-42c6-9c37-25d714ef4589_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_06a01fde-60d3-4b7f-9890-01ebabb3a6b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9d948cda-714a-447c-abed-86e566aa38d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_3cac745e-cfd7-4530-b75b-decd6b1ee40c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories and Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_c79c59cb-68ba-4f7f-8551-7e4ed1db47d6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5e37e8ad-d146-4172-827c-07d85aed12ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32125829-dda8-4afd-949d-ffa4558208f7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_PaymentsForCollaborativeArrangement_39dd6741-fbbd-4719-805a-9699373c6aeb_terseLabel_en-US" xlink:label="lab_fold_PaymentsForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for collaborative agreement</link:label>
    <link:label id="lab_fold_PaymentsForCollaborativeArrangement_label_en-US" xlink:label="lab_fold_PaymentsForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collaborative Arrangement</link:label>
    <link:label id="lab_fold_PaymentsForCollaborativeArrangement_documentation_en-US" xlink:label="lab_fold_PaymentsForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForCollaborativeArrangement" xlink:href="fold-20211231.xsd#fold_PaymentsForCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PaymentsForCollaborativeArrangement" xlink:to="lab_fold_PaymentsForCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_768dfb6b-a84f-4cd0-a6c7-ef1a0bc376d9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_956ae20b-dbbc-4866-8e11-66f628461347_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_3d77b5a2-991e-40c9-88d8-cc6ce367b385_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_57b1ae93-e6c7-4b80-9010-3d41668ae5e5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_ca62d59e-e51f-46da-bbb4-4364affe29ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d41206d4-b5f3-4ca8-9850-4133bb3e4fe2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_18dfa3f7-c982-42fd-8cae-15677108be22_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_3f5d1558-f473-410d-ae21-5aee2cc57dc1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periodic payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_597e0fc4-c16d-4a5b-9333-e16a6ff0d439_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>fold-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:420dc514-3d5c-42ec-9084-f88f3b76faf7,g:716e386a-5032-46b5-a55b-0ba5d954afee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Cover" xlink:type="simple" xlink:href="fold-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_77fb74aa-6760-4405-9809-63e051b7da78" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_DocumentType_77fb74aa-6760-4405-9809-63e051b7da78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_42108806-94e0-48c5-99cf-a662bb59ba7d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_DocumentAnnualReport_42108806-94e0-48c5-99cf-a662bb59ba7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d7f7f526-45ae-4625-a6a4-d79e5235b1ec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_DocumentPeriodEndDate_d7f7f526-45ae-4625-a6a4-d79e5235b1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8200f051-9185-450e-b459-9c6f246804a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_CurrentFiscalYearEndDate_8200f051-9185-450e-b459-9c6f246804a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_edf96777-9d34-4ba7-983a-8eb69b6d476f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_DocumentTransitionReport_edf96777-9d34-4ba7-983a-8eb69b6d476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_76096a05-d40e-43c7-b161-6e90dce3500f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityFileNumber_76096a05-d40e-43c7-b161-6e90dce3500f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0cdb1412-ca49-4d9e-ad47-a3f40eb996e9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityRegistrantName_0cdb1412-ca49-4d9e-ad47-a3f40eb996e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_03f8b0fe-9f21-446a-af05-de92f1b84727" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_03f8b0fe-9f21-446a-af05-de92f1b84727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6964d8b2-243a-488f-9913-0384701cfb57" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityTaxIdentificationNumber_6964d8b2-243a-488f-9913-0384701cfb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_befaa27a-2ec6-4217-baa8-fbc8077b5c9f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityAddressAddressLine1_befaa27a-2ec6-4217-baa8-fbc8077b5c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1256ccbd-da29-4c56-895e-44563889a645" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityAddressCityOrTown_1256ccbd-da29-4c56-895e-44563889a645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_26958b11-d1cc-4801-81f4-977d5f4360d6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityAddressStateOrProvince_26958b11-d1cc-4801-81f4-977d5f4360d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0e0bbd8e-c31b-4ead-ba0b-f13ebe3eade1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityAddressPostalZipCode_0e0bbd8e-c31b-4ead-ba0b-f13ebe3eade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a96ff67e-993f-4e33-908a-f8c3b091c3fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_CityAreaCode_a96ff67e-993f-4e33-908a-f8c3b091c3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_44ad10a9-27e0-45f1-ab97-503ef72335e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_LocalPhoneNumber_44ad10a9-27e0-45f1-ab97-503ef72335e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5075ef6c-fc36-4168-b557-0e72251b0ee0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_Security12bTitle_5075ef6c-fc36-4168-b557-0e72251b0ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6347b4de-d920-4410-8c1b-0799bfd01dc9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_TradingSymbol_6347b4de-d920-4410-8c1b-0799bfd01dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_14a2dac2-bc6d-4ead-8b10-1b95b5cc756f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_SecurityExchangeName_14a2dac2-bc6d-4ead-8b10-1b95b5cc756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_b8115a78-77fc-4d77-8ac3-99c018d5699d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_b8115a78-77fc-4d77-8ac3-99c018d5699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_3a2578c1-ca33-4afe-8c95-fd75c3db0b9f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityVoluntaryFilers_3a2578c1-ca33-4afe-8c95-fd75c3db0b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9c11a05a-ebf3-4134-9617-c6aaa86968b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityCurrentReportingStatus_9c11a05a-ebf3-4134-9617-c6aaa86968b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6e483233-c713-44d2-9a87-38f3cd9d197a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityInteractiveDataCurrent_6e483233-c713-44d2-9a87-38f3cd9d197a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_eb2be824-db4e-4951-a6a3-cbb0268fb8e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityFilerCategory_eb2be824-db4e-4951-a6a3-cbb0268fb8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0d35436a-a71f-45b4-af00-8e503b64e5e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntitySmallBusiness_0d35436a-a71f-45b4-af00-8e503b64e5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_37c3d6a5-ecbf-4954-b15a-f98512f754ce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityEmergingGrowthCompany_37c3d6a5-ecbf-4954-b15a-f98512f754ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_98e90a55-c67a-4719-9b87-0a34e150b4db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_98e90a55-c67a-4719-9b87-0a34e150b4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_faeaaae7-e9dc-4b84-9608-9136959c1f15" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityShellCompany_faeaaae7-e9dc-4b84-9608-9136959c1f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_8aae28f7-2677-403b-a96b-d65e8a698984" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityPublicFloat_8aae28f7-2677-403b-a96b-d65e8a698984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ebb8056b-acee-45bc-b2b3-18b39bf4d9de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ebb8056b-acee-45bc-b2b3-18b39bf4d9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_da836236-75d2-41ee-98d6-cbe9467f9a25" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_da836236-75d2-41ee-98d6-cbe9467f9a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6de7a6ce-3714-4cc2-807d-e4cb6edc8e59" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_EntityCentralIndexKey_6de7a6ce-3714-4cc2-807d-e4cb6edc8e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_719cf185-ad46-4d44-b7a5-876cd2593bf3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_AmendmentFlag_719cf185-ad46-4d44-b7a5-876cd2593bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_38131fc2-7258-453b-872f-53a7832471d6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_DocumentFiscalYearFocus_38131fc2-7258-453b-872f-53a7832471d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b07ca021-3a32-4308-8c72-806ccb8f06f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40042075-6ac0-40e4-b7d0-aa142f40c5c3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b07ca021-3a32-4308-8c72-806ccb8f06f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AuditInformation" xlink:type="simple" xlink:href="fold-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_AuditInformationAbstract_b21ba4c2-17d9-427c-99e4-890dbc7a1ac0" xlink:href="fold-20211231.xsd#fold_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c6d944a1-ffe2-4bbe-a623-f8154de6256f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_AuditInformationAbstract_b21ba4c2-17d9-427c-99e4-890dbc7a1ac0" xlink:to="loc_dei_AuditorFirmId_c6d944a1-ffe2-4bbe-a623-f8154de6256f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_0b3c9570-eb59-4fbd-82df-9092d524e2f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_AuditInformationAbstract_b21ba4c2-17d9-427c-99e4-890dbc7a1ac0" xlink:to="loc_dei_AuditorName_0b3c9570-eb59-4fbd-82df-9092d524e2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_dfb10456-a36f-402a-af80-18be411f515a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_AuditInformationAbstract_b21ba4c2-17d9-427c-99e4-890dbc7a1ac0" xlink:to="loc_dei_AuditorLocation_dfb10456-a36f-402a-af80-18be411f515a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c0664cad-86ce-453f-9b1b-809517e7f66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_17bae593-9037-4e56-b883-03fc5704b2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0664cad-86ce-453f-9b1b-809517e7f66b" xlink:to="loc_us-gaap_AssetsAbstract_17bae593-9037-4e56-b883-03fc5704b2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_db72846e-c5ba-46f2-b1d7-f0497a648bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17bae593-9037-4e56-b883-03fc5704b2e1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_db72846e-c5ba-46f2-b1d7-f0497a648bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_53da8c41-ec48-4050-b0b7-b9eafe2369db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db72846e-c5ba-46f2-b1d7-f0497a648bf3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_53da8c41-ec48-4050-b0b7-b9eafe2369db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_73aba4cc-69c7-4551-a81f-2fd00228666c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db72846e-c5ba-46f2-b1d7-f0497a648bf3" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_73aba4cc-69c7-4551-a81f-2fd00228666c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bd364333-790a-409a-9e3c-fb209544f8db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db72846e-c5ba-46f2-b1d7-f0497a648bf3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bd364333-790a-409a-9e3c-fb209544f8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a3d004ab-76b8-4338-8e87-6411c14e3c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db72846e-c5ba-46f2-b1d7-f0497a648bf3" xlink:to="loc_us-gaap_InventoryNet_a3d004ab-76b8-4338-8e87-6411c14e3c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_566ad1c4-f975-4314-bf20-aaf10c56fcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db72846e-c5ba-46f2-b1d7-f0497a648bf3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_566ad1c4-f975-4314-bf20-aaf10c56fcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf9ab631-c7fc-4a75-9cad-080fd4c17248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db72846e-c5ba-46f2-b1d7-f0497a648bf3" xlink:to="loc_us-gaap_AssetsCurrent_bf9ab631-c7fc-4a75-9cad-080fd4c17248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c64ddc6-184f-431e-a087-dedff19ced13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17bae593-9037-4e56-b883-03fc5704b2e1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c64ddc6-184f-431e-a087-dedff19ced13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_96a35801-5c94-4063-9a41-2f4bc4f51c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17bae593-9037-4e56-b883-03fc5704b2e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_96a35801-5c94-4063-9a41-2f4bc4f51c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b69bd9fd-a96a-4532-8c53-b2bbd64b3703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17bae593-9037-4e56-b883-03fc5704b2e1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b69bd9fd-a96a-4532-8c53-b2bbd64b3703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_92e1880f-f849-477b-8986-3cbb607aa78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17bae593-9037-4e56-b883-03fc5704b2e1" xlink:to="loc_us-gaap_Goodwill_92e1880f-f849-477b-8986-3cbb607aa78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fa6c7cf0-18ee-49a5-810f-7c49b6a5508f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17bae593-9037-4e56-b883-03fc5704b2e1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fa6c7cf0-18ee-49a5-810f-7c49b6a5508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f0d7bf4e-e210-4561-89b2-508cde30d77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17bae593-9037-4e56-b883-03fc5704b2e1" xlink:to="loc_us-gaap_Assets_f0d7bf4e-e210-4561-89b2-508cde30d77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0664cad-86ce-453f-9b1b-809517e7f66b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4faa3152-b0b3-48d6-bef1-22fadd309897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4faa3152-b0b3-48d6-bef1-22fadd309897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a22ce58b-8b59-4ab8-874c-19de1fb24e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4faa3152-b0b3-48d6-bef1-22fadd309897" xlink:to="loc_us-gaap_AccountsPayableCurrent_a22ce58b-8b59-4ab8-874c-19de1fb24e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b03bdd36-4303-4c31-8b82-78b9395f2619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4faa3152-b0b3-48d6-bef1-22fadd309897" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b03bdd36-4303-4c31-8b82-78b9395f2619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1d72c597-0d40-46cc-a404-4fe69e6e87fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4faa3152-b0b3-48d6-bef1-22fadd309897" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1d72c597-0d40-46cc-a404-4fe69e6e87fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9a6e747a-b65c-49a4-a780-a570d5475941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4faa3152-b0b3-48d6-bef1-22fadd309897" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9a6e747a-b65c-49a4-a780-a570d5475941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_69a0c04c-af43-4cf3-9059-8073caf39e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4faa3152-b0b3-48d6-bef1-22fadd309897" xlink:to="loc_us-gaap_LiabilitiesCurrent_69a0c04c-af43-4cf3-9059-8073caf39e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_b2336d17-6c07-4e22-a8ad-f2a818fa60aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_b2336d17-6c07-4e22-a8ad-f2a818fa60aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1b3993a6-9560-48d6-82df-5abcf8dfe8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_LongTermDebt_1b3993a6-9560-48d6-82df-5abcf8dfe8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_db1860d1-90d1-437a-afb9-2e5dea71f0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_db1860d1-90d1-437a-afb9-2e5dea71f0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f560c469-71f3-4ee4-bff8-fc47dd2bd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f560c469-71f3-4ee4-bff8-fc47dd2bd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b8d34264-6d31-490d-bd42-a5fc90aedf15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b8d34264-6d31-490d-bd42-a5fc90aedf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d28747df-e4a0-4027-8135-0bcb8876c5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d28747df-e4a0-4027-8135-0bcb8876c5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e89f5aee-9a25-4878-905f-70a0b15abbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_Liabilities_e89f5aee-9a25-4878-905f-70a0b15abbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0d3da79d-a852-4b8e-8088-5110dba4a323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0d3da79d-a852-4b8e-8088-5110dba4a323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_45843ef4-86a1-434c-a4af-41e3fbba1489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_45843ef4-86a1-434c-a4af-41e3fbba1489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_39f28b60-9e78-4f3e-ba35-12a2b3ab939f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_45843ef4-86a1-434c-a4af-41e3fbba1489" xlink:to="loc_us-gaap_CommonStockValue_39f28b60-9e78-4f3e-ba35-12a2b3ab939f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0fc66ec9-2837-45cf-9734-f4cb1723d485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_45843ef4-86a1-434c-a4af-41e3fbba1489" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0fc66ec9-2837-45cf-9734-f4cb1723d485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5935c759-93cf-40a6-98b4-e3c034e855c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_45843ef4-86a1-434c-a4af-41e3fbba1489" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5935c759-93cf-40a6-98b4-e3c034e855c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_8cb08ef3-6836-406b-88b4-c20a90e5ffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5935c759-93cf-40a6-98b4-e3c034e855c7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_8cb08ef3-6836-406b-88b4-c20a90e5ffc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d200b947-72e9-476f-9a9c-4745d9920740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_5935c759-93cf-40a6-98b4-e3c034e855c7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d200b947-72e9-476f-9a9c-4745d9920740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_00f3cc0a-46b1-430b-b4f7-0ceb5384ef24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_45843ef4-86a1-434c-a4af-41e3fbba1489" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_00f3cc0a-46b1-430b-b4f7-0ceb5384ef24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c398c821-0204-4832-a17e-c76a6e14416a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_45843ef4-86a1-434c-a4af-41e3fbba1489" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c398c821-0204-4832-a17e-c76a6e14416a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_704f7ec4-61b7-490a-a16b-cf0126545c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_45843ef4-86a1-434c-a4af-41e3fbba1489" xlink:to="loc_us-gaap_StockholdersEquity_704f7ec4-61b7-490a-a16b-cf0126545c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9bfd8e21-5d5a-4804-ae8c-a929fb56afda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28bcd76a-ea47-4bfb-841c-8df41d3f3bd3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9bfd8e21-5d5a-4804-ae8c-a929fb56afda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcb068c-6510-44fe-a6ba-cf539eec4800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4dcea473-0677-448d-a904-6fdd98abc3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcb068c-6510-44fe-a6ba-cf539eec4800" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4dcea473-0677-448d-a904-6fdd98abc3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8c870987-96a7-47df-8970-5e5ea8e8dd62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcb068c-6510-44fe-a6ba-cf539eec4800" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8c870987-96a7-47df-8970-5e5ea8e8dd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5c2cbad9-159f-43b3-83a1-598605ab1dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcb068c-6510-44fe-a6ba-cf539eec4800" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5c2cbad9-159f-43b3-83a1-598605ab1dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_868db231-db1c-4bd0-a0d6-ad30e8f63697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcb068c-6510-44fe-a6ba-cf539eec4800" xlink:to="loc_us-gaap_CommonStockSharesIssued_868db231-db1c-4bd0-a0d6-ad30e8f63697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cb964a4e-db6e-405d-aaf2-2a5912496fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcb068c-6510-44fe-a6ba-cf539eec4800" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cb964a4e-db6e-405d-aaf2-2a5912496fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b2d9e8f5-69d4-4b01-b43a-6f4e0f833f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b2d9e8f5-69d4-4b01-b43a-6f4e0f833f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f7a431cf-8ca4-406c-b46e-6996e46e7454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f7a431cf-8ca4-406c-b46e-6996e46e7454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7c584c1d-e90c-4935-8aad-9f5f4ef8b7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_GrossProfit_7c584c1d-e90c-4935-8aad-9f5f4ef8b7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d9b842c1-f84c-4df1-b18e-cff5f1f9930f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d9b842c1-f84c-4df1-b18e-cff5f1f9930f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6875b326-7eae-4a8a-8a2c-24a9917c1897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9b842c1-f84c-4df1-b18e-cff5f1f9930f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6875b326-7eae-4a8a-8a2c-24a9917c1897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7b81d1f8-401f-4348-aa50-9c4f0d6e2082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9b842c1-f84c-4df1-b18e-cff5f1f9930f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7b81d1f8-401f-4348-aa50-9c4f0d6e2082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_cdb56a9f-8d81-4b06-96b5-332bca5a18cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9b842c1-f84c-4df1-b18e-cff5f1f9930f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_cdb56a9f-8d81-4b06-96b5-332bca5a18cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ac124a52-b644-4809-9715-42cea5e7f52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9b842c1-f84c-4df1-b18e-cff5f1f9930f" xlink:to="loc_us-gaap_DepreciationAndAmortization_ac124a52-b644-4809-9715-42cea5e7f52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8c0e5be5-1c59-4b5f-a09f-4cf9842ecfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9b842c1-f84c-4df1-b18e-cff5f1f9930f" xlink:to="loc_us-gaap_OperatingExpenses_8c0e5be5-1c59-4b5f-a09f-4cf9842ecfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1eb7743b-9f29-408a-88a9-9dda76b54340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1eb7743b-9f29-408a-88a9-9dda76b54340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cbff0da1-0fd4-471a-b86c-fa9d0c30f06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cbff0da1-0fd4-471a-b86c-fa9d0c30f06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_bef030fb-fe0c-4faa-99e5-570b1288f3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cbff0da1-0fd4-471a-b86c-fa9d0c30f06c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_bef030fb-fe0c-4faa-99e5-570b1288f3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d1f71315-5ce5-4d2a-a4d9-793e90d629bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cbff0da1-0fd4-471a-b86c-fa9d0c30f06c" xlink:to="loc_us-gaap_InterestExpense_d1f71315-5ce5-4d2a-a4d9-793e90d629bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExchangeOfDebt_bf09084a-52c5-47df-b5c0-7be7c114a246" xlink:href="fold-20211231.xsd#fold_GainLossOnExchangeOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cbff0da1-0fd4-471a-b86c-fa9d0c30f06c" xlink:to="loc_fold_GainLossOnExchangeOfDebt_bf09084a-52c5-47df-b5c0-7be7c114a246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_49c0b550-2706-431f-a6fe-ce108e5e791b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cbff0da1-0fd4-471a-b86c-fa9d0c30f06c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_49c0b550-2706-431f-a6fe-ce108e5e791b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d5cf63c7-d837-4273-a027-f8c86947cc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cbff0da1-0fd4-471a-b86c-fa9d0c30f06c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d5cf63c7-d837-4273-a027-f8c86947cc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0dfad655-9b4f-426c-b72c-82351160e46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0dfad655-9b4f-426c-b72c-82351160e46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_50dc99cb-3d57-47a5-9db0-65d7f7411431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_50dc99cb-3d57-47a5-9db0-65d7f7411431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f0d1985b-0b47-40b0-b68f-bd4697e8f74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_NetIncomeLoss_f0d1985b-0b47-40b0-b68f-bd4697e8f74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cf6f49fd-45a1-4336-8301-83ea7a48e119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_EarningsPerShareBasic_cf6f49fd-45a1-4336-8301-83ea7a48e119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9cbe6dcf-ef17-4fa5-9d51-9c58802e4760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9cbe6dcf-ef17-4fa5-9d51-9c58802e4760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_046bd53b-e80b-4251-bdce-9660b571b11a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_046bd53b-e80b-4251-bdce-9660b571b11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa30a19c-7631-4cd8-9f1f-efd8c0a9c3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95e73883-7515-484d-a1f3-9a0d680fb1c1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa30a19c-7631-4cd8-9f1f-efd8c0a9c3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_229ae520-521c-4e12-ba73-060985256e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c1014974-bd67-4cb7-afff-37c085f23327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_229ae520-521c-4e12-ba73-060985256e41" xlink:to="loc_us-gaap_NetIncomeLoss_c1014974-bd67-4cb7-afff-37c085f23327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3648986b-0403-47d4-8cb0-b970d1800584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_229ae520-521c-4e12-ba73-060985256e41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3648986b-0403-47d4-8cb0-b970d1800584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a4e77e80-a1a1-484f-9b9f-9020cb9ec925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3648986b-0403-47d4-8cb0-b970d1800584" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a4e77e80-a1a1-484f-9b9f-9020cb9ec925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f7f30a37-e9f6-4802-909f-db3301a19702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3648986b-0403-47d4-8cb0-b970d1800584" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f7f30a37-e9f6-4802-909f-db3301a19702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8015985a-f4c0-4953-9acb-40b68fec0aab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3648986b-0403-47d4-8cb0-b970d1800584" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8015985a-f4c0-4953-9acb-40b68fec0aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_88864bcd-81b4-4a1a-9a04-3b18a365b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_229ae520-521c-4e12-ba73-060985256e41" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_88864bcd-81b4-4a1a-9a04-3b18a365b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedStatementsofComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b4d86d41-bbed-4208-b3b6-01a21c71e631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_963bf60f-a92f-4789-8f6d-95bf0cc48a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b4d86d41-bbed-4208-b3b6-01a21c71e631" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_963bf60f-a92f-4789-8f6d-95bf0cc48a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_35099d69-1205-458c-b707-d649bfab5a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b4d86d41-bbed-4208-b3b6-01a21c71e631" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_35099d69-1205-458c-b707-d649bfab5a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_55fb0a6f-df7d-4d2f-9d0d-d5e5be5ba8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a14287f4-ccae-4dd6-87c8-e757a4afe167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_55fb0a6f-df7d-4d2f-9d0d-d5e5be5ba8b6" xlink:to="loc_us-gaap_StatementTable_a14287f4-ccae-4dd6-87c8-e757a4afe167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cda0f192-630a-4fc0-a698-49ea49601dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a14287f4-ccae-4dd6-87c8-e757a4afe167" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cda0f192-630a-4fc0-a698-49ea49601dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cda0f192-630a-4fc0-a698-49ea49601dab" xlink:to="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4bc82576-9e97-4567-94cd-e703dd097141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_CommonStockMember_4bc82576-9e97-4567-94cd-e703dd097141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_96fa6ba6-c5de-4d20-845a-c5723c481485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_96fa6ba6-c5de-4d20-845a-c5723c481485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a958f909-4dc4-4a94-b0ad-7ca0bd75e72f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_WarrantMember_a958f909-4dc4-4a94-b0ad-7ca0bd75e72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_3e7395d8-8aa7-4278-a527-3a9b3bdb8c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_3e7395d8-8aa7-4278-a527-3a9b3bdb8c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3a966af8-5378-40b3-96af-1bb2374d6a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_551eb213-67d6-4687-9670-a5ab3d606f1f" xlink:to="loc_us-gaap_RetainedEarningsMember_3a966af8-5378-40b3-96af-1bb2374d6a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0e89e5e7-c21c-46e4-9ec3-af4af513fd39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a14287f4-ccae-4dd6-87c8-e757a4afe167" xlink:to="loc_us-gaap_StatementLineItems_0e89e5e7-c21c-46e4-9ec3-af4af513fd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e89e5e7-c21c-46e4-9ec3-af4af513fd39" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e96c792e-5a25-4e31-9730-9221b1bfcebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e96c792e-5a25-4e31-9730-9221b1bfcebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_048cf5dd-3eab-44dd-9412-e70178a9f682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockholdersEquity_048cf5dd-3eab-44dd-9412-e70178a9f682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de615cb9-7207-4fa4-89ec-e37457520f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_de615cb9-7207-4fa4-89ec-e37457520f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ce063b1d-985b-4db9-8c38-8809817cde8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ce063b1d-985b-4db9-8c38-8809817cde8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d6c308ba-69fb-4d11-a310-897096a9913f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d6c308ba-69fb-4d11-a310-897096a9913f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34cfac69-d846-42af-8f6a-a2683972a993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34cfac69-d846-42af-8f6a-a2683972a993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f061ccaa-e0d0-4075-8e43-28cd53d26e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f061ccaa-e0d0-4075-8e43-28cd53d26e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_71693e70-0755-46f0-ada5-1f964b0b7073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_71693e70-0755-46f0-ada5-1f964b0b7073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_45874c26-36a4-473b-9d77-34149a1c320f" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_45874c26-36a4-473b-9d77-34149a1c320f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_d9eb733a-16b7-4320-8a3a-f073e257abfb" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_d9eb733a-16b7-4320-8a3a-f073e257abfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_35f453b6-edca-40a3-b695-a2c30c7c2e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_35f453b6-edca-40a3-b695-a2c30c7c2e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_424f16ce-88f8-4f68-9f9b-0ce63c204022" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_424f16ce-88f8-4f68-9f9b-0ce63c204022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_24d935eb-9f42-4442-bd3b-417f3f6c8161" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_24d935eb-9f42-4442-bd3b-417f3f6c8161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f85cb269-55ae-436c-aaa7-7e5bd70b9e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f85cb269-55ae-436c-aaa7-7e5bd70b9e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_b51377ff-7685-447b-907d-95c42884cf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_b51377ff-7685-447b-907d-95c42884cf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_d0da5d07-b846-406a-894a-1aebcd5ceb35" xlink:href="fold-20211231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_d0da5d07-b846-406a-894a-1aebcd5ceb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f087df51-3f1c-4beb-8198-76e30d31b498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f087df51-3f1c-4beb-8198-76e30d31b498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d729eec0-c361-4f9a-a93e-b4d07938f0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d729eec0-c361-4f9a-a93e-b4d07938f0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_44fccc7d-94ee-4c84-9881-fc5e22f2c4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_NetIncomeLoss_44fccc7d-94ee-4c84-9881-fc5e22f2c4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bdb6174e-cedb-462b-a6e5-97cd0fdda3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bdb6174e-cedb-462b-a6e5-97cd0fdda3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a13ccd37-ec63-40ff-9531-de25d972ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c6683c5-3b15-4674-8269-16c61ed50d53" xlink:to="loc_us-gaap_StockholdersEquity_a13ccd37-ec63-40ff-9531-de25d972ee3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fold-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_19f2649d-9bee-4c7a-8c95-f8362de5e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43ab2cfc-e173-4c8d-893e-02891c3a8f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19f2649d-9bee-4c7a-8c95-f8362de5e9b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43ab2cfc-e173-4c8d-893e-02891c3a8f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_064333e5-865a-4493-8fcd-276231430ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43ab2cfc-e173-4c8d-893e-02891c3a8f3a" xlink:to="loc_us-gaap_ProfitLoss_064333e5-865a-4493-8fcd-276231430ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43ab2cfc-e173-4c8d-893e-02891c3a8f3a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a8443aa9-a7b9-43f0-99a0-e718dcd5c061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a8443aa9-a7b9-43f0-99a0-e718dcd5c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bb965347-0b51-4d26-aa1c-49f7b3d2d371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bb965347-0b51-4d26-aa1c-49f7b3d2d371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_32596937-6c34-493f-adaa-f7b1d9c24c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:to="loc_us-gaap_ShareBasedCompensation_32596937-6c34-493f-adaa-f7b1d9c24c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExchangeOfDebt_2b071601-84c3-4e19-80b9-7cb379668e9e" xlink:href="fold-20211231.xsd#fold_GainLossOnExchangeOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:to="loc_fold_GainLossOnExchangeOfDebt_2b071601-84c3-4e19-80b9-7cb379668e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df795bbb-9994-4e6b-9c37-8c1a397e3599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_df795bbb-9994-4e6b-9c37-8c1a397e3599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4d8b62fa-f500-415b-b761-8474e5e67966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4d8b62fa-f500-415b-b761-8474e5e67966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_4223a7f3-3b06-4a5d-9451-24e3421d2ee8" xlink:href="fold-20211231.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_4223a7f3-3b06-4a5d-9451-24e3421d2ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0495f17d-36ec-4035-93bd-ee1c9c805f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0495f17d-36ec-4035-93bd-ee1c9c805f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c5e5e93a-7116-4505-8d61-23d0c6f5eba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad6f7882-f9c7-4076-8c37-a0f5d5d4b234" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c5e5e93a-7116-4505-8d61-23d0c6f5eba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f872dd01-5a5f-4533-819a-f11051a5876a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43ab2cfc-e173-4c8d-893e-02891c3a8f3a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f872dd01-5a5f-4533-819a-f11051a5876a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_45fd248c-f7a1-400f-80da-9b66b5b0fb48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f872dd01-5a5f-4533-819a-f11051a5876a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_45fd248c-f7a1-400f-80da-9b66b5b0fb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_aab8b90f-a10d-491d-b493-d6c604faae1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f872dd01-5a5f-4533-819a-f11051a5876a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_aab8b90f-a10d-491d-b493-d6c604faae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b1ec9e9f-5628-4fcd-8fa8-bf13cfe4932f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f872dd01-5a5f-4533-819a-f11051a5876a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b1ec9e9f-5628-4fcd-8fa8-bf13cfe4932f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_33714679-bec6-4976-ab9c-b421cf0c04b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f872dd01-5a5f-4533-819a-f11051a5876a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_33714679-bec6-4976-ab9c-b421cf0c04b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_d301816f-1953-4d58-9c41-799e450926cc" xlink:href="fold-20211231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f872dd01-5a5f-4533-819a-f11051a5876a" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_d301816f-1953-4d58-9c41-799e450926cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInDeferredReimbursements_fab6ae27-258b-4049-9101-fd761ad4c913" xlink:href="fold-20211231.xsd#fold_IncreaseDecreaseInDeferredReimbursements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f872dd01-5a5f-4533-819a-f11051a5876a" xlink:to="loc_fold_IncreaseDecreaseInDeferredReimbursements_fab6ae27-258b-4049-9101-fd761ad4c913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_c7f86ffb-b15d-4241-8007-f477eb75912e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f872dd01-5a5f-4533-819a-f11051a5876a" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_c7f86ffb-b15d-4241-8007-f477eb75912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6df4bf0d-8b67-4c80-a6dd-21d92d36a090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43ab2cfc-e173-4c8d-893e-02891c3a8f3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6df4bf0d-8b67-4c80-a6dd-21d92d36a090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_86c5f619-9631-4597-a4b3-fc91e50b72b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19f2649d-9bee-4c7a-8c95-f8362de5e9b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_86c5f619-9631-4597-a4b3-fc91e50b72b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d831057e-1253-4025-8785-ea4111b9e4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_86c5f619-9631-4597-a4b3-fc91e50b72b3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d831057e-1253-4025-8785-ea4111b9e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1329f6be-afde-4811-b496-cf1cf4562171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_86c5f619-9631-4597-a4b3-fc91e50b72b3" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1329f6be-afde-4811-b496-cf1cf4562171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9ccc6b1f-3a48-44a8-9bd1-519fd376ba50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_86c5f619-9631-4597-a4b3-fc91e50b72b3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9ccc6b1f-3a48-44a8-9bd1-519fd376ba50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87488a7e-a7dc-48db-9770-c3804a6eb1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_86c5f619-9631-4597-a4b3-fc91e50b72b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87488a7e-a7dc-48db-9770-c3804a6eb1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19f2649d-9bee-4c7a-8c95-f8362de5e9b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_047b43b8-d8a7-4b38-b0b6-c7d642ae8fca" xlink:href="fold-20211231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_047b43b8-d8a7-4b38-b0b6-c7d642ae8fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_550b3d0e-214c-42bc-a81b-3fb6c661943d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_550b3d0e-214c-42bc-a81b-3fb6c661943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f7c20784-eadd-483e-9c7c-d282d4f1f958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f7c20784-eadd-483e-9c7c-d282d4f1f958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_fedd6c88-03a6-42a0-a288-cc3d2f1bf57f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_fedd6c88-03a6-42a0-a288-cc3d2f1bf57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ca040ab6-729a-4f89-be51-4d044a690ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ca040ab6-729a-4f89-be51-4d044a690ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_79b65d4d-3989-49d5-8895-6f73dd457e18" xlink:href="fold-20211231.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_79b65d4d-3989-49d5-8895-6f73dd457e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_8685ad4f-6eb0-4f64-86e2-3adb2898439d" xlink:href="fold-20211231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_8685ad4f-6eb0-4f64-86e2-3adb2898439d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8ae09900-c9e5-476c-8959-a171189f68fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8ae09900-c9e5-476c-8959-a171189f68fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_182e9927-7fdd-42fc-8186-bb9ff0674cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_182e9927-7fdd-42fc-8186-bb9ff0674cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_90453dfb-7ae2-4ecc-b97c-caa55f501997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_90453dfb-7ae2-4ecc-b97c-caa55f501997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32c70b0f-29c2-4f98-9f6b-30a90540bc41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d2631981-a98f-44e1-8750-fb4f71cd25bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32c70b0f-29c2-4f98-9f6b-30a90540bc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcf40fab-f197-453b-b8e5-8f3380c223d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19f2649d-9bee-4c7a-8c95-f8362de5e9b9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcf40fab-f197-453b-b8e5-8f3380c223d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69f29b1d-cacc-4bf2-8ea3-590a7dee1c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19f2649d-9bee-4c7a-8c95-f8362de5e9b9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69f29b1d-cacc-4bf2-8ea3-590a7dee1c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_201aa3ec-6b69-4a89-8038-44597d2f75fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19f2649d-9bee-4c7a-8c95-f8362de5e9b9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_201aa3ec-6b69-4a89-8038-44597d2f75fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_826ee566-3500-4004-8692-18119538269b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19f2649d-9bee-4c7a-8c95-f8362de5e9b9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_826ee566-3500-4004-8692-18119538269b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_31dc2b53-8dc7-467f-b0b4-44f453c1cb92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_19f2649d-9bee-4c7a-8c95-f8362de5e9b9" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_31dc2b53-8dc7-467f-b0b4-44f453c1cb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_f38b15cc-bc99-40a7-bdde-ee983206df1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31dc2b53-8dc7-467f-b0b4-44f453c1cb92" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_f38b15cc-bc99-40a7-bdde-ee983206df1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8bc36172-eccf-4ca6-93e7-5b133c7a8fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31dc2b53-8dc7-467f-b0b4-44f453c1cb92" xlink:to="loc_us-gaap_InterestPaidNet_8bc36172-eccf-4ca6-93e7-5b133c7a8fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationPaidInStock_2dbff587-0e35-4e9e-9220-12bee3dc559c" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationPaidInStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31dc2b53-8dc7-467f-b0b4-44f453c1cb92" xlink:to="loc_fold_ContingentConsiderationPaidInStock_2dbff587-0e35-4e9e-9220-12bee3dc559c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08a81f41-e594-4cf5-96f6-4e2df3e96da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31dc2b53-8dc7-467f-b0b4-44f453c1cb92" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08a81f41-e594-4cf5-96f6-4e2df3e96da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3cc0335a-505e-4b5c-b893-134b268aa33e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31dc2b53-8dc7-467f-b0b4-44f453c1cb92" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_3cc0335a-505e-4b5c-b893-134b268aa33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="fold-20211231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a22053c-80d2-40f4-bf40-79a7154888f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d187c4f3-7d53-439a-baee-0161e160e879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a22053c-80d2-40f4-bf40-79a7154888f7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d187c4f3-7d53-439a-baee-0161e160e879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_529b6dbf-a7ab-4e4e-9828-138ab85372c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_529b6dbf-a7ab-4e4e-9828-138ab85372c0" xlink:to="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c11dc9cd-fd4f-4265-b53f-846e15a504c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c11dc9cd-fd4f-4265-b53f-846e15a504c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_efe1d72d-ca29-4082-b64b-fbe402af8e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c11dc9cd-fd4f-4265-b53f-846e15a504c2" xlink:to="loc_us-gaap_EquityComponentDomain_efe1d72d-ca29-4082-b64b-fbe402af8e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_db3edfc4-2a7f-4249-aa08-a9aa026682a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_efe1d72d-ca29-4082-b64b-fbe402af8e6b" xlink:to="loc_us-gaap_CommonStockMember_db3edfc4-2a7f-4249-aa08-a9aa026682a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6dd43bf6-3c68-4ceb-9882-1dcb87401481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6dd43bf6-3c68-4ceb-9882-1dcb87401481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_709bf2e3-6ef2-49bf-a393-d0c1f7b94f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6dd43bf6-3c68-4ceb-9882-1dcb87401481" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_709bf2e3-6ef2-49bf-a393-d0c1f7b94f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_cb61d493-c5e4-4ba1-9299-0240e59c433e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_709bf2e3-6ef2-49bf-a393-d0c1f7b94f5a" xlink:to="loc_us-gaap_PrivatePlacementMember_cb61d493-c5e4-4ba1-9299-0240e59c433e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_28dfae38-b144-4475-a600-2e8b88974d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_28dfae38-b144-4475-a600-2e8b88974d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_98b969f3-40be-474b-8b23-321e418acc44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_28dfae38-b144-4475-a600-2e8b88974d1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_98b969f3-40be-474b-8b23-321e418acc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9d7383c8-b31a-4698-bc02-2888ff8aa548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_98b969f3-40be-474b-8b23-321e418acc44" xlink:to="loc_us-gaap_WarrantMember_9d7383c8-b31a-4698-bc02-2888ff8aa548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_26cea438-0a94-4c79-9196-8a99632789c9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19e57a46-99dd-4740-8711-cbdce3231f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19e57a46-99dd-4740-8711-cbdce3231f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2c13250d-6bd1-467b-bbe1-723b8b906a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2c13250d-6bd1-467b-bbe1-723b8b906a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_816cb4af-1e40-4f0d-81df-bec47892edcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_816cb4af-1e40-4f0d-81df-bec47892edcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_72c9c3c9-dee2-4409-acc3-e2d9b946c6ec" xlink:href="fold-20211231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_72c9c3c9-dee2-4409-acc3-e2d9b946c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a9a295b-f385-42da-9ff2-63e696e8c9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3bc0341f-e05d-45d9-a2a4-275e0c1d96c0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a9a295b-f385-42da-9ff2-63e696e8c9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3cddd2e7-48c2-41b5-9197-d310bfaf1a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e6c0ae9f-f514-40e7-a740-f689a764bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3cddd2e7-48c2-41b5-9197-d310bfaf1a53" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e6c0ae9f-f514-40e7-a740-f689a764bd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_04b9ee49-f3d2-4902-b100-9a76884831e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_04b9ee49-f3d2-4902-b100-9a76884831e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_c1cb0bad-4344-4f52-8e1b-4ef55ca93675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_c1cb0bad-4344-4f52-8e1b-4ef55ca93675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e54206d2-15e7-4465-b1e4-a6c7acbeb6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e54206d2-15e7-4465-b1e4-a6c7acbeb6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_65919fcf-a063-4f21-9876-26d32bd30f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_UseOfEstimates_65919fcf-a063-4f21-9876-26d32bd30f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_096d8a14-d228-4d4f-b25d-0a79dfdbd2e7" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_096d8a14-d228-4d4f-b25d-0a79dfdbd2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_689443a0-f341-4045-b12f-b7189101f3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_689443a0-f341-4045-b12f-b7189101f3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ce385d8f-f1ed-49f9-a3f2-86a536158515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ce385d8f-f1ed-49f9-a3f2-86a536158515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e2ff52cf-bffc-46f1-9c1a-2226019f7fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e2ff52cf-bffc-46f1-9c1a-2226019f7fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_3490c5df-d495-4392-bd98-096e721f23ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_3490c5df-d495-4392-bd98-096e721f23ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_79b347cb-8049-4d4d-a208-c3b0a431d2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_79b347cb-8049-4d4d-a208-c3b0a431d2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_b0227d76-b9c9-4960-93ec-dc65c7b1dc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_b0227d76-b9c9-4960-93ec-dc65c7b1dc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c44d8c1e-e00f-4a45-99d2-df247c8e8302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c44d8c1e-e00f-4a45-99d2-df247c8e8302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock_1efef898-7ae9-4a56-8d78-388f433c6f14" xlink:href="fold-20211231.xsd#fold_InterestIncomeAndInterestExpensePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock_1efef898-7ae9-4a56-8d78-388f433c6f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_a7424d13-8180-49f9-af3d-281f10f4ecb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_a7424d13-8180-49f9-af3d-281f10f4ecb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_f8b86abf-0c13-4dbc-8fd5-cf24b040d220" xlink:href="fold-20211231.xsd#fold_OtherComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_f8b86abf-0c13-4dbc-8fd5-cf24b040d220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_cb89f2d7-bd7a-42f4-9a69-ee674f4512ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_cb89f2d7-bd7a-42f4-9a69-ee674f4512ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_ed3f4f2e-886c-4c71-9b84-caeeef107a5b" xlink:href="fold-20211231.xsd#fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_ed3f4f2e-886c-4c71-9b84-caeeef107a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_03023cd7-5050-416d-8c41-8963c3f4f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_03023cd7-5050-416d-8c41-8963c3f4f1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_09ed0009-3caf-4ca3-a48b-bc2eb4cda8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_09ed0009-3caf-4ca3-a48b-bc2eb4cda8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d3a1d24d-84c4-450f-92b5-c396df62ba54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d3a1d24d-84c4-450f-92b5-c396df62ba54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_ab48ddef-31a5-4de3-9717-4375b5a168e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_ab48ddef-31a5-4de3-9717-4375b5a168e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_f6de1a41-8dc2-42dd-8f37-5dd8abc3fde8" xlink:href="fold-20211231.xsd#fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_f6de1a41-8dc2-42dd-8f37-5dd8abc3fde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7d3ced3d-308c-4b9c-8cd0-d5834ff7e9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7d3ced3d-308c-4b9c-8cd0-d5834ff7e9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_95bd6106-2eb2-412a-bf83-f7206d06c9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_10694a92-13ec-4b69-97d4-19a3193e4f09" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_95bd6106-2eb2-412a-bf83-f7206d06c9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8df64348-e6d1-4e76-baf8-805cb408b8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_74ff7bb1-a031-433e-a43c-69f1f1d6eba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8df64348-e6d1-4e76-baf8-805cb408b8c7" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_74ff7bb1-a031-433e-a43c-69f1f1d6eba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b6eff3a6-2431-4a89-b95c-48ac96087084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6eff3a6-2431-4a89-b95c-48ac96087084" xlink:to="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_08b52a19-8bcc-4fbe-ab12-56fc535bde04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_08b52a19-8bcc-4fbe-ab12-56fc535bde04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91a93519-03fc-4b38-8664-5b7bf4f5711c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_08b52a19-8bcc-4fbe-ab12-56fc535bde04" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91a93519-03fc-4b38-8664-5b7bf4f5711c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_e2e91820-6f39-4cf6-9276-ab9e2908f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91a93519-03fc-4b38-8664-5b7bf4f5711c" xlink:to="loc_us-gaap_SalesRevenueNetMember_e2e91820-6f39-4cf6-9276-ab9e2908f3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2d920c31-1da8-415f-a78a-2de686f60631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91a93519-03fc-4b38-8664-5b7bf4f5711c" xlink:to="loc_us-gaap_AccountsReceivableMember_2d920c31-1da8-415f-a78a-2de686f60631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_95099f33-8e0a-4cd0-9358-9b70e6b60956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_95099f33-8e0a-4cd0-9358-9b70e6b60956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9822d020-abda-4393-83c2-468649635f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_95099f33-8e0a-4cd0-9358-9b70e6b60956" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9822d020-abda-4393-83c2-468649635f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_94f97acb-7ede-43e7-b380-b82519b355ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9822d020-abda-4393-83c2-468649635f4f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_94f97acb-7ede-43e7-b380-b82519b355ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_81caa96f-7af9-403f-8276-9d35d8ff2465" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:to="loc_srt_MajorCustomersAxis_81caa96f-7af9-403f-8276-9d35d8ff2465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_60a9f57f-cf8b-4c3c-b07d-89dcfb89e861" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_81caa96f-7af9-403f-8276-9d35d8ff2465" xlink:to="loc_srt_NameOfMajorCustomerDomain_60a9f57f-cf8b-4c3c-b07d-89dcfb89e861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CustomerOneMember_a856c68b-9e63-4c8f-8bb4-22d75885ff30" xlink:href="fold-20211231.xsd#fold_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_60a9f57f-cf8b-4c3c-b07d-89dcfb89e861" xlink:to="loc_fold_CustomerOneMember_a856c68b-9e63-4c8f-8bb4-22d75885ff30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_8634ba6d-05ef-4e5d-872d-64206e3c0207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8152e4e3-ebf3-43b8-9a99-427d71754158" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_8634ba6d-05ef-4e5d-872d-64206e3c0207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_123bb4d4-241e-48cf-9a09-686e887f4003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8634ba6d-05ef-4e5d-872d-64206e3c0207" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_123bb4d4-241e-48cf-9a09-686e887f4003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b635bdd0-5096-40ec-aa04-b21aa1445794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_8634ba6d-05ef-4e5d-872d-64206e3c0207" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b635bdd0-5096-40ec-aa04-b21aa1445794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_04480332-42b1-4610-848e-3b6204f203fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cea0a26b-c603-4dbf-b31e-2ee227b7b169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04480332-42b1-4610-848e-3b6204f203fd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cea0a26b-c603-4dbf-b31e-2ee227b7b169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_715ce987-10f8-4d28-80f2-521d63ab1a76" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cea0a26b-c603-4dbf-b31e-2ee227b7b169" xlink:to="loc_srt_RangeAxis_715ce987-10f8-4d28-80f2-521d63ab1a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ea14473-e4a9-4efa-81e0-5e2649d838e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_715ce987-10f8-4d28-80f2-521d63ab1a76" xlink:to="loc_srt_RangeMember_4ea14473-e4a9-4efa-81e0-5e2649d838e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4012d23-dee9-46ac-9971-cd8b509a3d63" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4ea14473-e4a9-4efa-81e0-5e2649d838e0" xlink:to="loc_srt_MinimumMember_d4012d23-dee9-46ac-9971-cd8b509a3d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_793849b5-0c21-4a9e-85ef-ab3d445847a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4ea14473-e4a9-4efa-81e0-5e2649d838e0" xlink:to="loc_srt_MaximumMember_793849b5-0c21-4a9e-85ef-ab3d445847a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc223c61-c42a-4542-9612-1d3d0e408e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cea0a26b-c603-4dbf-b31e-2ee227b7b169" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc223c61-c42a-4542-9612-1d3d0e408e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2b852aae-a11a-4222-a3eb-f5390003af13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc223c61-c42a-4542-9612-1d3d0e408e21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2b852aae-a11a-4222-a3eb-f5390003af13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a2f8fe59-c54b-4310-b2bb-fa82b3dcf229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0ef02c23-f7c4-4fe4-a70b-c62213f8d2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2f8fe59-c54b-4310-b2bb-fa82b3dcf229" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0ef02c23-f7c4-4fe4-a70b-c62213f8d2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a789105b-a341-4195-8678-6d0787411942" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0ef02c23-f7c4-4fe4-a70b-c62213f8d2af" xlink:to="loc_srt_StatementGeographicalAxis_a789105b-a341-4195-8678-6d0787411942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2ce26c65-3282-4ca2-9140-8fd6917ecefb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a789105b-a341-4195-8678-6d0787411942" xlink:to="loc_srt_SegmentGeographicalDomain_2ce26c65-3282-4ca2-9140-8fd6917ecefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_332dcac2-6ac5-4cc7-aa8d-04249961e82d" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2ce26c65-3282-4ca2-9140-8fd6917ecefb" xlink:to="loc_country_US_332dcac2-6ac5-4cc7-aa8d-04249961e82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a13a4595-26ee-4d1c-b385-a2897d7db4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2ce26c65-3282-4ca2-9140-8fd6917ecefb" xlink:to="loc_us-gaap_NonUsMember_a13a4595-26ee-4d1c-b385-a2897d7db4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c179c26f-0f72-400a-876c-f59916bb92cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0ef02c23-f7c4-4fe4-a70b-c62213f8d2af" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c179c26f-0f72-400a-876c-f59916bb92cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93f4bcf5-fd42-4204-be52-7e0208b049ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c179c26f-0f72-400a-876c-f59916bb92cc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93f4bcf5-fd42-4204-be52-7e0208b049ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ef56718c-88f0-4d1b-9906-6cac64a5c751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_fcd09941-9f0e-4258-ae8c-1c2deb0eb1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef56718c-88f0-4d1b-9906-6cac64a5c751" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_fcd09941-9f0e-4258-ae8c-1c2deb0eb1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationNumberOfPlans_8c6dfecc-01e0-4c34-a46e-a9baccdbdbf3" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationNumberOfPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_fcd09941-9f0e-4258-ae8c-1c2deb0eb1c2" xlink:to="loc_fold_ShareBasedCompensationNumberOfPlans_8c6dfecc-01e0-4c34-a46e-a9baccdbdbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_25906665-2a23-4e7c-abd5-0122abca8657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_72748691-b0d2-4e92-aff5-9bd3dfcbbd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25906665-2a23-4e7c-abd5-0122abca8657" xlink:to="loc_us-gaap_NumberOfOperatingSegments_72748691-b0d2-4e92-aff5-9bd3dfcbbd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_f5e1c87e-c109-4710-a556-fbc9c703a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25906665-2a23-4e7c-abd5-0122abca8657" xlink:to="loc_us-gaap_NumberOfReportingUnits_f5e1c87e-c109-4710-a556-fbc9c703a19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="fold-20211231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_938769f6-eb25-459f-96c1-d1c7bf17e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e04920fe-3773-4be9-8327-261fab96d4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_938769f6-eb25-459f-96c1-d1c7bf17e6dd" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e04920fe-3773-4be9-8327-261fab96d4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="fold-20211231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50cb1185-3968-426a-b22f-48659f06d806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_0568cceb-7174-4b9c-a039-56a8bcaa5a55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50cb1185-3968-426a-b22f-48659f06d806" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_0568cceb-7174-4b9c-a039-56a8bcaa5a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_3b1ed1a1-2d49-475a-be14-733a76c52a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50cb1185-3968-426a-b22f-48659f06d806" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_3b1ed1a1-2d49-475a-be14-733a76c52a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7e4631bc-ad7a-48d2-9f42-ac7e65701060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cf473eb5-cb06-4064-8473-2e084bbdc4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7e4631bc-ad7a-48d2-9f42-ac7e65701060" xlink:to="loc_us-gaap_Goodwill_cf473eb5-cb06-4064-8473-2e084bbdc4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_013ed549-6bd1-48fd-b10e-f178ca458aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7e4631bc-ad7a-48d2-9f42-ac7e65701060" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_013ed549-6bd1-48fd-b10e-f178ca458aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#GoodwillandIntangibleAssetsChangesinIPRDDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e4f12a8b-164b-4cf9-a45c-2209d8d72a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_86a82004-c3dd-42a7-ba3d-10b3f01844a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e4f12a8b-164b-4cf9-a45c-2209d8d72a12" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_86a82004-c3dd-42a7-ba3d-10b3f01844a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9df65945-2171-4e7b-a019-2cb05bd2b392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_86a82004-c3dd-42a7-ba3d-10b3f01844a2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9df65945-2171-4e7b-a019-2cb05bd2b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_503dd9ba-4c15-4ccc-8617-6a500844b46d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_86a82004-c3dd-42a7-ba3d-10b3f01844a2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_503dd9ba-4c15-4ccc-8617-6a500844b46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_837bce96-14f2-42d9-8da2-b83fefe849df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_86a82004-c3dd-42a7-ba3d-10b3f01844a2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_837bce96-14f2-42d9-8da2-b83fefe849df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ad76562e-eac4-4027-ad4a-c0629431f008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e4f12a8b-164b-4cf9-a45c-2209d8d72a12" xlink:to="loc_us-gaap_GoodwillRollForward_ad76562e-eac4-4027-ad4a-c0629431f008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2968c569-8d79-40a4-9433-ea04eeabe89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ad76562e-eac4-4027-ad4a-c0629431f008" xlink:to="loc_us-gaap_Goodwill_2968c569-8d79-40a4-9433-ea04eeabe89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_7aca9302-0189-4e5e-bd3f-45b1ecd03e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ad76562e-eac4-4027-ad4a-c0629431f008" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_7aca9302-0189-4e5e-bd3f-45b1ecd03e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_28d00444-5272-4912-ae31-84c9adef60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ad76562e-eac4-4027-ad4a-c0629431f008" xlink:to="loc_us-gaap_Goodwill_28d00444-5272-4912-ae31-84c9adef60ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_3d99b1be-bc82-4615-97fb-1c1e94a03a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_c8db6ced-8c6b-4c7d-b149-8872113aea44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_3d99b1be-bc82-4615-97fb-1c1e94a03a77" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_c8db6ced-8c6b-4c7d-b149-8872113aea44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_147f14bb-49c8-4bda-a4b0-583a2d1727a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_4744f6d0-e092-4428-b16d-d14d2a5e40e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_147f14bb-49c8-4bda-a4b0-583a2d1727a5" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_4744f6d0-e092-4428-b16d-d14d2a5e40e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_a9e003ad-f1cd-4ec9-b287-c2e3cc4131b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_147f14bb-49c8-4bda-a4b0-583a2d1727a5" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_a9e003ad-f1cd-4ec9-b287-c2e3cc4131b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_93d839a1-237e-4699-a3d9-f2649ca35905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9491f99-c132-4f94-b2f9-4c3aaea9f2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_93d839a1-237e-4699-a3d9-f2649ca35905" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9491f99-c132-4f94-b2f9-4c3aaea9f2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6eb45223-2df5-48f8-b270-9e4d0240434e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_93d839a1-237e-4699-a3d9-f2649ca35905" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6eb45223-2df5-48f8-b270-9e4d0240434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_ce7b323f-9a76-4575-872c-fda4b4c5851c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_93d839a1-237e-4699-a3d9-f2649ca35905" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_ce7b323f-9a76-4575-872c-fda4b4c5851c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_820787df-d9b0-409c-b4e7-0adb13b0d1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_93d839a1-237e-4699-a3d9-f2649ca35905" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_820787df-d9b0-409c-b4e7-0adb13b0d1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_7b5c1e05-3351-4117-b895-338b7038cf01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0f084f7d-4ad8-4d67-9267-d11a2a9f652a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_7b5c1e05-3351-4117-b895-338b7038cf01" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0f084f7d-4ad8-4d67-9267-d11a2a9f652a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1cb529c5-c2b9-4251-a575-ff2bb14f3507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0f084f7d-4ad8-4d67-9267-d11a2a9f652a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1cb529c5-c2b9-4251-a575-ff2bb14f3507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1cb529c5-c2b9-4251-a575-ff2bb14f3507" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_8ddcd683-6c1e-4bca-9ee8-e4427d8577f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_8ddcd683-6c1e-4bca-9ee8-e4427d8577f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_a77fee62-099f-4672-9f76-024379ccc115" xlink:href="fold-20211231.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_a77fee62-099f-4672-9f76-024379ccc115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c1edbf3c-2da1-4870-9e6a-f894dbfd3633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c1edbf3c-2da1-4870-9e6a-f894dbfd3633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_92bdbd1d-ca05-45d1-97c4-948051026379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_92bdbd1d-ca05-45d1-97c4-948051026379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f7190033-fdf7-4117-a54f-59b5c3912439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f7190033-fdf7-4117-a54f-59b5c3912439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_598ea547-4221-4522-8598-8759cc854e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babdd6d2-dbb4-46e3-9008-ba0088367b8f" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_598ea547-4221-4522-8598-8759cc854e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0f084f7d-4ad8-4d67-9267-d11a2a9f652a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_270cb8c0-1211-4722-9c11-e49e2722b2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_270cb8c0-1211-4722-9c11-e49e2722b2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8cb5d486-1e22-4db3-8b07-681c7ce3bba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8cb5d486-1e22-4db3-8b07-681c7ce3bba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_3a509206-320f-4131-a7fc-6867d8b6a356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_3a509206-320f-4131-a7fc-6867d8b6a356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1d4e729e-72a9-49af-add0-20913d6c429d" xlink:href="fold-20211231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_1d4e729e-72a9-49af-add0-20913d6c429d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_71fc3ba5-2a7b-4bce-a0a8-3ff49b5fe887" xlink:href="fold-20211231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_71fc3ba5-2a7b-4bce-a0a8-3ff49b5fe887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3c20787-3166-48f2-b95b-a4818d018386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3c20787-3166-48f2-b95b-a4818d018386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c2fc676-f283-4b00-9363-0ffbad080afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0c2fc676-f283-4b00-9363-0ffbad080afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_faf05738-9149-40fd-afaa-72d1ae02c985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_faf05738-9149-40fd-afaa-72d1ae02c985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a8db1566-6241-4921-a1d4-29a87dc297aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a8db1566-6241-4921-a1d4-29a87dc297aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fc60f9e0-c60e-43ee-81a1-d6916ca4705e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fc60f9e0-c60e-43ee-81a1-d6916ca4705e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_fe27ddf8-80bf-432c-b57f-18062f0ccfab" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_fe27ddf8-80bf-432c-b57f-18062f0ccfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3dd91d6-83c9-4b11-b310-cee13a7e5228" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3dd91d6-83c9-4b11-b310-cee13a7e5228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_389ab8a1-6d43-425c-8720-e60ca76d5c01" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_389ab8a1-6d43-425c-8720-e60ca76d5c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_bf5214e5-0cfe-40c0-8e4a-7a29a9b2d5d6" xlink:href="fold-20211231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cf7dd85d-2df6-4580-a395-c5865a46d6a6" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_bf5214e5-0cfe-40c0-8e4a-7a29a9b2d5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_48652dcf-1694-4098-9679-bff30322096d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_608165a1-105f-4a00-9f37-e7458087697c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_48652dcf-1694-4098-9679-bff30322096d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_608165a1-105f-4a00-9f37-e7458087697c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_f7b9b0d1-ddf4-4d4a-8441-42ae11c27425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_48652dcf-1694-4098-9679-bff30322096d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_f7b9b0d1-ddf4-4d4a-8441-42ae11c27425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9627f63-78dd-40c9-a728-ac8cab24f3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_48652dcf-1694-4098-9679-bff30322096d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9627f63-78dd-40c9-a728-ac8cab24f3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="fold-20211231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6e71ef73-75e9-4e97-b11f-a27ef4b12d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_5c992ca8-f520-45da-8e87-72764873c964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6e71ef73-75e9-4e97-b11f-a27ef4b12d66" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_5c992ca8-f520-45da-8e87-72764873c964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="fold-20211231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4c62b606-aa7a-4919-a206-4574919a7976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_077565a3-86fa-46d1-b812-ac55aae30539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4c62b606-aa7a-4919-a206-4574919a7976" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_077565a3-86fa-46d1-b812-ac55aae30539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b5f84645-7354-4020-b8a1-b22d3dc6ccab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_477b0ee2-c12c-4752-87f9-7622cfad7ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b5f84645-7354-4020-b8a1-b22d3dc6ccab" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_477b0ee2-c12c-4752-87f9-7622cfad7ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6d9efc69-bc6d-4c29-831d-4a934238817e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b5f84645-7354-4020-b8a1-b22d3dc6ccab" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6d9efc69-bc6d-4c29-831d-4a934238817e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f429fabc-67fd-4d33-b4ff-e6d6f0293ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b5f84645-7354-4020-b8a1-b22d3dc6ccab" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f429fabc-67fd-4d33-b4ff-e6d6f0293ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_581bad3f-3445-44ca-ab76-6ebf78c12172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b5f84645-7354-4020-b8a1-b22d3dc6ccab" xlink:to="loc_us-gaap_InventoryNet_581bad3f-3445-44ca-ab76-6ebf78c12172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_bcdebc69-91b2-4383-a029-d401f8e84355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b5f84645-7354-4020-b8a1-b22d3dc6ccab" xlink:to="loc_us-gaap_InventoryValuationReserves_bcdebc69-91b2-4383-a029-d401f8e84355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="fold-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_66bcbfaa-db9b-408c-a6fd-8298d0184795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_df6c4ce9-f36e-4855-964d-95a8fff0c2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_66bcbfaa-db9b-408c-a6fd-8298d0184795" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_df6c4ce9-f36e-4855-964d-95a8fff0c2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="fold-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1cfe9aa5-0a5f-4c08-a257-9befa70825e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3dee112a-88f8-414f-8f4b-0cd9b9b95349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1cfe9aa5-0a5f-4c08-a257-9befa70825e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3dee112a-88f8-414f-8f4b-0cd9b9b95349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_09d253f4-5b0b-4d19-ba3e-26884affa8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8eb42f6-4ad2-4417-a5bc-bf30590657c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_09d253f4-5b0b-4d19-ba3e-26884affa8a7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8eb42f6-4ad2-4417-a5bc-bf30590657c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_234da121-ad0c-4d0c-a345-ff9396602638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8eb42f6-4ad2-4417-a5bc-bf30590657c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_234da121-ad0c-4d0c-a345-ff9396602638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_234da121-ad0c-4d0c-a345-ff9396602638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bbcf8fb7-e30a-4a80-b2db-cc06ebf0182c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bbcf8fb7-e30a-4a80-b2db-cc06ebf0182c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ResearchEquipmentMember_b23c0aa1-16b4-4c9a-8fe2-df9dd40d6606" xlink:href="fold-20211231.xsd#fold_ResearchEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_fold_ResearchEquipmentMember_b23c0aa1-16b4-4c9a-8fe2-df9dd40d6606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_21050389-635a-4b4b-90c9-296a23882476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_ConstructionInProgressMember_21050389-635a-4b4b-90c9-296a23882476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_72039f24-ddfd-4002-815e-31c9c9fb4527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_ComputerEquipmentMember_72039f24-ddfd-4002-815e-31c9c9fb4527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_099432e6-3e51-4ee8-b0ef-f56758299a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_LandMember_099432e6-3e51-4ee8-b0ef-f56758299a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2e3ba070-5232-4f7e-ba7f-efafcb9fa674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2e3ba070-5232-4f7e-ba7f-efafcb9fa674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_30cd2ce2-b2d2-4b2b-86ad-001edb9f51a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_30cd2ce2-b2d2-4b2b-86ad-001edb9f51a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_84f9715b-3223-4b6c-bffe-f5ea94acc072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24c8508e-6568-46e4-aa3a-1edce3e61a81" xlink:to="loc_us-gaap_VehiclesMember_84f9715b-3223-4b6c-bffe-f5ea94acc072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a8eb42f6-4ad2-4417-a5bc-bf30590657c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1ca8a13e-96a7-4851-a30c-90b43fa54a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1ca8a13e-96a7-4851-a30c-90b43fa54a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_982633b9-7dbc-4f29-b55b-dc7d0510e191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_982633b9-7dbc-4f29-b55b-dc7d0510e191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d29f382f-4f49-4b56-b502-d25646026b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d29f382f-4f49-4b56-b502-d25646026b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5eb48aa6-50f1-4fa7-a62a-977c4ef587d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e399645d-d88a-4039-83ef-e55e1bcb561e" xlink:to="loc_us-gaap_Depreciation_5eb48aa6-50f1-4fa7-a62a-977c4ef587d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="fold-20211231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_614f045d-5d4c-4c6f-87c6-3b7ed1184a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0d26acf7-fad0-4100-8e17-9c057c36ae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_614f045d-5d4c-4c6f-87c6-3b7ed1184a6a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0d26acf7-fad0-4100-8e17-9c057c36ae75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="fold-20211231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2633e44a-0cea-4c99-a11e-6e2025784cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5f436343-5066-4c3b-a373-8765bf8171de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2633e44a-0cea-4c99-a11e-6e2025784cc0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5f436343-5066-4c3b-a373-8765bf8171de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5b7a13cb-6c9d-48d7-91ba-a7db318627c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5b7a13cb-6c9d-48d7-91ba-a7db318627c5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dd6fe268-67b3-4049-99a1-105a7aa4978b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dd6fe268-67b3-4049-99a1-105a7aa4978b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_ffcc89f5-e4dc-403f-884e-56d6bdb5a9f3" xlink:href="fold-20211231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:to="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_ffcc89f5-e4dc-403f-884e-56d6bdb5a9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_b3a2e1b1-b5a0-430e-b985-2a888c3b32ca" xlink:href="fold-20211231.xsd#fold_AccruedSalesRebatesAndChargebacksCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:to="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_b3a2e1b1-b5a0-430e-b985-2a888c3b32ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedProgramFees_bd2cd107-771b-441a-b5ad-689f3bf3f12d" xlink:href="fold-20211231.xsd#fold_AccruedProgramFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:to="loc_fold_AccruedProgramFees_bd2cd107-771b-441a-b5ad-689f3bf3f12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_dca1c3ce-c673-46ca-9b98-7be54493aa88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_dca1c3ce-c673-46ca-9b98-7be54493aa88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_cafd827b-9285-47f4-a99a-97b7b4692335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:to="loc_us-gaap_TaxesPayableCurrent_cafd827b-9285-47f4-a99a-97b7b4692335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_f3436495-ba45-4917-957b-91fe65914d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_f3436495-ba45-4917-957b-91fe65914d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1e19cc79-c165-4b45-b97c-8953b196246e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1e19cc79-c165-4b45-b97c-8953b196246e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5f6100e5-025f-402d-9566-c53d286e1a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_8e5ed5f9-0257-4acd-bb1b-734cb3d84311" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5f6100e5-025f-402d-9566-c53d286e1a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="fold-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d22f3c7d-4254-4de5-bab4-434a14f7b057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a13dee45-693e-4d10-ab3d-7f119cd31def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d22f3c7d-4254-4de5-bab4-434a14f7b057" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a13dee45-693e-4d10-ab3d-7f119cd31def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#StockholdersEquityCommonStockandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f9bca8b5-d84e-4704-8bbf-9629d12273dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f9bca8b5-d84e-4704-8bbf-9629d12273dc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_68b9dacf-f24d-4b09-8d46-77e689995672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_68b9dacf-f24d-4b09-8d46-77e689995672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e3169bc4-db50-4bdc-8b40-ca547a10e69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_68b9dacf-f24d-4b09-8d46-77e689995672" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e3169bc4-db50-4bdc-8b40-ca547a10e69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4cd0bc97-7a92-4dff-88b2-8870c13fb9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e3169bc4-db50-4bdc-8b40-ca547a10e69b" xlink:to="loc_us-gaap_WarrantMember_4cd0bc97-7a92-4dff-88b2-8870c13fb9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1546c849-8034-4f87-ab59-f710da337b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1546c849-8034-4f87-ab59-f710da337b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_57ff24d4-489c-49d3-8adf-ceb73178c1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1546c849-8034-4f87-ab59-f710da337b6f" xlink:to="loc_us-gaap_ClassOfStockDomain_57ff24d4-489c-49d3-8adf-ceb73178c1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_afc84bf2-d465-4591-b66e-0437a89c8c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_57ff24d4-489c-49d3-8adf-ceb73178c1cf" xlink:to="loc_us-gaap_CommonStockMember_afc84bf2-d465-4591-b66e-0437a89c8c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1395d12d-d96e-4d6d-8abc-96976fe704ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1395d12d-d96e-4d6d-8abc-96976fe704ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ce87e81-6d42-489c-b736-74589567777f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1395d12d-d96e-4d6d-8abc-96976fe704ba" xlink:to="loc_us-gaap_EquityComponentDomain_6ce87e81-6d42-489c-b736-74589567777f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fd63546a-a71f-4941-82f3-9b85d87be70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ce87e81-6d42-489c-b736-74589567777f" xlink:to="loc_us-gaap_CommonStockMember_fd63546a-a71f-4941-82f3-9b85d87be70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e0c4665d-36da-4730-b0e7-09e42035c4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ce87e81-6d42-489c-b736-74589567777f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e0c4665d-36da-4730-b0e7-09e42035c4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9bdb3805-8683-47d2-86c9-bb879a51fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9bdb3805-8683-47d2-86c9-bb879a51fcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9bdb3805-8683-47d2-86c9-bb879a51fcc7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_UnderwrittenOfferingMember_28520d35-7646-4e89-888d-81650975c413" xlink:href="fold-20211231.xsd#fold_UnderwrittenOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:to="loc_fold_UnderwrittenOfferingMember_28520d35-7646-4e89-888d-81650975c413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_8f5cab07-0a12-4da4-bbf2-4ba3360d35e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:to="loc_us-gaap_PrivatePlacementMember_8f5cab07-0a12-4da4-bbf2-4ba3360d35e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt798Member_eae313f6-c91e-4594-952d-2be91151fedd" xlink:href="fold-20211231.xsd#fold_StockExercisesAt798Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:to="loc_fold_StockExercisesAt798Member_eae313f6-c91e-4594-952d-2be91151fedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt706Member_79269870-8c82-4ca4-9fb2-f9ced16321e7" xlink:href="fold-20211231.xsd#fold_StockExercisesAt706Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700235e2-5761-4fc8-8efc-47ffbb5427c0" xlink:to="loc_fold_StockExercisesAt706Member_79269870-8c82-4ca4-9fb2-f9ced16321e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf92acf8-b802-4114-931a-500457cff004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf92acf8-b802-4114-931a-500457cff004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d383e81a-c460-4e4c-a471-cad46184b30a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf92acf8-b802-4114-931a-500457cff004" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d383e81a-c460-4e4c-a471-cad46184b30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_22af94a4-2ce8-488a-bd50-2c199f84ce41" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d383e81a-c460-4e4c-a471-cad46184b30a" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_22af94a4-2ce8-488a-bd50-2c199f84ce41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e55f458f-e48d-45ab-a8f4-00b99c0a3020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e55f458f-e48d-45ab-a8f4-00b99c0a3020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2110bca4-9952-4c69-baa7-a30d0b38c10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e55f458f-e48d-45ab-a8f4-00b99c0a3020" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2110bca4-9952-4c69-baa7-a30d0b38c10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a5c2450d-1f5e-4562-bea4-3600cd2c03fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2110bca4-9952-4c69-baa7-a30d0b38c10a" xlink:to="loc_us-gaap_ConvertibleDebtMember_a5c2450d-1f5e-4562-bea4-3600cd2c03fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76f8bd9c-773c-4005-a640-80f2cb48b6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ea8bef2-0cf5-4cc2-8d16-fc601e95e777" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76f8bd9c-773c-4005-a640-80f2cb48b6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76f8bd9c-773c-4005-a640-80f2cb48b6bc" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a5476a0c-1344-41fa-9eb8-d1d8d399fbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a5476a0c-1344-41fa-9eb8-d1d8d399fbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CommonStockVotingRightsForEachShareHeld_f62a75bb-38d2-44b5-9005-d0bf0fde3b81" xlink:href="fold-20211231.xsd#fold_CommonStockVotingRightsForEachShareHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_fold_CommonStockVotingRightsForEachShareHeld_f62a75bb-38d2-44b5-9005-d0bf0fde3b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7719a698-578f-4ddb-aa54-a0eb0bcced7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7719a698-578f-4ddb-aa54-a0eb0bcced7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3e531e25-f129-46b0-97bf-c5ed122d971b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3e531e25-f129-46b0-97bf-c5ed122d971b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2a2b5c1d-b02b-4ca9-abfd-380f0830297a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2a2b5c1d-b02b-4ca9-abfd-380f0830297a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_925fc73a-8d22-460d-8018-405ebd82a0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_925fc73a-8d22-460d-8018-405ebd82a0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_447f115a-37d2-4118-bb26-644122c8b176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_447f115a-37d2-4118-bb26-644122c8b176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f3f9c73c-f8cb-45e2-80e7-45d5f81b7376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f3f9c73c-f8cb-45e2-80e7-45d5f81b7376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b513ef3a-c3e4-448d-ac15-cf806c91bf52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b513ef3a-c3e4-448d-ac15-cf806c91bf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1f2ce139-f800-420c-b53e-6a2d7bd1f9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1f2ce139-f800-420c-b53e-6a2d7bd1f9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6f479775-b2a0-4113-b35a-e2dfefedc28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6f479775-b2a0-4113-b35a-e2dfefedc28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bca1a079-71c3-4920-9694-ac6f7c705eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bca1a079-71c3-4920-9694-ac6f7c705eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMilestonePayment_707468ab-598a-489f-9007-bad24b2b4a20" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationMilestonePayment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_fold_ContingentConsiderationMilestonePayment_707468ab-598a-489f-9007-bad24b2b4a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration_99a6f2d1-03be-424c-b734-4d4e8e42da61" xlink:href="fold-20211231.xsd#fold_MilestonePaymentStockIssuedAsConsideration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_fold_MilestonePaymentStockIssuedAsConsideration_99a6f2d1-03be-424c-b734-4d4e8e42da61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_c89be902-8db9-4eb0-a7dc-a76985e8e165" xlink:href="fold-20211231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cc3b02f3-aa06-4d18-8d35-e3c39dc87b82" xlink:to="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_c89be902-8db9-4eb0-a7dc-a76985e8e165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_5c566922-1b3e-400f-97f4-2bffb1b605c0" xlink:href="fold-20211231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76f8bd9c-773c-4005-a640-80f2cb48b6bc" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_5c566922-1b3e-400f-97f4-2bffb1b605c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9c613651-c89b-4795-8d25-b16d501a541b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9c613651-c89b-4795-8d25-b16d501a541b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_30e48a45-9adc-4db7-bdbd-5b0955935cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:to="loc_us-gaap_VestingAxis_30e48a45-9adc-4db7-bdbd-5b0955935cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a69ab10e-eaa1-410c-95d4-0dba6e48d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_30e48a45-9adc-4db7-bdbd-5b0955935cd9" xlink:to="loc_us-gaap_VestingDomain_a69ab10e-eaa1-410c-95d4-0dba6e48d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d9016901-d9bb-41a5-a190-a44a0e310ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a69ab10e-eaa1-410c-95d4-0dba6e48d5ea" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d9016901-d9bb-41a5-a190-a44a0e310ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_63141b5d-7df9-48f2-b7a3-661331a36411" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:to="loc_srt_RangeAxis_63141b5d-7df9-48f2-b7a3-661331a36411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_027a3baa-087f-4bce-9bfe-bc7d7808a897" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_63141b5d-7df9-48f2-b7a3-661331a36411" xlink:to="loc_srt_RangeMember_027a3baa-087f-4bce-9bfe-bc7d7808a897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7ef595b-9041-4613-b151-272a6cce3588" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_027a3baa-087f-4bce-9bfe-bc7d7808a897" xlink:to="loc_srt_MaximumMember_f7ef595b-9041-4613-b151-272a6cce3588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fac5edef-70a7-4659-9519-9881d3152c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:to="loc_us-gaap_AwardTypeAxis_fac5edef-70a7-4659-9519-9881d3152c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6883f4f-7e51-4ad6-997c-40be5589f3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fac5edef-70a7-4659-9519-9881d3152c8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6883f4f-7e51-4ad6-997c-40be5589f3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_784bf682-a15c-4b96-a448-971d710a2654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6883f4f-7e51-4ad6-997c-40be5589f3a8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_784bf682-a15c-4b96-a448-971d710a2654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db2b4df1-1e0d-4a6f-a1c8-a35f8f57a249" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_38d53ff7-7ba6-4958-ac88-5687efcc8650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_us-gaap_TradingSecurities_38d53ff7-7ba6-4958-ac88-5687efcc8650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_357a425a-4a7b-4dcf-8196-1c5ac273e64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_357a425a-4a7b-4dcf-8196-1c5ac273e64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_43389596-3409-4a4b-9dbf-82ba206c04bc" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_43389596-3409-4a4b-9dbf-82ba206c04bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7fa48849-e5dc-4723-9bb3-07533a29e8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7fa48849-e5dc-4723-9bb3-07533a29e8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0d72474f-1627-4a1b-a5f4-8f84d525c0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b38df33e-fb3d-44a0-9dc3-53670791353a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0d72474f-1627-4a1b-a5f4-8f84d525c0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensation"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_279374a1-bcf6-4fed-bec0-2e16224a2a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_49bee7e5-0df1-473f-b01a-0ab4de856636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_279374a1-bcf6-4fed-bec0-2e16224a2a95" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_49bee7e5-0df1-473f-b01a-0ab4de856636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73474574-e77f-47b6-a258-b1ed341d45ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_59244734-4436-47fd-957e-484a0dbdce44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73474574-e77f-47b6-a258-b1ed341d45ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_59244734-4436-47fd-957e-484a0dbdce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fb44528f-e6de-4256-8ce3-0805f47a8772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73474574-e77f-47b6-a258-b1ed341d45ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fb44528f-e6de-4256-8ce3-0805f47a8772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2772c7b2-d980-4016-b523-eb1fc8c67039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73474574-e77f-47b6-a258-b1ed341d45ea" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2772c7b2-d980-4016-b523-eb1fc8c67039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f77803b8-eb71-4ee5-ba3e-45cac8a42dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73474574-e77f-47b6-a258-b1ed341d45ea" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f77803b8-eb71-4ee5-ba3e-45cac8a42dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f7a14f65-14f0-4549-823d-c228bd351dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e69ae40-e008-451e-bf6e-16c756b1cd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f7a14f65-14f0-4549-823d-c228bd351dc3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e69ae40-e008-451e-bf6e-16c756b1cd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a5f6e206-0a7b-478f-820e-d92cbbfd298f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e69ae40-e008-451e-bf6e-16c756b1cd98" xlink:to="loc_us-gaap_AwardTypeAxis_a5f6e206-0a7b-478f-820e-d92cbbfd298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02331ea9-02ee-452c-b066-f24f4b539f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a5f6e206-0a7b-478f-820e-d92cbbfd298f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02331ea9-02ee-452c-b066-f24f4b539f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_93eba05c-6d0e-4134-9451-fdec22bb47f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02331ea9-02ee-452c-b066-f24f4b539f82" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_93eba05c-6d0e-4134-9451-fdec22bb47f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_900bc49f-a2c5-4f5b-a16e-40c3bd350ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02331ea9-02ee-452c-b066-f24f4b539f82" xlink:to="loc_us-gaap_EmployeeStockOptionMember_900bc49f-a2c5-4f5b-a16e-40c3bd350ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e69ae40-e008-451e-bf6e-16c756b1cd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_10ee4558-5955-4e3a-b480-19caf291088f" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_10ee4558-5955-4e3a-b480-19caf291088f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_096185a3-6b3e-412a-b4db-0eba3cfc22fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_096185a3-6b3e-412a-b4db-0eba3cfc22fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ced26c5-2f89-4c56-be69-a52aa08a3e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ced26c5-2f89-4c56-be69-a52aa08a3e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3b3088cd-2317-4fc3-be68-04619ce20d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3b3088cd-2317-4fc3-be68-04619ce20d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64a92d77-bae9-4a15-adf7-446a9ee923fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_64a92d77-bae9-4a15-adf7-446a9ee923fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c2402371-3f3a-4bb9-8d6b-c023aa9825ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c2402371-3f3a-4bb9-8d6b-c023aa9825ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5d616cb3-be30-48de-a380-dd8c60a24d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5d616cb3-be30-48de-a380-dd8c60a24d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9a51de15-3332-44d7-a553-0adf9a3e5823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77ffb7c9-5ac3-4d46-bdd4-ad14673333de" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9a51de15-3332-44d7-a553-0adf9a3e5823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7de11816-92c4-4b00-ba88-4f16a78e9766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faf6c96c-b020-4f6b-ac85-7d43c3053fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7de11816-92c4-4b00-ba88-4f16a78e9766" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faf6c96c-b020-4f6b-ac85-7d43c3053fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cada5dc8-0a0a-42b2-8a30-275c3b6e4048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faf6c96c-b020-4f6b-ac85-7d43c3053fdc" xlink:to="loc_us-gaap_AwardTypeAxis_cada5dc8-0a0a-42b2-8a30-275c3b6e4048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62788b72-eb1d-43d2-babf-09817157766a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cada5dc8-0a0a-42b2-8a30-275c3b6e4048" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62788b72-eb1d-43d2-babf-09817157766a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ceac35b-c134-46e8-b485-aee8c2ec4f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62788b72-eb1d-43d2-babf-09817157766a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ceac35b-c134-46e8-b485-aee8c2ec4f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_faf6c96c-b020-4f6b-ac85-7d43c3053fdc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c148b504-c5e9-4811-b6e8-652c4f7a68d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c148b504-c5e9-4811-b6e8-652c4f7a68d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ea5f7142-c331-45bd-b4ed-8d41e1b28f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ea5f7142-c331-45bd-b4ed-8d41e1b28f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1838c93c-bda4-4480-a420-40e889243a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1838c93c-bda4-4480-a420-40e889243a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_72c53db1-1e21-44a0-8842-b6c996655124" xlink:href="fold-20211231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bdb11bfb-5511-4a7f-86b4-b51b79736141" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_72c53db1-1e21-44a0-8842-b6c996655124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28c13c53-287c-477b-a4ca-6e2fbd49cae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_432f66e7-cbd4-4ee6-afee-00ad1b3fdd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28c13c53-287c-477b-a4ca-6e2fbd49cae1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_432f66e7-cbd4-4ee6-afee-00ad1b3fdd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_383eaf72-69a1-48fa-82c5-95ec7a6841bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_432f66e7-cbd4-4ee6-afee-00ad1b3fdd9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_383eaf72-69a1-48fa-82c5-95ec7a6841bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fa7c2557-32bd-4e4c-b002-fdb9b366663a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_432f66e7-cbd4-4ee6-afee-00ad1b3fdd9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fa7c2557-32bd-4e4c-b002-fdb9b366663a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5fea3466-8265-4314-ac25-2ac499b4c15f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_432f66e7-cbd4-4ee6-afee-00ad1b3fdd9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5fea3466-8265-4314-ac25-2ac499b4c15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ad416dfb-4bcd-49a9-a843-b9247e736ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_432f66e7-cbd4-4ee6-afee-00ad1b3fdd9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ad416dfb-4bcd-49a9-a843-b9247e736ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a95a59e2-0e17-4b80-9b7a-9fb79b23e606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_432f66e7-cbd4-4ee6-afee-00ad1b3fdd9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a95a59e2-0e17-4b80-9b7a-9fb79b23e606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_83af8aaf-9301-486d-9eed-02cef8d7f68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_432f66e7-cbd4-4ee6-afee-00ad1b3fdd9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_83af8aaf-9301-486d-9eed-02cef8d7f68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_985cd5ff-3d19-4697-8dbf-15026b2f7d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28c13c53-287c-477b-a4ca-6e2fbd49cae1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_985cd5ff-3d19-4697-8dbf-15026b2f7d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_76b8dea0-feb9-447e-a62a-82102faa87ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28c13c53-287c-477b-a4ca-6e2fbd49cae1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_76b8dea0-feb9-447e-a62a-82102faa87ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b806441-86c3-4a30-b5fd-5b762f16073f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28c13c53-287c-477b-a4ca-6e2fbd49cae1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b806441-86c3-4a30-b5fd-5b762f16073f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_09a96336-03a2-47b8-bafa-8aaf575cdec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b806441-86c3-4a30-b5fd-5b762f16073f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_09a96336-03a2-47b8-bafa-8aaf575cdec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_495b1235-c641-46fb-a453-87a14cff0dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b806441-86c3-4a30-b5fd-5b762f16073f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_495b1235-c641-46fb-a453-87a14cff0dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05b525f5-ccd8-4923-9693-c6759e3e15de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b806441-86c3-4a30-b5fd-5b762f16073f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_05b525f5-ccd8-4923-9693-c6759e3e15de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8194a6ec-44e0-4155-9f5e-dab81b3ce87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b806441-86c3-4a30-b5fd-5b762f16073f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8194a6ec-44e0-4155-9f5e-dab81b3ce87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3c76b1f6-0ed2-44ff-be7a-b1e2b60f7c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b806441-86c3-4a30-b5fd-5b762f16073f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3c76b1f6-0ed2-44ff-be7a-b1e2b60f7c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46fd5087-1769-4724-90d3-3728f8ddd9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6b806441-86c3-4a30-b5fd-5b762f16073f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46fd5087-1769-4724-90d3-3728f8ddd9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_492917e3-581e-4711-8064-22271ed1a0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28c13c53-287c-477b-a4ca-6e2fbd49cae1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_492917e3-581e-4711-8064-22271ed1a0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fa5e0d1b-dfeb-4429-bd03-938ebed44976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28c13c53-287c-477b-a4ca-6e2fbd49cae1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fa5e0d1b-dfeb-4429-bd03-938ebed44976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bab28ca2-a1b4-4678-adc1-30c77275c124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28c13c53-287c-477b-a4ca-6e2fbd49cae1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bab28ca2-a1b4-4678-adc1-30c77275c124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_77a7f061-2b27-4b91-b12c-2d7c5b6a054a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bab28ca2-a1b4-4678-adc1-30c77275c124" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_77a7f061-2b27-4b91-b12c-2d7c5b6a054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2f6e01ba-c934-4d4b-b4cb-83dd0836783a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bab28ca2-a1b4-4678-adc1-30c77275c124" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2f6e01ba-c934-4d4b-b4cb-83dd0836783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_09ffc71f-329a-40ac-a4f9-90b4d019f278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bab28ca2-a1b4-4678-adc1-30c77275c124" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_09ffc71f-329a-40ac-a4f9-90b4d019f278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0480589d-a83f-4a85-aa26-8b9b7f5737e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bab28ca2-a1b4-4678-adc1-30c77275c124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0480589d-a83f-4a85-aa26-8b9b7f5737e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_36210078-1802-42d6-bd04-5526276348f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bab28ca2-a1b4-4678-adc1-30c77275c124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_36210078-1802-42d6-bd04-5526276348f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_919ece15-69e4-45fa-bbb2-86a32fdec4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bab28ca2-a1b4-4678-adc1-30c77275c124" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_919ece15-69e4-45fa-bbb2-86a32fdec4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae8d709-3432-4329-904c-3f40f551e542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a952005d-b567-4a27-a27d-f62dbc552da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae8d709-3432-4329-904c-3f40f551e542" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a952005d-b567-4a27-a27d-f62dbc552da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_66f5faa0-4a5d-4600-a80c-ecbf77b1019e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a952005d-b567-4a27-a27d-f62dbc552da9" xlink:to="loc_us-gaap_AwardTypeAxis_66f5faa0-4a5d-4600-a80c-ecbf77b1019e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24037dc-45c2-4aca-b6e8-4fc9e0b2f0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_66f5faa0-4a5d-4600-a80c-ecbf77b1019e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24037dc-45c2-4aca-b6e8-4fc9e0b2f0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e64c39fb-7360-4aac-a87d-cc2d5dc29b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24037dc-45c2-4aca-b6e8-4fc9e0b2f0d4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e64c39fb-7360-4aac-a87d-cc2d5dc29b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a952005d-b567-4a27-a27d-f62dbc552da9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9c0c4195-7082-4339-b0be-14fd67459a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9c0c4195-7082-4339-b0be-14fd67459a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_25f186bf-a5a9-466a-bb19-b92d6520a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_25f186bf-a5a9-466a-bb19-b92d6520a1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_38f0d728-fc85-4b21-b071-a4f1305283de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_38f0d728-fc85-4b21-b071-a4f1305283de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c02bfe41-0d8a-4f1c-bdfc-a67dafd177be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c02bfe41-0d8a-4f1c-bdfc-a67dafd177be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24e0719a-1ca0-450a-87fd-8b69bc10c7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dc150f10-5344-42af-918f-c3dfcc5e39d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24e0719a-1ca0-450a-87fd-8b69bc10c7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9430d8be-7dad-4add-bcec-145de820cee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9430d8be-7dad-4add-bcec-145de820cee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93d57436-26a5-4209-8d29-d66385a3a551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93d57436-26a5-4209-8d29-d66385a3a551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1ebd131e-c694-4188-a1f8-8df215c83090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1ebd131e-c694-4188-a1f8-8df215c83090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ae7abb7d-9f4c-4584-8412-e89e0e820307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ae7abb7d-9f4c-4584-8412-e89e0e820307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9a58684b-a141-4cef-935f-925b852ae5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_796d3982-03fe-4aeb-a6d7-94e529ff0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9a58684b-a141-4cef-935f-925b852ae5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_5d42053f-1dfd-49fa-a673-bb9356916c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd676bc-dfe1-4f3e-978b-919f78bcfb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_5d42053f-1dfd-49fa-a673-bb9356916c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_44e349e0-9319-4c49-9d11-6e498a322346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_5d42053f-1dfd-49fa-a673-bb9356916c6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_44e349e0-9319-4c49-9d11-6e498a322346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_ddb5e9aa-7be8-4e34-9315-51dc0f97ceb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_5d42053f-1dfd-49fa-a673-bb9356916c6b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_ddb5e9aa-7be8-4e34-9315-51dc0f97ceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#SharebasedCompensationExpenseSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f26b7cc4-095b-44d3-84c4-a77fad7867a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00e34c6d-fae6-487b-b2de-e73642df4462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f26b7cc4-095b-44d3-84c4-a77fad7867a7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00e34c6d-fae6-487b-b2de-e73642df4462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_23405601-311a-44bc-a23f-bfa6f2677525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00e34c6d-fae6-487b-b2de-e73642df4462" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_23405601-311a-44bc-a23f-bfa6f2677525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6f1f247a-5da4-4f5a-9667-e4e2e590b742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_23405601-311a-44bc-a23f-bfa6f2677525" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6f1f247a-5da4-4f5a-9667-e4e2e590b742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5abca7b2-95e1-47cc-868d-8cfdaeffc92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f1f247a-5da4-4f5a-9667-e4e2e590b742" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5abca7b2-95e1-47cc-868d-8cfdaeffc92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a0b502ee-d3dc-4670-b64c-214b4f38e50f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6f1f247a-5da4-4f5a-9667-e4e2e590b742" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a0b502ee-d3dc-4670-b64c-214b4f38e50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c14de78-0994-4dfb-8756-35cb1ec82c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00e34c6d-fae6-487b-b2de-e73642df4462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c14de78-0994-4dfb-8756-35cb1ec82c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c145629d-5f9e-4b32-82ae-49dbff3942f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c14de78-0994-4dfb-8756-35cb1ec82c1d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c145629d-5f9e-4b32-82ae-49dbff3942f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="simple" xlink:href="fold-20211231.xsd#AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8bb5ae50-1d9d-4d9f-97ec-542b058fea31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8e28d6d0-c808-42d8-8b55-eefe3c4e8cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8bb5ae50-1d9d-4d9f-97ec-542b058fea31" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8e28d6d0-c808-42d8-8b55-eefe3c4e8cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="simple" xlink:href="fold-20211231.xsd#AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_086c9de6-87a0-4078-95fe-f750dc67bb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0d7b4ceb-d35b-4d9a-90e4-efbbd2cf4738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_086c9de6-87a0-4078-95fe-f750dc67bb3c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0d7b4ceb-d35b-4d9a-90e4-efbbd2cf4738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f678a916-eb51-46c4-a16c-23a37cb07a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_086c9de6-87a0-4078-95fe-f750dc67bb3c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f678a916-eb51-46c4-a16c-23a37cb07a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_6e3eaa33-0ba7-44a3-8ae1-b86a23b47b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_086c9de6-87a0-4078-95fe-f750dc67bb3c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_6e3eaa33-0ba7-44a3-8ae1-b86a23b47b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2624b0e7-876a-473b-acfd-10d879342723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b7db52e-d721-46bc-ac2e-36e057a14777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2624b0e7-876a-473b-acfd-10d879342723" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b7db52e-d721-46bc-ac2e-36e057a14777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a563891-2b82-4678-8be5-95bd535d8dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b7db52e-d721-46bc-ac2e-36e057a14777" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a563891-2b82-4678-8be5-95bd535d8dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f4c12f3-aaa3-40d5-81d3-d0fe64656f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a563891-2b82-4678-8be5-95bd535d8dfa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f4c12f3-aaa3-40d5-81d3-d0fe64656f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3fe2b7fc-0025-4cd5-a4d5-dbc9c0fd4ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f4c12f3-aaa3-40d5-81d3-d0fe64656f72" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3fe2b7fc-0025-4cd5-a4d5-dbc9c0fd4ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b27c0c22-3040-40ee-a8e3-2bdec9e0e4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f4c12f3-aaa3-40d5-81d3-d0fe64656f72" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b27c0c22-3040-40ee-a8e3-2bdec9e0e4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_69a4a489-415f-49cb-ad2a-c0c351a74318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b7db52e-d721-46bc-ac2e-36e057a14777" xlink:to="loc_us-gaap_FinancialInstrumentAxis_69a4a489-415f-49cb-ad2a-c0c351a74318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69a4a489-415f-49cb-ad2a-c0c351a74318" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_909992f0-28f8-4e63-a6ae-9efad7673ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_909992f0-28f8-4e63-a6ae-9efad7673ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ac3f3b64-4d91-41f7-a68e-0cdc725368a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ac3f3b64-4d91-41f7-a68e-0cdc725368a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2960af89-8bb5-4341-b1b9-df8209c407b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2960af89-8bb5-4341-b1b9-df8209c407b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7faab34e-7d33-4f87-bb9f-3ba11aa03bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7faab34e-7d33-4f87-bb9f-3ba11aa03bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_57097d89-1025-4a19-8d49-3de17a3a2c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92f67ce4-0ddf-46a5-9555-be7dfaf00b4b" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_57097d89-1025-4a19-8d49-3de17a3a2c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ce5de60-d107-4914-bf4f-14b4be75e501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b7db52e-d721-46bc-ac2e-36e057a14777" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ce5de60-d107-4914-bf4f-14b4be75e501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_355e627e-1c2f-4c60-87f2-bd2c0513f2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ce5de60-d107-4914-bf4f-14b4be75e501" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_355e627e-1c2f-4c60-87f2-bd2c0513f2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b2e6e49d-cb24-4701-b34e-e8f4fed4be0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_355e627e-1c2f-4c60-87f2-bd2c0513f2ce" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b2e6e49d-cb24-4701-b34e-e8f4fed4be0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ce5de60-d107-4914-bf4f-14b4be75e501" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_367fc516-184a-4ddb-9bcc-f97da3eef890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_367fc516-184a-4ddb-9bcc-f97da3eef890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_3558e4a7-b91d-4c92-a980-8952f3c34073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_3558e4a7-b91d-4c92-a980-8952f3c34073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5f748e48-0ab4-4f14-8950-20cfe9614ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_eb07a358-d8e9-4929-beeb-1a23c79adc61" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5f748e48-0ab4-4f14-8950-20cfe9614ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3a993255-cfcb-4a9a-ac1f-e8bd389c9af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3a993255-cfcb-4a9a-ac1f-e8bd389c9af7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_185cd271-9935-46ca-90d9-4a512521ce39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_DebtInstrumentAxis_185cd271-9935-46ca-90d9-4a512521ce39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e1424c91-98db-4874-8e74-076a85140feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_185cd271-9935-46ca-90d9-4a512521ce39" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e1424c91-98db-4874-8e74-076a85140feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_63e11f6e-f3a3-4442-b621-03212cf3e618" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1424c91-98db-4874-8e74-076a85140feb" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_63e11f6e-f3a3-4442-b621-03212cf3e618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f027788a-4147-4981-ab39-5e68ec7de84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f027788a-4147-4981-ab39-5e68ec7de84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_93cbf623-1d9b-486d-b9fd-bd278e25fa2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f027788a-4147-4981-ab39-5e68ec7de84b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_93cbf623-1d9b-486d-b9fd-bd278e25fa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_6da9d8cc-2199-4f60-8c3e-399e9d667ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_93cbf623-1d9b-486d-b9fd-bd278e25fa2d" xlink:to="loc_us-gaap_ConvertibleDebtMember_6da9d8cc-2199-4f60-8c3e-399e9d667ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e82a37da-cffa-4aa7-807b-0ce4eaa392ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e82a37da-cffa-4aa7-807b-0ce4eaa392ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e03e0413-a92c-4bba-b3b1-0d820402db5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e82a37da-cffa-4aa7-807b-0ce4eaa392ec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e03e0413-a92c-4bba-b3b1-0d820402db5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_bd5956e5-e4df-49d4-9ba2-4cfd51965645" xlink:href="fold-20211231.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e03e0413-a92c-4bba-b3b1-0d820402db5f" xlink:to="loc_fold_CallidusBiopharmaIncMember_bd5956e5-e4df-49d4-9ba2-4cfd51965645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_8b466cd5-6df9-4592-ad87-e572f29f28b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_8b466cd5-6df9-4592-ad87-e572f29f28b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_321e8ead-2f24-406d-a163-8e3cf1ab91f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_8b466cd5-6df9-4592-ad87-e572f29f28b1" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_321e8ead-2f24-406d-a163-8e3cf1ab91f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_35dafcec-4b09-48f5-8d0f-7e367edd9db2" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_321e8ead-2f24-406d-a163-8e3cf1ab91f4" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_35dafcec-4b09-48f5-8d0f-7e367edd9db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a103758-bc11-41d1-8e06-e6fd6ceb6ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a103758-bc11-41d1-8e06-e6fd6ceb6ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb31b658-0f9b-46eb-833d-42dcc81fad3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a103758-bc11-41d1-8e06-e6fd6ceb6ca6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb31b658-0f9b-46eb-833d-42dcc81fad3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_eeef30a7-1c40-4bb2-ae0f-b04654b101bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb31b658-0f9b-46eb-833d-42dcc81fad3b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_eeef30a7-1c40-4bb2-ae0f-b04654b101bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_39b81976-5f99-4b15-a835-f4bd0453bbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_39b81976-5f99-4b15-a835-f4bd0453bbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_96fd4f0f-cbc0-47c6-a5fe-eaf0abfcc9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_39b81976-5f99-4b15-a835-f4bd0453bbe0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_96fd4f0f-cbc0-47c6-a5fe-eaf0abfcc9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b4e2b4b7-e3ad-4aac-8c2d-0176b422cdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96fd4f0f-cbc0-47c6-a5fe-eaf0abfcc9eb" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b4e2b4b7-e3ad-4aac-8c2d-0176b422cdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_ba4ef51c-b31c-4212-bfa9-f38bfd39c50c" xlink:href="fold-20211231.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96fd4f0f-cbc0-47c6-a5fe-eaf0abfcc9eb" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_ba4ef51c-b31c-4212-bfa9-f38bfd39c50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_413ea636-5ddd-4eaf-93dd-4aa1bd574d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_413ea636-5ddd-4eaf-93dd-4aa1bd574d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02e1e522-8484-4c65-8aa1-c3bfdee49fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_413ea636-5ddd-4eaf-93dd-4aa1bd574d84" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02e1e522-8484-4c65-8aa1-c3bfdee49fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_TB200PompeProgramMember_87181b46-489a-4baa-96e1-b034e049624b" xlink:href="fold-20211231.xsd#fold_TB200PompeProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02e1e522-8484-4c65-8aa1-c3bfdee49fbe" xlink:to="loc_fold_TB200PompeProgramMember_87181b46-489a-4baa-96e1-b034e049624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a811a44f-4215-4808-bdb2-0a639e4f8eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a811a44f-4215-4808-bdb2-0a639e4f8eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f200d9a3-5141-4274-ab85-cf57eaf1a13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a811a44f-4215-4808-bdb2-0a639e4f8eea" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f200d9a3-5141-4274-ab85-cf57eaf1a13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_faf6fb76-6279-4c99-a8d1-4a3da968bdc6" xlink:href="fold-20211231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f200d9a3-5141-4274-ab85-cf57eaf1a13a" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_faf6fb76-6279-4c99-a8d1-4a3da968bdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dc882962-c28c-4f24-8152-9dba6f9e59c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_srt_RangeAxis_dc882962-c28c-4f24-8152-9dba6f9e59c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a44aa53b-be73-40b3-8d5a-94d0cb997533" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dc882962-c28c-4f24-8152-9dba6f9e59c9" xlink:to="loc_srt_RangeMember_a44aa53b-be73-40b3-8d5a-94d0cb997533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9e91cfdc-6cc5-4b4d-b760-2cf013ee322d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a44aa53b-be73-40b3-8d5a-94d0cb997533" xlink:to="loc_srt_MinimumMember_9e91cfdc-6cc5-4b4d-b760-2cf013ee322d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d38d319-067c-45d5-ac7c-963e86bd233f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a44aa53b-be73-40b3-8d5a-94d0cb997533" xlink:to="loc_srt_MaximumMember_2d38d319-067c-45d5-ac7c-963e86bd233f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ddc6ffa8-384e-4fad-b560-1330a4e12e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ddc6ffa8-384e-4fad-b560-1330a4e12e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a42b5240-aab7-4f1f-9d02-a8a98b5d8008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ddc6ffa8-384e-4fad-b560-1330a4e12e53" xlink:to="loc_us-gaap_EquityComponentDomain_a42b5240-aab7-4f1f-9d02-a8a98b5d8008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_660eef35-0076-4c38-9eed-9da00b5f44f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a42b5240-aab7-4f1f-9d02-a8a98b5d8008" xlink:to="loc_us-gaap_CommonStockMember_660eef35-0076-4c38-9eed-9da00b5f44f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a37386b-b340-4627-8d65-d04d7993e86c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_7c1dfad2-5e02-4c74-928e-57eb81ba23d3" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_7c1dfad2-5e02-4c74-928e-57eb81ba23d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c9119442-955f-4d18-9c0b-c1b2d0394730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c9119442-955f-4d18-9c0b-c1b2d0394730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MilestonePaymentStockIssuedAsConsideration_c0b9cdf9-1120-4e34-a6e7-d2bf63eb29c0" xlink:href="fold-20211231.xsd#fold_MilestonePaymentStockIssuedAsConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_148f4446-3a11-41cd-9e6d-a6659ab90b7c" xlink:to="loc_fold_MilestonePaymentStockIssuedAsConsideration_c0b9cdf9-1120-4e34-a6e7-d2bf63eb29c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_afc2c4e3-42e7-414a-a150-58f2928fc1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b9dfe3c7-e28a-4006-881e-933267e5fd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_afc2c4e3-42e7-414a-a150-58f2928fc1e8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b9dfe3c7-e28a-4006-881e-933267e5fd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8a4363e3-c7c6-49ed-833a-2b9c66041043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b9dfe3c7-e28a-4006-881e-933267e5fd43" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8a4363e3-c7c6-49ed-833a-2b9c66041043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1c1f7736-bd43-4885-8dc6-8b1949830667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b9dfe3c7-e28a-4006-881e-933267e5fd43" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1c1f7736-bd43-4885-8dc6-8b1949830667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationPaidInStockAdjustment_5605a6d4-6e4f-4ae9-853d-e29d36faaff3" xlink:href="fold-20211231.xsd#fold_ContingentConsiderationPaidInStockAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b9dfe3c7-e28a-4006-881e-933267e5fd43" xlink:to="loc_fold_ContingentConsiderationPaidInStockAdjustment_5605a6d4-6e4f-4ae9-853d-e29d36faaff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3b0e6b2b-268b-4685-a771-3c038eb69f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b9dfe3c7-e28a-4006-881e-933267e5fd43" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3b0e6b2b-268b-4685-a771-3c038eb69f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:type="simple" xlink:href="fold-20211231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a96f0cf1-810a-4202-9eda-432e6c014c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_506e48e8-592c-4d97-a16b-ea73a2cdf186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a96f0cf1-810a-4202-9eda-432e6c014c1c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_506e48e8-592c-4d97-a16b-ea73a2cdf186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="simple" xlink:href="fold-20211231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9074b5b7-aea9-4477-ab89-2537728951fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_a3516f36-b50a-4634-a3da-5985f77ccf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9074b5b7-aea9-4477-ab89-2537728951fd" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_a3516f36-b50a-4634-a3da-5985f77ccf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_9c4805bf-ed61-43ac-99f3-525a9e6b6cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9074b5b7-aea9-4477-ab89-2537728951fd" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_9c4805bf-ed61-43ac-99f3-525a9e6b6cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6c220168-57b6-45cd-b62a-bac082e2e80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_07ff7296-bce7-47d7-9bd4-0c5067da6186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6c220168-57b6-45cd-b62a-bac082e2e80f" xlink:to="loc_us-gaap_DebtInstrumentTable_07ff7296-bce7-47d7-9bd4-0c5067da6186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f1149d18-b170-4dce-90f9-213d0a8bbb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07ff7296-bce7-47d7-9bd4-0c5067da6186" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f1149d18-b170-4dce-90f9-213d0a8bbb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_edf5ada1-c226-4885-b70a-c053536490ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f1149d18-b170-4dce-90f9-213d0a8bbb7c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_edf5ada1-c226-4885-b70a-c053536490ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_37a8fea4-a03e-478e-b4d5-b6579d56e05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_edf5ada1-c226-4885-b70a-c053536490ff" xlink:to="loc_us-gaap_ConvertibleDebtMember_37a8fea4-a03e-478e-b4d5-b6579d56e05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e84431cf-b2ad-4546-b6db-b3e1dc505015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07ff7296-bce7-47d7-9bd4-0c5067da6186" xlink:to="loc_us-gaap_DebtInstrumentAxis_e84431cf-b2ad-4546-b6db-b3e1dc505015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ae7ce6b9-a52e-459b-b51e-3e10a8fbac73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e84431cf-b2ad-4546-b6db-b3e1dc505015" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ae7ce6b9-a52e-459b-b51e-3e10a8fbac73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_17c3b93d-7772-4a3b-8c78-6ad64ca190b3" xlink:href="fold-20211231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ae7ce6b9-a52e-459b-b51e-3e10a8fbac73" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_17c3b93d-7772-4a3b-8c78-6ad64ca190b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_53f261e7-1860-414a-a6a5-37004759a2fd" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ae7ce6b9-a52e-459b-b51e-3e10a8fbac73" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_53f261e7-1860-414a-a6a5-37004759a2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5f712b5b-f41c-4af9-ba7b-a5b2db665766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07ff7296-bce7-47d7-9bd4-0c5067da6186" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5f712b5b-f41c-4af9-ba7b-a5b2db665766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f712b5b-f41c-4af9-ba7b-a5b2db665766" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_36aa876f-586c-42db-a559-6ac4c2344031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_36aa876f-586c-42db-a559-6ac4c2344031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9790652c-1753-4200-b06d-c980f04714e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9790652c-1753-4200-b06d-c980f04714e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_ea24152f-5573-4c39-a5cf-5fbe2cc8cbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:to="loc_us-gaap_DeferredOfferingCosts_ea24152f-5573-4c39-a5cf-5fbe2cc8cbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_546a1e85-a09f-4d6b-9886-b3140e758dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_94439ab9-dea0-4f1a-bd91-ebb9151cf67f" xlink:to="loc_us-gaap_LongTermDebt_546a1e85-a09f-4d6b-9886-b3140e758dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_503ccfcd-938d-43c0-be35-e8fa265e0598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_503ccfcd-938d-43c0-be35-e8fa265e0598" xlink:to="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bc43726d-aedc-4ab6-b363-80dc3271bb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_CreditFacilityAxis_bc43726d-aedc-4ab6-b363-80dc3271bb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8b0709db-6ad3-4d08-9d7f-229588ff59e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_bc43726d-aedc-4ab6-b363-80dc3271bb8b" xlink:to="loc_us-gaap_CreditFacilityDomain_8b0709db-6ad3-4d08-9d7f-229588ff59e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2dd2fc71-4a9f-4edb-97ba-c097cfbcdc30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8b0709db-6ad3-4d08-9d7f-229588ff59e5" xlink:to="loc_us-gaap_SecuredDebtMember_2dd2fc71-4a9f-4edb-97ba-c097cfbcdc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_64c7c6c2-6f61-43e9-8c8b-d51b8117dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8b0709db-6ad3-4d08-9d7f-229588ff59e5" xlink:to="loc_us-gaap_LineOfCreditMember_64c7c6c2-6f61-43e9-8c8b-d51b8117dd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_969e864c-6d60-4f94-a43e-42dab6ff76c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_969e864c-6d60-4f94-a43e-42dab6ff76c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a1cfb399-08a8-4af8-9313-cd3ca7fa6125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_969e864c-6d60-4f94-a43e-42dab6ff76c8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a1cfb399-08a8-4af8-9313-cd3ca7fa6125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_25b00e2c-d5a7-455c-ae85-a2c9dee6b184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a1cfb399-08a8-4af8-9313-cd3ca7fa6125" xlink:to="loc_us-gaap_SeniorLoansMember_25b00e2c-d5a7-455c-ae85-a2c9dee6b184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_16f8bf6c-fbcc-4797-8660-03e2ee01be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a1cfb399-08a8-4af8-9313-cd3ca7fa6125" xlink:to="loc_us-gaap_ConvertibleDebtMember_16f8bf6c-fbcc-4797-8660-03e2ee01be4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_71b94789-9261-414e-96e4-cc505f88a509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_VariableRateAxis_71b94789-9261-414e-96e4-cc505f88a509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_253847c8-f891-4760-a2e3-2e26ca0af639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_71b94789-9261-414e-96e4-cc505f88a509" xlink:to="loc_us-gaap_VariableRateDomain_253847c8-f891-4760-a2e3-2e26ca0af639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a26d3b28-d1fe-4cc2-bb32-b749c1e321b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_253847c8-f891-4760-a2e3-2e26ca0af639" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_a26d3b28-d1fe-4cc2-bb32-b749c1e321b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_432917f4-3c0b-4fca-a115-4e9ef206d501" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_srt_RangeAxis_432917f4-3c0b-4fca-a115-4e9ef206d501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dea5cf4b-22a0-4e6e-ba9d-8875293ab3ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_432917f4-3c0b-4fca-a115-4e9ef206d501" xlink:to="loc_srt_RangeMember_dea5cf4b-22a0-4e6e-ba9d-8875293ab3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6cf24f05-2364-41fc-8ee3-212515b31db1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dea5cf4b-22a0-4e6e-ba9d-8875293ab3ea" xlink:to="loc_srt_MinimumMember_6cf24f05-2364-41fc-8ee3-212515b31db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d34f7f31-7086-476f-8377-9d9b1861698b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dea5cf4b-22a0-4e6e-ba9d-8875293ab3ea" xlink:to="loc_srt_MaximumMember_d34f7f31-7086-476f-8377-9d9b1861698b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2302ccee-b71e-42e4-aa3f-3cc51ab3e132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_DebtInstrumentAxis_2302ccee-b71e-42e4-aa3f-3cc51ab3e132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0873abd7-76bb-4faf-b1c5-79a838332bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2302ccee-b71e-42e4-aa3f-3cc51ab3e132" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0873abd7-76bb-4faf-b1c5-79a838332bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_e31f94f8-f222-4e0f-8ac3-5a4090284b47" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0873abd7-76bb-4faf-b1c5-79a838332bf1" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_e31f94f8-f222-4e0f-8ac3-5a4090284b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_1ce3ceb5-2166-431c-9f4a-93aa3e0a4c38" xlink:href="fold-20211231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0873abd7-76bb-4faf-b1c5-79a838332bf1" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_1ce3ceb5-2166-431c-9f4a-93aa3e0a4c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ba55e2ad-ed4a-4319-9167-e9a5a690fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ba55e2ad-ed4a-4319-9167-e9a5a690fc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8593ede4-9f74-4baa-ad34-25e45674144a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ba55e2ad-ed4a-4319-9167-e9a5a690fc6e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8593ede4-9f74-4baa-ad34-25e45674144a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PrivatePlacementPurchaseAgreementMember_6a650f04-e001-4ab1-8e07-afd1e0ed81e1" xlink:href="fold-20211231.xsd#fold_PrivatePlacementPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8593ede4-9f74-4baa-ad34-25e45674144a" xlink:to="loc_fold_PrivatePlacementPurchaseAgreementMember_6a650f04-e001-4ab1-8e07-afd1e0ed81e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f99db92f-1f04-49db-9b2d-6e1bfd1b3bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f99db92f-1f04-49db-9b2d-6e1bfd1b3bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa0201ca-fd45-473b-8e06-ded107fc6d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f99db92f-1f04-49db-9b2d-6e1bfd1b3bdb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa0201ca-fd45-473b-8e06-ded107fc6d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_94531bb4-898f-47d8-a508-9ffb6f608bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fa0201ca-fd45-473b-8e06-ded107fc6d39" xlink:to="loc_us-gaap_OverAllotmentOptionMember_94531bb4-898f-47d8-a508-9ffb6f608bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c9dc6a51-6844-4d5a-b9df-49d919da59ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c9dc6a51-6844-4d5a-b9df-49d919da59ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_739772ed-e7e7-4045-8b93-030c50221d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c9dc6a51-6844-4d5a-b9df-49d919da59ab" xlink:to="loc_us-gaap_EquityComponentDomain_739772ed-e7e7-4045-8b93-030c50221d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4762b261-a380-4979-ad0d-8e20a8c9abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_739772ed-e7e7-4045-8b93-030c50221d23" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4762b261-a380-4979-ad0d-8e20a8c9abbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2df357c3-3d06-407b-86f7-a0d6f6e12875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_739772ed-e7e7-4045-8b93-030c50221d23" xlink:to="loc_us-gaap_CommonStockMember_2df357c3-3d06-407b-86f7-a0d6f6e12875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0e17bf2c-b777-49b3-a7b3-1c9fcd10ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1acf5201-e770-48b0-8e08-2cf81e349c3b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0e17bf2c-b777-49b3-a7b3-1c9fcd10ef8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e17bf2c-b777-49b3-a7b3-1c9fcd10ef8b" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4cba314b-65c3-4141-ad9b-5b4367cba43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4cba314b-65c3-4141-ad9b-5b4367cba43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentVariableRate_fd43ab0b-8013-4d81-8e91-29aaaa366fd1" xlink:href="fold-20211231.xsd#fold_DebtInstrumentVariableRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentVariableRate_fd43ab0b-8013-4d81-8e91-29aaaa366fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_af1b767e-82ce-477e-b4c8-57e45a0bb90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_af1b767e-82ce-477e-b4c8-57e45a0bb90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_d048b8ca-400f-4650-9ca3-a84f8d24a026" xlink:href="fold-20211231.xsd#fold_DebtInstrumentPeriodicPaymentNumberOfPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_d048b8ca-400f-4650-9ca3-a84f8d24a026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_2aff818d-3c9f-4bd5-88cd-909bcf8d5c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_2aff818d-3c9f-4bd5-88cd-909bcf8d5c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_56ef99fe-e3bf-43dc-90d6-27ccaa6116ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSecuredLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_56ef99fe-e3bf-43dc-90d6-27ccaa6116ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_59d134d3-ee17-4bec-9047-b8805f9978d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_InterestExpenseDebt_59d134d3-ee17-4bec-9047-b8805f9978d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EarlySettlementPremiums_9bff61e9-984b-462f-aa0d-8fa0ed25eb7e" xlink:href="fold-20211231.xsd#fold_EarlySettlementPremiums"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_EarlySettlementPremiums_9bff61e9-984b-462f-aa0d-8fa0ed25eb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_656658d2-d339-4a46-bc35-b99a3e3c1b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_656658d2-d339-4a46-bc35-b99a3e3c1b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount_4a31ff89-19ff-4224-80dc-952d0a5105a2" xlink:href="fold-20211231.xsd#fold_DebtInstrumentLiquidityCovenantMinimumAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount_4a31ff89-19ff-4224-80dc-952d0a5105a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_49dbbead-59c7-4b51-8cb4-a444b7ae272f" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConsolidatedRevenueCovenantAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_49dbbead-59c7-4b51-8cb4-a444b7ae272f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5aeb3645-4169-4b2e-879b-ff3342aaa6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5aeb3645-4169-4b2e-879b-ff3342aaa6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1593cb4f-b66f-44f0-a71e-d486e1cbf88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1593cb4f-b66f-44f0-a71e-d486e1cbf88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PremiumsPaidForCappedCallConfirmations_1c8e44f8-add3-42ec-a670-18337ba3ab81" xlink:href="fold-20211231.xsd#fold_PremiumsPaidForCappedCallConfirmations"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_PremiumsPaidForCappedCallConfirmations_1c8e44f8-add3-42ec-a670-18337ba3ab81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_9b54dee7-4694-4e52-afcc-5a7e50533c58" xlink:href="fold-20211231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_9b54dee7-4694-4e52-afcc-5a7e50533c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_de167f9d-3905-46a3-85d4-6860846c94d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_de167f9d-3905-46a3-85d4-6860846c94d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7285ecab-58c2-4c48-a7f6-e950654744c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7285ecab-58c2-4c48-a7f6-e950654744c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_a89cb4b5-7e30-48c0-a644-b3659676ed64" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_a89cb4b5-7e30-48c0-a644-b3659676ed64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_ce0e07e5-b15f-43ba-ba39-0b2943b1f405" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_ce0e07e5-b15f-43ba-ba39-0b2943b1f405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b52f2e0e-3b55-418c-8b1a-5a70720a4329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b52f2e0e-3b55-418c-8b1a-5a70720a4329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_814ac992-dbb2-4a72-a713-f59e63e36cb6" xlink:href="fold-20211231.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_814ac992-dbb2-4a72-a713-f59e63e36cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ed4c8743-abe2-4fd3-b150-16c01965f2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ed4c8743-abe2-4fd3-b150-16c01965f2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_0a155dfe-390d-4727-a67b-f51d6ea0d1c8" xlink:href="fold-20211231.xsd#fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_0a155dfe-390d-4727-a67b-f51d6ea0d1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExchangeOfDebt_3f439835-35c5-4c33-9e7b-8b36780ba114" xlink:href="fold-20211231.xsd#fold_GainLossOnExchangeOfDebt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_GainLossOnExchangeOfDebt_3f439835-35c5-4c33-9e7b-8b36780ba114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_b747fc27-0463-4c86-b191-40b49e5d7ec5" xlink:href="fold-20211231.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_b747fc27-0463-4c86-b191-40b49e5d7ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4236958c-5996-46df-b5ea-a9d4f5c70249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4236958c-5996-46df-b5ea-a9d4f5c70249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_eedb5cfa-66d9-4066-bc38-71de6bbd5927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_cb42acdf-99d6-47bb-8350-2936e5771057" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_eedb5cfa-66d9-4066-bc38-71de6bbd5927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e3cb1185-32db-435a-b8a5-a338b4e29b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_87f2ad2f-2e74-408b-a872-b30547888b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e3cb1185-32db-435a-b8a5-a338b4e29b61" xlink:to="loc_us-gaap_DebtInstrumentTable_87f2ad2f-2e74-408b-a872-b30547888b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3af95d70-9b85-4c9a-b990-27061533ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87f2ad2f-2e74-408b-a872-b30547888b95" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3af95d70-9b85-4c9a-b990-27061533ceca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a9e8616b-4a06-4deb-bc6b-ab7584218be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3af95d70-9b85-4c9a-b990-27061533ceca" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a9e8616b-4a06-4deb-bc6b-ab7584218be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_20da0da8-5e3e-4be5-8bc2-b1d0c688c902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a9e8616b-4a06-4deb-bc6b-ab7584218be9" xlink:to="loc_us-gaap_ConvertibleDebtMember_20da0da8-5e3e-4be5-8bc2-b1d0c688c902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fe981fa8-804c-4ed8-98a9-b72f96b7be71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a9e8616b-4a06-4deb-bc6b-ab7584218be9" xlink:to="loc_us-gaap_SeniorNotesMember_fe981fa8-804c-4ed8-98a9-b72f96b7be71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5af2caa2-3cf7-4922-81d6-4d557e25d638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87f2ad2f-2e74-408b-a872-b30547888b95" xlink:to="loc_us-gaap_DebtInstrumentAxis_5af2caa2-3cf7-4922-81d6-4d557e25d638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d37a1c53-d865-498a-8122-eff3d3429095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5af2caa2-3cf7-4922-81d6-4d557e25d638" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d37a1c53-d865-498a-8122-eff3d3429095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_abe1201a-9ca5-4ab4-9e52-2dfcf3b16668" xlink:href="fold-20211231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d37a1c53-d865-498a-8122-eff3d3429095" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_abe1201a-9ca5-4ab4-9e52-2dfcf3b16668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_df502923-c034-4675-8653-58b62bcc5e2b" xlink:href="fold-20211231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d37a1c53-d865-498a-8122-eff3d3429095" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_df502923-c034-4675-8653-58b62bcc5e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_265583d4-52bb-4c1f-a361-483d723b5742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87f2ad2f-2e74-408b-a872-b30547888b95" xlink:to="loc_us-gaap_DebtInstrumentLineItems_265583d4-52bb-4c1f-a361-483d723b5742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_265583d4-52bb-4c1f-a361-483d723b5742" xlink:to="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_93b4207d-053d-4e77-a186-932cbf88dd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_93b4207d-053d-4e77-a186-932cbf88dd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_3f38161e-0c8e-45fc-8865-b7eb3d3b18b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_3f38161e-0c8e-45fc-8865-b7eb3d3b18b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_a341acbc-88b9-4828-8352-ca2cf64ea395" xlink:href="fold-20211231.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:to="loc_fold_AmortizationDeferredFinancingCosts_a341acbc-88b9-4828-8352-ca2cf64ea395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_044fef09-24c6-4926-9926-50dee94352e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_4b502dee-d206-4604-9ed7-48dfdb2db0db" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_044fef09-24c6-4926-9926-50dee94352e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Leases" xlink:type="simple" xlink:href="fold-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e1f3a0b5-8396-46a7-8c71-7669cdea663b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a7024dbd-8db6-4c18-96a0-79735a099886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1f3a0b5-8396-46a7-8c71-7669cdea663b" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a7024dbd-8db6-4c18-96a0-79735a099886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="fold-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d0c28d1a-edab-4504-98b7-9a49607748f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_064d6e14-a1d7-4676-aaf8-ee4f4c332e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d0c28d1a-edab-4504-98b7-9a49607748f8" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_064d6e14-a1d7-4676-aaf8-ee4f4c332e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6e12e1fd-8a01-4598-bf80-976c40fba402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d0c28d1a-edab-4504-98b7-9a49607748f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6e12e1fd-8a01-4598-bf80-976c40fba402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9ab19d9d-a3c4-4f32-938f-7caa11c81c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_OperatingLeaseExpense_9ab19d9d-a3c4-4f32-938f-7caa11c81c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_5a75ae9b-b0cf-47f7-8361-a25f9889ab54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_VariableLeaseCost_5a75ae9b-b0cf-47f7-8361-a25f9889ab54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ff9e8fda-0323-4493-b9b8-87c381453dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_OperatingLeaseCost_ff9e8fda-0323-4493-b9b8-87c381453dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9dcecb93-5c99-4230-b36a-f0b9620ae4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9dcecb93-5c99-4230-b36a-f0b9620ae4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_9b692ddb-bc25-477b-853f-606c0e0ed91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_9b692ddb-bc25-477b-853f-606c0e0ed91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_664e9d8c-cf8c-4af6-a39d-e8f5a4fa96a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_664e9d8c-cf8c-4af6-a39d-e8f5a4fa96a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_75a9a1bf-d9f5-4fca-9fbc-34df2afc3298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_75a9a1bf-d9f5-4fca-9fbc-34df2afc3298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e971af9-2e97-4964-8601-84ca9c81f036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e971af9-2e97-4964-8601-84ca9c81f036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f6f2bc1a-dd4a-4745-b95f-3e33b986a972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_OperatingLeaseLiability_f6f2bc1a-dd4a-4745-b95f-3e33b986a972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_559630c4-ce02-4fac-a1f7-2405dbeab36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_559630c4-ce02-4fac-a1f7-2405dbeab36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6723d425-ed34-40e0-838c-c8ad4c50410a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6723d425-ed34-40e0-838c-c8ad4c50410a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_db7651fb-55ec-4a42-89ee-fbf399f5b8be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_db7651fb-55ec-4a42-89ee-fbf399f5b8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_31fbe48e-c566-4572-9f93-5ac48873f842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_31fbe48e-c566-4572-9f93-5ac48873f842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ed51bc93-a5a0-4fe5-a2fa-e887f622780b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ed51bc93-a5a0-4fe5-a2fa-e887f622780b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8548a9a9-b08d-4a86-9eac-34eaeb22747d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8548a9a9-b08d-4a86-9eac-34eaeb22747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4b305e48-7b66-494e-a22e-5cb4d4e7c6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4b305e48-7b66-494e-a22e-5cb4d4e7c6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e4380005-e385-4efc-b76d-9eb051f2fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e4380005-e385-4efc-b76d-9eb051f2fe5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f46a0ca0-8831-46b1-8016-5cd441215f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f46a0ca0-8831-46b1-8016-5cd441215f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_fd6d77d2-e9fc-4db7-a19f-443151855d00" xlink:href="fold-20211231.xsd#fold_LesseeOperatingLeaseLiabilityTenantIncentives"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_fd6d77d2-e9fc-4db7-a19f-443151855d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b5a78366-ae60-47f8-b0fc-8f26b090a8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b5a78366-ae60-47f8-b0fc-8f26b090a8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4463cedb-6edd-4ccd-b229-5082238dde23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f52f8c06-2241-4f41-a603-d78d4c7d6b6a" xlink:to="loc_us-gaap_OperatingLeaseLiability_4463cedb-6edd-4ccd-b229-5082238dde23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability_2be19813-02cb-4cfd-9640-0d0839fae9d3" xlink:href="fold-20211231.xsd#fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability_2be19813-02cb-4cfd-9640-0d0839fae9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0ca9870d-9103-4043-9f88-ad272a9d04ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd690802-b66b-444c-88ad-62b440ef967d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_0ca9870d-9103-4043-9f88-ad272a9d04ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesDetails_1" xlink:type="simple" xlink:href="fold-20211231.xsd#LeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="fold-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8d51dc46-f46e-4655-94be-c429211d48e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_202e1def-02e8-4f51-8e35-a155fbcfc405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d51dc46-f46e-4655-94be-c429211d48e8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_202e1def-02e8-4f51-8e35-a155fbcfc405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="fold-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_87f4b170-c233-473b-a41f-70e06d5ac626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a14a6650-1ed8-44cd-92ea-6c1e9358abd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87f4b170-c233-473b-a41f-70e06d5ac626" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a14a6650-1ed8-44cd-92ea-6c1e9358abd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5b61d5f6-c969-45aa-9d2e-f8fad7fe6aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87f4b170-c233-473b-a41f-70e06d5ac626" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5b61d5f6-c969-45aa-9d2e-f8fad7fe6aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_be00dc19-1768-40c1-9059-bbcf1a8a613c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87f4b170-c233-473b-a41f-70e06d5ac626" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_be00dc19-1768-40c1-9059-bbcf1a8a613c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2fadf34c-3cf2-4d98-b032-17237ee776b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87f4b170-c233-473b-a41f-70e06d5ac626" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2fadf34c-3cf2-4d98-b032-17237ee776b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#IncomeTaxesStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_19e98b04-e161-4bd3-ac9f-e226245a7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_57e8040d-3575-4992-a091-9804d4ba54c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19e98b04-e161-4bd3-ac9f-e226245a7e91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_57e8040d-3575-4992-a091-9804d4ba54c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1251d4d0-b5f3-4c01-a808-66fdfb5eec35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_57e8040d-3575-4992-a091-9804d4ba54c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1251d4d0-b5f3-4c01-a808-66fdfb5eec35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b3292839-5340-4078-8e99-95efb10311de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_57e8040d-3575-4992-a091-9804d4ba54c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b3292839-5340-4078-8e99-95efb10311de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0eb336f9-23fc-4035-868d-800d421735dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_57e8040d-3575-4992-a091-9804d4ba54c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0eb336f9-23fc-4035-868d-800d421735dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b47583b-d714-418c-8d15-e7d935c5ef4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19e98b04-e161-4bd3-ac9f-e226245a7e91" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b47583b-d714-418c-8d15-e7d935c5ef4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_637d8d63-5cbe-494f-b839-e4fc4351b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b47583b-d714-418c-8d15-e7d935c5ef4b" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_637d8d63-5cbe-494f-b839-e4fc4351b50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8879773d-17ac-4f54-ba40-b4d500785f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b47583b-d714-418c-8d15-e7d935c5ef4b" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8879773d-17ac-4f54-ba40-b4d500785f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_56faa6f3-1fa1-43b0-bb72-72e612ca1007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b47583b-d714-418c-8d15-e7d935c5ef4b" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_56faa6f3-1fa1-43b0-bb72-72e612ca1007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_48c2cc58-a161-42a0-b1fe-51a7573d7657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19e98b04-e161-4bd3-ac9f-e226245a7e91" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_48c2cc58-a161-42a0-b1fe-51a7573d7657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_eaaafb4d-f3ba-4f35-881f-f8939385b723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_48c2cc58-a161-42a0-b1fe-51a7573d7657" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_eaaafb4d-f3ba-4f35-881f-f8939385b723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b27d9e3a-5603-4c5b-8ca9-c43c9a97f8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_48c2cc58-a161-42a0-b1fe-51a7573d7657" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b27d9e3a-5603-4c5b-8ca9-c43c9a97f8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_55288f88-698d-41e7-a5ab-30e901a6672b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19e98b04-e161-4bd3-ac9f-e226245a7e91" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_55288f88-698d-41e7-a5ab-30e901a6672b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f82f9238-6586-4f58-9b65-3fc2faeccfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19e98b04-e161-4bd3-ac9f-e226245a7e91" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f82f9238-6586-4f58-9b65-3fc2faeccfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19e98b04-e161-4bd3-ac9f-e226245a7e91" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6b37d756-1ecc-4305-a94c-a3b23124a6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6b37d756-1ecc-4305-a94c-a3b23124a6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4d5841c1-d278-4ace-af41-dffcdf6360be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4d5841c1-d278-4ace-af41-dffcdf6360be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d5c5c172-3a8d-4cd4-a671-8bbced3a0ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d5c5c172-3a8d-4cd4-a671-8bbced3a0ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_9e097f3f-dd91-4835-8300-43327e5b1f68" xlink:href="fold-20211231.xsd#fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration_9e097f3f-dd91-4835-8300-43327e5b1f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_702f2ee7-2e7c-49c8-91ff-3781febf0487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_702f2ee7-2e7c-49c8-91ff-3781febf0487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f317db93-e1c7-494b-829b-668c7c3ebca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f317db93-e1c7-494b-829b-668c7c3ebca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8dc4a09f-6b07-42e1-932a-50b398317a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8dc4a09f-6b07-42e1-932a-50b398317a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_e9a486f9-e485-4e05-9245-49fd4d609ff0" xlink:href="fold-20211231.xsd#fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion_e9a486f9-e485-4e05-9245-49fd4d609ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f0ff6176-921d-49b5-9d2d-e77331d9094d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f0ff6176-921d-49b5-9d2d-e77331d9094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_654b227f-4a73-414d-8256-21cd79888a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_654b227f-4a73-414d-8256-21cd79888a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ca7ac9fa-7594-468d-8905-65f47a3250ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_76b1687a-2cd5-4203-b668-a62331bec9d4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ca7ac9fa-7594-468d-8905-65f47a3250ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_157e442f-c230-443b-aad4-23b038aef281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19e98b04-e161-4bd3-ac9f-e226245a7e91" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_157e442f-c230-443b-aad4-23b038aef281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#IncomeTaxesDeferredandValuationDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4c60921e-772a-4dd5-a4be-e9006b0fd46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_cd7828b2-9b1e-40b0-9349-eb808e4b9259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4c60921e-772a-4dd5-a4be-e9006b0fd46f" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_cd7828b2-9b1e-40b0-9349-eb808e4b9259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_cd7828b2-9b1e-40b0-9349-eb808e4b9259" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsIntellectualProperty_35927f99-dd3e-4f80-b3e6-bf2c4138082b" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsIntellectualProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_fold_DeferredTaxAssetsIntellectualProperty_35927f99-dd3e-4f80-b3e6-bf2c4138082b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_a5cdf3d2-d63e-4312-8ae5-a06adbfcecf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_a5cdf3d2-d63e-4312-8ae5-a06adbfcecf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_217bd5bd-7b5d-4d44-afb4-367cb53c4bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_217bd5bd-7b5d-4d44-afb4-367cb53c4bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_36430127-37ae-40a3-ac64-cc27473e2bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_36430127-37ae-40a3-ac64-cc27473e2bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_446d09a0-a820-4cd5-b090-0b8900b72a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_446d09a0-a820-4cd5-b090-0b8900b72a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_a612791a-60b3-4196-896e-cba8dbe5d472" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_a612791a-60b3-4196-896e-cba8dbe5d472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_109e3cfa-e5e2-4d66-9d4e-649b9701a466" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsInterestCarryforwardLimitation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_109e3cfa-e5e2-4d66-9d4e-649b9701a466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLeasingArrangements_fe72a7fc-c77a-4904-93b3-e449894473fb" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsLeasingArrangements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_fold_DeferredTaxAssetsLeasingArrangements_fe72a7fc-c77a-4904-93b3-e449894473fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5a170579-748c-42c4-8e7b-6a4248242007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_5a170579-748c-42c4-8e7b-6a4248242007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ffdfe387-8096-4827-9d9e-7245b5ae4d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_780dafab-074c-4171-9d10-9e79218dfe7c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ffdfe387-8096-4827-9d9e-7245b5ae4d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fd9f5499-b48f-46d4-b32d-c796f000bc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_cd7828b2-9b1e-40b0-9349-eb808e4b9259" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fd9f5499-b48f-46d4-b32d-c796f000bc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_3b12f4d0-b2de-4196-932c-cab359244f3a" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesBusinessAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fd9f5499-b48f-46d4-b32d-c796f000bc93" xlink:to="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_3b12f4d0-b2de-4196-932c-cab359244f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_9aebcfff-3eb5-4b14-a6ae-4319c99d5270" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fd9f5499-b48f-46d4-b32d-c796f000bc93" xlink:to="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_9aebcfff-3eb5-4b14-a6ae-4319c99d5270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_8d244a64-a630-49c4-a781-035197937629" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fd9f5499-b48f-46d4-b32d-c796f000bc93" xlink:to="loc_fold_DeferredTaxLiabilitiesConvertibleNotes_8d244a64-a630-49c4-a781-035197937629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_909eadf4-83e9-4549-8408-c2692b43ff21" xlink:href="fold-20211231.xsd#fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fd9f5499-b48f-46d4-b32d-c796f000bc93" xlink:to="loc_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments_909eadf4-83e9-4549-8408-c2692b43ff21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ea5ff9f8-9439-4c47-9591-eac47b32f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fd9f5499-b48f-46d4-b32d-c796f000bc93" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ea5ff9f8-9439-4c47-9591-eac47b32f88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross_8340c2f4-d81b-4a51-ae6f-ab441f094736" xlink:href="fold-20211231.xsd#fold_DeferredTaxAssetsLiabilitiesGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_fd9f5499-b48f-46d4-b32d-c796f000bc93" xlink:to="loc_fold_DeferredTaxAssetsLiabilitiesGross_8340c2f4-d81b-4a51-ae6f-ab441f094736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f52cbc23-3c57-4561-9c04-3a5122303fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_cd7828b2-9b1e-40b0-9349-eb808e4b9259" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f52cbc23-3c57-4561-9c04-3a5122303fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3af54a88-c54f-47eb-830b-3f46e6e00263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_cd7828b2-9b1e-40b0-9349-eb808e4b9259" xlink:to="loc_us-gaap_DeferredTaxLiabilities_3af54a88-c54f-47eb-830b-3f46e6e00263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6adcdeae-a589-437e-a0cb-ef3677b8746f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_cd7828b2-9b1e-40b0-9349-eb808e4b9259" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6adcdeae-a589-437e-a0cb-ef3677b8746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#IncomeTaxesLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2d509ed1-12f1-4de3-8b66-670bb21fccd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_fd9080eb-5d18-4036-abf0-801256ff18b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d509ed1-12f1-4de3-8b66-670bb21fccd9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_fd9080eb-5d18-4036-abf0-801256ff18b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_bf14403d-d1e8-4c68-9c28-8d9e5a0817c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fd9080eb-5d18-4036-abf0-801256ff18b3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_bf14403d-d1e8-4c68-9c28-8d9e5a0817c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d5fb7b57-562e-4bf6-b8a7-aa5f449d6fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_bf14403d-d1e8-4c68-9c28-8d9e5a0817c6" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d5fb7b57-562e-4bf6-b8a7-aa5f449d6fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a7cd6fb3-6b95-4093-bc93-d6927f224609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d5fb7b57-562e-4bf6-b8a7-aa5f449d6fb3" xlink:to="loc_us-gaap_DomesticCountryMember_a7cd6fb3-6b95-4093-bc93-d6927f224609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_77d7bd8d-55e0-49d7-9cdf-2c644ea68097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d5fb7b57-562e-4bf6-b8a7-aa5f449d6fb3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_77d7bd8d-55e0-49d7-9cdf-2c644ea68097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5a9dd8fb-0f16-41e6-9523-7c5081b17cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fd9080eb-5d18-4036-abf0-801256ff18b3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_5a9dd8fb-0f16-41e6-9523-7c5081b17cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0d6f5f6-d356-4cce-9949-a5553eea217b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5a9dd8fb-0f16-41e6-9523-7c5081b17cac" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0d6f5f6-d356-4cce-9949-a5553eea217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_69a79a7f-2efd-4118-b452-78d1b5a9167b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0d6f5f6-d356-4cce-9949-a5553eea217b" xlink:to="loc_us-gaap_ResearchMember_69a79a7f-2efd-4118-b452-78d1b5a9167b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OrphanDrugTaxCreditCarryforwardMember_616415c1-af83-466d-b5e3-6c57038ec138" xlink:href="fold-20211231.xsd#fold_OrphanDrugTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0d6f5f6-d356-4cce-9949-a5553eea217b" xlink:to="loc_fold_OrphanDrugTaxCreditCarryforwardMember_616415c1-af83-466d-b5e3-6c57038ec138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_754873b7-723c-4207-9f3a-499ce11535ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fd9080eb-5d18-4036-abf0-801256ff18b3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_754873b7-723c-4207-9f3a-499ce11535ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_fd579987-237b-440b-911b-6a4157337d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_754873b7-723c-4207-9f3a-499ce11535ec" xlink:to="loc_us-gaap_OperatingLossCarryforwards_fd579987-237b-440b-911b-6a4157337d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_25efeb6d-6ecb-4987-aeca-eadf287284e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_754873b7-723c-4207-9f3a-499ce11535ec" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_25efeb6d-6ecb-4987-aeca-eadf287284e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="fold-20211231.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementDisclosureAbstract_095eeea6-653b-4f8f-8f92-36f07a71f8c3" xlink:href="fold-20211231.xsd#fold_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_58343897-1611-41a2-9ea8-e8a97bc4fcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_CollaborativeArrangementDisclosureAbstract_095eeea6-653b-4f8f-8f92-36f07a71f8c3" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_58343897-1611-41a2-9ea8-e8a97bc4fcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementDisclosureAbstract_3d236ed1-b678-4b60-8f81-a28ff3bc34bf" xlink:href="fold-20211231.xsd#fold_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c7e0f71-12eb-43c2-882b-e64c75a9de1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_CollaborativeArrangementDisclosureAbstract_3d236ed1-b678-4b60-8f81-a28ff3bc34bf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c7e0f71-12eb-43c2-882b-e64c75a9de1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ed57c30e-9bd0-481e-89e6-bb6608e74db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c7e0f71-12eb-43c2-882b-e64c75a9de1c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ed57c30e-9bd0-481e-89e6-bb6608e74db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0955a609-a5f6-40f4-b088-fcec2091d8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ed57c30e-9bd0-481e-89e6-bb6608e74db6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0955a609-a5f6-40f4-b088-fcec2091d8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5d440c5f-0764-4e29-8903-916213bd4ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0955a609-a5f6-40f4-b088-fcec2091d8f5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5d440c5f-0764-4e29-8903-916213bd4ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_RevisedCollaborationAgreementMember_9640ea74-691c-4ae7-b59c-81877d82698d" xlink:href="fold-20211231.xsd#fold_RevisedCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0955a609-a5f6-40f4-b088-fcec2091d8f5" xlink:to="loc_fold_RevisedCollaborationAgreementMember_9640ea74-691c-4ae7-b59c-81877d82698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f57440f0-662d-434a-b5b9-142c055629ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c7e0f71-12eb-43c2-882b-e64c75a9de1c" xlink:to="loc_srt_CounterpartyNameAxis_f57440f0-662d-434a-b5b9-142c055629ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0e9f214-0645-4849-8042-ef6344513ed2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f57440f0-662d-434a-b5b9-142c055629ba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0e9f214-0645-4849-8042-ef6344513ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GlaxoSmithKlinePLCMember_a8032f94-f657-436e-9a25-2d35dc51f954" xlink:href="fold-20211231.xsd#fold_GlaxoSmithKlinePLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0e9f214-0645-4849-8042-ef6344513ed2" xlink:to="loc_fold_GlaxoSmithKlinePLCMember_a8032f94-f657-436e-9a25-2d35dc51f954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c7e0f71-12eb-43c2-882b-e64c75a9de1c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_39e1dc84-5d8a-4cf1-beb3-af982459cc24" xlink:href="fold-20211231.xsd#fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_39e1dc84-5d8a-4cf1-beb3-af982459cc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborationAgreementAnnualContributionByCompany_fc828ec8-5c42-4c7e-af2e-27e575645f8c" xlink:href="fold-20211231.xsd#fold_CollaborationAgreementAnnualContributionByCompany"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_CollaborationAgreementAnnualContributionByCompany_fc828ec8-5c42-4c7e-af2e-27e575645f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeAgreementTermOfAgreement_2d57d501-dd78-4190-a6cd-0d6b5849ba35" xlink:href="fold-20211231.xsd#fold_CollaborativeAgreementTermOfAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_CollaborativeAgreementTermOfAgreement_2d57d501-dd78-4190-a6cd-0d6b5849ba35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForCollaborativeArrangement_af4d7118-b1e4-4538-9e22-200d904b18f4" xlink:href="fold-20211231.xsd#fold_PaymentsForCollaborativeArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_PaymentsForCollaborativeArrangement_af4d7118-b1e4-4538-9e22-200d904b18f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_03cac6b5-d63e-412f-a2d9-aa95646ec757" xlink:href="fold-20211231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_03cac6b5-d63e-412f-a2d9-aa95646ec757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_8e8c7dbe-3a83-4ef1-b9d1-ff3e2c4c9eca" xlink:href="fold-20211231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_8e8c7dbe-3a83-4ef1-b9d1-ff3e2c4c9eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7c0dbfa7-8899-4ca0-99ed-42fa80135786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7c0dbfa7-8899-4ca0-99ed-42fa80135786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_3fe64d46-d581-4ae9-ad47-fe626efdae89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_3fe64d46-d581-4ae9-ad47-fe626efdae89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_09f9cbaa-52f1-4b14-aec7-f4af085499a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bae0bfd7-9173-4b27-9ec0-54b5240c4437" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_09f9cbaa-52f1-4b14-aec7-f4af085499a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="simple" xlink:href="fold-20211231.xsd#BasicandDilutedNetLossperCommonShare"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_61a3b3b7-8576-4f5b-8ce5-42da9807651c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_074a79e8-a533-4074-9022-ec41a075167b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_61a3b3b7-8576-4f5b-8ce5-42da9807651c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_074a79e8-a533-4074-9022-ec41a075167b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="simple" xlink:href="fold-20211231.xsd#BasicandDilutedNetLossperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4577c9e1-34d6-4027-9e72-abff14d2f16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56b71ceb-da4d-43ff-9f83-f8372afabbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4577c9e1-34d6-4027-9e72-abff14d2f16e" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56b71ceb-da4d-43ff-9f83-f8372afabbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_84e8d8e4-052c-41ad-a369-43092b0496db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4577c9e1-34d6-4027-9e72-abff14d2f16e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_84e8d8e4-052c-41ad-a369-43092b0496db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20211231.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_75c95c46-6d98-4a7b-9b3e-05e7f22af06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_35509c06-08c5-42db-8a4f-c9bfb77613c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75c95c46-6d98-4a7b-9b3e-05e7f22af06a" xlink:to="loc_us-gaap_NetIncomeLossAbstract_35509c06-08c5-42db-8a4f-c9bfb77613c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_df3a256d-6e50-43c6-940f-def4d9d2f97c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_35509c06-08c5-42db-8a4f-c9bfb77613c3" xlink:to="loc_us-gaap_NetIncomeLoss_df3a256d-6e50-43c6-940f-def4d9d2f97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e35b5093-79fb-47ee-baf2-c84904432773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75c95c46-6d98-4a7b-9b3e-05e7f22af06a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e35b5093-79fb-47ee-baf2-c84904432773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1db6b603-7e2b-4de5-bf93-86a3503f96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e35b5093-79fb-47ee-baf2-c84904432773" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1db6b603-7e2b-4de5-bf93-86a3503f96a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d9722074-7a45-40ec-b12c-f2e91ad4dbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e35b5093-79fb-47ee-baf2-c84904432773" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d9722074-7a45-40ec-b12c-f2e91ad4dbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ba536fe5-ced7-4c8e-82d4-0ff828d64787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75c95c46-6d98-4a7b-9b3e-05e7f22af06a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ba536fe5-ced7-4c8e-82d4-0ff828d64787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbd3567b-0113-4a70-b96d-fa607cbdeb83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ba536fe5-ced7-4c8e-82d4-0ff828d64787" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbd3567b-0113-4a70-b96d-fa607cbdeb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbd3567b-0113-4a70-b96d-fa607cbdeb83" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b8833a02-d6de-454e-8344-888556cc8292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b8833a02-d6de-454e-8344-888556cc8292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a81f284d-f2b8-44ab-9d77-45513df45820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a81f284d-f2b8-44ab-9d77-45513df45820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_199ca76f-a239-4d8b-bc20-867b1beda2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:to="loc_us-gaap_WarrantMember_199ca76f-a239-4d8b-bc20-867b1beda2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_82799194-2d47-43b4-b799-4237071c57a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23c48f67-e63c-4995-8784-6e3bbdfe5d81" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_82799194-2d47-43b4-b799-4237071c57a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f96240ad-9eb3-4053-9292-7989e8dcf193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ba536fe5-ced7-4c8e-82d4-0ff828d64787" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f96240ad-9eb3-4053-9292-7989e8dcf193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_458bbe12-8d94-4f30-8304-763562db9501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f96240ad-9eb3-4053-9292-7989e8dcf193" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_458bbe12-8d94-4f30-8304-763562db9501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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M9,^>76=Z5/>DNY8G0R:3JU3M8*KJ-FW:8)1(^^]__XN]M//\\\]C%"\<.'!
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MT8F(*!H$(E43$1&1&:9J(B*B0&.J)B(B"C2F:B(BHD!CJB8B(@HTIFHB(J)
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&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>fold-20211231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fold-20211231_g1.jpg
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MWRG'I5I=VM_:Q7UC<QS031K)#-$X9)$(R&4C@@@Y!% $E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^)?\
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M_P A?1_^OT_^@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L?Q+_R%]'_Z_3_Z":V*Q_$O_(7T?_K]/_H)H V****
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MNF?M!?!+6-#\:V49VPW=QHRWFH6=[(HX:9$5H%D.2(W*]* /LKXP?MH?LJ_
M'Q2/!7QC^._AW0-56P6_N[*]O?GL+-GV+=W6T$6EN6!43S;(R58;OE./2K2[
MM;^UBOK&YCF@FC62&:)PR2(1D,I'!!!R"*_-S_@W#U]?VOOV//C#^V3\8--A
MUC6?CU\9]?O-?;48Q+YFE1Q0V=IIIW=;:"%9(TC.0JNP[FMO_@VA^,'BWQU^
MP%XD^"?BW7+C4A\$/C'XA^'FC7MY*9)7TRS:">U5F)R1''=B%?1(57H!0!^A
ME%%9_BOQ7X<\#>'+OQ;XMU>&PTVPA,MY>3G"1)TW'';F@#0KPO\ X)[_ /)$
M]6_['O6?_2DUN_\ #<_[(_\ T7K0?^_S_P#Q-<;_ ,$\_&OA2;X':G/%KD#)
M)XVU:2-@3\R//O4_0JP/XT ?1-%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E6/XE_Y"^C_]?I_]!-3?\)CX8_Z#4'_?59>O
M>)=!N=3TR:#5(F6&Z+2L#]T;>IH Z:BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_
M +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
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M0?\ ?59>O>)=!N=3TR:#5(F6&Z+2L#]T;>IH Z:BLW_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J
M -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,
M?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J (;+_D=[W_KR
MB_F:V*YFT\2Z"GBV[O7U2(1/:QJDF>"03D5J?\)CX8_Z#4'_ 'U0!I45F_\
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M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
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M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
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M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM
M/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L
M[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"LCQ'96::KI*I:1
M ->$,!&.1M-;M8_B7_D+Z/\ ]?I_]!- &E_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H5-10!A6=E9GQG>Q&TBVBSC(7RQ@')K7_ +.T_P#Y\8?^
M_0K-LO\ D=[W_KRB_F:V* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.
MT_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"
MIJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^
M?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_
M0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJX+]H+XXV
M/P4\*0SV6FMJOB+6)Q9^&-!AYEO[IL # Y"*2"S=A@=2*Z<)A,1CL3&A0C>4
MG9+_ #[);MO1+5Z'-C,7A\!AI8BO*T(J[?\ DMVWLDM6]%J<[^T7\5-6TC4+
M'X&?!?3K:Y\=^)(S]G=H@8]'M.CWTW!P%&=H/5AT. K=9\%?@?X/^"?@6W\&
MZ' +J;<9]3U2Z0-/?W3<R32$Y))/09.  .U8_P"SI\#K[X9:??>-?B!J2ZMX
MX\32"Y\2ZN>0K?PVT7]V&,84 <'&> %"^EUZN98O#X>@LNP<KTT[SE_S\FNO
M^".J@O63UE9>3EF$Q&(Q#S+&QM4:M"#_ .7<'T_QRT<WZ16D;N'^SM/_ .?&
M'_OT*/[.T_\ Y\8?^_0J:BO!/?(?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ*
M(?[.T_\ Y\8?^_0K(L[*S/C.]B-I%M%G&0OEC .36[6/9?\ ([WO_7E%_,T
M:7]G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^
M,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% '._$CX4> _BOX.
MO/ OC7P_#<V%['A@J!7B;^&1&QE74\@C]1D5Y3\)O'?B+X(^-[7]G#X_W"7:
MW)*>!O&<\0":M$.!;3,?NW*@@<GY^.I*E_>*YKXL_"?P9\:?!-UX$\<:?YUK
M<#=%-&=LMK,/N31-_"ZGH?J#D$@^UEN8T84G@\8G*A)WT^*$MN>'G_-'::T=
MFHM>)F>75IUEC<$U&O%6U^&<=^2?E_++>#U5TY1EO_V=I_\ SXP_]^A1_9VG
M_P#/C#_WZ%>,_!KXL>,_AKXUB_9L_:&U#S=5*G_A$/%;C;%K]NO 1B?NW*C
M*DY;W)#/[97)F.75LMK\DVI1:O&2^&47M*+[=UNG=-)IHZ\MS&CF5!S@G&2=
MI1?Q0DMXR7?L]FFFFTTR'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:BN ] A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH PK.RLSXSO8C:1;19QD+Y8P#DUK_V=I__ #XP_P#?
MH5FV7_([WO\ UY1?S-;% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:
M?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4
MU% $/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\
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M .@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?I_\ 036Q0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XE_Y"^C_]
M?I_]!-;%8_B7_D+Z/_U^G_T$T ;%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 8]E_R.][_ ->47\S6Q6/9?\CO>_\
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M?Q+_ ,A?1_\ K]/_ *": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ K'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYF@#8HHHH
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M,S,T-I/9Q>8T .Q9D+H%WONY3]I[P9J7PR_X.:?V<?C_ .(8&CT#XA_ O7O
MVEWSC]TFJV+WNHF$MT5GAN%" XW%6 R0:3]IWP3JWQL_X.:?V<+?PQ$\UO\
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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MS\WO_@6U?B9^XFQ16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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MYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P#
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M    %:%% !1110 5X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\
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M(Q>)_M+&QM-JU.#_ .7<'W_Z>2T<WT5H+1-R****\ ^@"BBB@ HHHH ****
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MCBXNA4>B52R3?]V:;A+T4N;ND>J44 @C(-%>&>Z%%%% !1110 4444 %%%%
M!1110 4444 %8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?_030!L4444 %%%%
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MH **** "BBB@ HHHH **** "L>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F:
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MTA?$/]CZ1+Z_Z': ;<^SCBO2OA'_ ,$Y_P!AKX&^5+\-_P!E[PC;7$./*O\
M4--%_=(?43W1DD!^C5[516E/+<#2ES*FF^[U?WN[_$YL5Q7Q%BZ3I3Q,HP_D
M@^2'_@$.6/X#8HHH(E@@C5$10J(@P% Z #L*=117:?/A1110!X-\2_ GBO\
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M8V<(BM;2UB"1Q(.BJHX JW117S<I2G)RD[MGTT8QA%1BK);(****DHQ_$O\
MR%]'_P"OT_\ H)K8K'\2_P#(7T?_ *_3_P"@FMB@ HHHH **** "BBB@ K!^
M('PO^'GQ5T<Z!\1/!UAJ]K@[$O( S1D]T?[T9]U(/O6]16E&M6P]15*4G&2V
M:=FO1HSK4:.(I.G5BI1>Z:NGZIZ'AI_9N^,7P</VO]F+XQS+81\KX-\9L]Y8
MX_N13#][ /89R3RU3Z;^V$O@J_B\.?M-_#35/ E[(XCBU5U-WI5PW^Q<Q A2
M>NUA\H/+5[74&I:9INLV$NEZQI\%W:SH4GMKF)9(Y%]&5@01[&O<_MNEC=,R
MHJK_ 'X^Y4^<DFI?]OQD_-'@_P!AU<%KEE9TE_)+WZ7RBVG#_MR45Y,CT/7]
M"\3Z7%KGAO6;34+*==T%W97"RQ2#U5E)!JW7C&N_L;>']"U27Q9^SOXYU3X=
MZO(V^2+26\W3KAO^FMHYV$=@%P!Z&JG_  O?]H+X*_Z-^T/\(&UG2H^&\8>!
M5:>-5_O3VK8DC]68?+Z T?V-A\;KEM93?\DK0J?)-N,_+EDY/^5!_;6(P.F9
MT'37\\+SI_-I*4//GBHK^9GN5%<S\-/C+\+OC#I?]K_#7QO8:M&%!ECMY<2P
MY_YZ1-AX_P#@0%=-7B5Z%?"U72K0<9+=--->J>I[E#$4,5256C-2B]FFFGZ-
M:!11161L%%%% !1110 4444 %8_B7_D+Z/\ ]?I_]!-;%8_B7_D+Z/\ ]?I_
M]!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/9?\CO>_\ 7E%_,UL5CV7_ ".][_UY1?S-;% !1110 5\_>.M4
MU']L+XBW'P:\(7TL/P\\.W:CQMK5LY7^UKE2&&G0L.J @&1A^GR[];X^_$?Q
M;\0?&*_LM_!#4C!K%[ )/%OB"+E=!L&ZX(_Y;R X5<Y (/&0R^G?#3X<>$OA
M+X)L/ '@G31:Z?I\(2->K2-U:1S_ !.QR2>Y-?2X5+(<+'&3_P!XFKTU_)'_
M )^M=W_R[7_;_2-_F,4Y<08J6#@_]G@[57_/)?\ +I>2_P"7C_[<ZRMK:7I>
MG:)IMOHVCV,5K:6D*PVUM @5(HU "JH'     J>BBOFY2<FVW=L^F45%))62
M"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** /+_VLOVP_@3^Q7\,V
M^*/QU\4-9VLDIATW3K.(2WFI3XSY4$61N..2Q*HHP69<U^?L'_!RS\.X?B)/
M??\ #*&M'1)E6+[9_P )3#]J" _>\CR-F?\ 9\W'O7S?_P ' /Q8\4^.?^"@
MVJ_#[5;V0Z7X*T/3[+2+;=^[7S[:*[ED Z;F:<*3U(B4?PBOB&OS7.N*LQI9
MA.CAFHQ@VMDVVM][]>Q_6OA_X,\+8SABACLV@ZM6O!37O2BH1DKQ2Y6KNS3;
M=]=+'].'[)O[8?P)_;4^&:_%'X%>*&O+6.40ZEIUY$(KS39\9\J>+)VG'(8%
MD89*LV*]0K^>?_@C]XB_:1N/VO+/X,?LW?'$^ ;[QUI=W9ZEK<F@PZI'##;P
M278?[-,0C2#R2JL2"OFL,X8@_K'_ ,.H=*^(H\[]J[]L+XO_ !-\S_CXTBZ\
M4-IFDR>N+2U"[,^S]*^ER?.L9FF"52-&\D[-W2C?\9;-?9/R7COP_P CX/X@
MEAJN/Y:4DIPCR2G5Y6VM=(4]&FE^\3=KM(]C^+G[;G[(GP'\V+XM?M'>$-&N
M8<^9I\VMQ278QUQ;QEI3^"UX\W_!73X7>/7-K^RO^SG\6OBR[G$&H^&?!4UO
MIN?62YNO+\M?<H:]0^$?_!/C]B7X%^5+\,?V8O"%C<08\G4+G2EO+M,>EQ<^
M9*/^^J]B5510B* H&  . *]3V>:5?BG&"_NIR?WNR_\ )3XWZSP?A/X6'JUW
MWJ3C3C\X04I?=5/DS_A9_P#P6#^,?R^"/V;?AC\([&7_ )>?'GBJ76KU4_O)
M'8 1A^^V3@=#2'_@G]^UE\5AYG[3O_!3'Q_=P2\RZ-\,M.MO#4"C_GD98@[R
MIV)8 D'\:^M:*/[-IS_C3G/UDTONCRK\ _UKQ6'_ -QP]&A_AIJ4EZ3J^TFO
ME)'S=\._^"2/[ 7P_P!2_P"$ANO@+:^*=6=@UQJWCB^GUB6X;^\ZW3O%GZ(*
M^@/"_A#PGX(TE- \%^%].TBQB_U=EI=E';PI]$C 4?E6C1730PN&PRM2@H^B
M2/(S#.<WS:5\;B)U?\4I2MZ7;M\@HHHKH/-"BBB@ HHHH **** "BBB@ HHH
MH *1E5U*.H((P01P12T4 ?/GB?0-?_8P\677Q+\ :;/??#/5;GS?%7ANU4LV
MARL<&]ME_P">7]^,< #T V>[>'?$6A^+="M/$WAG58;[3[Z!9K2[MWW)*A&0
M0?\ .*MSP0W,+VUS"LD<BE9(W4%64C!!!Z@U\@?&[XI:C_P3S\:S:!\++BQU
M30?%-K-?67A'4)9 -#N=X!EC*_\ +!SN_=Y'*G!&,G[#!X:KQC*.'@O]L2T?
M2K%+[3Z3BOM/225G[R3E\;C<32X,C+$S?^Q-ZKK2DW]E=82?V5K%NZ7*VH_5
M-E_R.][_ ->47\S6Q7YFQ_\ !1;]J:/Q-)XE3Q=IX\P /8_V-!Y)4=%^[OQ_
MP//O7V-^QU^V+HW[3NC7.EZIID6F>)M,B$E]8PN3%/$3CSHL\[<D J<E21R<
M@UTY]X><1</8'ZW749TUNX-OEOW32^]71R\/^(W#?$6.^IT'*%1_"II+FMV:
M;5[='9GME%%%?#'W@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_
M['O6?_2DT >Z4444 %%%% !1110 4444 %%%% !6/XE_Y"^C_P#7Z?\ T$UL
M5C^)?^0OH_\ U^G_ -!- &Q1110 4444 %%%% !1110 4444 %%%% !1110
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M]3)<N+Z)IG9I9OF*O$N-P"%%R&!_+_\ X5I\1_\ A*?^$&_X5_K?]M^;Y?\
M8_\ 94WVK?\ W?*V[\^V,U_5+6/9?\CO>_\ 7E%_,U\_F/!V#QF(]K1G[.^Z
M2NOEJK'Z7PMX[Y]D66_5,=1^M-7Y9RFXSUUM)\LN9+IL[:7V/SI_X(9_\$N_
MB5^SUK=W^U?^T9X;ET77KW3'L?"OAN\7%S90R$&6YG7K%(RJ$6,_,JL^X L
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M/[8_X:QT;^S-_D_V???VCMZ>3]G?&?;S/*_'%0I_P3H_:ED\32>&D\)Z>?+
M+WW]LP>2%/1OO;\?\ S[5]B_L=?L=:-^S%HUSJFJ:G%J?B;4XA'?W\*$101
MY\F+/.W(!+'!8@<# %?LO&O&O#L.':]"A7C5J58N*46I6YE:[M>UD[ZZW/Q7
M@?@?B2?$E"O7H3I4Z4U.4IIQORN]E>S=VK::6/;****_F$_J8**** "BBB@
MHHHH **** "BBB@ HHHH **** "BN/\ CW\0/&/PO^$6M>-/AU\.[CQ;XB@A
MC@\/>&X)O*%_?SRI!;QR2X(@A\V1#+,01%$'D((0BOSG_:F_;2_X+2?\$L]8
M\'?M/?MI:Q\&?B9\&?$'BZRT3Q]H?PZ\/7MA?>$OMDFR.>TEN)"UU&C?+NE!
M+MM0JF\2( ?J117RY^W'^VUXV^%_[1GP<_8,_9U&E?\ "T/C3J%_+'K&MVC7
M-IX8T'3[=KB^U*2!'0SS%5,5O$71'E)+$B,H]7X-_MA_$OX;_P#!0K4?^":G
M[3OB/3]>U75_ ">-?A;XYL]+6P;6;%)WM[W3[N!&,8O()$\U7B"I) ^2B-&2
MX!]6T5\2_!']KK]JO_@HIXB^,WC;]C3XB>%O!_@?X5^,[WP9X)N-<\,G4CXT
MUVQB1[NXNG\Z,P:;YLL<$8M\2N/,E,H^6(>R?\$V_P!N3PK_ ,%$?V0O#/[3
M?A_P[)H5]?FXT_Q3X:GF\R31=7M96AN[1FP-P612R,0"T;QL0"V  >[4444
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MZ? S]DC]F;]FFR6R^!7P0\.^&V$>Q[VQT]3=RKC&)+E]TTG_  )S4^TS*O\
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MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
M@6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO
M_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U9FN>%=.M=1TV&.>Y(G
MN2KEKAB0-O;TKJZQ_$O_ "%]'_Z_3_Z": #_ (0?2/\ GYO?_ MJ/^$'TC_G
MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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M":V* ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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MIHH8H$\N&)47^ZJX%?!^WX97_,/6_P#!T%_[@9]]]7XH?_,317_<";_]V$>
M?\-H?L;/\UK\4M5G7^_%I&HD9].811_PV3^R:_-KXR\13KW>+1;\@'TYB%?0
M-%'UGAI;86K_ .#X_P#RA!]5XG>^*I?^")__ "]GS]_PV%^S(_-KJ7BZ<=VA
MT*]('MR@H_X:Y_9\DYM+#QW< ?>,/AZ[./KD"OH&BCZWPZML)4_\'+_Y4@^I
M\2/?%T__  2__ES/GX_M9?!1_P#CT\'_ !(N,?>\GPW<G;]<XH_X:J^%<G_'
MI\+OBK.1]X0^&)SCZY85] T4?7<@6V$E_P"#?_M$'U+B%[XR/_@G_P"Z,^?O
M^&H_ ;\6OP.^,,Y[K#X5E)'YR"C_ (:;\-/Q:_LW?&Z=NZP^$G) ]>917T#1
M3^OY$ML&_P#P;+_Y%!]0SY[XU?\ @J/_ ,DSY^_X:2L9?EM?V5_CB6])?"Q0
M8^IFH_X:'N9?EMOV4?C(6])=&"#\S+7T#11_:&2K;!+_ ,&3_P" ']G9V]\<
M_P#P7#_@GS]_POSQ!)\EO^R7\6"_82VRH/S,E'_"\/&\GR6_[(GQ++GH))XT
M7\27XKZ!HI?VEE"VP,?_  .I_P#)(/[,SA[X^7_@NG_\BSY^_P"%R?$]_E@_
M8^\?%S]T2:Q H_$[N*/^%L_&=_EA_8W\8EC]T/XHMU'XGM7T#11_:F5+_F A
M_P"!U?\ Y8@_LK-GOF%3_P  H_\ RMGS]_PL[X_M\L7[&/B4L?NAO'%JHS[G
M'%'_  L+]I9OE3]BK6-QZ;OB19@9]SMXKZ!HH_M;+5ME]+_P*O\ _+D']D9G
MUS&K_P" T/\ Y2SY^_X3?]JP\#]B:\&>Y^*]C@?^.4?\)5^UL>/^&00/<_$Z
MV_\ B:^@:*/[8P'3+Z/WU_\ Y>']C9AUS&M]V'_^4'S]_;G[7_\ T:[8_P#A
MQ(__ (FOC+]M!OB6_P =[Z7XI^&X])U%K&V,5A#J'VJ..'RP 5D_B!8.3Z$D
M=J_4ZO$_VQ?V.M&_:=T:VU32]3BTSQ-ID1CL+^9"8IXB<^3+CG;DDAADJ2>#
MDBOK^".+LJRC/8U,1AJ=*$DXN<?:-J]FF^:<]+K6RO\ D?'\<\'YMG&02I8?
M$U*LXR4E"?LTI6NFERPAK9Z7=OS/S'KW+_@G5IVH:I^U/H]I:M,+8V%Z=1,+
ME2(1 ^,D=O,\K\<4J?\ !.C]J63Q-)X:3PGIY\L O??VS!Y(4]&^]OQ_P#/M
M7V+^QU^QUHW[,6C7.J:IJ<6I^)M3B$=_?PH1%!$#GR8L\[<@$L<%B!P, 5^I
M<:\:\.PX=KT*%>-6I5BXI1:E;F5KNU[63OKK<_*.!^!^))\24*]>A.E3I34Y
M2FG&_*[V5[-W:MII8]4_X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBBOYA/ZF
M,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBJ^JZMI6@Z;-K&N:G;V5I;1E
M[BZNYECCB4=69F("CW-#:2&DY.RW,_\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
M"#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\
M_-[_ .!;5L44 8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?
M\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO
M_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _
M-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;
M5L44 8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!
M;4?\(/I'_/S>_P#@6U;%% '*6OA73I/%-U8-/<[([:-E(N&W9)/4UI_\(/I'
M_/S>_P#@6U%E_P CO>_]>47\S6Q0!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_
M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M:\:"*-8U)PJ@#)YI:* "BBB@ HHHH **** "BBB@ HHHH **** "O"_^">__
M "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2: /=**** "BBB@
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MC^)A&HW-[G)/K71445WQC&$>6*LCYJK5JUZCJ5).4GNV[M^K844451F%%%%
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M:SM=NWZ'I%%>;_\ #,'@W_H<_%W_ (44E'_#,'@W_H<_%W_A125]W]>XB_Z
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MP\Z/-*,93YH.T7>]N63:;=E?S:O=H\[-<5BJ>$?+%QN[7NOT9P']O:Y_:/\
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M%QI.F2^F+JY;C\4H_P"%D_\ !8[XJ''A+]F[X2_"RVDZOXW\73ZU=1+ZJ-/
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MWX-$T!&_*24[A7I5%+_5Z%3_ 'C$UJG_ '$</PI*F@^JI_%.3^=O_2;'FO\
MPS98ZG\WC+XK>,=8S]^&?6C'"?HB 8_.K^C_ +,_P+T1A);_  ZLIWSDO?L]
MR6/J?-9A7=T5I3X8X?ISY_JT)2[R7/+_ ,"E=_B-83"IWY$WYZ_F4='\,>&O
M#R>7H'AZQL5 P%L[1(AC_@(%7J**]JG3ITH<L$DNRT1T)**L@HHHJQA1110
M4444 %%%% !1110 4444 %%%% !6/9?\CO>_]>47\S6Q6/9?\CO>_P#7E%_,
MT ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 8]E_R.][_ ->47\S6Q6/9?\CO>_\ 7E%_,UL4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%_P#!/?\
MY(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI- 'NE%%% !1110 4444
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M;'LVKZ#/ K=\(?\ !,K]F'PU()?#7_!,[0W;=DW7BOQM)?EV[EDGED_PJ?\
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M+?0HW]#NFD?"GU]*!^T#_P %;O&O_(J?\$__  1X.5_]7+XR^*45]@=BRV*
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MT?V-_P %NH/EB\9_LS3A/NM/IVNJ9,?WMIXSWQ7L_P#PL_\ : M_^/S]FEF
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M*+^9H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Q[+_D=[W_ *\HOYFMBL>R_P"1WO?^O*+^9K8H **** "BBB@
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M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
M;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C0!L4V6&&==D\2NOHZY%9/V+QO\ ]!NR_P#
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M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
MZ#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'
M^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\
M:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'
M_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W
M9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H
M-V7_ (#'_&@ LO\ D=[W_KRB_F:V*Y2UM?%)\4W4<>J6PN!;1F20P':5R< "
MM/[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
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M;F9FZVBBO>PN%PV"P\:&'@H0BK))627DC>,8PBHQ5D@HHHK<H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q+_R%]'_ .OT_P#H
M)K8K'\2_\A?1_P#K]/\ Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Q_$O\ R%]'_P"OT_\ H)K8K'\2_P#(7T?_
M *_3_P"@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:V*Q[+_D=[W_ *\HOYFMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L>R_Y'>]_Z\HOYFMBL>R_Y'>]_Z\HOYF@#8HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#'LO^1WO?^O*+^9K8K'LO^1WO?\ KRB_F:V* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_P#@GO\ \D3U;_L>
M]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)H ]THHHH **** "BBB@ HHHH ****
M"L?Q+_R%]'_Z_3_Z":V*Q_$O_(7T?_K]/_H)H V**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$O_ "%]'_Z_3_Z"
M:V*Q_$O_ "%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Q_$O_(7T?_K]/_H)K8K'\2_\A?1_^OT_^@F@
M#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYFMB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L>R_Y'>]_Z\HOYFMB
ML>R_Y'>]_P"O*+^9H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH Q[+_D=[W_ *\HOYFMBL>R_P"1WO?^O*+^9K8H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2: /=
M**** "BBB@ HHHH **** "BBB@ K'\2_\A?1_P#K]/\ Z":V*Q_$O_(7T?\
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M:R_Z1/\ Q3_\"Q_\CU]C44 ?'/\ P\I_:R_Z1/\ Q3_\"Q_\CT?\/*?VLO\
MI$_\4_\ P+'_ ,CU]C44 ?'/_#RG]K+_ *1/_%/_ ,"Q_P#(]<_XP_X*B?M&
MZ7KV@6>N?\$Q/B-8W-[J!CTVVNM157O)=A)CC!@^9L<X':ON:O"_VL/^2V?
M_P#['N7_ -)FH \M_P"'E/[67_2)_P"*?_@6/_D>C_AY3^UE_P!(G_BG_P"!
M8_\ D>OL:B@#XY_X>4_M9?\ 2)_XI_\ @6/_ )'H_P"'E/[67_2)_P"*?_@6
M/_D>OL:B@#XY_P"'E/[67_2)_P"*?_@6/_D>C_AY3^UE_P!(G_BG_P"!8_\
MD>OL:B@#XY_X>4_M9?\ 2)_XI_\ @6/_ )'H_P"'E/[67_2)_P"*?_@6/_D>
MOL:B@#XY_P"'E/[67_2)_P"*?_@6/_D>C_AY3^UE_P!(G_BG_P"!8_\ D>OL
M:B@#XY_X>4_M9?\ 2)_XI_\ @6/_ )'H_P"'E/[67_2)_P"*?_@6/_D>OL:B
M@#XY_P"'E/[67_2)_P"*?_@6/_D>C_AY3^UE_P!(G_BG_P"!8_\ D>OL:B@#
MXY_X>4_M9?\ 2)_XI_\ @6/_ )'H_P"'E/[67_2)_P"*?_@6/_D>OL:B@#XY
M_P"'E/[67_2)_P"*?_@6/_D>C_AY3^UE_P!(G_BG_P"!8_\ D>OL:B@#XY_X
M>4_M9?\ 2)_XI_\ @6/_ )'H_P"'E/[67_2)_P"*?_@6/_D>OL:B@#XY_P"'
ME/[67_2)_P"*?_@6/_D>C_AY3^UE_P!(G_BG_P"!8_\ D>OL:B@#XY_X>4_M
M9?\ 2)_XI_\ @6/_ )'H_P"'E/[67_2)_P"*?_@6/_D>OL:B@#X9\8?\%1/V
MC=+U[0+/7/\ @F)\1K&YO=0,>FVUUJ*J]Y+L),<8,'S-CG [5T'_  \I_:R_
MZ1/_ !3_ / L?_(]>I?M8?\ );/@?_V/<O\ Z3-7NE 'QS_P\I_:R_Z1/_%/
M_P "Q_\ (]'_  \I_:R_Z1/_ !3_ / L?_(]?8U% 'QS_P /*?VLO^D3_P 4
M_P#P+'_R/1_P\I_:R_Z1/_%/_P "Q_\ (]?8U% 'QS_P\I_:R_Z1/_%/_P "
MQ_\ (]'_  \I_:R_Z1/_ !3_ / L?_(]?8U% 'QS_P /*?VLO^D3_P 4_P#P
M+'_R/1_P\I_:R_Z1/_%/_P "Q_\ (]?8U% 'QS_P\I_:R_Z1/_%/_P "Q_\
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MV? __L>Y?_29J /+?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\
MY'K[&HH ^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_BG_X%C_Y'K[&H
MH ^.?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\ Y'K[&HH ^.?^
M'E/[67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_BG_X%C_Y'K[&HH ^.?^'E/[67
M_2)_XI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\ Y'K[&HH ^.?^'E/[67_2)_XI
M_P#@6/\ Y'H_X>4_M9?](G_BG_X%C_Y'K[&HH ^.?^'E/[67_2)_XI_^!8_^
M1Z/^'E/[67_2)_XI_P#@6/\ Y'K[&HH ^.?^'E/[67_2)_XI_P#@6/\ Y'H_
MX>4_M9?](G_BG_X%C_Y'K[&HH ^.?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2
M)_XI_P#@6/\ Y'K[&HH ^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_B
MG_X%C_Y'K[&HH ^.?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\
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M^1Z/^'E/[67_ $B?^*?_ (%C_P"1Z^QJ* /CG_AY3^UE_P!(G_BG_P"!8_\
MD>C_ (>4_M9?](G_ (I_^!8_^1Z^QJ* /CG_ (>4_M9?](G_ (I_^!8_^1Z/
M^'E/[67_ $B?^*?_ (%C_P"1Z^QJ* /CG_AY3^UE_P!(G_BG_P"!8_\ D>N?
MT[_@J)^T;/\ $?4=!M?^"8GQ&EU6#3X9+K2DU%3/!$Q.V1E\C(5NQK[FKPOP
M#_RD$\?_ /8B:5_Z,:@#RW_AY3^UE_TB?^*?_@6/_D>C_AY3^UE_TB?^*?\
MX%C_ .1Z^QJ* /CG_AY3^UE_TB?^*?\ X%C_ .1Z/^'E/[67_2)_XI_^!8_^
M1Z^QJ* /CG_AY3^UE_TB?^*?_@6/_D>C_AY3^UE_TB?^*?\ X%C_ .1Z^QJ*
M /CG_AY3^UE_TB?^*?\ X%C_ .1Z/^'E/[67_2)_XI_^!8_^1Z^QJ* /CG_A
MY3^UE_TB?^*?_@6/_D>C_AY3^UE_TB?^*?\ X%C_ .1Z^QJ* /CG_AY3^UE_
MTB?^*?\ X%C_ .1Z/^'E/[67_2)_XI_^!8_^1Z^QJ* /CG_AY3^UE_TB?^*?
M_@6/_D>C_AY3^UE_TB?^*?\ X%C_ .1Z^QJ* /CG_AY3^UE_TB?^*?\ X%C_
M .1Z/^'E/[67_2)_XI_^!8_^1Z^QJ* /CG_AY3^UE_TB?^*?_@6/_D>C_AY3
M^UE_TB?^*?\ X%C_ .1Z^QJ* /CG_AY3^UE_TB?^*?\ X%C_ .1Z/^'E/[67
M_2)_XI_^!8_^1Z^QJ* /CG_AY3^UE_TB?^*?_@6/_D>C_AY3^UE_TB?^*?\
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M7_2)_P"*?_@6/_D>C_AY3^UE_P!(G_BG_P"!8_\ D>OL:B@#XY_X>4_M9?\
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M)!!V88CZ.H **\!^'G[>&D_M'>/]:\'?L??#*\\?Z/X9U5],\0_$:;4X]/\
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MJ[E)5@&1ARK(P#*RLK $$4 =717SSK?[?^G:5X*\7^,]&^"'B7Q1+IWQ*O\
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M3]C/XH_ +Q;X]BD?X<W'Q!M;9[#Q"Z#)MTN+>1ECN,$?N_F&XA"P=XU?WO\
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M=ZO;ZAIGBFVM@#=Q6EU"0?M5N"'EMY(T81D2(77) !]"T444 %%%% !1110
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MLZR;22VM88XM-N[J.WM(O->>1Y)1)))%"BQ;<R4 9_\ P<, '_@B]^T""/\
MF38__2VVKZ/_ &4?^37/AK_V(&C?^D,->&?\%MOA!\>_VD/^";7Q,_9I_9L^
M".J^-_%GCG1$T_3;:PU?3+*&V875O(7GEO[NW 78KD;-YRN"!D9W=0M?VF#_
M ,$S+;X=>#/A)KOA3XFS^!--\)V>G7U]83SZ/>W$5OI\FI>99W,T+16OFR71
M(DW%+9OER0" 3?L/^'=!^.'A?QW^U/XNT>VU*#XK_$9M8\.K=PB1$T3298K/
M0Y8\\;'6P74X_P"[)?LW!Z>8?\%G_@Q9?MV>%_AU_P $VO#]DMWJWC?Q[IGB
M+Q1=HFX^&O"^EW FO=2=O^6;RL([* '!EDN6 ^6.4K]#_%,^/?V5_P!DTZ!^
MQ_\ LX7/Q UCP?X:M=)\"_#^QUVRTU9UAB2WMXWN;V6***&-%4NV2VU#L1FP
MI^&O@M^T/_P6_P#@]H.LZ_-_P08G\1_$7Q9*ESXM\;:O^TWX7B6]N%4K#&D,
M>XP6-N&*0VB.=B%B7>666:0 M_M)ZMJOBS_@Z>_9T\#:W*[Z3X1_9RU[7]"B
M<_)'?WDVHV5PZCLQAAA!/H!3_P!MO7M1\&?\'+/[&=UX8=TG\5_#7QGHOB%(
MC@W&GQ65U=Q(^.JK.@DP>,I7KO[8'[&_QUO/VDOV=_\ @H_\,]"M?%OQ*^#E
MK<Z-\1/#&CRQ61\5:'J-H8+W[$;F18UGMYW>Y@AEEC5PSHT@;;F;X:?LJ?$W
M]HO_ (*DP_\ !2WXW_#:_P#!>A?#_P"&[^#_ (3^$M=N;:34[BYN9I9-0UFY
M6UEECME:.06T4/F-(R;WD6,[5(!Y]_P6Z _X:G_8/..?^&JM._\ 2:2M;_@Y
M(_:>^*?[-'_!+GQ%9?!'4YM/\5_$OQ'IO@71]3MY2DEI_:#OY[*PY1FMXIXP
MXP5,@8<J*D_X*X?!#]JWXY_M)?LM^)O@#^ROXB\8Z+\)?C99>+O&&KV/B'0K
M.-;&./8Z0I?:A!++*-[';L"G8?FY&?4O^"KW["NJ_P#!2K]A#6?@5X?U7_A%
M?&23V/B+P1?:IL9=+URS<30).8C(NT_/ [(7"B5F7?M (!\U?$O]I+]IS_@@
MI\ O@KIGQ,^"_P +K[]F_2KK2_!GB7_A!9M0&M>$GE4A=2EGGVPZE&\BR22N
M(+=WEDZ9DS7Z: @C(-?!G[97P6_:/_X*S?LL^$OV./C'^RQKGPU@UOQ/HM_\
M9]6US5=.FL]/M-/N$N;FUTQ[6ZFDO)+F6%8X9-BHD3L\I1PL+_>8 4!5   X
M H **** "BBB@ HHHH **** "LKQV ?!&L@C_F%7'_HIJU:Y?XSZMXFT7X7Z
MW=^#OAUJOBO4FTZ:.ST+1KFSAN+EV1@ KWL\$*C)&2T@_&@#XP_X-A/^4&'P
M*_Z]_$/_ *D>J5]/?M1?$SX>_LH?LJ:]KT/@F&[M-/T;^RO"_@K3;,,^MW\X
M^SV6DV\('SR7$SQPJN,?.2V%#$>#?\$"O@-^TA^R+_P3#\ _LI?M1? 35O!?
MBWP,NJQWD=SK>E7UO?BYU:^O(VMY+"\GZ1SQAO-$>&) W 9KR;Q!^T!_P65U
M7]I[4/C7XE_X(6ZOXMTOP[=36_PGTZ]_:+\)Z?'HML\9CEOY8!-.'U&=6=&F
MWD00.8(@-]Q)< 'M7[!WP0@_X(U_\$<?#W@#XH70U*]^%?@'4=<\41V,F_[1
MJ,LEQJ-Q:6Y'^L_TB=K>+ R^$P,MBO:_V/?@[X@_9^_98\*>!?&, U'Q7;Z9
M+JOBZ6UV9OO$%]))?:G+&78*/-O;FY898 !P"V.:\1TB+]O#]KWX;_#OP_\
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M9);VEYX@\/W2O(EQ9?:)4A$UK>.UQY#R+YD;NJOO50X!X[\?->U'P=_P=1?
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MPZ_9V_:*^ 6M>$_&'@'P_+97^ESZQI-XM_)]HN)%-M+9WLT9!5D_UK18+X/
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M!L6OV^OBI^V)\*/V?;[5/V%/V7Y/BG\1;Z46FD:9+XBTW3;33=RG=>W#WUS
M)$3'$499G<J#L7<Z@'AW[=/P8LOVXO\ @HO^SM\(O#5DLUK\ /%H^)WQ#\01
M)D:4Z1%-(TL/_P ][N<&=HL@K!9[V^_%O\L_91U;5?&__!T5^U1?>)I7D/@G
MX&^%]!\-^:<^58W46GW\RIZ*;EY"<=R:TOV?_C;_ ,%C?A[HFF_!GP7_ ,$2
MW\(R>(]?CD\7?%GQI^T?X=UF6*YN9$6[UV^MK-4EOY%3+^1$4 2*.&)4C2.-
M?5/C%^RI\3_@'_P5(T__ (*;? KX<7WC'2?&'PW?P/\ %WPCH=Q;1ZB@BGCN
M-/UFV6YEBCN"GE"VFB\Q7$11HUD(9: /'/@]KVH^&O\ @ZN^+?@O0'==-\4?
MLJZ9JOB&",_+)>VFHV5O;S/CJRPRL@)YQ)71?M= ?\1&'[(9QS_PJKQW_P"D
MPKT[]B#]CWXD0?MO_&K_ (*:?M!>$6\->)OBA:Z;X>\%>#+F\@N+OP[X:L(8
MU NI+=Y(?M-U.@N'BCDD2(+&HD8E@.$_:C^#?[6GBO\ X+6? 3]J_P #?LA^
M*=:^'7PS\&>)-&\1>([7Q'X>B,DVH0LD+P6]QJ<<[QJRKN+(K /PK8(H P_^
M"['AWXS?#GXR_LI_M]^!_AWKWBWP9\"_BG=7GQ,T;PSI\E[>6VEW\,-N^I+;
MQ@M*+=(YL[02#,I.%W,OCW_!3G]KGX/_ +77_!0[_@GQI?[)VNZGKNK+\;IM
M736H_#=_:0G1HTM6U%(YKF&-90;<-YBH6V!/G"Y /ZF_%7XD:A\-=#34M&^%
MOB?Q?>SLRVNC^%K6!II6 S@R7,T,$(/0-+*BY[U\Y_LS_L0?$SQ3^V5K'_!3
M']M;^S?^%B3:"?#OPS\"Z3=_:K'X?Z"69GC$Y51<ZC<%F:>X50JAFAC+1_,P
M!]:4444 %%%% !1110 4444 %%%% 'S5_P %E #_ ,$F_P!I#(_YHKXC_P#3
M?-6I_P $S]$TCQ+_ ,$K?V?O#GB#38;RPU#]G[PI;7MG<(&CGADT.U5XV4\%
M64D$=P:A_P""K?@3XP_&#_@GO\6_@3\!_@[JOC3Q3X\\ ZKX?T?3M,U/3K18
MI[JU>%)9I;^ZMT6,%\DJS-@<*:?^P38_&OX*?\$WOAOX!^)/[.GB+3O&_P .
M?A1I&AWO@IM8T>6YU.^T_2X(&2UN(;Y[7;++$5C>::(<@OY8YH Y_P#X*^S/
MXA_8/\7_ +*G@/PS;:QXT^-6DS^ OA_X;V@"6\OH6B>Z( (C@LK?S;V24C$:
M6I/WBH-GXG^&=6_81_X)C:#^SE\%_$,DOB71O!>@_#3X>:G*F))-8N5MM'L;
MME!Z)+(MS( ?ECBD.0%)'S!\//VB?^"W/A[XH:]\>_B+_P $%;OQ5XSU%9K#
M1+I_VF_"MK:Z!HWFAX].M(LR&+>4CDN9R6>XE12VV.*WAA^E? 'AC]K7]H#X
MA_ GQ1^U?\);/PK+X3TS6O&_BW1]+U"*[L],\03!K#2=($R.RW;VUC?7[RS+
M^[:>"&1  RA #W/PAX#T7]GCX&:-\./A)X%N-1LO!7A>UTCPWH=I/!%-+;VT
M*0PPB29DC7Y8UR68#C/)XKX"_P""67[4$7C+_@K'^T=\._VMOV3=;^$?[17B
MO2]-UBSL=0UF#4;"_P#!VGHEG9K97,*A'97D:25E+B5Y&P5$'E1_7_[5?[2W
M[2?P \=>#[+X2_L'^*OB[X5UG[2OBO7/!GBG3+>^\/NFSR0MC?RP"[$@9R66
M9 GEX.2RBN,^$G[-WCOXO_\ !0!O^"COQE^%L_@671/A<? W@;PAJM]:76J^
M3/>_;+R_OWLI9K>)BRQPPP133;4,KNP:01Q@'BW_  <1 'P#^R;D=/VX_A__
M "U"ON;XT_%?PI\!_@_XJ^-OCJ=HM%\(>';W6=5=!EOL]M \T@4=V*H0!W)
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MI!X()%>/_P#!:?1KWXT_L5:O^P]X"TJ#5/'?QVGA\+>$M,F3>ENIFBEO-5F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !17F7C3]LK]F/X?ZT_A[Q/\
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MV8_*K;&&*^;O^"A7Q]^%'P=_X+4_L7_M3_$_Q.^B?#[4O OC73+3Q1?Z=<)
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MJTS$',+>;B59:HS/I/\ X*C:)J/[2OA;PM_P36\+>);W2KKXYW5U#XRU32V
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M?1/B]>^)[2*ZBN[_ #]CN9=%VFYAM)=I;?*\<JH,M"K%8V^+?BU\<_@M<_\
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M8X 'K6=_PF7A#_H:M-_\#H_\:OW-M!>6TEG=1!XI4*2(W1E(P1^5<9_PS?\
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M &9O'VD:QXU\3_M&>-]8\/:1IVK1-/J-J9]-NK<HH;/E70@>!)3^[9G(W<'
M!]Y?$_\ X*O_ !1^#?[,&C?M_?$']B?4(?@5JL-EJ%[J]EXR6?Q3HVC7C(+?
M5+O1A:"(1$2Q.\<5]+-&D@+)E75.!_X*9_MX_M,>&_VDOV0_ O[*_AKP[KGP
MZ^,'CRVU&+7HO%S6TOB>.*T-W!9@BW=;>T820SF8^8TA1%"*H8OQ6K_M]_L\
M_M*_\$ M;^#VF^(;*;XLZS\#;CX</\'-X_X22/Q@=,;3!IZZ8?\ 2=ZW6) ?
M+&(5\TX521Y_^V'\-_\ AW/\/?\ @F%;_M&^)(].T3X/^+K71_'_ (JG+/8Z
M7=OHR18>500L7FI*JL>-D>> #@ _1+QI^UE\1+/XBZ-^S;\,O@OI6O?%N[\&
M+XG\1>';_P 9M9:/X<L&E,"/=:DEG/*QFN$EB@6*T=I/L\S,L:INKS']G?\
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M!&VN0 G4XM;BEDL1\_-PJ$,8?O@9)& : />/V5/^"JVM_M#_  5^,OB7Q/\
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MUIHE^)_[+/B(^--+C0[6U/0=H36]-=AR(I;0&1L<[8"HY>O<O^"<7@OQ9;_
M*;X^_%'0I=.\:_&C79_'?BBPNN9M/%XD::?ISG^]9Z;#86C=M]N[#[U 'OU%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!YEXS_8V_9C\?ZT_B'Q/\(=.>\E??--:2RVOF,>K,('0,3W)
M!)KLO 7PV\ _"[11X>^'OA&QTBSW;FALH GF-_><]7;W8DUMT5WU\TS/%8=4
M*U><H+:+E)Q7HF[(X*&597A<0Z]&A"-1[R48J3]6E=A1117 =X4444 %%%%
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M@ HHHH **** "BBB@#C_ (T? #X*?M%>%?\ A"?CC\,='\3Z8KEXK?5K-9#
MY&"\3_>B;'&Y"#CC->7_  D_X)9?\$_O@?XLA\<?#G]F/0X-5MI1+:W>I7%S
MJ)MY <AXUNY95C8'D,H!';%?0%%<]3"82K552=.+DNK2;^\]3#9YG6#PDL+A
M\34A2EO",Y*+OO>*=G]P4445T'EA1110 4444 %-$,*S-<+"HD=0K2!1N*@D
M@$^@R?S/K3J* "BBB@""XTS3;P3+=Z?!*+F$0W DB#>;&-V$;(^9?F;@\?,?
M4U6\-^$_"O@W3O[(\(>&=/TJT,A<VNFV201[CU;:@ R?6M"B@ HHHH ****
M"O)OVS_V(/V9?^"@/P2OO@!^U1\,K3Q)H%VWFVS.3'=:;<@$)=6LZ_/!,N3A
ME.""58,K,I]9HH ^7?V"OV1/VGO^"?OP[TW]EK2_B_I/Q3^%N@.(/!FH^+9I
M=-\1>'=-W?+82/!#-!J:1KQ$^+0HH$>"H39]1444 5-<T#0O$^F2Z)XET6TU
M&RF $UI?6RS128.1N1P0>?44:%X?T'POID>B>&=$M-.LH<^3:6-LL,29.3A$
M  Y]!5NB@"CK_ACPWXJM$L/%'AZQU*".598X;^T29%=?NN X(##L>HJ\ % 5
M1@#H!110 4444 ?#/Q6_9:_:3\9?\%M?!W[:2? ./4/A;H7P9OO >KRW6NZ>
M;JXGN;Z2X^U):/+A[8 H"'99""Y$9V@-]OZ9I>F:)I\6DZ-IT%I:P)L@MK6%
M8XXU]%50 !["IZ* *-WX7\,W^MV_B6^\.V,VI6B%+34);1&G@4YR$D(W*#D\
M ]ZLWMA8ZE;O9ZC917$4B%)(IHPZLIZJ0>"#Z5+10!5T;1-%\.:9%HOA[2+6
MPLX%VP6EE;K%%&,YPJJ !SZ"K5%% #+>WM[2$6]K D<:_=2-0 ._055T;PYX
M>\.+.GA[0;*P6YG,UR+.U2(2R'J[;0-S'N3S5VB@ HHHH **** "BBB@ HHH
MH *YKQO\'?AC\1Y1<^,_!MI>S*NT7.&CEQV&]"K$>V:Z6BN?%83"8ZBZ6)IQ
MG!]))27W.Z)G"%2/+-77F<YX(^$7PU^'#-+X+\'VEC*Z[6N%!>4CTWN2V/;.
M*Z.BBC"X3"X*BJ.'IQA!;**22^2L@A"%./+%67D%%%%=!04444 %%%% #8H8
M;=#'!"J*69BJ* "Q))/'<DDGU)IU%% !69KO@OP=XHTLZ'XE\)Z9J-DTQF:S
MOK".:(R%BQ?8X(W%B3G&<DGO6G10!':6EI86L=C8VT<,$*!(884"HB@8"@#@
M #L*DHHH **** "BBB@#Y+_X*2_\$<?V6/\ @I'<:)\1_%CZGX(^*OA&>&Y\
M%?%GP<RPZMI<T,@E@#Y&VYB24!PC_,ASY;QEF)]M_9[L_P!JOP_X=M?"/[2^
MH>#/$-[I]F(7\;>&)+BSDUF1< 3RZ9)$R6;,,EECNI5W [0JD*OH]% !1110
M 4444 48O"_AF'7Y/%</AVQ35)H1%+J2VB"X>,8PADQN*\#@G'%6Y[>WNH_*
MN8$D3<&VR*",@Y!P?0@'\*?10!6UC1M'\0Z;-HNOZ5;7UG<+MGM+R!98I%ZX
M96!##ZBI;6UM;&VCLK*VCAAA0)%%$@544# 4 <  =JDHH IV/AWP_I>I76L:
M9H5G;W=\5-]=06J))<%1@%V R^.V<XJY110 4444 -FAAN87M[B)9(Y%*NCK
MD,#P00>HJKH7AWP_X7T\:3X9T*STZT5BRVMA:I#&&)R3M0 9)ZU<HH *HZEX
M7\,ZQJ5IK.K^';&ZO+!R]C=W-HCRVS>L;,"4/N"*O44 ?-?_  4W^!/[8GQP
M^%_@Z?\ 8S\7^$H]:\'_ !"T[Q)K'@[QR9XM+\7VEH7==.GG@#/"/.\J9?E9
M3)!'NP!7F&M_![]M3]NSP%K'P*_:F_X)W_!CX4>'/$FG3:?XI\4/X]B\5ZDU
MM*ICF.G6J:7!''.R$^7<33_N&*OY4Q38?N.B@#XT^,/P?_X*7?M-?'_Q+^S!
M\2O#7PHT#]EFXN]-8Z_IE[>W'B;7M)B$4MSH\L3N84%S(C6\TA50MM)(J>8[
MAU^RP !@"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969478745352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amicus Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">71-0869350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">921-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FOLD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,540,615,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,029,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Proxy Statement for the registrant's 2021 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969478657928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young&#160;LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477659336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 245,197<span></span>
</td>
<td class="nump">$ 163,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="nump">237,299<span></span>
</td>
<td class="nump">320,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">52,672<span></span>
</td>
<td class="nump">46,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">26,818<span></span>
</td>
<td class="nump">19,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">34,848<span></span>
</td>
<td class="nump">29,721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">596,834<span></span>
</td>
<td class="nump">579,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">20,586<span></span>
</td>
<td class="nump">23,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, less accumulated depreciation of $19,882 and $14,487 at December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">42,496<span></span>
</td>
<td class="nump">43,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research&#160;&amp; development</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">24,427<span></span>
</td>
<td class="nump">19,095<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">905,140<span></span>
</td>
<td class="nump">886,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">21,513<span></span>
</td>
<td class="nump">17,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">98,153<span></span>
</td>
<td class="nump">96,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration payable</a></td>
<td class="nump">18,900<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">7,409<span></span>
</td>
<td class="nump">6,872<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">145,975<span></span>
</td>
<td class="nump">129,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="nump">5,906<span></span>
</td>
<td class="nump">7,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">389,357<span></span>
</td>
<td class="nump">389,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">1,439<span></span>
</td>
<td class="nump">16,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">4,930<span></span>
</td>
<td class="nump">4,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">43,363<span></span>
</td>
<td class="nump">45,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">6,801<span></span>
</td>
<td class="nump">6,379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">597,771<span></span>
</td>
<td class="nump">600,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 500,000,000 shares authorized, 278,912,800 and 262,063,461 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">2,808<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,595,419<span></span>
</td>
<td class="nump">2,308,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">5,251<span></span>
</td>
<td class="nump">8,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on available-for securities</a></td>
<td class="num">(270)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,295,922)<span></span>
</td>
<td class="num">(2,045,462)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">307,369<span></span>
</td>
<td class="nump">286,380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 905,140<span></span>
</td>
<td class="nump">$ 886,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477400248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation of property and equipment</a></td>
<td class="nump">$ 19,882<span></span>
</td>
<td class="nump">$ 14,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">278,912,800<span></span>
</td>
<td class="nump">262,063,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">278,912,800<span></span>
</td>
<td class="nump">262,063,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477462808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 305,514<span></span>
</td>
<td class="nump">$ 260,886<span></span>
</td>
<td class="nump">$ 182,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">34,466<span></span>
</td>
<td class="nump">31,044<span></span>
</td>
<td class="nump">21,963<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">271,048<span></span>
</td>
<td class="nump">229,842<span></span>
</td>
<td class="nump">160,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">272,049<span></span>
</td>
<td class="nump">308,443<span></span>
</td>
<td class="nump">286,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">192,710<span></span>
</td>
<td class="nump">156,407<span></span>
</td>
<td class="nump">169,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="nump">6,514<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
<td class="nump">3,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,209<span></span>
</td>
<td class="nump">8,846<span></span>
</td>
<td class="nump">4,775<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">477,482<span></span>
</td>
<td class="nump">476,840<span></span>
</td>
<td class="nump">464,311<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(206,434)<span></span>
</td>
<td class="num">(246,998)<span></span>
</td>
<td class="num">(304,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">3,226<span></span>
</td>
<td class="nump">10,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(32,471)<span></span>
</td>
<td class="num">(22,425)<span></span>
</td>
<td class="num">(18,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_GainLossOnExchangeOfDebt', window );">Loss on exchange of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(40,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(257)<span></span>
</td>
<td class="num">(7,276)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(2,901)<span></span>
</td>
<td class="num">(781)<span></span>
</td>
<td class="num">(2,626)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(241,554)<span></span>
</td>
<td class="num">(274,254)<span></span>
</td>
<td class="num">(355,910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(8,906)<span></span>
</td>
<td class="num">(2,598)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (250,460)<span></span>
</td>
<td class="num">$ (276,852)<span></span>
</td>
<td class="num">$ (356,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss attributable to common stockholders per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss attributable to common stockholders per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">271,421,986<span></span>
</td>
<td class="nump">258,867,380<span></span>
</td>
<td class="nump">240,421,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">271,421,986<span></span>
</td>
<td class="nump">258,867,380<span></span>
</td>
<td class="nump">240,421,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_GainLossOnExchangeOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Exchange Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_GainLossOnExchangeOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477786392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (250,460)<span></span>
</td>
<td class="num">$ (276,852)<span></span>
</td>
<td class="num">$ (356,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment (loss) gain, net of tax impact of $0, $1,552, and $889, respectively</a></td>
<td class="num">(3,161)<span></span>
</td>
<td class="nump">5,627<span></span>
</td>
<td class="nump">2,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on available-for-sale securities, net of tax impact of $0, $(50), and $182, respectively</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) gain</a></td>
<td class="num">(3,246)<span></span>
</td>
<td class="nump">5,402<span></span>
</td>
<td class="nump">2,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (253,706)<span></span>
</td>
<td class="num">$ (271,450)<span></span>
</td>
<td class="num">$ (353,631)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477578248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax', window );">Foreign currency translation gain (loss), tax impact</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,552<span></span>
</td>
<td class="nump">$ 889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Available-for-sale securities, tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (50)<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969474685160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,383,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 342,912<span></span>
</td>
<td class="nump">$ 1,942<span></span>
</td>
<td class="nump">$ 1,740,061<span></span>
</td>
<td class="nump">$ 13,063<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="num">$ (1,412,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="nump">1,967,000<span></span>
</td>
<td class="nump">1,967,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">$ 11,476<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">11,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,720,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued from equity financing</a></td>
<td class="nump">188,994<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">188,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to restricted stock unit vesting</a></td>
<td class="num">(3,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesContingentConsideration', window );">Stock issued for contingent consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueContingentConsideration', window );">Stock issued for contingent consideration</a></td>
<td class="nump">9,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">44,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="num">(676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Equity component of the convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,995,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="nump">215,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations', window );">Termination of capped call confirmations</a></td>
<td class="nump">19,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding gain on available-for-sale securities</a></td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(356,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(356,388)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,417,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 476,425<span></span>
</td>
<td class="nump">$ 2,598<span></span>
</td>
<td class="nump">2,227,225<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
<td class="num">(1,768,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="nump">5,243,000<span></span>
</td>
<td class="nump">5,233,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">$ 42,282<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">42,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,411,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to restricted stock unit vesting</a></td>
<td class="num">(10,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">49,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding gain on available-for-sale securities</a></td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">5,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (276,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(276,852)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">262,063,461<span></span>
</td>
<td class="nump">262,063,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 286,380<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">2,308,578<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">8,227<span></span>
</td>
<td class="num">(2,045,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="nump">1,483,000<span></span>
</td>
<td class="nump">1,461,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">$ 10,228<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">10,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued from equity financing</a></td>
<td class="nump">199,747<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">199,552<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to restricted stock unit vesting</a></td>
<td class="num">(15,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">57,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,554,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">19,230<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">31,591<span></span>
</td>
<td class="num">(12,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="nump">2,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding gain on available-for-sale securities</a></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(3,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (250,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,460)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">278,912,800<span></span>
</td>
<td class="nump">278,912,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 307,369<span></span>
</td>
<td class="nump">$ 2,808<span></span>
</td>
<td class="nump">$ 2,595,419<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 4,981<span></span>
</td>
<td class="num">$ (2,295,922)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from Termination of Capped Call Confirmations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants (in shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969475104248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (250,460)<span></span>
</td>
<td class="num">$ (276,852)<span></span>
</td>
<td class="num">$ (356,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and deferred financing</a></td>
<td class="nump">2,490<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,209<span></span>
</td>
<td class="nump">8,846<span></span>
</td>
<td class="nump">4,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">57,838<span></span>
</td>
<td class="nump">49,151<span></span>
</td>
<td class="nump">44,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_GainLossOnExchangeOfDebt', window );">Loss on exchange of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">7,276<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Non-cash changes in the fair value of contingent consideration payable</a></td>
<td class="nump">6,514<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
<td class="nump">3,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax', window );">Foreign currency remeasurement loss</a></td>
<td class="nump">3,565<span></span>
</td>
<td class="nump">5,471<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Non-cash deferred taxes</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="num">(1,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(8,189)<span></span>
</td>
<td class="num">(11,219)<span></span>
</td>
<td class="num">(11,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(7,790)<span></span>
</td>
<td class="num">(4,639)<span></span>
</td>
<td class="num">(5,114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(5,919)<span></span>
</td>
<td class="num">(8,766)<span></span>
</td>
<td class="num">(3,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="nump">7,430<span></span>
</td>
<td class="num">(10,610)<span></span>
</td>
<td class="nump">46,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities', window );">Other non-current assets and liabilities</a></td>
<td class="num">(2,617)<span></span>
</td>
<td class="nump">4,420<span></span>
</td>
<td class="num">(10,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInDeferredReimbursements', window );">Deferred reimbursements</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(5,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment of contingent consideration</a></td>
<td class="num">(10,353)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(202,491)<span></span>
</td>
<td class="num">(233,290)<span></span>
</td>
<td class="num">(250,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and redemption of marketable securities</a></td>
<td class="nump">424,043<span></span>
</td>
<td class="nump">354,826<span></span>
</td>
<td class="nump">499,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(341,398)<span></span>
</td>
<td class="num">(365,178)<span></span>
</td>
<td class="num">(383,882)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(3,884)<span></span>
</td>
<td class="num">(3,227)<span></span>
</td>
<td class="num">(20,012)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">78,761<span></span>
</td>
<td class="num">(13,579)<span></span>
</td>
<td class="nump">95,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing', window );">Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">199,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">188,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(155,249)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">385,929<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance leases</a></td>
<td class="num">(479)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits', window );">Payments of employee withholding taxes related to restricted stock unit vesting</a></td>
<td class="num">(15,009)<span></span>
</td>
<td class="num">(10,028)<span></span>
</td>
<td class="num">(3,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt', window );">Proceeds from termination of capped call confirmations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised, net</a></td>
<td class="nump">10,228<span></span>
</td>
<td class="nump">42,282<span></span>
</td>
<td class="nump">11,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised, net</a></td>
<td class="nump">19,230<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="num">(1,647)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">212,073<span></span>
</td>
<td class="nump">262,858<span></span>
</td>
<td class="nump">217,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(5,049)<span></span>
</td>
<td class="nump">3,830<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">83,294<span></span>
</td>
<td class="nump">19,819<span></span>
</td>
<td class="nump">63,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the beginning of the year</a></td>
<td class="nump">166,162<span></span>
</td>
<td class="nump">146,343<span></span>
</td>
<td class="nump">82,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the end of the year</a></td>
<td class="nump">249,456<span></span>
</td>
<td class="nump">166,162<span></span>
</td>
<td class="nump">146,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid through lease incentive</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="nump">19,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">30,468<span></span>
</td>
<td class="nump">24,683<span></span>
</td>
<td class="nump">16,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationPaidInStock', window );">Contingent consideration paid in shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures unpaid at the end of period</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="nump">1,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">$ 20,032<span></span>
</td>
<td class="nump">$ 10,371<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationPaidInStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration liability in stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationPaidInStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Remeasurement Gain (Loss), Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ForeignCurrencyRemeasurementGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_GainLossOnExchangeOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Exchange Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_GainLossOnExchangeOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInDeferredReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of deferred reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInDeferredReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInNoncurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire restricted stock units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentsForRepurchaseOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Warrants And Equity Financing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477142184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). We are committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of the Company's portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, the Company announced, with ARYA Sciences Acquisition Corp IV ("ARYA"), a special purpose acquisition company (or "SPAC"), sponsored by Perceptive Advisors, it has agreed to mutually terminate the previously announced definitive business combination agreement, originally executed in September 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in September 2021, the Company entered into securities purchase agreements with certain investors for the private placement of an aggregate of 11,296,660 shares of the Company's common stock, at a purchase price of $10.18 per share, and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. The net proceeds from these private placements were approximately $199.8 million. The Company expects to use the net proceeds to further fund initiatives in the global commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the anticipated global launch of AT-GAA and to further support the Company's discovery work on next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations have not been significantly impacted by the novel coronavirus (&#8220;COVID-19&#8221;) pandemic to date. However, the Company observed increased lag times between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation due to the resurgence of COVID-19 in 2021. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimal disruptions. Whether the Company will continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had an accumulated deficit of $2.3 billion as of December 31, 2021 and anticipates incurring losses through the fiscal year ending December&#160;31, 2022 and beyond. The Company has historically funded its operations through stock offerings, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, debt issuances, collaborations, and other financing arrangements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, and net proceeds from the September 2021 private placement of securities, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477223944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of December 31, 2021 and through the issuance of these financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's accounts receivable at December 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of December 31, 2021, the Company recorded an allowance for doubtful accounts of $0.2 million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDYwOA_36c2035c-6429-44ec-a5ff-c15bdbc6abf6">three</span> to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2021, one customer accounted for 24% of net product sales and 14% of accounts receivable from product sales. In 2020, one customer accounted for 25% of net product sales and 12% of accounts receivable from product sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by geographic area:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"/><td style="width:53.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Interest Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company had one equity-based employee compensation plan, which is described more fully in "&#8212;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss per Common Share</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#8212;&#160;Note&#160;15. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently operates in one business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is one reporting unit.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. If it is determined the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value, an impairment loss is recorded for the difference. No indicators of impairment were noted during the years ended December 31, 2021 and December 31, 2020.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2019-12 - In December 2019, the FASB issued Accounting Standard Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969482162872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, in connection with the acquisitions, the Company had goodwill of $197.8 million </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D of $23.0 million, which are reported at fair value on the Company's Consolidated Balance Sheets. Intangible assets related to IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D assets below their respective carrying amounts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. A goodwill impairment loss, if any, is measured as the amount by which the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value.   An IPR&amp;D impairment loss, if any, is measured as the amount by which the carrying amount of the asset exceeds its fair value. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in IPR&amp;D for the years ended December 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in Goodwill for the years ended December 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477216856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company held $245.2 million in cash and cash equivalents and $237.3 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:46.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:46.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021 there were no realized gains or losses. For the fiscal year ended December 31, 2020, there were nominal realized gains. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss positions in the marketable securities as of December 31, 2021 and 2020 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $173.4 million and $124.9 million as of December 31, 2021 and December 31, 2020, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:44.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.138%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477080968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of raw materials, work in process, and finished goods related to the manufacture of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table summarizes the components of inventories: </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:66.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.459%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,818&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,556&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a reserve for inventory of $1.1 million and $0.1 million as of December 31, 2021 and December 31, 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477528328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $5.7 million and $8.4 million for the years ended December 31, 2021 and December 31, 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477121848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of the following: </span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing&#160;&amp; contract research costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales rebates and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued program fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477107016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Warrants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company was authorized to issue 500 million shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to one vote for each share held.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a securities purchase agreement with certain entities, the (&#8220;Purchase Agreements&#8221;) for the private placement of an aggregate of 11,296,660 shares of the Company&#8217;s common stock, at a purchase price of $10.18 per share, and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. Proceeds from the private placement, net of offering costs, were $199.8&#160;million. Each pre-funded warrant has an initial exercise price of $0.01 per share and is exercisable at any time after its original issuance, subject generally to the lock-up period, at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds of the initial exercise price for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. Certain of the Purchase Agreements provide for a lock-up period of either 60 days or nine months based on the individual agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first quarter of 2021, 1,294,999 and 1,260,000 warrants were exercised at $7.98 and $7.06 per share of common stock, respectively, resulting in gross cash proceeds of $19.2&#160;million. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As discussed in ''&#8212; Note 11. Debt'', during the first and third quarters of 2021, the Company entered into separate, privately negotiated exchange agreements with the holders of the Convertible Notes (the "Holders"). Under the terms of the exchange agreements, the Holders agreed to exchange the remaining aggregate principal amount of $2.8&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 472,356 shares of Company common stock, par value $0.01 per share. This transaction resulted in an increase of $2.7&#160;million and five thousand dollars to additional paid-in-capital and common stock, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As discussed in ''&#8212; Note 11. Debt'', during the first and second quarters of 2019, the Company entered into separate, privately negotiated exchange agreements with a limited number of Holders. Under the terms of the exchange agreements, the Holders agreed to exchange an aggregate principal amount of $247.2&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 44.0&#160;million shares of Company's common stock, par value $0.01 per share. These transactions resulted in an increase of $215.0&#160;million and four hundred forty thousand dollars to additional paid-in-capital and common stock, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2019, the Company completed an underwritten equity offering and issued 18.7 million shares of its common stock at $10.75 per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of $189.0 million, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2019, 101,787 warrants were exercised at $7.98 per share of common stock resulting in gross cash proceeds of $0.8&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2018, the Company reached a clinical milestone, which was the dosing of the first patient in a Phase 3 study, related to the contingent consideration from the acquisition of Callidus Biopharma, Inc. ("Callidus"). The milestone for this event was $9.0 million, which was paid by issuance of 771,804 shares of Company common stock, par value $0.01 per share, in the first quarter of 2019.  This transaction resulted in an increase of $9.3&#160;million and eight thousand dollars to additional paid-in-capital and common stock, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Deferral Plan, (the "Deferral Plan") provides certain key employees and members of the Board of Directors as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code of 1986 as amended.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a deferred compensation investment balance of $4.8 million and $4.1 million as of December 31, 2021 and December 31, 2020, respectively, with corresponding approximate amounts of liability. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral Plan investment assets are classified as trading securities and are recorded at fair value with changes in the investments' fair value recognized in accumulate other comprehensive gain (loss) in the period they occur. Deferred compensation liability amounts under the Deferral Plan are included in other long-term liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plan </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. Under the provisions of the Plan, no option will have a term in excess of 10 years. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest 25% on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for 100% of the shares vested at any time after the date of grant. As of December 31, 2021, the Company has reserved up to 18,322,154 shares for issuance under the Plan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477134376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share based Compensation</a></td>
<td class="text">Share based Compensation The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors. advisors, and consultants at a price to be determined by the Company&#8217;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan provides for certain benefits to qualifying Plan participants who separate from service with the Company due to death, disability or "retirement" (as such term is defined under the Plan) ("Qualified Participants"). Options granted under the Plan ("Options") to a Qualified Participant shall continue to vest until the 2nd anniversary of the Qualified Participant&#8217;s separation and all vested Options held by such Qualified Participant shall remain exercisable until the earlier of the 4th anniversary of the Qualified Participant&#8217;s separation or the original expiration date of the Option. Options that are not exercised during this exercise period shall be forfeited. Time-based restricted stock units and restricted stock granted to a Qualified Participant under the Plan that was scheduled to vest within the two year period following the Qualified Participant's separation shall accelerate and be delivered upon such separation. Any time-based restricted stock units or restricted stock that would have vested after such two year period will be forfeited upon the Qualified Participant's separation. Also, per the Amendment, any performance-based restricted stock units under the Plan ("PRSUs") received by the Qualified Participant, shall remain eligible to vest after the Qualified Participant&#8217;s separation based on the actual performance of the Company through the end of the performance period applicable to any such PRSUs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the fair value method of measuring stock-based compensation, using the fair value of each equity award granted. The Company chose the &#8216;&#8216;straight-line&#8217;&#8217; attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007. The average expected life is determined using our actual historical data. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life of options (years) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value per share of options granted during 2021, 2020, and 2019 were $9.08, $6.40, and $6.67, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock options for the year ended December 31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,432&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $8.5 million, $40.9 million, and $11.8 million respectively. Cash proceeds from stock options exercised during the years ended December 31, 2021, 2020, and 2019 were $10.2 million, $42.3 million, and $11.5 million, respectively. As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock options granted was $28.9 million and is expected to be recognized over a weighted average period of three years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the year ended December 31, 2021 is as follows:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, 1,863,436 RSUs have vested and all non-vested units are expected to vest over their normal term. As of December 31, 2021, there was $47.6 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of two years.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense Related to Equity Awards</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,340&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,817&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,151&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477150184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text">Assets and Liabilities Measured at Fair Value<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs that are unobservable for the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"/><td style="width:72.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,903&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, the Company's Convertible Notes fell into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. As noted in ''&#8212; Note 11. Debt," the Convertible Notes were fully settled during the third quarter of 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets as of December 31, 2021 or December 31, 2020.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Money Market Funds and Marketable Securities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended December 31, 2021. No transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the year ended December 31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable resulted from the acquisition of Callidus. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable for Callidus has been classified as a Level&#160;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe disease program:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.386%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75%-88%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reached regulatory milestone in September 2021 associated with FDA approval of the first BLA and in November 2021 associated with EMA validation of the MAA, both related to the contingent consideration of Callidus for the ATB-200 Pompe disease program. The satisfaction of these milestones resulted in  the collective milestone payment of $12.0 million, which was payable in cash, resulting in a decrease in the current portion of the contingent consideration liability on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2021 and December 31, 2020, respectively:  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:71.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration  in cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477059128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Senior Secured Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,254&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Term Loan due 2026</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a definitive agreement for a $400&#160;million credit facility with Hayfin Capital Management (&#8220;Senior Secured Term Loan due 2026&#8221;) with an interest rate equal to 3-month LIBOR, subject to a 1% floor, plus 6.5% per annum and requires interest-only payments until mid-2024. The Senior Secured Term Loan due 2026 will be repaid in nine quarterly payments of $44.4&#160;million, starting on July 2024 with the final balance due on the maturity date in July 2026. This transaction resulted in net proceeds of $385.9&#160;million, after deducting fees and expenses. There were no warrants or equity conversion features associated with the Senior Secured Term Loan due 2026. The Company used the proceeds to voluntarily settle the Senior Secured Term Loan with BioPharma Credit PLC, which included the $150&#160;million principal, $1.1&#160;million accrued interest, and $5.2&#160;million in early settlement premiums. As a result of this early extinguishment, the Company recognized a loss on extinguishment of debt of $7.3&#160;million in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Term Loan due 2026 is subject to mandatory prepayment provisions that require prepayment upon a change of control, the incurrence of certain additional indebtedness, asset sale, or an event of loss, subject to certain conditions set forth in the Senior Secured Term Loan due 2026. The Company may prepay the Senior Secured Term Loan due 2026 in whole, at its option at any time. Any prepayment of the Senior Secured Term Loan due 2026 is subject to certain make-whole premiums and prepayment premiums, the latter of which decrease until the fourth anniversary of the transaction date at which point no prepayment penalty shall exist. The obligations under the Senior Secured Term Loan due 2026 are secured by a first lien security interest in certain assets of the Company. The Senior Secured Term Loan due 2026 contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company. The Senior Secured Term Loan due 2026 also contains a minimum liquidity covenant of $75&#160;million, and an incremental minimum consolidated revenue covenant, measured as of the previous four consecutive fiscal quarters. The minimum consolidated revenue covenant ranges from $140&#160;million, beginning March 31, 2021, and peaks at $225&#160;million by June 30, 2023, continuing at that level until the Senior Secured Term Loan due 2026 is repaid. If an event of default occurs and is continuing, Hayfin Capital Management may declare all amounts outstanding under the Senior Secured Term Loan due 2026 to be immediately due and payable.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued at par value $250 million aggregate principal amount of Convertible Notes, which included the exercise in full of the $25 million over-allotment option granted to the initial purchasers of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act (the "Note Offering"). Interest was payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes would mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Convertible Notes were convertible at the option of the Holders, under certain circumstances and during certain periods, into cash, shares of the Company&#8217;s common stock or a combination thereof. The net proceeds from the Note Offering were $243.0 million, after deducting fees and expenses. In addition, the Company used approximately $13.5 million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The Convertible Notes were initially convertible into approximately 40.8 million shares of the Company&#8217;s common stock under certain circumstances prior to maturity at a conversion rate of 163.3987 shares per $1,000 principal amount of Convertible Notes, which represented a conversion price of approximately $6.12 per share of common stock, subject to adjustment under certain conditions. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with a limited number of Holders. Under the terms of the Exchange Agreements, the limited number of Holders agreed to exchange an aggregate principal amount of $247.2&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 44.0&#160;million shares of Company common stock, par value $0.01 per share. In addition, pursuant to the Exchange Agreements, the Company made aggregate cash payments of $1.3&#160;million to the limited number of Holders to satisfy accrued and unpaid interest to the closing date of the transactions, along with cash in lieu of fractional shares. These transactions resulted in $215.0&#160;million in additional paid-in-capital and common stock of $0.4&#160;million on the Consolidated Balance Sheets as of December 31, 2019. Additionally, the Company recognized a loss on the exchange of debt of $40.6&#160;million on the Consolidated Statements of Operations during the year ended December 31, 2019. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first and second quarter of 2019, the Company terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for proceeds of $19.9 million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first and third quarters of 2021, the Company entered into separate, privately negotiated exchange agreements with a limited number of Holders. Under the terms of the Exchange Agreements, the Holders agreed to exchange the remaining aggregate principal amount of $2.8&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 472,356 shares of Company common stock, par value $0.01 per share. This transaction resulted in $2.7&#160;million in additional paid-in-capital and common stock of five thousand dollars on the Consolidated Balance Sheets as of December 31, 2021. Additionally, the Company recognized a net loss from extinguishment of debt of $0.3&#160;million in the Consolidated Statements of Operations for the year ended December 31, 2021.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2021 and 2020 respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:73.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.950%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except interest rate amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate of the liability component, Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate of the liability component, Senior Secured Term Loan due 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477241432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has operating leases for office and research laboratory space, equipment, and vehicles under agreements expiring at various dates through 2044, which include renewal options on leases which the Company is reasonably certain to exercise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, and 2020, operating lease expense was $10.0 million and $11.1&#160;million and variable lease expense was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.1&#160;million and $1.8 million, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the years ended December 31, 2021, and 2020, the Company paid $8.4 million and $9.6&#160;million, respectively, for amounts included in the measurement of operating lease liabilities and recorded $0.3 million and $1.7&#160;million, respectively, of&#160;right-of-use assets and $0.3 million and $0.5&#160;million, respectively, of tenant improvements paid through lease incentives in exchange for new operating lease liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments under finance leases are not significant for the year ended December 31, 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except year and discount rate amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the future minimum operating lease payments were as follows:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:83.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less lease incentives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,478)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company has an additional operating lease for office space that has not yet commenced, with minimum lease payments of $15.1 million.  This operating lease commenced during the first quarter of 2022 with a lease term of ten years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477147944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, income (loss) before income taxes includes the following components:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393,955)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,554)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,254)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355,910)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following were the components of income tax expense (benefit) for the years ended December 31, 2021, 2020, and 2019:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(984)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2021, 2020, and 2019 are as follows:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible debt conversion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Tax Act also introduced an additional U.S. tax on certain non-U.S. subsidiaries&#8217; earnings which are considered to be Global Intangible Low Taxed Income (referred to as "GILTI"). After consideration of the relevant guidance and completing the accounting for the tax effects of the Tax Act, the Company has elected to treat GILTI as a period cost. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $8.9 million in 2021 for taxes in foreign jurisdictions. Due to the loss position and full valuation allowance, there is nominal tax expense in  2021 for taxes in U.S. federal and state jurisdictions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had minimal interest or penalties related to UK corporate taxes during the period ended  December 31, 2021 and did not accrue for any interest or penalties as of December 31, 2021. The Company had a nominal accrual for uncertain tax positions as of  December 31, 2021. Tax returns for years 2016 through 2020 are open to examination by tax authorities. The Company is also subject to examination in any period for which it has net operating losses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization/depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry forwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock issue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest carry forward limitation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,453)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced R&amp;D payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,896)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2021 and 2020, the Company recorded valuation allowances of $581.8 million and $528.9 million, respectively, representing an increase in the valuation allowance of $52.9 million in 2021, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D that may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had federal and state net operating loss carry forwards ("NOLs") of approximately $1,292 million and $1,000 million, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the 2017 Tax Act.&#160;Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through 2021 will expire in 2029 through 2040. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. The Company may experience ownership changes in the future as a result of shifts in the stock ownership some of which are outside the Company's control. The Company completed a detailed study of the NOLs and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on the Company's ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently decrease the amount of state attributes and increase state taxes owed. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has research and experimentation and orphan drug credit carryforwards of approximately $30.3 million and $165.2 million, respectively, which will expire in the years 2021 through 2040. Deferred tax assets for these carryforwards are subject to a full valuation allowance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477244152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborativeArrangementDisclosureAbstract', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">University of Pennsylvania</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, as amended, the Company entered into a collaboration agreement with the University of Pennsylvania ("Penn") to pursue research and development of novel gene therapies. The Company's gene therapy portfolio pipeline expanded to include Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), ceroid lipofuscinosis, neuronal ("CLN1"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of other rare diseases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $88.0&#160;million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country- by-country basis. The Company will provide $10.0 million each year during the five-year agreement to fund the discovery research program. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, as amended in November 2013, the Company entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease (&#8220;Collaboration Agreement&#8221;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent milestone payments due to GSK are recorded within the short term and long term deferred reimbursements accounts on the Consolidated Balance Sheets. Sales based tiered royalties due to GSK are recorded within the cost of goods sold within the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, under the GSK collaboration agreements, the Company paid $1.5 million in sales-based milestones and the Company incurred approximately $25.4 million of royalty expenses. As of December 31, 2021, $7.4 million was recorded as deferred reimbursements and the Company recognized a liability of $4.5 million related to royalties payable to GSK in accounts payable and accrued expenses in the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477053944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text">Basic and Diluted Net Loss per Common Share<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:56.241%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,421,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,867,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,421,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969478837048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of December 31, 2021 and through the issuance of these financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div>Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>. The Company's accounts receivable at December 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDYwOA_36c2035c-6429-44ec-a5ff-c15bdbc6abf6">three</span> to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2021, one customer accounted for 24% of net product sales and 14% of accounts receivable from product sales. In 2020, one customer accounted for 25% of net product sales and 12% of accounts receivable from product sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories and Cost of Goods Sold</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div>Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_InterestIncomeAndInterestExpensePolicyTextBlock', window );">Interest Income and Interest Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Interest Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_OtherComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock', window );">Nonqualified Cash Deferral Plan</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company had one equity-based employee compensation plan, which is described more fully in "&#8212;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Common Share</a></td>
<td class="text">Loss per Common ShareThe Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently operates in one business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is one reporting unit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock', window );">Contingent Consideration Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and GoodwillThe Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Developments</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2019-12 - In December 2019, the FASB issued Accounting Standard Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_InterestIncomeAndInterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest income and interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_InterestIncomeAndInterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_OtherComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_OtherComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477144776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue Disaggregated by Geographical Area</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by geographic area:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"/><td style="width:53.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969559271304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Changes in IPR&amp;D</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in IPR&amp;D for the years ended December 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Goodwill</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in Goodwill for the years ended December 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477056120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Available for Sale Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:46.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:46.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:44.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.138%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477131880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories for the Period</a></td>
<td class="text">The following table summarizes the components of inventories: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:66.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.459%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,818&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,556&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477121848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477131880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of the following: </span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing&#160;&amp; contract research costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales rebates and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued program fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969481811640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Options</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life of options (years) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock options for the year ended December 31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,432&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Non-Vested RSU Activity under the Plan</a></td>
<td class="text">A summary of non-vested RSU activity under the Plan for the year ended December 31, 2021 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity Compensation Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,340&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,817&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,151&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969478741992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Subject to Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"/><td style="width:72.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,903&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe disease program:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.386%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75%-88%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Changes in Contingent Consideration Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2021 and December 31, 2020, respectively:  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:71.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration  in cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969482823240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Liability Components of the Convertible Notes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Senior Secured Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,254&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of Total Interest Expense Recognized Related to the Convertible Notes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2021 and 2020 respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:73.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.950%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except interest rate amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate of the liability component, Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate of the liability component, Senior Secured Term Loan due 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969481567944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Cost</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except year and discount rate amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Operating Lease Payments</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the future minimum operating lease payments were as follows:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:83.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less lease incentives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,478)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969481554488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss before Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, income (loss) before income taxes includes the following components:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393,955)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,554)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,254)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355,910)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following were the components of income tax expense (benefit) for the years ended December 31, 2021, 2020, and 2019:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(984)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the Statutory Tax Rates and the Effective Tax Rates</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2021, 2020, and 2019 are as follows:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible debt conversion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of the Deferred Tax Assets and Liabilities</a></td>
<td class="text">The significant components of the deferred tax assets and liabilities are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization/depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry forwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock issue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest carry forward limitation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,453)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced R&amp;D payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,896)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477180888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:56.241%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,421,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,867,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,421,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969474803864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing', window );">Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">$ 199,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,750<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,295,922<span></span>
</td>
<td class="nump">$ 2,045,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued (in dollars per share)</a></td>
<td class="nump">$ 10.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares called by warrants (in shares)</a></td>
<td class="nump">8,349,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued (in dollars per share)</a></td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="nump">11,296,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,720,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Warrants And Equity Financing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969478705704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net product sales | Customer Concentration Risk | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Customer Concentration Risk | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=fold_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=fold_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969481900552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477478248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Geographical Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 305,514<span></span>
</td>
<td class="nump">$ 260,886<span></span>
</td>
<td class="nump">$ 182,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">95,387<span></span>
</td>
<td class="nump">80,046<span></span>
</td>
<td class="nump">52,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Ex-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 210,127<span></span>
</td>
<td class="nump">$ 180,840<span></span>
</td>
<td class="nump">$ 129,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477035176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>plan</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationNumberOfPlans', window );">Number of equity-based employee compensation plans</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of plans under the equity-based arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969481598856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>unit </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477314856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 197,797<span></span>
</td>
<td class="nump">$ 197,797<span></span>
</td>
<td class="nump">$ 197,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research&#160;&amp; development</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477481784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Changes in IPR&amp;D (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Changes in IPR&amp;D</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Change in IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Change in goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 197,797<span></span>
</td>
<td class="nump">$ 197,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969475033304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 245,197,000<span></span>
</td>
<td class="nump">$ 163,240,000<span></span>
</td>
<td class="nump">$ 142,837,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">237,299,000<span></span>
</td>
<td class="nump">320,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Debt securities, realized gain (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of available-for-sale debt securities in unrealized loss positions</a></td>
<td class="nump">$ 173,400,000<span></span>
</td>
<td class="nump">$ 124,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969475449400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 245,197<span></span>
</td>
<td class="nump">$ 163,240<span></span>
</td>
<td class="nump">$ 142,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value, cash balances</a></td>
<td class="nump">245,197<span></span>
</td>
<td class="nump">163,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">237,371<span></span>
</td>
<td class="nump">320,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">237,299<span></span>
</td>
<td class="nump">320,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities', window );">Cost, cash balances and available-for-sale securities</a></td>
<td class="nump">482,568<span></span>
</td>
<td class="nump">483,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, cash balances and available-for-sale securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, cash balances and available-for-sale securities</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure', window );">Fair value, cash balances and available-for-sale securities</a></td>
<td class="nump">482,496<span></span>
</td>
<td class="nump">483,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">174,578<span></span>
</td>
<td class="nump">217,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">174,531<span></span>
</td>
<td class="nump">217,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, cost</a></td>
<td class="nump">32,322<span></span>
</td>
<td class="nump">39,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized loss</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, fair value</a></td>
<td class="nump">32,311<span></span>
</td>
<td class="nump">39,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, cost</a></td>
<td class="nump">30,070<span></span>
</td>
<td class="nump">9,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized loss</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, fair value</a></td>
<td class="nump">30,056<span></span>
</td>
<td class="nump">9,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969474521256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 245,197<span></span>
</td>
<td class="nump">$ 163,240<span></span>
</td>
<td class="nump">$ 142,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">4,259<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 249,456<span></span>
</td>
<td class="nump">$ 166,162<span></span>
</td>
<td class="nump">$ 146,343<span></span>
</td>
<td class="nump">$ 82,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969475035320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 12,289<span></span>
</td>
<td class="nump">$ 5,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">10,699<span></span>
</td>
<td class="nump">7,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,830<span></span>
</td>
<td class="nump">6,316<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">26,818<span></span>
</td>
<td class="nump">19,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for inventory</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477774968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 62,378<span></span>
</td>
<td class="nump">$ 58,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(19,882)<span></span>
</td>
<td class="num">(14,487)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">42,496<span></span>
</td>
<td class="nump">43,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">24,168<span></span>
</td>
<td class="nump">24,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">16,663<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,229<span></span>
</td>
<td class="nump">5,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,720<span></span>
</td>
<td class="nump">5,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,190<span></span>
</td>
<td class="nump">3,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,163<span></span>
</td>
<td class="nump">2,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969474789016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">$ 24,258<span></span>
</td>
<td class="nump">$ 23,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccruedContractManufacturingAndContractResearchCostsCurrent', window );">Accrued contract manufacturing&#160;&amp; contract research costs</a></td>
<td class="nump">20,361<span></span>
</td>
<td class="nump">19,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccruedSalesRebatesAndChargebacksCurrent', window );">Accrued sales rebates and discounts</a></td>
<td class="nump">15,989<span></span>
</td>
<td class="nump">12,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccruedProgramFees', window );">Accrued Program Fees</a></td>
<td class="nump">13,294<span></span>
</td>
<td class="nump">16,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">9,377<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes</a></td>
<td class="nump">6,154<span></span>
</td>
<td class="nump">11,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="nump">6,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,198<span></span>
</td>
<td class="nump">4,094<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 98,153<span></span>
</td>
<td class="nump">$ 96,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedContractManufacturingAndContractResearchCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedContractManufacturingAndContractResearchCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedProgramFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable related to a pharmaceutical program, including but not limited to clinical studies or commercial preparation activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedProgramFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedSalesRebatesAndChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Rebates And Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedSalesRebatesAndChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969470231480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock and Warrants (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CommonStockVotingRightsForEachShareHeld', window );">Voting right for each share held, number | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross cash proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,230,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 812,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,476,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from the issuance of common stock after deducting underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">188,994,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMilestonePayment', window );">Contingent consideration, milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_MilestonePaymentStockIssuedAsConsideration', window );">Milestone payment, stock issued as consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueContingentConsideration', window );">Stock issued for contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,316,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing', window );">Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">$ 199,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,750,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member', window );">2016 Convertible Notes | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fold_UnderwrittenOfferingMember', window );">Underwritten Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares called by warrants (in shares) | shares</a></td>
<td class="nump">8,349,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,349,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt798Member', window );">Stock Exercises at $7.98</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt706Member', window );">Stock Exercises at $7.06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="nump">11,296,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,720,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Equity component of the convertible notes (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,995,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueContingentConsideration', window );">Stock issued for contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,036,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueContingentConsideration', window );">Stock issued for contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants | Stock Exercises at $7.98</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants | Stock Exercises at $7.06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CommonStockVotingRightsForEachShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes entitled for each share held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CommonStockVotingRightsForEachShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_MilestonePaymentStockIssuedAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Stock Issued As Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_MilestonePaymentStockIssuedAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Warrants And Equity Financing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt798Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt798Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt706Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt706Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969475385752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Deferred compensation investment</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="nump">18,322,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage', window );">Monthly vesting percentage</a></td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477750584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 21, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.08<span></span>
</td>
<td class="nump">$ 6.40<span></span>
</td>
<td class="nump">$ 6.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 40,900<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,228<span></span>
</td>
<td class="nump">$ 42,282<span></span>
</td>
<td class="nump">$ 11,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting', window );">Period following separation for accelerated vesting</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested and non-vested units expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,863,436<span></span>
</td>
<td class="nump">2,164,000<span></span>
</td>
<td class="nump">921,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969481447352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Weighted-average Assumptions (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">65.40%<span></span>
</td>
<td class="nump">75.10%<span></span>
</td>
<td class="nump">74.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 8 months 1 day<span></span>
</td>
<td class="text">5 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare', window );">Expected annual dividend per share (in dollars per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969474467096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">14,032,000<span></span>
</td>
<td class="nump">16,724,000<span></span>
</td>
<td class="nump">15,810,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted (in shares)</a></td>
<td class="nump">3,262,000<span></span>
</td>
<td class="nump">4,362,000<span></span>
</td>
<td class="nump">4,091,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="num">(1,483,000)<span></span>
</td>
<td class="num">(5,243,000)<span></span>
</td>
<td class="num">(1,967,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="num">(844,000)<span></span>
</td>
<td class="num">(1,376,000)<span></span>
</td>
<td class="num">(879,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="num">(236,000)<span></span>
</td>
<td class="num">(435,000)<span></span>
</td>
<td class="num">(331,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">14,731,000<span></span>
</td>
<td class="nump">14,032,000<span></span>
</td>
<td class="nump">16,724,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and unvested expected to vest as of the end of the period (in shares)</a></td>
<td class="nump">13,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">9,141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 9.54<span></span>
</td>
<td class="nump">$ 9.15<span></span>
</td>
<td class="nump">$ 8.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="nump">16.53<span></span>
</td>
<td class="nump">9.98<span></span>
</td>
<td class="nump">10.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="nump">7.05<span></span>
</td>
<td class="nump">8.11<span></span>
</td>
<td class="nump">5.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="nump">12.97<span></span>
</td>
<td class="nump">10.42<span></span>
</td>
<td class="nump">11.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="nump">13.28<span></span>
</td>
<td class="nump">13.33<span></span>
</td>
<td class="nump">13.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">11.08<span></span>
</td>
<td class="nump">$ 9.54<span></span>
</td>
<td class="nump">$ 9.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and unvested expected to vest as of the end of the period (in dollars per share)</a></td>
<td class="nump">10.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 9.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at the end of the period</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and unvested expected to vest at the end of the period</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 30.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options vested and unvested expected to vest</a></td>
<td class="nump">28.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969478887240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - RSUs and PBRSUs Summary (Details) - Unvested restricted stock units - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units as of the beginning of the period (in shares)</a></td>
<td class="nump">7,080,000<span></span>
</td>
<td class="nump">5,792,000<span></span>
</td>
<td class="nump">3,712,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,191,000<span></span>
</td>
<td class="nump">4,692,000<span></span>
</td>
<td class="nump">3,526,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,863,436)<span></span>
</td>
<td class="num">(2,164,000)<span></span>
</td>
<td class="num">(921,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(1,067,000)<span></span>
</td>
<td class="num">(1,240,000)<span></span>
</td>
<td class="num">(525,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units as of the end of the period (in shares)</a></td>
<td class="nump">7,341,000<span></span>
</td>
<td class="nump">7,080,000<span></span>
</td>
<td class="nump">5,792,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units as of the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 11.35<span></span>
</td>
<td class="nump">$ 11.18<span></span>
</td>
<td class="nump">$ 10.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">16.94<span></span>
</td>
<td class="nump">11.29<span></span>
</td>
<td class="nump">10.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">15.77<span></span>
</td>
<td class="nump">10.70<span></span>
</td>
<td class="nump">8.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">12.82<span></span>
</td>
<td class="nump">11.14<span></span>
</td>
<td class="nump">10.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units as of the end of the period (in dollars per share)</a></td>
<td class="nump">$ 13.90<span></span>
</td>
<td class="nump">$ 11.35<span></span>
</td>
<td class="nump">$ 11.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested units, weighted average remaining years</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Non-vested units, aggregate intrinsic value</a></td>
<td class="nump">$ 84.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969474816248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Expense Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 57,838<span></span>
</td>
<td class="nump">$ 49,151<span></span>
</td>
<td class="nump">$ 44,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">17,340<span></span>
</td>
<td class="nump">20,817<span></span>
</td>
<td class="nump">17,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 40,498<span></span>
</td>
<td class="nump">$ 28,334<span></span>
</td>
<td class="nump">$ 26,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969475495000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">$ 242,048<span></span>
</td>
<td class="nump">$ 324,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">20,339<span></span>
</td>
<td class="nump">25,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,078<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">25,139<span></span>
</td>
<td class="nump">29,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">174,531<span></span>
</td>
<td class="nump">217,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">32,311<span></span>
</td>
<td class="nump">39,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">30,056<span></span>
</td>
<td class="nump">9,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">5,150<span></span>
</td>
<td class="nump">4,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">242,048<span></span>
</td>
<td class="nump">324,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,078<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">174,531<span></span>
</td>
<td class="nump">217,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">32,311<span></span>
</td>
<td class="nump">39,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">30,056<span></span>
</td>
<td class="nump">9,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">5,150<span></span>
</td>
<td class="nump">4,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">20,339<span></span>
</td>
<td class="nump">25,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">$ 20,339<span></span>
</td>
<td class="nump">$ 25,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969478781640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,339,000<span></span>
</td>
<td class="nump">$ 25,825,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_MilestonePaymentStockIssuedAsConsideration', window );">Milestone payment, stock issued as consideration</a></td>
<td class="nump">$ 771,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,339,000<span></span>
</td>
<td class="nump">$ 25,825,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Clinical and Regulatory Approval Milestones | ATB-200 Pompe Program | Probability weighted discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Clinical and Regulatory Approval Milestones | Level&#160;3 | Discount rate | ATB-200 Pompe Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_MilestonePaymentStockIssuedAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Stock Issued As Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_MilestonePaymentStockIssuedAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969481457592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of the period</a></td>
<td class="nump">$ 25,825<span></span>
</td>
<td class="nump">$ 22,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value during the period, included in the Consolidated Statements of Operations</a></td>
<td class="nump">6,514<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
<td class="nump">$ 3,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationPaidInStockAdjustment', window );">Payment of contingent consideration in cash</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of the period</a></td>
<td class="nump">$ 20,339<span></span>
</td>
<td class="nump">$ 25,825<span></span>
</td>
<td class="nump">$ 22,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationPaidInStockAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Paid In Stock, Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationPaidInStockAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969477764968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Long Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value of Long-term debt</a></td>
<td class="nump">$ 389,357<span></span>
</td>
<td class="nump">$ 389,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | Senior Secured Term Loan due 2026:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="num">(6,074)<span></span>
</td>
<td class="num">(7,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="num">(4,569)<span></span>
</td>
<td class="num">(5,592)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value of Long-term debt</a></td>
<td class="nump">389,357<span></span>
</td>
<td class="nump">386,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value of Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969469908248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (257,000)<span></span>
</td>
<td class="num">$ (7,276,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 385,929,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_GainLossOnExchangeOfDebt', window );">Loss on exchange of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">40,624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt', window );">Proceeds from termination of capped call confirmations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,656,000<span></span>
</td>
<td class="nump">$ 215,036,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Equity component of the convertible notes (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,356<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,995,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount', window );">Exchange agreement, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance', window );">Exchange agreement, authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest', window );">Accrued and unpaid interest on exchange agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued', window );">Gain (loss) on extinguishment of debt, fair value of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_GainLossOnExchangeOfDebt', window );">Loss on exchange of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt', window );">Proceeds from termination of capped call confirmations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PremiumsPaidForCappedCallConfirmations', window );">Proceeds for capped call confirmations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt', window );">Shares issued per increment of convertible debt (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt conversion ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1633987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 247,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes | Private Placement Purchase Agreement | Over-allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Secured Term Loan due 2026:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_EarlySettlementPremiums', window );">Early settlement premiums</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(7,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentPeriodicPaymentNumberOfPayments', window );">Number of payments | day</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payment</a></td>
<td class="nump">$ 44,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredLinesOfCredit', window );">Proceeds from secured lines of credit</a></td>
<td class="nump">385,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentLiquidityCovenantMinimumAmount', window );">Minimum liquidity covenant</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Loans | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConsolidatedRevenueCovenantAmount', window );">Consolidated revenue covenant, amount</a></td>
<td class="nump">140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Loans | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConsolidatedRevenueCovenantAmount', window );">Consolidated revenue covenant, amount</a></td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Loans | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentVariableRate', window );">Variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConsolidatedRevenueCovenantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Consolidated Revenue Covenant, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConsolidatedRevenueCovenantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentLiquidityCovenantMinimumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Liquidity Covenant, Minimum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentLiquidityCovenantMinimumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentPeriodicPaymentNumberOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Number Of Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentPeriodicPaymentNumberOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_EarlySettlementPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early Settlement Premiums</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_EarlySettlementPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_GainLossOnExchangeOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Exchange Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_GainLossOnExchangeOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PremiumsPaidForCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for premiums paid for capped call confirmations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PremiumsPaidForCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969475024952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 30,473<span></span>
</td>
<td class="nump">$ 20,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AmortizationDeferredFinancingCosts', window );">Amortization of deferred financing</a></td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Secured Term Loan due 2026:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AmortizationDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AmortizationDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969474728312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Cash paid for amounts included in operating lease liabilities</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid through lease incentive</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="nump">$ 19,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets, net</a></td>
<td class="nump">20,586<span></span>
</td>
<td class="nump">23,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of the operating lease liabilities</a></td>
<td class="nump">7,409<span></span>
</td>
<td class="nump">6,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of the operating lease liabilities</a></td>
<td class="nump">43,363<span></span>
</td>
<td class="nump">45,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 50,772<span></span>
</td>
<td class="nump">$ 52,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease terms (years)</a></td>
<td class="text">19 years 7 months 6 days<span></span>
</td>
<td class="text">19 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">13.10%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 8,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">8,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">8,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">8,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">8,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">145,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">188,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_LesseeOperatingLeaseLiabilityTenantIncentives', window );">Less lease incentives</a></td>
<td class="num">(28,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(108,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">50,772<span></span>
</td>
<td class="nump">$ 52,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability', window );">Lease not yet commenced, liability</a></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease not yet commenced, term of contract</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_LesseeOperatingLeaseLiabilityTenantIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Incentives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_LesseeOperatingLeaseLiabilityTenantIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969474462952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Statutory Rate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract', window );"><strong>Income (loss) before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (333,571,000)<span></span>
</td>
<td class="num">$ (365,332,000)<span></span>
</td>
<td class="num">$ (393,955,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,017,000<span></span>
</td>
<td class="nump">91,078,000<span></span>
</td>
<td class="nump">38,045,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(241,554,000)<span></span>
</td>
<td class="num">(274,254,000)<span></span>
</td>
<td class="num">(355,910,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,857,000<span></span>
</td>
<td class="nump">4,163,000<span></span>
</td>
<td class="nump">2,877,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="num">(1,410,000)<span></span>
</td>
<td class="num">(984,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="num">(155,000)<span></span>
</td>
<td class="num">(1,415,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,906,000<span></span>
</td>
<td class="nump">$ 2,598,000<span></span>
</td>
<td class="nump">$ 478,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the statutory tax rates and the effective tax rates</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(16.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Impact of foreign operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nondeductible executive compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion', window );">Nondeductible debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969475424120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred and Valuation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsIntellectualProperty', window );">Intellectual property</a></td>
<td class="nump">$ 105,453<span></span>
</td>
<td class="nump">$ 68,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Amortization/depreciation</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research tax credit</a></td>
<td class="nump">205,095<span></span>
</td>
<td class="nump">182,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">334,762<span></span>
</td>
<td class="nump">305,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred reimbursements</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent', window );">Non-cash stock issue</a></td>
<td class="nump">11,779<span></span>
</td>
<td class="nump">17,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsInterestCarryforwardLimitation', window );">Interest carry forward limitation</a></td>
<td class="nump">8,285<span></span>
</td>
<td class="nump">5,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">9,105<span></span>
</td>
<td class="nump">9,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">15,884<span></span>
</td>
<td class="nump">10,855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">692,227<span></span>
</td>
<td class="nump">602,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesBusinessAcquisition', window );">Business acquisition</a></td>
<td class="num">(4,930)<span></span>
</td>
<td class="num">(4,937)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesRoyaltyPayable', window );">Royalty payable</a></td>
<td class="num">(105,453)<span></span>
</td>
<td class="num">(68,209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesConvertibleNotes', window );">Convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments', window );">Advanced R&amp;D payments</a></td>
<td class="num">(1,802)<span></span>
</td>
<td class="num">(1,776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(3,130)<span></span>
</td>
<td class="num">(3,420)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsLiabilitiesGross', window );">Total net deferred tax assets</a></td>
<td class="nump">576,912<span></span>
</td>
<td class="nump">523,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(581,842)<span></span>
</td>
<td class="num">(528,895)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">(4,930)<span></span>
</td>
<td class="num">$ (4,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in the valuation allowance</a></td>
<td class="num">$ (52,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsInterestCarryforwardLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Carryforward Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsInterestCarryforwardLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Leasing Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carry forwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carry forwards expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsNonCashStockIssueNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from advanced Research and Development payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Business Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from royalty payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969481267368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Loss Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and experimentation tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 30.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=fold_OrphanDrugTaxCreditCarryforwardMember', window );">Orphan drug tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">165.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">1,292.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=fold_OrphanDrugTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=fold_OrphanDrugTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969470542056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2013 </div>
<div>USD ($) </div>
<div>market</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,514<span></span>
</td>
<td class="nump">$ 260,886<span></span>
</td>
<td class="nump">$ 182,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,906<span></span>
</td>
<td class="nump">7,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,153<span></span>
</td>
<td class="nump">$ 96,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication', window );">Conditional aggregate payments per indication</a></td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborationAgreementAnnualContributionByCompany', window );">Discovery program fee</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborativeAgreementTermOfAgreement', window );">Term of agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentsForCollaborativeArrangement', window );">Payments for collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember', window );">Revised Agreement | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments', window );">Potential milestone payments upon achievement of post-approval and sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones', window );">Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones | market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborationAgreementAnnualContributionByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Contribution By Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborationAgreementAnnualContributionByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Conditional Aggregate Payments Per Indication</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeAgreementTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Term of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeAgreementTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentsForCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentsForCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969481324408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (250,460)<span></span>
</td>
<td class="num">$ (276,852)<span></span>
</td>
<td class="num">$ (356,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">271,421,986<span></span>
</td>
<td class="nump">258,867,380<span></span>
</td>
<td class="nump">240,421,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">271,421,986<span></span>
</td>
<td class="nump">258,867,380<span></span>
</td>
<td class="nump">240,421,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">22,072,000<span></span>
</td>
<td class="nump">24,129,000<span></span>
</td>
<td class="nump">25,533,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">14,731,000<span></span>
</td>
<td class="nump">14,032,000<span></span>
</td>
<td class="nump">16,724,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">7,341,000<span></span>
</td>
<td class="nump">7,080,000<span></span>
</td>
<td class="nump">5,792,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,555,000<span></span>
</td>
<td class="nump">2,555,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">462,000<span></span>
</td>
<td class="nump">462,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>fold-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:fold="http://www.amicustherapeutics.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fold-20211231.xsd" xlink:type="simple"/>
    <context id="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b1e363eba974f6ea7542b9e4c4333c1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2e067fbb488e4a8480dd4ccdf00e2d6e_I20220215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="iecb1de42def1452da99c0b437348ff0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65709436b74a491bb3674af00ed88b22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i59b0f5748c0040d4ba044c170c4498a5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7eaeeea22e1c450bb0f3ef7f208d55da_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8e06cd88eed94c93bd863d9d2fa7e86a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4fde1813dc7d44159942aa86b1104baf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie4b02a7b929749bcbb33c5ac89bfc395_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id112dec781f849479a5fea1933c18841_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d174a7fea084bb889559168de083956_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i20b1ffa344ad4c46a05f2baded3c95de_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie7c2736e1c5f4bbdbe8ee555092181b6_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i92d9f0aae1dd4a489dc1c015715214d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iec7f88d07a8f4a3196f84540950c1ba1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i295c47ed72d64074b5f32eeaad26a5cd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7f87ef3b9001442e9d1783fa4ab6164a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idebd74e031ad4aa8847d48abfeb2cb4c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic1a49ef645774a039703edbf41d99de6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0283e0a778b241b69b7dc2f9f44b0620_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb03c87cbb644915a36d8589d01d130f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i31157945f1834f739f2eb29aa5b1c152_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0925432d607c491d8c8762f88a8343ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife0397e8e64147d183a31226e47071e0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4d67ba7a78d4493685eb33d08eab6fe3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1caab1a891c34d6db105ce12805fe47d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59667a8b6b6e402abb2689a16193a16e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45f392c0af90404aa7ba763120f8093c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a9abca8aab34fa6938b4176b42afcca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a2dd5b7af4a40d8b104a56e99abd5c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8631b1d954a432cab195334e4ab3c22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fc96de0a30247109dd0e367a5fda28e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib685c8f6567a444dafe12c28724621c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4be7fadcd724e6e96874c8bdf5adad5_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b570f4240774f97a85fc8f243de27b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i640ccbc1c3154c0080c449287054612e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibbf5bb75d47341398ad73aa8e894bf9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i07df4fa1308d4f84a4aa5160e8a69ceb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9f9159fe2d74c02899336811f098a03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic68cc19d3396498d82b2a8b900bcb129_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e1512bc26b649368f7c7a1f80c153cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia89d77f8f61e4f3997ffe7f4c43ce4bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cac20d40d594fdb84c482f1f832ea26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f7acdfb076641c09f78a07d2ad0884d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ida79dc6999b2473ca1d1e66873b93aae_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i526b094eedf24604a14d40a8149d2578_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia0e62c3f34054304bc488a828183c4ef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i016a712198df44609ada40ce0ec6040e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb5f7d12a2e74e94b84af411c94b825f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id98a23a12f314c0399ddc82d07f167d9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d0ef6f58f21490982734d184ffa708c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a13db14f0fd48d7b5bae936a24df08c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1fd944574f2a423983b2d669ba0a005a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i141786068eaa494eabbae0eed4ca91ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3697f78d277b440cb2fdcf968fe349c8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i73069b90118447438bdbc91aa2291082_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1211cdc53247450f9cf2280aa82ab844_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e29c1f134e24ca6a71a18a5867402ee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9e86b2f8a2ae449789640b3a74210938_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9de1351a52bd4f60a456ac8231b36fa1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4951a0821e7472faa395694373f197f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24c9330e046a4e39b05065c516da655f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bac4dce92ae48faa8415719eeb29418_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9989c222dbf4f51a1e18465f25d9679_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i790f73964a7348a8861ffaa0cd855ce6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c294134d0304a859adb3c48427afe95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9043474a4a1d4089aaaa1c119c5ded63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i506e380918854e4287cf7b8f4aec8307_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i961d1290b5bb44a89495cd0f93b4d7c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16cd09ac01f449a786ec0c0e00df7434_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib9f1194f778c47b687d90861adf8f887_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66e8c7b22d7744d49e714d729f4a3155_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18b897fa4f7e47f09f12e76a909b949f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4a56fb4793d42e9983d44923f0ea779_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie154cc033bab496a99fb346732f0a456_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i582c365c59c5453c936ce8bba128fd1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe3018b481564885813a6100e4a32e2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50bd891b09b1476badb04c23c7939da3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc60489656e8435486f90d2cf2907e4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79912bf414894f7c880e3b24a7d15884_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08e5b99eaef547c5b606f006be101008_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b21949c52d343ef9e73e3897f897333_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d2bcc60d5354077b1fcf38386ec3c2e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id196c02fecfc4cba9917670db7d5c97a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if6ead177e0cc4421928422190e6ada54_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iba81fbdcb57c4b63b3261c40099c722f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9a9bcf319bae47bdbd01835594ec4441_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia8b8a5ba609f4354b35e10b27be3ff0f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10d2bc422365419a845cd1b651b3a636_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1b32bb1228f4457281ae01a46fc12e65_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i90c6ab2b0ea94811b533075e4f2a87ff_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3c032683abb24387a73c8bc636880d41_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i74af5a78ba0e4e39b3e7266e28299ef6_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7f3536bcc2ae4952bcd1f4f308635ac0_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i482c3a76c4274a0e899e18ce88699cb5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia0f988918ba344f883b74b4646d25fbe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f26112489e84068b2efcf3e81829b41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bf65e4e37b3456d95b9a66cf49959fa_D20181221-20181221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-21</startDate>
            <endDate>2018-12-21</endDate>
        </period>
    </context>
    <context id="if7512772b097432b956535d96e9b7951_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia272441483a740d6812f2646381f7580_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia576c72c43a84ff6b63f05447685167d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ab772d198ff45af9c40e229d45fba03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03c9e518216b4905aab06b70874e18f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie35de6676f38491e98b8f52cc5c3919b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i971ea6dc71dd40bfbe43d1b72669ed21_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i056c458b470c4579b84a162e7b90dbda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96486b3a389847dea0287bfe980e800b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i71a1701b3e114ced8682f3b8ad409f43_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62afedf6cc6c4e2faa6b8366f3d4d566_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00d2388394104afb8de4248ba2dcc24a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie54f245a14704edc868849226467c804_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61c7b7702b4a40ddb250ad6a54dbfb5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia66fbce7b1254986b68bdecf5d3984a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9a5acb325e646a18e6704ab00914755_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i162893650e38441e88ef4089246a0337_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i559389e21f1d4d0d9353f0f940507a03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica7968ff22354a119a411677a353c84c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ddce89a114b41f59eb1562989c82baf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia17c20a9953e4a9cafbd1c6bf678b365_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fa6cf6f33a74c329c64fa2645338266_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0e5b1225df74406a3b71f72661e0aa3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i209e1f50b3fd43be91783671c328accb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66d2efb30f714078b268efed578feb16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e0e4ee9e39849208ef9727b7981c2e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48fbd33b6e4d4c73ac985cc9959e7635_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib485fdd881d140c3ade6dc51f9633b29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6966889240c4972b480adb57c32195c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20e3e42521364090aa637b816999865a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b67daeb3434490faa14ce758326fde1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8216eb3ec03f429fae6e1e74d98807b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie69b50b330c64830b70c78bcaaeb37d6_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i33fc42c9674f4e879bc61864ba60a261_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ib3f9db4f690745eda3163dd56d581246_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i7c3d9dd50f724a0da7d1eefc3d5f135e_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i7600524d0cbe42d4b2f4532af786aeb3_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ice065bd0045f4f5f9e31f898f0f63b1f_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i3cdaaf76680246429703216e122dbd6c_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i9778c3d9e7be42298274edd0168bd81d_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i98061b690c584def995fd5b3650941ec_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ie195a0454be34ff68a307be34a84c86c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib94c7a79d6b04897ba7c2cd123307880_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i49b24aa516c24be2963d03b2a2fe67c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iacb244f94b724eb4939e9350be861b33_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8c034a30ff14ec285bf6a0f3a25e67a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie25229baab7b448a94693d9550e33f9e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i110a74da32da49fd9b6d03056e710aca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia902df35c10346d3815341846f96d4a9_D20171222-20171222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2017-12-22</startDate>
            <endDate>2017-12-22</endDate>
        </period>
    </context>
    <context id="id37d238be9634e70925be89cb7453666_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd581809cdbc4334985e5a98f01fe250_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3afe69e33524b46a12ea4a1d4d0b740_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee21a641b74a48e686ea400e8e04484c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fold:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i322b8d6caffd45d09d34af4c5317a66d_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ie02d2bc95ee4441cafb8448b58435d04_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i812c13b023674c2a8bf3fe358c45cc8e_I20131130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-11-30</instant>
        </period>
    </context>
    <context id="ice787d3f9d9b45d5ac985f96cbc7cab8_D20131101-20131130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-11-01</startDate>
            <endDate>2013-11-30</endDate>
        </period>
    </context>
    <context id="ib092d444dccf4d32aa8a33c7b683e7f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86b66068ec6445888b7a4f287f32fe7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice1a09fdb4bb4d548e2ccf3315079cb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie569617484754b05a11d764873af2392_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2fd1ccf9f8ab4f1c93b7b88a953bacde_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17b033bab30245779ca01d44c1085c54_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0bf1bdab05104ab9b9570bc2365d7aba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7c7aceb760548b4b27547de88d2a4c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13e30b656f4141acbe98c23e31bd8683_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8dc30a51972343fbbfeeb2ead881ceef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65d605eafe9c435eabdcab7621bec3fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie53bbf1d49be45c8b6aeb0307b4fcf08_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e11e6d8d67c45cb824db13d53516217_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i953f7cedc14842d1ba60adb562f671c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63e57c6c2cd049289478bad341710825_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>fold:plan</measure>
    </unit>
    <unit id="segment">
        <measure>fold:segment</measure>
    </unit>
    <unit id="unit">
        <measure>fold:unit</measure>
    </unit>
    <unit id="vote">
        <measure>fold:vote</measure>
    </unit>
    <unit id="day">
        <measure>fold:day</measure>
    </unit>
    <unit id="market">
        <measure>fold:market</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM180L2ZyYWc6NTE2OWIzOTliNDE2NDIzOGFlNjViMWRhNGQ5ZDk0MjUvdGFibGU6YTkyNmVkMjkwODI3NDk3Y2JhNGUyNDQzZThiMTc1MDUvdGFibGVyYW5nZTphOTI2ZWQyOTA4Mjc0OTdjYmE0ZTI0NDNlOGIxNzUwNV8zLTEtMS0xLTEwNTYy_98534ec4-06bb-4eda-ac51-69b8672a98f9">0001178879</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM180L2ZyYWc6NTE2OWIzOTliNDE2NDIzOGFlNjViMWRhNGQ5ZDk0MjUvdGFibGU6YTkyNmVkMjkwODI3NDk3Y2JhNGUyNDQzZThiMTc1MDUvdGFibGVyYW5nZTphOTI2ZWQyOTA4Mjc0OTdjYmE0ZTI0NDNlOGIxNzUwNV80LTEtMS0xLTEwNTYy_539f8c6f-6aed-488e-905a-41f7a3da7780">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM180L2ZyYWc6NTE2OWIzOTliNDE2NDIzOGFlNjViMWRhNGQ5ZDk0MjUvdGFibGU6YTkyNmVkMjkwODI3NDk3Y2JhNGUyNDQzZThiMTc1MDUvdGFibGVyYW5nZTphOTI2ZWQyOTA4Mjc0OTdjYmE0ZTI0NDNlOGIxNzUwNV81LTEtMS0xLTEwNTYy_a69b5516-f9f7-40b0-851f-0c66b9080342">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM180L2ZyYWc6NTE2OWIzOTliNDE2NDIzOGFlNjViMWRhNGQ5ZDk0MjUvdGFibGU6YTkyNmVkMjkwODI3NDk3Y2JhNGUyNDQzZThiMTc1MDUvdGFibGVyYW5nZTphOTI2ZWQyOTA4Mjc0OTdjYmE0ZTI0NDNlOGIxNzUwNV82LTEtMS0xLTEwNTYy_556f0b15-e9e1-4894-836a-c307277419d8">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia0e62c3f34054304bc488a828183c4ef_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDYwOA_36c2035c-6429-44ec-a5ff-c15bdbc6abf6">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage
      contextRef="ia0f988918ba344f883b74b4646d25fbe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDMvZnJhZzpkMjlhYmNmOGYwNzM0NTg3YmYwMjRiM2U3ZTVhYWE2MS90YWJsZTpiMjE4YTRiYjA0NDg0NTE0YmM2MzgwMmYxNGMyY2RhOS90YWJsZXJhbmdlOmIyMThhNGJiMDQ0ODQ1MTRiYzYzODAyZjE0YzJjZGE5XzAtMS0xLTEtMTA1NjI_6e25d797-6680-40fb-bc70-6bbda2c48af9"
      unitRef="number">0.0208</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i98061b690c584def995fd5b3650941ec_D20161201-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTUvZnJhZzo4ZTBmZjI2MWZlNzA0NDQyYWY1MGViZThkYmY1ZjJhYi90YWJsZTplM2M1YmFkNzhkYWM0MTU5OTE3Y2NhM2IwN2ZlOTQ1OC90YWJsZXJhbmdlOmUzYzViYWQ3OGRhYzQxNTk5MTdjY2EzYjA3ZmU5NDU4XzEtMS0xLTEtMTA1NjI_486be392-9c7b-4d27-80f0-fd24ecc87bb6"
      unitRef="number">0.1633987</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjY5_56427cee-2273-45c7-8ee1-d2cbaec687bd">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjcw_337e3735-f57a-45a8-9937-3a106ee01099">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zMjk4NTM0ODg3MTMz_99c27a1a-b9a7-4240-af03-4a1031061bab">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zMjk4NTM0ODg3MTMz_1b871c8c-b85b-4fd6-9bfc-d11ab4f0f691">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjcy_33e7e208-83ba-44f9-aabc-16128cc6c996">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjYy_a1249539-1f1d-4c59-8977-6b7b935c2703">001-33497</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjY0_9d8becc2-e740-4f33-b4da-f63d0e0326af">Amicus Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl8wLTAtMS0xLTEwNTYy_c11d1a7b-4be4-4d36-92a1-136bf59681a8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl8wLTQtMS0xLTEwNTYy_6381aec3-145d-4745-b0d0-398c4a8d712a">71-0869350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl80LTAtMS0xLTEwNTYy_ff9165d8-386b-4a88-bf1a-c041cff0ca5b">3675 Market Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl80LTEtMS0xLTEwNTYy_e96be47b-af8e-4726-bffc-85d7d64c0f45">Philadelphia,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl80LTItMS0xLTEwNTYy_28aa2462-ef3d-4057-81bc-62a4a6461784">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl80LTQtMS0xLTEwNTYy_21028228-2e56-4846-8dfc-6694742ff6be">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl83LTAtMS0xLTEwNTYy_4ed1d959-bc8b-4a10-871f-390be40b8b41">(215)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MjFiYzdjMDI4N2ZlNDg3MDk0ODZmOGRmNzFhMDg3NGYvdGFibGVyYW5nZToyMWJjN2MwMjg3ZmU0ODcwOTQ4NmY4ZGY3MWEwODc0Zl83LTMtMS0xLTEwNTYy_6429b96b-30f1-4e2e-a1dc-db2e58ccdc08">921-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6YTQ4ZDM2MGZkMDJmNDIxZTgyZDkzNjg4NGI0YzkxMGMvdGFibGVyYW5nZTphNDhkMzYwZmQwMmY0MjFlODJkOTM2ODg0YjRjOTEwY18xLTAtMS0xLTEwNTYy_9685e92f-aa67-4369-8f0f-024a9eec2757">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6YTQ4ZDM2MGZkMDJmNDIxZTgyZDkzNjg4NGI0YzkxMGMvdGFibGVyYW5nZTphNDhkMzYwZmQwMmY0MjFlODJkOTM2ODg0YjRjOTEwY18xLTEtMS0xLTEwNTYy_cedf17f7-129a-46bb-a722-bd5a6989a6c7">FOLD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6YTQ4ZDM2MGZkMDJmNDIxZTgyZDkzNjg4NGI0YzkxMGMvdGFibGVyYW5nZTphNDhkMzYwZmQwMmY0MjFlODJkOTM2ODg0YjRjOTEwY18xLTItMS0xLTEwNTYy_7de80f87-dd9a-4c4c-a998-3245f9a504a4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjc0_1729829d-1c22-4407-9c8f-61e3ccdfa66f">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjc1_07cd4a05-8906-4ee0-a5d9-885cb5e30504">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjY1_d8314e6a-ccd2-4d11-8c31-4b79e3aa2e2b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjcz_9b15d250-b3cb-4176-8c5f-56eaa6c5e217">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MGQzZTRlYTJlY2M3NGE5NGJiZTM4NDg2ZTJhYzFkNjgvdGFibGVyYW5nZTowZDNlNGVhMmVjYzc0YTk0YmJlMzg0ODZlMmFjMWQ2OF8wLTAtMS0xLTEwNTYy_46ff1324-d57f-4d7d-9290-416951d761e9">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MGQzZTRlYTJlY2M3NGE5NGJiZTM4NDg2ZTJhYzFkNjgvdGFibGVyYW5nZTowZDNlNGVhMmVjYzc0YTk0YmJlMzg0ODZlMmFjMWQ2OF8xLTQtMS0xLTEwNTYy_8eb55442-c75f-489c-b700-e1a82a76f01d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGFibGU6MGQzZTRlYTJlY2M3NGE5NGJiZTM4NDg2ZTJhYzFkNjgvdGFibGVyYW5nZTowZDNlNGVhMmVjYzc0YTk0YmJlMzg0ODZlMmFjMWQ2OF8yLTQtMS0xLTEwNTYy_ec28fc9a-8593-4e53-b85f-503fb7188a3f">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjYx_63ef3d42-72b7-4800-9522-184030ffbe01">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjcx_5edd76d1-fc8a-4881-80ab-7a49355fe948">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i3b1e363eba974f6ea7542b9e4c4333c1_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV85ODk1NjA0NjUzODQ2_355fc9d3-09f5-4a6e-a771-d706c660a7b7"
      unitRef="usd">2540615589</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2e067fbb488e4a8480dd4ccdf00e2d6e_I20220215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV80Mzk4MDQ2NTE0ODkz_00230286-2a21-4fdf-b420-9fbfd53e803a"
      unitRef="shares">280029345</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xL2ZyYWc6MTgwZmI1MGI2YWI1NGIxY2FlYTQ3OTMwYzU5ZTcyYTUvdGV4dHJlZ2lvbjoxODBmYjUwYjZhYjU0YjFjYWVhNDc5MzBjNTllNzJhNV8zNjY4_a1fe2218-ad90-41c9-a09c-b9d19abb15d9">Portions of the Proxy Statement for the registrant's 2021 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181NS9mcmFnOjQ0NzJjYjI0Y2I2NDQ3NDZhYmEyM2NhYWY3NTUyNTcyL3RhYmxlOjg2MWJkZjc2MWYzMjQzZTU5MTVlNTM4ZWNjNWQ1ZGQxL3RhYmxlcmFuZ2U6ODYxYmRmNzYxZjMyNDNlNTkxNWU1MzhlY2M1ZDVkZDFfMC0wLTEtMS0xOTg3Ni90ZXh0cmVnaW9uOjlhZTk0YjNlY2UzZTQ3OGNiNTczMjc2MThmZTYxOWMwXzI3NDg3NzkwNjk0ODM_bbb820ed-06db-478f-8357-dca623b103ee">Ernst&#160;&amp; Young&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181NS9mcmFnOjQ0NzJjYjI0Y2I2NDQ3NDZhYmEyM2NhYWY3NTUyNTcyL3RleHRyZWdpb246NDQ3MmNiMjRjYjY0NDc0NmFiYTIzY2FhZjc1NTI1NzJfMjc0ODc3OTA3MjkzOA_ee40e853-f906-42e3-a3a9-d20c70064450">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNC0xLTEtMS0xMDU2Mg_9ad745cb-f9b9-4a50-8d76-abbff256186b"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNC0zLTEtMS0xMDU2Mg_9625d06c-521f-42af-8f56-a127dd5d420c"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNS0xLTEtMS0xMDU2Mg_2831069d-5fae-4a8d-a41b-7f755cb99da8"
      unitRef="usd">237299000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNS0zLTEtMS0xMDU2Mg_04ad8165-a432-4d7f-8208-96629c2faf2c"
      unitRef="usd">320029000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNi0xLTEtMS0xMDU2Mg_df52aa41-5f4e-4ec2-a1ea-0a45d04cb2bb"
      unitRef="usd">52672000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNi0zLTEtMS0xMDU2Mg_c75c372d-1ea0-40a8-8786-a0f83d109316"
      unitRef="usd">46923000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNy0xLTEtMS0xMDU2Mg_bde58b82-2b2a-4bb2-be44-03cb42301646"
      unitRef="usd">26818000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNy0zLTEtMS0xMDU2Mg_62b03aa3-1c0f-459f-bb9f-1ef01f02ebe7"
      unitRef="usd">19556000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfOC0xLTEtMS0xMDU2Mg_7c60d2f6-3aa3-4c63-8b08-8c496c72d7f3"
      unitRef="usd">34848000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfOC0zLTEtMS0xMDU2Mg_fb664c3b-3d7d-4b18-8c5b-13ab60a87bcd"
      unitRef="usd">29721000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfOS0xLTEtMS0xMDU2Mg_e7b67df8-12b5-4b66-bcff-38503cc008b2"
      unitRef="usd">596834000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfOS0zLTEtMS0xMDU2Mg_07c5ad09-59df-44f3-bddc-b0af8f02dd9b"
      unitRef="usd">579469000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTAtMS0xLTEtMTA1NjI_13e12317-e294-4cfa-b21b-788d73fb9f50"
      unitRef="usd">20586000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTAtMy0xLTEtMTA1NjI_393accc8-4bea-432f-ad34-f790cba7460b"
      unitRef="usd">23296000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTEtMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjowNzliZTJjYTNjNWE0MzkyODJhNjhlMTNmMzQ3MmM2NF82MQ_d95ca163-b68c-4a26-bc3e-b02545454532"
      unitRef="usd">19882000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTEtMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjowNzliZTJjYTNjNWE0MzkyODJhNjhlMTNmMzQ3MmM2NF82OA_39442663-7419-4900-aeb5-285950e86603"
      unitRef="usd">14487000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTEtMS0xLTEtMTA1NjI_bccee835-d78a-4b66-945c-8a8c1635ba3b"
      unitRef="usd">42496000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTEtMy0xLTEtMTA1NjI_33332037-40f9-47b3-8960-3e4269b98aec"
      unitRef="usd">43863000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTItMS0xLTEtMTA1NjI_c246838e-ab96-459f-9428-d88d09806542"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTItMy0xLTEtMTA1NjI_88e788f3-f1e9-4c19-aee0-9d978cb0fd95"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTMtMS0xLTEtMTA1NjI_61f9f4da-075a-4907-8341-9627aad7e34f"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTMtMy0xLTEtMTA1NjI_9a3ac179-082b-4dc1-9e98-9e33430a3862"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTQtMS0xLTEtMTA1NjI_ecf74a80-66c2-45b9-a39d-56d383727ee1"
      unitRef="usd">24427000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTQtMy0xLTEtMTA1NjI_0de0db0f-43a8-4a8b-97bb-3c0333fae35c"
      unitRef="usd">19095000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTUtMS0xLTEtMTA1NjI_94772685-9bf9-4af6-aaf9-8bbdccf9e96c"
      unitRef="usd">905140000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTUtMy0xLTEtMTA1NjI_030d4b25-c13e-4ba9-92e0-5cacdb4a618c"
      unitRef="usd">886520000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTgtMS0xLTEtMTA1NjI_ce844bcf-2433-4cbd-a735-e23c9641f1a2"
      unitRef="usd">21513000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTgtMy0xLTEtMTA1NjI_83d1dec0-0806-43dc-a16c-50ebc6ac3981"
      unitRef="usd">17063000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTktMS0xLTEtMTA1NjI_3bfa70fe-a366-4629-ae61-b524ce57a43d"
      unitRef="usd">98153000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMTktMy0xLTEtMTA1NjI_d3d704a9-9f73-4006-8658-accd3756671d"
      unitRef="usd">96841000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjAtMS0xLTEtMTA1NjI_6fafe1e7-fe4e-4160-9bbd-ff537e9fdfaf"
      unitRef="usd">18900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjAtMy0xLTEtMTA1NjI_7b742119-5f7d-4f06-9200-6aa6c0cd3f0f"
      unitRef="usd">8900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjEtMS0xLTEtMTA1NjI_62c3f504-62ad-4846-9d9b-c3a7e239b124"
      unitRef="usd">7409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjEtMy0xLTEtMTA1NjI_a292de8e-64df-45c7-8ae2-6c30d29b3f0b"
      unitRef="usd">6872000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjItMS0xLTEtMTA1NjI_ee0eacae-b130-45cc-ab6d-d3d5cc28578d"
      unitRef="usd">145975000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjItMy0xLTEtMTA1NjI_1845c4dd-b844-49e5-84ad-df1922b3c586"
      unitRef="usd">129676000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjMtMS0xLTEtMTA1NjI_7d72b251-7678-4a2f-89e7-39f95fffdcfe"
      unitRef="usd">5906000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjMtMy0xLTEtMTA1NjI_884e2eab-e871-4493-97dc-126bad16793d"
      unitRef="usd">7406000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjQtMS0xLTEtMTA1NjI_e5d9553a-9800-417c-8ad9-1c1e8e8d2866"
      unitRef="usd">389357000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjQtMy0xLTEtMTA1NjI_02e682be-4f7b-4299-aa9b-800b2698bc87"
      unitRef="usd">389254000</us-gaap:LongTermDebt>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjUtMS0xLTEtMTA1NjI_66f0ce7b-6832-41e8-8b56-c55a88033b24"
      unitRef="usd">1439000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjUtMy0xLTEtMTA1NjI_51e199f3-cafc-401b-9866-9b658cb1316e"
      unitRef="usd">16925000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjYtMS0xLTEtMTA1NjI_9f4cec08-f0ae-4e72-b283-c31522b40d49"
      unitRef="usd">4930000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjYtMy0xLTEtMTA1NjI_6187859e-a02a-45de-a972-cf7fc3ad600c"
      unitRef="usd">4896000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjctMS0xLTEtMTA1NjI_0181a129-a787-4259-9dd5-b72c6447bd3f"
      unitRef="usd">43363000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjctMy0xLTEtMTA1NjI_7ab834b0-de1d-436c-8500-d9c226e287b8"
      unitRef="usd">45604000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjgtMS0xLTEtMTA1NjI_c1d1d931-f03d-45b2-b462-a965bb25ef63"
      unitRef="usd">6801000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjgtMy0xLTEtMTA1NjI_2de2d22c-34b5-4582-8b47-3f78b1b1d57c"
      unitRef="usd">6379000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjktMS0xLTEtMTA1NjI_9c78ac48-385e-4442-b16f-c7fac8c3cb71"
      unitRef="usd">597771000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMjktMy0xLTEtMTA1NjI_fd26a9d5-e1ec-48e7-8b3a-0f5b8080b66f"
      unitRef="usd">600140000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzAtMS0xLTEtMTA1NjI_e0f9dd99-4193-417f-9b66-eb92ea06b1da"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzAtMy0xLTEtMTA1NjI_4ebda449-fad2-4fc4-a4d6-03d6816e3c34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV8xOA_15b4ac42-f940-4903-9fb1-01ddd0746a01"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV8xOA_7743eea2-d485-4568-982a-b661e4bf067a"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV8zMg_9c01dfc1-04ac-47f8-8560-a19aa48bbb48"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV8zMg_c39cb335-c91f-4dd3-be89-024fea7ae547"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV81NA_7263a9b6-44e8-4fb2-9f50-0e32da92eba3"
      unitRef="shares">278912800</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV81NA_971b0da3-87b6-4a68-87f7-d301794ebd08"
      unitRef="shares">278912800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV82MQ_5d789d12-4034-41a1-b410-272f638b1ce8"
      unitRef="shares">262063461</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjo3Zjc0OWM2NzcxNmE0NjJkODU2YTAxYjYxZDA4NGM3YV82MQ_60529c14-000b-4a65-84c9-5e11a586f3ca"
      unitRef="shares">262063461</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMS0xLTEtMTA1NjI_f5bede04-7d54-4e81-851c-a439d46b42d9"
      unitRef="usd">2808000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzItMy0xLTEtMTA1NjI_91b2f44d-a291-47ba-bdb4-a515996bccaf"
      unitRef="usd">2650000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzMtMS0xLTEtMTA1NjI_b8a4b9cd-a4c9-46a7-bfdd-e5b7373f8d88"
      unitRef="usd">2595419000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzMtMy0xLTEtMTA1NjI_18a82038-3e1b-4a00-8107-186c9e75557d"
      unitRef="usd">2308578000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzUtMS0xLTEtMTA1NjI_aa1722ce-efb7-44ee-b244-f66608aa6433"
      unitRef="usd">5251000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzUtMy0xLTEtMTA1NjI_bc8b7b5f-7be3-4748-b7a5-f9bc539a6508"
      unitRef="usd">8412000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzYtMS0xLTEtMTA1NjI_1db42aaa-76b8-476e-b7a7-4561aaf1b303"
      unitRef="usd">-270000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzYtMy0xLTEtMTA1NjI_c023e9be-bb35-4a53-8c65-2c0b4fc1e6d3"
      unitRef="usd">-185000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzctMS0xLTEtMTA1NjI_47684e79-640e-4764-8559-1f536e0cad0e"
      unitRef="usd">83000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzctMy0xLTEtMTA1NjI_03ea7f95-9a4a-4179-8678-99febf9d8770"
      unitRef="usd">12387000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzgtMS0xLTEtMTA1NjI_47b5e7ed-4bcd-495c-aacd-ca4f2e0cd9af"
      unitRef="usd">-2295922000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzgtMy0xLTEtMTA1NjI_635bc4b5-272a-41ca-8a0f-be2036fb09b8"
      unitRef="usd">-2045462000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzktMS0xLTEtMTA1NjI_27544176-c980-4a0b-83dc-76e493893f3a"
      unitRef="usd">307369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfMzktMy0xLTEtMTA1NjI_81e0771c-b639-40c9-97b8-2cbef9adc3e9"
      unitRef="usd">286380000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNDAtMS0xLTEtMTA1NjI_2e9cccfc-3278-42f7-a57c-f237101058ee"
      unitRef="usd">905140000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM181OC9mcmFnOjMwNDRkYTdlYzJkMjQ2NDQ5Mjc4NGM5ZGUzYzIyNzVlL3RhYmxlOmViZDdiN2ZkMjAzNDRlYWE5NTk3NGYwMjg3ZWMzY2NlL3RhYmxlcmFuZ2U6ZWJkN2I3ZmQyMDM0NGVhYTk1OTc0ZjAyODdlYzNjY2VfNDAtMy0xLTEtMTA1NjI_ef17f285-27db-4b55-b0bb-586a8dadb1ea"
      unitRef="usd">886520000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMi0xLTEtMS0xMDU2Mg_ef16f3cd-3fb3-4082-b734-4a80c751f8ff"
      unitRef="usd">305514000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMi0zLTEtMS0xMDU2Mg_1cbc33c5-2b52-44ba-951d-f9d0488d8b53"
      unitRef="usd">260886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMi01LTEtMS0xMDU2Mg_65e7d822-d534-4291-ba9e-ab38335cba29"
      unitRef="usd">182237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMy0xLTEtMS0xMDU2Mg_a09da487-d708-412e-bb76-4ac469d745e7"
      unitRef="usd">34466000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMy0zLTEtMS0xMDU2Mg_61dd5305-837a-41dd-b4d1-1a0a7d3d4f9b"
      unitRef="usd">31044000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMy01LTEtMS0xMDU2Mg_ce9001d8-9623-47b6-a9d5-9cf1793d3cda"
      unitRef="usd">21963000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNC0xLTEtMS0xMDU2Mg_74a2b0e0-6609-4c04-a35c-f7f56d676f0c"
      unitRef="usd">271048000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNC0zLTEtMS0xMDU2Mg_c7f20b5b-c8a3-4d1a-8f3a-83601332dd68"
      unitRef="usd">229842000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNC01LTEtMS0xMDU2Mg_a2ee0b30-6eee-4419-abf9-01b16755f928"
      unitRef="usd">160274000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNi0xLTEtMS0xMDU2Mg_f2f1f776-e4d8-496d-ac7e-1e52ff13bb49"
      unitRef="usd">272049000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNi0zLTEtMS0xMDU2Mg_5eaf89d4-0582-46b7-85d3-aa6b22e6d563"
      unitRef="usd">308443000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNi01LTEtMS0xMDU2Mg_309f810c-2ea4-4e6f-a995-36c77ce3f82e"
      unitRef="usd">286378000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNy0xLTEtMS0xMDU2Mg_f277fc5a-eaa1-4e48-b48c-a5b732f5fb97"
      unitRef="usd">192710000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNy0zLTEtMS0xMDU2Mg_1d2f0c22-7e48-4d2e-b708-1b6a91822d9e"
      unitRef="usd">156407000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfNy01LTEtMS0xMDU2Mg_bb997386-f1bf-4643-90cd-b93fa02fcdc9"
      unitRef="usd">169861000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOC0xLTEtMS0xMDU2Mg_e3a83433-cc11-446a-9cdc-0a175007083c"
      unitRef="usd">-6514000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOC0zLTEtMS0xMDU2Mg_324e5309-4df6-4a51-ae72-22f8fbfd1be5"
      unitRef="usd">-3144000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOC01LTEtMS0xMDU2Mg_c52b1f7f-a7e0-4cff-99e4-f1641d6d9e13"
      unitRef="usd">-3297000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOS0xLTEtMS0xMDU2Mg_7cd21738-3511-49b5-9353-922124a070f7"
      unitRef="usd">6209000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOS0zLTEtMS0xMDU2Mg_06f5df84-7c02-4aa0-ac45-25e0065fe4ff"
      unitRef="usd">8846000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfOS01LTEtMS0xMDU2Mg_5ba19e07-e4a2-4099-bd20-f1e95feb1d21"
      unitRef="usd">4775000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTAtMS0xLTEtMTA1NjI_bc8ae2a2-ba28-42ae-8c0d-c21e58bf7592"
      unitRef="usd">477482000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTAtMy0xLTEtMTA1NjI_c947045c-3e00-42b4-a6a0-6594c2b95dd8"
      unitRef="usd">476840000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTAtNS0xLTEtMTA1NjI_1c92e66d-3cfe-4c47-9799-0583840b4211"
      unitRef="usd">464311000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTEtMS0xLTEtMTA1NjI_d53cc99c-1728-47a5-838b-a7323faf6f05"
      unitRef="usd">-206434000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTEtMy0xLTEtMTA1NjI_8c125a04-bc5c-4818-8e2b-9211c23ebfda"
      unitRef="usd">-246998000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTEtNS0xLTEtMTA1NjI_c306948d-c5d0-4714-adcd-082a04f9202e"
      unitRef="usd">-304037000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTMtMS0xLTEtMTA1NjI_4d3e88e6-fed6-414e-9920-ed058351a458"
      unitRef="usd">509000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTMtMy0xLTEtMTA1NjI_74723a17-6a12-4186-9786-8410251b2efd"
      unitRef="usd">3226000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTMtNS0xLTEtMTA1NjI_46b2b147-b8f2-49e7-b880-2557686d1905"
      unitRef="usd">10249000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTQtMS0xLTEtMTA1NjI_a8174f3c-1350-4337-9236-b2ceabc3bedc"
      unitRef="usd">32471000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTQtMy0xLTEtMTA1NjI_2f0b6ac2-6432-4c1d-bb6a-38d933f6afe8"
      unitRef="usd">22425000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTQtNS0xLTEtMTA1NjI_84002f13-24ac-4527-8f2c-5f863c99027e"
      unitRef="usd">18872000</us-gaap:InterestExpense>
    <fold:GainLossOnExchangeOfDebt
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTUtMS0xLTEtMTA1NjI_a6d5ebae-1cb2-44b6-9db2-86382c040a12"
      unitRef="usd">0</fold:GainLossOnExchangeOfDebt>
    <fold:GainLossOnExchangeOfDebt
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTUtMy0xLTEtMTA1NjI_709e6744-ba2f-4f35-a07e-1c51a38eb6a2"
      unitRef="usd">0</fold:GainLossOnExchangeOfDebt>
    <fold:GainLossOnExchangeOfDebt
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTUtNS0xLTEtMTA1NjI_aacee89e-b51c-4ed4-9989-cd05ea06de8e"
      unitRef="usd">-40624000</fold:GainLossOnExchangeOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTYtMS0xLTEtMTA1NjI_ca95a2c8-fbc1-4494-858b-8ac3ae4b9f4b"
      unitRef="usd">-257000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTYtMy0xLTEtMTA1NjI_269aed97-dc48-4610-a90b-0127db92954d"
      unitRef="usd">-7276000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTYtNS0xLTEtMTA1NjI_04398041-7eac-462a-a70e-63367367042e"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTgtMS0xLTEtMTA1NjI_2744d1bf-0133-47d1-8e4c-c637865ea134"
      unitRef="usd">-2901000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTgtMy0xLTEtMTA1NjI_71e6f9ec-b001-4c54-af0c-d72e8f99a7be"
      unitRef="usd">-781000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTgtNS0xLTEtMTA1NjI_f2b90097-a4ee-4d56-80e0-e3ba1ded2b87"
      unitRef="usd">-2626000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTktMS0xLTEtMTA1NjI_ded1a9df-d032-4353-ab41-de3578c57e6d"
      unitRef="usd">-241554000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTktMy0xLTEtMTA1NjI_58b8c412-f413-4a02-937b-5dbebe56cbd7"
      unitRef="usd">-274254000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMTktNS0xLTEtMTA1NjI_1c7a9853-e56f-4b66-8f86-05c61473edbb"
      unitRef="usd">-355910000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjAtMS0xLTEtMTA1NjI_4994ec6b-df6d-422d-bc0f-5f0675e464f6"
      unitRef="usd">8906000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjAtMy0xLTEtMTA1NjI_64e8ddb6-8d0d-42fc-810a-8ca09c414c4b"
      unitRef="usd">2598000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjAtNS0xLTEtMTA1NjI_ed65873b-d004-4c52-8b2c-173f460662e4"
      unitRef="usd">478000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjEtMS0xLTEtMTA1NjI_f431c726-9191-4225-92ea-a7b018de1b2a"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjEtMy0xLTEtMTA1NjI_1d484c12-893a-4877-ad12-67b366f2eaca"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjEtNS0xLTEtMTA1NjI_12893a33-8114-4250-aaf8-0a0c00df15e4"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItMS0xLTEtMTA1NjI_5ece9cad-7d75-4ab5-8160-1d004ef5aba9"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItMS0xLTEtMTA1NjI_dcb39d0f-4ae9-4c0b-8ceb-07a99d078163"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItMy0xLTEtMTA1NjI_ce055133-2374-43e8-b87b-7affcde74783"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItMy0xLTEtMTA1NjI_eb44722a-9fb3-4143-a11b-75197d6fa094"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItNS0xLTEtMTA1NjI_1d911fbb-bb7e-4082-8cd1-d5a1bd00d742"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjItNS0xLTEtMTA1NjI_b6eec001-7479-4fe0-9773-75c0d7fa235a"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtMS0xLTEtMTA1NjI_c4f03da6-fd79-4db6-9d8c-3181219a12cc"
      unitRef="shares">271421986</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtMS0xLTEtMTA1NjI_cf3fc10d-ff35-4d59-a8fe-ca65e1e7dea1"
      unitRef="shares">271421986</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtMy0xLTEtMTA1NjI_a1e2eeb4-dd4b-4f1e-9f70-ea1e71cfbe50"
      unitRef="shares">258867380</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtMy0xLTEtMTA1NjI_c9884a9f-0689-4695-a881-952166d78014"
      unitRef="shares">258867380</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtNS0xLTEtMTA1NjI_3e7e2bbe-450a-407d-b664-c3d5c9fdbef8"
      unitRef="shares">240421001</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182MS9mcmFnOjFiNjU2Yjk3Y2U1NTQwNWQ5NzhhOTEwOTc2M2Q0MzM0L3RhYmxlOmY3Njg1ZTRkNjExZDQzMzc4YzI5MjRiNGEwZTBiNjA1L3RhYmxlcmFuZ2U6Zjc2ODVlNGQ2MTFkNDMzNzhjMjkyNGI0YTBlMGI2MDVfMjMtNS0xLTEtMTA1NjI_7dc4de5f-46bb-48db-9fbe-caaadd5d30df"
      unitRef="shares">240421001</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfMi0xLTEtMS0xMDU2Mg_5e10d2b1-349f-4bd1-a326-9b96f5e5d58e"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfMi0zLTEtMS0xMDU2Mg_0639bd5c-5b3f-4828-8c08-8ef02764a29e"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfMi01LTEtMS0xMDU2Mg_a4e79d91-cc39-4b0a-85e1-26f83f7bfe8a"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOmQzMjBlZDkzZGI4ZjQ4ODViZjk3NWMzMzI0ZmQ0MWNjXzcx_8c5c33d1-9664-4de4-8b86-9ad8b22af674"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOmQzMjBlZDkzZGI4ZjQ4ODViZjk3NWMzMzI0ZmQ0MWNjXzc1_4d04ca20-f3b4-473d-9888-225515015ff1"
      unitRef="usd">1552000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOmQzMjBlZDkzZGI4ZjQ4ODViZjk3NWMzMzI0ZmQ0MWNjXzgz_8adc9c9a-19c6-4d33-96c4-9c42e0643ed1"
      unitRef="usd">889000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0xLTEtMS0xMDU2Mg_d37c76dd-79f3-4ef0-b209-3281cb85fc2e"
      unitRef="usd">-3161000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC0zLTEtMS0xMDU2Mg_361a3252-4402-4e60-94e8-d222ce469247"
      unitRef="usd">5627000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNC01LTEtMS0xMDU2Mg_a014537f-da6e-4ea3-bb96-20fb154d7e8c"
      unitRef="usd">2290000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOjNiZjg3NzljYjk0YzQzMmE4MzkyNWJhZTUxNDk2NDgyXzgy_8fae8d13-db4d-4b38-8965-bd4735601fb4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOjNiZjg3NzljYjk0YzQzMmE4MzkyNWJhZTUxNDk2NDgyXzg2_a86ad2bd-0335-499e-a92e-f945a6d024b6"
      unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0wLTEtMS0xMDU2Mi90ZXh0cmVnaW9uOjNiZjg3NzljYjk0YzQzMmE4MzkyNWJhZTUxNDk2NDgyXzk0_31d09a62-2865-4492-a464-ace759c1c8aa"
      unitRef="usd">182000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0xLTEtMS0xMDU2Mg_f4c30434-49bc-45b6-9630-0388ade22e75"
      unitRef="usd">-85000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS0zLTEtMS0xMDU2Mg_d34700a0-41f9-4ae8-b5a4-56e3a5bdeb0a"
      unitRef="usd">-225000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNS01LTEtMS0xMDU2Mg_65ef39c2-83d8-409f-b7e4-850fb2648034"
      unitRef="usd">467000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNi0xLTEtMS0xMDU2Mg_66d5b8f2-718d-46a9-8653-ac0550065433"
      unitRef="usd">-3246000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNi0zLTEtMS0xMDU2Mg_fd240db3-84d4-4eea-b103-d48db4916067"
      unitRef="usd">5402000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNi01LTEtMS0xMDU2Mg_b6ae41ef-5b9e-4bac-8ddb-9725bbd47b29"
      unitRef="usd">2757000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNy0xLTEtMS0xMDU2Mg_82a45857-f451-4792-8b3b-e9f9e28b00b7"
      unitRef="usd">-253706000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNy0zLTEtMS0xMDU2Mg_307b9a44-139c-4f03-99a4-ada35f979088"
      unitRef="usd">-271450000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182NC9mcmFnOjYxMzQ0ODVhMzBhYTRmNDVhN2ZhODJhNmNiNzM2Y2Y0L3RhYmxlOjg2M2U0ZTdkZDcwMDQ2YjJiZDJiYzk1YmM0MjA2YTI3L3RhYmxlcmFuZ2U6ODYzZTRlN2RkNzAwNDZiMmJkMmJjOTViYzQyMDZhMjdfNy01LTEtMS0xMDU2Mg_44b597a1-f163-41a2-989e-18d57e20380b"
      unitRef="usd">-353631000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i59b0f5748c0040d4ba044c170c4498a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi0xLTEtMS0xMDU2Mg_18aeb0cf-80ac-4123-9d70-9fa13f6a864e"
      unitRef="shares">189383924</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i59b0f5748c0040d4ba044c170c4498a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi0zLTEtMS0xMDU2Mg_78912207-21ed-40b7-a16d-e8a3c504a441"
      unitRef="usd">1942000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7eaeeea22e1c450bb0f3ef7f208d55da_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi01LTEtMS0xMDU2Mg_3a2f1cb6-3e79-4f1d-8d88-355de248caa2"
      unitRef="usd">1740061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e06cd88eed94c93bd863d9d2fa7e86a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi03LTEtMS0xMDU2Mg_cd866b41-4ca2-4e30-b749-13e683655b54"
      unitRef="usd">13063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4fde1813dc7d44159942aa86b1104baf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi05LTEtMS0xMDU2Mg_5a04a25b-6901-438f-8452-ba47aa5552e1"
      unitRef="usd">68000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie4b02a7b929749bcbb33c5ac89bfc395_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi0xMS0xLTEtMTA1NjI_da2118f3-b138-450a-8633-2a204ef9e610"
      unitRef="usd">-1412222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id112dec781f849479a5fea1933c18841_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMi0xMy0xLTEtMTA1NjI_c4027a32-17f5-4440-9f8f-9f75b24a6139"
      unitRef="usd">342912000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMy0xLTEtMS0xMDU2Mg_499fbf7e-1ba1-4c19-b7ba-321916efc860"
      unitRef="shares">1967087</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMy0zLTEtMS0xMDU2Mg_18ef7b26-6ad5-41ec-aa94-5367752e6d9a"
      unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMy01LTEtMS0xMDU2Mg_2f983a19-7b6b-4cb5-ab47-3a196dc1b63c"
      unitRef="usd">11456000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMy0xMy0xLTEtMTA1NjI_ecef27b4-b71f-4069-b725-6b6d705cbc57"
      unitRef="usd">11476000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNC0xLTEtMS0xMDU2Mg_3b760959-8aa5-4bc3-b0f6-5c796d11c487"
      unitRef="shares">18720930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNC0zLTEtMS0xMDU2Mg_0a964463-854b-4448-9b69-ac13e5cceeef"
      unitRef="usd">187000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNC01LTEtMS0xMDU2Mg_596e9b96-368d-4f51-b726-f62d459d16a7"
      unitRef="usd">188807000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNC0xMy0xLTEtMTA1NjI_6ee0aef4-cbf8-43ff-9b88-4a90d250a3e3"
      unitRef="usd">188994000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNS0xLTEtMS0xMDU2Mg_96d40b0c-1640-408d-b33c-118bf4f83b94"
      unitRef="shares">477198</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNS01LTEtMS0xMDU2Mg_efe5bfde-de0b-414b-b7ad-e88fa61a069d"
      unitRef="usd">3235000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNS0xMy0xLTEtMTA1NjI_35dfa79f-c877-45a2-acd9-7ac0b5f5ab50"
      unitRef="usd">3235000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <fold:StockIssuedDuringPeriodSharesContingentConsideration
      contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNi0xLTEtMS0xMDU2Mg_6f00c51d-dc09-4a3b-b573-57e2f2249b87"
      unitRef="shares">771804</fold:StockIssuedDuringPeriodSharesContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="i20b1ffa344ad4c46a05f2baded3c95de_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNi0zLTEtMS0xMDU2Mg_d36d9b8e-0753-40fa-bd5e-217ce7b361f8"
      unitRef="usd">8000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="ie7c2736e1c5f4bbdbe8ee555092181b6_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNi01LTEtMS0xMDU2Mg_c2a67281-7eff-4394-9ac1-3adfeb5bbb26"
      unitRef="usd">9308000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNi0xMy0xLTEtMTA1NjI_fc3fabe7-396c-41af-abcf-91414b2ecf2e"
      unitRef="usd">9316000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNy01LTEtMS0xMDU2Mg_256693bb-7d0e-461f-9f70-b1421c0e93e6"
      unitRef="usd">44430000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfNy0xMy0xLTEtMTA1NjI_4b48c063-52ca-4cf4-908b-5b329aa4560c"
      unitRef="usd">44430000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <fold:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC0xLTEtMS0xMDU2Mg_c75cd793-a148-4365-98b4-249fb54e73eb"
      unitRef="shares">101787</fold:StockIssuedDuringPeriodSharesWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC0zLTEtMS0xMDU2Mg_703131d9-fe4a-47de-9656-bec869c4ccd0"
      unitRef="usd">1000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC01LTEtMS0xMDU2Mg_d0f98460-be4d-499b-83a1-79747bf7785b"
      unitRef="usd">1487000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i92d9f0aae1dd4a489dc1c015715214d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC03LTEtMS0xMDU2Mg_b79535e7-e510-42b4-9c62-ca8ff783fa79"
      unitRef="usd">-676000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOC0xMy0xLTEtMTA1NjI_350909c7-2ba6-4c89-acbf-db1f4c7c9d44"
      unitRef="usd">812000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i47360a00d7e8465fad41ec5acaa33d4b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOS0xLTEtMS0xMDU2Mg_da217097-2b60-47f4-8275-626baed5b01d"
      unitRef="shares">43995139</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iec7f88d07a8f4a3196f84540950c1ba1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOS0zLTEtMS0xMDU2Mg_7e848fd7-af46-4801-aa8a-73df6f7177ea"
      unitRef="usd">440000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i295c47ed72d64074b5f32eeaad26a5cd_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOS01LTEtMS0xMDU2Mg_4bc8024f-33d5-42e2-9cb7-90e8377d1e0e"
      unitRef="usd">215036000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfOS0xMy0xLTEtMTA1NjI_9c8094b1-ce5e-46c4-9efc-5c4129a185b0"
      unitRef="usd">215476000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations
      contextRef="i9d174a7fea084bb889559168de083956_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTAtNS0xLTEtMTA1NjI_a213b349-877e-4ac9-a50b-5e75aed985ed"
      unitRef="usd">19875000</fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations>
    <fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTAtMTMtMS0xLTEwNTYy_1dc11d7a-0610-4e37-8acf-776d0b0552c0"
      unitRef="usd">19875000</fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7f87ef3b9001442e9d1783fa4ab6164a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTEtOS0xLTEtMTA1NjI_78cc2146-de12-4480-bcaa-a82922b837e2"
      unitRef="usd">467000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTEtMTMtMS0xLTEwNTYy_f727a34d-58ff-4bdb-b107-2a3069c8fb3b"
      unitRef="usd">467000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7f87ef3b9001442e9d1783fa4ab6164a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTItOS0xLTEtMTA1NjI_5a5ab19f-d8c3-4e9d-91f8-4a163f7a99d5"
      unitRef="usd">2290000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTItMTMtMS0xLTEwNTYy_d74561a6-ec2c-4edb-b8c8-fc1908cd2a40"
      unitRef="usd">2290000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="idebd74e031ad4aa8847d48abfeb2cb4c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTMtMTEtMS0xLTEwNTYy_b9ddbe65-c10f-42f1-a3b6-944432eb7198"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTMtMTMtMS0xLTEwNTYy_c170a285-ce99-4785-bee2-b04e4f71ea84"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic1a49ef645774a039703edbf41d99de6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtMS0xLTEtMTA1NjI_7a618142-89b3-4dfb-bf80-a54b6e62781d"
      unitRef="shares">255417869</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic1a49ef645774a039703edbf41d99de6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtMy0xLTEtMTA1NjI_e68c3012-0474-44ea-b340-fc63b9080516"
      unitRef="usd">2598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0283e0a778b241b69b7dc2f9f44b0620_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtNS0xLTEtMTA1NjI_5d573f91-344e-4e8b-a5ea-7cec0d4cedc3"
      unitRef="usd">2227225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb03c87cbb644915a36d8589d01d130f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtNy0xLTEtMTA1NjI_129902b4-8c42-4328-a4a5-e14b99205585"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i31157945f1834f739f2eb29aa5b1c152_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtOS0xLTEtMTA1NjI_64e15a16-c571-40f4-93ef-e2c61e5f0e1c"
      unitRef="usd">2825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0925432d607c491d8c8762f88a8343ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtMTEtMS0xLTEwNTYy_fb2a8803-87d1-48eb-8b77-b64427e8a43a"
      unitRef="usd">-1768610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTQtMTMtMS0xLTEwNTYy_7d691f8d-36e7-4cf8-87e6-1b410427cec6"
      unitRef="usd">476425000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4d67ba7a78d4493685eb33d08eab6fe3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTUtMS0xLTEtMTA1NjI_603e00f6-e17e-4de4-ab74-660047a105b0"
      unitRef="shares">5233672</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4d67ba7a78d4493685eb33d08eab6fe3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTUtMy0xLTEtMTA1NjI_f0399ea7-c469-4e65-843d-78843c2b4cb9"
      unitRef="usd">52000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1caab1a891c34d6db105ce12805fe47d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTUtNS0xLTEtMTA1NjI_6c3d9152-acbf-45db-8a89-fb9cb5cfeae6"
      unitRef="usd">42230000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTUtMTMtMS0xLTEwNTYy_bd6ba483-abc7-40a1-80ac-7409adb2be52"
      unitRef="usd">42282000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i4d67ba7a78d4493685eb33d08eab6fe3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTYtMS0xLTEtMTA1NjI_f1c25a77-c244-4b30-b2ed-a835295a8d9b"
      unitRef="shares">1411920</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1caab1a891c34d6db105ce12805fe47d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTYtNS0xLTEtMTA1NjI_c2ddd70e-3f2c-4b06-a88a-20dc219f95fb"
      unitRef="usd">10028000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTYtMTMtMS0xLTEwNTYy_fbd2c6f4-384b-4774-91da-d2719cdb4c1e"
      unitRef="usd">10028000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1caab1a891c34d6db105ce12805fe47d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTctNS0xLTEtMTA1NjI_4888da19-cf59-4a53-b301-a708c4c46b12"
      unitRef="usd">49151000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTctMTMtMS0xLTEwNTYy_f214f82b-6d58-463d-88b3-2b273aa01d63"
      unitRef="usd">49151000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i59667a8b6b6e402abb2689a16193a16e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTgtOS0xLTEtMTA1NjI_99fab089-2692-435f-b36d-99219bf619f7"
      unitRef="usd">-225000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTgtMTMtMS0xLTEwNTYy_33d3b483-e95f-4961-9af5-02c3dbe70ba1"
      unitRef="usd">-225000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i59667a8b6b6e402abb2689a16193a16e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTktOS0xLTEtMTA1NjI_38817806-bbec-4daa-b15b-97351ff07b62"
      unitRef="usd">5627000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMTktMTMtMS0xLTEwNTYy_9dd4224d-9382-4475-843a-259ab15d100f"
      unitRef="usd">5627000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i45f392c0af90404aa7ba763120f8093c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjAtMTEtMS0xLTEwNTYy_1fa27334-0297-44ba-bdc9-5e7550c16411"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjAtMTMtMS0xLTEwNTYy_356be1c0-8ee1-4b89-a66c-a4d8bffd975b"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a9abca8aab34fa6938b4176b42afcca_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtMS0xLTEtMTA1NjI_59ffade5-a071-426a-b5bb-d740323faac4"
      unitRef="shares">262063461</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5a9abca8aab34fa6938b4176b42afcca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtMy0xLTEtMTA1NjI_17efd813-fce6-4598-bc20-512885ea4ff3"
      unitRef="usd">2650000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a2dd5b7af4a40d8b104a56e99abd5c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtNS0xLTEtMTA1NjI_e0f0ef39-941b-4e85-839f-747b82cd8588"
      unitRef="usd">2308578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8631b1d954a432cab195334e4ab3c22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtNy0xLTEtMTA1NjI_321a998b-0c30-436d-a6a0-2d1ed6ca16c5"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fc96de0a30247109dd0e367a5fda28e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtOS0xLTEtMTA1NjI_61208550-560d-442a-9c55-0fdc22bb4749"
      unitRef="usd">8227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib685c8f6567a444dafe12c28724621c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtMTEtMS0xLTEwNTYy_3a23a618-df20-4132-bf80-54de398b1605"
      unitRef="usd">-2045462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjEtMTMtMS0xLTEwNTYy_20feceac-fcdb-4f7f-9e5f-7f015f6dd8f7"
      unitRef="usd">286380000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjItMS0xLTEtMTA1NjI_426bc2af-a8f2-422a-b480-ec2a472d81d4"
      unitRef="shares">1461189</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjItMy0xLTEtMTA1NjI_54363327-2d68-451b-a271-ed55b2617a7d"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjItNS0xLTEtMTA1NjI_541cdae9-70c2-499b-9155-594e63773266"
      unitRef="usd">10213000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjItMTMtMS0xLTEwNTYy_ec6687bc-f471-498e-94ec-6e704de4b6cf"
      unitRef="usd">10228000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib4be7fadcd724e6e96874c8bdf5adad5_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMS0xLTEtMTUyODI_bd8d7f1a-0866-43f5-8fb5-e8d137eee530"
      unitRef="shares">11296660</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMy0xLTEtMTUyODI_72ce679a-f5d2-41cf-b55e-a66eacc20b49"
      unitRef="usd">112000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtNS0xLTEtMTUyODI_789bdde8-58ba-4fdf-bae8-0a5327e562ee"
      unitRef="usd">199552000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8b570f4240774f97a85fc8f243de27b6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtNy0xLTEtMTUyODI_9d8767e2-738b-4372-a547-ab1b4df5bbc8"
      unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMTMtMS0xLTE1Mjgy_c23f11b3-746b-48e4-a713-2eaeead43bf8"
      unitRef="usd">199747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMS0xLTEtMTA1NjI_39788ce0-1319-4b5e-9b8c-8688f8e5f3c5"
      unitRef="shares">1064135</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtNS0xLTEtMTA1NjI_62e166ca-65d2-4e4b-9914-4272366fde23"
      unitRef="usd">15009000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjMtMTMtMS0xLTEwNTYy_4b5c575a-5b46-40ad-89cf-cdcd5baa62d4"
      unitRef="usd">15009000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjQtNS0xLTEtMTA1NjI_18c6ee5b-ddad-48f3-9825-18cc12403000"
      unitRef="usd">57838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjQtMTMtMS0xLTEwNTYy_08230c45-d07a-4fa4-ad42-97334b4ed5a8"
      unitRef="usd">57838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <fold:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtMS0xLTEtMTA1NjI_2411d500-004f-440f-bb13-3208c0792d73"
      unitRef="shares">2554999</fold:StockIssuedDuringPeriodSharesWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i8ffc95e604ae4c188f681de6950562c5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtMy0xLTEtMTA1NjI_30c5b944-fc2f-48ca-97ce-14a4cf1d69e5"
      unitRef="usd">26000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i1a5551b5de314904a0afb603cf70ae80_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtNS0xLTEtMTA1NjI_56194a31-b908-4ac3-8923-c9338ed5c6a2"
      unitRef="usd">31591000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i8b570f4240774f97a85fc8f243de27b6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtNy0xLTEtMTA1NjI_d2a37808-024d-429e-9e4f-b2e60f6d6733"
      unitRef="usd">-12387000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjUtMTMtMS0xLTEwNTYy_5223f8b5-79dc-48e2-a2d1-d4d77d4274c6"
      unitRef="usd">19230000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjYtMS0xLTEtMTA1NjI_50375b84-f793-4cff-b91d-084c499b76df"
      unitRef="shares">472356</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjYtMy0xLTEtMTA1NjI_8e26d893-e883-42e0-94f8-665a7a161439"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i640ccbc1c3154c0080c449287054612e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjYtNS0xLTEtMTA1NjI_f5871155-f236-49b5-bc39-2d764c62e74a"
      unitRef="usd">2656000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjYtMTMtMS0xLTEwNTYy_ae4e83f1-9830-4e23-a1c2-2e758f85249c"
      unitRef="usd">2661000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibbf5bb75d47341398ad73aa8e894bf9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjgtOS0xLTEtMTA1NjI_de92fe16-5045-4a55-b25b-dedd3ff34f6e"
      unitRef="usd">-85000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjgtMTMtMS0xLTEwNTYy_6de672b6-8535-461e-a580-6c9be7d0fb58"
      unitRef="usd">-85000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibbf5bb75d47341398ad73aa8e894bf9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjktOS0xLTEtMTA1NjI_25951cf0-36aa-49af-9f4b-e1ee3f5382a9"
      unitRef="usd">-3161000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMjktMTMtMS0xLTEwNTYy_b78358b4-1fcb-4286-8357-d8eee2171109"
      unitRef="usd">-3161000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i07df4fa1308d4f84a4aa5160e8a69ceb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzAtMTEtMS0xLTEwNTYy_0b801a07-2de7-455a-b4ca-1ffe713b080e"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzAtMTMtMS0xLTEwNTYy_06531270-9a89-48e9-af56-e633741a7c8c"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if9f9159fe2d74c02899336811f098a03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtMS0xLTEtMTA1NjI_5b7af8d0-aad0-46c0-9aac-b77e28a46f82"
      unitRef="shares">278912800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if9f9159fe2d74c02899336811f098a03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtMy0xLTEtMTA1NjI_c1dcad91-706d-4ded-9f39-55ed5fdc7749"
      unitRef="usd">2808000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic68cc19d3396498d82b2a8b900bcb129_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtNS0xLTEtMTA1NjI_ee41f4cc-d7ac-428d-9115-771f806f4d76"
      unitRef="usd">2595419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e1512bc26b649368f7c7a1f80c153cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtNy0xLTEtMTA1NjI_35b4e0e7-f731-4405-9828-1347ccf88135"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia89d77f8f61e4f3997ffe7f4c43ce4bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtOS0xLTEtMTA1NjI_1c9e32b8-e000-4e05-a0fa-737703bc0693"
      unitRef="usd">4981000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0cac20d40d594fdb84c482f1f832ea26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtMTEtMS0xLTEwNTYy_4a554f48-8a43-4b8c-93b8-23b55d6df8db"
      unitRef="usd">-2295922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM182Ny9mcmFnOmJiODU0MDMxZTBiNTQ1OGNiY2Q4ZTMwOWY3YzJhMGU2L3RhYmxlOjcxZjdhZDE1NzdjNDRkY2JiOGE3MTZmNzk0ZDI1MmZlL3RhYmxlcmFuZ2U6NzFmN2FkMTU3N2M0NGRjYmI4YTcxNmY3OTRkMjUyZmVfMzEtMTMtMS0xLTEwNTYy_2ce4ce71-6994-4898-b19d-59adc0852a6b"
      unitRef="usd">307369000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMy0xLTEtMS0xMDU2Mg_11ab8732-8499-4da3-a911-bac1eebc627d"
      unitRef="usd">-250460000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMy0zLTEtMS0xMDU2Mg_a86e9a34-e280-43a8-93fd-79584a7239a8"
      unitRef="usd">-276852000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMy01LTEtMS0xMDU2Mg_fceac09e-80b3-4732-88fc-a12090b5f835"
      unitRef="usd">-356388000</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNS0xLTEtMS0xMDU2Mg_855064a6-172a-4119-b150-2678a4f7d9e2"
      unitRef="usd">2490000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNS0zLTEtMS0xMDU2Mg_2925fc62-23f2-4a2d-aece-dbdd6286e6c6"
      unitRef="usd">1794000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNS01LTEtMS0xMDU2Mg_2b68402a-cd47-468c-a121-9da9fb94c9bc"
      unitRef="usd">2546000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNi0xLTEtMS0xMDU2Mg_98562624-fa17-41c1-8b63-08c806e70463"
      unitRef="usd">6209000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNi0zLTEtMS0xMDU2Mg_54b25cdb-6986-4c26-8da5-37f9d2226f47"
      unitRef="usd">8846000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNi01LTEtMS0xMDU2Mg_b9f93e5a-1d36-4e25-b168-d4ebef3d0679"
      unitRef="usd">4775000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNy0xLTEtMS0xMDU2Mg_918c411b-66d7-48e3-8ad6-544076b22150"
      unitRef="usd">57838000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNy0zLTEtMS0xMDU2Mg_1ce64edf-d8ad-4f77-a8f3-9b2d870d651c"
      unitRef="usd">49151000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNy01LTEtMS0xMDU2Mg_fa9729d4-2247-4d30-9ba8-d62edc859d95"
      unitRef="usd">44430000</us-gaap:ShareBasedCompensation>
    <fold:GainLossOnExchangeOfDebt
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOC0xLTEtMS0xMDU2Mg_62fa0fb7-963b-4677-8f80-82f4d9bace58"
      unitRef="usd">0</fold:GainLossOnExchangeOfDebt>
    <fold:GainLossOnExchangeOfDebt
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOC0zLTEtMS0xMDU2Mg_5abb8ec7-1302-465c-b8e5-0315f4677bda"
      unitRef="usd">0</fold:GainLossOnExchangeOfDebt>
    <fold:GainLossOnExchangeOfDebt
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOC01LTEtMS0xMDU2Mg_685362ee-bb9f-42f9-b51c-efba4e3a13de"
      unitRef="usd">-40624000</fold:GainLossOnExchangeOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOS0xLTEtMS0xMDU2Mg_42fce7fd-3db6-463a-ba14-48b14e70aa81"
      unitRef="usd">-257000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOS0zLTEtMS0xMDU2Mg_a86ec58d-90af-4464-b3ed-b9b0b6b82cab"
      unitRef="usd">-7276000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfOS01LTEtMS0xMDU2Mg_ce9ec704-359f-40cd-86c4-084e89f6039e"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTEtMS0xLTEtMTA1NjI_159bc39c-7f37-4e36-980a-1e6eb2f33393"
      unitRef="usd">6514000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTEtMy0xLTEtMTA1NjI_c4bd0aa2-fab7-449a-8f0f-ed71d739abb1"
      unitRef="usd">3144000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTEtNS0xLTEtMTA1NjI_07e4b8d7-5cf7-48c7-a115-36902040bb9c"
      unitRef="usd">3297000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTItMS0xLTEtMTA1NjI_5ccb0cc3-b9c7-406e-b5bc-03c322eb9ae1"
      unitRef="usd">-3565000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTItMy0xLTEtMTA1NjI_58fde154-0c76-4e66-bcab-1b8652ab7c28"
      unitRef="usd">-5471000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTItNS0xLTEtMTA1NjI_9a4eea00-10a4-40d9-b971-1bdaaddc9a34"
      unitRef="usd">-254000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTMtMS0xLTEtMTA1NjI_09c98504-8e4f-46d4-ab3f-3a94e9259974"
      unitRef="usd">34000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTMtMy0xLTEtMTA1NjI_de180773-8d84-4c6d-b01b-d2133ea44e17"
      unitRef="usd">-155000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTMtNS0xLTEtMTA1NjI_37610c68-ff27-469a-80e5-5a348f5da9ce"
      unitRef="usd">-1415000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTQtMS0xLTEtMTA1NjI_da8c13be-6204-4ed3-ba8b-4695b3233d21"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTQtMy0xLTEtMTA1NjI_90d7d9df-b91d-4657-8183-c694b4abe298"
      unitRef="usd">-99000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTQtNS0xLTEtMTA1NjI_c268305d-1fc3-48f2-8448-3d13048b5421"
      unitRef="usd">149000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTYtMS0xLTEtMTA1NjI_ab10031c-1b2e-4329-a9dc-9ffa336e4845"
      unitRef="usd">8189000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTYtMy0xLTEtMTA1NjI_46c934c2-ddc8-40ee-980e-8d032d43d185"
      unitRef="usd">11219000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTYtNS0xLTEtMTA1NjI_f4534ed4-8cee-4ad4-9c60-cad3f8aafac0"
      unitRef="usd">11114000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTctMS0xLTEtMTA1NjI_7bf39791-3b2b-4bc1-aefc-59989a9f1167"
      unitRef="usd">7790000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTctMy0xLTEtMTA1NjI_f95b9194-b24a-46df-bf81-a29e75ab2571"
      unitRef="usd">4639000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTctNS0xLTEtMTA1NjI_046b5836-29fe-4bdd-b36f-0f4614c58099"
      unitRef="usd">5114000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTgtMS0xLTEtMTA1NjI_63d81193-534c-4e33-bcfe-a49dfe309670"
      unitRef="usd">5919000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTgtMy0xLTEtMTA1NjI_5815c8f1-6e48-4a54-a9f9-7f44cbe79e1b"
      unitRef="usd">8766000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTgtNS0xLTEtMTA1NjI_a95c0e8f-f8ac-4218-8748-8f23507ccad8"
      unitRef="usd">3287000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTktMS0xLTEtMTA1NjI_2fe14888-1e05-459f-b356-0b1980661eac"
      unitRef="usd">7430000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTktMy0xLTEtMTA1NjI_0989c167-3d48-40e7-8f5c-8674be3953ef"
      unitRef="usd">-10610000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMTktNS0xLTEtMTA1NjI_25a0bafe-9f29-4438-9ea4-de2c48f4d354"
      unitRef="usd">46742000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjAtMS0xLTEtMTA1NjI_0b716f7d-28c7-417d-b9e8-b1e77d92e684"
      unitRef="usd">-2617000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjAtMy0xLTEtMTA1NjI_e4d37dc3-ef86-4db1-8903-2f2ebc9f8e66"
      unitRef="usd">4420000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjAtNS0xLTEtMTA1NjI_45787fd0-3fab-43df-bcee-d6cd9b5bdea6"
      unitRef="usd">-10117000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInDeferredReimbursements
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjEtMS0xLTEtMTA1NjI_bf24869c-3d32-4a2c-a61a-daf4600e9e7e"
      unitRef="usd">-1500000</fold:IncreaseDecreaseInDeferredReimbursements>
    <fold:IncreaseDecreaseInDeferredReimbursements
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjEtMy0xLTEtMTA1NjI_392757a5-33b8-4c6d-9c06-f2aa7d14ac1e"
      unitRef="usd">-1250000</fold:IncreaseDecreaseInDeferredReimbursements>
    <fold:IncreaseDecreaseInDeferredReimbursements
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjEtNS0xLTEtMTA1NjI_5b9c8618-3639-4612-ab24-c0fdd4b643ea"
      unitRef="usd">-5500000</fold:IncreaseDecreaseInDeferredReimbursements>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItMS0xLTEtMTM3MjA_0b4d1d04-c2a5-433e-8100-b1be7493ce3d"
      unitRef="usd">10353000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItMy0xLTEtMTM3Mjg_ccc9c438-ad61-46ab-9213-8d7cffc795b0"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItNS0xLTEtMTM3MzU_454871aa-5802-42be-9db5-2ba061ad6ecf"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItMS0xLTEtMTA1NjI_5ba35a71-1265-40ae-ba80-918e9b4c44c5"
      unitRef="usd">-202491000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItMy0xLTEtMTA1NjI_9f728bbd-c056-4474-8907-fb92ae37b529"
      unitRef="usd">-233290000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjItNS0xLTEtMTA1NjI_f5a4660e-f9cc-47b2-be24-f17ebf0d5c31"
      unitRef="usd">-250416000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjQtMS0xLTEtMTA1NjI_de68cf57-6587-45b0-9915-b38789a8c7a9"
      unitRef="usd">424043000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjQtMy0xLTEtMTA1NjI_64512ed0-45fb-4f73-a1c7-e4bec9c2dd97"
      unitRef="usd">354826000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjQtNS0xLTEtMTA1NjI_796f007b-9eef-46da-8ec2-346ec16d7b80"
      unitRef="usd">499047000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjUtMS0xLTEtMTA1NjI_8e2c05da-1839-407b-ae18-996303b2030e"
      unitRef="usd">341398000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjUtMy0xLTEtMTA1NjI_2760913e-b4a9-475b-af65-9914bcaead7f"
      unitRef="usd">365178000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjUtNS0xLTEtMTA1NjI_dd0a6762-71ec-47dd-bb97-a90dc601ad67"
      unitRef="usd">383882000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjYtMS0xLTEtMTA1NjI_273c07ee-6ee5-405f-935f-bbdc8dbde53f"
      unitRef="usd">3884000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjYtMy0xLTEtMTA1NjI_3ef47115-2f5d-4565-96dd-84f93d47b389"
      unitRef="usd">3227000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjYtNS0xLTEtMTA1NjI_66afe7fe-27c7-4675-a3a4-bd38a75bb6dc"
      unitRef="usd">20012000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjctMS0xLTEtMTA1NjI_ca6b6846-fa5d-4e78-af56-544ecef19e0a"
      unitRef="usd">78761000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjctMy0xLTEtMTA1NjI_e8fefadd-00d7-4a8d-ac32-10ba599e365e"
      unitRef="usd">-13579000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjctNS0xLTEtMTA1NjI_b9869a85-ff2e-4821-ad7a-d09fe23d7901"
      unitRef="usd">95153000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjktMS0xLTEtMTA1NjI_b624ff62-9f4c-478d-b011-324ac6ad3056"
      unitRef="usd">199750000</fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing>
    <fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjktMy0xLTEtMTA1NjI_059c962a-45a7-4c32-acda-25803c016749"
      unitRef="usd">0</fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing>
    <fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMjktNS0xLTEtMTA1NjI_5923d42c-5e3d-4cae-afc8-c4a6e828cad9"
      unitRef="usd">0</fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtMS0xLTEtMTU2NzU_d17c9ff8-2909-4be2-b6fe-cb2f9bcfb487"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtMy0xLTEtMTU2ODE_fef23e1a-5cbb-4009-ad86-9d7722cd28f2"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtNS0xLTEtMTU2ODc_53eec8ea-7441-4a7f-88c1-b6f073a56aeb"
      unitRef="usd">188994000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzAtMS0xLTEtMTA1NjI_02ae450a-c639-478b-8d99-b1a2bafa63bd"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzAtMy0xLTEtMTA1NjI_b52e29c0-8205-4bc4-9519-e676feec3014"
      unitRef="usd">155249000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzAtNS0xLTEtMTA1NjI_c33d075b-5c73-4b96-a0fb-1ed480193ee0"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtMS0xLTEtMTA1NjI_f29a0075-c4d8-460f-8c94-bfd60b477b8d"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtMy0xLTEtMTA1NjI_3eb4703f-b2eb-484a-890b-f0655c6440ec"
      unitRef="usd">385929000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzEtNS0xLTEtMTA1NjI_252d528c-3ab9-47c4-bcd1-12ed3819b9f2"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzItMS0xLTEtMTA1NjI_ca988eb9-e839-48a7-a9c1-a9438a562bad"
      unitRef="usd">479000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzItMy0xLTEtMTA1NjI_b47cdaca-d98c-4fb3-8aac-026b734ce589"
      unitRef="usd">76000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzItNS0xLTEtMTA1NjI_dbd8040e-5f18-4d7c-8c37-6bb2522154c5"
      unitRef="usd">420000</us-gaap:FinanceLeasePrincipalPayments>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzMtMS0xLTEtMTA1NjI_851aa74b-b3d1-4341-b93b-0b993931f5ed"
      unitRef="usd">15009000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzMtMy0xLTEtMTA1NjI_69f37d3b-9bde-4f31-8a0e-c2ae9e961724"
      unitRef="usd">10028000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzMtNS0xLTEtMTA1NjI_d55f6afe-abd8-4258-9d6c-4059971c007b"
      unitRef="usd">3235000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzQtMS0xLTEtMTA1NjI_45f3190a-d43d-4638-ae32-17131f3fe643"
      unitRef="usd">0</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzQtMy0xLTEtMTA1NjI_7273cd8c-f1c6-46ce-bea5-cafc83cf651d"
      unitRef="usd">0</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzQtNS0xLTEtMTA1NjI_f8afee67-2b71-47e3-adbd-ec8949cf1038"
      unitRef="usd">19875000</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzUtMS0xLTEtMTA1NjI_f370d769-6287-4454-87ac-73d0f6c8bb8d"
      unitRef="usd">10228000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzUtMy0xLTEtMTA1NjI_62652a69-8988-4bad-ba03-1cd3dcd5c540"
      unitRef="usd">42282000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzUtNS0xLTEtMTA1NjI_788a8d01-8252-4e8c-aa27-41c44800b7f8"
      unitRef="usd">11476000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzYtMS0xLTEtMTA1NjI_a3a7442c-ab14-49a9-93cb-39bac2ced38a"
      unitRef="usd">19230000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzYtMy0xLTEtMTA1NjI_097562da-7eaf-4f09-adfb-2a87471f32c6"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzYtNS0xLTEtMTA1NjI_cb76f6d7-14e7-4104-bf48-78654e4c912c"
      unitRef="usd">812000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtMS0xLTEtMTM4MTU_ccf4bc23-57c4-4a68-a1e2-4b78f2c55f7a"
      unitRef="usd">1647000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtMy0xLTEtMTM4MTU_b07eed40-6796-4530-9c34-278379637baf"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtNS0xLTEtMTM4MTU_1fb60fe7-3641-4aa0-825b-3a530915ceed"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzctMS0xLTEtMTA1NjI_508626b7-0991-4df2-b54d-7f1ebf481c7b"
      unitRef="usd">212073000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzctMy0xLTEtMTA1NjI_70cbbb75-aaf2-46b4-a159-0b140880dce3"
      unitRef="usd">262858000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzctNS0xLTEtMTA1NjI_90bc60c3-fce5-42ef-9e59-fe8e33ed6edd"
      unitRef="usd">217502000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtMS0xLTEtMTA1NjI_c3e3d679-d2ed-4e5b-9c1b-3b91406d9781"
      unitRef="usd">-5049000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtMy0xLTEtMTA1NjI_53c5e8b7-8eb7-42c2-8b1c-39a31f866096"
      unitRef="usd">3830000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzgtNS0xLTEtMTA1NjI_d95b8ccf-7855-4136-b3ec-acd7bd635e6f"
      unitRef="usd">1729000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzktMS0xLTEtMTA1NjI_0e171812-d3f7-4891-9f74-17a4edf9cd2f"
      unitRef="usd">83294000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzktMy0xLTEtMTA1NjI_27fced79-af33-4c27-b3f0-7f383d09089f"
      unitRef="usd">19819000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfMzktNS0xLTEtMTA1NjI_607a5d62-cb7e-46ad-9b24-dca84b935e47"
      unitRef="usd">63968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDAtMS0xLTEtMTA1NjI_86f1cdf2-a298-4886-8269-19aa82414b06"
      unitRef="usd">166162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDAtMy0xLTEtMTA1NjI_2b9255cd-e2a5-47f6-a56a-892149886815"
      unitRef="usd">146343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id112dec781f849479a5fea1933c18841_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDAtNS0xLTEtMTA1NjI_ad663dde-2678-4122-9b90-a308f7c0947f"
      unitRef="usd">82375000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDEtMS0xLTEtMTA1NjI_0aa4b8fb-d7ac-47c5-8bdd-5ac9d594bf62"
      unitRef="usd">249456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDEtMy0xLTEtMTA1NjI_38708e89-8609-42c9-b013-002a2e43f50d"
      unitRef="usd">166162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDEtNS0xLTEtMTA1NjI_4fa23a2b-5389-4fa5-af92-0eb9fdeedd11"
      unitRef="usd">146343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDQtMS0xLTEtMTA1NjI_d5fc7d20-f689-4490-b71f-1b6f16a5875d"
      unitRef="usd">300000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDQtMy0xLTEtMTA1NjI_507b53be-6ae4-46ca-a2f2-4825705be823"
      unitRef="usd">470000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDQtNS0xLTEtMTA1NjI_68b6c107-fd1a-4792-aeab-f1dc82cba21f"
      unitRef="usd">19388000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:InterestPaidNet
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDUtMS0xLTEtMTA1NjI_608f4ce3-deff-4cb1-a551-2754e7fa99bf"
      unitRef="usd">30468000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDUtMy0xLTEtMTA1NjI_009ad721-cfb9-4716-a107-346062a2e6c0"
      unitRef="usd">24683000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDUtNS0xLTEtMTA1NjI_06b1af51-5be1-4c0a-9f61-a7423e156d8c"
      unitRef="usd">16966000</us-gaap:InterestPaidNet>
    <fold:ContingentConsiderationPaidInStock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDYtMS0xLTEtMTA1NjI_20755f14-5610-45f8-a5bf-1bb5effb0f86"
      unitRef="usd">0</fold:ContingentConsiderationPaidInStock>
    <fold:ContingentConsiderationPaidInStock
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDYtMy0xLTEtMTA1NjI_d08cb89c-39a3-4fd8-969d-799b5a7efd2f"
      unitRef="usd">0</fold:ContingentConsiderationPaidInStock>
    <fold:ContingentConsiderationPaidInStock
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDYtNS0xLTEtMTA1NjI_db4bbf8a-03c8-4890-9180-2b8c79532f49"
      unitRef="usd">9316000</fold:ContingentConsiderationPaidInStock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDctMS0xLTEtMTA1NjI_c47ebe86-0a75-4f2b-ab7a-fb2dd1f25df7"
      unitRef="usd">1448000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDctMy0xLTEtMTA1NjI_63eaf7f8-5f01-40b9-84e8-d15ef713c803"
      unitRef="usd">985000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDctNS0xLTEtMTA1NjI_e9ff6e07-1358-4fb8-bb33-98fbf68f6925"
      unitRef="usd">1865000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDgtMS0xLTEtMTA1NjI_c25e2834-6d47-440f-a570-002f8d1da0e9"
      unitRef="usd">20032000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDgtMy0xLTEtMTA1NjI_6442cf1c-a3a8-4150-851d-de8309dccd9a"
      unitRef="usd">10371000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183MC9mcmFnOjc0NTkwNGIwYzNmZDRiNWY5YTBhNDNkNjA4YThhZTZlL3RhYmxlOjNjNWQyYjhiY2VhYzRiZGI5ZWY0YWU5OTljNTU3YmZmL3RhYmxlcmFuZ2U6M2M1ZDJiOGJjZWFjNGJkYjllZjRhZTk5OWM1NTdiZmZfNDgtNS0xLTEtMTA1NjI_e1e8a8ec-66da-4133-b3d7-78d6c4a5fb77"
      unitRef="usd">691000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfNTYzNg_3f5b689c-9acb-450e-acbb-fc515c8c4264">Description of Business&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). We are committed to discovering and developing next generation therapies in Fabry and Pompe diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cornerstone of the Company's portfolio is Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#x201c;MAA&#x201d;) in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 24, 2022, the Company announced, with ARYA Sciences Acquisition Corp IV ("ARYA"), a special purpose acquisition company (or "SPAC"), sponsored by Perceptive Advisors, it has agreed to mutually terminate the previously announced definitive business combination agreement, originally executed in September 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in September 2021, the Company entered into securities purchase agreements with certain investors for the private placement of an aggregate of 11,296,660 shares of the Company's common stock, at a purchase price of $10.18 per share, and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. The net proceeds from these private placements were approximately $199.8 million. The Company expects to use the net proceeds to further fund initiatives in the global commercialization of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the anticipated global launch of AT-GAA and to further support the Company's discovery work on next generation therapies in Fabry and Pompe diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operations have not been significantly impacted by the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic to date. However, the Company observed increased lag times between patient identification and Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; initiation due to the resurgence of COVID-19 in 2021. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimal disruptions. Whether the Company will continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had an accumulated deficit of $2.3 billion as of December 31, 2021 and anticipates incurring losses through the fiscal year ending December&#160;31, 2022 and beyond. The Company has historically funded its operations through stock offerings, Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues, debt issuances, collaborations, and other financing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, and net proceeds from the September 2021 private placement of securities, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib4be7fadcd724e6e96874c8bdf5adad5_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU1Ng_bd8d7f1a-0866-43f5-8fb5-e8d137eee530"
      unitRef="shares">11296660</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU2OQ_22512cc7-d765-421d-ad7b-73a347e9694e"
      unitRef="usdPerShare">10.18</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU4NQ_54ae2f10-b288-4e94-8e7e-2c242bcff12e"
      unitRef="shares">8349705</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ida79dc6999b2473ca1d1e66873b93aae_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU3Nw_efa68023-eda4-497c-b453-ed2df159d2fd"
      unitRef="usdPerShare">10.17</us-gaap:SaleOfStockPricePerShare>
    <fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing
      contextRef="i526b094eedf24604a14d40a8149d2578_D20210901-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfMTA5OTUxMTY0NjU5Ng_7859fb1c-b64c-446b-ab05-9813eb29c151"
      unitRef="usd">199800000</fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183Ni9mcmFnOmIxZDMwMDYyOTY5ODQ0NzA5ODAxMjExYzM1YTcyMWMxL3RleHRyZWdpb246YjFkMzAwNjI5Njk4NDQ3MDk4MDEyMTFjMzVhNzIxYzFfNDg3MQ_e000025a-2d2d-40be-9c1d-ea2cfefdcd33"
      unitRef="usd">-2300000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MTI_f8a7c77f-d792-454b-a2d3-3be1ac6a2fcf">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of December 31, 2021 and through the issuance of these financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company's accounts receivable at December 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of December 31, 2021, the Company recorded an allowance for doubtful accounts of $0.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDYwOA_36c2035c-6429-44ec-a5ff-c15bdbc6abf6"&gt;three&lt;/span&gt; to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product sales consist of sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2021, one customer accounted for 24% of net product sales and 14% of accounts receivable from product sales. In 2020, one customer accounted for 25% of net product sales and 12% of accounts receivable from product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Income and Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonqualified Cash Deferral Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, the Company had one equity-based employee compensation plan, which is described more fully in "&#x2014;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#x2014;&#160;Note&#160;15. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently operates in one business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is one reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. If it is determined the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value, an impairment loss is recorded for the difference. No indicators of impairment were noted during the years ended December 31, 2021 and December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2019-12 - In December 2019, the FASB issued Accounting Standard Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#x2019; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3Mzg_119c5da4-7054-4f3b-942c-71030234caa9">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MjQ_47b6401c-c171-41d1-b04e-ecc81c52bf03">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MTU_e8d5c12f-d8ad-42e6-b59c-9361f5640baf">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjY_f71e9a8b-d117-4124-b92e-49c7b85ef377">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of December 31, 2021 and through the issuance of these financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MTY_695114b3-f447-4661-bd95-c987c0210354">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.</fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3Mzk_d84777f3-8a27-4e2d-9044-c1826577bf6f">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;. The Company's accounts receivable at December 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDQwNQ_dbccf7f1-669d-447a-a293-65fa4e7e4226"
      unitRef="usd">200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MDQ_b568b26f-6468-49c5-abc1-7a8215052d63">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDYwOA_36c2035c-6429-44ec-a5ff-c15bdbc6abf6"&gt;three&lt;/span&gt; to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i016a712198df44609ada40ce0ec6040e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfNDYxNA_6ca1d88f-3c1b-447f-9fb8-4b47a8262882">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NTg_731fb34b-da22-44f5-ae68-98006ce753e3">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product sales consist of sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2021, one customer accounted for 24% of net product sales and 14% of accounts receivable from product sales. In 2020, one customer accounted for 25% of net product sales and 12% of accounts receivable from product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icb5f7d12a2e74e94b84af411c94b825f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTA5OTUxMTY2MjMwNA_64679d3e-3186-4bf1-8223-227e3ef4e93c"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id98a23a12f314c0399ddc82d07f167d9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTA5OTUxMTY2MjMwOA_ff57d371-c3ff-41f9-b5ce-4a583f5e74a1"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8d0ef6f58f21490982734d184ffa708c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTA5OTUxMTY1MzU4NQ_b4110db2-b837-44f3-85e6-d2cb2b0f01a4"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3a13db14f0fd48d7b5bae936a24df08c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTA5OTUxMTY1MzU5NA_ebcacfed-89f6-486c-aab1-99f5aabeb8d8"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDI_19032961-6aa7-42dd-a19f-348b3b3200b5">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fd944574f2a423983b2d669ba0a005a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMi0yLTEtMS0xMDU2Mg_f6cd196e-3a5e-41b4-9773-4258f6e4914f"
      unitRef="usd">95387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i141786068eaa494eabbae0eed4ca91ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMi00LTEtMS0xMDU2Mg_f685a48f-7018-4f65-8e95-a75cf6b2adcb"
      unitRef="usd">80046000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3697f78d277b440cb2fdcf968fe349c8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMi02LTEtMS0xMDU2Mg_3afa01ab-db68-4fdf-9a55-80e1f3f0f029"
      unitRef="usd">52478000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73069b90118447438bdbc91aa2291082_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMy0yLTEtMS0xMDU2Mg_5b559663-df3b-4afa-b854-2041d66ebc1e"
      unitRef="usd">210127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1211cdc53247450f9cf2280aa82ab844_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMy00LTEtMS0xMDU2Mg_5c895113-7d85-4768-8c75-7064da3151a7"
      unitRef="usd">180840000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e29c1f134e24ca6a71a18a5867402ee_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfMy02LTEtMS0xMDU2Mg_c23ba2af-6225-4171-b5f0-cc02021eef1a"
      unitRef="usd">129759000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfNC0yLTEtMS0xMDU2Mg_f0ab6e1c-c0f7-4285-ad66-4bc543e785bd"
      unitRef="usd">305514000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfNC00LTEtMS0xMDU2Mg_f1e83ebd-5148-4076-9681-e21a89340de9"
      unitRef="usd">260886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RhYmxlOmUyYWFlNTc4ZTg4ODQyOTM4NmFmMTMxYTgyODlmYzg5L3RhYmxlcmFuZ2U6ZTJhYWU1NzhlODg4NDI5Mzg2YWYxMzFhODI4OWZjODlfNC02LTEtMS0xMDU2Mg_25de01cc-cda0-4a16-adf3-9c07a225a8a9"
      unitRef="usd">182237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NTk_599acc63-171e-4485-ae63-adf47cfbdd54">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU2OTQ_71146110-7fad-4cc9-9732-e293b8c8f704">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MTk_8f504944-6fc6-4c47-acfc-dabaae9dfb62">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDA_b3e82d68-1752-44a3-9aea-12a4c5a5e414">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <fold:InterestIncomeAndInterestExpensePolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NTU_de4108c9-b2fe-4f9b-b119-71239e4525a9">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Income and Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.&lt;/span&gt;&lt;/div&gt;</fold:InterestIncomeAndInterestExpensePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjI_608c509c-472f-4e3f-b1d6-33e813ea3d12">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <fold:OtherComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NTE_2e50a905-ebc5-405f-9b67-0a50df754f2d">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) include unrealized gains and losses on available-for-sale securities and gain (loss) on foreign currency transactions and are included in the Statements of Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</fold:OtherComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3Njk_9a8177aa-4cd1-43f8-adbf-d86015f4fdb6">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <fold:NonqualifiedCashDeferralPlansPolicyPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3MzU_2eff3779-addf-4db4-938d-d3f80cf70c68">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonqualified Cash Deferral Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</fold:NonqualifiedCashDeferralPlansPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjA_81daae62-0094-41ac-8f72-82a7626251e3">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, the Company had one equity-based employee compensation plan, which is described more fully in "&#x2014;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <fold:ShareBasedCompensationNumberOfPlans
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTU5MTA_2c19bf31-69a4-4b58-b295-5af035e3c924"
      unitRef="plan">1</fold:ShareBasedCompensationNumberOfPlans>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDQ_79d6297a-9496-44bd-9e40-bcc21872083a">Loss per Common ShareThe Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDU_07a84854-7f3a-441e-b2b9-3d3c470297fd">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently operates in one business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is one reporting unit.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTY5MzM_35e3b1c2-0250-4dcb-a97a-675de8603c84"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportingUnits
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMTc1NTI_8522e65d-4408-4425-b0ef-f8f19ea48e6d"
      unitRef="unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDc_74b067de-0323-4c73-b05b-48c97a758f96">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjE_b4acb720-919a-451f-8bcd-11e84adad43d">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NDE_7d795497-09ba-487d-a406-e1ce17c7e046">Intangible Assets and GoodwillThe Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM183OS9mcmFnOjQ2OTViNDJjZDQ4YjQzMjA5NzNjNTQzY2E1MjFiNjBkL3RleHRyZWdpb246NDY5NWI0MmNkNDhiNDMyMDk3M2M1NDNjYTUyMWI2MGRfMjU3NjU_44275227-5f72-475f-9ff9-56ca5590e2ac">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2019-12 - In December 2019, the FASB issued Accounting Standard Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#x2019; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTMzOA_708ab278-be4a-46c6-bc84-4750193c2d87">Goodwill and Intangible Assets&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, in connection with the acquisitions, the Company had goodwill of $197.8 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D of $23.0 million, which are reported at fair value on the Company's Consolidated Balance Sheets. Intangible assets related to IPR&amp;amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D assets below their respective carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. A goodwill impairment loss, if any, is measured as the amount by which the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value.   An IPR&amp;amp;D impairment loss, if any, is measured as the amount by which the carrying amount of the asset exceeds its fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the changes in IPR&amp;amp;D for the years ended December 31, 2021 and 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the changes in Goodwill for the years ended December 31, 2021 and 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTI5_648bebaa-7f3c-488a-b9f3-85c4b9545dfe"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTQ1_e10a8085-9f88-4699-bf40-19c151f0c84a"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTM0MA_69b5e782-640a-4f3c-82ec-4f8115b30287">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the changes in IPR&amp;amp;D for the years ended December 31, 2021 and 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfMS0yLTEtMS0xMDU2Mg_3ec055f1-1968-49fb-97f2-c0b1d51208f6"
      unitRef="usd">23000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfMi0yLTEtMS0xMDU2Mg_a2a2dd72-905a-4305-a52e-7481037b9d29"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfMy0yLTEtMS0xMDU2Mg_64b5a3f7-8066-482e-a8da-20e1552168a1"
      unitRef="usd">23000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfNC0yLTEtMS0xMDU2Mg_fb62b521-65fb-46b0-972e-07583a90c3ac"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmY5Mjc5MTM0OGViMzRkZjZhMWM5YzQ1OGIwOThiODMxL3RhYmxlcmFuZ2U6ZjkyNzkxMzQ4ZWIzNGRmNmExYzljNDU4YjA5OGI4MzFfNS0yLTEtMS0xMDU2Mg_e897b667-904f-4dcd-87f7-90dd91ecefe7"
      unitRef="usd">23000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RleHRyZWdpb246NThhODQ4YWMyNDNhNDkwMGFiYjczODA1YWE1ZDg3YTlfMTMzNg_906ce590-d29b-42df-8723-92e0d6843155">&lt;div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the changes in Goodwill for the years ended December 31, 2021 and 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfMS0yLTEtMS0xMDU2Mg_5c6fc1d0-7391-4763-bf5f-a25f4c463986"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfMi0yLTEtMS0xMDU2Mg_bfc71f45-3cf9-41e0-8c3d-6c5ae1664c19"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfMy0yLTEtMS0xMDU2Mg_f38a336a-9cae-49e3-91c7-178e427c17ee"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfNC0yLTEtMS0xMDU2Mg_0a7c9217-1554-4168-9798-a436f5093006"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184NS9mcmFnOjU4YTg0OGFjMjQzYTQ5MDBhYmI3MzgwNWFhNWQ4N2E5L3RhYmxlOmI5MGY5ZGJjMjM3MzQwMTFiY2ZlZjNlMDM0YTJjZTA2L3RhYmxlcmFuZ2U6YjkwZjlkYmMyMzczNDAxMWJjZmVmM2UwMzRhMmNlMDZfNS0yLTEtMS0xMDU2Mg_43d04e3c-3836-4c6d-810a-bd8551b1bc7c"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjk3OA_765fa047-18ab-4311-a816-0ef554bde660">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company held $245.2 million in cash and cash equivalents and $237.3 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#x2019;s fair value is determined to less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in marketable securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2021 there were no realized gains or losses. For the fiscal year ended December 31, 2020, there were nominal realized gains. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized loss positions in the marketable securities as of December 31, 2021 and 2020 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $173.4 million and $124.9 million as of December 31, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMTAy_f9f155f4-49e0-411b-9589-f5bb4f50684c"
      unitRef="usd">245200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMTM4_01f57765-3f38-41e0-a866-707d20f74ac7"
      unitRef="usd">237300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjk4MA_54a81824-d20c-4589-a825-2004e607db86">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in marketable securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMi0yLTEtMS0xMDU2Mg_24d74a75-ee9e-4540-a01b-10bf1eb73b62"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMi04LTEtMS0xMDU2Mg_e364620a-1204-4fda-b811-adb54432594b"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMy0yLTEtMS0xMDU2Mg_0c1ef0bf-b2f9-458d-890a-1b40f6145c53"
      unitRef="usd">174578000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMy00LTEtMS0xMDU2Mg_d785de7f-8171-4996-b068-7184d04081fb"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMy02LTEtMS0xMDU2Mg_f50626fb-fb6e-4c12-b8bf-693f340340f1"
      unitRef="usd">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMy04LTEtMS0xMDU2Mg_f37dafc6-66ca-4347-8aaa-f7cfca11e9d4"
      unitRef="usd">174531000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i9de1351a52bd4f60a456ac8231b36fa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNC0yLTEtMS0xMDU2Mg_970712c8-d9c4-46c0-8717-01f2792dc6d4"
      unitRef="usd">32322000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i9de1351a52bd4f60a456ac8231b36fa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNC00LTEtMS0xMDU2Mg_068f8fd6-58ff-4ec3-be5b-cd54b85e73f4"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i9de1351a52bd4f60a456ac8231b36fa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNC02LTEtMS0xMDU2Mg_34157c17-6c30-4006-b26b-7157e3a6ffd6"
      unitRef="usd">11000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9de1351a52bd4f60a456ac8231b36fa1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNC04LTEtMS0xMDU2Mg_28a54fb6-7676-414c-a177-f03043f2e281"
      unitRef="usd">32311000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ie4951a0821e7472faa395694373f197f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNS0yLTEtMS0xMDU2Mg_3b774dea-7580-416f-9372-476c1aa5d898"
      unitRef="usd">30070000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ie4951a0821e7472faa395694373f197f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNS00LTEtMS0xMDU2Mg_a6f3dc32-5cdb-484e-9be4-ff49593b6d7e"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ie4951a0821e7472faa395694373f197f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNS02LTEtMS0xMDU2Mg_b1727da0-89c8-4635-a944-7b9c32e18503"
      unitRef="usd">14000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie4951a0821e7472faa395694373f197f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNS04LTEtMS0xMDU2Mg_53503166-1831-45f8-8f13-9051f69e7884"
      unitRef="usd">30056000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i24c9330e046a4e39b05065c516da655f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNy0yLTEtMS0xMDU2Mg_d7392f91-02ab-4371-8bd5-2dca52d11652"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i24c9330e046a4e39b05065c516da655f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNy00LTEtMS0xMDU2Mg_b10aa3be-37c1-4170-9609-d3d5151cf5b7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i24c9330e046a4e39b05065c516da655f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNy02LTEtMS0xMDU2Mg_cd5d6660-192f-4365-b504-60573e1e54dd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i24c9330e046a4e39b05065c516da655f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfNy04LTEtMS0xMDU2Mg_01d94dcf-ced8-42c7-ba5d-b44a16020096"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0bac4dce92ae48faa8415719eeb29418_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOC0yLTEtMS0xMDU2Mg_5f42d1ac-e91e-4976-b182-27ca7ae72451"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0bac4dce92ae48faa8415719eeb29418_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOC00LTEtMS0xMDU2Mg_016b6c1b-c506-4107-839d-eb38cdb01b92"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0bac4dce92ae48faa8415719eeb29418_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOC02LTEtMS0xMDU2Mg_714fbb23-79e9-4af8-9d31-cc91b01343b9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0bac4dce92ae48faa8415719eeb29418_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOC04LTEtMS0xMDU2Mg_8c5f3b2b-a81c-4354-a29d-2f7ac843be4e"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOS0yLTEtMS0xMDU2Mg_8d9116c2-fe69-4745-9a3e-4ca412087314"
      unitRef="usd">482568000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOS00LTEtMS0xMDU2Mg_15f6b72a-b016-4394-8de4-c8b84e6ee014"
      unitRef="usd">7000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOS02LTEtMS0xMDU2Mg_fa547f61-675e-4425-b265-3abd1a1cfad5"
      unitRef="usd">79000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfOS04LTEtMS0xMDU2Mg_4bfdac9f-69ca-47ca-be43-a43450f573b8"
      unitRef="usd">482496000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTAtMi0xLTEtMTA1NjI_cf64dccb-6cac-4b23-839d-8e4173214efb"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTAtOC0xLTEtMTA1NjI_acdd7d6e-3ca6-4752-8c2c-62120a1ed3a2"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTEtMi0xLTEtMTA1NjI_9d12d390-ed45-4b0a-a3a1-b9164a5aa4f5"
      unitRef="usd">237371000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTEtNC0xLTEtMTA1NjI_0db8d7ae-1231-4ab4-883b-6b07a09fe099"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTEtNi0xLTEtMTA1NjI_30d1f1b4-92e8-44fe-afaf-908e62ed7651"
      unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTEtOC0xLTEtMTA1NjI_8c9c35c4-e3db-4800-be7a-a5b358e1ad1c"
      unitRef="usd">237299000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTItMi0xLTEtMTA1NjI_9cb04255-7755-42c0-bccd-23bc2fdd265a"
      unitRef="usd">482568000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTItNC0xLTEtMTA1NjI_3f2a05f0-5e1e-4f06-878c-ada8b17d9790"
      unitRef="usd">7000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTItNi0xLTEtMTA1NjI_c5afc037-5a15-4dc3-b5fb-355e90166d57"
      unitRef="usd">79000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjc0MTQzNzdkNjU3NzRhZjBiZmE3YTBhNGI4ZGZkNjRhL3RhYmxlcmFuZ2U6NzQxNDM3N2Q2NTc3NGFmMGJmYTdhMGE0YjhkZmQ2NGFfMTItOC0xLTEtMTA1NjI_d8ce9780-8da0-415b-afd3-861ca8a8b97c"
      unitRef="usd">482496000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMi0yLTEtMS0xMDU2Mg_c30ab330-b7a7-49cb-a9da-9780be2c2aff"
      unitRef="usd">217087000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMi00LTEtMS0xMDU2Mg_6a08a8e5-c7fd-4511-9e2b-77b1204dac7b"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMi02LTEtMS0xMDU2Mg_469fa6c5-9e4d-4396-9222-9122a4210bf8"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMi04LTEtMS0xMDU2Mg_ec81d4f4-38af-4092-955b-50324ee66355"
      unitRef="usd">217095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMy0yLTEtMS0xMDU2Mg_c262ab9e-e98f-408e-a9d9-82198e638acf"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMy04LTEtMS0xMDU2Mg_8e9b6e1e-12ea-463b-9a69-7435ab39c15a"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNC0yLTEtMS0xMDU2Mg_3f7f7b0f-251f-4ecb-a15f-c85056ce3e12"
      unitRef="usd">53583000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNC00LTEtMS0xMDU2Mg_9f35046d-4b82-4c7a-9b46-ba335b3e8fca"
      unitRef="usd">3000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNC02LTEtMS0xMDU2Mg_2cff54b2-99b8-493b-afbb-fb8ae947707f"
      unitRef="usd">4000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNC04LTEtMS0xMDU2Mg_d933e4ac-1322-41fc-ba96-32e9bd22fd15"
      unitRef="usd">53582000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="id9989c222dbf4f51a1e18465f25d9679_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNS0yLTEtMS0xMDU2Mg_67ff605b-6d16-454a-a07e-a10bf611405d"
      unitRef="usd">39525000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="id9989c222dbf4f51a1e18465f25d9679_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNS00LTEtMS0xMDU2Mg_b98ebf55-0d8f-4cb5-9f49-08ef1d292c40"
      unitRef="usd">4000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="id9989c222dbf4f51a1e18465f25d9679_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNS02LTEtMS0xMDU2Mg_de53a5a5-2c5f-47cf-b43c-ae40e9681962"
      unitRef="usd">16000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id9989c222dbf4f51a1e18465f25d9679_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNS04LTEtMS0xMDU2Mg_7459f0dd-58fb-4270-899b-8b292e956d61"
      unitRef="usd">39513000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNi0yLTEtMS0xMDU2Mg_289bdbf3-b335-46b8-ad42-478886117863"
      unitRef="usd">9420000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNi00LTEtMS0xMDU2Mg_6e18a581-c133-4cf6-a407-c2273447ad28"
      unitRef="usd">18000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNi02LTEtMS0xMDU2Mg_2c1e3878-abff-41ec-a0e7-b517683860b4"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNi04LTEtMS0xMDU2Mg_409083ca-ffd8-490e-b41d-e77ac19db365"
      unitRef="usd">9438000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNy0yLTEtMS0xMDU2Mg_a63aa18b-6dd8-4185-9caf-ccd631457d60"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNy00LTEtMS0xMDU2Mg_186966e1-0315-48dc-b16d-b4fb3bb4a451"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNy02LTEtMS0xMDU2Mg_927ebf89-6d75-4eb7-b391-0b5d626e11b0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfNy04LTEtMS0xMDU2Mg_786b50b2-e9d4-43cf-aeb8-4dc532137b0b"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8c294134d0304a859adb3c48427afe95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOC0yLTEtMS0xMDU2Mg_7dce6af2-ac48-4845-a0c7-446926bcaf14"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8c294134d0304a859adb3c48427afe95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOC00LTEtMS0xMDU2Mg_4aa026a4-30ef-49a5-b530-8933f58c9dc5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8c294134d0304a859adb3c48427afe95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOC02LTEtMS0xMDU2Mg_b9b2ae9d-dae1-49f5-9344-1f501bfe159a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c294134d0304a859adb3c48427afe95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOC04LTEtMS0xMDU2Mg_feb1ca18-abee-4848-b004-f8a6efd48cdf"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOS0yLTEtMS0xMDU2Mg_32b2d660-f8b3-4a97-b1fb-a582523da740"
      unitRef="usd">483256000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOS00LTEtMS0xMDU2Mg_3c5b22f5-671a-42ee-b3d0-5eed4aa327db"
      unitRef="usd">39000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOS02LTEtMS0xMDU2Mg_75c619f8-a253-41e8-9c38-e9229fd3506a"
      unitRef="usd">26000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfOS04LTEtMS0xMDU2Mg_b44769ad-854f-4439-96c5-90b48780a515"
      unitRef="usd">483269000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTAtMi0xLTEtMTA1NjI_3cab3b96-238d-4206-959a-0ded1d2c5d33"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTAtOC0xLTEtMTA1NjI_90c89626-5adf-4fbc-84f3-cd4f5e9f4b23"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTEtMi0xLTEtMTA1NjI_7a5cec10-df97-4cc7-8a5c-9887a66c8f41"
      unitRef="usd">320016000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTEtNC0xLTEtMTA1NjI_b239e42f-fc11-4cd3-827e-5f9940230ecb"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTEtNi0xLTEtMTA1NjI_ca82c0e7-0853-460e-857a-5a9061e92ae6"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTEtOC0xLTEtMTA1NjI_49e5cf25-9759-4b49-8642-51eddb411e91"
      unitRef="usd">320029000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTItMi0xLTEtMTA1NjI_e1d1c12c-c1cb-412a-aac4-d637518081e8"
      unitRef="usd">483256000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTItNC0xLTEtMTA1NjI_45803ea0-2c7e-4442-9ecd-00bbc58c722b"
      unitRef="usd">39000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTItNi0xLTEtMTA1NjI_bbede4b6-6936-4bc6-90d4-2f94f8f88c71"
      unitRef="usd">26000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjY0OTVjMWUxMmE1ZTQ1Y2U4MzYyMzllNWVlZmIxNjA3L3RhYmxlcmFuZ2U6NjQ5NWMxZTEyYTVlNDVjZTgzNjIzOWU1ZWVmYjE2MDdfMTItOC0xLTEtMTA1NjI_f2cd38c3-2481-4065-82e8-8caebecde6d7"
      unitRef="usd">483269000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjA4Mw_361d3b5f-a1f9-4888-a6b9-8da692df4afb"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjE0OA_f2f706ec-186b-445b-9062-52e7caaf3849"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjY5Ng_3bb81c4a-2b7f-44ea-8ee2-ca017a776391"
      unitRef="usd">173400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjcwMw_bc1e3d8b-1bc5-4d64-b9d7-cb073bdbcf85"
      unitRef="usd">124900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RleHRyZWdpb246YWI1ZmRkMjk3Yzg4NDQ5MDgyM2VmZmJmYTBmMDIwYjhfMjk4Mw_abdd9a24-e98c-48f6-84a4-13eb2c5ab9d0">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMS0yLTEtMS0xMDU2Mg_03206182-aea3-496c-80e9-59f51fcd6ad2"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMS00LTEtMS0xMDU2Mg_d2f8b072-911d-476c-9032-c9d66ee64ee5"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMS02LTEtMS0xMDU2Mg_fc4090c1-136d-46f8-b73b-b8ac7ebec17a"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMi0yLTEtMS0xMDU2Mg_b0750c08-d5cb-4449-8f4a-4ea8a4b9b6ad"
      unitRef="usd">4259000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMi00LTEtMS0xMDU2Mg_52d99417-81f4-4c91-a4e6-115e870d0bcb"
      unitRef="usd">2922000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMi02LTEtMS0xMDU2Mg_a7963acd-3091-4a73-9e51-0128d846093a"
      unitRef="usd">3506000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMy0yLTEtMS0xMDU2Mg_808de7ed-ae92-4a2b-b305-32fd49865f28"
      unitRef="usd">249456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMy00LTEtMS0xMDU2Mg_6c4c7d59-88ff-42f6-bc6c-f85c4ca4f506"
      unitRef="usd">166162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM184OC9mcmFnOmFiNWZkZDI5N2M4ODQ0OTA4MjNlZmZiZmEwZjAyMGI4L3RhYmxlOjhmYjhkMGNiZWE2ZjQxMGY4ZTRhY2E5NjM0Zjc0NDU2L3RhYmxlcmFuZ2U6OGZiOGQwY2JlYTZmNDEwZjhlNGFjYTk2MzRmNzQ0NTZfMy02LTEtMS0xMDU2Mg_db3cff77-b044-48a8-9a6d-8dfa682cd27b"
      unitRef="usd">146343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RleHRyZWdpb246ZDE0MTA4MzQwNDA5NDdkMTliZTM4MTk0Yjg0NDAxZDBfMjg4_faa91466-2103-4a7f-bd5c-f26a9f62880f">Inventories&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of raw materials, work in process, and finished goods related to the manufacture of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The following table summarizes the components of inventories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a reserve for inventory of $1.1 million and $0.1 million as of December 31, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RleHRyZWdpb246ZDE0MTA4MzQwNDA5NDdkMTliZTM4MTk0Yjg0NDAxZDBfMjg2_3f0712b6-b8f1-4bc5-81f6-9a9c7239bf65">The following table summarizes the components of inventories: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMS0yLTEtMS0xMDU2Mg_9680a38e-b4e0-407e-b66b-2c8d93adcd4d"
      unitRef="usd">12289000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMS00LTEtMS0xMDU2Mg_80aa6284-8388-484a-91b9-a96c189b984a"
      unitRef="usd">5547000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMi0yLTEtMS0xMDU2Mg_1bda04e2-3693-4818-9a05-29d876955a24"
      unitRef="usd">10699000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMi00LTEtMS0xMDU2Mg_459ee99c-8e19-46f6-9a88-95fe946552ae"
      unitRef="usd">7693000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMy0yLTEtMS0xMDU2Mg_56ffe7e1-407b-44e5-8911-02528cf59db1"
      unitRef="usd">3830000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfMy00LTEtMS0xMDU2Mg_b681fde3-7a4a-46ee-b668-80b1a1117915"
      unitRef="usd">6316000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfNC0yLTEtMS0xMDU2Mg_9304cbf5-2988-43bb-8262-d1da24c76a87"
      unitRef="usd">26818000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RhYmxlOmFiNWRmNzUwM2ZjYTQwZDZiNWMxOTIyYzIwMzhjYjQzL3RhYmxlcmFuZ2U6YWI1ZGY3NTAzZmNhNDBkNmI1YzE5MjJjMjAzOGNiNDNfNC00LTEtMS0xMDU2Mg_35b1e5f0-7ebd-4344-9979-e392626b5b28"
      unitRef="usd">19556000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RleHRyZWdpb246ZDE0MTA4MzQwNDA5NDdkMTliZTM4MTk0Yjg0NDAxZDBfMjQ3_aba45824-6d47-4f82-8998-1e2ed7501eae"
      unitRef="usd">1100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185MS9mcmFnOmQxNDEwODM0MDQwOTQ3ZDE5YmUzODE5NGI4NDQwMWQwL3RleHRyZWdpb246ZDE0MTA4MzQwNDA5NDdkMTliZTM4MTk0Yjg0NDAxZDBfMjU0_de8f2a7b-23a2-4781-9e2e-be266aaef9f8"
      unitRef="usd">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RleHRyZWdpb246OGFjOGJjY2E2NzUxNGQzMmIwNGMwYTk1NzM3MmE5YjJfMTYw_ed4a9cef-6ec5-49f1-a5c9-f79dc4ce33c2">Property and Equipment&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $5.7 million and $8.4 million for the years ended December 31, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RleHRyZWdpb246OGFjOGJjY2E2NzUxNGQzMmIwNGMwYTk1NzM3MmE5YjJfMTY0_9c936e62-8d21-4e83-87bc-5be18ce3cb6c">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9043474a4a1d4089aaaa1c119c5ded63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMy0yLTEtMS0xMDU2Mg_ca195921-6172-4497-b4a6-5b809db8ab8b"
      unitRef="usd">24168000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i506e380918854e4287cf7b8f4aec8307_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMy00LTEtMS0xMDU2Mg_78966031-8f53-4193-acc0-ec1f989aac5f"
      unitRef="usd">24146000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i961d1290b5bb44a89495cd0f93b4d7c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNC0yLTEtMS0xMDU2Mg_5866d74a-f885-496b-8c52-30175dbbecc3"
      unitRef="usd">16663000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i16cd09ac01f449a786ec0c0e00df7434_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNC00LTEtMS0xMDU2Mg_1b4e3442-5b4f-4b56-a29f-7bc97563f52c"
      unitRef="usd">15387000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib9f1194f778c47b687d90861adf8f887_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNS0yLTEtMS0xMDU2Mg_41d9e597-b053-4d0d-bf73-b8ac46fc0b42"
      unitRef="usd">8229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i66e8c7b22d7744d49e714d729f4a3155_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNS00LTEtMS0xMDU2Mg_ce7073cf-9ad0-400b-ac0a-7689d7a6ac88"
      unitRef="usd">5870000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i18b897fa4f7e47f09f12e76a909b949f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNi0yLTEtMS0xMDU2Mg_521440c5-c393-43ef-a18a-d521e1eb03db"
      unitRef="usd">5720000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib4a56fb4793d42e9983d44923f0ea779_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNi00LTEtMS0xMDU2Mg_c9a94e73-c39e-442d-9f5a-c31619012efa"
      unitRef="usd">5546000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie154cc033bab496a99fb346732f0a456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNy0yLTEtMS0xMDU2Mg_ff6e089e-33ae-465c-9704-c2ad2be44946"
      unitRef="usd">3190000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i582c365c59c5453c936ce8bba128fd1d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfNy00LTEtMS0xMDU2Mg_2663a6ec-6037-40c0-9a62-0d8a0d99d70b"
      unitRef="usd">3190000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibe3018b481564885813a6100e4a32e2f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfOC0yLTEtMS0xMDU2Mg_9594922a-d22c-41ba-951d-f48cc7da3001"
      unitRef="usd">3163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i50bd891b09b1476badb04c23c7939da3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfOC00LTEtMS0xMDU2Mg_0981234c-fccb-4fef-8af7-bd70c7aed41e"
      unitRef="usd">2880000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc60489656e8435486f90d2cf2907e4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfOS0yLTEtMS0xMDU2Mg_f0ec6595-2f90-4432-b1ef-e6241c2e7bb4"
      unitRef="usd">1174000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i79912bf414894f7c880e3b24a7d15884_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfOS00LTEtMS0xMDU2Mg_af086139-7f7e-4d9d-b43f-0fa399064579"
      unitRef="usd">1207000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i08e5b99eaef547c5b606f006be101008_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTAtMi0xLTEtMTA1NjI_b01945b3-29e0-4cba-af0d-1ffc213886ef"
      unitRef="usd">71000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5b21949c52d343ef9e73e3897f897333_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTAtNC0xLTEtMTA1NjI_6b98ba1f-c805-4a48-bcc9-6b206720ab7e"
      unitRef="usd">124000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTEtMi0xLTEtMTA1NjI_27187a4b-dcff-42c0-ad15-6ddcdd0164ec"
      unitRef="usd">62378000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTEtNC0xLTEtMTA1NjI_534ad63f-16bc-4682-bff5-a84d5b3577be"
      unitRef="usd">58350000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTItMi0xLTEtMTA1NjI_a6a403c8-0fe5-40f3-ac7b-b6f59e4ccbaa"
      unitRef="usd">19882000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTItNC0xLTEtMTA1NjI_921e56bf-0ce5-4cb7-8738-0e771ea1fd4f"
      unitRef="usd">14487000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTMtMi0xLTEtMTA1NjI_1eb8c681-3712-459b-ba22-e81c75da9479"
      unitRef="usd">42496000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RhYmxlOmVhNDc5M2YzODA3MjQzNDE4NWM1ZDVmMmJiZjNlZmFjL3RhYmxlcmFuZ2U6ZWE0NzkzZjM4MDcyNDM0MTg1YzVkNWYyYmJmM2VmYWNfMTMtNC0xLTEtMTA1NjI_0b9d586b-d0fa-4028-9f65-969a3347c6c0"
      unitRef="usd">43863000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RleHRyZWdpb246OGFjOGJjY2E2NzUxNGQzMmIwNGMwYTk1NzM3MmE5YjJfMTA2_fce7eed7-d8ed-4e3d-8360-e365e6012803"
      unitRef="usd">5700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185NC9mcmFnOjhhYzhiY2NhNjc1MTRkMzJiMDRjMGE5NTczNzJhOWIyL3RleHRyZWdpb246OGFjOGJjY2E2NzUxNGQzMmIwNGMwYTk1NzM3MmE5YjJfMTEz_c1e2fa00-c1a1-4cfa-813b-95aa9c233fec"
      unitRef="usd">8400000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RleHRyZWdpb246ODE1ODY1YTFmYWUxNDAwMjhlM2M3MDcxZGQ3Zjk1OTNfMTMw_117aaff7-c8d6-49be-9dfc-c3f37aa3d867">Accrued Expenses and Other Current Liabilities&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contract manufacturing&#160;&amp;amp; contract research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued program fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RleHRyZWdpb246ODE1ODY1YTFmYWUxNDAwMjhlM2M3MDcxZGQ3Zjk1OTNfMTMy_ad148642-b447-42ad-9442-259017da7f7b">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contract manufacturing&#160;&amp;amp; contract research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued program fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMi0yLTEtMS0xMDU2Mg_dde9148f-f59b-486e-832f-1f1e8fe2509d"
      unitRef="usd">24258000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMi00LTEtMS0xMDU2Mg_6c0d38a8-fefb-4b58-a309-f24dc0f021b2"
      unitRef="usd">23025000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <fold:AccruedContractManufacturingAndContractResearchCostsCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMy0yLTEtMS0xMDU2Mg_1356a849-08a0-4679-9dd1-47a41f7d41e6"
      unitRef="usd">20361000</fold:AccruedContractManufacturingAndContractResearchCostsCurrent>
    <fold:AccruedContractManufacturingAndContractResearchCostsCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMy00LTEtMS0xMDU2Mg_0dd8dc4b-b8d3-4e9f-861a-e68641f88d8a"
      unitRef="usd">19617000</fold:AccruedContractManufacturingAndContractResearchCostsCurrent>
    <fold:AccruedSalesRebatesAndChargebacksCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNC0yLTEtMS0xMDU2Mg_c852dca0-54d1-43ff-8afa-ce366bd8477e"
      unitRef="usd">15989000</fold:AccruedSalesRebatesAndChargebacksCurrent>
    <fold:AccruedSalesRebatesAndChargebacksCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNC00LTEtMS0xMDU2Mg_f6bd1767-5896-4002-a123-a507e85358d3"
      unitRef="usd">12079000</fold:AccruedSalesRebatesAndChargebacksCurrent>
    <fold:AccruedProgramFees
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNS0yLTEtMS0xMDU2Mg_cddaf89e-1e37-4722-9644-e9b1a8598e44"
      unitRef="usd">13294000</fold:AccruedProgramFees>
    <fold:AccruedProgramFees
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNS00LTEtMS0xMDU2Mg_affc156e-2480-48aa-8f64-1fe3378d0597"
      unitRef="usd">16599000</fold:AccruedProgramFees>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNi0yLTEtMS0xMDU2Mg_7f45118a-3c44-4771-bb75-0c500d45c785"
      unitRef="usd">9377000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfNi00LTEtMS0xMDU2Mg_d6d74136-7124-4c74-b7e7-9cc25d7bee48"
      unitRef="usd">3700000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfOS0yLTEtMS0xMDU2Mg_259ca495-d6a6-44b9-8175-b48bf5573b5f"
      unitRef="usd">6154000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfOS00LTEtMS0xMDU2Mg_99a89314-defb-48da-ab50-c9ef4f84940b"
      unitRef="usd">11177000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTAtMi0xLTEtMTA1NjI_0290bd5c-9fea-4593-a7ef-671c9856249a"
      unitRef="usd">4522000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTAtNC0xLTEtMTA1NjI_3c7b3ff6-4956-4ad1-b704-731fcace9fa4"
      unitRef="usd">6550000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTEtMi0xLTEtMTA1NjI_3ccbccfd-01d3-45c9-96d4-c37ca31f10c4"
      unitRef="usd">4198000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTEtNC0xLTEtMTA1NjI_b3699b6c-f1e6-44b0-987b-067680d15fd1"
      unitRef="usd">4094000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTMtMi0xLTEtMTA1NjI_7ed08490-5c83-41ca-87b4-75afffd71f2c"
      unitRef="usd">98153000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM185Ny9mcmFnOjgxNTg2NWExZmFlMTQwMDI4ZTNjNzA3MWRkN2Y5NTkzL3RhYmxlOjMyYzFmMTM3YzljZTQxMGZiY2Q5MDlkYjhkYTA4OWFlL3RhYmxlcmFuZ2U6MzJjMWYxMzdjOWNlNDEwZmJjZDkwOWRiOGRhMDg5YWVfMTMtNC0xLTEtMTA1NjI_f10d8797-8f27-462d-a97a-fc6413b85182"
      unitRef="usd">96841000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQ3NjU_171dab99-d11f-425f-b0f5-7f310027765c">Stockholders' Equity&lt;div style="margin-bottom:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company was authorized to issue 500 million shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to one vote for each share held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a securities purchase agreement with certain entities, the (&#x201c;Purchase Agreements&#x201d;) for the private placement of an aggregate of 11,296,660 shares of the Company&#x2019;s common stock, at a purchase price of $10.18 per share, and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. Proceeds from the private placement, net of offering costs, were $199.8&#160;million. Each pre-funded warrant has an initial exercise price of $0.01 per share and is exercisable at any time after its original issuance, subject generally to the lock-up period, at the option of each holder, in such holder&#x2019;s discretion, by (i) payment in full in immediately available funds of the initial exercise price for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. Certain of the Purchase Agreements provide for a lock-up period of either 60 days or nine months based on the individual agreements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the first quarter of 2021, 1,294,999 and 1,260,000 warrants were exercised at $7.98 and $7.06 per share of common stock, respectively, resulting in gross cash proceeds of $19.2&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As discussed in ''&#x2014; Note 11. Debt'', during the first and third quarters of 2021, the Company entered into separate, privately negotiated exchange agreements with the holders of the Convertible Notes (the "Holders"). Under the terms of the exchange agreements, the Holders agreed to exchange the remaining aggregate principal amount of $2.8&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 472,356 shares of Company common stock, par value $0.01 per share. This transaction resulted in an increase of $2.7&#160;million and five thousand dollars to additional paid-in-capital and common stock, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As discussed in ''&#x2014; Note 11. Debt'', during the first and second quarters of 2019, the Company entered into separate, privately negotiated exchange agreements with a limited number of Holders. Under the terms of the exchange agreements, the Holders agreed to exchange an aggregate principal amount of $247.2&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 44.0&#160;million shares of Company's common stock, par value $0.01 per share. These transactions resulted in an increase of $215.0&#160;million and four hundred forty thousand dollars to additional paid-in-capital and common stock, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2019, the Company completed an underwritten equity offering and issued 18.7 million shares of its common stock at $10.75 per share, inclusive of the fully exercised option to purchase additional shares from the initial offering. This transaction resulted in net proceeds of $189.0 million, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In March 2019, 101,787 warrants were exercised at $7.98 per share of common stock resulting in gross cash proceeds of $0.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2018, the Company reached a clinical milestone, which was the dosing of the first patient in a Phase 3 study, related to the contingent consideration from the acquisition of Callidus Biopharma, Inc. ("Callidus"). The milestone for this event was $9.0 million, which was paid by issuance of 771,804 shares of Company common stock, par value $0.01 per share, in the first quarter of 2019.  This transaction resulted in an increase of $9.3&#160;million and eight thousand dollars to additional paid-in-capital and common stock, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonqualified Cash Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Deferral Plan, (the "Deferral Plan") provides certain key employees and members of the Board of Directors as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code of 1986 as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had a deferred compensation investment balance of $4.8 million and $4.1 million as of December 31, 2021 and December 31, 2020, respectively, with corresponding approximate amounts of liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferral Plan investment assets are classified as trading securities and are recorded at fair value with changes in the investments' fair value recognized in accumulate other comprehensive gain (loss) in the period they occur. Deferred compensation liability amounts under the Deferral Plan are included in other long-term liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. Under the provisions of the Plan, no option will have a term in excess of 10 years. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest 25% on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for 100% of the shares vested at any time after the date of grant. As of December 31, 2021, the Company has reserved up to 18,322,154 shares for issuance under the Plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwMQ_e7f6581c-d822-4e13-8c0b-fc3ab5482d0b"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <fold:CommonStockVotingRightsForEachShareHeld
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzM0Mw_688f2869-29a9-47f9-a654-47bebea6afe0"
      unitRef="vote">1</fold:CommonStockVotingRightsForEachShareHeld>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib4be7fadcd724e6e96874c8bdf5adad5_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwODM_bd8d7f1a-0866-43f5-8fb5-e8d137eee530"
      unitRef="shares">11296660</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwNzU_33753c57-b7a1-4fa5-915b-5132a5071ba4"
      unitRef="usdPerShare">10.18</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwMjk_12e5ba1f-81ab-40ff-bbd1-0522b6cd77bd"
      unitRef="shares">8349705</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ida79dc6999b2473ca1d1e66873b93aae_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwNjA_7e679356-0225-4ba3-8116-885755a8b294"
      unitRef="usdPerShare">10.17</us-gaap:SaleOfStockPricePerShare>
    <fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing
      contextRef="i526b094eedf24604a14d40a8149d2578_D20210901-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwOTI_7859fb1c-b64c-446b-ab05-9813eb29c151"
      unitRef="usd">199800000</fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4f7acdfb076641c09f78a07d2ad0884d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjgwNDY_9a07b43d-87da-4243-8e9a-798be7d8932f"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5d2bcc60d5354077b1fcf38386ec3c2e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjQzNzE_9a96ae43-0e97-4eb2-b3a0-8f0fcf90fdb6"
      unitRef="shares">1294999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id196c02fecfc4cba9917670db7d5c97a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzUwMDk_4c3314ad-427a-45a4-ac1e-fc75b0a5e4da"
      unitRef="shares">1260000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if6ead177e0cc4421928422190e6ada54_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjQzODI_1e102f73-ca48-4ed2-875a-1368caa9b030"
      unitRef="usdPerShare">7.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iba81fbdcb57c4b63b3261c40099c722f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzUwMzE_5df7a3c9-0d63-4e78-a104-ab0acf391633"
      unitRef="usdPerShare">7.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i9a9bcf319bae47bdbd01835594ec4441_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyOTg1MzQ4OTcyOTM_1e2e2cd7-7b58-4cfa-ae96-26f787fe5080"
      unitRef="usd">19200000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ia8b8a5ba609f4354b35e10b27be3ff0f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzU3NjQ_70b04105-6fbc-4dc4-8c5f-ce98ed6ec132"
      unitRef="usd">2800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzU3NTk_50375b84-f793-4cff-b91d-084c499b76df"
      unitRef="shares">472356</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzU3Nzc_65dde109-9348-4168-a56b-b384d76733d4"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i640ccbc1c3154c0080c449287054612e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyOTg1MzQ4OTczMDI_f99bf60a-28f9-45df-a4a7-6f246461efca"
      unitRef="usd">2700000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyOTg1MzQ4OTczNDg_e02507e4-307e-4a49-90f3-9aae7836b96a"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i10d2bc422365419a845cd1b651b3a636_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjYxODI_23b6ce7f-f5f8-4600-ad21-5528bdd5e359"
      unitRef="usd">247200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iec7f88d07a8f4a3196f84540950c1ba1_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjYxOTg_a1273226-b82b-4417-b106-4858109cbf99"
      unitRef="shares">44000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjYxNzU_8b00d149-902e-4c2d-8b12-1c60227bb92f"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i295c47ed72d64074b5f32eeaad26a5cd_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2NDE4MTY_90450925-f698-4075-9910-1ff78c21b620"
      unitRef="usd">215000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iec7f88d07a8f4a3196f84540950c1ba1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzIxOTkwMjMyNjYyNjM_7e848fd7-af46-4801-aa8a-73df6f7177ea"
      unitRef="usd">440000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1b32bb1228f4457281ae01a46fc12e65_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzU5MA_2183b1df-63f9-44e8-9012-d8263cefbb7b"
      unitRef="shares">18700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i90c6ab2b0ea94811b533075e4f2a87ff_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzYyMw_435aa4bc-b0ab-4b8a-9441-52009a76e636"
      unitRef="usdPerShare">10.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1b32bb1228f4457281ae01a46fc12e65_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzc3OQ_4e08703c-195b-433e-8e9b-4df21ebc7e92"
      unitRef="usd">189000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3c032683abb24387a73c8bc636880d41_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzg3Nw_50465457-04c3-403a-9146-48eb37d285c7"
      unitRef="shares">101787</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i74af5a78ba0e4e39b3e7266e28299ef6_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzkwNw_6300f421-98dc-4a0c-af60-6ff2c4f2cfb2"
      unitRef="usdPerShare">7.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i7f3536bcc2ae4952bcd1f4f308635ac0_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzk3Mg_977b709c-ba7d-4793-aaa1-a99d46524e76"
      unitRef="usd">800000</us-gaap:ProceedsFromWarrantExercises>
    <fold:ContingentConsiderationMilestonePayment
      contextRef="i482c3a76c4274a0e899e18ce88699cb5_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEzMjc_df9a4434-124c-48d8-93a4-26e12ef431d3"
      unitRef="usd">9000000</fold:ContingentConsiderationMilestonePayment>
    <fold:MilestonePaymentStockIssuedAsConsideration
      contextRef="i482c3a76c4274a0e899e18ce88699cb5_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzU5NDU_e23ba845-de80-4baa-97b5-a746d11c60bf"
      unitRef="usd">771804</fold:MilestonePaymentStockIssuedAsConsideration>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2MzYwMDQ_65dde109-9348-4168-a56b-b384d76733d4"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="ie7c2736e1c5f4bbdbe8ee555092181b6_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyOTg1MzQ4OTczNTk_b80490af-86fd-46c3-99a8-9cc8017d26a2"
      unitRef="usd">9300000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="i20b1ffa344ad4c46a05f2baded3c95de_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzEwOTk1MTE2NDE4MjY_7974077e-9f05-416b-b2b4-afa4af261762"
      unitRef="usd">8000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <us-gaap:TradingSecurities
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyMDY_affe5e0e-3986-4b89-96ad-ab549ceb626a"
      unitRef="usd">4800000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzMyMTM_13178e5a-da26-42d2-9b1f-e2d576322c1f"
      unitRef="usd">4100000</us-gaap:TradingSecurities>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQxODQ_e0827b78-9964-4726-81ce-1d0a9992d3f3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia0f988918ba344f883b74b4646d25fbe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQ0Nzg_3cec992d-056f-4df6-9b1a-d3a381f58c00"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQ2MjI_a978cbe7-f1af-45b3-9e28-a866b8abac1e"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4f26112489e84068b2efcf3e81829b41_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDAvZnJhZzo1NWFiYmVhM2I1YWI0ZDQ3OGIwZGZjZDcxNWEwOWM4YS90ZXh0cmVnaW9uOjU1YWJiZWEzYjVhYjRkNDc4YjBkZmNkNzE1YTA5YzhhXzQ3MjQ_8e6c85f8-ca2e-4ee1-930b-f98801544986"
      unitRef="shares">18322154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMTA_a795f554-24ae-4ada-a388-ac636dddfa4d">Share based Compensation The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors. advisors, and consultants at a price to be determined by the Company&#x2019;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#x2019;s business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plan provides for certain benefits to qualifying Plan participants who separate from service with the Company due to death, disability or "retirement" (as such term is defined under the Plan) ("Qualified Participants"). Options granted under the Plan ("Options") to a Qualified Participant shall continue to vest until the 2nd anniversary of the Qualified Participant&#x2019;s separation and all vested Options held by such Qualified Participant shall remain exercisable until the earlier of the 4th anniversary of the Qualified Participant&#x2019;s separation or the original expiration date of the Option. Options that are not exercised during this exercise period shall be forfeited. Time-based restricted stock units and restricted stock granted to a Qualified Participant under the Plan that was scheduled to vest within the two year period following the Qualified Participant's separation shall accelerate and be delivered upon such separation. Any time-based restricted stock units or restricted stock that would have vested after such two year period will be forfeited upon the Qualified Participant's separation. Also, per the Amendment, any performance-based restricted stock units under the Plan ("PRSUs") received by the Qualified Participant, shall remain eligible to vest after the Qualified Participant&#x2019;s separation based on the actual performance of the Company through the end of the performance period applicable to any such PRSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the fair value method of measuring stock-based compensation, using the fair value of each equity award granted. The Company chose the &#x2018;&#x2018;straight-line&#x2019;&#x2019; attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007. The average expected life is determined using our actual historical data. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life of options (years) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value per share of options granted during 2021, 2020, and 2019 were $9.08, $6.40, and $6.67, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's stock options for the year ended December 31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $8.5 million, $40.9 million, and $11.8 million respectively. Cash proceeds from stock options exercised during the years ended December 31, 2021, 2020, and 2019 were $10.2 million, $42.3 million, and $11.5 million, respectively. As of December 31, 2021, the total unrecognized compensation cost related to non-vested stock options granted was $28.9 million and is expected to be recognized over a weighted average period of three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the year ended December 31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2021, 1,863,436 RSUs have vested and all non-vested units are expected to vest over their normal term. As of December 31, 2021, there was $47.6 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation Expense Related to Equity Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting
      contextRef="i3bf65e4e37b3456d95b9a66cf49959fa_D20181221-20181221"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzI3NDg3NzkwNzQ3NTQ_200d4f06-6280-46e2-95a5-cfcfc162bbe3">P2Y</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting
      contextRef="i3bf65e4e37b3456d95b9a66cf49959fa_D20181221-20181221"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzI3NDg3NzkwNzQ3NTU_58c05e55-37b8-46fb-af1f-b9273ebc75a9">P2Y</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMTE_8605bc20-8425-4b9c-be5f-79f4563261e0">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life of options (years) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzItMi0xLTEtMTA1NjI_aeb35af7-e712-46da-9615-345670a7d18e"
      unitRef="number">0.654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia272441483a740d6812f2646381f7580_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzItNC0xLTEtMTA1NjI_9039c02f-b50e-4772-baf2-b8cc66141711"
      unitRef="number">0.751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzItNi0xLTEtMTA1NjI_27d2be83-61f1-44dc-a870-765eb5061f06"
      unitRef="number">0.741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzMtMi0xLTEtMTA1NjI_9e1d218c-34de-41a4-98da-a863bce3a9d6"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia272441483a740d6812f2646381f7580_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzMtNC0xLTEtMTA1NjI_aff098e9-305a-42c1-bef6-7a744c5a21d6"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzMtNi0xLTEtMTA1NjI_080aab89-ffc6-46db-94bc-1ca5a99de036"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzQtMi0xLTEtMTA1NjI_9a687b44-828e-478e-8ca9-c79d46084b8c">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia272441483a740d6812f2646381f7580_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzQtNC0xLTEtMTA1NjI_f9df2818-0178-4e7d-bad1-d37228fc9c1e">P5Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzQtNi0xLTEtMTA1NjI_fa2e9948-d1dc-4f85-9bf5-2f4da913e6b1">P5Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzUtMi0xLTEtMTA1NjI_4fc43062-95cd-4e82-967a-08d0c27ac3fc"
      unitRef="usdPerShare">0.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="ia272441483a740d6812f2646381f7580_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzUtNC0xLTEtMTA1NjI_07299ed4-c5f2-4c8d-9af8-b916ddae9d26"
      unitRef="usdPerShare">0.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="if525fb7d660d400eb829890eb1df21f4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZToxN2E3ZWY5NWU3MjU0YzQ3OGUyMGM5NjM1ODJkNzE4Mi90YWJsZXJhbmdlOjE3YTdlZjk1ZTcyNTRjNDc4ZTIwYzk2MzU4MmQ3MTgyXzUtNi0xLTEtMTA1NjI_8c17ac28-d3da-4284-a80d-86862cea7af9"
      unitRef="usdPerShare">0.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM2MDY_46e445ce-031b-466e-9faa-b7bfba9e453c"
      unitRef="usdPerShare">9.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM2MTA_48cf72b1-b4e2-4bc0-9305-1445dfc5891c"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM2MTg_9cedfc8b-6a95-4e75-ae1c-03b9b5c13622"
      unitRef="usdPerShare">6.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMDk_8f37f9d2-c4f5-44ae-b4da-bd324ed14c0e">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's stock options for the year ended December 31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id112dec781f849479a5fea1933c18841_I20181231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzItMS0xLTEtMTA1NjI_5e651ecd-3c1c-4e39-9e24-70a3dc525f0e"
      unitRef="shares">15810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id112dec781f849479a5fea1933c18841_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzItMy0xLTEtMTA1NjI_3ceab119-9877-484a-b951-d217c539e536"
      unitRef="usdPerShare">8.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzMtMS0xLTEtMTA1NjI_b4b769e1-0718-46fd-b57c-182e536ed82d"
      unitRef="shares">4091000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzMtMy0xLTEtMTA1NjI_d58d9726-23b2-4ebb-adbd-9685bdbdbfd9"
      unitRef="usdPerShare">10.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzQtMS0xLTEtMTA1NjI_eda85862-e228-4ae6-8c2f-5bc86a6b3a6f"
      unitRef="shares">1967000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzQtMy0xLTEtMTA1NjI_426afee6-edce-4acd-bb96-760f744573bc"
      unitRef="usdPerShare">5.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzUtMS0xLTEtMTA1NjI_cdc8e33d-84e0-4322-abf5-87f9f2a85808"
      unitRef="shares">879000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzUtMy0xLTEtMTA1NjI_9b1ce0f6-b369-4dfa-b57f-187d72a368b6"
      unitRef="usdPerShare">11.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzYtMS0xLTEtMTA1NjI_01d32d6b-6086-490c-98d2-4be5cbbe0e88"
      unitRef="shares">331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzYtMy0xLTEtMTA1NjI_605a25f1-0f23-442f-b7c1-43626aa73f96"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzctMS0xLTEtMTA1NjI_9831f281-4cf5-415d-abc6-a65144daea21"
      unitRef="shares">16724000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzctMy0xLTEtMTA1NjI_e807e011-3c50-4aa2-ab9a-43867082d25a"
      unitRef="usdPerShare">9.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzgtMS0xLTEtMTA1NjI_aa547438-7d25-4482-9ca0-9b792c478770"
      unitRef="shares">4362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzgtMy0xLTEtMTA1NjI_b3dcb525-642c-4e19-b27b-747d98fe0371"
      unitRef="usdPerShare">9.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzktMS0xLTEtMTA1NjI_a0b6e191-3837-4094-971e-ba529d909154"
      unitRef="shares">5243000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzktMy0xLTEtMTA1NjI_18848584-3520-4356-9e1c-03e43fe230b1"
      unitRef="usdPerShare">8.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEwLTEtMS0xLTEwNTYy_04ed8ff6-3ea1-4903-b9cb-3ba07a4c451c"
      unitRef="shares">1376000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEwLTMtMS0xLTEwNTYy_e6fb31f0-2afb-417d-b399-b77341055738"
      unitRef="usdPerShare">10.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzExLTEtMS0xLTEwNTYy_cce7c45b-c7d9-4dd8-8fb0-1e44d9d871a2"
      unitRef="shares">435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzExLTMtMS0xLTEwNTYy_c66c4490-6a7e-4e37-94d6-887a25fde5ae"
      unitRef="usdPerShare">13.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEyLTEtMS0xLTEwNTYy_e826443b-0292-4fbb-92b6-83ea5f2103e4"
      unitRef="shares">14032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEyLTMtMS0xLTEwNTYy_63bce7bf-1932-4177-9107-c77bbb25d1d3"
      unitRef="usdPerShare">9.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEzLTEtMS0xLTEwNTYy_c89c6de7-114d-42d1-86fe-9fb3d194fb42"
      unitRef="shares">3262000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzEzLTMtMS0xLTEwNTYy_1b86f45f-bf56-4192-aa9d-ebaed4947a63"
      unitRef="usdPerShare">16.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE0LTEtMS0xLTEwNTYy_4e5fe010-e4dc-4ab8-9b7c-3a4f5bb854b8"
      unitRef="shares">1483000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE0LTMtMS0xLTEwNTYy_b5fc58ef-8311-4afa-a8b0-089d0125487e"
      unitRef="usdPerShare">7.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE1LTEtMS0xLTEwNTYy_b4033652-5e85-4ea7-bc79-cb106d861543"
      unitRef="shares">844000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE1LTMtMS0xLTEwNTYy_a21fa33a-b2ef-470f-9d0e-21c4007e6d25"
      unitRef="usdPerShare">12.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE2LTEtMS0xLTEwNTYy_9cd4a5a8-bc7b-4d73-9eb7-bb0dc47a495a"
      unitRef="shares">236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE2LTMtMS0xLTEwNTYy_36bb0c8e-9d01-479e-971a-d9d9d14fd807"
      unitRef="usdPerShare">13.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE3LTEtMS0xLTEwNTYy_6339a789-c491-4c52-951e-5bb35243079e"
      unitRef="shares">14731000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE3LTMtMS0xLTEwNTYy_d8684cf3-2a77-4b96-ab3d-6561b784ed5b"
      unitRef="usdPerShare">11.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE3LTUtMS0xLTEwNTYy_2d3e18c6-66e2-4d36-aa40-d9c3da508685">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE3LTctMS0xLTEwNTYy_2a72adc8-a8ea-470d-8578-25925b9b50b9"
      unitRef="usd">30300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE4LTEtMS0xLTEwNTYy_38aadd05-8a08-43a0-b73b-235d4724c8f4"
      unitRef="shares">13432000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE4LTMtMS0xLTEwNTYy_ac94e5c2-a2bc-487c-961e-e5489a2bec16"
      unitRef="usdPerShare">10.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE4LTUtMS0xLTEwNTYy_4b0ecdff-53a6-4d33-bdc4-d39d0c0c0d71">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE4LTctMS0xLTEwNTYy_0dcf2e0e-6a2c-46ce-92c3-66719c0df60b"
      unitRef="usd">28800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE5LTEtMS0xLTEwNTYy_dfd18171-8e1b-4df3-a62b-ca1d686982ce"
      unitRef="shares">9141000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE5LTMtMS0xLTEwNTYy_cf4f2778-8ceb-442a-ad97-652ebb2e379f"
      unitRef="usdPerShare">9.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE5LTUtMS0xLTEwNTYy_2577ad32-d7da-4326-b874-3394643b833d">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowNzQ5Y2RjZjA1YWE0NGMxOTMyNDY2ZTRhZmE4OTMwNS90YWJsZXJhbmdlOjA3NDljZGNmMDVhYTQ0YzE5MzI0NjZlNGFmYTg5MzA1XzE5LTctMS0xLTEwNTYy_68a2be16-bd1f-4cc6-864c-fb4ae0b2574d"
      unitRef="usd">24500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM4MDk_e741c7c9-1389-4108-90ed-06757b4fb7db"
      unitRef="usd">8500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM4MTM_9e666315-c687-449c-ac8c-16325a758170"
      unitRef="usd">40900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM4MjE_4e3301ac-6f4f-4d94-b05d-0fa5cd60c1a1"
      unitRef="usd">11800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM5MjQ_974d083c-39ef-47e2-a44c-0281f42d1b6d"
      unitRef="usd">10200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM5Mjg_23de9ff9-c16b-45f1-9a04-cec50ea592b7"
      unitRef="usd">42300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzM5MzY_4656315a-4106-4637-89c5-d4b7df88f338"
      unitRef="usd">11500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzQwNTM_cd8e64b4-17ab-4c30-bcfe-2f18af7023f8"
      unitRef="usd">28900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if7512772b097432b956535d96e9b7951_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzQxMjM_459a4d44-729d-410d-9c2b-061d2d85e716">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMDQ_6b63f35b-acfa-4d18-b463-016c8eacb408">A summary of non-vested RSU activity under the Plan for the year ended December 31, 2021 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia576c72c43a84ff6b63f05447685167d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzItMS0xLTEtMTA1NjI_ebd6c588-df35-4dc7-bd11-57b94fa84efe"
      unitRef="shares">3712000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia576c72c43a84ff6b63f05447685167d_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzItMy0xLTEtMTA1NjI_bf422e2e-1870-455f-a71e-b95c7e5f7150"
      unitRef="usdPerShare">10.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzMtMS0xLTEtMTA1NjI_969a0691-92a5-4f04-bb86-6820d10e6351"
      unitRef="shares">3526000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzMtMy0xLTEtMTA1NjI_5c57682a-68d9-49f3-83a4-5275585faa3c"
      unitRef="usdPerShare">10.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzQtMS0xLTEtMTA1NjI_2e293e1a-5ed1-4c12-8875-46234436c581"
      unitRef="shares">921000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzQtMy0xLTEtMTA1NjI_7e1dec01-5813-4a90-a484-a9027be066c8"
      unitRef="usdPerShare">8.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzUtMS0xLTEtMTA1NjI_29a461a0-1609-4efd-bf82-f3eeb9c999e4"
      unitRef="shares">525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i19c89adb061e400eb1e0e0df72d80720_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzUtMy0xLTEtMTA1NjI_a7de2252-21f8-485c-ad41-9a7fee922110"
      unitRef="usdPerShare">10.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0ab772d198ff45af9c40e229d45fba03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzYtMS0xLTEtMTA1NjI_0365b459-49b1-47f3-ab3e-ed802193940a"
      unitRef="shares">5792000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0ab772d198ff45af9c40e229d45fba03_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzYtMy0xLTEtMTA1NjI_6478294d-72b4-455a-a632-d5c119a15da1"
      unitRef="usdPerShare">11.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzctMS0xLTEtMTA1NjI_e9deede7-3b42-4d1c-be35-4fdcc0ac7b3b"
      unitRef="shares">4692000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzctMy0xLTEtMTA1NjI_240b2934-c5ca-4233-acd7-9f1ab75ab614"
      unitRef="usdPerShare">11.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzgtMS0xLTEtMTA1NjI_6dc6d989-19bc-4ec3-abae-77eacf3f7d76"
      unitRef="shares">2164000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzgtMy0xLTEtMTA1NjI_3a93f813-8cb7-4050-ba43-7dda211ffb32"
      unitRef="usdPerShare">10.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzktMS0xLTEtMTA1NjI_3eb19cfa-8e06-45ec-a818-190b779656ed"
      unitRef="shares">1240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="idd71088d956a43acb1ecd470e99c511f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzktMy0xLTEtMTA1NjI_0bd5c6aa-4e87-44eb-ab29-f15cc0c0c3df"
      unitRef="usdPerShare">11.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i03c9e518216b4905aab06b70874e18f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEwLTEtMS0xLTEwNTYy_210c4b6e-e219-4533-be8a-fe75d119b6d7"
      unitRef="shares">7080000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i03c9e518216b4905aab06b70874e18f0_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEwLTMtMS0xLTEwNTYy_0a8786e3-b214-496e-aa09-dcbf99254a14"
      unitRef="usdPerShare">11.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzExLTEtMS0xLTEwNTYy_79c381bf-ae6f-441b-9ab4-db1d81dbd0a3"
      unitRef="shares">3191000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzExLTMtMS0xLTEwNTYy_b4e367f9-400e-47ec-92e7-d028d5d2ef72"
      unitRef="usdPerShare">16.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEyLTEtMS0xLTEwNTYy_ba4d6ead-d0d9-42ec-b337-bad7f862e0ae"
      unitRef="shares">1863000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEyLTMtMS0xLTEwNTYy_610eaf2f-6fd7-4de6-a7ce-703b22400012"
      unitRef="usdPerShare">15.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEzLTEtMS0xLTEwNTYy_54e164b2-3760-4ecc-b1f5-63838215c8da"
      unitRef="shares">1067000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzEzLTMtMS0xLTEwNTYy_05f86df2-4d90-4c46-a2c6-6d58705b5ab8"
      unitRef="usdPerShare">12.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie35de6676f38491e98b8f52cc5c3919b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzE0LTEtMS0xLTEwNTYy_a8d66cba-875d-4f13-aa01-6ef11780a494"
      unitRef="shares">7341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie35de6676f38491e98b8f52cc5c3919b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzE0LTMtMS0xLTEwNTYy_52733e02-7fdf-40f7-a0c2-fdb77377c462"
      unitRef="usdPerShare">13.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzE0LTUtMS0xLTEwNTYy_7d58712d-4781-4589-a04f-f681aa691a5e">P2Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="ie35de6676f38491e98b8f52cc5c3919b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTphMjc4YjY5MWQyNWU0YzUzYThhYmEyZjU1MjhiMGIxMS90YWJsZXJhbmdlOmEyNzhiNjkxZDI1ZTRjNTNhOGFiYTJmNTUyOGIwYjExXzE0LTctMS0xLTEwNTYy_deef1e35-b081-4d01-8de8-ff7144f98fa7"
      unitRef="usd">84800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzQ3OTk_cecb693c-59be-4ed4-8108-250e8e2a7984"
      unitRef="shares">1863436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ie35de6676f38491e98b8f52cc5c3919b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzQ5MDk_763448f5-8fc4-4c49-89a7-15c8aa3db6cf"
      unitRef="usd">47600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1efb08be4b154d9c81b15b4425216e5d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUwOTI_0476ee9a-9c9c-4f2d-b258-b4da101344a4">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90ZXh0cmVnaW9uOjBhNzVlZWI3M2RjYjQwOGE5NDA3NWY4M2U2MGE2ZGU5XzUzMTM_63ac1059-7df1-40a2-950e-2ae32f9ecbe9">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i971ea6dc71dd40bfbe43d1b72669ed21_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzMtMi0xLTEtMTA1NjI_2dbd8210-ce50-4e4b-8205-0427adb13d9b"
      unitRef="usd">17340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i056c458b470c4579b84a162e7b90dbda_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzMtNC0xLTEtMTA1NjI_690a3909-b434-4e9f-ba34-9f17b50c3df3"
      unitRef="usd">20817000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96486b3a389847dea0287bfe980e800b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzMtNi0xLTEtMTA1NjI_fa699b60-5c18-473e-b6f5-d4ed4a019390"
      unitRef="usd">17575000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i71a1701b3e114ced8682f3b8ad409f43_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzQtMi0xLTEtMTA1NjI_02c46181-f5a1-4325-a737-dd9a879381ba"
      unitRef="usd">40498000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i62afedf6cc6c4e2faa6b8366f3d4d566_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzQtNC0xLTEtMTA1NjI_72db1638-6776-4dd1-8839-dbf83616baac"
      unitRef="usd">28334000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i00d2388394104afb8de4248ba2dcc24a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzQtNi0xLTEtMTA1NjI_9129311e-724a-47b4-b386-d5403c311a59"
      unitRef="usd">26855000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzUtMi0xLTEtMTA1NjI_369b2bdd-4ff9-4cd1-9214-96ed3a86b6c2"
      unitRef="usd">57838000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzUtNC0xLTEtMTA1NjI_70e862be-e154-4b64-b1e8-f0c755c5791c"
      unitRef="usd">49151000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDYvZnJhZzowYTc1ZWViNzNkY2I0MDhhOTQwNzVmODNlNjBhNmRlOS90YWJsZTowOGZlMDM0M2E5MDQ0NGNjYTIzNjQzZGIzZjYxM2I1ZC90YWJsZXJhbmdlOjA4ZmUwMzQzYTkwNDQ0Y2NhMjM2NDNkYjNmNjEzYjVkXzUtNi0xLTEtMTA1NjI_683133c4-92ab-42fc-98fe-621b0e83c18e"
      unitRef="usd">44430000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzQ1MzA_2779f615-8ed9-4fa0-876c-8946a80a4eca">Assets and Liabilities Measured at Fair Value&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs that are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Previously, the Company's Convertible Notes fell into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. As noted in ''&#x2014; Note 11. Debt," the Convertible Notes were fully settled during the third quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets as of December 31, 2021 or December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Money Market Funds and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended December 31, 2021. No transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration payable resulted from the acquisition of Callidus. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration payable for Callidus has been classified as a Level&#160;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe disease program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75%-88%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reached regulatory milestone in September 2021 associated with FDA approval of the first BLA and in November 2021 associated with EMA validation of the MAA, both related to the contingent consideration of Callidus for the ATB-200 Pompe disease program. The satisfaction of these milestones resulted in  the collective milestone payment of $12.0 million, which was payable in cash, resulting in a decrease in the current portion of the contingent consideration liability on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2021 and December 31, 2020, respectively:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of contingent consideration  in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzQ1MjU_01ebfbd6-6b0a-41ff-a9ab-48c062adbc4f">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie54f245a14704edc868849226467c804_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzItMi0xLTEtMTA1NjI_4aa8fb2a-1e2f-403a-935a-298fd15ef721"
      unitRef="usd">174531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9e86b2f8a2ae449789640b3a74210938_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzItNC0xLTEtMTA1NjI_a0e1d06a-a726-4cdb-8c0c-635ff9b6526e"
      unitRef="usd">174531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i61c7b7702b4a40ddb250ad6a54dbfb5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzMtMi0xLTEtMTA1NjI_ade147ef-e17d-4881-90e2-ee6bbcca0702"
      unitRef="usd">32311000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia66fbce7b1254986b68bdecf5d3984a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzMtNC0xLTEtMTA1NjI_e89cf1d7-c8a6-4aed-a8aa-db7f07853d6a"
      unitRef="usd">32311000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9a5acb325e646a18e6704ab00914755_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzQtMi0xLTEtMTA1NjI_1cae2a6f-e7ff-4dbf-984b-1b65da2c92db"
      unitRef="usd">30056000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie4951a0821e7472faa395694373f197f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzQtNC0xLTEtMTA1NjI_b6a42a88-f089-4055-8fa0-0314630e0e69"
      unitRef="usd">30056000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i162893650e38441e88ef4089246a0337_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzYtMi0xLTEtMTA1NjI_eea009f8-a533-43fd-ae39-d93ee1733bb9"
      unitRef="usd">5150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i24c9330e046a4e39b05065c516da655f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzYtNC0xLTEtMTA1NjI_76f9bf4d-c7d6-4b48-9f3e-0d46ccf96ee8"
      unitRef="usd">5150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzctMi0xLTEtMTA1NjI_5141fae9-7880-4987-b6a3-c7b593e414f9"
      unitRef="usd">242048000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo2NzE2M2Y4OWY4Mzc0MzgxYjEwYmM0OGQ2OTEzM2I5Yi90YWJsZXJhbmdlOjY3MTYzZjg5ZjgzNzQzODFiMTBiYzQ4ZDY5MTMzYjliXzctNC0xLTEtMTA1NjI_bfa83d28-4e04-4479-b77d-1fabde53145b"
      unitRef="usd">242048000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzItMi0xLTEtMTA1NjI_f738c1cd-623a-45ad-a536-8827f44a66f3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i559389e21f1d4d0d9353f0f940507a03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzItNC0xLTEtMTA1NjI_67d5df85-cfe2-41a3-af26-05ae90576980"
      unitRef="usd">20339000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzItNi0xLTEtMTA1NjI_9899b803-0550-4a59-8c50-99f73b51e66b"
      unitRef="usd">20339000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzMtMi0xLTEtMTA1NjI_7c1bb98f-7777-4304-ada8-5b1748d7e41b"
      unitRef="usd">4800000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i559389e21f1d4d0d9353f0f940507a03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzMtNC0xLTEtMTA1NjI_6d3dac31-cc15-4b84-8242-44ea85f2b501"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzMtNi0xLTEtMTA1NjI_2681809c-4fa0-48bc-b019-4cc0231aba1d"
      unitRef="usd">4800000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8aa2a5c422be44dd9a7ff04791afdbd8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzQtMi0xLTEtMTA1NjI_3740a9df-7234-402e-9216-ee7e7bfca0cf"
      unitRef="usd">4800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i559389e21f1d4d0d9353f0f940507a03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzQtNC0xLTEtMTA1NjI_3e48c34d-47ff-48e0-a5a9-10dd24a5449b"
      unitRef="usd">20339000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTozNGJiYmQ4Yzk5ZDE0YjFjOTVkMTdjOTA5M2UyMTU2Yy90YWJsZXJhbmdlOjM0YmJiZDhjOTlkMTRiMWM5NWQxN2M5MDkzZTIxNTZjXzQtNi0xLTEtMTA1NjI_639e63bc-ab4d-4916-9cd6-9360635eb3d2"
      unitRef="usd">25139000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ica7968ff22354a119a411677a353c84c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzItMi0xLTEtMTA1NjI_85e2a11e-777a-46cb-ac5c-b0adc0155a54"
      unitRef="usd">217095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i63f5c7c9838040c9a3d3ee684d8fcc95_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzItNC0xLTEtMTA1NjI_07da0f57-1667-419d-b16c-3f4a4852deea"
      unitRef="usd">217095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3ddce89a114b41f59eb1562989c82baf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzMtMi0xLTEtMTA1NjI_bb4290e6-7419-4bc1-a99c-192cd07fefe7"
      unitRef="usd">53582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14c5f015a2dc493e8dcfbfb5da2df56a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzMtNC0xLTEtMTA1NjI_0daf4830-af21-49f0-8d61-241b3b06adde"
      unitRef="usd">53582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia17c20a9953e4a9cafbd1c6bf678b365_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzQtMi0xLTEtMTA1NjI_ea8ce179-6dd8-44fe-92bb-96b40b9211c6"
      unitRef="usd">39513000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7fa6cf6f33a74c329c64fa2645338266_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzQtNC0xLTEtMTA1NjI_4bb6635d-d074-4398-abdf-6bcd2c63b691"
      unitRef="usd">39513000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0e5b1225df74406a3b71f72661e0aa3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzUtMi0xLTEtMTA1NjI_8d54b321-75f3-4ef5-af02-a765ea114cd5"
      unitRef="usd">9438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie7e38ad14c31431785e6db6a05f5ca2e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzUtNC0xLTEtMTA1NjI_4c8a46fb-d77e-414e-bc36-ddbfa942f063"
      unitRef="usd">9438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i209e1f50b3fd43be91783671c328accb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzYtMi0xLTEtMTA1NjI_80deeb21-4723-4c6d-9714-b0ff897ab019"
      unitRef="usd">4427000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i790f73964a7348a8861ffaa0cd855ce6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzYtNC0xLTEtMTA1NjI_38cc0d06-4b4d-4fff-80bf-a8ff94901a2d"
      unitRef="usd">4427000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i66d2efb30f714078b268efed578feb16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzctMi0xLTEtMTA1NjI_185289d7-03c6-46ff-ad22-88fcf17169e8"
      unitRef="usd">324055000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTo4YjBkOGM5YTcwNjk0ODY5OWFhMWQzNmZmYzkzZDJjOC90YWJsZXJhbmdlOjhiMGQ4YzlhNzA2OTQ4Njk5YWExZDM2ZmZjOTNkMmM4XzctNC0xLTEtMTA1NjI_b36de926-9bd7-4a4f-93d1-1acf9d2bbc7e"
      unitRef="usd">324055000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i66d2efb30f714078b268efed578feb16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzItMi0xLTEtMTA1NjI_66d2db84-7960-4601-9820-b528d852d380"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6e0e4ee9e39849208ef9727b7981c2e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzItNC0xLTEtMTA1NjI_b75df211-00a0-4ac2-8126-557946d07447"
      unitRef="usd">25825000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzItNi0xLTEtMTA1NjI_693372ce-1903-4ec3-a837-96682f329b21"
      unitRef="usd">25825000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i66d2efb30f714078b268efed578feb16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzMtMi0xLTEtMTA1NjI_4a6ade36-0057-4c56-8b85-112cb19fe905"
      unitRef="usd">4078000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i6e0e4ee9e39849208ef9727b7981c2e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzMtNC0xLTEtMTA1NjI_b6180548-7d63-4edb-914c-f7d7596cf41f"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzMtNi0xLTEtMTA1NjI_a1491866-5792-4f43-beef-9b784607e50e"
      unitRef="usd">4078000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i66d2efb30f714078b268efed578feb16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzQtMi0xLTEtMTA1NjI_663bbc1d-9f60-487a-b935-f16cc7ea8aaf"
      unitRef="usd">4078000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6e0e4ee9e39849208ef9727b7981c2e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzQtNC0xLTEtMTA1NjI_ee285f96-52cb-406c-8bf8-e91df6940d43"
      unitRef="usd">25825000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTplY2NmNmM3ZGQ1NzY0ZGU2YjNjMjM0ZjA2MTczMzM4ZC90YWJsZXJhbmdlOmVjY2Y2YzdkZDU3NjRkZTZiM2MyMzRmMDYxNzMzMzhkXzQtNi0xLTEtMTA1NjI_cbdf1feb-1ddb-422a-8070-d50c15add130"
      unitRef="usd">29903000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzQ1MjY_725379c6-9221-41bd-a389-baa7571216cb">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe disease program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75%-88%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="i48fbd33b6e4d4c73ac985cc9959e7635_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZToyMmZlOWUwYmFiNjE0NDc5YjY1MzA4YmNmMmQzY2E5MC90YWJsZXJhbmdlOjIyZmU5ZTBiYWI2MTQ0NzliNjUzMDhiY2YyZDNjYTkwXzItOC0xLTEtMTA1NjI_1e042542-d081-4b07-89a9-e69cbbbdec29"
      unitRef="number">0.075</fold:ContingentConsiderationMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib485fdd881d140c3ade6dc51f9633b29_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZToyMmZlOWUwYmFiNjE0NDc5YjY1MzA4YmNmMmQzY2E5MC90YWJsZXJhbmdlOjIyZmU5ZTBiYWI2MTQ0NzliNjUzMDhiY2YyZDNjYTkwXzMtMi0xLTEtMTA1NjI_182608c4-70cd-4ab5-afdb-48891498980c"
      unitRef="usd">18883000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="ic6966889240c4972b480adb57c32195c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZToyMmZlOWUwYmFiNjE0NDc5YjY1MzA4YmNmMmQzY2E5MC90YWJsZXJhbmdlOjIyZmU5ZTBiYWI2MTQ0NzliNjUzMDhiY2YyZDNjYTkwXzMtOC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjpiNzhjOWUyOWU0MzA0ZjFmYTYwZTFhNDMzNGEyODFlNF80_f06f3d10-58ac-4afc-bc41-222f4f2b6aaf"
      unitRef="number">0.75</fold:ContingentConsiderationMeasurementInput>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="i20e3e42521364090aa637b816999865a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZToyMmZlOWUwYmFiNjE0NDc5YjY1MzA4YmNmMmQzY2E5MC90YWJsZXJhbmdlOjIyZmU5ZTBiYWI2MTQ0NzliNjUzMDhiY2YyZDNjYTkwXzMtOC0xLTEtMTA1NjIvdGV4dHJlZ2lvbjpiNzhjOWUyOWU0MzA0ZjFmYTYwZTFhNDMzNGEyODFlNF83_5e3b763d-d78f-44e3-ae37-f465ff60c448"
      unitRef="number">0.88</fold:ContingentConsiderationMeasurementInput>
    <fold:ContingentConsiderationPaidInStockAdjustment
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzMyOTg1MzQ4OTAzNzA_df4c1d59-22d9-4748-bc81-85daf7fa0cec"
      unitRef="usd">12000000</fold:ContingentConsiderationPaidInStockAdjustment>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90ZXh0cmVnaW9uOjM1ZmZkMmExZjY0NzQ4ZWRhMGRkMWE3ZDcxN2Y1MjQyXzQ1MjM_b07586e8-15e3-498e-bd87-4bc03a1c69cf">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2021 and December 31, 2020, respectively:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of contingent consideration  in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzItMi0xLTEtMTA1NjI_4c515590-425f-41f7-82bc-84e7266c23a2"
      unitRef="usd">25825000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ife0397e8e64147d183a31226e47071e0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzItNC0xLTEtMTA1NjI_5f0fbf94-09d0-478a-8667-9e0d0e030162"
      unitRef="usd">22681000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzMtMi0xLTEtMTA1NjI_39df2e1c-7b8d-4a54-9a40-b5a577208987"
      unitRef="usd">-6514000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzMtNC0xLTEtMTA1NjI_4d5258f4-6700-43f7-97d5-d6f3e02c6d8b"
      unitRef="usd">-3144000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <fold:ContingentConsiderationPaidInStockAdjustment
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzQtMi0xLTEtMTA1NjI_df4c1d59-22d9-4748-bc81-85daf7fa0cec"
      unitRef="usd">12000000</fold:ContingentConsiderationPaidInStockAdjustment>
    <fold:ContingentConsiderationPaidInStockAdjustment
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzQtNC0xLTEtMTA1NjI_e96a4e0e-c7f9-4d85-97fa-2f07747cecd9"
      unitRef="usd">0</fold:ContingentConsiderationPaidInStockAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzUtMi0xLTEtMTA1NjI_d478f9fa-fd98-4b83-a9c1-cf953efc189d"
      unitRef="usd">20339000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMDkvZnJhZzozNWZmZDJhMWY2NDc0OGVkYTBkZDFhN2Q3MTdmNTI0Mi90YWJsZTpjMDliOWViMzEzM2I0NDMyOWE1Mzg2YWU1ZmZhYjRmNy90YWJsZXJhbmdlOmMwOWI5ZWIzMTMzYjQ0MzI5YTUzODZhZTVmZmFiNGY3XzUtNC0xLTEtMTA1NjI_975f0cae-05ef-40a9-948d-2a02d52efdb1"
      unitRef="usd">25825000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMzE3_1caef82f-16b8-468b-a20f-21a428a5b82b">Debt &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Term Loan due 2026:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of the Senior Secured Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Convertible Notes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of the Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net carrying value of Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Secured Term Loan due 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a definitive agreement for a $400&#160;million credit facility with Hayfin Capital Management (&#x201c;Senior Secured Term Loan due 2026&#x201d;) with an interest rate equal to 3-month LIBOR, subject to a 1% floor, plus 6.5% per annum and requires interest-only payments until mid-2024. The Senior Secured Term Loan due 2026 will be repaid in nine quarterly payments of $44.4&#160;million, starting on July 2024 with the final balance due on the maturity date in July 2026. This transaction resulted in net proceeds of $385.9&#160;million, after deducting fees and expenses. There were no warrants or equity conversion features associated with the Senior Secured Term Loan due 2026. The Company used the proceeds to voluntarily settle the Senior Secured Term Loan with BioPharma Credit PLC, which included the $150&#160;million principal, $1.1&#160;million accrued interest, and $5.2&#160;million in early settlement premiums. As a result of this early extinguishment, the Company recognized a loss on extinguishment of debt of $7.3&#160;million in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Term Loan due 2026 is subject to mandatory prepayment provisions that require prepayment upon a change of control, the incurrence of certain additional indebtedness, asset sale, or an event of loss, subject to certain conditions set forth in the Senior Secured Term Loan due 2026. The Company may prepay the Senior Secured Term Loan due 2026 in whole, at its option at any time. Any prepayment of the Senior Secured Term Loan due 2026 is subject to certain make-whole premiums and prepayment premiums, the latter of which decrease until the fourth anniversary of the transaction date at which point no prepayment penalty shall exist. The obligations under the Senior Secured Term Loan due 2026 are secured by a first lien security interest in certain assets of the Company. The Senior Secured Term Loan due 2026 contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company. The Senior Secured Term Loan due 2026 also contains a minimum liquidity covenant of $75&#160;million, and an incremental minimum consolidated revenue covenant, measured as of the previous four consecutive fiscal quarters. The minimum consolidated revenue covenant ranges from $140&#160;million, beginning March 31, 2021, and peaks at $225&#160;million by June 30, 2023, continuing at that level until the Senior Secured Term Loan due 2026 is repaid. If an event of default occurs and is continuing, Hayfin Capital Management may declare all amounts outstanding under the Senior Secured Term Loan due 2026 to be immediately due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company issued at par value $250 million aggregate principal amount of Convertible Notes, which included the exercise in full of the $25 million over-allotment option granted to the initial purchasers of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act (the "Note Offering"). Interest was payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes would mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Convertible Notes were convertible at the option of the Holders, under certain circumstances and during certain periods, into cash, shares of the Company&#x2019;s common stock or a combination thereof. The net proceeds from the Note Offering were $243.0 million, after deducting fees and expenses. In addition, the Company used approximately $13.5 million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The Convertible Notes were initially convertible into approximately 40.8 million shares of the Company&#x2019;s common stock under certain circumstances prior to maturity at a conversion rate of 163.3987 shares per $1,000 principal amount of Convertible Notes, which represented a conversion price of approximately $6.12 per share of common stock, subject to adjustment under certain conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the first and second quarters of 2019, the Company entered into separate, privately negotiated Exchange Agreements with a limited number of Holders. Under the terms of the Exchange Agreements, the limited number of Holders agreed to exchange an aggregate principal amount of $247.2&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 44.0&#160;million shares of Company common stock, par value $0.01 per share. In addition, pursuant to the Exchange Agreements, the Company made aggregate cash payments of $1.3&#160;million to the limited number of Holders to satisfy accrued and unpaid interest to the closing date of the transactions, along with cash in lieu of fractional shares. These transactions resulted in $215.0&#160;million in additional paid-in-capital and common stock of $0.4&#160;million on the Consolidated Balance Sheets as of December 31, 2019. Additionally, the Company recognized a loss on the exchange of debt of $40.6&#160;million on the Consolidated Statements of Operations during the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first and second quarter of 2019, the Company terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for proceeds of $19.9 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first and third quarters of 2021, the Company entered into separate, privately negotiated exchange agreements with a limited number of Holders. Under the terms of the Exchange Agreements, the Holders agreed to exchange the remaining aggregate principal amount of $2.8&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 472,356 shares of Company common stock, par value $0.01 per share. This transaction resulted in $2.7&#160;million in additional paid-in-capital and common stock of five thousand dollars on the Consolidated Balance Sheets as of December 31, 2021. Additionally, the Company recognized a net loss from extinguishment of debt of $0.3&#160;million in the Consolidated Statements of Operations for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2021 and 2020 respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except interest rate amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate of the liability component, Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate of the liability component, Senior Secured Term Loan due 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMzE5_1c853ec4-92e3-4425-b53a-caa73bb24ed7">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Term Loan due 2026:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of the Senior Secured Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Convertible Notes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of the Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net carrying value of Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9b67daeb3434490faa14ce758326fde1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzItMi0xLTEtMTA1NjI_152be20f-7fd0-4cb0-a80c-b4f29c73316b"
      unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzItNC0xLTEtMTA1NjI_6406e99b-9c7d-40b4-b22c-3d147368bc24"
      unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i9b67daeb3434490faa14ce758326fde1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzMtMi0xLTEtMTA1NjI_076ecbdf-d68c-48fe-b16e-76bcfaa34fbb"
      unitRef="usd">6074000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzMtNC0xLTEtMTA1NjI_86eea45a-4d7e-4385-bda6-8e347ca8a389"
      unitRef="usd">7434000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="i9b67daeb3434490faa14ce758326fde1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzQtMi0xLTEtMTA1NjI_2a4f299e-0fd2-4b0f-93fd-1ea51f628691"
      unitRef="usd">4569000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzQtNC0xLTEtMTA1NjI_c8cfaedd-2b27-44fc-9cd3-664a785d8559"
      unitRef="usd">5592000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LongTermDebt
      contextRef="i9b67daeb3434490faa14ce758326fde1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzUtMi0xLTEtMTA1NjI_8cd428a7-5d4a-447b-91e4-a95e9cd8b024"
      unitRef="usd">389357000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1f73d2d59ed04b02bb69a476bb4890b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzUtNC0xLTEtMTA1NjI_9ccf4f22-3b74-405f-b3a8-36d44de5304c"
      unitRef="usd">386974000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE0LTItMS0xLTEwNTYy_570bf20c-ddcd-40f6-8199-fe0d58328799"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE0LTQtMS0xLTEwNTYy_b81b2dfc-40ac-4434-90d3-3479a18e05f3"
      unitRef="usd">2825000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE1LTItMS0xLTEwNTYy_60f956c9-63df-4901-8bda-fb57867e9df2"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE1LTQtMS0xLTEwNTYy_bcf5eb17-5114-45b0-b731-3cc4f90f0a49"
      unitRef="usd">518000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE2LTItMS0xLTEwNTYy_24c3be61-aeef-46df-af55-65746360fe24"
      unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE2LTQtMS0xLTEwNTYy_2b279b05-4e1a-405f-88c3-863aabd0dba3"
      unitRef="usd">27000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LongTermDebt
      contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE3LTItMS0xLTEwNTYy_fceb5ba5-dce2-494e-b5a8-e4fe58848453"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE3LTQtMS0xLTEwNTYy_38c94c40-971d-4b8f-9400-6a5a51173d4c"
      unitRef="usd">2280000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE5LTItMS0xLTEwNTYy_811be4b7-8971-4329-9603-977b8df5429b"
      unitRef="usd">389357000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpjZWJlY2Y5ZWU3YmU0NzBiOWU1MTdmNzAwYWU3YjE0ZS90YWJsZXJhbmdlOmNlYmVjZjllZTdiZTQ3MGI5ZTUxN2Y3MDBhZTdiMTRlXzE5LTQtMS0xLTEwNTYy_26744b1c-0ee0-47fe-80a4-a951fb537d35"
      unitRef="usd">389254000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie69b50b330c64830b70c78bcaaeb37d6_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzg1Mw_5335be1c-6d06-4392-993b-28b719e1fa26"
      unitRef="usd">400000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <fold:DebtInstrumentVariableRate
      contextRef="i33fc42c9674f4e879bc61864ba60a261_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMDA_23001580-4443-4d0a-9327-195a9f0e7a6e"
      unitRef="number">0.01</fold:DebtInstrumentVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i33fc42c9674f4e879bc61864ba60a261_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMTU_503854cd-4324-4d25-ac2a-f677076a89fc"
      unitRef="number">0.065</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <fold:DebtInstrumentPeriodicPaymentNumberOfPayments
      contextRef="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzExMzY_a8118734-cdf2-4bd3-b7bc-57838f739a23"
      unitRef="day">9</fold:DebtInstrumentPeriodicPaymentNumberOfPayments>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzExNjE_e01e49d4-d8fc-40a0-be2f-009cbb4262f0"
      unitRef="usd">44400000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ProceedsFromSecuredLinesOfCredit
      contextRef="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEyOTQ_cb6acf94-cda0-4766-a547-39a2c96c395b"
      unitRef="usd">385900000</us-gaap:ProceedsFromSecuredLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib3f9db4f690745eda3163dd56d581246_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY2MzU_23949d5e-f2d3-4f19-bb11-1bb1f2736f5f"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:InterestExpenseDebt
      contextRef="i7c3d9dd50f724a0da7d1eefc3d5f135e_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY2NDk_491c111c-d408-436c-a3ce-0163dbda9dd4"
      unitRef="usd">1100000</us-gaap:InterestExpenseDebt>
    <fold:EarlySettlementPremiums
      contextRef="i7c3d9dd50f724a0da7d1eefc3d5f135e_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY2NjM_4d2b5af9-730e-48d2-912b-c48c61864934"
      unitRef="usd">5200000</fold:EarlySettlementPremiums>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7c3d9dd50f724a0da7d1eefc3d5f135e_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY2Nzc_295d6db4-af35-4e79-8f79-2dd84b8d9ca4"
      unitRef="usd">-7300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <fold:DebtInstrumentLiquidityCovenantMinimumAmount
      contextRef="i9ff50a38d4dc417980d4fb03579e497e_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI2Njc_f5d30453-86f2-4043-85f6-f154a5f97aa6"
      unitRef="usd">75000000</fold:DebtInstrumentLiquidityCovenantMinimumAmount>
    <fold:DebtInstrumentConsolidatedRevenueCovenantAmount
      contextRef="i7600524d0cbe42d4b2f4532af786aeb3_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI4NDU_e5c35e8f-b975-4ef7-80a4-bcf2f848bb61"
      unitRef="usd">140000000</fold:DebtInstrumentConsolidatedRevenueCovenantAmount>
    <fold:DebtInstrumentConsolidatedRevenueCovenantAmount
      contextRef="ice065bd0045f4f5f9e31f898f0f63b1f_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI4ODg_bfb7c08b-2a4e-4505-bd58-8be4f59237f3"
      unitRef="usd">225000000</fold:DebtInstrumentConsolidatedRevenueCovenantAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3cdaaf76680246429703216e122dbd6c_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzQ4MTg_7ce93222-9667-4305-ad5c-f5e96cbb8f83"
      unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9778c3d9e7be42298274edd0168bd81d_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzQ5MTM_163a7e6b-a7a2-432d-b1e2-2ffc5be32886"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i98061b690c584def995fd5b3650941ec_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzU2NDg_b5ce1ae9-8195-4766-8778-e0bd6686d140"
      unitRef="usd">243000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <fold:PremiumsPaidForCappedCallConfirmations
      contextRef="i98061b690c584def995fd5b3650941ec_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzU3MzE_550682cc-a31e-4046-ad54-4c90e4e2eb29"
      unitRef="usd">13500000</fold:PremiumsPaidForCappedCallConfirmations>
    <fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt
      contextRef="i98061b690c584def995fd5b3650941ec_D20161201-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzYyMDE_15a6da9e-40dd-4d7a-8286-1ba2c6c02899"
      unitRef="shares">40800000</fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i3cdaaf76680246429703216e122dbd6c_I20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzY0MjQ_37b1643f-db9e-41a2-94de-a2c677408422"
      unitRef="usdPerShare">6.12</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount
      contextRef="ie195a0454be34ff68a307be34a84c86c_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzkxNzQ_5f4f4db1-d8c2-42fb-b03a-6f17ec00873b"
      unitRef="usd">247200000</fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance
      contextRef="ie195a0454be34ff68a307be34a84c86c_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzkyNTc_6e2782af-dd95-444d-bbef-1c9498d7f704"
      unitRef="shares">44000000</fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie195a0454be34ff68a307be34a84c86c_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzkzMDI_3dd232e3-6475-4e03-9502-7cba05ec9a8a"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest
      contextRef="ib94c7a79d6b04897ba7c2cd123307880_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzk0MTA_40b8f669-25fd-46d4-be00-4b73fc31a878"
      unitRef="usd">1300000</fold:DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i49b24aa516c24be2963d03b2a2fe67c4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzk2MDM_9fa1179e-49fe-4a45-be87-250ba7334bcc"
      unitRef="usd">215000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <fold:GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued
      contextRef="iacb244f94b724eb4939e9350be861b33_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzk2NTY_1a498bc1-ce96-4009-b459-7f7ec6927eff"
      unitRef="usd">400000</fold:GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued>
    <fold:GainLossOnExchangeOfDebt
      contextRef="iacb244f94b724eb4939e9350be861b33_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1Xzk3OTA_601ef007-54ac-422e-a4d7-4234a32c63a8"
      unitRef="usd">-40600000</fold:GainLossOnExchangeOfDebt>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="ib94c7a79d6b04897ba7c2cd123307880_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMTU5_67c12c6d-ce07-410d-a90a-6ceaca3346c8"
      unitRef="usd">19900000</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ia8b8a5ba609f4354b35e10b27be3ff0f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwOTk1MTE2Mzk1Nzg_32ff7061-4f66-47b9-80b2-b0e8e9b6735d"
      unitRef="usd">2800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwOTk1MTE2Mzk1NjE_50375b84-f793-4cff-b91d-084c499b76df"
      unitRef="shares">472356</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwOTk1MTE2Mzk1NzE_ff7d750c-e52a-4a45-9aef-5d410890bcc8"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i640ccbc1c3154c0080c449287054612e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwOTk1MTE2NDUxMTI_f99bf60a-28f9-45df-a4a7-6f246461efca"
      unitRef="usd">2700000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id5fec3b9ca114cb2975129f4586e4a62_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzI3NDg3NzkwODY3ODg_96e848cc-598e-44bb-b273-c44fc057d5b1"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzMyOTg1MzQ5MDA1ODI_0c3bb682-d97e-4a85-b5e9-acaf55a662a2"
      unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90ZXh0cmVnaW9uOjVkZmMyYmVmYTA4MjQ4MjliNGQyMDRhNzg1MWU3OGY1XzEwMzEz_05313dc3-1062-4b52-9871-66f7f029dde2">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2021 and 2020 respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except interest rate amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate of the liability component, Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate of the liability component, Senior Secured Term Loan due 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzEtMi0xLTEtMTA1NjI_f2e867c6-4361-4e42-9628-fdc8ba42fa29"
      unitRef="usd">30473000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ic8c034a30ff14ec285bf6a0f3a25e67a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzEtNC0xLTEtMTA1NjI_29f10b2b-d915-4543-82f5-43de8a263682"
      unitRef="usd">20933000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzItMi0xLTEtMTA1NjI_cbf7dfb1-64c0-4038-b326-2b7ed0c3f0ea"
      unitRef="usd">1462000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ic8c034a30ff14ec285bf6a0f3a25e67a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzItNC0xLTEtMTA1NjI_9f4c9675-d869-48f8-b980-5425ebc22a38"
      unitRef="usd">1267000</us-gaap:AmortizationOfDebtDiscountPremium>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzMtMi0xLTEtMTA1NjI_b8ec88f0-34ec-43ad-adb6-10b408628d75"
      unitRef="usd">1028000</fold:AmortizationDeferredFinancingCosts>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="ic8c034a30ff14ec285bf6a0f3a25e67a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzMtNC0xLTEtMTA1NjI_4fafe5f0-cc06-4892-b350-3c9dfc0543c0"
      unitRef="usd">527000</fold:AmortizationDeferredFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i60f0d8017f8c4882ac0cfc325b3ea26e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzQtMi0xLTEtMTA1NjI_5d9a0a6e-9f91-4607-a222-a65e55482947"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8216eb3ec03f429fae6e1e74d98807b9_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzQtNC0xLTEtMTA1NjI_b789b263-250e-4191-9acd-178404219ddd"
      unitRef="number">0.106</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie25229baab7b448a94693d9550e33f9e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzUtMi0xLTEtMTA1NjI_ed6d179b-ddf2-48e4-9e2a-00c1b48a6cea"
      unitRef="number">0.084</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i110a74da32da49fd9b6d03056e710aca_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTIvZnJhZzo1ZGZjMmJlZmEwODI0ODI5YjRkMjA0YTc4NTFlNzhmNS90YWJsZTpkNDhhM2FlYmU1ZjM0OWUwOTZkNTU5YjQ4Zjg2MjIzYS90YWJsZXJhbmdlOmQ0OGEzYWViZTVmMzQ5ZTA5NmQ1NTliNDhmODYyMjNhXzUtNC0xLTEtMTA1NjI_3e586d9f-7400-4731-91ca-16ba79620193"
      unitRef="number">0.084</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzExNTI_29ed5cef-4787-4620-a1d0-659f6db1cca2">Leases&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has operating leases for office and research laboratory space, equipment, and vehicles under agreements expiring at various dates through 2044, which include renewal options on leases which the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2021, and 2020, operating lease expense was $10.0 million and $11.1&#160;million and variable lease expense was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.1&#160;million and $1.8 million, respectively.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For the years ended December 31, 2021, and 2020, the Company paid $8.4 million and $9.6&#160;million, respectively, for amounts included in the measurement of operating lease liabilities and recorded $0.3 million and $1.7&#160;million, respectively, of&#160;right-of-use assets and $0.3 million and $0.5&#160;million, respectively, of tenant improvements paid through lease incentives in exchange for new operating lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commitments under finance leases are not significant for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except year and discount rate amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of the operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of the operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease terms (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, the future minimum operating lease payments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company has an additional operating lease for office space that has not yet commenced, with minimum lease payments of $15.1 million.  This operating lease commenced during the first quarter of 2022 with a lease term of ten years.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzM0MQ_a2d9a9db-adb6-4e8f-9e7d-0c606dc8c805"
      unitRef="usd">10000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzM0OA_53902f2c-9925-439d-9422-ccbb9d127a1d"
      unitRef="usd">11100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzEwOTk1MTE2MzAyMTQ_9de0666e-053d-4819-8414-bf3248a75c76"
      unitRef="usd">2100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzEwOTk1MTE2MzAyMjI_ef248c19-a0ec-49cb-bede-466564c81825"
      unitRef="usd">1800000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzQxNw_55ecf719-0446-4d9e-8656-20c488327709"
      unitRef="usd">8400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzQyNA_04a835c5-16f7-48ed-95e4-c6c0dc589d63"
      unitRef="usd">9600000</us-gaap:OperatingLeaseCost>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzUyNg_41b77d7f-abdd-4893-8575-17685b61a75e"
      unitRef="usd">300000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzUzMw_7cd964e9-08bd-4bea-979c-7f67af4a89aa"
      unitRef="usd">1700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzU3OA_12a41509-b666-4c7f-929b-020f45fa8ac8"
      unitRef="usd">300000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzU4NQ_f257d36b-ef37-4d32-a7bf-f099a9d33c2f"
      unitRef="usd">500000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzExNDg_f9829233-1c22-45e7-9d1a-7a432677660c">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except year and discount rate amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of the operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of the operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease terms (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzEtMi0xLTEtMTA1NjI_4f3f5a32-b48e-4a4b-9182-32ef2f52c0bd"
      unitRef="usd">20586000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzEtNC0xLTEtMTA1NjI_7810b2a3-0825-425b-901f-e372067842ab"
      unitRef="usd">23296000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzMtMi0xLTEtMTA1NjI_52c50cbf-421f-4f20-9f36-2acc8126f724"
      unitRef="usd">7409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzMtNC0xLTEtMTA1NjI_d739b03f-ef1e-4962-bc7c-ec8bb843742c"
      unitRef="usd">6872000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzQtMi0xLTEtMTA1NjI_e653d119-ac9d-43b7-b94e-cc35cd12d26d"
      unitRef="usd">43363000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzQtNC0xLTEtMTA1NjI_654ddea3-2c75-4578-87df-77665ed07c31"
      unitRef="usd">45604000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzUtMi0xLTEtMTA1NjI_2724b7ff-d188-4f5c-be6c-b8023c1c1cbb"
      unitRef="usd">50772000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzUtNC0xLTEtMTA1NjI_e85f1cf0-f09d-4fc8-b253-126e32d45d1e"
      unitRef="usd">52476000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzctMi0xLTEtMTA1NjI_08c008b5-0536-44ab-b2c9-9ede11bcec20">P19Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzctNC0xLTEtMTA1NjI_98cf3ea8-3562-4498-8a34-f146d0092f59">P19Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzgtMi0xLTEtMTA1NjI_fb66270a-835e-4dd1-9ec2-2cb43c4b5c1b"
      unitRef="number">0.131</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTpmYjE4YmM0MzEwNDE0ZDFkYTg3MjBiYmU2ZjM4MjAwMi90YWJsZXJhbmdlOmZiMThiYzQzMTA0MTRkMWRhODcyMGJiZTZmMzgyMDAyXzgtNC0xLTEtMTA1NjI_84ca0293-6876-4a6f-be7d-7a324288bdd0"
      unitRef="number">0.130</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzExNDc_b4ec8ddb-9f21-4017-bc98-667bd11d54d9">&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, the future minimum operating lease payments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzEtMi0xLTEtMTA1NjI_fd7eece1-db57-4b99-b42f-24bc7b052c6b"
      unitRef="usd">8514000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzItMi0xLTEtMTA1NjI_2978ca9f-106a-46d4-ab79-57b73cad5040"
      unitRef="usd">8622000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzMtMi0xLTEtMTA1NjI_6b5cc704-7568-4749-93d5-60f57a7ef2be"
      unitRef="usd">8347000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzQtMi0xLTEtMTA1NjI_10396213-b154-4acc-9b42-59550b0aba53"
      unitRef="usd">8304000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzUtMi0xLTEtMTA1NjI_243adc5a-e4ac-4f1a-8506-c28550909c2f"
      unitRef="usd">8454000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzYtMi0xLTEtMTA1NjI_3df4e656-abe3-4bfa-b7eb-0976bd093710"
      unitRef="usd">145948000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzctMi0xLTEtMTA1NjI_29355d60-fbc2-44ab-bc2c-15266ed8f46b"
      unitRef="usd">188189000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <fold:LesseeOperatingLeaseLiabilityTenantIncentives
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzgtMi0xLTEtMTA1NjI_96753417-b105-43de-92e0-4354436d7bb7"
      unitRef="usd">28939000</fold:LesseeOperatingLeaseLiabilityTenantIncentives>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzktMi0xLTEtMTA1NjI_663ff462-54d1-4bcc-810d-eb2a547acb27"
      unitRef="usd">108478000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90YWJsZTo3ZWI4Y2I2MmY2YzQ0ZGRjYWU1NmUxNzhkNjczMjJiMC90YWJsZXJhbmdlOjdlYjhjYjYyZjZjNDRkZGNhZTU2ZTE3OGQ2NzMyMmIwXzEwLTItMS0xLTEwNTYy_94256e15-50ce-41f8-8477-3cf7dde309db"
      unitRef="usd">50772000</us-gaap:OperatingLeaseLiability>
    <fold:LesseeOperatingLeaseLeaseNotYetCommencedLiability
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzEwOTk1MTE2Mjk2OTg_b92bd0cf-2a41-4096-9c88-5019e01ae564"
      unitRef="usd">15100000</fold:LesseeOperatingLeaseLeaseNotYetCommencedLiability>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMTgvZnJhZzo2ZDc1ZWQ4OGRkODU0MTE0YTgwN2IyM2U0MTU4ODNkYS90ZXh0cmVnaW9uOjZkNzVlZDg4ZGQ4NTQxMTRhODA3YjIzZTQxNTg4M2RhXzI3NDg3NzkwNzIwNzY_b9622ffe-6e5e-41cf-8ac3-bd2d48077d67">P10Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzQ5OTY_c82e1e4b-f53d-4f51-bedb-d0ed26e3480f">Income Taxes&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial reporting purposes, income (loss) before income taxes includes the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393,955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following were the components of income tax expense (benefit) for the years ended December 31, 2021, 2020, and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2021, 2020, and 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible debt conversion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Tax Act also introduced an additional U.S. tax on certain non-U.S. subsidiaries&#x2019; earnings which are considered to be Global Intangible Low Taxed Income (referred to as "GILTI"). After consideration of the relevant guidance and completing the accounting for the tax effects of the Tax Act, the Company has elected to treat GILTI as a period cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded income tax expense of $8.9 million in 2021 for taxes in foreign jurisdictions. Due to the loss position and full valuation allowance, there is nominal tax expense in  2021 for taxes in U.S. federal and state jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had minimal interest or penalties related to UK corporate taxes during the period ended  December 31, 2021 and did not accrue for any interest or penalties as of December 31, 2021. The Company had a nominal accrual for uncertain tax positions as of  December 31, 2021. Tax returns for years 2016 through 2020 are open to examination by tax authorities. The Company is also subject to examination in any period for which it has net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization/depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash stock issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest carry forward limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advanced R&amp;amp;D payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2021 and 2020, the Company recorded valuation allowances of $581.8 million and $528.9 million, respectively, representing an increase in the valuation allowance of $52.9 million in 2021, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;amp;D that may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company had federal and state net operating loss carry forwards ("NOLs") of approximately $1,292 million and $1,000 million, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the 2017 Tax Act.&#160;Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through 2021 will expire in 2029 through 2040. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. The Company may experience ownership changes in the future as a result of shifts in the stock ownership some of which are outside the Company's control. The Company completed a detailed study of the NOLs and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on the Company's ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently decrease the amount of state attributes and increase state taxes owed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has research and experimentation and orphan drug credit carryforwards of approximately $30.3 million and $165.2 million, respectively, which will expire in the years 2021 through 2040. Deferred tax assets for these carryforwards are subject to a full valuation allowance.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzUwMDY_5c478a1b-383a-48de-9d8c-95b1987030ce">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial reporting purposes, income (loss) before income taxes includes the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393,955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzItMi0xLTEtMTA1NjI_21d57f84-18b4-4553-9a9f-5b9295ce7f9a"
      unitRef="usd">-333571000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzItNC0xLTEtMTA1NjI_aa208732-a271-46cc-b5b4-4631ad582964"
      unitRef="usd">-365332000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzItNi0xLTEtMTA1NjI_181ab1b2-f3b9-44d9-82bc-b6ca8780e6f8"
      unitRef="usd">-393955000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzMtMi0xLTEtMTA1NjI_ab32a698-cc05-4a3e-8f93-38a6012e52bb"
      unitRef="usd">92017000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzMtNC0xLTEtMTA1NjI_fdc6229e-e7de-4a7c-adde-590fc074e503"
      unitRef="usd">91078000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzMtNi0xLTEtMTA1NjI_f7bc2c3c-2140-4536-819e-e66b4bc225ff"
      unitRef="usd">38045000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzQtMi0xLTEtMTA1NjI_683a0587-0b38-4acb-a0cb-b3aa44d3e749"
      unitRef="usd">-241554000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzQtNC0xLTEtMTA1NjI_fd8de9e7-5392-47c2-b63d-8ac3620222d8"
      unitRef="usd">-274254000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo1YjE3OGU4NzA4OWM0OGRhYTMxZDVjNjEzMjA5YWQ3YS90YWJsZXJhbmdlOjViMTc4ZTg3MDg5YzQ4ZGFhMzFkNWM2MTMyMDlhZDdhXzQtNi0xLTEtMTA1NjI_255a0780-3cb2-4d38-a043-0535b5017349"
      unitRef="usd">-355910000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzUwMDk_0f607c6d-3eba-4ab0-8cde-9b7da7a825e4">&lt;div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following were the components of income tax expense (benefit) for the years ended December 31, 2021, 2020, and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzItMi0xLTEtMTA1NjI_1747b65f-4b47-43b1-b54b-e70767439f10"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzItNC0xLTEtMTA1NjI_69b6cc73-cec1-47be-83f5-229438a45bea"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzItNi0xLTEtMTA1NjI_cc5b7b37-bfb5-4be9-8939-48f5d9c57838"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzMtMi0xLTEtMTA1NjI_8af884d7-09e5-49fc-885c-52167a1b48cc"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzMtNC0xLTEtMTA1NjI_21a1c93b-c941-49b3-b3b4-33cdf8976bec"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzMtNi0xLTEtMTA1NjI_7b7c568f-ba6f-478e-b299-098a8de99331"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzQtMi0xLTEtMTA1NjI_d11151ce-9b29-4b1a-9957-e8e847af5235"
      unitRef="usd">8857000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzQtNC0xLTEtMTA1NjI_93497493-d828-44b0-af57-623b8f0f166e"
      unitRef="usd">4163000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzQtNi0xLTEtMTA1NjI_8ed0ebd9-8fb4-4247-b418-4debbe994b93"
      unitRef="usd">2877000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzYtMi0xLTEtMTA1NjI_968e6464-c932-4549-9fec-3a09cfc02a54"
      unitRef="usd">15000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzYtNC0xLTEtMTA1NjI_f3225341-26ec-4363-897d-e4ff99760792"
      unitRef="usd">-1410000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzYtNi0xLTEtMTA1NjI_c21d9c3e-00b4-4560-a43f-a8442eb7a32b"
      unitRef="usd">-984000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzctMi0xLTEtMTA1NjI_60690a0f-d76c-42e0-a85d-2153f4ee3025"
      unitRef="usd">34000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzctNC0xLTEtMTA1NjI_556b1fc9-5904-494c-af16-f6e87dff9418"
      unitRef="usd">-155000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzctNi0xLTEtMTA1NjI_7bbad955-27f2-4ffd-b376-a11d665ed5a4"
      unitRef="usd">-1415000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzgtMi0xLTEtMTA1NjI_eedb7145-830e-47bc-892c-ed149f617693"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzgtNC0xLTEtMTA1NjI_412a1dd7-9b1d-42c4-bc4b-0027a7ed8fae"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzgtNi0xLTEtMTA1NjI_f7a9e566-10f4-41e2-8032-15fec5c2746c"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzktMi0xLTEtMTA1NjI_730dc6f5-c7c6-41d6-994b-9b53141bea2c"
      unitRef="usd">8906000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzktNC0xLTEtMTA1NjI_2e83eb06-95c9-4376-9b55-15beaaf495f0"
      unitRef="usd">2598000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTowZWI1MTYwNTc4YTQ0NzBjOGNhNDMwOGJkMGM2MmQyMC90YWJsZXJhbmdlOjBlYjUxNjA1NzhhNDQ3MGM4Y2E0MzA4YmQwYzYyZDIwXzktNi0xLTEtMTA1NjI_223a662f-39a1-44c1-84fb-55a5b7a81f70"
      unitRef="usd">478000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzQ5OTk_7fe434b8-f133-401d-a533-351d1e977dfd">&lt;div style="margin-bottom:12pt;margin-top:20pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2021, 2020, and 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible debt conversion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzItMi0xLTEtMTA1NjI_dba07ad3-f150-4c66-8e3d-cfb76e36278a"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzItNC0xLTEtMTA1NjI_c5127792-ef02-4b35-b16a-9d32b9b2b14f"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzItNi0xLTEtMTA1NjI_2ac93d11-2b2f-440a-be04-9ee54a29dbf1"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzMtMi0xLTEtMTA1NjI_e688025b-7a40-4765-9253-aded42fc9ad4"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzMtNC0xLTEtMTA1NjI_f5bd2b1f-89fd-4e42-86ea-73465571e4b6"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzMtNi0xLTEtMTA1NjI_5e64b4c7-b845-4c7b-a46e-411012976b57"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzQtMi0xLTEtMTA1NjI_1a34146a-0833-49a3-ac41-ae44d0fb8e32"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzQtNC0xLTEtMTA1NjI_018de4b2-5b22-44a8-8bb8-8182a80a71dc"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzQtNi0xLTEtMTA1NjI_f6881cce-107d-47ba-a743-d1ff876d4a29"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzUtMi0xLTEtMTA1NjI_c2a603f9-92a1-4618-9c05-ed0692faf2dc"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration>
    <fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzUtNC0xLTEtMTA1NjI_6dda0275-763a-4d62-aa60-a75a91e80f87"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration>
    <fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzUtNi0xLTEtMTA1NjI_bc55cd00-6fd2-4761-a331-017e41b0a152"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzYtMi0xLTEtMTA1NjI_383c4d9e-4804-4629-b26b-2e1cc3805f55"
      unitRef="number">-0.09</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzYtNC0xLTEtMTA1NjI_b23fedd9-3367-4628-8e13-7fe31599ed91"
      unitRef="number">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzYtNi0xLTEtMTA1NjI_ffff1bc1-b67d-425c-923c-0f53803761de"
      unitRef="number">-0.16</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzctMi0xLTEtMTA1NjI_b83eec86-ebdc-4941-9db0-7519c409d39a"
      unitRef="number">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzctNC0xLTEtMTA1NjI_3f9a7515-7a2f-469f-bdfd-b0d3020a128f"
      unitRef="number">-0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzctNi0xLTEtMTA1NjI_330b6c3d-87f6-4aa9-b0e8-ab69586004f3"
      unitRef="number">-0.09</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzgtMi0xLTEtMTA1NjI_6f4330df-44fb-42e0-a46b-2ec8ca094651"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzgtNC0xLTEtMTA1NjI_f24e4c6b-4768-4d9d-a941-50f50a2e912e"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzgtNi0xLTEtMTA1NjI_0ba5100a-8546-4d1c-b15e-303bafe31ae6"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzktMi0xLTEtMTA1NjI_25cfa47a-a27a-4b0e-b752-d9a805f9892f"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion>
    <fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzktNC0xLTEtMTA1NjI_e4dc2f60-1f2c-428c-b6ad-796e5846d2c5"
      unitRef="number">0</fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion>
    <fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzktNi0xLTEtMTA1NjI_5178f5d0-ce5b-49a5-bd56-289b77099fd0"
      unitRef="number">0.01</fold:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEwLTItMS0xLTEwNTYy_e743c89e-12c0-4f51-b52e-8d85455512ed"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEwLTQtMS0xLTEwNTYy_7e9a3469-2dcd-4ba6-a6f1-61415c1636b4"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEwLTYtMS0xLTEwNTYy_7d1515b4-c592-47ba-ac3e-6b1910f3ebc0"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzExLTItMS0xLTEwNTYy_74ae4a3f-3d11-42f3-9d13-ae9cb72b2ccb"
      unitRef="number">-0.28</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzExLTQtMS0xLTEwNTYy_8b6f201c-6ac7-4c68-842f-49d6d810a268"
      unitRef="number">-0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzExLTYtMS0xLTEwNTYy_b6dfffb8-dfc3-4077-8e65-6b675fef90c6"
      unitRef="number">-0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEyLTItMS0xLTEwNTYy_ac39e366-d858-47ff-8102-7ab6b11e8eb5"
      unitRef="number">-0.04</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEyLTQtMS0xLTEwNTYy_e2b76090-f521-48cd-bcd0-12a54020ef79"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo4Y2E3ODZmYWZjNTk0OWExYTViOWU2ODhkZWQ0ZGM0MC90YWJsZXJhbmdlOjhjYTc4NmZhZmM1OTQ5YTFhNWI5ZTY4OGRlZDRkYzQwXzEyLTYtMS0xLTEwNTYy_e49ca9cc-e895-42c5-9255-6b365aec7628"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia902df35c10346d3815341846f96d4a9_D20171222-20171222"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzU1OQ_15a86e38-e778-4b55-b981-2de94e3baae6"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzExMDU_23dca4ff-f265-4444-b6e0-807f95ed62f4"
      unitRef="usd">8900000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzEzMzY_1549b89d-1ca9-4498-88c9-65f84c991bc9"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzUwMDM_9088fb20-9d4c-4263-95ab-d87e9066ddfe">The significant components of the deferred tax assets and liabilities are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization/depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash stock issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest carry forward limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advanced R&amp;amp;D payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <fold:DeferredTaxAssetsIntellectualProperty
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzMtMi0xLTEtMTA1NjI_6ef01ea7-0476-4b31-8db8-6bc6c9a39606"
      unitRef="usd">105453000</fold:DeferredTaxAssetsIntellectualProperty>
    <fold:DeferredTaxAssetsIntellectualProperty
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzMtNC0xLTEtMTA1NjI_4dcbcd62-ee4f-4043-9475-ac356847b384"
      unitRef="usd">68209000</fold:DeferredTaxAssetsIntellectualProperty>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzQtMi0xLTEtMTA1NjI_950e70ce-dc1b-4360-b6a4-44d3e1ab3e7f"
      unitRef="usd">277000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzQtNC0xLTEtMTA1NjI_df0c7d8d-1961-49e6-82dc-c31e7bc45d8d"
      unitRef="usd">489000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzUtMi0xLTEtMTA1NjI_e1d642cc-316e-4312-9b61-8e5d93ef514d"
      unitRef="usd">205095000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzUtNC0xLTEtMTA1NjI_84d4c6b3-e039-4963-a251-6808aa26101f"
      unitRef="usd">182651000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzYtMi0xLTEtMTA1NjI_f42f6ac4-923d-4212-b3c4-2f0248c521db"
      unitRef="usd">334762000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzYtNC0xLTEtMTA1NjI_a76890b5-bfae-4109-996f-ff1db0fd006b"
      unitRef="usd">305876000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzctMi0xLTEtMTA1NjI_fb8676c9-d8ab-4821-a81f-5f8e650aa0ac"
      unitRef="usd">1587000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzctNC0xLTEtMTA1NjI_85a596da-4373-4d29-bf98-5d005ab40a5c"
      unitRef="usd">1912000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <fold:DeferredTaxAssetsNonCashStockIssueNonCurrent
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzgtMi0xLTEtMTA1NjI_40f2fdd2-1473-4301-bd78-9f7ae9045830"
      unitRef="usd">11779000</fold:DeferredTaxAssetsNonCashStockIssueNonCurrent>
    <fold:DeferredTaxAssetsNonCashStockIssueNonCurrent
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzgtNC0xLTEtMTA1NjI_117df6d4-99db-4e2c-9243-1203f4554f50"
      unitRef="usd">17553000</fold:DeferredTaxAssetsNonCashStockIssueNonCurrent>
    <fold:DeferredTaxAssetsInterestCarryforwardLimitation
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzktMi0xLTEtMTA1NjI_f907c882-9eae-4514-81e6-9c8fd287ce20"
      unitRef="usd">8285000</fold:DeferredTaxAssetsInterestCarryforwardLimitation>
    <fold:DeferredTaxAssetsInterestCarryforwardLimitation
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzktNC0xLTEtMTA1NjI_7d396299-035c-44da-8f7c-4a0588ad48bf"
      unitRef="usd">5655000</fold:DeferredTaxAssetsInterestCarryforwardLimitation>
    <fold:DeferredTaxAssetsLeasingArrangements
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzEwLTItMS0xLTEwNTYy_a64bbc27-8c7e-419c-87b4-4312c8adbe39"
      unitRef="usd">9105000</fold:DeferredTaxAssetsLeasingArrangements>
    <fold:DeferredTaxAssetsLeasingArrangements
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzEwLTQtMS0xLTEwNTYy_f3f1bdf5-36a1-426f-9bca-8872135a0aec"
      unitRef="usd">9235000</fold:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzExLTItMS0xLTEwNTYy_b1d2372d-f0bd-4a74-8985-0ba4284f7cc7"
      unitRef="usd">15884000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzExLTQtMS0xLTEwNTYy_30f895d6-0ec9-4860-8681-2ce2af42521c"
      unitRef="usd">10855000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzEyLTItMS0xLTEwNTYy_82190673-5604-46d3-9150-ea9db9fd8dd6"
      unitRef="usd">692227000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzEyLTQtMS0xLTEwNTYy_f5783f4e-ca80-4dc1-ab27-53c1f8d6a9b9"
      unitRef="usd">602435000</us-gaap:DeferredTaxAssetsGross>
    <fold:DeferredTaxLiabilitiesBusinessAcquisition
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE0LTItMS0xLTEwNTYy_1b8bf22d-1119-4c33-8d07-0a524ef480d9"
      unitRef="usd">4930000</fold:DeferredTaxLiabilitiesBusinessAcquisition>
    <fold:DeferredTaxLiabilitiesBusinessAcquisition
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE0LTQtMS0xLTEwNTYy_cfbb2f6e-3545-4c52-b8f7-c74406d700fd"
      unitRef="usd">4937000</fold:DeferredTaxLiabilitiesBusinessAcquisition>
    <fold:DeferredTaxLiabilitiesRoyaltyPayable
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE1LTItMS0xLTEwNTYy_014d0f35-96f7-4bc3-9c65-6e07feba8d01"
      unitRef="usd">105453000</fold:DeferredTaxLiabilitiesRoyaltyPayable>
    <fold:DeferredTaxLiabilitiesRoyaltyPayable
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE1LTQtMS0xLTEwNTYy_f7f3453d-8ae1-42ff-9eb0-2f80758e8af7"
      unitRef="usd">68209000</fold:DeferredTaxLiabilitiesRoyaltyPayable>
    <fold:DeferredTaxLiabilitiesConvertibleNotes
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE2LTItMS0xLTEwNTYy_9714a2b4-e88c-44d4-9a3c-6e6e4152c1fb"
      unitRef="usd">0</fold:DeferredTaxLiabilitiesConvertibleNotes>
    <fold:DeferredTaxLiabilitiesConvertibleNotes
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE2LTQtMS0xLTEwNTYy_cfba82fb-eb13-4d77-a859-857904d4cb91"
      unitRef="usd">94000</fold:DeferredTaxLiabilitiesConvertibleNotes>
    <fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE3LTItMS0xLTEwNTYy_b55134c4-8b78-42f6-b1eb-da6fcb5d3f92"
      unitRef="usd">1802000</fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments>
    <fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE3LTQtMS0xLTEwNTYy_f07a11ac-bfa0-4b73-a9c9-fc7d10079b0e"
      unitRef="usd">1776000</fold:DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE4LTItMS0xLTEwNTYy_68a48ab3-c75f-484a-9e22-ba8a4dfc7b5a"
      unitRef="usd">3130000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE4LTQtMS0xLTEwNTYy_78d23f54-3964-4f48-9782-ae25503f30ff"
      unitRef="usd">3420000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <fold:DeferredTaxAssetsLiabilitiesGross
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE5LTItMS0xLTEwNTYy_a285c1c4-90ac-4679-af1a-bbc3c5c6115a"
      unitRef="usd">576912000</fold:DeferredTaxAssetsLiabilitiesGross>
    <fold:DeferredTaxAssetsLiabilitiesGross
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzE5LTQtMS0xLTEwNTYy_93be33fc-31ab-4520-87fb-56ca7cbf88a4"
      unitRef="usd">523999000</fold:DeferredTaxAssetsLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzIwLTItMS0xLTEwNTYy_35e509d6-f82e-4360-85eb-8ac50e667939"
      unitRef="usd">581842000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzIwLTQtMS0xLTEwNTYy_712a1eb1-a7d4-468a-8e17-97310378b39a"
      unitRef="usd">528895000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzIxLTItMS0xLTEwNTYy_efc86d98-27e4-4a20-88f4-098abb256fc9"
      unitRef="usd">4930000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90YWJsZTo2ZjJjMmM5ODFlZTE0MzQwODU5ZGQxZWYwMWQwZjJkNi90YWJsZXJhbmdlOjZmMmMyYzk4MWVlMTQzNDA4NTlkZDFlZjAxZDBmMmQ2XzIxLTQtMS0xLTEwNTYy_e38dd389-3ed2-42bf-8c22-7aa15c042663"
      unitRef="usd">4896000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iecb1de42def1452da99c0b437348ff0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzIxNDc_a5c3b1b0-e1b2-41eb-82ff-f3c04bb93b94"
      unitRef="usd">581800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i65709436b74a491bb3674af00ed88b22_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzIxNTQ_cc985447-0355-4b27-8927-fa119c6a3d36"
      unitRef="usd">528900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzIyMjc_9606e5de-8ff0-4538-bd4c-054cf095cdb3"
      unitRef="usd">-52900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id37d238be9634e70925be89cb7453666_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzI5MTU_45d6b3ef-377c-4ff6-b5e1-62d75f7d08d7"
      unitRef="usd">1292000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ifd581809cdbc4334985e5a98f01fe250_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzI5MjI_a1bad3a4-3c9e-4e7c-8300-b30c1f411f0c"
      unitRef="usd">1000000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ie3afe69e33524b46a12ea4a1d4d0b740_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzQ4MzY_9ce09dfd-a835-43f2-bf53-eb0f15deff52"
      unitRef="usd">30300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="iee21a641b74a48e686ea400e8e04484c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjEvZnJhZzoyMzQzNjE0ZjYwZjg0ZGFhODQ4NDlkODdkNDA2MWU2Mi90ZXh0cmVnaW9uOjIzNDM2MTRmNjBmODRkYWE4NDg0OWQ4N2Q0MDYxZTYyXzQ4NDM_215eb801-22ff-4fba-af4b-d8b35f5988d7"
      unitRef="usd">165200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI3NjE_2938a659-543e-44ac-b744-22b6a48b43b2">Collaborative Agreements&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;University of Pennsylvania&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, as amended, the Company entered into a collaboration agreement with the University of Pennsylvania ("Penn") to pursue research and development of novel gene therapies. The Company's gene therapy portfolio pipeline expanded to include Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), ceroid lipofuscinosis, neuronal ("CLN1"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of other rare diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $88.0&#160;million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country- by-country basis. The Company will provide $10.0 million each year during the five-year agreement to fund the discovery research program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GlaxoSmithKline&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2012, as amended in November 2013, the Company entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as a monotherapy and in combination with ERT for Fabry disease (&#x201c;Collaboration Agreement&#x201d;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent milestone payments due to GSK are recorded within the short term and long term deferred reimbursements accounts on the Consolidated Balance Sheets. Sales based tiered royalties due to GSK are recorded within the cost of goods sold within the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2021, under the GSK collaboration agreements, the Company paid $1.5 million in sales-based milestones and the Company incurred approximately $25.4 million of royalty expenses. As of December 31, 2021, $7.4 million was recorded as deferred reimbursements and the Company recognized a liability of $4.5 million related to royalties payable to GSK in accounts payable and accrued expenses in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication
      contextRef="i322b8d6caffd45d09d34af4c5317a66d_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzEwOTQ_b872b6b4-34e1-4609-a38e-4d2ed01ea6e2"
      unitRef="usd">88000000</fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication>
    <fold:CollaborationAgreementAnnualContributionByCompany
      contextRef="i322b8d6caffd45d09d34af4c5317a66d_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzEyNzI_19c7878c-a57b-4443-ba3a-530d39e1e455"
      unitRef="usd">10000000</fold:CollaborationAgreementAnnualContributionByCompany>
    <fold:CollaborativeAgreementTermOfAgreement
      contextRef="ie02d2bc95ee4441cafb8448b58435d04_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI3NDg3NzkwODA1MDY_bc3ba75a-ac74-45f3-909a-76e267864f32">P5Y</fold:CollaborativeAgreementTermOfAgreement>
    <fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments
      contextRef="i812c13b023674c2a8bf3fe358c45cc8e_I20131130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzE5OTc_c244206f-00d7-4659-9aa7-68c4fda62d17"
      unitRef="usd">40000000</fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments>
    <fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones
      contextRef="ice787d3f9d9b45d5ac985f96cbc7cab8_D20131101-20131130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzIwNDk_4a422318-fe15-4e85-a892-f8b1a4710099"
      unitRef="market">8</fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones>
    <fold:PaymentsForCollaborativeArrangement
      contextRef="ib092d444dccf4d32aa8a33c7b683e7f0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI0NjA_563bf2f6-37e3-4f39-95aa-cb64a02b8740"
      unitRef="usd">1500000</fold:PaymentsForCollaborativeArrangement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86b66068ec6445888b7a4f287f32fe7c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI1Mjg_fd4dd098-7208-4b17-b3d3-ec49cd0684c2"
      unitRef="usd">25400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="ice1a09fdb4bb4d548e2ccf3315079cb4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI1NjI_6db669da-42d1-48ff-8044-24754d67e24b"
      unitRef="usd">7400000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ice1a09fdb4bb4d548e2ccf3315079cb4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjQvZnJhZzplYmE1YjMyMGEzMTI0OWE2Yjk0MGZlZDdjN2EzNTdjMy90ZXh0cmVnaW9uOmViYTViMzIwYTMxMjQ5YTZiOTQwZmVkN2M3YTM1N2MzXzI2NDc_64a31649-c437-4b23-8ecd-0ff2b6dbd1a2"
      unitRef="usd">4500000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90ZXh0cmVnaW9uOmQ4MDc1NjRhOTMxMTRhMDE4YTkzMTQxNTI2Y2MwYjQ3XzcxOQ_548ece3c-5e84-45ba-97da-0fa9291dbe70">Basic and Diluted Net Loss per Common Share&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,421,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,867,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,421,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90ZXh0cmVnaW9uOmQ4MDc1NjRhOTMxMTRhMDE4YTkzMTQxNTI2Y2MwYjQ3XzcyMQ_04bd3a3d-e817-4f0b-b554-f4b02fbd359a">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,421,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,867,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,421,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzMtMi0xLTEtMTA1NjI_68d22838-7a4f-454a-8139-d2a31155fc27"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzMtNC0xLTEtMTA1NjI_17690ddd-de4c-43b5-a4d0-0313253436b5"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzMtNi0xLTEtMTA1NjI_2d2dbac9-4dbe-4149-8d27-41216b61e3dd"
      unitRef="usd">-356388000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtMi0xLTEtMTA1NjI_9862d1cf-8584-4dc7-921a-9a22cfbf270c"
      unitRef="shares">271421986</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtMi0xLTEtMTA1NjI_b091edd9-efb0-4745-a3cc-3761fffb705e"
      unitRef="shares">271421986</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtNC0xLTEtMTA1NjI_1d58ebc3-2039-410b-8df5-802c4e628712"
      unitRef="shares">258867380</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtNC0xLTEtMTA1NjI_fe186b35-e1e5-4a0e-a9bb-d18c1301807a"
      unitRef="shares">258867380</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtNi0xLTEtMTA1NjI_a87a84f8-6678-4735-8088-5d3dc40ed6cf"
      unitRef="shares">240421001</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo2MmQ2ZDMwOGU0Mzk0NWI4ODczMTg4M2U0Mjc5YjAxZi90YWJsZXJhbmdlOjYyZDZkMzA4ZTQzOTQ1Yjg4NzMxODgzZTQyNzliMDFmXzUtNi0xLTEtMTA1NjI_fe17d8ef-d79f-44cc-b67e-23e055b8de85"
      unitRef="shares">240421001</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90ZXh0cmVnaW9uOmQ4MDc1NjRhOTMxMTRhMDE4YTkzMTQxNTI2Y2MwYjQ3XzcyNA_30d59e84-92fd-429e-ade2-f943d84b34ac">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie569617484754b05a11d764873af2392_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzItMi0xLTEtMTA1NjI_36ce5cb3-8730-4117-85a9-b57be9b4e405"
      unitRef="shares">14731000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2fd1ccf9f8ab4f1c93b7b88a953bacde_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzItNC0xLTEtMTA1NjI_b63a48ec-051d-48b4-bd58-f2311fb416ad"
      unitRef="shares">14032000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i17b033bab30245779ca01d44c1085c54_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzItNi0xLTEtMTA1NjI_8f6cc605-cd79-4b27-8ed3-e293f6e2a583"
      unitRef="shares">16724000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0bf1bdab05104ab9b9570bc2365d7aba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzMtMi0xLTEtMTA1NjI_f1f0329b-9786-43d8-94f0-0f56eabc050b"
      unitRef="shares">7341000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib7c7aceb760548b4b27547de88d2a4c7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzMtNC0xLTEtMTA1NjI_456c8153-4f00-448a-99e2-69138243f0cd"
      unitRef="shares">7080000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i13e30b656f4141acbe98c23e31bd8683_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzMtNi0xLTEtMTA1NjI_75a4793f-5fcd-4674-9962-d148dfe5c6de"
      unitRef="shares">5792000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8dc30a51972343fbbfeeb2ead881ceef_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzQtMi0xLTEtMTA1NjI_dccd52a3-0801-4932-a8d2-5f92ed39051c"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i65d605eafe9c435eabdcab7621bec3fa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzQtNC0xLTEtMTA1NjI_4837d6a3-675e-4c4b-8ee9-af9cc10c7458"
      unitRef="shares">2555000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie53bbf1d49be45c8b6aeb0307b4fcf08_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzQtNi0xLTEtMTA1NjI_da6e5fa8-06d1-40be-8d7e-0f870d3bceda"
      unitRef="shares">2555000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7e11e6d8d67c45cb824db13d53516217_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzUtMi0xLTEtMTA1NjI_2488a93f-d4fe-49ff-a755-00366380039d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i953f7cedc14842d1ba60adb562f671c4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzUtNC0xLTEtMTA1NjI_cc84ec24-a22a-4fad-a605-b8b95fec78e9"
      unitRef="shares">462000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i63e57c6c2cd049289478bad341710825_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzUtNi0xLTEtMTA1NjI_2d5e8406-c756-4dbe-86dd-13e9d1896b2e"
      unitRef="shares">462000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzYtMi0xLTEtMTA1NjI_4e682518-7bdb-4713-86b4-9a6e5258a43c"
      unitRef="shares">22072000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ief381047c66a4ef7ab0134ec97fab725_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzYtNC0xLTEtMTA1NjI_3ac15066-8fdc-4e52-afb1-426b18a7923f"
      unitRef="shares">24129000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0ce704fda5ac44789cd02eaba0830efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xMjcvZnJhZzpkODA3NTY0YTkzMTE0YTAxOGE5MzE0MTUyNmNjMGI0Ny90YWJsZTo3OWRiZWU3ZGE4Y2U0ZTg5YmZmNWY3OTY0NGQwNDI5ZS90YWJsZXJhbmdlOjc5ZGJlZTdkYThjZTRlODliZmY1Zjc5NjQ0ZDA0MjllXzYtNi0xLTEtMTA1NjI_51696287-a187-40eb-b21c-354d919816e9"
      unitRef="shares">25533000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <dei:AuditorFirmId
      contextRef="ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlMTgyNjM2MWVlYTQzYTliOGVjNTdhZDVmOTNlZjMzL3NlYzo0ZTE4MjYzNjFlZWE0M2E5YjhlYzU3YWQ1ZjkzZWYzM18xNjMvZnJhZzo5MWZkNDNlOWJiZDk0NGQxYTM4YTM0OWFkODcyZWJlZC90YWJsZTowOWM4N2M5MjNhZmE0MzNlOTY1YmRlMjM0YjlhMWFlMC90YWJsZXJhbmdlOjA5Yzg3YzkyM2FmYTQzM2U5NjViZGUyMzRiOWExYWUwXzEtMC0xLTEtMTk4NDMvdGV4dHJlZ2lvbjpmMzIwNDE3N2NmZTA0NTIxYWJjZmJhZWY4OTc3ODczNl8yNzQ4Nzc5MDY5NTg3_187e05b8-47f3-43f3-8f2f-6487e83b6d3e">42</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#$>L2%4A][26W$\3P]6VJ+?+7+:G6LH,1ZQ@5J@]K:7V6=>1$9C02JI2R:C
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M#++_ 3[ZZ4U%>U.+:)"XA'1$QN$EB8(H'."-^R+'CC<^MTCR:[[51N$O\7L
M/^GQ$X>?#.&E(O=,<;):'CO!8< D&G!QU;NX.LO%(^5PS,*P^DX);2X^A-/@
MYH+RZH;\E+7(VXGU>C/@;]K[FY[E;RW3DS_:,&&%S<S$)7G$7O\*2L/[,5O^
M03-P4+EK>4U2K,>T?='/]K?*O&VF?^GME?1 5<Z$)B7L4!J,/N(9JK;-V\#(
MRK765AIL5#<L\&8$91-P?2>EV0=V@_ZN3?X"4$L#!!0    ( &:"6%3Q[2X*
M"0<  &8<   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK9EK;]LV%(;_
M"N$%NP!VS8LN5)<$2--U&]"AQ;)NGQF)CKE*HD=23K-?/U)V+%LDY6S8A\22
M?4B]/"3/<WAT^2C59[WFW( O3=WJJ]G:F,WKY5*7:]XP_4IN>&M_64G5,&-O
MU<-2;Q1G5=^HJ9<8PFS9,-'.KB_[[SZJZTO9F5JT_*,"NFL:II[>\%H^7LW0
M[/F+7\7#VK@OEM>7&_; [[CYM/FH[-WRT$LE&MYJ(5N@^.IJ=H->WQ+J&O06
MOPO^J(^N@1O*O92?W<W/U=4,.D6\YJ5Q73#[L>6WO*Y=3U;'7_M.9X=GNH;'
MU\^]O^L';P=SSS2_E?4?HC+KJQF=@8JO6%>;7^7C3WP_H-3U5\I:]__!X]X6
MSD#9:2.;?6.KH!'M[I-]V3OBJ %*(@WPO@%^:0.R;T#Z@>Z4]<-ZRPR[OE3R
M$2AG;7MS%[UO^M9V-*)UTWAGE/U5V';F^E:V6M:B8H97X VK65MR<.>ZTV !
M/MV]!=]>? <N@&C!;VO9:=96^G)I[)-=^V6Y?\J;W5-PY"EO>?D*$#0'&&(4
M:'[[\N;PM/G2CO<P:'P8-.[[([%!=TKQU@"FM1WGZXD>R:%'TO>8Q'ID>@VL
M;T#I+OA?G=BRVCXBZ*M=5VG?E=MFVVN<I*C(+Y?;8Y_X9B@C.($'LQ.ER4%I
M,JGTYW;+M6F<-C>I=N]^YH;=UQQH7G9*&,&#HG>]9L>B28Z+8B3:-R,VHN B
M+#H]B$XG1=^4I>R<8L5+;EUKY88TIM[#4YSE>"31MTJR I.PPNR@,#OKUM9(
M%?%>YGLOHXB.E/E6J$C3+*PL/RC+)Y5]5'S#1 7X%QOZ-=?],I5FS96-+\?[
M(*0[]Z<SH<E8MV^%B]QM])!N>M!-)W7_)@VK7R"1^I->9)0D(XT!L[RP$Q\6
M61Q$%I,B/VRX8D:T#Z#F%B9 .6HLY&K1V9N=YCEHN0D)+WROP91F(]T!*X*+
MR)I < C[\,RJL)F ,D_]:G#Q:N-"PMP.0]L54I9=T]4]$RINTX-2L!ZZ<@4N
M4#&G%/?M+E R3V@.F $V1//FWJZIYRC?&XR_A7.[@_6&]^RNGX(@@?[VQ$DQ
M=DO(C- LLHO1$0[1F7V\V"A9.B]8I9RI<OWU5RB#WW_-FLWWUAM6M^Q]%12/
M K,%(1R+/V=V*G[ &L*3XG^4LGH4=1V4A@/!)<\]ZIRW.Q4W$!)-(_)#'W):
MV2[.[^E]5R<.2A+L:?7-4 &+-")U0"2:9N0N]-S$Y?F4*V"*$F^>?3M*LQ3'
M)GK (4I?E,#4@MV+NF?V5!:#!HJA:8P=0+MA3S'*H@#,4(K(>/ !FN4PND,'
MG*%IGEF)JN.3/#MR2W  /J\*BE)O  &SC"81K*&!:V@:;#;E=L1P0DN;?8NJ
M1XB-KE,^]_&%:.$'%M_LQ.I4\0 Y].\H=\Z_/K/R!(XSQ8!51H^2M=/,?@ ;
MG@;;:=IP1BGV*8*2M,C3D=:0G85P'L$P'G"#IW'SEJ^X55I9V(CFOE.:-[%3
M _:AD19PS,6 E?5]3.?1@6F:+.]E^[ P7#66@/=!]&&?&X06)!W'[+ =3I.(
MQ($O^,P1[#]L*QP 2$+&*S5D94\,$<S@ 3-X&C.'R1=M*1L.#/L26:8^1Y*"
MC#=_R(K&,D4\L 9/G[W^Y>;'@>,5(=DXN(;,T@S&5L$ ,#P-,#_+.*?7QU1&
M(1K+#5B1/')XP /+\#3+=L'JG$*?0S9$Y;FGT;?+($2Q@@$>@(7/ :MIQ+YD
MT-<XGG=:&5,\V9^K3+[6&U;RJ]G&)=EJRV?7(%06^A\Z.AWS@#Q<3&98=T:6
MG]>RME%$?],?D,S39*%H !29!I3SIHU*VCU@#B[@*XALB%)@R^J.ST$*X1SN
M_H!>,^42G,ZLI1)_\\H>HG(Z+Q">4_NSFPN<X;E-JN9)AI[-A=8N/^K3HLYH
M8R_<[OT_#VG$YR&F<%P6"%EE:60YDH&99)J9-U4E7&"W.\<5-A:B!27;"+N3
M@E(#9ZVT2!,TCO(A0P)IFM.(X &>9+K<>'-TG-XGJK*Q"W;MJN%;#AZ8'<*W
MM=3ZN\DE=E2,G$;A.VG3B8=VGP653\ HUNIZAT-6_=GM"H!!=_FL2W$Z#C4!
M*YL81W(W,@"13 /Q4ZLXJ]U"!\X;P*G=,E$[?"]64ITI41(?@ N<CS$9LD(T
M G,R8)),8_(/IJR3(P5?'W9T#,2 #<*$1H[=9  B.7NB.ZKEK$0IPO/N VZ!
M<9$6>%P^#5K")$VRV/P/."0OP:$.A-Z@Y$!Q$N8D\S9VH#Q),T)C@6C@(GE)
MA?+]0.\^G)Z2XX>X?.K5]X-%A(!=L(BP/'H)Y-[ _<+4@VBUS=I6MB%\E=L>
MU.ZEUN[&R$W_7NA>&B.;_G+-F97M#.SO*RG-\XU[U71XM7C]#U!+ P04
M" !F@EA4*^0.J\8"  "=!P  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;)5534_C,!#]*Z.( TAL\]$V*2BM!$5H][!219?=PVH/;N(V%HX=;*<%?OV.
MG1"UT$+IH;&=>6_>FXSM="/5@RXH-?!4<J''7F%,=>G[.BMH271/5E3@FZ54
M)3$X52M?5XJ2W(%*[D=!$/LE8<*;I&YMIB:IK UG@LX4Z+HLB7J^IEQNQE[H
MO2[<L55A[((_22NRHG-J[JN9PIG?L>2LI$(S*4#1Y=B["B^GB8UW ;\9W>BM
M,5@G"RD?[.1'/O8"*XARFAG+0/"QIE/*N25"&8\MI]>EM,#M\2O[K?..7A9$
MTZGD?UANBK$W\B"G2U)S<R<WWVGK9VCY,LFU^X=-$QM?>)#5VLBR!:."DHGF
M29[:.FP!PL$!0-0"HF,!_1;0=T8;9<[6#3%DDBJY 66CD<T.7&T<&MTP8;_B
MW"A\RQ!G)E,IM.0L)X;F<$TX$1F%N:73<#HCB@I34,,RPL_@&]S/;^#TY Q.
M@ GX5<A:$Y'KU#>HQ/+Y69OUNLD:'<AZ0[,>],-SB((HW .?'@\/=N$^^N^*
M$'5%B!Q?_P#?W*!];$T#<@FW3& 1&.$PDYJY7OM[M=!&8<?]^R!9OTO6=\D&
M!Y)=95E=UMP5/*>X]3"7RX*Y*X7;4YEGP+("?:Q9957MJV^38^ARV)VZGH07
MHU&4^NOM,NZ)&@Q&21>U8V#0&1A\:& JRQ+E8FMF#^=0$05KPFL*I]@3N>2<
M* WH G2![7.V3WS#GVS)"GI!^$;[)T$[TH>=].$7I#N!&DAM"JG8"WX/:Z%9
MW:N[(8^W) V#]O=&_#&1.P[BSD'\=0=,Z_IS]?$[35$RN@BCT3OU>R+C*(C[
M@_A _9-.??)U]7BW:(,-S\3J,PO)T1;V1!ZPX&\=GO;B^DG4B@D-G"X1&_02
M_):JN0R:B9&5.T\7TN#I[(8%WI]4V0!\OY32O$[L$=W=R)/_4$L#!!0    (
M &:"6%26&J^R P8  ,<7   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
MI5C;;MLX$/T5PNA#"]0Q25&WP#'0Q'L)L-TMFG;[L-@'VJ)MH9+H%>DDW:_?
MH:1(CC124^R+K<N9$<]P.&?(Y8,NOYJ#4I8\YEEAKF8':X^7BX79'E0NS84^
MJ@+>['292PNWY7YACJ6226649PM.:;#(95K,5LOJV8=RM=0GFZ6%^E 2<\IS
M67Z[5IE^N)JQV=.#C^G^8-V#Q6IYE'MUI^SGXX<2[A:MER3-56%279!2[:YF
M[]CEF@?.H$+\F:H'<W9-')6-UE_=S6UR-:-N1"I36^M<2/B[5S<JRYPG&,<_
MC=-9^TUG>'[]Y/WGBCR0V4BC;G3V)4WLX6H6S4BB=O*4V8_ZX5?5$/*=OZW.
M3/5+'AHLG9'MR5B=-\8P@CPMZG_YV 3BS( %(P:\,>!] S%BX#4&WDL-1&,@
MJLC45*HXK*65JV6I'TCIT.#-753!K*R!?EJX>;^S);Q-P<ZN;G1A=)8FTJJ$
MW%GX@TFUAN@=^>.H2NDFQY Y^7RW)J]?O2&O2%J03P=],K)(S')A80S.TV+;
M?.^Z_AX?^1[CY+TN[,&0GXI$)<\=+&#P+0/^Q.":3WI<J^T%\=A;PBEGR(!N
M7FY.$?/UB\U9/,'&:^?#J_QY(_YNBZW.53<3Y*]W&V-+6!Y_3W@7K7=1>1<C
MWG^'0G(L=7+:6F)DIM )K%WXE0M7-NY7'O5])I:+^_.P#F$\H%$4/(>MAS 6
M<>Z%+>P9$;\EXD\2N='&NAS=:YT8 AF<8$QJ'\$Y$R&"W@AO$!2CHD=W/41Q
M%@<>3B-H:023-'XIM3%N1G:IQ0@$PX^&,+:HQP"!\3@2O$=A"&,!Y:' .80M
MAW R8YLR4>R)>@0U,LI<3F1JU'J-)B/S41DER^V!0)F!.GX/ G5TZP&+4H1$
MB5,1]Z(TA'DT$L+K10GQ%@5>&.%1BEL^\22?.U VB-%;LE<%Q"M[6Q&3"93T
MU*UOIWX8MW@X9['+@1XW!.8'@H8];@@LB*. X=P8[42$3B_'@RSVRCAMV,FT
M)/<R.RFW/K=0ZX&V*V1P:=*DD11RE-_D)D,I-]\Z'V4P+#\(RF.#58NA>#Q2
M?-B9:+))OFL%3=8VK:E4$YGKTJ;_5@]03FS(B=-^AB*H*!+]BHJ@1!CZ(YQX
MQXE/<OJDK<R('JQFE ['AB BWB>$X8)(T#XE!!<(CXTE9J>FS)LD]9NKK[M2
MYT_$( E10MY@ '-.80B#M,. (HCCJ$\) 7I4T#'E8YV&,S%=<.U!E>1U,S]O
M8-&YEF&JZ+).5MFTKMX65I4*M+5VBH9JJ(3^,),14>5\D,E#%*/\K' _9]&I
M*IN6U99%$R.4QE -YQX7(>LS07"<"^[WN2 X%D4A'R'3R2L+OY_"4&;4X[:J
MLDU9O5=0<*""DD+;D44:#D;4EXWO0]8(9"YHP$>Z!M8)/)M6^(Z7*S>GU!RJ
M?A?8)6J#ZCP;2O.<^V&?$X(*>3C(O2&,CE#J-)Y-BWR],J>2;BC <Q[30<XA
ML#!B?0:8L^!LD3W?3G5BSJ?%O)J8C=KI4C5E@%CYB-'A0W6%8LA\OU\U46 (
MBZBOUQC0\_V8C<P-[R2;3TOV;<MD:H+X4%OG44S[6P8,QOV!!F P,=9)\DZI
M^;12NUU<YB9)6ENFFY-UG12Q&LI"GL.*,E9OOQY@3Z1*M# T[OWGHZ<BZ)<'
M% CZ[?=W%AC0\P,O&N/:"3B?%O ?X4I XMOG!PGI.W=G0NF6O(;&--%9)AM0
M]?8-&IMZ..$Y$WH1]QL;#,8N!OTV#A-C4>E: /[]??S_B4J29B=WX/,#<1$O
MBPL"P^*"PD;CTK4O?+I]^5(=\ZED+D$>)6CE.6]0FY,U%MIUU]Z>IT;]&N>-
M[/M#)F#OWS_IN,&@?A0%H1?U116#"@I>*1UI>7G7_/#IYN>'8G">"%-10 \B
M\"@@T+$H(-"1*"S.3CAS5>ZKDV(#U$Z%K8\*VZ?M:?2[Z@RV]_R:7:[K,^7.
M37W$_5Z6^[0P)%,[<$DO0IBCLCXUKF^L/E;GJ!MMK<ZKRX.2L,0< -[O-'1B
MS8W[0'MVO_H/4$L#!!0    ( &:"6%3<)[[Z9@,  /H)   8    >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&ULC59=;]LV%/TKA."'!' BB?IT8!M([ TKL*Y!
MLVP/0Q]HB;;44J1'TG;27]]+2E%M65;S8HG4.??RG&M><GH0\ILJ*-7HI6)<
MS9Q"Z^V=ZZJLH!51MV)+.7Q9"UD1#4.Y<=564I);4L5<['FQ6Y&2._.IG7N4
M\ZG8:59R^BB1VE45D:\/E(G#S/&=MXG/Y:;09L*=3[=D0Y^H?MX^2ABY;92\
MK"A7I>!(TO7,N??OEA.#MX!_2GI01^_(*%D)\<T,/N0SQS,+HHQFVD0@\-C3
M!67,!()E_-_$=-J4AGC\_A;]=ZL=M*R(H@O!_BUS7<R<U$$Y79,=TY_%X0_:
MZ(E,O$PP97_1H<%Z#LIV2HNJ(<,*JI+73_+2^'!$\.,+!-P0<)<07B $#2%X
M+R%L"*%UII9B?5@23>93*0Y(&C1$,R_63,L&^24W97_2$KZ6P-/SA>!*L#(G
MFN;H2<,#:JH5$FNT$!7\DPI3XCU%?PJET UZ?EJBJ]$U&J&2H[\+L5.$YVKJ
M:EB+B>AF3=Z'.B^^D-?'Z*/@NE#H-Y[3_#2 "R):)?A-R0,>C+BDV2T*_#'"
M'O9[%K1X/]WKH2_?3?<G VJ"MBZ!C1=<B->6XKP2'W@F*HK^NU\I+6'??!E(
M%[;I0ILNO)#N+V@P#"K<5\B:&5FFZ2+[^0V.O# &E_;'_O;ADCB-\"ENV8,+
MHCA(TQ9W(B%J)42#CGW2!94H.['JRFBZ1AMH?W<#+L5MBGC0)>@TT$<X[$LI
M*<]>$?C/%2-U!\N_PG:U)3M*.T:<VAIJ\H+*:@OU,J.1-T8C?QQ%>(Q@ Z%1
MFD[&T$;5EMI&R%[[*E&O+CYQSH_]3AW.45&,DTX1SD$83[S^"B2M/<F@/<\<
M#AY6?H=.<N0 ,M[L2<G(BM$;.*AN%&$4*0HNEKJD:LBBJ\B[;ASR4_QKAY)S
MA]*HXT\/!N,.:'D."N.DWYZTM2<=M.<7?] ^.6E/P7$8=P2=HZ+0Z^ZZ<Q!.
MH@N*)JVBR:"BT[YTJ7],^OI'D'A=&7VXQ ^C3I]9]N""*(@#OR/&/3H5*RHW
M]G:AH  [KNMCI9UM+S#W]MSNS#_ Q::^A_P,4]^*/A*Y*;E"C*XAI'>;P*ID
M?=.H!UIL[=F[$AI.<OM:P.6,2@. [VLA]-O )&BO>_,?4$L#!!0    ( &:"
M6%3UCCD3L0(  ,H&   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULC57)
M;MLP$/V5@9"##221)=NI$]@&O+1H@ 8PXJ8]%#W0TM@B0I$N22_Y^PXI676\
M-1>)R[PW\SCB4W>C]*O)$"UL<R%-+\BL73Z$H4DRS)FY54N4M#-7.F>6IGH1
MFJ5&EGI0+L*XT;@+<\9ET._ZM8GN=]7*"BYQHL&L\ISIMR$*M>D%4;!;>.:+
MS+J%L-]=L@5.T;XL)YIF8<62\AREX4J"QGDO&$0/X[:+]P$_.&[,WAB<DIE2
MKV[RF/:"ABL(!2;6,3!ZK7&$0C@B*N-/R1E4*1UP?[QC_^*UDY89,SA2XB=/
M;=8+.@&D.&<K89_5YBN6>GR!B1+&/V%3QC8"2%;&JKP$4P4YE\6;;<MSV -$
M=V< <0F(#P&M,X!F"6A^%- J 2U_,H44?PYC9EF_J]4&M(LF-C?PA^G1))]+
MU_:IU;3+"6?[(R6-$CQE%E.86GI13ZT!-8>1RNE+RER+UPC?E#%0FS!-VQE:
MGC!1AQMXF8ZA=E6'*^ 2OF=J99A,33>T5)O+$"9E'<.BCOA,'5$,3XJ8#7R6
M*:;O"4(252F+=\J&\47&,2:WT(RN(6[$T8F"1A^'-T[ QQ^&1_<7U#2K/C4]
M7_,,7]6:X\X\RD3E"+\&,V,UW:/?%]*UJG0MGZYU)AW=*;HQDKY 30U/WH"8
MI1',W]4%N0G4!'T0]6NP; L\7U+>4TTOLK1]%N= ZSZ=Y7J_"\<14;L=OP\:
M'P=U.O=5S#N%[4IA^Z+"P9IQP68";\@[;PP3" 9)+K<<32$+MV2N!J$V0XES
M;NNG%+;_J_ XXJ9]$#,^CHDZ\8' <.^6YZ@7WBT-)&HE;7$MJM7*D ?>AP[6
MAV34A:_^HRE<_HGI!9<&!,Z)LG'[B2K2A7,6$ZN6WDMFRI(S^6%&/QO4+H#V
MYTK9W<0EJ'Y?_;]02P,$%     @ 9H)85%BT,+L5"   VR@  !@   !X;"]W
M;W)K<VAE971S+W-H965T."YX;6S%6FMOV[@2_2N"L<"VP+H6'WIPD038.'&V
MP'T4?>Q^5F4ZUJTL>B4Y:>^OOT-9,2UR]&C3[NV'6K+/C Z'Y)P91A>/JOQ4
M;:6LO<^[O*@N9]NZWO^Z6%3I5NZ2ZI7:RP)^V:ARE]1P6]XOJGTIDW5CM,L7
MU/?#Q2[)BMG51?/=F_+J0AWJ/"ODF]*K#KM=4GZYEKEZO)R1V=,7;[/[;:V_
M6%Q=[)-[^4[6'_9O2KA;G+RLLYTLJDP57BDWE[/?R*]W7&B#!O%')A^KLVM/
M#^6C4I_TS>OUY<S7C&0NTUJ[2.#C02YEGFM/P..OUNGL]$QM>'[]Y'W5#!X&
M\S&IY%+E?V;K>GLYBV?>6FZ20UZ_58^_RW9 @?:7JKQJ_O<>6ZP_\])#5:M=
M:PP,=EEQ_$P^MX$X,R"LQX"V!G2J 6L-F&5 HQX#WAKPJ4\(6H/ ,F"TQR!L
M#4*;4E^4HM8@:B;K&-UF:FZ2.KFZ*-6C5VHT>-,7S?PVUC C6:&7XKNZA%\S
ML*NOEJJH5)ZMDUJNO7<U?, ZJRM/;;SE-BGN9>5E!?R@TD];E:]E6?WLW?YU
MR.HOWMS[\.[&>_'32^\GC7F_58<J*=;5Q:(&8MK](FU)7!])T!X2[U6=Y(C9
M<MALJ78[U9)#K&^&K7];KS.]&Y+<>Y-DZ_GKPELF^PQG<COLZ\^D+!,(&V*Y
M&K;\=[V5I0<C@42RU3O\07IWD$&\%_]05?42<7@W,JPT/>P.>3.?-W*3I5G=
M=;* %7):)O2T3&CCE?=XO4[RI$BE]P*85=NDE-5++ZGA >DKCY%?/.J3&)O
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M5-(: +]O%.2M]D:_&W9ZG_'J?U!+ P04    " !F@EA402D_B? )  #S*P
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M8G?2&*<R0.:#8UV@*9# #EF #93P]&W+'C9;8<" &[8_$D#2SJ"\HYZL'TS
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M Q?G67=E 1TV/P@TE ,_, J%;8+6U1]\>MKV<\\^:<?;.;"[$6#C]\,TG.B
MD>1+V81-FLMX"_(+E:C-H:YEDBJ<4MD@ZJS*M:!'LF;/ZR[!L-Q$6.PU1F3?
M1?^Q>[;ISH4G.D+!U[JLH8[I[G-X.]P<+]*%Z79YNG;&J0(S;L#!-L?6P\G+
MYR/ATU5N^A%=P]>G2Q>CJ_@1]0GG?EJ [[D#TMT/4C#<IY_]#U!+ P04
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M!,A3R$)TD\+<L&&-=IYB(+S*S+T#EP+.!+>-B9T"P0T;)#\ ^&TA2:$RG<'
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M;AB9P0'IPA+CG">6U%)Y<]+5%E?%6\)!E]BNE5,9[:3!1^=,TAP6@N1O!O"
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M[KYTM-+.*)D+EKT02N@,X9;+WHWWF8J6J445)+W9P]&=L5MBZV2.MA5)D2)
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M3KW;D>]W#P==>3T==H:IML-D*!\;FBYI]Q5[LG;D_@Q4<SQN<U \;)MWMMC
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M  HLV4K8:[7^C%L_ \>7*V'\$]9M;I8&D*^,5?463 IJ+MLW>]BNPQY@'+\
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MZ9H<H[)-+!U/YD/NH_N'FE(I; MX1;CWR["OGF1YKL*?=1716BSGR=7US2C
M.J"/?0,XBWM9@HJ<Y-"I^+E "@4W,UY&PAX])[H IV-D,@JFN)=EOQ<R^992
M /A.X^DNMR78"%<IF>>:I $*HBW/M7F>R5H'@@8C'_?</^^&8 G6G/KA;/U_
M\$/D$5UI&C*DNM9KOJJ['?G >1];+(=(_OI>MIB>XZ\MEA>G+.>+SJ:H0 S>
MYK_L;K/KT<KL<+9QHD#Z)^-173A\;?<;I?%C3SKO2!!5EXKTA_)4EMP>%#4H
M !R/%#TEBFP%QP&D_M4HC@9 B:H<%4@J "!GR^LQ-P1"9>,I\%J7(CIQ&)6-
MEJH<<<4!CW:YGLQU#*/3\S<R A7VXQJR6@\V2EK2A>K<9%Q]>DCHAN*:?-;W
M5@ @[ 5TWR.E/M?*>.7Y?/"CQ!Y:X&?I+%FNEK]=,!\MD[^O+J9CNCJNZ_ ^
MQ/VQ0ZR.'<(1/R1=1(8CI\X +40IK&Y@O$BIZ)Q(<W+K271G1TYAM<2Y)?)$
M*>[8>E?0O<FYJ)><D5J.!.^DG=!H7'K0&V0Q,EAO7)G!";WNJ.M;$%T0%R_>
M:%L#GDHF@!@G_J>3[A552D3IH'/+-8EGW_,Q"[H_.3+YL"<^H2+'=#2;UEPN
M9\DJ7?SO)2KIF-\95@4"\\<*V'IZ=91/N'OTM5/(3]9 RU)O-91X2]YU5T*1
MGP<O0<Y\I^#M.'GPNZ2E*T</)\\ZUNK[<^U'A4A'QK$'I6+45'QX[NO+FZX#
M\*[K  @8)K;CACX!J8$0B]Y"30]*6>2>7-;@*W6-W-H82F# (B>U6M8#VE]S
MT6'2#ZL%3>7(A(M(DX67@!#.NK&F\?$HVW4C,&2KZ%!.)[VZ+A$=*%#1X8ZV
M3L<ZE&;%-!\*;.#*PHQA996H"&3CK=0TESL6G)>I4] S1L8R9AMH_Z%M3R[2
M]6V'W0]$"LC@[\G5&X(IC\?]]>J&=:Y8H^G8E#BV4K"?UT>C"OO Y[X-8&E#
MXLEB1 F9VR^FL^'!^4X3#SQ]FI[2_M@$L8Z>HG9QW1EJ>4L9>(%2RXTN8>#I
M*?2#SA(<C)(U\FA6XB9"+SG<6/:H(T/JT4!8&B>YF(RW4G=!'15CQN&[@!Y6
M\A?CL21B9[B%1B&<90T=!8F9\!F-$':JH XUBN".PN)IB43^K#\BQE,=+E%^
M,=MU6SPU3X]!#TS3L[9C4&AG7'CSJ%34I+1F]YSH72])4]5JFXG(K-2&@HYG
MPO\VNA+#]AXH<%Z?I^GRD=DQ/YRFA:X/L*-RV)82F#XXS=$>2QZ%<5MAZ\BY
MQM3@N!]HCFH9D= NV21#3Q'QFR.4XA7G0D,9ERMR[#%QDR+&[>B0/TH^$82'
MR2J&UKD4H RH@Y,@K'9OD/ *77,68KTWIUEQK-)Q:RX>56W?$!CE>=U!W@-;
MM2,K.GDP)6RRC/HDQS(I]8&2&;P9$__CC!/:C25(9!U'X]9N(>\IO;$?16+>
MKC!+Q4')#I2'8"74INA(8YO!-3/JFN@ -Y.LZRW0L9BA?^%;&['[],RQ/9 ,
M9YK.;;CS->I^L/9M(R@9=\FB_4_ZF?'TT[6QAL8+"8WSIN+O[4J=0O!28A*A
M8SSL&$/+CM*'F%]_TW5F(D,@S+"B@5;.HQ2)O#W5L%34B(;[C"/#SRX7*Z2G
MOD7-71^2".+ ?)8+K3P05@/;Y Z9+;F/AFLJA2QBEJ;?= 9O60\I&E/B27>2
M6>!8O>GO^]) O5((5NZ>6WN$#XCHU7R>S*Y[KD7*]%1LR&P$XO3<=YC+T?>L
M2KD=?[4C[T)JC)^V^J?]A\';^#UL&!Z_*H*U[S0,6:HMIM(19B)<_%(7;X*M
M^>O8QH9@*[XLE(2*- #OMQ8AU][0 OWGTM?_!5!+ P04    " !F@EA4)\NA
M$?$+  "3(   &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RM6FMSV\85
M_2L[K-M(,Q!$/$B"CNT9R8\V'Q*K5NQ,I],/2V!);@UB&2PHFOGU/??N @0?
M4I2V7T02V+WWW/=90*^VIOYJETHUXMNJK.SKP;)IUB^OKVV^5"MI0[-6%>[,
M3;V2#7[6BVN[KI4L>-.JO(Z'P_'U2NIJ\.857[NKW[PRFZ;4E;JKA=VL5K+>
MW:K2;%\/HD%[X9->+!NZ</WFU5HNU+UJ/J_O:ORZ[J04>J4JJTTE:C5_/;B)
M7MZFM)X7?-%J:WO?!5DR,^8K_?BA>#T8$B!5JKPA"1(?#^JM*DL2!!B_>IF#
M3B5M[']OI7]@VV'+3%KUUI2_Z*)9OAYD U&HN=R4S2>S_9OR]HQ(7FY*RW_%
MUJU-DX'(-[8Q*[\9"%:Z<I_RF_=#;T,V?&1#[#?$C-LI8I3O9"/?O*K-5M2T
M&M+H"YO*NP%.5Q24^Z;&78U]S9O[I:P5VU6(MV:%6%M)[GIUW4 ZK;G.O:1;
M)RE^1%(4BQ]-U2RM>%\5JC@4< U8';:XQ78;/RGQG<I#D42!B(=Q](2\I+,U
M87G)4[9>.5OOY ZIU8B;NI;50O'W?][,;%,C3_[UA+*T4Y:RLO3_X-@G)5%9
MOK1KF:O7 ]2=5?6#&CPJ7OR\5.*NE)58U^9!%\H*5*YH<'4!2QM=+829HYQ@
MJ<X;[$:*Y5_%IM*-%;(JA%F3'"L:(]:;.E]"A<C-:@79;JFN6!QIE=6.UJG5
MNC0[I6P@"EVCWDQM0R&+!VWQ+6"Q.62B4@ !:AHA@4_GBG;/%,JH436R&W!F
MN[[TO_PIBZ/)]U;<&ED7A/S=7D%GJK8 U2A*.X93Y693HZ4(LZU4;9=Z33L=
M>LCOX)X PZJ^:72;W. \"8,*3;Z1)=3ER!CTD\Z]*[]R91K%0NPFSY4]EMD9
M--M8V&N]&:?F!0)R*2;D>]TT2@5D)P*W!F ]*Q5K;CU'<24UNBHTP&YD:;UO
M.>RJBVO RZK-:J9J4MB&6\E\V=N--E26T)8K&.GVN)4^;FOLMI2#+KIT7WU3
M=:XMW].&K6&A;E_X2&;FJFXP.X"T4G.R%ZA_!0 ]WY%-;H.L&YWK-<=HNS3"
M*ER2</0<#A=4$H1IJYOE0?R*#2=8H62SI-2T<J9+W>S(M8-:-? U%?Y 7$A+
M\<)N.)/<C+[.V;A!3KGJ(2"7XF+P=\:FN87L40TN0_'1>[)U^.%>;/4+!I<$
M2HJSDLBI<#R2$J7JX"/)&@AK=,G"8KA;5A7"4EN,T3:_SDKKLLT[C.<@[8<*
M$HO5+>JE*KGXV U/08//*%X^VI(2<0].R;K4+K'H9XJ _"]8?><RM5YH*COU
M;:W]K8+"[^5]]!G6VM(LJ<.@/U:FZ=*R0#K4KDP0X.-D=;;-N*CF2L,S2%BP
M#S\NGNB7)[?:^#\1Y*/48+Q;RD%PKF)3NLT<=\IIWW";K1$[.+B%/#<E*%5;
M^&<5?7?@36>C1%LJ%5</P>?N6U*$*&77M(PR8+\M%#?4Y7_7%XC5R1UGF-D@
MM9;R0;4Y)^<-M0\NN".CN.WTP^ P/<]"0"VM";@YT8X;5'=!%4Y-:D>7F<6B
M=S]MRDGEWGVZ_TQUZ_MA-Z7.0@J."J5$\E*5M"%UUO^A.G!HO1] 4*A!]ZPY
MGEO-LC:;A>N%JBK:V_T=WMURO2YU+CT\VLM187M#<<\^<54E_EIS^_VYIV=C
ME67)<ZEK\2!+-*R5:I:N^:^4M*[BV+?>Y7F/K 2"AN#B6$0[.-2O&VK6<DNS
MT5=5>  @7QKKIBU[;?R]_R :1W3\BKB4=ZC_ /E R&<;MLF#I3F$B)E<,C_J
M0\0/VQ5Z;A:5_DT5CP%V.>3G)+5:<0"$PHC68QY\^"D;2-]^7M+56I62BX3,
MMN%YA]^6$AZ]A_TEKO0F,\E;&50TYJ1"\D'#REG544#7.GOPR?Q^B%K-GRV;
M)GF9\X8375-D4#LXB%32DV>DSTI^5=T\EQ;G/-^/>3 3<P&UH87N4 9-3IRN
MUAN<+,7[;VMW^<' !6Y24U?LLA^L3J!Y@QXA9\O^,JNY#' ?5*C15!Z;&3(;
M^.>*<Q"0?I0['"6&$^=3]"/FB*K5BE)4;O9W9-2E)XGU1=?3#B]*)ZG6]NO5
MO%:*62CU%,'M5?>@?P[OL;CFDM@%XC=5FRNP5.IM&IY2WDG2=PT.&'$115R(
M?.885A\J>YC"U?#-=B!RC$/QP370#86)1J'/!.I=+2;X#Y.;YK(SV/<:A5:M
M38V>"5"*)@8D]"U'T,L=9_*\]8O/P/E>J7/-89$P+>[5R)XKT43N /H^=V"0
M#X5\5N:W/' _(;=\.E?%51OU7GJ^%/_  /+'5H%#IV)NW!X\Z<\0?Z+I/D&=
M$8X)][)P/ I3\6<Q&841?:3\\0G9(<YDQS <XV[$?V/>]_X@O#UN?D$3TEX*
MB!_BSWA"?[+]>E L"@)S=^KW'3D7+Z!F.#SZH,"T#NG*@+U\==P:]I)Z<-J@
M>3Y%3F)7#=U9@%VU5:1]&@ZS0+P8 [>[AZ_C2=#V HS2<H>AW3X2.IIC--L/
MLJ4]R3)A4(^$BS5+ZX./Z/[4G75^:8WNOMPL%K5:D-$7S++,Q@(F7$T_5^ B
MI/>R(Y8&?0HGQ0)F!\>JHTQ$HR"+R,U9.$[<P(2.-!A.(UR,AF%,.=32T8LH
MF(XGE[@S"K.D+5BZD4VF=#F*PN&$HJR)FUTD2<17DS#)GH=H*J)Q,(E3[)J&
MT:B'*!G'?'&:]0&-@CA-+AE_%/4!14$R&5\Z&])X#RE-1BVDY%F04$D1_)$X
M[:.T@Y0$,4.*QN$H.712FC&F23@<'3@I35EW'$Y[3HJ3L4<4/\])R!@@FB21
M=W@FD*WXG@S#1'SQ?+6BTYPGKUT3]GSNK,0D2-E&^"N;0B)]C[.P\S8S+C3N
MTZW3($HCYYU,4"/!QC0<N9'592M:"6K/8L!US;4[R)^>=US%V,=*Q@=F7[NH
MGA<9=/H"0 6GPW"Z_\F5#&=E[:6C@GXK[9).^;E2A?5G](-"_F\QGC08JJD^
MS!A!.X'9,^2H\? (.Z.+CUNF04_=5#W:=T(,.[*&7*A,=>53Y/R,8[<B"3I'
M,D ^B^XS:J;Z/).IHCQMUGW&2).%71>*3_OCC*/NG[M3ZEWO['/+!."1Q1<Y
M^F;K(C'P!Q_Z<+SP],$&38>%JH"L+.G\,/NWIWDPG):W-)<?/-3*/]M8$&ED
M'W3/X[ZSW7./HGVH$WK5C^G8,PZAYUZ2XZ.>TH D8$[3X# MO5;2$=L66'L*
MI&@=\FV*3-5R;@ZXGU $*@#%UO30[( RNAAV!P2,M:^J.:) -% Y]0Z>J[);
MRUU;#L[N,]PN(/Z !K+;GR1\/OAB<K#Z)XR^A:*4:ZN.IFXO>:'7O2LA1G,4
MZF<-8/CC=\;OC4]C;O[B'1GW@9SUA;UTLNQ31XD=4=L/[1^Z-NBV/CG$?]K;
MZ)_>G"M_C/$DF$2^>8^FO0DUBL?NZC1N)\/%-([<P$RG_>$TBD=^7([BYRJ>
MBE$PF<9N#@'&?EJ/VZO@#ZWB.(C&J=<Q&1X.ZS@=>OX0I<_4COX_"8;9T&U+
M1CVS(\=>QN$T[;1'03;FJ1R-PLGD4/O0D1H,YNRYMB-K)D'"<P^3>PJZC3X.
MKZ88,1^>D7.!8$ 8NF-7-P=/F_P#S^H$2JU.IGE74TC'BAIFR9WDZ5D!.=S<
MTPG8?-O<J=C_X CI. ;;P,<8WP;]R;RM9[1)]RK"]2NKVL<41Q;]X6GBG\9!
M[,%+I?>N#Z(2.ZSOW<.9&WY6X,YZ^^>13&]<>X%F>COC7A\[JM#).'"&[[5]
MP-V;ILJ:4A?2S2I\4(?G>'Q<*_>(S/;E\EFY]_#HJ2/>4<LX.O%A2&)CON0D
M*A1FHEGS>&G1(F$I<ZEN0$^R:.*NC"8C<8^S,S-./[@<(9$%O:VAYT(T8CLY
M.""E(.-Q%B1)*N)QD(W ^3A_O"5GG86SPR3(<!YX(5(PQQ%54)JB#H;BW#O,
MZ]Z+XI6J%_PZG*;NIFK<.^/N:O?&_<:]:-XO=Z_K?Y3U0M,T47-L10\:#43M
M7H&['XU9\VOGF6D:L^*O2P5"4-,"W)\;T[0_2$'W?PAO_@-02P,$%     @
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M^U=X_L:JE7MMAORUJG272\'A) W _W.% T^XH07:]ZBO_PM02P,$%     @
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M(.EA)V_A&[:DZ&^X=(F&%! ,*FNLTI6/A!A.IZ-IXTX88#&(XJWVD9IZ)SC
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MV6D7<#2I7>]MB4!LN'$*\=;7\,^-!,UW2>7F0V?G@AR\%:)#FPTP]:B%P"D
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M)^ZE4;JSHI .K*XTNEN5B'R:!F(-@%*H)J^Z@J"YH;6L8"%W$2QM=B;V?.[
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MKBA(. [&?6:Z^/":C2[C,?VKG,NG.TC0A:3YD1.LP77'<91#@L7K13.IV&%
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M+>EMA=H)T/>UHHCZA7,PO-:6?P%02P,$%     @ 9H)85)ZB)M]C'0  %&$
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M=*;9%J]M;4JC?7$6_CK__DD'2R. )Z4L\X*769U8YGI5_&J;;N>+ETVEJR&
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M?8/1!)/8%+>]<[HI#\7O&0)39/P,<$363=_0)R!E&1Y"P=A;WTU(D<#+R5>
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MP5XR%X F'6@'6P1>0QC2@*3@&P5P9J_> 3?B4D1I#\%>R]PC/5&;#41CQ"7
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M X!A6H6UU,")R^(&M\:1*JI,T#)\Y1CV8'T ?H)IR]B])&(G"L>:IA\286=
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MWAU?P<\?.MO2M?=KVW5V3W_NM(+ $!^ WS?6=N$#+A#_1P@__C]02P,$%
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ME!KU1\, =#L86L>JQHMQK2Q)VYLES5+4+H#.<Z7LD^,*=--Y_AM02P,$%
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M;5^:2=U@?Q^OGZEKIG,N#0A<$C3JG)*4NF[]]<2JRK?;A;+4O/VPH-<2M3M
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M/P:U8Z#]F5)VMW &ZC^CT7]02P,$%     @ 9H)85#Y+YZB2 @  7 4  !D
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MJAXTUJO@,KZX2IV_=_@F<6^.;'"9;)7ZY38?JE40.4'88FD=@J"?.[S&MG5
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M<R]S:&5E=#,R+GAM;(U766_C-A#^*X31H@F@R")U!TD 9X]V'W8;Q'N@*/K
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MDCP-*?X2][N7YI',M!!$@JG@'4LT6A:%&>Q2]V6.;F#?R)FS?.NELR=4\)P
M^P@^68Z?8G>>=]V*-Z26:UF+KB9+4-\X'/T"8J+HQ>](#*5##*4GQ]#4.:./
M'3+!K ;..!1$1WD>#J+)-CMOXP=S N^>?C,O(@F> [>/KB+BE:O<@/_AZOO
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MC;/0> #V9TK9[00%#*WXS7]02P,$%     @ 9H)85/$:MLYH!0  '0\  !D
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M2K, _Z^$T-W *.A?Q/-_ %!+ P04    " !F@EA4-RR%]!$$  "%"@  &0
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M?%KP))LD\-Y]8GA_A'W3D7W3HPSZU-F."'!%H35=<]"BGI;7[,&QR[Q&S:/
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MFV!WI;K35/=@Y-*=8&;2X#SDA@L<0$G9"?@^EX"B?[ *AB/MT7]02P,$%
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M6;SF_;3$=Q5H)X#?5PH1=0OGH'^IS?\%4$L#!!0    ( &:"6%2?7195$00
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M$V1B,_1";[MP1Y<K;1?\T2 G2YRCOL]GTLS\FB6A&7)%!0>)Z= ;AU?3,+
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M3PKBG4YVL\EN%CE7-S@'!XOC7T+_P[V:N%>1^^,-[N^=/(()G81Y%9"MT!<
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MM^:UF166,.?T#\E4,?5&'LI@C3=4W?'Z)S2&^H8OY53:7U0WL8&'THU4O&S
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M7;!" ]3O2\[ERX5^KE_]\6/R'U!+ P04    " !F@EA4!RS7/=("   ""
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MEPJB3A"Y1%LRE]8UT62WD>*,I+4VWNS"U<:I33:4V[_Q5DOSE!J=WGW(<]G
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MW4SE\PF8"I#S"TK%KJ,6J!]D@_]02P,$%     @ 9H)85+]CE03T!   /AH
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M@#@\K#CL*+XI[O?/N5(\+3;7C.IK(@_0GR\Y5Z\[^2.$ZI'1Y#]02P,$%
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MRP!R7+%*V'NU^XB-GX'CRY0P_A=V36P40%89J\H&3 I*+NLG^]WD80\0#T\
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MEE?TIWEE8EJ" 7+?DHN>C%S4DHL>[*Y^,J8-6V2XS: 68A2&&!S3S]/QM^^
M\[Z%E7^RO;%O$>3#"/J32<&,1KT_X4V1.R"/+QSG7Y EECL^S)TQRT2&RA?S
M3'U_.6@9K,^_H+!E%D0^#*+/^MKP>-+ XUV5ECC^R8CC6^+X,'&.JNN?_(93
MN99SCO[6*V$1E\OB%<1,+SR]VLJ7,S9W-Z\YWA8O]^W='^/+"6ZX?X<O[YON
M/^++:?ERHWUL^:[E%R:7>EN(0K[0)C@7 ^V'+%]?+"]4DA8OJCTG2B51\7&E
M,XM+,T!_OTCT)JRZ, _8O$1Z\U]02P,$%     @ 9H)85'@?>382 P  9 D
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M@-< JM"M.O:*N#7E=+DHV!$5TEIXDQ<5^Q5:\)7D,E$>>2'>)@+'EW=YQ#)
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MT V;RRVC&9.U ?R^%E#=FIMZ@/8OD.7_4$L#!!0    ( &:"6%1<\(:+H@(
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M47.C-A#^*QK//=S-] +"!N.,XYG$3MI.Y]I,<FF?95AC-8"H).QDIC^^*R"
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 9H)85*OJ%Y%3!0  *"X
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M#2!S!#+?(^3W&$ >(9!'^X-<<3BRCQ'(X_U!<KL"D)\1R,^TD%-A"R/787\
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M^=Q\O?QE^;T3[Q?-!>?ZMJ(\_0502P,$%     @ 9H)85*3(PW?Z 0  M"@
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MJT&1U:#(:E!D-2BR'O^GK/?.K?\X?GR6G6WZMWPV_EEQ\0)02P$"% ,4
M" !F@EA4!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( &:"6%1P[ZP*[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &:"6%297)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 9H)85-<H)Y1<!@  GQD  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &:"6%3_OUBC
M)@(  '<%   8              " @9\.  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " !F@EA4\>TN"@D'  !F'   &
M@('[$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 9H)8
M5"OD#JO& @  G0<  !@              ("!.A@  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( &:"6%26&J^R P8  ,<7   8
M      " @38;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" !F@EA4W">^^F8#  #Z"0  &               @(%O(0  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 9H)85/6..1.Q @  R@8  !@
M             ("!"R4  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( &:"6%18M#"[%0@  -LH   8              " @?(G  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !F@EA402D_B? )  #S
M*P  &               @($],   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ 9H)85$T&KLL9"@  6Q<  !D              ("!8SH
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !F@EA4'*;Z
M6_T=  "_6@  &0              @(&S1   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( &:"6%2XEO\*; 0  ,P+   9
M  " @>=B  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M9H)85..IO7XG"   2A8  !D              ("!BF<  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " !F@EA4AV>,:=H"   S!@  &0
M            @('H;P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( &:"6%0?_#ZT&P,  +T&   9              " @?ER  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 9H)85.W6/<'W @
MB 8  !D              ("!2W8  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " !F@EA43//=Y<D*   Z'0  &0              @(%Y
M>0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &:"6%0G
MRZ$1\0L  ),@   9              " @7F$  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ 9H)85&!<RNK."0  4QT  !D
M     ("!H9   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &:"6%2I\ H#. 0  +D)   9              "
M@?"^  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 9H)8
M5)ZB)M]C'0  %&$  !D              ("!7\,  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " !F@EA4NC.X)\8"  "I!0  &0
M        @('YX   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( &:"6%0>XT7)K (  (L'   9              " @?;C  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 9H)85""AK%BZ!   )0T
M !D              ("!V>8  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " !F@EA4/DOGJ)("  !<!0  &0              @('*ZP
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &:"6%3<M*/L
M_P(  $\&   9              " @9/N  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ 9H)85*5ZU*8- P  908  !D
M ("!R?$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !F
M@EA47^>)4?X%  "6#P  &0              @($-]0  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( &:"6%3Q&K;.: 4  !T/   9
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M970S-RYX;6Q02P$"% ,4    " !F@EA4GUT651$$  !/#P  &0
M    @(%>$P$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M &:"6%31(X_'V (  )\(   9              " @:87 0!X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ 9H)85$GL)L<W @   08  !D
M             ("!M1H! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " !F@EA4N;\@ENH"  #8"   &0              @($C'0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( &:"6%2["S*%!@(
M !T$   9              " @40@ 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ 9H)85#UK;C\] @  +@4  !D              ("!
M@2(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !F@EA4
M2>EX&5$"    !@  &0              @('U) $ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( &:"6%2 T*$8KP(  (T(   9
M      " @7TG 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ 9H)85%O=UE[\ @  2 @  !D              ("!8RH! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !F@EA4:_-%E.0%   $(@
M&0              @(&6+0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( &:"6%0'+-<]T@(   ((   9              " @;$S 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 9H)85$(CMA.#
M @  T08  !D              ("!NC8! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " !F@EA4OJM$W@X$   $$@  &0
M@(%T.0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( &:"
M6%0R(]T^-@,  /()   9              " @;D] 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ 9H)85#^@6V[K!P  E"H  !D
M         ("!)D$! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
M    " !F@EA4I:@-FBH#  !["0  &0              @(%(20$ >&PO=V]R
M:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( &:"6%06H=OR!@0  .,-
M   9              " @:E, 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL
M4$L! A0#%     @ 9H)85(>3D*XA P  ;0D  !D              ("!YE !
M 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !F@EA4:M'!
M*&\%  #(%P  &0              @($^5 $ >&PO=V]R:W-H965T<R]S:&5E
M=#4V+GAM;%!+ 0(4 Q0    ( &:"6%1DMO;MF@0  ),0   9
M  " @>19 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
M9H)85%]-ZJ@! P  G D  !D              ("!M5X! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    " !F@EA4OV.5!/0$   ^&@  &0
M            @('M80$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    ( &:"6%0R)X$YR0,  %,/   9              " @1AG 0!X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ 9H)85)U4=2P\ P
MHP@  !D              ("!&&L! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4    " !F@EA49G(]+"0#   P"P  &0              @(&+
M;@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( &:"6%3D
MI(]P; @  % J   9              " @>9Q 0!X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#%     @ 9H)85'@?>382 P  9 D  !D
M     ("!B7H! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &:"6%2-7R-]<P0  "80   9              "
M@360 0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ 9H)8
M5'<V594D!   [1   !D              ("!WY0! 'AL+W=O<FMS:&5E=',O
M<VAE970W,"YX;6Q02P$"% ,4    " !F@EA4"[^"E38#  #6$P  #0
M        @ $ZF0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &:"6%27BKL<
MP    !,"   +              "  9N< 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( &:"6%2KZA>14P4  "@N   /              "  82= 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !F@EA4VW:P<3$"  ")*0  &@
M    @ $$HP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !F@EA4I,C#=_H!  "T*   $P              @ %MI0$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     3@!. %D5  "8IP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>189</ContextCount>
  <ElementCount>494</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1007009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Share based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensation</Role>
      <ShortName>Share based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Assets and Liabilities Measured at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2157114 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2159115 - Disclosure - Basic and Diluted Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Inventories</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/PropertyandEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Share based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SharebasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2345309 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Debt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2350310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2353311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2360312 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DescriptionofBusiness</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Goodwill and Intangible Assets - Changes in IPR&amp;D (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Changes in IPR&amp;D (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/InventoriesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Share based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails</Role>
      <ShortName>Share based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails</Role>
      <ShortName>Share based Compensation - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Share based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails</Role>
      <ShortName>Share based Compensation - RSUs and PBRSUs Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Share based Compensation - Expense Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails</Role>
      <ShortName>Share based Compensation - Expense Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Assets and Liabilities Measured at Fair Value - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Debt - Summary of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails</Role>
      <ShortName>Debt - Summary of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/LeasesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - Income Taxes - Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2455430 - Disclosure - Income Taxes - Deferred and Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails</Role>
      <ShortName>Income Taxes - Deferred and Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2456431 - Disclosure - Income Taxes - Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2458432 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CollaborativeAgreements</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="fold-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2461433 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="fold-20211231.htm">fold-20211231.htm</File>
    <File>exhibit21_2021.htm</File>
    <File>exhibit231_2021.htm</File>
    <File>exhibit311_2021.htm</File>
    <File>exhibit312_2021.htm</File>
    <File>exhibit321_2021.htm</File>
    <File>exhibit322_2021.htm</File>
    <File>fold-12312021xex1025.htm</File>
    <File>fold-12312021xex1026.htm</File>
    <File>fold-12312021xex1027.htm</File>
    <File>fold-12312021xex1028.htm</File>
    <File>fold-12312021xex1029.htm</File>
    <File>fold-12312021xex1030.htm</File>
    <File>fold-20211231.xsd</File>
    <File>fold-20211231_cal.xml</File>
    <File>fold-20211231_def.xml</File>
    <File>fold-20211231_lab.xml</File>
    <File>fold-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fold-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="927">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fold-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 189,
   "dts": {
    "calculationLink": {
     "local": [
      "fold-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fold-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "fold-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fold-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fold-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fold-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 615,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://www.amicustherapeutics.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 7
   },
   "keyCustom": 67,
   "keyStandard": 427,
   "memberCustom": 17,
   "memberStandard": 46,
   "nsprefix": "fold",
   "nsuri": "http://www.amicustherapeutics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.amicustherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Inventories",
     "role": "http://www.amicustherapeutics.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Property and Equipment",
     "role": "http://www.amicustherapeutics.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Stockholders' Equity",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Share based Compensation",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensation",
     "shortName": "Share based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Assets and Liabilities Measured at Fair Value",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue",
     "shortName": "Assets and Liabilities Measured at Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.amicustherapeutics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Debt",
     "role": "http://www.amicustherapeutics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Leases",
     "role": "http://www.amicustherapeutics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Income Taxes",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157114 - Disclosure - Collaborative Agreements",
     "role": "http://www.amicustherapeutics.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159115 - Disclosure - Basic and Diluted Net Loss per Common Share",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare",
     "shortName": "Basic and Diluted Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Inventories (Tables)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.amicustherapeutics.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Share based Compensation (Tables)",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationTables",
     "shortName": "Share based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables",
     "shortName": "Assets and Liabilities Measured at Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345309 - Disclosure - Debt (Tables)",
     "role": "http://www.amicustherapeutics.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350310 - Disclosure - Leases (Tables)",
     "role": "http://www.amicustherapeutics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353311 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360312 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables",
     "shortName": "Basic and Diluted Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i1b32bb1228f4457281ae01a46fc12e65_D20190401-20190630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i016a712198df44609ada40ce0ec6040e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i016a712198df44609ada40ce0ec6040e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i1fd944574f2a423983b2d669ba0a005a_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "fold:ShareBasedCompensationNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails",
     "shortName": "Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "fold:ShareBasedCompensationNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i65709436b74a491bb3674af00ed88b22_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Goodwill and Intangible Assets - Changes in IPR&D (Details)",
     "role": "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails",
     "shortName": "Goodwill and Intangible Assets - Changes in IPR&D (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Inventories (Details)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails",
     "shortName": "Stockholders' Equity - Common Stock and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "fold:CommonStockVotingRightsForEachShareHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails",
     "shortName": "Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Share based Compensation - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
     "shortName": "Share based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "if7512772b097432b956535d96e9b7951_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details)",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
     "shortName": "Share based Compensation - Weighted-average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "if7512772b097432b956535d96e9b7951_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i65709436b74a491bb3674af00ed88b22_I20201231",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Share based Compensation - Stock Option Activity (Details)",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails",
     "shortName": "Share based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "id112dec781f849479a5fea1933c18841_I20181231",
      "decimals": "-2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i03c9e518216b4905aab06b70874e18f0_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
     "shortName": "Share based Compensation - RSUs and PBRSUs Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ia576c72c43a84ff6b63f05447685167d_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Share based Compensation - Expense Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails",
     "shortName": "Share based Compensation - Expense Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Assets and Liabilities Measured at Fair Value - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ib485fdd881d140c3ade6dc51f9633b29_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i65709436b74a491bb3674af00ed88b22_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "fold:ContingentConsiderationPaidInStockAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Debt - Summary of Long Term Debt (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
     "shortName": "Debt - Summary of Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i9b67daeb3434490faa14ce758326fde1_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie195a0454be34ff68a307be34a84c86c_I20190630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "icae918ebffbc468ba0d20d631fee56f8_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - Leases (Details)",
     "role": "http://www.amicustherapeutics.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - Income Taxes - Statutory Rate (Details)",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails",
     "shortName": "Income Taxes - Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "fold:DeferredTaxAssetsIntellectualProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455430 - Disclosure - Income Taxes - Deferred and Valuation (Details)",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails",
     "shortName": "Income Taxes - Deferred and Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "iecb1de42def1452da99c0b437348ff0a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "fold:DeferredTaxAssetsIntellectualProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie3afe69e33524b46a12ea4a1d4d0b740_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456431 - Disclosure - Income Taxes - Loss Carryforwards (Details)",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails",
     "shortName": "Income Taxes - Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie3afe69e33524b46a12ea4a1d4d0b740_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458432 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i322b8d6caffd45d09d34af4c5317a66d_I20181031",
      "decimals": "-5",
      "lang": "en-US",
      "name": "fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461433 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
     "shortName": "Basic and Diluted Net Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i59b0f5748c0040d4ba044c170c4498a5_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "i59b0f5748c0040d4ba044c170c4498a5_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20211231.htm",
      "contextRef": "ie7a94a18af7640358ef37f727770ebf6_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fold_AccruedContractManufacturingAndContractResearchCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).",
        "label": "Accrued Contract Manufacturing and Contract Research Costs Current",
        "terseLabel": "Accrued contract manufacturing\u00a0&amp; contract research costs"
       }
      }
     },
     "localname": "AccruedContractManufacturingAndContractResearchCostsCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AccruedProgramFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable related to a pharmaceutical program, including but not limited to clinical studies or commercial preparation activities.",
        "label": "Accrued Program Fees",
        "terseLabel": "Accrued Program Fees"
       }
      }
     },
     "localname": "AccruedProgramFees",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AccruedSalesRebatesAndChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Sales Rebates And Chargebacks, Current",
        "label": "Accrued Sales Rebates And Chargebacks, Current",
        "terseLabel": "Accrued sales rebates and discounts"
       }
      }
     },
     "localname": "AccruedSalesRebatesAndChargebacksCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from Termination of Capped Call Confirmations.",
        "label": "Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations",
        "terseLabel": "Termination of capped call confirmations"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AmortizationDeferredFinancingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Amortization Deferred Financing Costs",
        "terseLabel": "Amortization of deferred financing"
       }
      }
     },
     "localname": "AmortizationDeferredFinancingCosts",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "fold_CallidusBiopharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Callidus Biopharma, Inc.",
        "label": "Callidus Biopharma Inc [Member]",
        "terseLabel": "Callidus"
       }
      }
     },
     "localname": "CallidusBiopharmaIncMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities",
        "totalLabel": "Cost, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecurities",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "terseLabel": "Gross unrealized gain, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Gross unrealized loss, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure",
        "totalLabel": "Fair value, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents and Marketable Securities [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_CollaborationAgreementAnnualContributionByCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Annual Contribution By Company",
        "label": "Collaboration Agreement, Annual Contribution By Company",
        "terseLabel": "Discovery program fee"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualContributionByCompany",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Conditional Aggregate Payments Per Indication",
        "label": "Collaborative Agreement, Conditional Aggregate Payments Per Indication",
        "terseLabel": "Conditional aggregate payments per indication"
       }
      }
     },
     "localname": "CollaborativeAgreementConditionalAggregatePaymentsPerIndication",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CollaborativeAgreementTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Term of Agreement",
        "label": "Collaborative Agreement, Term of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "CollaborativeAgreementTermOfAgreement",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.",
        "label": "Collaborative Arrangement Achievement of Post Approval and Sales Based Milestones Potential Payments",
        "terseLabel": "Potential milestone payments upon achievement of post-approval and sales-based milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CollaborativeArrangementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Agreements",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "fold_CommonStockVotingRightsForEachShareHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes entitled for each share held.",
        "label": "Common Stock Voting Rights for Each Share Held",
        "terseLabel": "Voting right for each share held, number"
       }
      }
     },
     "localname": "CommonStockVotingRightsForEachShareHeld",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.",
        "label": "Contingent Acquisition Consideration Payable [Policy Text Block]",
        "terseLabel": "Contingent Consideration Payable"
       }
      }
     },
     "localname": "ContingentAcquisitionConsiderationPayablePolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to clinical and regulatory contingent consideration milestones.",
        "label": "Contingent Consideration Liability Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Approval Milestones"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ContingentConsiderationMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Measurement Input",
        "label": "Contingent Consideration, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input"
       }
      }
     },
     "localname": "ContingentConsiderationMeasurementInput",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "fold_ContingentConsiderationMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of milestone payment.",
        "label": "Contingent Consideration, Milestone Payment",
        "verboseLabel": "Contingent consideration, milestone payment"
       }
      }
     },
     "localname": "ContingentConsiderationMilestonePayment",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ContingentConsiderationPaidInStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of contingent consideration liability in stock during the period.",
        "label": "Contingent Consideration Paid In Stock",
        "terseLabel": "Contingent consideration paid in shares"
       }
      }
     },
     "localname": "ContingentConsiderationPaidInStock",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ContingentConsiderationPaidInStockAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Paid In Stock, Adjustment",
        "label": "Contingent Consideration Paid In Stock, Adjustment",
        "negatedLabel": "Payment of contingent consideration in cash"
       }
      }
     },
     "localname": "ContingentConsiderationPaidInStockAdjustment",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ConvertibleSeniorNotes2016Due2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the \"Convertible Notes).",
        "label": "Convertible Senior Notes2016 Due2023 [Member]",
        "terseLabel": "2016 Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2016Due2023Member",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One",
        "label": "Customer One [Member]",
        "terseLabel": "Customer One"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_DebtInstrumentConsolidatedRevenueCovenantAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Consolidated Revenue Covenant, Amount",
        "label": "Debt Instrument, Consolidated Revenue Covenant, Amount",
        "terseLabel": "Consolidated revenue covenant, amount"
       }
      }
     },
     "localname": "DebtInstrumentConsolidatedRevenueCovenantAmount",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest",
        "label": "Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest",
        "terseLabel": "Accrued and unpaid interest on exchange agreement"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount",
        "label": "Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount",
        "terseLabel": "Exchange agreement, aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance",
        "label": "Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance",
        "terseLabel": "Exchange agreement, authorized (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_DebtInstrumentLiquidityCovenantMinimumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Liquidity Covenant, Minimum Amount",
        "label": "Debt Instrument, Liquidity Covenant, Minimum Amount",
        "terseLabel": "Minimum liquidity covenant"
       }
      }
     },
     "localname": "DebtInstrumentLiquidityCovenantMinimumAmount",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentPeriodicPaymentNumberOfPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Number Of Payments",
        "label": "Debt Instrument, Periodic Payment, Number Of Payments",
        "terseLabel": "Number of payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentNumberOfPayments",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_DebtInstrumentVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate",
        "label": "Debt Instrument, Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentVariableRate",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "terseLabel": "Corporate debt securities, gross unrealized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "negatedTerseLabel": "Corporate debt securities, gross unrealized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsIntellectualProperty": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.",
        "label": "Deferred Tax Assets Intellectual Property",
        "terseLabel": "Intellectual property"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntellectualProperty",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsInterestCarryforwardLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest Carryforward Limitation",
        "label": "Deferred Tax Assets, Interest Carryforward Limitation",
        "terseLabel": "Interest carry forward limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestCarryforwardLimitation",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsLeasingArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Leasing Arrangements",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carry forwards, net of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Assets Liabilities Gross",
        "totalLabel": "Total net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsNonCashStockIssueNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carry forwards expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Deferred Tax Assets Non Cash Stock Issue Non Current",
        "terseLabel": "Non-cash stock issue"
       }
      }
     },
     "localname": "DeferredTaxAssetsNonCashStockIssueNonCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 5.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from advanced Research and Development payments.",
        "label": "Deferred Tax Liabilities Advanced Research and Development Payments",
        "negatedLabel": "Advanced R&amp;D payments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesBusinessAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 2.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Business Acquisition",
        "label": "Deferred Tax Liabilities, Business Acquisition",
        "negatedLabel": "Business acquisition"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesBusinessAcquisition",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesConvertibleNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 4.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from convertible notes.",
        "label": "Deferred Tax Liabilities, Convertible Notes",
        "negatedLabel": "Convertible notes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesConvertibleNotes",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesRoyaltyPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 3.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from royalty payable",
        "label": "Deferred Tax Liabilities, Royalty Payable",
        "negatedLabel": "Royalty payable"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRoyaltyPayable",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_EarlySettlementPremiums": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Settlement Premiums",
        "label": "Early Settlement Premiums",
        "terseLabel": "Early settlement premiums"
       }
      }
     },
     "localname": "EarlySettlementPremiums",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value of contingent consideration.",
        "label": "Effective Income Tax Rate Reconciliation, Fair Value of Contingent Consideration",
        "negatedTerseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Conversion",
        "negatedTerseLabel": "Nondeductible debt conversion"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_ForeignCurrencyRemeasurementGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "label": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "negatedLabel": "Foreign currency remeasurement loss"
       }
      }
     },
     "localname": "ForeignCurrencyRemeasurementGainLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_GainLossOnExchangeOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Exchange Of Debt",
        "label": "Gain (Loss) On Exchange Of Debt",
        "negatedTerseLabel": "Loss on exchange of convertible notes",
        "terseLabel": "Loss on exchange of convertible notes"
       }
      }
     },
     "localname": "GainLossOnExchangeOfDebt",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued",
        "label": "Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued",
        "terseLabel": "Gain (loss) on extinguishment of debt, fair value of common shares issued"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_GlaxoSmithKlinePLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Glaxo Group Limited, an affiliate of GlaxoSmithKline PLC (GSK).",
        "label": "Glaxo Smith Kline P L C [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlinePLCMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_IncreaseDecreaseInDeferredReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of deferred reimbursements.",
        "label": "Increase (Decrease) In Deferred Reimbursements",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredReimbursements",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_IncreaseDecreaseInNoncurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.",
        "label": "Increase (Decrease) In Noncurrent Operating Liabilities",
        "terseLabel": "Other non-current assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentOperatingLiabilities",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_InterestIncomeAndInterestExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for interest income and interest expense.",
        "label": "Interest Income and Interest Expense [Policy Text Block]",
        "terseLabel": "Interest Income and Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpensePolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_LesseeOperatingLeaseLeaseNotYetCommencedLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Liability",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Liability",
        "terseLabel": "Lease not yet commenced, liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiability",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_LesseeOperatingLeaseLiabilityTenantIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Incentives",
        "label": "Lessee, Operating Lease, Liability, Tenant Incentives",
        "negatedTerseLabel": "Less lease incentives"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantIncentives",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_MeasurementInputProbabilityOfMilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "label": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "terseLabel": "Probability of achievement of milestones"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfMilestoneAchievementMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_MilestonePaymentStockIssuedAsConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment, Stock Issued As Consideration",
        "label": "Milestone Payment, Stock Issued As Consideration",
        "terseLabel": "Milestone payment, stock issued as consideration"
       }
      }
     },
     "localname": "MilestonePaymentStockIssuedAsConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.",
        "label": "Nonqualified Cash Deferral Plans Policy [Policy Text Block]",
        "terseLabel": "Nonqualified Cash Deferral Plan"
       }
      }
     },
     "localname": "NonqualifiedCashDeferralPlansPolicyPolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.",
        "label": "Number of Major Markets Outside United States from Whom Parties to Contractual Arrangement is Eligible to Receive Post Approval and Sales Based Milestones",
        "terseLabel": "Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones"
       }
      }
     },
     "localname": "NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal.",
        "label": "Number Of Shares Issued Per Increment Of Convertible Debt",
        "terseLabel": "Shares issued per increment of convertible debt (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesIssuedPerIncrementOfConvertibleDebt",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_OrphanDrugTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to orphan drug tax credit carryforward.",
        "label": "Orphan Drug Tax Credit Carryforward [Member]",
        "terseLabel": "Orphan drug tax credit carryforwards"
       }
      }
     },
     "localname": "OrphanDrugTaxCreditCarryforwardMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_OtherComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for other comprehensive income.",
        "label": "Other Comprehensive Income Policy [Policy Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_PaymentsForCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Collaborative Arrangement",
        "label": "Payments For Collaborative Arrangement",
        "terseLabel": "Payments for collaborative agreement"
       }
      }
     },
     "localname": "PaymentsForCollaborativeArrangement",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_PaymentsForRepurchaseOfRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire restricted stock units during the period.",
        "label": "Payments For Repurchase Of Restricted Stock Units",
        "negatedLabel": "Payments of employee withholding taxes related to restricted stock unit vesting"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRestrictedStockUnits",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_PremiumsPaidForCappedCallConfirmations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for premiums paid for capped call confirmations.",
        "label": "Premiums Paid for Capped Call Confirmations",
        "terseLabel": "Proceeds for capped call confirmations"
       }
      }
     },
     "localname": "PremiumsPaidForCappedCallConfirmations",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_PrivatePlacementPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to private placement purchase agreements.",
        "label": "Private Placement Purchase Agreement [Member]",
        "terseLabel": "Private Placement Purchase Agreement"
       }
      }
     },
     "localname": "PrivatePlacementPurchaseAgreementMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ProbabilityWeightedDiscountedCashFlowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to valuation technique of probability weighted discounted cash flow.",
        "label": "Probability Weighted Discounted Cash Flow [Member]",
        "terseLabel": "Probability weighted discounted cash flow"
       }
      }
     },
     "localname": "ProbabilityWeightedDiscountedCashFlowMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt",
        "label": "Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt",
        "terseLabel": "Proceeds from termination of capped call confirmations"
       }
      }
     },
     "localname": "ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Warrants And Equity Financing",
        "label": "Proceeds From Issuance Of Warrants And Equity Financing",
        "terseLabel": "Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrantsAndEquityFinancing",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ResearchEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents tangible property used for research.",
        "label": "Research Equipment [Member]",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_RevisedCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the License and Collaboration Agreement entered into by the entity on November 19, 2013.",
        "label": "Revised Collaboration Agreement [Member]",
        "terseLabel": "Revised Agreement"
       }
      }
     },
     "localname": "RevisedCollaborationAgreementMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_SeniorSecuredTermLoanDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Term Loan Due2026 Member",
        "label": "Senior Secured Term Loan Due2026 [Member]",
        "terseLabel": "Senior Secured Term Loan due 2026:"
       }
      }
     },
     "localname": "SeniorSecuredTermLoanDue2026Member",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage",
        "terseLabel": "Monthly vesting percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share",
        "terseLabel": "Expected annual dividend per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting",
        "terseLabel": "Period following separation for accelerated vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_ShareBasedCompensationNumberOfPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of plans under the equity-based arrangements.",
        "label": "Share Based Compensation Number of Plans",
        "terseLabel": "Number of equity-based employee compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationNumberOfPlans",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_ShortTermCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Short Term Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "ShortTermCorporateDebtSecuritiesMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockExercisesAt706Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Exercises at $7.06",
        "label": "Stock Exercises at $7.06 [Member]",
        "terseLabel": "Stock Exercises at $7.06"
       }
      }
     },
     "localname": "StockExercisesAt706Member",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockExercisesAt798Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Exercises at $7.98",
        "label": "Stock Exercises at $7.98 [Member]",
        "terseLabel": "Stock Exercises at $7.98"
       }
      }
     },
     "localname": "StockExercisesAt798Member",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockIssuedDuringPeriodSharesContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Contingent Consideration",
        "label": "Stock Issued During Period Shares Contingent Consideration",
        "terseLabel": "Stock issued for contingent consideration (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesContingentConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants (in shares).",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_StockIssuedDuringPeriodValueContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Contingent Consideration",
        "label": "Stock Issued During Period Value Contingent Consideration",
        "terseLabel": "Stock issued for contingent consideration"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueContingentConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_TB200PompeProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to ATB-200 Pompe program.",
        "label": "T B200 Pompe Program [Member]",
        "terseLabel": "ATB-200 Pompe Program"
       }
      }
     },
     "localname": "TB200PompeProgramMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_UnderwrittenOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Offering [Member]",
        "label": "Underwritten Offering [Member]",
        "terseLabel": "Underwritten Offering"
       }
      }
     },
     "localname": "UnderwrittenOfferingMember",
     "nsuri": "http://www.amicustherapeutics.com/20211231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r60",
      "r62",
      "r127",
      "r128",
      "r282",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r205",
      "r352",
      "r355",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r281",
      "r320",
      "r371",
      "r373",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r566",
      "r606",
      "r609",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r281",
      "r320",
      "r371",
      "r373",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r566",
      "r606",
      "r609",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r205",
      "r352",
      "r355",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r281",
      "r320",
      "r361",
      "r371",
      "r373",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r566",
      "r606",
      "r609",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r281",
      "r320",
      "r361",
      "r371",
      "r373",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r566",
      "r606",
      "r609",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r127",
      "r128",
      "r282",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r202",
      "r203",
      "r352",
      "r354",
      "r607",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r352",
      "r354",
      "r607",
      "r617",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41",
      "r535"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r22",
      "r206",
      "r207"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r47"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r47"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39",
      "r259"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "terseLabel": "Accumulated depreciation of property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized loss on available-for securities"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r68",
      "r69",
      "r495"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Accumulated other comprehensive gain (loss):"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r410",
      "r411",
      "r412",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Employee withholding taxes related to restricted stock unit vesting"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r374",
      "r376",
      "r416",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r376",
      "r406",
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total equity compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r208",
      "r226",
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r89",
      "r106",
      "r301",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r106",
      "r301",
      "r313",
      "r314",
      "r514"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and deferred financing"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r217",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r122",
      "r184",
      "r193",
      "r199",
      "r224",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r471",
      "r477",
      "r499",
      "r533",
      "r535",
      "r574",
      "r594"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r59",
      "r122",
      "r224",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r471",
      "r477",
      "r499",
      "r533",
      "r535"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gain, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized loss, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r213",
      "r234"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r210",
      "r214",
      "r234",
      "r578"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities, available-for-sale",
        "verboseLabel": "Fair value, available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r212",
      "r234"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Corporate debt securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r377",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r370",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r370",
      "r372",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r105",
      "r464"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Non-cash changes in the fair value of contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r460",
      "r461",
      "r463"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures unpaid at the end of period"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r36",
      "r108"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair value, cash balances"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r102",
      "r108",
      "r113"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at the end of the year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at the beginning of the year",
        "totalLabel": "Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r102",
      "r502"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r119",
      "r122",
      "r146",
      "r147",
      "r148",
      "r150",
      "r152",
      "r161",
      "r162",
      "r163",
      "r224",
      "r266",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r318",
      "r319",
      "r323",
      "r327",
      "r499",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r341",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of common shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r465",
      "r466",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r362",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r53",
      "r264",
      "r579",
      "r600"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r131",
      "r132",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r535"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.01 par value, 500,000,000 shares authorized, 278,912,800 and 262,063,461 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Significant components of the deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income [Member]",
        "terseLabel": "Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r72",
      "r74",
      "r75",
      "r83",
      "r583",
      "r602"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r171",
      "r172",
      "r205",
      "r496",
      "r497",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r171",
      "r172",
      "r205",
      "r496",
      "r497",
      "r616",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r171",
      "r172",
      "r205",
      "r496",
      "r497",
      "r616",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r166",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r171",
      "r172",
      "r205",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r169",
      "r171",
      "r172",
      "r173",
      "r496",
      "r498",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r171",
      "r172",
      "r205",
      "r496",
      "r497",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.",
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Contingent Liabilities"
       }
      }
     },
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r281",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r311",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Liability Components of the Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r362",
      "r369",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r86",
      "r568"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r440",
      "r447"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r440"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r440",
      "r447"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r170",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r110",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r295",
      "r302",
      "r303",
      "r305",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r121",
      "r129",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r311",
      "r312",
      "r313",
      "r314",
      "r515",
      "r575",
      "r576",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r18",
      "r306",
      "r576",
      "r593"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r280",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r50",
      "r280",
      "r335",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt conversion ratio (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r278",
      "r311",
      "r312",
      "r513",
      "r515",
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r49",
      "r309",
      "r513",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate of the liability component"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Debt Instruments"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r51",
      "r121",
      "r129",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r311",
      "r312",
      "r313",
      "r314",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r51",
      "r590"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r51",
      "r121",
      "r129",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r311",
      "r312",
      "r313",
      "r314",
      "r335",
      "r337",
      "r338",
      "r339",
      "r512",
      "r513",
      "r515",
      "r516",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r291",
      "r512",
      "r516"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]",
        "terseLabel": "Debt Instruments"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r213",
      "r234"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
        "totalLabel": "Corporate debt securities, cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r219",
      "r235",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair value of available-for-sale debt securities in unrealized loss positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Realized Gain (Loss)",
        "terseLabel": "Debt securities, realized gain (loss)"
       }
      }
     },
     "localname": "DebtSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation plan liability"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).",
        "label": "Deferred Credits and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r441",
      "r447"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r441",
      "r447"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r106",
      "r123",
      "r441",
      "r447",
      "r448",
      "r449"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Non-cash deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r58",
      "r245"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "negatedLabel": "Less: deferred financing"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r441",
      "r447"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 1.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Amortization/depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r436",
      "r438",
      "r439"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research tax credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r423",
      "r433"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 6.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r106",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r106",
      "r257"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r106",
      "r182"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r84",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r144",
      "r146",
      "r150",
      "r151",
      "r152",
      "r156",
      "r157",
      "r484",
      "r485",
      "r584",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss attributable to common stockholders per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r84",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r146",
      "r150",
      "r151",
      "r152",
      "r156",
      "r157",
      "r484",
      "r485",
      "r584",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss attributable to common stockholders per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of the statutory tax rates and the effective tax rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r125",
      "r425",
      "r451"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedTerseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r425",
      "r451"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r425",
      "r451"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedTerseLabel": "Impact of foreign operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r425",
      "r451"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "negatedTerseLabel": "Nondeductible IPR&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r425",
      "r451"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "negatedTerseLabel": "Nondeductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r425",
      "r451"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r425",
      "r451"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedTerseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r425",
      "r451"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation costs, period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r77",
      "r78",
      "r79",
      "r131",
      "r132",
      "r133",
      "r135",
      "r141",
      "r143",
      "r160",
      "r225",
      "r334",
      "r340",
      "r410",
      "r411",
      "r412",
      "r443",
      "r444",
      "r483",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r509",
      "r610",
      "r611",
      "r612",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets and liabilities subject to fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Subject to Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r293",
      "r311",
      "r312",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r487",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r293",
      "r311",
      "r312",
      "r362",
      "r363",
      "r368",
      "r369",
      "r487",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r293",
      "r311",
      "r312",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r487",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Changes in fair value during the period, included in the Consolidated Statements of Operations",
        "negatedTerseLabel": "Changes in fair value of contingent consideration payable"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of the period",
        "periodStartLabel": "Balance, beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r293",
      "r311",
      "r312",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r520",
      "r525"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r221",
      "r222",
      "r223",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r304",
      "r332",
      "r482",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r106",
      "r315",
      "r316"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r246",
      "r247",
      "r535",
      "r573"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails",
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r248",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Change in goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r85",
      "r122",
      "r184",
      "r192",
      "r195",
      "r198",
      "r200",
      "r224",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r499"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r106",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Change in IPR&amp;D"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r124",
      "r450"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r184",
      "r192",
      "r195",
      "r198",
      "r200",
      "r569",
      "r581",
      "r586",
      "r604"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (loss) before income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r124",
      "r450"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r125",
      "r426",
      "r429",
      "r435",
      "r445",
      "r452",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r126",
      "r142",
      "r143",
      "r183",
      "r424",
      "r446",
      "r453",
      "r605"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r420",
      "r421",
      "r429",
      "r430",
      "r434",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Indefinite-lived Intangible Assets [Roll Forward]",
        "terseLabel": "Changes in IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r250",
      "r252"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "In-process research\u00a0&amp; development"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails",
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r80",
      "r181",
      "r511",
      "r514",
      "r585"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r89",
      "r299",
      "r310",
      "r313",
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r91",
      "r300",
      "r313",
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Components of Total Interest Expense Recognized Related to the Convertible Notes"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r99",
      "r103",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r243"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r56",
      "r535"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r57",
      "r116",
      "r159",
      "r240",
      "r241",
      "r244",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories and Cost of Goods Sold"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r243"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r56",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Reserve for inventory"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r243"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r88",
      "r180"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease not yet commenced, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/LeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r122",
      "r194",
      "r224",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r472",
      "r477",
      "r478",
      "r499",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r122",
      "r224",
      "r499",
      "r535",
      "r577",
      "r598"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r122",
      "r224",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r472",
      "r477",
      "r478",
      "r499",
      "r533",
      "r534",
      "r535"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r486"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Fair value of liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r292",
      "r307",
      "r311",
      "r312",
      "r576",
      "r595"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Net carrying value of Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Abstract]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "LongtermConvertibleDebtCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r51",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r6",
      "r46"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r102",
      "r104",
      "r107"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r70",
      "r73",
      "r79",
      "r82",
      "r107",
      "r122",
      "r134",
      "r136",
      "r137",
      "r138",
      "r139",
      "r142",
      "r143",
      "r149",
      "r184",
      "r192",
      "r195",
      "r198",
      "r200",
      "r224",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r485",
      "r499",
      "r582",
      "r601"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Developments"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Ex-U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r184",
      "r192",
      "r195",
      "r198",
      "r200"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r523",
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Cash paid for amounts included in operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Lease"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liability",
        "verboseLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of the operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion of the operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease ROU assets, net",
        "verboseLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r528",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r527",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease terms (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Amount of net operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r47"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r469",
      "r470",
      "r476"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized holding gain on available-for-sale securities",
        "verboseLabel": "Unrealized (loss) gain on available-for-sale securities, net of tax impact of $0, $(50), and $182, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r469",
      "r470",
      "r476"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment (loss) gain, net of tax impact of $0, $1,552, and $889, respectively",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": {
     "auth_ref": [
      "r63",
      "r67",
      "r500",
      "r501",
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax",
        "terseLabel": "Foreign currency translation gain (loss), tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r64",
      "r65",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "terseLabel": "Available-for-sale securities, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r71",
      "r74",
      "r469",
      "r470",
      "r476"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive (loss) gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive (loss) gain:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "negatedTerseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Tenant improvements paid through lease incentive"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Net proceeds from the issuance of common stock after deducting underwriting discounts and commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r92",
      "r93",
      "r211"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sale and redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSecuredLinesOfCredit": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from Secured Lines of Credit",
        "terseLabel": "Proceeds from secured lines of credit"
       }
      }
     },
     "localname": "ProceedsFromSecuredLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r95",
      "r409"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised, net"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Gross cash proceeds from warrant exercises",
        "verboseLabel": "Proceeds from warrants exercised, net"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r70",
      "r73",
      "r79",
      "r101",
      "r122",
      "r134",
      "r142",
      "r143",
      "r184",
      "r192",
      "r195",
      "r198",
      "r200",
      "r224",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r469",
      "r474",
      "r475",
      "r479",
      "r480",
      "r485",
      "r499",
      "r586"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r39",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r262",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r38",
      "r258"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r260",
      "r535",
      "r588",
      "r599"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net property and equipment",
        "verboseLabel": "Property and equipment, less accumulated depreciation of $19,882 and $14,487 at December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r260",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Payment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and experimentation tax credit carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r13",
      "r108",
      "r113",
      "r572",
      "r596"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r340",
      "r413",
      "r535",
      "r597",
      "r613",
      "r614"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r131",
      "r132",
      "r133",
      "r135",
      "r141",
      "r143",
      "r225",
      "r410",
      "r411",
      "r412",
      "r443",
      "r444",
      "r483",
      "r610",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r178",
      "r179",
      "r191",
      "r196",
      "r197",
      "r201",
      "r202",
      "r205",
      "r351",
      "r352",
      "r568"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue Disaggregated by Geographical Area"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r526",
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock issued (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r171",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contingent Consideration Payable"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash and Available for Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of the Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Statutory Tax Rates and the Effective Tax Rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r376",
      "r405",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of loss before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r253",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Changes in IPR&amp;D"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories for the Period"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r39",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r13",
      "r113",
      "r572",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r377",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r383",
      "r394",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested RSU Activity under the Plan"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A senior loan takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors.",
        "label": "Senior Loans [Member]",
        "terseLabel": "Senior Loans"
       }
      }
     },
     "localname": "SeniorLoansMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested units as of the end of the period (in shares)",
        "periodStartLabel": "Non-vested units as of the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested units as of the end of the period (in dollars per share)",
        "periodStartLabel": "Non-vested units as of the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Non-vested units, weighted average remaining years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "verboseLabel": "RSUs vested and non-vested units expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options, Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r385",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options vested and unvested expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and unvested expected to vest as of the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and unvested expected to vest as of the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r375",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First Anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r377",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "verboseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Non-vested units, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r401",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and unvested expected to vest at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r114",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r119",
      "r122",
      "r146",
      "r147",
      "r148",
      "r150",
      "r152",
      "r161",
      "r162",
      "r163",
      "r224",
      "r266",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r318",
      "r319",
      "r323",
      "r327",
      "r334",
      "r499",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r55",
      "r77",
      "r78",
      "r79",
      "r131",
      "r132",
      "r133",
      "r135",
      "r141",
      "r143",
      "r160",
      "r225",
      "r334",
      "r340",
      "r410",
      "r411",
      "r412",
      "r443",
      "r444",
      "r483",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r509",
      "r610",
      "r611",
      "r612",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r160",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r54",
      "r296",
      "r334",
      "r335",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Equity component of the convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r334",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Stock issued from equity financing (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r20",
      "r21",
      "r334",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Restricted stock tax vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r334",
      "r340",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, Exercised (in shares)",
        "terseLabel": "Stock options exercised, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r55",
      "r334",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Equity component of the convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r334",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock issued from equity financing"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r55",
      "r334",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r122",
      "r209",
      "r224",
      "r499",
      "r535"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r319",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Deferred compensation investment"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r217",
      "r218",
      "r221",
      "r222",
      "r223",
      "r304",
      "r332",
      "r482",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrual for interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r168",
      "r174",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in the valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r524",
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "verboseLabel": "Outstanding warrants, convertible to common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r145",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r144",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(b))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r633": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r634": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r635": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r636": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r637": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r638": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r639": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r641": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r642": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r643": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r644": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r645": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r646": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r647": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r648": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r649": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001178879-22-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178879-22-000006-xbrl.zip
M4$L#!!0    ( &:"6%1D,V2_I@,  ),D   2    97AH:6)I=#(Q7S(P,C$N
M:'1MW9I;;QHY%,??]U.X5+NE4N;*=2<4*4":T) TR@Q-^[0RXP,<Q3,>>4PH
M_?3U,$$-VPW9A[V,P\-(OI_SX\CVWSJ]5Z./P^C+]2E9JH23Z^E@,AZ2FN4X
MMXVAXXRB$3F/+B>D:;L>B21-<U0H4LH=Y_2J1FI+I;+ <=;KM;UNV$(NG.C&
M*:9J.ER('&RF6*W?*VKT%RCK_])[95ED).)5 JDBL02J@)%5CNF"W#+([XAE
M/?0:BFPC<;%4Q'=]G]P*>8?WM&Q7J#CT=_/TG++<<[:+]&:";?H]AO<$V;L:
MPJS3;79BF'<;M-EM^3.WX[>ZGMMN=RB-V_"'IXUT=/=R3*XV'-[5$DRM)13K
M!TW?[K0R=;Q&II:!Y[J_UO:Z*OBJ+,IQD09;@W7K7&CW'IICP84,7KO;WW'1
M8LUI@GP3O(DP@9Q<P9K<B(2F;XYR#=G*0>*\[)CC-] KZL6WQ75I4$?/PS&%
MG8&>7YAT^OE\/!A'Q/=Z3M%[Y]3/KE&YT-[-A%(B"0K/'FJ4R+;%1P[%FB_(
M_\FC">:*B#D)5[,<&5*)>FY=5DL@-[#0K3HHU6^OO;9[O._S/^&M#B39?W+:
MC#*FH];B,%=!H[V;!U.FYP@LKYO]^W'0_$MJGKTS^K]?_7@/B^?:K0+#D'*.
M;)63 8IL265"C\H_;9S&-JF/@-,UE?#60-A^]6 #AQ2^'A'SX38J!S>,43"0
MR8N)WV;E$%\BO03V8@"W*@?X),%8[\71$B3-8*4PSO5>H<^]E);7.W(N>#&,
M3##!XGY6GUZ8B+YM!/KIA>F<.Z9P_ICI<A'CN>G(NT8@#T]"4G^O[^BQD5OW
M[R9 +L_)@?U)GY-7H)61Y#1EN8F\M9=5 =YZAO=9,CLG]3-]$Z3IQDC6U5&)
M3[,FH3VQISJPPXQB:B3FZNC#YT(ZM*7-->NQHMS,D*Z.7#P0TA?VA8;\@6;4
MS("NCF \ 'E(4\KH8PE9UAA)O#H*\@#QZ^A+B7L2C4C]9%4\S7(T$WAU=.,!
MX-/PB$PF0\-?1[SJ:,=]U@/4)BPTZ-T[ZGMM$1JZ@U1'+1X(Z),L+&(Y3:B\
M,Y)R=>3B <JG*RDR^/'\,990Z$43@?LFR$42KE%]*T4Y*57CHQHCL5=5.9Y%
MNX?K?'LTFGTR^I53CD,J4=']\'X)H(V0C>4K*@E!WF,,SSRM_IW\A3_EMF2B
M3.X)BO- X3T\F>WRD$CA_AA"9[G@*_7SD"?MV/N6Z3K;Q*'^=U!+ P04
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M+FA7WDTKC4,0DS).YQ9@U^A\_.O[TW>G(^1Z+?QZ#[>=@X=J+U>XQM;Z3A'
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MAVX)'[S4KG[ZVW?W_P!.?@=02P,$%     @ 9H)85(;>=5C4!P  E2   !,
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M!S9@<T-TK2GQ=/JE,J@H30%@65\5XU@;X17P[<E$YBAV*?"%$5D0<$D$K5?
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M-VP<D/V+X'YXVS.3]W[5KO*XM9K"(X"E=/=/N>_#XKU?OJO?\,'>_]>!PS\
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M-P_5[,&&64<B$V,PY!PO17:P[,E$1B;&8X2[9M1W*-%Z\."6CU^D<B9M68Q
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M&/6M$<2( "[:C_CNXX=2]30R5%(?^HQ)!ZI<?<<2'GKZ*CKZ(GS.1MP:D1E
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M.HW%#?AO',%'H-TVD[.Q\1A"]T>RX5-5F=AD#UDRB=,,F83TJ9.+(4B%AE&
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M^&R0*\/H$.-?S?9]"_I<][JWQ+HQ^]!T8UZ9%GS?;-SW#6@TEMW,SG6W=]O
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M#LMD2%TL"V  Q.&=T D/9:8DN64K):V2KVQ(2ER(.#5$).E)'H,#>>Z8+SF
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M(@MUM?I_70M/$\#)&7E._<=)\K]P^O1?4$L#!!0    ( &:"6%1KL)O=,PP
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M.B6C0%.!4+"\ ]AC:8"X# )T$"IY@!$X3$@**6W,?(:=@6DL<  <-D(_U+I
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M3,']:# 3")=FDBX !MJY^Y(5;5@!MZE+' ::$;[2(/CXQ#QFS&,X&&*'%4Z
MTP9H1C&RP9JPUK8>'_C,YE.N3,V!B5&PP=LW]<LK7./I9/2=<K)SHY9GPC(;
M+Q,6V66L@10V"P(PVXW&$L)ZD:&VR2,/R8N2P*"3N>VI=;RB[6V;&TSP]DVM
M<06GA!_R!?\S#LBG$$%ZT93:821QOI#9<P]D,5NI>0[:IK*U4^S,-(WS$YU^
M)<\F5-\V(3 /D/_GR+.5!)<</%.(-8]U?IPV,U28,C44KPH.*'%9" <(7=N.
MF@4T"=2F )$8XH+BP""VK3R7")20[O1S96YI]2U+R](S-/YO4+V-6$\L 9#!
M'($XQ7 .H8K@7L,2F.")!^AWD\S]2)B#D U8B%P" $=/D[*44Q..[Z:2AE')
MM;.^ )WT^H\%W)4:6C?]H9403L =)M>DC2('F;*94$X 5(-LK3W'3 B=:SQ1
M-Z(3EZ4OU[J6$)!S7SD&$D33*;<Y\VQ5$E/.""MK6$C @IK]!1#A,F?&G#10
MD@&H;=3T%$ @EN@?+D[U#_6]K+!2-0[IK?JRVHKFA8K%,K(ET\B.>M,BO(S%
MT&%3&.>0,9.+K.H+2C0&:5-?;<MA[2_$Y9 HB&//%",H0'H"HLEX[7$U*YA3
MUR5S^J3"$;)@U$/DSR#94^%K$ %F]<1JSJ.,5""1YV)LJXP%:(YM)13Z9B>R
MDOE-GN(@O,_59#G&=PV46,D,W[4C^+X7#N@MS@"SPG=-X7N\'?$I/L1 3SG-
MY]PCL*>F<B1.!+1DL6,]F42_=8.Q5C<N#Q'M!HG9PPZY@_X@V)DGW#T-.Q-L
M7H4B;]^8Y^6K_;]94NR(Z7S$A CGI:!LX]L=!JF(YF$>JI( ERS4FVB2^2ZU
MX62<XFS!]"^ \^1X^H5B<0S7C$ 8YU9*N#G(LSH\L,43DRNLU*BD?P 3"2<'
M^99RS8$N_JDUD0D#O2IOG>[20HP!/^()5??>.F?$DQT%2WSGJBHO"-W;UY3,
MI5C]W6MV2ZZ:B# 4BV9Y<PF=!,*-POU+7NB/VRSHM#:]VKI-;RXW;#QCQ8ED
M]$N13B%T:5)W25?!V;%6OO-+P_S?6OE2K5WF,1/;BTTN<^81)J\4B+SL$9)
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M&"T6:G="]7?!4K$NN1/.?6=CNLB_,=5R9TP]0?H*7=M5DRPMR"#65YOY>H]
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M?DL0>A]*'90',JEO[6!_]$L;52GB\+IR3'?SBF_?L9T6)AOV!_M@WTZK%UO
MT"F,.OC$<,FZRBN^<]S; _>]2Y5.N\#26]VTGYHRK6/?G0R[:I#EHT;:=<4
MM/BBK+!H)F)OK1#8@K8T5%G'K8FQEQSDG,CYE^@@(R5EVLYT^NE_AM>)"!RL
MQ_3ZZ$)Q)F<G/.7**-I.-SN?%F?-#EMF(LXK0;H1)^>2<Q&6)I%A8,* 8"%E
M0Z%<2K",S?P+TD_&O@]KH_*]MR]?0Y*6O^3.3=-)776L[H_VZ[X*,B 8WZX@
MLQ+8[PPG..K*?764,R214IPF6F NI10\5BN!70GL\Y1\6@GL]VW;TSRQRFG*
M*&,2>:7"UI D%I1P;]T"E".;KXK*51GE,@SL;!NZ]2Y3_:J8\G/7O)]:?IA/
MJ"4VELXBIA'1FDL5SM<#ZTLBO0#1HQ5+3#N@B#RR N'$"\.$(,H@X\$&CS5U
MBO %.+]OOEAB!G77GR=',-1/ !XPB'I&I%>..^P29J40*-$+< STBB^>Y=QI
M+G584Z3(<"8HT@DRB=!&!4LCL>/E(I3,+U]L 5:G@QUE2EOO]@ZT$LJGR1%?
M9\.*%X+:>.YE991,*2N->L.(D3QAGCF@C38<"\["B3"@,/!X_^GX_)>YYH0/
M*@>3O^M"N/S6H=99WV;]/1AVKE7_4WEB@+/AOG=[;UO[4W-8?AI6O+V9]K$G
MS=SBVQ^I@>!]C!05EEG#<"+#V0E>(QHGTC&9N 7BVQ7;/"O;7)X8:M7H_@-#
MX<+DV4>?%ZJIEU8SSR5*6.RLHIA3:V-N8X$)JTY_$/-\P-'7V.Y=VG<M7]WQ
MG(H,BYN'!?U(LJ.A5@(!D$\(4\B&@Z^= ]_'QA[3>)$ X3D<U!=&HT4!AYLL
MQ!&*";/(:,>(99IX%E.B?")XL(<7@(5>8!EEI:U>C"&-0SS6%B$6>^9C+QW%
M7DCAD>=47Y8<G6>&7'"V^2Z!>ZZ3+V;/D-18!7#(N4!@XS B$T1#9 D38K7E
MY3(_YJLPTD*$D3"?8DW)1 3[RR5!<Q(I2,*<M? *H:W =O[YXBLG#DYN:0&I
M-KO=;!":GLZY.3/ERJ\M8[_/T\^ $>^[RI27W@]STU&%VSS)W526CW\>T1"(
M8PUNHHD%L\Y+&7L;A\UZ2#+L3%GU"T2CJOHUUS+RTV/GC<)B)8L\KK 8GUYA
M,2QC!>8@TXZ&\S>$HB@<U<V48$:,%?!<'^TZ32;Z,1F?WIFN6C*3J$1:KA$3
M,M$J,<18D&6@CA"WC]]8D><YSG.<TN')3&K"E(HQ-P2DC$A.+:*:*.(=3\PB
M'54T$[R^+ H9*C0,1N'0R*P/7XM;6S&M+5/V0J&'U.[UM]19.E#=>>*HJ9V9
M9("CF)=,)X0YS2253M(8:2? ,J#T)^6HA:2E44YBX;3WVC >SGZV!%E.L7<N
MYEXL4&7FE34W\^+/1A@$IAM%WF/F#!&Q]EPA3U4H#Y@L4J7^%3?-O+ZT(S$A
M4BNE$\V84))Q2:V,0_U ZN7"Y_Y=H^3RIH).,3L8(Y4PJRBQBDEOI>9@R**8
MNP2N&+7H*7\_!3M,L7241,1Z&AL,*H=;*G!,&1:,>\DM4[*T0A-,"*E-/CPW
M7SS5XDO*$Z+)8RR^6[?^ *I:FH2R_=J!(\A<@B2)P7"71B<LIGQ<1&FN4;4J
MUM]6%YO#02?+[RR_;</58I":K; O.!\M"+SYD&@CD#06+'%*F12QBU58&P5;
MG,1H\>E2>M*;?1M.5^C^-<S3PJ;F>0X6?A8*.:J\XQ*,CY@P'8I=$Z>8*LN>
M@O0L (6 -M6Z]9;*\Y'/\G >W/UG$RT*31S!BC,,\Z^8<%QP( E"3C@$)B-;
M@'W:7Z%)J:I;^5D'=',^/+GWS@6A$R5$"\N-\MZRV")IP4_TS,04)XKSR3G;
M:([I=/_JXI5'V.TJG55'P5R[ZYFS#3&:DAR!,46TD;%SC#$<"G$*$" ="T:!
M7%64&.A3Q?16A'JRK5>2ZG'1O5M4_0%;3V!B,-6(4)XP0Y30GGI'8V%8;(PH
M/6A,,9[?Y9NOK>GON\]IX>PU@F;]J:WGA\2GTH!T^1F0:M14O>M[M'>[ZB([
MZ*6#SK^Z:=^]?[?UK().:QA/9VG/N$0D-B1[2PU ')<UO\!E,MHD1NDRX!M8
MHA+T%6_,*6_<P):2.QZ'+;<8Z3MW'O3*FI;W;SZHKDU:>/S^ W!$+:@>:XQG
MEA*EA*+4))H+ZA*/%F@AXGD4T*)QY6Q6(,()41QQX0QG+!9"Z$0Q3T3B*?$N
M,8O/1C\=O,UH*<MAA:2WFFG-; R^)0%DHA3'*)%&+\")AS\S_SQ/K"'FDN.$
M"9;$3*-886P3SD1"E2=4D@7"EDUHP:;=85!!5Y7#ZQ?5T20[>=8+>2[#0<D8
M+5]7>3_MGQ3O77[04;E[.[J_@9N*KMX[ZV8CY\K4XT?E%R\D4A!O,4"#]$)I
MYK&15"=:""5CJI6Q;H$6O9>4+6:R>HT3C2AP@*:(L#@!I:$0!@O78"1B$R]2
MWMURLL5L$JZ0]EA;!>HC')JMI99Q@K0AE,<V45JME,B=]8A!GIJ!LR5C'(+_
M6.P?'"ZC(M&)291Q.N$([$TP/ G8&8EU0EBBF$E6BF0>6&,VRH0ZBC2/N6>8
M866TDP(PPU' $L'%(J7<+B]KS$:A"&LH4C&6":&,>JV]<YHX%8K &^?\2J'<
M9(V/*GC$SUWO828*!$P(4!U.>2<-H_!!6Z- G1"LG:%^D=)OEX@59I,["\ZG
M#B?R2NU8;(0.!3]0V%O'O/%(K!3&#%AA-@HB<1@[;H4-N[UBHP5A5F-J8QIC
M@(9DI2"^FMO_G ?KS5YER)CZQ#AK,!.,6%R62;0ZYL2'L_C82F7,!W/,1(EP
MZN+$\+#U%S%)A&2)T,I2AA.,!(E72F0NF.,%U,JK].)U[HILF!M75%\[X&*4
MG;?IYS>_PS_C[<8."\(IQ\XI1I74PIDX43;VDCI/Z3^!1:Z>*0:C+C!#+^W7
M.N6)3J^Q.!O\=I[:0><U1NC_K)7WO?F].%/]-[_K_!4\77VN&KG;E,I/H#6=
M#099[W4,C84AU%0W/>F_-BZL2JU5S4V>,%DWRU__%RK_^\W#F&M>]=+NZ/7_
MM(&3BJCISJ/]K*?Z_[->J'Y1*V"6?'5CD7YQT$]X2_GUO!H#@W;"VM;EF$@8
M2#3I^2!4=9V\76<YS&/-A*6XL\*]GGSXS:;%65>-7J?]LJGRH=_NCJ[D.*.Z
MXQ&6@ZTNCV=1R@T1TS"1 R#7P$Y>/)[CC7*.7PWLW6M2;$CT\&6T@2^OO2K;
MSB<WC,=-ST*2"#P'@PI#_V.-KMT:]W@D^&P0%5DWM=&$#N/K@^SL-;ES\4Q9
M"_+Y&D6X?,55'UZ5\W0/7SP_%XA;7)#<RP6'S;UV?3LZ:&^VZP<W>7D.>WM0
MWSK<WVOOU0^BS>9V5/_WUI^;S=UZM-5J-/8.#O9:S0>'<)-5DYD(XOV#^JB*
M#G#/(.NO1]L;6QL103&3WQI(X,27&<7C2+/3VF_\]W]ACG[['>"XG_6;PQZT
M9*(Q:N\['QS!1$FFL A5SABBL0 03GQ"DB1!3GM^G_4?]570T-:EK[<S4^X=
M"\D$:Y,-1!]&>CO[_([L?SZBC:$]K7\^WI6GK=/];J-],FJ>-DCCXX?N4?OO
M+T?M;MK:_7#:;-O.\?:'7JO=[!Z?-KZ\H\WNT9<,';?KK'%Z]*5YNM,]_EA'
M#5*/CTX[<.V0'GW\&Q^??OIR_/'H2P.+BW?D>'3TT7!XQ_EQ;P\W=O?(T<<]
MW-S=NS@B.^%]M-5NG,.S\7';C([:AY_M[@=F__RK>TRZG_5I=M':?ML[.CT\
M/SH][L!?='2Z<WKT\4.GN6WBQI>WT,]NM_GEKT[S@X ^'<7_Q)P1L(]=C9"$
MUL!]2FK".5RSQ&CE#!>)MFMO,*K]JU2*5U2X0OM+?IH-L_\2#J".6GWWZ]?!
M)NT',ZMDOL<S]&:>JFYTV$]-9EW4./@Q!?D"?+S9[P]5=]^=9?E@+?)9WE,#
M:!W&#T;H:YUE7:U"232=7?QT[&[._Z$T<32A<<V#S0;LKD1-2IK4J,*(.P?3
M*^7:F__^+YDP_MMMCI_PUTQMJ^F^G#Q*Q"H4?NC?E^G9'$[+9K-YN/DNVJ^_
M;^VWH_>'^P>'F\UVU&Y%8%6TP72(,(U:^Q&.?[&_1JV=J/UG/;IF<%P:&YM;
M[7 92\IF:# ]#FYWLCP:=%SDTP*,\FCD5!Z!E^5L] +H]KYTW^J54W<#WEY;
M^*76@W=VPF,UJT:UT+>:Z_]D.-<X_<2:[09J;9_01KOQY1\I#4D45C4M55)C
MA*&:\@B4O0J[G$*Q0Z6?53=M#?,<B+=3<LP1$.6Q!%S1#FN18"-,38M8UYBW
MO":U-S6+<4C&0YY+O/9FVYDJ,!0"'S=UUGH4*/*0)GN$3_/BSL'C8*BU_^+F
MYP,::/S?$Q71PAF6[1SZ5U: 6QF7]QJ7(S N7>(($C5!-1B7S,N:4MK40I%8
M80PW4O*Q<<E6QN4LC<L%F);V_F;S8*^T(A\V,*LYNF9E5C\LF:DYN(2>J(K?
M1S[/>M'7&>?Q_PZR^8F,/6YBMK)>+RW" A"8X5T7]8>E]G]&+5 OEVIVX&7-
M\ET_';P?C?Y1F# 94UG#'ML:,[&L"9DD-:X3+6D,1C:B87D/UT)UF^3;\;(Y
MC[\^.SOMNY.T",(]"#NH?CZ60O](*[0SAM1< EX9\Y36-+.JYD,-8X<HX<JO
MO=GLI6981.V.R]69&PY24ZQ7T+77-QN/Y[-Y62?\I7ZAS" *1(\R'UVQ0:2*
MZ.#,F; 6;J.T'^T-BFBKHW+HZZ\S6ER,-SAFW[.X2,A&4BU+?G-Q\2G-8K1!
M>3+U9N4&BQ^W$OJD.=A(")EZJTQN@)7]E&7;FVNT\G*-=K+,2LXNPD+K7>B]
MPR#9V;2%1GX+C-&+@'$H;I:?C;?*EI7,QN7EML!!O>OL%>&.LSS['-I9T#C-
M3JIW#WGC="<]^F)/&]M[K$F.N\T0>]G^A%K;Q[W6[GZO^66GTX#?FKM'XV<^
MP+OB_G$[&S4^_G7:)(WSQND)/>X=PC/FO-7^FS5[1^QX%V;@8_T<?D/'77'^
MKKTY:!R@BW?M^GFS#?:$P=ABE>@:TX[5F*6\)HG"-4RY]K'D BL18CM==:YR
M]V (9RP"]V0@?(6[N\[? ;\*]YZ;O>^H!'3E!/[8F'XVB6VKB[UQYI@II7:!
M3?.7%L6_;XHBIR!LSM :9C&8]@F+:QI95*-2&*:$33!1:V\27$."AY, OBJ,
M"ZAS[A?*7THU$($7W@(W/(^NE[0$PVV%0/-.O[V-_8V#C6B\\SA?3BZ]8;B4
MS)J?J'[ZI?S^ZXI)YYU\-U185.FP7^]CU6_F7M[EWAOIDU^?J>^]]5XY^G'F
MNC\\Q&^VD(>)6%+K9M/:W!7%^$\XWQRO+)MO63;HCI/AO<0\MJ)&!0=/0PE1
MTQZKFD$,&^^14;%>>T-Y$D>-LK!==##(G1NL?WW)^!G@]%$<_SQQJ_EB^2WX
MV,K;V?G*JWX,P]=O,KR3'-QI\*J5%PY,><*!X;VIB=@FEC.#/(O7WKSOI%UE
M7?>LDZHY8O7E9NS2G6CE[_/L<]HWBQGP?VGNWKO)W40H11@G-2 #.*HH3FH"
M:U/C1#'%&<>)8,#=FS_,TD\PAU9 _YWR\#XK!JI[G)Y5(=:5-'Q3&FZ%;6"B
MB2!$U(B+>8T)QFO" M9S+EG"B/>@"M;>8(D1>X1 3-LCGJ6C^,N8Q<+ZVOL<
MT#8]4]VH?N%,N<$S:GGPN%SQ%/?XQQ!A#J<(!"\*DO<89S.>8V?S42RZ<C8?
MR$T.<)P[M8+@QT PO>-?,F>QE;&L:2-TF5)>$PGV-2H1F.%("\TPR!K!\:]/
MM$GXRLQ^-!>7)TZ][V3]14[/>FE.;MQ: V)$:G >:Q1Y7&..N)K"UM2L!NM"
M&&,-$FMO),&UA*.'5X"^84_@>)GLYP<TZU5&S_\44=MUW5E@S7%L]RIUJ3L,
MXX\"_-Y2Q+<F\<$][W.:GWE5&"/*RZEPN;/1V3 OAB'+:9!%<$<9[L;D%_UK
M,-)"GNNF&;R>3983T&T#52#UU#0GRC<X8M//'*(;3$X_(:GL+?_^U*$[Y1V"
MI'Z]N,/=BPME)K?30;=,TW/*="+3547Q"*?AIYF=7)48=C#JZ:S[RZ,<JD?-
M35Z]9(FG;I+^6?*5NS"=<(Q#!)AXWDGAERO@_/:R]9.+KBP]7SZCK3E6;B-,
M=(D-"VQKPC5VO W]VCW^U-C^J]?<WKLXAKX>;W^"=Y\P: ,=??ETT=AMW+(U
MSSK-[<ZGQI<C>.??YXW>$0*[M=O:_NL3O(NTMD_0T>G^:0MLRZ/0Q]M>D^0B
M=I+XFE(\J3'*94UXY&N(,"6=,R2)DVJ;!\A#6>%W/3I3>?19=8<N^M^@K''8
M"A,5G>_+#%R)R;.+R5@S5(IA)2./D)%;"WG&68]APFN82%5C7.N:2@BI:1LK
M+H54W"2A2-"[[5D)P/+KZ!=0(_6QYJ^V -U.,P]VP<)GF+^<"-U:+0QG*R O
MDIJU080,,S4EI:A1PF(O58R88F"(;1YL;_X=[78SK;KC+)!O)[A^RR=_0@F!
MW[Z_/M/LW/:3&VY[U,SZ;BI5%4Z'Q2#UHY>?D_OW:NWU;4C-<Y$>1:;CS*<H
MG'\9I=70\ZNM6VD1J>C<=;NU3_WL'/KI5 %S8N%",73Y>MC;99U/^]7.KOTA
M>)4,Q9-)O#;W,)\;T?-O9OT(??U7Z.K!N*=[94<7$F=^J' !^@<G1 HB;0T;
M4+",H:0FC? UCATUQGK%N5][<^2*!_<:SJ3JQ669KAF6" #!GX-)8+]]'_;$
M2X,]_6P O_QGF ;(!J0N]\7G9:62XGX(IR%7_/);6:+K"M !@(#=YXJRLV'O
M9X?A#UEWV!^HO"PND!<_'_SB?U!B+%,HK@F)>(TYAVHJMK(F1&QT["@"0PW,
MM&RNT?<G )[SCBOW0=U"GU_PN.Q*!TR<@#LV4MWN)?A<1R7MQC= PV/HN2SA
M FATK83+7;-HXB@%> I(%4JX1!:N]D_*6\]R!RYS^(9)5-91*Z)?H%%PJ:)B
M:#I1T<G"1OI)#95!1PUN#^5<%7=1M'QX/)I?P8[KV^@7<FW(&KPSN$F?PH#"
M0^7]\&3HRKBQ4$"J*'M2]E05@TBBR*I1L5&U\P) ,ZY"5U6O"I&9@1H,?SZ\
M.<+_6$$Q<US5P+8#<\]B7!.&XAK3B714*>*(7IE[*W-OKE$W( ^ 3B\=# "K
M7!? )\_Z(6[6'47NL\M'T5X(+BA3)CQNJX&*=BJC\ 8>7[5QW4H,[FF%3&,?
M==^=#+O5%K6#6COZ)5Q,?B.4;%PZL6"% D*?A5HESXW+5:<OD=85O[X<CEZ;
MU3"I8UC]Z7#4?/E':AQ;$J.:ID;7&$XXX&CL:S%W2G$3.X*3%8ZN<'2N<;2,
MVW5A;"Y2Q@".YBJ 84"5$+3KW_LKN-O]VKT7BAX ,+PEGYA9@$ ]F(31>C!P
MH3FP!<,\GD0G>78^Z$PN;X"IZ\J^E4'"LMI?F;V^]E#?UJ*U>W]\N =KI>VZ
M]D /UB9AR;%%3G2-3"("UVWOC1D5HA(;,N'?58A*;# V_2I,9 .AAY_\[O)6
MR0;!CTO0FH,YP&*#2CF-=+(G+POV4FN[[N4AYF5V2)7!H"T0[),L']VS+%C>
M5(J\&=^TT"N$C=V_OQRW]^&>O[I'I$&;N_6XN?M7>MQNL.;V"3EN_]4Y^K+S
MJ7EZ<COI^?QXN]EM[G[H-'H?H*<&';4_H:/>7]W&EY.0--UM]'9.&Q__)JV=
M>VI0,>X]IH35;)QX< 436Y-$(C!FN(RQ33AV<NW-N_LA^.'*@U/<(O14/I^:
MF8#N"W+-9IO43&5]\R[9EY+*[+>G)!HN%@V;]YEKRRJN[*<6UX.'S-_EH_:S
M6R'E7+X=%O#FHEC& P]>U/JXN+-_6S@=QV"7UTP2@_4AI*GI!*&:PTH0E7"/
ML/WF@0E/0>L7V**[#!A2O]]#7B'(DQ%D,I.[Y41N32(-*R3Y(209W4$29XCP
M1JJ:B"6M,1?3<&*2K\6(>IU@(13U3T"2[TMNG/.PH/]*^&T]2A^;;!,67LKE
M%K C0];-((N&116Z@X%61\'=<V)'EI?OZH["R\]3>#6\-NK#V+)@K'Q.B](N
M[:N^"1(.UFHH/QUN+@:J;U5NBRC4FT[M_3F9DW7T7]3-%?0;H;MH%?:]1L5Q
MKL+85 Q;KT)\5 T&KJC.B0_3FPX*:*BO3LI%_/_^+T%P\EL1J:( FRC\-(F1
M.N]=N2K4']<="4^F ?/[0,\ K7G6C3+ _VMDOK)2AS"!5_E8#+%K&V,/5*X5
M-%MK773=J$R ^ 7'T>'&03C<."$\[*+]-0S\:I3CW%W=!5R_QDP^S7O5$ML9
MO%N%FX#_RAQ56_98#6TZF$Q)M/&,&F+/^'PSO"W+-Z_F?*>K3I910?Q0SL+%
M/YR&BE=@*B9$)V J@I4H8T)J6,#,(^^U0_B;![?^O.)>KO(4'=?M3A _^N5N
M0O8W5CY^G61%/KO?%3JZQ,;2#ZT[7_P3.VL3;G'-&Z% %@2N":1T+5%,TCCV
M3C+QH+%3+KTN<>Y>&YA6G9P [P?AZ%4U3:M]DV.6)IRNQTRN4QI7&RA+;?4Y
MFP1+PI[+D&LQ&$7 AV6N7KG<Z4-.&S1:3!JZDJ_U4JJ&@RJS+W<>M$_?N* _
MPXVFFQ6A\3,@@(O*7(Z@7H+NZ8=C?:+[MN"4.R;&;^J&C#D]#D2$O+F[7?@?
M4--9$317<+2ZH\K:<N$E(#19WTY.[/W/L#Q/)_KEKV'?1115)X3^6N:8_.^Q
M:.^4"1[0N6$_K01[6-BUFY).-7848%DKX"7/G4IB1K1TS#!*J<'_[)62SBE:
M YPQ:4]UBS_6T%UI?U\JZ9UNIFX>*OFZ/^S5;#:HC9\&)Q/Z[\HV?B:ACUO;
MGW#S=!,U3P^_M+;_)O\$(3?2TAJ2/JXQQ5U-)0FNV01QPSE2B4[6WA#@<K3.
M<;P>"SF!@0EEWVQ$![=Y/UA_@=/'7XNP[_A2!-QE[;BLK!V7%^N138';P'PI
MJJS03M8%&ZYLL9?EP24 \<?H_TR8-1L.2EO^6N,*VBOS1]U%* ?CQD?[5<E4
MJFLF.5?:&16\C#+C"5R*HLP. ,.M#^ S&%;9 CV0"QT2",!4!3OV4EXW0,;2
MH.R [7M@>H[/+[BZ([@8@V$QV4>@ J-#=XHPVIM/!3<F*Q4LN"!G&=C &\L*
MHN-#!6&>)B!YC7SWP<\8.HMJN_IXD_KEIO7+[>H37-MQ.@<H&HV-CKC$(5+"
MT(,H5/7D%A 1AWCBM09%Z)@28!M:R\*V)80<L=R50!2P*+X.1'O-G7MRA,LA
ME!ON*^EH78UYA4WW8!-J?/G$&H!)S78= 4Y]^0<A0A$1O$84P>'$:E_3C("U
M[K6W,74"4078)- Z(J"#67P'F<;\MI2"M=W:.FS4F^V#:*^YU=I_W]K?;->W
MH[='T7Y]I[Y?;V[57S^G?3TYS;FX.C7#V;>C_8G%TH87O>T"^_]<;!Q\3/:/
MPMX1@D5-V3(%PLB:0F%-0EHLE0[9GG(M<B#I9S"=@WSHUMZ\#^&+<:I:0,3W
M>78QBLI*UV5P9++GX092!LI$F_W^,!A[S@W&B%KBSD2)5E5P0"-=WS92#'4!
MIJFK(E]EMEQ07Z"/7-!GH'/3:W2]:8NF?7CD/=A^T=[>WF7&\K@7^Y<AH!T
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MV?$4?&6N0, >$+SBCN0I#=PRD9L@-@- A\T)8<[AG1635G(=FKV&(R ,P.9
M%:!.OVHQ.D\'G9)3OM)!5<JH*K)^4,[KX34@ "470.-P<90-JQ>&AJZ_,'3_
MQG@"CX8!A1YF03!!QX*0@.0>01L5+T>ENH7W!VZ<M%K);.A8V@O@"Z)90EB6
M!V8+3RGOH:%RS)>X4@R[@ZH7U3U&#8LP-UEQ=14$HY(!F%F3!?: GMD46@/>
MASG(00R[H\CG66_\)(P('@ZT#>C1 Z<+/J85%1^>QM>/Y'D>K.DJ#%$+,8?7
ME-_+]-5/:3_(UNL:%F>S6V,6A/ 9NBPWIPNSX&"MO0E<4QC01*46.0D46[_%
M$D6E%4OI@T9+O3@(]+[\V>;#D\#L-K7!0_YM1<,7IV$@TUC-#X/$#_,@5R5A
MBN'961#-(,*!AEFOY_)@8ZQ?T;-"4'?YO1@,;6ED704X'G[+^ZQWYJ)Z_\NH
MYX+5UU6F%.9@9^3J;!3]LE;?;Z\%'%C;;+\E"%6?@]%PTAU"H\ W13#0O%K[
M=<4]+\\]MU0!4/@Z,\#/3N6F4W)),=2%^\\PD/<V&@0..TO/RA#--3@(FC 8
MF!/[9JPD8%Q!AX2_U]FLU,8Z[::#46DXZ])"RMW)$*SI+!^%^!UHQO"^"IXF
MW S3,+8B!B7;I>-0W;B%$-!SH(N-<6>@%TVIRV$TIG-U_Q18;\5GWT*IX$Z!
MT5S:RH$\E3T1>.X:D<'92:$K8_T"!+=#L%JN>.I&Y+5=V]W<7-'N&6FG^J/(
M@*-\XLJ8^#5"E0:H"F[1=7<WT'I%PKDB8>GG#GL:[/4J<OW9=;.S4DWG@.=I
M?A7_J S]NQ2K_ Q \[-A7@S=BEPO@9:!(->5W#C6% ([Z>"6B38A6:7K2H@M
M5'<2*[-I 8I:#T,#*]H],^U FO(3%\R,BGYGKL)&9SI]Z-K)I752RIJRG\&7
M=Q,CY9IPKFR2YZ34+6,3K$$##K ?AE#&3<MRM53Z TNEOX"U'A;:O<OS$.O+
M(E5$:[WT!"8UA'ZB/[>Z:[\&>0 TJ^R%:R:&!_KT3\8Q_-)\#ZOX?3OV!)Q=
M7]D/+RXJ5Q$ %Y5^5!EC*(;>IR:]X1QFUT,.$Q5U0VTMNFQ%LQ0N$(3%F[>9
MSM@*+%X:+"Z#.&E/@^M0!0=#^&71)7_6"4@K=;D@$E  9Q5^%%;U![5+]ZQ4
MC.E@['CG-QUQ7RK./MPW! +>$P -GL5*@+Z?<]8O)6@B&1,Q"?FAY1KN2E!F
MI"KN1NN7@-EG;2?.6ENLEN6^-P!XEKLSE9<!O8I@ZY.<E\*98:E*0OX56%4W
MLMO#/;V0+P?_+Q]R?= JYO)Y"QYYOW3!0N)5M^O GZM\M#/@Y%&MY/&09M95
M:>^&R_:G&IA.[:.Z@+%'(+OIB9I26''%)$]DDK1WIDRY*G]%ARI2WU%%I)WK
M!]-BG.&G\Y "!6QR$A(P!]&PRNRY^^RY*R&AC/27R[)5$U7D__+Q,GJY"E$^
M>S#YHI1M4(_GG=24&6S*E*9BE9GYV14A63;2PP+:+(IQDN@XT%+E*U[%G5="
M.C]!YH"[)R$MN,I[J(AJ+XEWAW;A@2J;>$+K]2K\=JU-FY;\ #^#)G#],A4O
M+0;7%HCN:;?,R;C9[LW4'S!\BG0RBDF^896U&'*$7=_YM%)6X<(@ATE4YEHZ
M8TB$U"'3)'0Q=V54O<PMKB H@,M ?7)1-^N?A+3L;')3E:$]>=,*:UZ.4X&+
MP U*B\Z8D0(KJ)/<31+HH:M=I;/+''8P409]T >=].Q:PN@D0UKE>4@@&"?+
M]NUU:S_MPKNR/GA<>392W<%H_>KY,S4:.\2!14,F0IFT<_7R##30MW=@/=OV
MJWNV0;[0AI3[>:N&:P_O EMMZ)K/35 _]X:NE:7Q?+;B=9T^SN\'-3Q.. @6
M2.D^5*JX?+[<('"IR/O99]<-^P^ROOJ<YJ"L?UG;:GW8VZYAN?9KR-XK,>2Z
MM6"'96+G1/N7*GX].H&&\OYDZU6YDP,@OP>]J+Z6*XAI]36_W)N5YK94*VFU
MX2#$0_.L6_:L *=8V5)FQOTIGPR[E<J'.RYLQ8G<66I=+S75WA[0.^67E0T\
MJVB&*HK,I&58(>RJF22!WC \0KX,L&9UO<RD"7SE^L" 6<E"(7>];*;*7*]X
MJPP37N8CKB@\4]M1&3,,?DVU\:#<X#?9P;@^V?@8: IF?=^F(8W@NN#WW" /
M(EN!T]AS ?]B_(*5$_",A/3=80@#5N -QGD@'\C!>.>=&0'-JE3@*"\W^T37
M,A >LU%Q19 G$N1:XC5(53;L#\9;YBJ@F_(NT1O4F"$Q]D)<.80J*T.D&.\"
M+_'^UD;P\?Z2<JME&<$&T%&F,][AZ29[HLO-Q15; ]#<V' 9MG9WL^(Q&Q0K
MA36ZVH<97EMN>0H[,H<A[[V;5BM6WVIJ(]JL N[7-EE6NU7'AMJ#^ROO&=/Z
MW6VD-T;UC=VKY1Q^<AO19%ON>+^WO6<GZ;@UH\I48E7M I@T=/5<N.NA:@!E
M.;@J8I":85?E92PL>@_?H[WUJ*HSN!FM!9'$Y+=H'V@?[53O7X.A@KG8ZX4W
M W=4=NXXP.U!/H*%V\W.UR\CV9/MOM>WMZJ'IOYK^UJ_.H63MU7SV"XWP4ZF
MK-JEZ\;J+7#RY27K"I.G&F8L;#@/0IZ[DJGZ+L3T5)X&=NYV)Q;Y77J4+_[Z
MV*YG%#]AYV[H37\TV</Q-4YNE0,;]C_UL_-RP6'8'^_(+SW;RWD(B:!55SLJ
M[XU7(\MN0AM??4=DLW):P!,-"U7CH.2X L"U59#0X?%^MML!*AAH*9KP\9I+
MU--I_[X0UOJD8D-J@I]3NPJ"A93N<;$H,&==52%B').OPD6WMM#58!@G[FJ_
MY>1[M<Q]/>!;%B!0 Q]DY$: ]M(VJL+]UZ1V-.:X+1A!M3.O.UJORA>$S1M!
M*OI9M0F]Q*627;[!(E<U'28QVC*(J]U5Z#;+UTN1"8O*85-@8,F*E2:WK%\&
MBD?5XR6PW(@;FTF?3>G@E2;@I0?:7X<7;T2[:7A+I0-N(7\U%R5CY9> Y"I,
M!BY_");+ .)7N'DY->JUV@&EY_P-=+[$+)N9X4V$ XS/\K.L7+?0HRJQN]SK
M\&W,KWP[5SH&X067E16NRAE4*PZ3P@P5G][:H#H&^VOP50%:F5<8@.Q\W-.*
MT2853[X"+L694Y^@IZ%;E\$/6R[,^&I,>3F84D&6?2U7*_HAAMT=KYQ6*CA4
M8DE]D/+0K1("7(6BUVX,S#F$[P;N&9Y5[\G++7-%=?/7#)")U(7!Y6FUR>2R
MG,,-,0[ $*4A&=NIO)K4J^(QD\E\J%!#*277381KRSA7(@[>@#L+-2XF1!DG
ML96XT57G#PO3SQ>9)ZO(_#ST9169?UJIM5LJ;E:%UL86_W578#D5=?MF)9_B
MIKM3VKTYJ& PS[ICI[A$]A+LH;=7!N+$FPUIQL'L&63F4ZF?AA7(ECH'&A@%
M!0GOF;S%9C"8TIVV-JB&Z^['M1>>EW:]*[4>//T?4-2@^"KE$7(!@FF>N\'H
MIHTPWA[>RTIE!;9<*,I:.4%GDZ#3E0OY.(_P5O_'5DZEI\)"\XFKZG=5QD;P
M<1Y^?7 3LE""*]P<9J\RNP_J6Y?)DMJ%H%B8\'))_,:4@Y2"#Y#U'VM$W@F)
M!<;[=OR95K&A59QL4#ZR]N9C(&<()H>%G\_!9PX<'W8_+T/J\$PWFH 8UH=Y
M62.JK(:\<;!1ROQ?"GJS$>WY2;:@A8&-*CMR6%9!&R_FK/;13H<0U].\UA]8
MV;WF$X4(B[./!2*Z J*I -&5.)0:="P%5:;3>A5HJ:0D*&=]F9I]Z3;=5^JH
MC'%?][_N%Z[KA5:R^VNN7&./$#)+\WMJ+IVXOBM]^_&"W8J#9L5!_S][;_[<
M-I*LB_XK")V9TW8\2JW-6_>=%R'+2_N,W5;8[NGS?KH!DD42(Q#@8)',_NM?
M?IE9&PC*\BJ9YHUS>RR2  I565FY?/FEUZ(>BQ>"^O6 DX]<41FI95[,3'.J
MHN;(M)&H)E=O2WD-PA4&METD.%%-U*!7C.@<R*H>7A+$ % $;JJMT'QSH6&S
M6E:V7"!8U18L!([Z[TK=P )7STDU6%;DB"C5+/$#7OE"P_;"1VSC/AY2)!RC
M$!V+[7#'U%8^;DH^MH;79QA>917FP=8Q8X$]&UYU7ZTN!']"SJ9@8WQN>FP
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MF6=D#R3O^! Q;8.?/S\YH=41NK0=6AZH@/,"" W:_"?O'A_N[_]\\N[P\/!
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M!4_K2.?9F*SEG^ID6(Z7>GBVM374L1^A,VFGSK20$IP-Q0I'S5['C,&0:J6
M8P(B[O6952@D(/^;0[45F?XZX$%"IC:V$!_/%V5^84=0D(E.(T -137.TM%
M67/XP%^28S3O\!S:EB'2@U3]#_&^Z^5\0<(NRS<TTAR$GBV]H23Z8\DS/:NK
M)76=8AX;SMIQH3L/6TP:VVPDX,RP<:!!,FM)W#/:/B/GQ^3-;"1AOQKPM:[O
MQ"4 J(.?&$"JY A2HD9R6 JI?"VU>E$+M^9! Q1>7SXM+Q@"S02)%C E/IN?
M)UX&G<H?1ETD5H^#-D'9B,N*L_X,$BN*EB=\I*[="NZ,W>_+85FAW /-M6$]
M,MR')I[\/Q5F1!'GJ09V2>0.:(0#>MG=@U_N\S^2._]3MF ]MIOR9&YPL?8)
M@Y*HN3,J+_K_I 4'-0\>/7K$PH3!OD(144FKSY^\$F,JK;@ZB&7AA?,EK(?U
ML)E)5S^C/78/]_</[@8DB<"L,*,"B;)]SWI$%G<!6;*%CC0)+\C%(P?]79I=
M I5T0@M/1_@@>;NPO>,#HAGM )WGTOR7YD?NR=B#RHB7?F]?)@;3*J5WAO^I
MPT"38 >9BA8(2MVK:)EORXE[\,OAX/CX'CX]^.7AX/C>\2!X)-G[RJ&K<0#^
MU%(1N464.DEF<J;)=M;+';=DP5+^AEUO_:<:\WM_H!^^LLA$^E"[UKQ$+(_A
MX@>#\"YGM#XI32C?X>"!=D@Z>772^>;A73U;\K(\9U1:(R96-'/V-!"XFR[B
M8'4B8TD/#D^N3F.V'OK?@U\.!D<']SGD>7#P*_W]8'#OP;WDSFE600!MX.,4
MBKLD1212&4X)O?VUY\YUDUH_/7<W5'W]V2G@BYLQ'-W;O;?_=ZL^XK6SI]FB
M7-@5$4I3YB[7VCV'U14S?&MM?U;9>!K"J+H!V$O?*$-9 M)+.GVX[E ;32G;
MC;-55O8C:$%TUQ8MUUN"-LTJ(X5*VZ B1UMM%SV0+%LN+T3VY5_C> S1PP82
ML^:=J[7JVF2'#CF)U, 0I0-O'F!9H(!ZY; >L/@Q'PC".6X$"'&[#I<AV#MV
M$8.WV="M?FK[%G*/-#5B/:$WUZ4_??,.-F\58-E["V*B)?B%[-4T5UP9G8HI
M_**W:5%.LN2$;4I%Z/M?,7,2_>I=2EY5*A*7<SMVW%U+A54(.HA9[I*Z!10Y
M0-&#+:#H-HQE"RCZ@0!%S 5%NC+H'?DC0(DZ5%V^]^<ZMBYAOG/-.8,SA,[^
M=)Q-YWW=-Y4OCX/FM8244O#\_Z>%31K@'*H9?B>!M($V#5W;+73@4J&@]9S3
MVR,>50W+V7+,>2OR+EOAI*$W4 R$S5>13] N&CJL!C&L/2NBIGO26-!W+0V(
M8M@HF[2%32W7@M'F_)3+,%3<:UC;:R('4:\D(>H/O^>"*34T<L2))==C068,
MHPX<*9A+<SYD!;C!+\JSSJYT  P_-^[0W^WFX3L!*V^ C<@FJU*;LW.QQ2!E
M.$BF^7*$)$KX_O;\+^PXZ,XTYQK$1*ZP1#'&L(7W/,Z0N<N7PK2S"B>XLV,?
M@6[H&[M+M8\,4VPJ2:BTI;3,H-B+'9[1#JS,$XUR[0NRJK&EO*YE+7X?T)\>
M/+1L9]>@/XUH4]?PD:ZG(+4T,?:-8BY2EQ*GY^@WW'<0!?.EZ('#7PZ2NM0]
M2M-EF!@05K)[]>#7$OZ) !96T2&?B#*OJW^]RB*ZE[R>]%%RV:>; FR?:$OV
MX,'?9?@"2/G ?9,[Q3\>W;M+^WO.\0PH4,=#*C=E=6P1,F^9M-0!W+" AT=_
M3V8I0%\H,.0P9 =;LN2CD)YT^/"NN]/OZ7__U^'1(W*I/4SM )TC [[M@-XT
M7#)Q%LBAQ.\OR POFK3*6/7++#@P@2L*I@THN7J[Z.^$KGP."3+%>(%.;S:.
M(0^YU)3\'($? 1S@OO=W2;VWZ"V4YN=8B$;XHFL/<./7MK$!7%^WEG",Y.?>
M(:V/.:]M-%Q#Z*3-41A,$R5SS"^)/_U$]814:D7)9;6_1Q!P<9-)&IO[ RM#
M</&/A[3H> .A$DCYW#;)X0$-ER:,^X))*BD8<(C@>V!_J,XQ(%#7D+6C!W<U
MZ[TR^18:T?,:7!AIT:P<"&BY2PXWCI(J; #8BE8">KD'D@T2SD'4C2@PER11
MQ%1XG_**><0 ).# C$_>Z;5$Q21B:;T"<>R9 _SRSN(?^WO[#PXW-69XYGHS
MDE15H]G2;RR_%FF1DNV4";7>(("TP8:HR>LHQA^]-Q=HHTRC6\ ,X)SC,S1@
M&B?_8H*K4[)"1UAJJX.>_>O4J[(/[$PO#9^TY2+,(\S=N79<#N8DCYN4A8W5
M$$ZG=Z4;3MI<DX:F5XJE,>8UMJ.SHV,$9ITS7I3QBDJ+3^?H(JN$%7',*/.X
M2(P#!F[V@@.UYPBT>-0TV=][]/?$AE&B^ZZNXK].!]'F2I/CO?W^JS^X[PZ/
M[@9#]&D)OYHB8\&:=I'1:Q9,C631]%KS__SM\U,G;\_3C"R;MTV:H;_W<YJ(
MRB&%3F?TJ9/&_DW@TECI GY([>@&,3ME-7:]O<'P5PKNNCMQEV552R9-RCI6
M9FJE\85.#R2+JT#\O-Q9_'?>_$IS>N]N-]H,*:J25Z_HW ?W+NV^5VU-EG[R
M3L*M9&CJ&NR^L7;;Z[9!DXTZ>>6/3-IK#GF>O.5,L9M.L@E>O7CK&UO.2)]
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M BK]?%TOI!?2"RF,27T=',SA]7 PV]2_2_T_W*;^;\-8MJG_'RCUW\,E\@,
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M,N.:!T72!DU3UF\-EVSB+C#B*IOW*7A_!_@MJP 9<&U][ K$3Z6H17Z:R)X
M)O$WMQD<H/.JP/SC&7;$X.+2I-D\4B):DH4@6=0>5I;&9J>YTS>7]*(6<L(9
M;(E-",^5(&*,,,4/#>>;N'0OG=)CZR9I:ULNQR3F^$$K%.BB8AC\:9LJ3S*N
M]N698X8_R5N!-#Z;0)9&LQ+19\A.Y7KXC9W:36T8<>#_*8&1OE%;591>I%EN
MVZ!*SA YS(4T3M:H,O,#TSQMJ-M.T@E<-;TF'&8W=WI:\OQ*4)Z+/,9N$B$_
M3$;,_2N-""N?,O*[</,-<-[%W6MLP[%!\C_I(BW"Y.J_VRJKP<KD]ZVLN9/@
M[[V'5O)5!G[-!>>)IFVV0IIDDPF_7%/0[R-B@&!,,=W-S:3YY>C^AR5]]P9%
MG5E4[]]@![-XN@Z.(2MN!^J^"<\#J\DMMUXKQ'KS;)KFJ6VI86QK".WNS=8%
M'_FV4P1;Z-_[GKG)+3-PG+9K^W^Y3L?O%UG%=9&'^X</!OCO0_[O(_SWZ $4
M+?VO](7@?C) 33C5^.S)2?*:44K)X[(\WP.Y-SL&X<%O<P21J.!>5@W3,U2:
MZ+8]>M:&.WOT+3U1&/[8@F-;R=XU>%QL6K& XA>VN"9%>9*,<RMVGR=VUJ<+
M7)C=<K(K'DSHJ+C.@(ZSL]NK,&X9R!]Y36*QIEGE?-%0Y/:2DV+I9 W"Y5A:
MQ;:*!((Q:.%..+K/TL\[X8AWPK$T[Z%_'.QQ=P,@?&@A,CR#-X7Z\('=UK]'
M8""*M%_70ML>7%_TX.H8B.L.L![E #,$,0J:[:GU<!"WB*F=.]0KMK^'-/?Y
MV7::2ID5^F<]!)WC.YJ1OUT!\A X\7=#7[)/W&W(([9YT=*X;GQSQI3+WB'K
MJB+)4>J9 WE]&6X4BO ;N1LGZ U,6 .[N^D=YF%UVQWQAKNGA\X#'TGX2,4>
MCGK0.X#UP10-;[FWLQRM=K./9<C+>,@#KS4>>-WAM<;A=K-_V\W^S#:8LH"A
M(+$;PRQZ440(L?0>84+SY4MU1(QBX;Y2-C&F"'[&%1'V-.P _ITW:67_$US2
MU;,0/"#7/@J/5(+WM4&3O)M[G;3XT'3$IF;M]PT@7%V[3SJ:XWT^*GZQW3%?
M:,=P0B1&T(&^Q5O7P0;!%P[G9B/;9=5,P,&!:F0;]:;?7M 96E:!B/;#LJ.]
MT#E(._[+Z9,G ZZ8'R2OVE&Y*/-EG8[ [9:-N5WT.]3)O7CQXC%04V=O\2_N
MI>>/TI19)Y. ==+6U) \7GW3$W?3$^ #/VN'/=K04)VD&I.XMD?;2H\QUKE8
M*75+\\,"UTFWP>]CPM'&EC-X=FRKLI&YXU9+XUJKSD#',\DE5Z/JDJ=;^P8Q
M38]ZL>FPO#".38;'. X&\ /0D]O4P4I43<](N)]H=*6I$3:.P.38=\2%S;[E
MF(R-U4KK3'P7TG#K:YGH[LI(.*C@<Q"7'PH KTE22C'(ATYF5TRWC2I^V]/G
M>0>1'Q&7Q4G?7[?@, \..]B"PV[#6+;@L(\#AVU5YA=6F7?,WG1/>;+55H:-
M_/*?]\@^%NM7<J =BU>-V+NNMZW>B/D$[\85.S:G@V@3C/3$]\CZ$C6.M]AB
M^M-86L*AHQLC![:\1"Q104B=A#/;^4-P1T[0\%2V?.7*2-.Q^0^7.0?VKF((
MG+/?9ZWP;3WM8_S0K<_\C;?@"UHH6DXN@M1U5R\"GBQ8UW@=U3\1 *)V66._
M1"C+40^F?5T5:.<[S74$P-9'V]_K+R &P*IXVNC<3($4@N\5W<R9Z=XDIP\D
M0D,?+]F)$L":&>]92FGM9A7ZMY&U7X7O,N& D0#ZI;&AZ_8.]I(,)"A%6?!.
MJ"6*KJ^-M[*]J'G.;%4%4Z<;BQYBJ@KA_6>XD&'XC6WU)0L@/UT$+JCW.9.R
M\@ZIA+7L1'5]!F0!9(I2)OYF0!"'1=SP.82L2X1-GI<CYD:Y'##UGN=/H[?Z
MC&G93,7ZSHK0DZJ=)F?DV1NRBN@,:S+?+E86\1V6Z U*5O3H.AEQ<N/@T<-C
MQ1_2XHZUP 9(KJ8<2",!H<ND)7#4EICUW])F--O],WT_3_EFKI1%07]%P$C"
M/(EV#PW\?=+X+DA-MEQ=XRX=^')-S-GIS,S9O7U:--SW>N?WTZ?H62$!9[H&
M.]L6J%6V#HFS^>!4H2-7:(OZ:$>[)3Y""+.7_.8/*A0JO>?FIO[E2#"#+J16
M@_CO]>A3S18HIJ%9EO3)P7&O5",U-L:RAOJ+WO?)"4@VM5P8O3>$O3(,$54A
MV,T%A],@D!"LP5L?/V(\OSU.3WWXB![[]NR4'NL?TA,V=S</9BQ4<Y=*5X+)
MP--);2KB+RU(0:Y] >FRD,ID9+6C16)>+M\H+HKMLSG>43+X]C'4Q%D$G1%Q
MM97'(LF^( V8T297+JBH[K+.WN\RMY55MOX\B8T2)3()0V[,(PZF9-/("6?C
M<GT][00>:A&.G!#70^3,7?=GE7'FXPV917C%H9EP"Y T&P</Q@TE=KK!^M"%
MT@,(N)3Q9ARZ/&?,L0C9U)[/"9C<E$J%8V],3JIK]%[,@8C9I@8_..\/S7FF
M4A##TR]YH]=KJB,8BUOFV1ATZVO+!B B^#(H1N;=(U:0K;ZPQ1E2=#%?<,]L
M.?;ZS%^0'D.M:.^HS :&@0YR*'MOBBB:F$GWV Z7.!\3O<E7)0YT<G'($1]S
MOEGH>-BS065PTTA) IY\Q;CPLE'66"C<F%9_Z?#U;DX<4KM#RT"S[,R88L;&
M1NDK"[H;4)OXZKUX]!\JZ@@60TEM,/N81:V*&<!L A@;+7(<I0UN8TB2RJ7!
M;SWI4(G"%"]*I%XNP.MFV8=BOCB4@9+?DFH%+$U(6]D<)Q..N?(/<7!"S([@
M:?$E4/\0?;;^&"YD!6<0<HQ)"?D$;0%&7@7W6-1\^I&"'-@0](1VU)!W%*Y9
MM$-O?*\SRUW] ZD44;4MQYOK=OAO+ /S\'&(F@/N0]E&-GC-*S<NPW/%2 \&
M@8,S_)6Q\[U;(FB#W5]&(+@]?I0=6\>-M. 1D3A!SUN?DM5 #YI:'NKK(? +
M>R]ILC#P8XL?/["'TPBEP*:88O:+M*K04 "B2(8!UU/1'Z.L&K5S2 ;^0BM4
M[-%6:J&&QOX8W[1%X&S;M/.(T?-@GVRZY5YD2B[$ZFJ0W5#314X[X=,3"+?;
MK6)>T;^-XW'I/S2E=93Q!1S=C;]'!X;TV;A$SDJ^E$G"0+37F-7H]G92O^#9
M,DO=,[)^?ON(5^0J%$1VRLJOPM4ID8Y=HKO8S9)4OSA^:Z8/E)H;2T3>I3P;
MMW)SPX(5Z""]4)RUUMN>FLU1O:S&$.N(6 YM.ZL5:C?ZZ9SL15K%29N[T>-(
M( U%-TW1K<R6?DB6-GA%ARJ%]P .;>ZQ9K>_VGD7:I&[X@ZL<=0#0'I*:-'2
MBEDN[*^^JD=%@\0?_KRK"//ZT8FCK)BD+#F/3.H=.ZUDE1-U&6/M6XP4%*6*
M6+D<M=YEN!29MBDP-T$==:>90D?ZIN>'B/-F6F-_R@Y&'1L?D-P,1A22-"ZO
M!ROU;=W3UTM[Z(=%5\AI!EI<J&-__=H3/;S\FD<Z9ZFT0*MT)R,$C]L!6,B'
M[I_@T+;%=BNG?F0/N(/]*FM G2RQ+=S''[0WU-Z<&WL67M^DB.>Y8U4P#[\\
MQ4:%]'8,;*J,+UAK@ZI&OR"D-2HMSD/9V]1U5NA.KXZ;"8]9Q47#HOM;NX7-
MR]FR%@_*C-HJN!ST]UEM4^7V5VS; NY0E639KUR4X42<:RVHEQ3I]X&WFF7<
MM$^.J<!BRFQ/C\S%.)F><4I:]2_'-LF-)OA6@U"(H(?L0$@/U]R50L]\I"%'
M,VMOZ2$))2X<VS8N3B]KQJX D]92KNLYF^+9Q-U\\:/V&9!8@1@/UG?@\S$\
MQ89Z(9@O2Z_IE;%9!"^0\TB0RRK>'MIMJI<DSPJ5%G#+1&<5.N^="_$TBG6S
M>M$V.FMIA7=)'<Y7CT=VK>5,H*N\=-L"6^L)JEFP[9D0Y,T/MWGSVS"6;=[\
M"Y"JW$:>D=.H#R 4T4M%:IVX8V)CC48YR2S W$/30FZ"T!PWH6\8L(DXSE1U
MW+Q'1,>'+5#1,GK)8WDR^+J=HS'R7T9H^\'K7S%QM2=S5:XR=AE;9;@,G/5K
M5];>5LGL7Y\>MLZ?/!?H9LKD+:+_[2/9DQ*-+TKNNN5LO8F]]4>!@'>M_@<*
M!.IE?D$>0_HYKQM!+QAYX3ZJ9##\V:W>?J_)4?";#_(]9Y2";$28PK*M2F8:
MB<[.U7(,=C]!*NW["FO"(>)U*<C-Z7:=E'!NO$5]S8;5 4XS<(A1V/ZO7XXA
M<+./*+40#)HB/]RSU[02%B_<I>IMR,\K"QW3KFLZJ8T>^,A;".'1RI'LXG Y
MOU352LL^))OBR>JM6]' BV@Z;'6NO'SY1*L=I#LG\KENJBVOEW0+V'#XG%7%
M9MWB]I8<\6*OT<6NY:?5NX.D*I=IK@$8Z^,O_?YPW*O2H\%P62]NZ8/B-LSO
M=#5"'[8/XZL5,G(IS$N7[)5XP^N:#.SKZ(FE:2([]YTQ# +V9,>PRBS%#_<\
M@3L=Q=&XW^BT1*.60XN3J8V2K:-KT,I,E$&6RGV\.USN=C_3UP%^8KE+)L2N
M_MNV$K&=7FR@_F\'^\&8^46Y;Y VX)0<QX619D)>.C@_JCF"OC66+?C=DS3W
M[Z+G>?J^?#LG\?TGOMQ,51'0H1^&YR3VP^]@ ]1#]*CGX%S1(YT92^[L/'_[
M3Q0!+H*.#)(F/)EGW(9'D8_)-"^'WENZTG?;<H9\^G*+;3 OB](>L(KF"#D,
M>2V!38=BCFE![C P>/_7.-S@0@S\[<&O00>'3O>--=<-$A*4=6>/- *T[2ZN
M\ 34#3AVBBXF!916%W)L*5**\7G9>+<Q1@KJ>*[(>?^W@V'!G6]J[40DN+3O
MKZ_0JY E8C,5V9\F:FMFN3!MUB DG:B$N XPQF7(D#6TG/.])%E2B\DX:. *
M[4&,/;+52)_#8J0%ZNN866K).L&?V0W\&>BG/CY@BX/J1D4Z/Y3PW4<N?(0X
MTTZJ 2*,3;U SBR08M16W-+^>5F.DV@K)F><AAWAJ!P]?W6&VO9W,\%&T*L'
MY0,K UB)</#3'?*:FX\X#J_5%XPP-KB2U20J[VE !G',<3@)>\E)#@KEZ0QF
MP-6;*Z0&0X?T@IQB=1DMD&.5M>8_K:1N@Z;G $ @NF&,30;V/(Q-77Y8-E=4
MLK!+NBZ%?%VIJ%UF&;46KWTFG4W,B?P9:@ =W'49K!L<%A !%PSFU#RK9PXK
M)V)AZQL"O,JPY$2L[?&922;>+C/ C99)6*(+5KY2W\#2<L]ZTMM8_UF_H&X!
M@V ZL/_ 0-/FA#8!+B$#&\MFM3DWIHGH>1P"N>%X]]C,T:9VF_P,DI]'V^3G
M;1C+-OGY6<G/&[)=@_*D[SS,T/]^K^F, SYQ,\UR6#-QAS1!4W7.US&-FBO_
MV(B)K!#@)=-%-@;&$E#)44Q?+\"[AO--(R\JBA!'=X 2)0IS>B0(A<J59A-Z
M?$<P)\M9F-,\KS#G^MH0[H-0@!L>9/GYNJYO+AE@;<:8*#:*2/N\'2._1LFT
M*B^;V2#,X5ERGJ#O;P L&Y)I;RZ,1U'%<P6P4F[&Z*GI;2U%EGDDH6NW[(KT
M7."_']S+1A_9%R;JE>P+"Q7J72P9>6G87G&/B'A,;826C^P%D%AXWU$Z1B%?
M @!QUK0Z#5,8B(7$=Z? W3KB(NE<*O_FB@(?M0QOH512?4@ @8!KO<RDS0/<
M]6I,2MMJXWW5GF.+TK70$"J RT 4')!?(7-1_9W']&]HAN)54&K1Q;JS-8_*
M#K:B&2HXY?8+E6\:'O0#9T F)+D1T%Y=CC(V3&WBH3=?%_8N=,61*CR^(L%6
M#@9ZXET7O"[YL6CM6\4*CJHV<\M?&8LX9;^#:1Q"["X_N$C5?G>N4Q3#XKIH
MAQ6(&VS/ U(O5.*65= JG13/(+3IZ47>HKN#E'*C'GHIC;T#[<9(2)O[LWT<
M@G4))T&ZD -0C5LY)19DG: MO'^BND3T*Z]@X!ZY(6RH\+^.,=5Q2Y61[3XA
MA2\,-34HIRD$";*Z9]9K)>?DN[*D.IUP9YLR9! 8:,V,N41S1.AZ^0K; 1$-
M*>D&KC7CG4,/^ED[;7!7'^P^+=! __7XJ0HXUD'VP(F# B&[B12YG/(H8 )H
M08@K">"3,F/P>>7;KW2:O"PQ.18]3H<#/0P"'C#E<S@)_>>#W9T%2LAS1@AM
M[3FW3ZHDH^I>D^<@;011KQNE72(VL9'VZBL.CI]Z =S<32IY@'"O67!&QR3D
MNHJ>/L!!FL'1Y*4,3I#-(<!%>\AXXT#,1/VCD\B&#?GR"8 E6M\1G$351XWL
MLX806ZWX1!)[ZQFVPS9B97] UVY\Q^Y!]IDKH->V4:Y9$O:D-=2#$VR0D-D\
MZT[$X,J9D-[U(R@Z5V]5&2[IQJQR^:,ER9MG-6+]I I^]8Q$.BZ45<C87$F,
M:R\4NPT:LZ.S$F4(RMKJP#&Q!N4389R1/8'?1Y8&"M-]"RD<UBM3\Q$"0=,@
MQ5'>=[&H5^>QR%H+U FMHOB&8;!=(MCG9AEY"A.IW%"=;B.PMAK=!QR[=KC4
MTIXCX"P&B-1N&(0MTQ%)!$ZT9CGP!Y3U9A8@-]F&(8,PY/$V#'D;QK(-0W[I
MQK:WQ6;X6K$$WXG3G<B?'E#HU"U(,SL0-->J@\G&R19!^*94DB*)HR ,%]S9
M5SLJQQI3,EF\1^:9CM6]M--3(@A$S_]PT<-'KKN\CU/7%4GJ+KNAB]K\8O_Q
M*\K]\G3Y2U;P*O)%O\:RUY,WY\?)UZKP'AWM'1P^A,YK*OK_8_M@58=[K Y_
M;L8]WSW:.[Y_;^W7^WL'G_C=O8?'GW3EE8/=W[O_X.@[&>SA_M[^H^]EL ?W
M]XX.OQLQ.-H[.C[\3@;[B.YZO;'^S'M7]B]I"*BC?^P<[7B#B&L??CE<O$\.
M8CV$"HD5< WKAP]809]V##W\J(09F>E?!=AS;^_P&N-8!T@ZW'MX%2#ISL'=
MCH6@JW?%PNQC67:N]=.>-12C?.TJ?ML%W!=,KH63NZGX\29!X30_\ R<YJFX
MQMNI>,M&Y8\Y :S3#_</#Y*W@#U'D_"!DTO-7[:@%XUP""9VK)\P5=?XZ?:1
M/]@C;_OV8?UQ1TK74!-0W^W;09VHX,&Q^)+QM%3EI?S[V$]1.CJ?<GQX5U^%
M7'PSF5PU/7U&XSP;CW-S0\HU+<I)EIPP;\UUE.P'7_HZLO6%)HZ$\VO/VDJL
MAV=-ZF*>2 +DNYRT;QFC_N"<'MHY3?]:SLTW\EL^II#B WY+7$CQ0=?EIJ2A
M7S7?V"9Z^N;=+=XZMVRR7C$LR8R_ZHP=?MR,[2<]\\9%G+=FVO[[OQX>W3_^
M]>&QLN9WI^\C!81?>/]Z&O:C+8Q;>U;<P+H)_\7V@/V2!^RK9;D)Q^L-S-S/
MR<MVGFW"Y&UMDZUMLK5-;L>TJ6UR,-C?/]I:)]^3=?*]N/^W3$_\RQ33O 5&
M9#MGUYVSUT!Q/C]]F[PH9MD0>=WMW%W;B9C1]A3->G2+9^UVG4J__WSRR3'R
M[1FQ]6"_JFR:]Q?9C<:(][=^V-8/NX63=;CUPS[;#WMPHT[8%P(@NESR#0 0
M>3;?I>=FG-X8^/#3%?2=PV\-/KQ5]LK'^K1?;PI"#.WM,4!8P[XQBSR=^L8%
M&QL&_OZA=)]C3VSJVW^$@? 1=L!W=]P?W+_WZ[W#P;W]_2M/_*]\L&\">NS%
MN*SJS)_VM]!&_ZX/V=OEV-RDZGK9CDR5?I>QXYN<-@X?OY/:_.W$_2"QXYN<
MMS7AX^N_\X3_W_=T")Y5)>ASWB>/,R769[J-3P-3=U[_D\3FTZ;P.SX4O\VD
MW4(E]>9_=P_V#[=S]@TBRC_J?/%!F'S:&?AMYFSSSL#OSQ%\5AD3]4FZ?:;2
MAIUY/ZIA_NSEN]V#1_O;.?N(.7L.AK:M%_A97N#!SY]F9VW]P!_%#WR;%M-T
M7MYB2VG#CL ?U21_^V[WT>&GG8 _ZI1]]@GXHT[<%S@!MU[@#^ %,CSB^,FK
MVPS7V[#C[T<URH^?[!X=;!W K0/XS:*?6]]OZ_M=??*=U.>/LS*Y\SA=FNKN
M+3:3;M49^/DU,C^J67YR^NZ/M[L'^P?;6=MZ@5LO<(//PN_/"SQI0<E/M[MS
M4C<FS]/ZTP[$'] I_%Z*1F^?ACIYM_OP^-YVRK9.X7=Q&FX]PQ_ ,^17?E.B
M']V=MXNT.M\ZAEO'\&OG!L_^N7NTOW]_.VE;O_"[. FW?J$_"7_F5F3_[X<:
MX]U0'[Q'URJ1_K]7_;^U[=X^\#J'AWOWOOP+W=M[>.\S*JZ/]@YZVL1%W8R^
M#@W"]1;BC9GDZ..=!-W&76]9Z9&ZTJS0=_)]\?N3A#9W,C2F2"99+KW(T9 U
M*UQ;O[ O\/IFJQNYMH>W8VVKMBA(Y24'A\F<KIJA<;$I6I.DW#SHB1F9^=!4
MR='!($$;F0&^$(J.GVBYLQJKN#1IE9AB7*.-XZNTHN77WQ_N?2TBCZ^Z.LE:
M6?QPA]$O+8@KW4/[@V;/2WJ;@AMLOS'3-H\[@&U2"_EG3TZ2$VXY3J)W5I7H
MBKJ97>1?^.;O [3=[C3CMLIXH(WEL8^#7MJ9H6^@<.MV^&_:[&B!3>]EBAHM
MM2LG),EPR8^A>97VKL_,F'M_/RO+\2!Y4K53Z8E]6M9S0X].3D;-(#GCAJ[)
M;R;-26V\-=5%1BLAW^'77,J83/1>^ 3%U]KBM=$FM'X4--8IBS!=39IHJM<W
M,WHK^@X#K RY<Z1<!N&Q05\9;F\[2&B^6W0*;RLSH,>4%?=SK]!Y>'QNS()_
ME*KD#)(\'6*[TV?TR;SDJ<"8YDQRP5^,L[JILF&+[^AG94V"8B6/!@DV34RZ
MO,FBK.2J.ITOY,;X(IOC"_ZG><__)+VZ?C'WDF=IEK=H E_BY%V@R3O:^/JV
M]BP0],#_M%EEI*LZ.O?:94X3Z<G./<]3[L%N&FXEGX[G=.[2*[$JQ'G\;Y(:
M/MA)3$>Z#'5+^INT//99929M35_3G7"&BZ6>^BFRHY()HE]E==U*M_H<#8AI
MR19T4Y/07^1ZU'@F_8H[W?-$FF1!!P?N]/N3$_Z:IB8OIR19UKR@^QO<(GA4
MG=S9>?SRI-ZY.] [RG,OTXI/,WW:(&F+)FM@>[A/GI75/#E^>%0/W -(0M(\
M#SZH3?87K0#$#I6Y>,0BI<7%/+7U CL(+8LG]@+^J^I(2U;\NW5S.J&]3?\S
MRBZR'&],>X:W9TZGTU1G;^HU>%9<0*CM-]SEN<IH\410:C/BAZPWF;YKM?=X
MW>8(][WM2\U[H5DN\#O:*C1S94Z31R)6."N3=CJ:CY?5DJ<R+;(Y9)JF6#4+
M;9TY21#6D61)E2'OF")Y$:X%78:7A$X,Y9'$D>Q=2*,8OW.:4-M)VTPFM"NQ
MWX:&S&/CC5]57+QYV<8N1D86.QW3YH:RQ!^7)L_)42V:JLPARO[ZBB2R9K5>
MP_'+ZIF\33K!AF>-8Q].XF?;:B=CC!Z6NDEIK)GK%QI8[WA]I^FR.JG+EM9G
M+WE+/ZRA8W4#X'>+RNR*0O"71,K)KTY#AB.4%>DFV(QR!F!(T-IX(Q(C>^U8
M-%>-Q:'7*[#]Z!8PTL9)N]"&X71OFC/1-^^S9BGS5]!6RD7GX4>N;3CO480$
M]\AP,-%"U'J(FE!:#+U+FS;Q;D]&,S/'5J>'H8&Y'F#RY*9\3PJ5QU'SRN%_
M5>#JAK2MX05+ZQH+@L&-2-3I]6FKU"CZQS'3F$*4#2_DP*XDC774?2<YL4DZ
MM"^Z?M=]-Q;(\#2QYW)P .LQ%BR<-RN>DRF0O/03<X8ADUXFP7_^\FSGK@R#
M5&:;-[7,E5F1<[5%YAFIXG&XT6B*H%_MAB//,<UA O!(Q0X(>\7[886?TN#:
MIF^-O%E@SVK=3+5N-CIB2";H\05/*QWS*[L,GS<E*<"]Y"6-;)>6:QZ]H^XY
M+S#!01KJ&[PCF0IZ;EP8)S R,#)OLJ(D(TZ%""/-X(Z-9?28,<S/@F&%=*_0
M@2;#O^_&5NPP_6YO00;SO+R4R;3GV24I+/[':);EXR%M43S4"V3HNHOV@<8S
M%4U?=^S]CX6&(9%3&X1.L*[<T O"6G!S;.]R6;8Y;0)T&6Q%#]"<F)I.Q2'=
MEL;EK 6UZC;T;#Q)CO9WQW1@D)^>T2T7=!O:FNFD86,Y.LID/X],M@BW%FES
MMQP+NKBR.]$>07RZ0@:Z^Y=F>=;2&]2R:KB9G'%U<,@=*2<:C;'6866(,^@X
MO*^A^E+.,!R!0Y*+ KNQF=%_%F5&PVB+W.I)* JR&[,)JU"\*2Q+#'_&UYC8
M:JJ[KD_J7VA6YN/U\J'S?8P(P6K\0%O'<PPVO$K%:=]?D@[K,B=/9^TE7YV3
M\IHRM7MP;[=#[!C\=^:HVQ?D3^T.:;.?[_+"_I+FE[3*.S_'VXLVDM[^ ?92
M]^W7ON-D\M7>47;O&)X@"\<O+6WD2F(]_R>]-6-)9N1O_6/GO[)C<_#P\/[1
M_0-CTN.C]-'PH1G=>Y".[TT>'9G)T='_?0">7+B"M$]/Z8$D/O_GY_2[?9>:
M!]\C@INBMD\[-GM;MZ&[(C9PX)W+<;RBU.@&!0V(#7A2:3..O2P3N@<YND;]
MZP7]E,TW7@P]%!:(S]AC/DW(N\BA2<?!_<MJ+^F.4QT9:V#*4<MV9);24;$2
MF0A\V"BTP_:CNWEH/9Z>P6T*C&49M;6W:CKEFS3+K?%3LC[/X.'I!/%(Q8TC
M(S*=&XXST.S0L-M:1AS$:D*;&M?$'A+9$[#$4[U>S3DSWDN>PE>RH])UXT'I
MX4@SRZZHFWV.>)'K0F<MIL-=2B,LQAJUT=G]D%&L5M^&FC3O](5A W#/<%E6
M@[A96BU9I,D43 M,(_EO:A.[79)V;?44T;:E.)-T,0)P,);9CW!QKB2;D&&2
MP%@T%VQ1J!71N5E6<[1J:+#(T39(1P@L^FT@\;+ ?<+ $;,4:2#!IBO,@E.T
M"7E[Y\[PZK@:*D%B9<$ 7@;2@X@B>SV&_9A:0B'>#9J$&F#57A>9HW^4*X+'
ML0Z2C*955?-&3,S'95J-$>%X\QA;%0^P?OY><D(7O7G,:\<WU0GH>R^=7[*.
MC&ZO&:DO,QXD)I-8KRXYB5BTZ+DXVLFD/S#*N^/-XY_J:/8Y,(AA1<N/!63K
MK-[0S=15X#17I/PU HT8*Z;E\<L3GM HC"N!&QC-/EX3R7M#)SHMG^@S%E0X
MH331PU965OZ6?4S'0)XN]DBBDA#C,= S+5-WL@D"J$%PBK[PIQO['-:2CTZX
M07!%S9I8)5FB*W04I,,RS^KY(-& 8GE.,Z9A%OV$@\UX<Q?_SL;V6*AQJW*4
MX0@082-W&=XNYFQ<\MO3CAQ F9"4U1EM;1+GM,H1"J#[0#G0N]EGC9<%+?JH
M]K?OQN@V5"P#&3CL&C^UE57HU"3/2"/!-94UIFE=V#P5K>P8ISN92:;G[.Y&
M-U,)VH_H\BJ,<I;A7[2 M([DV-#=<U.E+@1;+NC\:.?ZK:9R,(TTJ^PJP\$>
MDYC7)EI-#01!OY,&?S'1= S01C1ZNHH-/+C,3CXF/K@GX>DD."CT?K0]D8#!
M'$5S&06<0LY9.ZG8T&Q2(?;*<U@.R: JU.04;<A[L1M*<^H[&IV.1]:*Y(^4
M:M$R1 !1/WOP8/]S% =JG39,PR:A!"NP;9V&H4-A:LIIE2YF^@F=\ O,ZDH(
M#@<'IV3X9,@:9RDA *Z&FMB(%PAMYG3"%&:2-;M\UHH#3],TRQ:1J$C4%A.,
M!?&A]^ZAB@ML<"F\P8;N6&N5 </CT@M&;.;7$ @6W'>2=\,<GHPOL'O&BH/D
MH%V&]"U?<LH!#I[(QYK@JY.G/KR..[QQ^5WZU>GCIV\&<M07-2GQL5U=#7S1
MPX-<]U*#73EK:I\8QZ=];W!*S@;TPB!\@P#%B='3"V4U@MVGM-MA);'ED>)3
MP\/#)I#8%D:TH7+PHG!:PMJK8<X ]GA;8[>2TK@P?"*3QH'620/%$"@:Y'+&
M9%&JR0WGD3/574/5NU@QID$Q"BJ:O'J2*BK;.IFVF5CDXW+4BA5.HZ6G]6$C
M)-5%J@YO'0X1V8*R"GP"/.TR(Y4"8<S@HM 7G#U31< OCU>;BF,:)BJ]9-)K
M]J$;?K$)G04[OCZI(':,C<?&P_]5Y/C5::2H>,3UC(/E0V-36N*N:&;%9RU_
M#9\[-C5)'[\/YREH1>9DZ,#>MJ%US@.,6/=;F]*'E=6LC&[/: JY22TG#PGA
M!0+W>;J$R'3.SRPP\RYG9 &FG#6E8PO(B5J,NVY ))X6I"-$X[#6I_%Q%L8]
MH4YF)-Q[R;.VPC4#M[S6* %<!'%P*Y\:9:[=X-T(V=-RJ9%0&>U:1;3RHA<L
MDF*='-S;9>"<G(HAB"=-$ F"]4'CGR"J+ME2GNT"B5+S/@4:0/;@I$0FAQXS
M7"8'^RN_)7N]8GE7-PO)$AJ-6$)T"7U?XT9%2K[37O+[B]]<<$1VV07V\H+A
M/CBQ1P!<P=)-2">GR,?*+$)] AWTJAQG$VML.7_$*G?R"+RXOEV2R3ZW.U&E
MM8XDFOXOTO/6K($I@O6H)<.6&. 9JY(>1D)2"F(E'65YUOB#0Q$Z:F6E^;+.
M9*+BY9'4<JVAI7KO<]" MUBSGW!R1J$Z@0?FLD/=!-"@XT+2Y)&V(B,;$B[1
MKM4PEC6=K.7NPC8]5N5>C#O0\<1/=*-3-(7W83O)?I]2"I$B[^(;<C3$)OZ;
M.!4)$S+0QH/$_\OCVUQN&R+%DYGE[A6Q/]3P+*9V4G1\/]6A!XI4;U_&6AT/
MF["VV?ZZT1S[(G5);9U]^;,S:0&$8B_Y@P.L%@"0IY<K&!BZ]QS/8$@6[@VL
M%>[CS\A\&>?6@B=$P)BVYF<9.@S(F0>*A"6BK.CE"[:?:]UL]"/Q5BY3TGAC
M'Z%%MDZMB,*BQL;1(MK@TS!.^(GZL_+ KK8U _E,M6.3:0V'$.*)V-]G"2_X
MA-@F#H/$X?UMXO VC&6;.-S4Q&'HZ]P/H163JIQ'R K1CX%:C,)E9!:KQQ$!
M:<6K&1J-."E"9R+Y-H':*=".MC#9_C_5' :NH9,[1SI;RUDCQPW.]HQ#]QX+
M[ ,W[K"XL.[\7O(:7EOG',*)LSHN;[/S\<[6'RWFF'XW<[<+YRV=5D:,DA'"
M8&+_LH6)9TY+C3W&P87H[-M+7O4AGN6P("^-!,>,[<4,<*]#Q);.IQCZ>S:O
MHK\;66=-S7/K'TOZ*"NK#(;1*YS' B@+GX]9<1?H\P5PA7]JT)K>[>!01(=K
M?&R.]>S)'\].DG\E=YK+,M%O@N5?Y"V"ZD7XE=SWKI_?M$'61OQ%^WR)J[FJ
M,)6,FDST;,I^PR1X-7N5#K3.WNOS."GLPPM#\J<O+5Q,H$]2^J&&GI0VC,4+
MBHU/I"T"[UY?)XP:SM-_PR7SF5EOR@;+"*!KO3 C29S;V=/1C/)R=.[G)4B(
M34RUNFB,4)6)<C5U@*=&'XA;I#E$F@OL*K).G<?&9JH&9 'GM1:U)/-2&[\:
MN?@53[S4;<BPHU!L0OJ-!B7+97TQ,7JS5/&A8O62.TX[J1X$,C$(0M&*J_2^
MM,;X>-+7:2(?M; VGI]-FX3E*+JN;^?F:AZNO+.DI[*&O<B*7U3\Y5JV4WP;
MVNF/Q:^00:Q8TU[YL.8,#46(AH!(D5J+D-X<NM;,%"(J703%\].SO>0D,*X[
MC[$W9V4B7BVO>/ W0RT;%9DP+18X$^,>^72Y 9Z^EH: J0S1\^R ](3B_<UX
MC&%-1^B'>3V@8+[NRX^>OSKC4\-BRRU.O^/\P0E*H>_9K1*0H ;M0^_#Y55<
M],[.!'9*G'&S:C_(#@G@=&S3 D/K86+RGH2Z0+T*ZZRJ-O(+Q[/+,[-Z"J<2
MG3)Q_'ONBD$221+!+:27?_/TU=L![P&#1P 3X46I4< _O)FN"^RFGH2+[Z*'
MC75XY\:]-@*GAK.BRYJW.^^@MK#?+W*K 4QN8?UN#/;Y'O),*HLDA3/'854,
M4K(SS@#9])Z"@3/-I*I^X=GA&%CVE\W]L?O[8N+F=U1:%97*N_$$D5<['D3P
MT-4H CO]HN&A]"SB&S?Y-=YW79D.;@+1198LM<LS<:&)#<T$G#B,,>;'GIUU
M=V+LSHUA]UY+#<1(K%LN ?0;2"JTN$A\;?W8'G(QZRK+-(XOP2:Q/T>9<:9=
M6.,CNH/#?0'T@6O_E@["$H4TO/G@ %]5;XI0$Y(X5C15T#GH)"F,NAZ)5 .<
M$HW71[WIJ?2:=110^RE0E%(,P;-H39?5(-SZLPO/M]FO[CK$%K0]3<?>S&,L
MG1R@?F9ELLF:A%GJ+#EZ/5OD%U3M:$5DH]F-U0*/S=U(JU*?MB0(%=TC8EM8
MB6WR2<:'IMJA([8.4071+8=AS\#^*, [T%%0\PY3()3Z.D'^1LMCF\!2Z-L2
M<36L2(C#O<7U7Z4K4.K91R0&/V.L;75A2"S9+FA*"]ETK_U3W6?IVCV[!N05
M)E6B<PC7N62^/:Q8@,6 HI.3[LM04#:-V6"0L]5E?&S-FS!A3+(F':IA%H #
MQ*^=5C1I.)BZ9H/S7K"HXRJ]+'"0="TD3;C"+O+94[6)YV02P2S2NY-[-1>W
M5,$J&?O.,'A%0K(FDBPV,'@IO;"%:XD[\6/,%00=WS.; -3<;VDSFNW^F;X'
MT.QDU&RFVGE!3S3F/(+[2292\.2SBL/SXNX,[)%EA2"L',MI*WGL)1MC-K"2
M8G?<J>^J:9^GV5P3J2/&! 6'8<$Y$%^:Z4+[8B1B&[6HU/P#M9YA4D@&/(@2
M\/+@FH=FX8JQ?SD)E G#!7'\L3/,J!"]0D[8$SL4+O0]<_XXWNF=[]"</*4Y
MH4&QN_$T1&()0(PTQWE17HKG"]P,J8&I21Z7Y?D>W[H[WN '4$$#_KP%)P(P
M^(R+(^_7JR H"MJS#%;H9.7#^2*A'@YQ;'-2VA4PGT0%S">TZBCDI-,)_[2^
M5=U!BKKY=TO'JSO35ZQ35/"2+6:ZA ,<%K!>UY0D29!B]*4IILU,S'_%XN$8
MLY.F,^2P6HY4J)YA:JW8#K/2!*MA3Q=VX092 X 26$&L-GX-6;^[*QMK-05/
MW9/YZ.P'*,5P3[@2W,JZ%FNJ8>D'G>)<19]Y7\X=<BOHQBP.$0T<CB2U\4MW
M[O*Z]<^*%3ZWXUC\:$]<(BH@\0D17XY>V7K1.MGA( H)OI^P>J=GRK28%<8%
M HA#M1P +5<1EM1G5C>^X(/MF(6>PA7,3;]IR3::,ON!/F0G*PH2;Q+\G0^
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MZ_&G?3V6M#7'U354P8^'0#C<WR(0;L-8M@B$'PB!D*&U=#:JD[,*_)FGVBW
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M) ZH<D?^]WMNMF^08$,QH[XX697+[7]_^<V[=]O))]QN_^=__>GL[)OO/UU
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MV'1&"&( L42OGB GQ;ZS$+E9AFX"2S'\- VXV>^![9[:$AU_,_.=97#'IO#
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ML7S+TU8JWZ^+MTSO1J"&8R0Z.T.__<-O44C>E,7*$("75#N/TKL20FV*'1V
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MS-/LZ<V="80S'?;NO_K2F6/D7F2W:*$0W8$7+?Q]X4R[%F3GF^!H=\$J"48
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MZ'^ED:&SA:_/K4 W$7Q_>+*^DY94*1:F#RS*<JTDCM4Z':_(1@. :K\QA(/
MQ5>C@'TFVP@EZ'P&*?)*3M%(=#E9AA<-'UA5_PH^+$O[2Y9"!2F_*5LK-VC=
M2F 1Z=?T112V+)RM,:?7*:=5(^)@Y2S,GV@5/:NUK:'HM+N?A7\+S*5/7B]M
M"R!XM4YU0#_IW%I!U(=%@-4OCC!6!89MQ0(!EG!+Y&YB-C 8Y$Z>T99)B,!0
M0W=BUH;_CLJQ?K>DIAA6@UD-634-\__I&J>3%RL2&1,68(Y2^1:$>UE'%@$H
MN<*V;UH5:"AN<K)_$_4WM1#W5#_W-_U<VE=6;3-'+^[0#PHL/QL+_I+;[Z7:
M"'5_S]-2_)&2@UM9HJ_"HR+)J^0,OYB+"5HOMSH$'RC_\G.IZ-HHQX=-5:S*
MF %;HH":))-_+%9%6.&+WR1@^N;TZU_T'B.>/Q(9)U_R>L$ LA"F4X",K_B%
MX23_]JO?FH?J R>$;,1/^C;8SY3LF8I0K%@L[3\H42[97/)X>A[.-\1D[.Y0
MF&!?6X>?5S8HCQ/X6PLJ*:R=_A.3>0[GZ<^517C3'4^-!9ESNF::=],Y9?AX
MI(/ZT37N_+X]SI^C5B0.52J'9P<OVA:2#H?5F F-BKY*PE'J\>LKIN&;M[7<
M;Z2;^WP7]\V)J1MDR+T*? OWDDFF>'(<A_TCACVXKV$?5X3DZEG <8;2$2T%
M1UG7^_N<#S_EW347YNG$Z,$:!5MQ=SI)R^U[!N1)B?;-[[6I5SZ3!D.2@"DD
M>T]9Y[A /K+N-2LO"DO'VOA.5@5!#<?Q_;@-J%OKR>D_3KF"_W'ZUU.2Y8=
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MKNU[=GG_(BN^)[5XU/VIDED6E$X<US'34<K.EI%R7A.%+26-X%*P&5ZA6)G
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M!'L&-!AP3\=9^MQFB=DK&FU),*&$WG6]GAHN7>'4W*4D!C9B0LF/,_KI9]1
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M<XH><#+U.%WP.Y*]_2EO<*G+BV9;D6NO@SIPF>-D1D>FV)-,MWJ158F05FP
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MZQRCYA^4?SS\=G+VX.$#08QH=TDQ9"CG+^8#FO(8=6<-.<?%<+N+88N_$UZ
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MTC:[=_DIO_=N J&C4SS:9;4QL8KPF,V::S!'VX+EGMC'*)2H_PKC=5'4REN
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MJGMSQ$Q^TEP44=DZ_9-S+.&_JB,Q>1760I\:R,..OJQF["QP?1[89.$PGDZ
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M1UP01*5PGLL#+RN".'ZCZPPY#'.V@6B!Q3GORX3?B7-TB&_.H!3$+L19G#G
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MHR<!8LJ./(%G<.I"^]<*5U[RRS]^T4KG*NMBXK%VG# @/6XR'R%,<CS.,*:
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ME)OHM$5\# _-O$7-CHZ<OV6#!T/GDD=17+%@(*@J;JT^[B&:K$W3GEMGJ0]
MJLPQ3&B F,Y\TXFB\. FIDP^;V5M4)RX9?Q@#(_W'VWV@&Q1AT)LQLPZUN67
MJ@':/=CE=?)KWY\KD_[A6B;]$-[E6B:]X#+I/Q241;[\@7UYR<)8D*#M=0LK
MD@JA/>L>C8VAY3#@3\QV4_O[3C$]M.SNN(N0<M%$,Y"N37><9+%T>79RO"LV
MSSXK,C@;N00BB:'+\;5'+IZD"1CC-3PJ1011BT5>-VA\4DK):KPZF$O;GK@K
MA4$@!?B6&8K^F<&]!JN..#'"CLB>X*7,O N<?T6OK[9-TPW3;7.W1;F9&^'B
MOX6);J/XDCE'M6X4 1B>07X-AH":-/#I L<=NB?12WU;WHB#XE'0W&4Q4PF<
MV#-P@-Q6YFS5X$4'F2"ZYW1BUPJ5/@N)R.U82;HLSB#9&I=^&?(%9GMNDP14
M\E% ^KXBX5KY9@[1!"_/.+E$8US,(>^,5VJ<*WSYYL\OGCW#NGY-<1IJ9]NX
M6Q2U*$I#=V<#?HB/Z/+70,82K HESBZ!1^_V#"O#T:- L\S_&8V<@''QP7X0
MJ21K.0)?EITRFSSAD"UJ.5&ST6K:,7]7*:N-BX>38DC",>1VWC![<3\;Z*7G
MB#(''ZXS=]&7-VV02&4SL%X<(@I(?-*RM*:AE]T^VG7B7,P.0TJBY]S:[B5X
M]M.KC+80MV4 'S#>/*;?1)T25$& ,4O8TOB OONEL*>Z ?9DM@D[P74$:<PN
MVY8@U#S_YV>:\EP"GD9E:FY!$ *;L $.EH0CRUF-_W/5P?VIHHM)-=5\XH([
MA4_"@6LI$@>1]Y;?,EA7">/'G;JL?Z56FYP=;TEW@]-N/OW9K;9AW0,WLV*A
ML<K52S-O[#JSCSNSF>*M]Q8S=K%$MSE#O:"ZQ^R12Q7S.I<?R%PNRV/<@5V:
MRP7U.,(!$69'9V0M:?_I0X%BU_G[">9O"\(-U([@(P'V\;9"7_1=T[XE)R<K
M; TB> M1K[OP?>Y"E,:RKD KVNJYF:SH=:H>>:H8;]#4 H4[],>,>I^!3FB%
MIF#F7(,^@<NX+]9UK:P+ P(;%>8ZQ-NL[7)K+;S._>/./4/7N@YPB273)8A#
M.D@^:CY NUE=W'*=M/<X:?NJ2R+KK@F>_RJ>FI")R\05-5^(/OB6('!=6+7:
MR4\ P2?;YNY3_.E'I^*N<_ON<\M@5V._J)NZ#76X2]1CYW8E:F",6U=N9&F]
M!Y%&#$%O0XUB&RMXO6M'Q(>2=*.TMI)CI)PVTX!P3_O@"/.LWI3F'Z)MC/AD
M2#0I;"3 ?Y;'[5C8.M,R1*Y;=5Y9I"T5@;ZE^J6^M4!*F)U&'Z9AI:/CV)75
M'G(A_"]M(/)O]Q==J/X-2ABBY! I6(##$CY<'LED7PI]H>_95;>A/172[G!+
M'!N>8\** PX#0_/5])UONDE,' DSA)>_D 3O&]?_>1^G7$XCI[1#Y]>E9W99
M_>6KUYY41VM*GC>5Z4&H=%@*?\_485[H5!?#:I)\" 'CWX9P8"!;@DS-Z1X(
M74P.C)+R6.8*^M/GRL7[X]==H8W@"KB^#X)Z&=OMZPPXYW5H7;?@N3T#J(AH
M+LSE\$8\B?14.U"XNNG.ER&9T*!.,WBAL:R@[-MQB95);4")1W_BGM:I=A)M
M\=TY9K4I%/+7/V+W:G>%[.1#. JMX"P]LQ3E^5:H\ZT40ST'(5& -&IDAH6N
M^_TR/J(91IS<7"*H% "VQM/,L!%*\X&F:RD $@:<C:'X=@Y?094)5/G'*ZCR
M0WB7*ZCR4L04OIPH])FQ#?4-T:W-E)^2Y%9">)$/U^4X+X'@=%L<)RO&7#99
MEP+#039"X4&P3*$3VU5OZ9RY$XZ_B:8;!F0)6JL+^K0[I30!>UP<[U1'V= 3
MD#A$C)HSC-U-8&&,WGIT$;?@$FY%&FI;SQ$"5,F@\Z#*I*,'3S"*OOL/3CWS
MP>KM1-K05#R8K_B[/0C\3"EZ3BM;#]8S+K6>MT9O<3&M79 &9<RCN!^I1UG
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M@Z[0 K9" ]?;>B?F[;A8JJ4%QYG*Y!TM_3T[2?)#87*&E(*U+FLE;PJBC4H
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M-SK]N#:C;V2)%LG+3*6^SL2!YVGSB76C@9Z[9G$D1>1/U4/?KL 6G%@R[&5
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M+U@GB*1R^:T2Q0YS'M";>$8&IFT=#OV0?":KPU_*8IU!.5@Q/R>N> "+<#<
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MIYPM%+W]DZ;>G32"Z.+I?ZQV\=W73^+W_$[..\+A0;FEJ[Y?G$+9BHS+BT\
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MMCT5XI;-^L1<$5C'>"K=F(Q>#&?.]B&GGI-5<U.CASVU?WKL(VJU2BTU44E
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M)-F\DC/UYM,9!S(JI2^PNJ&N?.'@&"5:D<8ST4SMPA<WX4XFIY+)C;TE:;+
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MFPTK.$FG-8^6%HE=I(S1Z#"R0.A#N=R4VH]%).I$9-[AK.UX[V!RA&L$/[T
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M%:D$S3>L;U?#2^#&6RJ%8NF S+[&YI&J>;:Q#B"8G7<4SWEA2G8L!93RL2W
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M5V6BUM>%>[X,*9MS9[O<)O;]J *I]\DIBQZ4!7EGNI0(N[@HW![IPC5$ \E
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MABHJHEJR_82VT8_T'Q4)<746M^U(*7>6Z**J/\LLRK$92'-WFE46EB)J=1N
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M4K4*5HV@+S='-? NS29>K[O]NP<6*\K:*.68(P,UGI[Z'E:.>0=DK9"X47:
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M)3!IT<0D!R@=P/C9::'U(R,+)I-.\!B1*AXHA;JWB/)1I$+M6*7#89F1JQ"
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M_=([373_]P\3X)XZ"Q&9Z=?,I.7"W0>';E'+&<&W-#R0*@6%DH7Z0+3ACJ"
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M\,<7<'NE3@FGBF4V(]YYK)]0A31B81-*HF6!)-.TDOF<=\Q<O7=?M2<H#A1
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MSK!(DG+A]30KD6C>UF3>UUK\$\\!UK7[)PJL'QG6LZ.6*+<N]R4F,H]:PLZ
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M'@,VR$A//8O:)CSC-F(/]DT5/#<7S[5;&07/CX+G66/"!9U8URO0@N2^P%:
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MI?BR!CA?;?UXIT9(5P>1G;5)O&86V<K6TM>_0,T^&IIA>UYS/IR?#>4 J.T
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MH!*4<1&D%!Y9Q#EQJ(':SPKDJ'T<C$*ZBM/@6^<S=[^8WJ"50&V^FU[?V'Z
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M^_^U,1JN/?[]Q+QU]>SG .\;I<NY_C*.QDW[NZJ1;13E5CHL>1*\#88@A65
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M:5WBZ(/)\@H:R<YK!)D-L:@7E2>NPQ.]00.. .RPOT7;&@.N9;#,[##'/OA
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M3\DJK'UA&#QC&%P9YKH,0_;_+E-Q' !R#K8CIYG*U@Y#6D2) O6..ISR3'3
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M\V/]7F=4OY22/ORPRAELKC%W3-C$&6MS[:J$B>9DR?I)'D&51MKX?Z/&_XO
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M<D:@%E9A%.&-,1J-4RZ!$DH"'3528% 1"'DQ3M?.."TY(VMLO9:<D3OE"BR
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M?=<]"-]I6M\HFXO2.GY9\]/]FYCG'@?AZ;W+\-[V^>>@0O3! DTA)Q@],62
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MYB&*??1:EAV6ZT<@BD _715^TPA$,<]7+]*+@0@L-:/!<""XX( B:H%&0H
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M>#0?%04RKC>PTDCJN?<PP>&C(18O0%B \*[*==8/"0N+Z4\@X1*+J694!(X
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M<!IE_5FHBYM/0-$7I1WG@W8:V]L>MSOP6U8*>]LH?N8SL=H0HSC 1#I ,>1
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M;.,%WR1H555.]V"</"8;9"^W#.C,)NO=^LAX/NVDI/J7C/Z[-\,B5!> 7A5
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M4('I^"?B2,6U\Z&FIRP-R^\Y:TGW78F/W"FC &+46DB(T8:J:("H8 CE@N
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MARY=VW6&WHX'P]%6ZY6V1ZT*SQ;O&C=A*TI/9]RM]N37J&S2[76\8=P"XXB
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M3;+*OUMV9^'R,5MX;U82IHCDZ^$EF6G(XRTB*\7VUJ>]2)G+D2$P.1KGDBK
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M(2M"0I;4[70S$+W>WQ_$?3N*C5OJ@4 SXY;"P2<:<432YF[6TD=DJ&=(2D5
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MM %;AI<IO@6/VBO!T-MN]R(_XM0L]9OWWYZ==3L_0,LI;SVYA3/@] KHLA9
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MU,FB4ETM4/?1W4B*XL@BF!:4,,FQP=9*IIPFTABCI; 52;T.DF)'(C('=GU
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M4@6N@9:^P8Q6HSOGLH__(NL8X[M9;^/85)%_,W$CN$K)MG>09D"$!4TNQ35
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M;RN47U8!5 503YH07P'4TP#4; 1<&B>]5PSYZ D"L(I(LR00I88S;;EPT58
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M QM08,2]E$A'!K2?G)*12:JT!6PB#T_F?DP7Q'/PSS\J0'I>0'I8B*D"I-4
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M<B%/W,2!P7%:0G5:VWSP<.R*R5>:R9_50JF8?.E,/NM-9-A)SP+2*DG$K37
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MN[+I<\9U557*C3PK]E%+M2>4:F1*2[$(CZR8V:;O@"SC0<A,/W1LTY&6&\M
M@,I"YO>V6%RNZ?/&%6;F)>HIFIF7R<R3_C@W9L"FD>D)B5%0<6SZ,K!,&GN6
M:WL2&_3.;03Q(KR\93Z5_;2MAH.M9MMI]X$.M^TVP%9#21G9R1/<R'')%B<W
M,C)_RRS50NU^0HU.:2B^2[B@ 3>EYZD<%&[Z@H6@H3B2$YN&) YVWO[/?WF4
MT#]6*+A3<_,:J2G3[*S9]IYL.^TN$1Z- U,&!.OXN*XI/-LW/=OU+:RP'/A@
M6/C3@8S:5_(,O:BB7Z(=RL@X_Q_1ZOQQ@$X376QPK;TFU996->+WVM&!_"6;
MJ>IM<U;NKS; GE#HL>D(;MLFC(?<] +70P/,,0,B S,23AP&=L1BGV+Q,L^:
M+EZF?2D;P>)+5%(TB[\$BT_Z6"Q7$")"+*9LF3QPF2G\T#?CT(V 6EP_L"2R
MN#NCE+)VL3S#,1!^-M+8Z.6R"._6/I:5UFEF1'".R#R=2KM< <>G=!C'$]P3
M 3-#UXY-[G%A^I)2$\PYP2,0<X$M=MZR&M%Q*YO*TDL(RM8L_9PL/:&SN%Y$
M66QSD_D.-WG,/=-W/6H*26W;8C&SXAA9FM,58>EMB,&^3+NB:;1E]\DRTI[0
M2)L;9;^.HN_ER_L,A9].2WEJ<6=/U_:AGAT2[&1E@9W&'=<W14R$&00A"^W0
M(00U&-MUGK"(_&(,LT9NFFV5 $NJ"*0EP%(EP(3"X[- ,A9C@UYL"&-3R_3<
M.#!M)Q1N&,0>F#(@ 2BK^?ZCZZL_BP38AOS\CS+/WQB_1+.G2GL:HME,K]'C
MJ3TXZ^;!*:3>W]56[E4[J>7>T\F]H^FJALR6MN5'CAE[%!N38_$16P:F)T+;
MD@YH0EC5T/9(S>./.8'2WIL59N>EI=1K=EXV.T_Z;0@51 ;$%&Z$]34\87J2
MN*;O,F(QUPN8CX8,]6J>/YU?KSTW2^P\'LW*H']8[>4[C+8%]<YB1=XPV+<H
M[6& <;40CZLNLG*K_]\/5,R?8H$V!R26>VJG<>$)<6&Z4*2,0\^)?,^DK@1<
M$&C>>C$W+=\304!M)PZ?(+7\R=GGA;U?6I!J0;H6VK86I$L3I!,*MF1>%#'/
M-YF,J,EI$)M>2*GI"D'LT.+4<1@*4L]_@F"NEQ>D2CG?[6(FYELU'Z3DI%T8
M=?!-E/QZ^T_XIYI*2V172;L:,:' /.57.$9JC0NX'[V\F\3]XJND'<DV\).G
M1/ S,S%5YZL-:>RG+7ASW\AD"&N;&V*6=Q%9S.C*5B?-1-8WHB0&3I3P0ZY^
MN6XD8<-(ND:2&ZTTPTXK/V6S;W0;,*=VVL4/^,_P;==)LZE^@=?*Y!>\H-?M
MP8UH*@2R+>.DF]>-O:YQ +^W ID9C-0,U+<,T8[P@U4;>V Q?# V9HP^QUBW
M_UZ^YF<OS3W@K*GT^O;OAA6V_FZ++W[O],<12!X8W^5YZ^3'N];IP?G/KU\.
MX;XKZ_0+W$\_6<<'7V^^@=1!271R$'X7=L@"$EBF) $('XP3]S!E-V8@>8+
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M6.?FH!.UT>EE>0^^QHLNI**"8GV81ZOE4<VLVW#?.>IT/4272-E@Q/<<T,5
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M#A\)LE6V<^4.5:>NQ89)@6>S[2@)U0CKQG'UIN&3<*?*!C=P#VIHU?$[W)P
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M.>Y%%T-'P]@5(_29&U>]))*X7./G3I%$*+G.TO95E.(31 &((.);:;=H-=H
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M#28$_]9 KO'60BL3SWW/B&I:OY/,C8NP(2/L4+"&,=5[S::15^-7$=-5Y;9
MAJ*7J]H/??4#UC\;9"L!T(]<,/Q^-+4IR:?*E-T=*0H/;BL!@VTO9#>]5X[7
MZM(1JQN'!9?G@VHTSQLO[OMUVR$/"1=WZHZW6%SW_7ZS&7_R&'1.ZJ[[L-#V
MYQ\LL>L^8VLR6+]NL76A@G6B6+_NT,5H8$D*\S-GL:EXV]D=$V^9U-Q>I]L^
M?V(OL@!%FN;S+(&WT H<3:0WGU?IS:I79#=5?9_>)\W1C@J;0R:+K=$,*KE#
M!HSW%!WO&HI#72L2*14F11 G(XK@LLE@]5;BO<IB+-?#.)!YF"6J(L?3KLE=
MU#.W(>W:D1866UY@[1::L%[8D84] 'FN%W9YPM!X<D&X49!1",JR[VB2*^@8
M+ZS^ #2]-_7,[+X-3WE^'X]5^+#(BZI0Q<RU7_ZA[MA&M]MYL[N+98-AF/6K
M]-?N7A8VL''EKHRN1+8;B:[8)<3U/-??A>$28G'']@F\S[<<OBL(-VW7I=^)
MO*$1J3>ZP)][5YD<ELY31?#2V#B6V166HBU<="?I+W5X5_*/CV=WA-54JU.X
M2;32]I6QIVH98\_<3'1D#[8^KY7-(-IAO6;LOS/VPO_TDJ*(D($UA?%;T01V
M@OO>)>E90V0M,7:3*@7>@\<77QZD#SI,6%S^W9O)YU/Z2_#X4,AY$S+NQ19H
M-CJ\H!C<)707R)>OQO)L.D@\+=FTDBAJRA=:F_O;X>NT[U0K!UNI'-B6XS'B
M@G)@F]1B%BFT UIJ!Z,5^1=1%2YDISNB*S!+Z0KVA*Z AX!%90@L.5\S+I,N
M/*QXDG'1"PKMH.BH&28I3+8UHA8L2P?0,/\ A]C+K8*_RRQ$<OO95F"+A;;&
MXV>=V__1.M. O)6 [!!&J++6'9-PQNEW>D]S_:]>LU\PAZW0UYE W^-$',MH
MS,X>!^2B^C;,)OLE\A%8UABL,7A\%=Q=!R'8V5X(?CZGJH;@YX;@)_81:0A>
M$PCV+-NCO@<0[)G,MJ@SXC'_K_((CGXGWRU.+<H6 ^6B#-+ /#9*+[JW@!?=
M*!WH:;/7"GKYE)T,/\FF;,N;XLK";&Z(3):];\YE)Y,Y#$\5^H<Q9+^2$/;A
MX\?]&GKD9+./D;D8E!J*C@BQ-8[(BS;(P\?DJDFI^\?$X[0BH!4!98Q3&S4!
M3VL"3SSUL4LW!EV9/HW>.G#UP;"U";4\VR7N;D1]W_/=2-ZPTK8]EZIS?:2Z
MO24Q[%97%O6$JR#1LAWJN+7ZTE6#ZQK^9L?5;!/^T5WJ(?X]GT=VBP6ZMH2?
M>6OUX?!V8;7EVR#*F.5:ED,IV^TS2GPBP K^Q:[Y!%J_ZYM-<9U/ [-V$E^8
M9'?/>,48,PDGL)JOMQ8@^2YU 2 M=WL!\OG<B1H@GWEK]6'M=@'D,'J*<]NS
M5/0489YGH:>858>U$W;L6##5.%2J1EH+6+\U=,R*EJJII.%5NUYQ%9Q=LMUQ
M4-KTW&!DU6>PVXFLGL5\RRG.8 %FW5%DK<Y@F3J#M1FABV#M O"J$54CJD)4
M;ZO/,I<&J)MYELGU6>:6@=2(?]2U?:?RCU)Y\XM?DWKW!C;XHB-#F$79[& ,
M=N2O))+M$%N@YAA@HWRG8=IJI;AY</76X]"%2;3;5(GB(LEE>]VFSRE<M7'W
MS%NKSQ6W"S>'.2[P/V7<.:;O6S;:=CQR"Z\IVB!5&_%VMY?I$-.A579ALKV+
M\ZU%0[Y+^5;GF_#Z\RD"&@V?>6OU(>*ZHV%^7SA4'ZDB+6+OEE/B7C2L[9C&
M!2J.E'N<CK3YW]R 5_:RI)O(A_5;6)>2J?= 3.-9 U)G2I,770.VBX6.L"7:
MUBX!KR_)ASOMR)S;Z*(<$,?R_)VTJ'[V)I--E3U55N4O1CMZ5UF(T1K>(H(\
M;?:Z\V\9DXYYK]4267\:SY]_)U3G Q/^8TY(I9%_&]EPA:^D&612_#1%#.-]
M(YK7HI_O[(YW?4C:U?-=;/EPGS5YH16X5'T>5&MDV ?5%V=Z->[?V$*WC]#M
M(W3["-T^0K>/V& E5[>/T.TC=/L(W3Y"MX]8J075[2-T^XBU6EC=/N+YVT>L
MTPG$M@9;$[KB)Q"W#_ Q)Q#J0)[""RR;N+O=%B74<UP2D>_RAIMD_$C^+)/F
M^YYJZ/Y%9)/%-[;\;'Z;(Z;]7>KC8</SQ6JMG.S4(=/W6J[GRU;34+,&4 -:
M%2NPYF)PD&V<]>"1(I?#S@-3;08,JNHH4C*HHQC([K645:/Q%NQN\?VYC&"A
MI/$A2WL=K'VHH4M#EX:NG;?$6E;DT:9BU_.%'VKL6@_LXLO%KC.9A7 75N_]
MF,02F^+@*4=N'(L<A*F!-EG-^-C5-2$TJ&E0*T%M2<ZL306UYPLLUZ"V'J!F
M/PVH#5N^C4(:_ET]+LL-3(C%_%AX5%K@7PYD(3#]Q\"00%6./I/=I36 U0"G
M 6Z=!#8 W))<:)L)</^ !=-E&E84XI:58'-+'5MB584:J&51X_ _/6Q[<M1&
M08=V%G9Q&:VV5_0BCT'XJFH-:9&)(RH<+/%)#7KK(4J7O1W-6-WNLK?/*G9U
MRNIS[ZVNX+"]D,I=VRXAM014MT#4*ESD(,EDV$TS!9VG<9R$8!]B68=6NRB%
MA! Z,"4U;.JB1[KHT0 T=:&'#47-?RSOP%7#YHK#)CS?]@FQ=D.+VFX)F[1L
M[5T8FF6P2EFM%J7@$$=/"ZM3=1BMS-%9UNC60ZEVDI:5X54AVQ<N ;$E!HJ&
MT0TYX=4HNJHH6M4/9);G$$9W!6$FY:[#OU,\L:SZKBQT8GF2_E('E@6/4$NU
MXV9W'UIV9AY:*N]OH@O(:^!5LHD ["+R/I^>OWK26;M]-Q1Y_V]Y9\\:>E<6
M>BWN<L<G\$+B6@"]E!+/MNW?\L8DUG?N#* W';5?[X!=XH_#[F@ [+"\H?KI
M0U/<I%7V1M)*X&$:;77S[=)?C&#[?.; B@ED-(6>+R=!H^VSNXNW->%D>]&V
M-'1=R[4YQ?ZBKDE]^!HKY0\-W;U6$O9RH_S/)=B@HB-[L'=Y#4.9ZL9,GS)^
MR))0A>VJWC2?VZH@4"RS3#25=UDCJ[9C$5CH+E4>Y*T^B=7(NKG(NJU9+UN/
MK-QBEF-C"QIN$D(X&T?6PU:GF?95 ]&!"5M:L'N=+&F67F.FS%=>N\UP_2MM
MM(O+W]>-_2R];LJ^QE>-KT5TL+WMEJN&UPV&U^=KH:OA=47@%8#5(92 4+.Y
MO=L.X544OO1NR/=(QH2+NZ*=9J;B;#U@'AR^-PC?VV:H=+<ZX?.EMU[CY!)Q
MTM<XN6TX675"M:G/;-4)E8)!ZLQT\(YY=@M>4.[=?9$WM.-6&Y8S[*K2<;NU
MG5*U9;FYB(E[^WPQ[1HQEX.8#P5,A]LN+0"3^;8U#IB#2N4RP^08 4:D^4[D
M<T\]]ZY%-A*E9*B1*B^N-E U\#[HQ%3EKFK@7=G"1+?*\^K^R?5]ZL5TZO8B
M@G2Z82QVH3%9?4:WS@#$7 $"__A'M0$O10!D942AQNCGQ&CUD?@X=H<!1ENT
M(]MMH:S86_R^\$$*>';-V,>.M4$Y)N-_1*OSA_$Q 2D_*X7G6/0-ZJDC6'^J
MAN[\H*@JD^<RZ^5=*?.JGSHH!$!".6*[TB#:[;S?_"7:B=#@7O93_[2UP.[M
M*GOZ^1QUJP?K2TJEW<QZ@XB"NCC2NN/?@X.+7.*K_%1N4LI]=]*K"QBHS,W_
M(D8W+<W->7 U[>355=ZUL5EY>1T=/Z11Z5[KI6L/;1TJC9AE+MTMIT2L:3BB
M&HXT'#W"]TG\;3>2-!S=MRB[KN*SG7A$%741>XA'G/^(0U5O75QED]ATDM8-
M92W=E9IA5%D9=R5E&#H?8\K!]WSHM6*BB.U2#"_=YE)Y7'?,NB]VZ3(X&KM*
M[+)ELRG;69K+=G!G#N%[&60]D?4-HHZOJ'4;5AWB@XV+.BP)/EQF5X;&*XU7
M&J]T ZS[XI4N)*/QJL0K)\A$!*8/&%R=^^/5K1GO[XHG&Q_16]CJ!(",&K T
M8&G 6I+XW6# <@V-6!JQ"L3R(M%IM.5_>DDK>6+$.E!/-C[AHS54::C24+6D
MRAW34+7;%4%35JPV$H)?#HECJ/MT'/QU$G4;Y7A'[PK2;C=MO;&&MX@@3YN]
M[OQ;QB1HWFNU0&Q,G[,^_UY0'*A)*#$GQ-'(OXULN,)7T@PR*7Z:(H;QOA'-
M:]'/=W;'YMI*VM7S70H#N,^:O- *7")]8$3V/ER*K79GK<;H%$5V!;,L"8'@
M+$OJ,U'.OF&.HD!%=D.JR0"YS!"CSSNY?%-]^"-*\DY3]-\D;34P==,?XV^8
MD8JAB*?XN5QAWZ_;#L%%+E6S\L7E^M?5^E?\,_:;4W<\.O=74)$>^)O-^(/N
MO&VLG-1=UUN3P1*[[C.V)H/UZQ9;%RI8)XKUZPY=C :>-N&L$ Y+EZCNHKGA
MSZW=;LC\B?WP0*WE+(&WT H<M<%FZZ#9!J92T =S*):9;(?RGT&V^[:;&A>'
M^\;[!&Z\VD R66R-[E]!H=0B*LVCTS5 \TPBHQKJ6I'(86%W*X(X2>LO'-7X
MDBL!? !<4JZ'<2#S,$M4P\VG79.[J*?\'1. UYRTT,&PP-HM-&&]L",+>P#R
M7"_L\H2A\>2"<*,@HQ"4UTFW870;2:Z@XY8619MU4J%+W>J#BO*@PF_TVE=1
M:LI6I_FTH6!_PH.-@U0?4>@C"GU$L:0TH\T\3?\_[-KYC)E9&J16#Z0HF\K]
M?)]D>=<89MD,TC\?7Z6GQ+<#&:J&GT;98MM?9J$>G8KZ_)5Z5DS0V;ONMB.C
MSD&]+S ^([EH8%QM8*1CC:R7B8S'>(M!G<KLT["H85'#HJY?MS+K]7P%]#4H
MKAXH,K9;%&XU;YJI:(L*O60!D!_AN^F2K$*AT5^]9M\@[B#PND VT4K;5[-P
M#6"M*[.VFH=H&G^F3:03XV,WJN$#WZ59EE[+K'8;)N;&F<ADZ285QH>>0*=I
M"C>%0%8B ?KI!7D2)2)+"LBLKL\-I,ORW8/[X,'*X2KZ,=Q[(;-?@.*Y\?'C
M&=ZQ=X6WQFDV>'H3U8(LUT"K*\7N8ET^#;4::N]Q?$AUK=AMP-HAQH["+5$4
MQG>Q8TD:!ZG(HFS0K23'9B7CS4W>X16ZH<G&G3&N&I*Q7;+5+3=!+C-]R'A?
M)-/U9362C2"9PJ]4Q<L*P*992%; UZFZ1@.8!C -8$\8):,/ ^\+8+H@K0:P
M L FL O+TLIQ -/0I:%+0]>2H$M[$>\+7;H>[3I#5YPV(Y-01I#Q;[!C%+7'
MX6;-?7[ZTO5H'O_OS<S3*D+]MK4&*J$K+B-O'^!\&>D4,O*RD63+#=@;A+*S
M%PG9&Q#-6Y59J06U%M0;+:C=+174&ZO,NI4RV\NZC6=*.GH94;T.$FZ=+M72
M^,6E\;;6-]A8M=FK,D#C)0OCHBM;D>9"M"!>ZTNU('YQ0;RM.?P;*XC],N,P
MN5FV(.Y=@2@UB);$&W#IVDIB7?#]KH+O5!=\UP7?Y_RZ6N6S=<%W7?!]O2A6
M%WQ_&;MA0^:O"[ZO(YGH@N\+3%\7?-<%WY>UH+K@NR[XOE8+JPN^ZX+O=SCB
MV;;6#-Q41SRSJM)_OX#3ENN*OY"=;AFAXFEW_ 9<NK;N^$V0Q[I2W:J*XH5"
M!<OQ4/(=!6%97B[)NRK!<J1JV]:G13ZS'V_5<B*?>?HK)N168O,U>BT!O=BR
M*K9K_'I6_&*C +:?@M[?5AAV!#=TT'2 /XN&3C(#&^"L%S23T-@+P[37[L)^
M&>^3K*5K=:^$H-N:Z:^8,%R)S=<HMX2"%D2CW":@'"-C*(=K',,J*Y\7NIVR
MI!TF'=$T#F]DV%.E!4YCN$)F 'A9WA.%/^V\UY2EFY@)D_!7XG7EQ[J ^[*D
MBV6Z#V_"AFA?20!)A:3$9UP#Y$K(R*V9_HK)T978? V02P%(701\(P"2+@:0
M[Y.V@(_P20/D!LK(K9G^BLG1E=A\#9!+ $BJ+<B- $@ZVX*4=]F/G1%X))[Q
MN7Y1WZ\C&N+K*JRT+14@,?:M;SD#[!19(-HR-T]OFK)?P2:U+*IA<R4DY]9,
M?\6DZTILOH;-I<"FMBLW C9GVY7R+JM2P^862,ZMF?Z*2=>5V'P-F\LH0'\?
M8W/SA-3*S^@28"E.F\WT&D-GX@'L)6ULWE'X6^,L;:G4%&.OW>[!C^>RDV:
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M '('-A1^ )&6=-&=T!#-N%"$92'.B@O4DS,) C(M'BAZW4::P=35O>]ED/5
M<A4#IUPY,.E =CUO#P7JU6W+>T@/!<+JU'Y87X+;'NOQNLT7JW0_\S3 >719
M[!<3/'O'1_N?+XS+/P_/]\X./U\>[5_42F?"R?X\;'ON0;X:J@*O9X0D/FU%
M_[O#6I<ZUW?]-_>.NEP;:MO-=XUI??JOM $2JF[L9^EU4_8?OL.+U^F]=RGC
MU5S/6U=NF:.::Z/,/O?8;R0RGL[\F;?3]S@361?%84'E(*D"RX:'!Z4"$,AF
M>ET!_S ^K@,*@/))MBO=H'S94&0J=U'2KIQ>(AP>#:3%MY'R&2>E]SAZ(;7
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M12%(WPQDWZ/ZR2?GQ2;,,ZL6TST#*7/DG8EJ"\H#\]@LG%4RNS:!-)65^>N
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ME?4]!5N-+K/&L!7R?V#!_!\-\" OBIG9B8(M[(L:2$V=N-.^9)QQ^SB.UW!
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M%Q^?35/][==_G]+;.J$/73Q;/L?Y_!OIA?^#D],\TE*8R).#S%,&I8*%D+
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MI\W(J>*5Y+:3D>A9YBS3KH1.]TJ[8QZ2*]N88P<29#/BO?ZT@C/]\"KC(M_
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MR6,-1]E4$]>,!JSU\TK:K()U1;H^$<X[ &T9X8%'Q:?]MK]=CL><EO-F/JL
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M;G[JB&]?(VG"V>2,\BJ7;M;!&89'<.#ORY-;#OQ=!-#L=;A<E_.Z7+@9J\O
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M%Z';],H=\&[$MF/?;_=G6W/1'N!,?(/?JF:M@?T8YZ<Y79Z7G;7GKK;]DW7
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MUD+8,''Q[.OUESIP_>]_^G]02P,$%     @ 9H)85,XW_P&_70  _2($ !4
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MU()6!)\*"\ #L]ZBK_=7.6]4O+T7O@,LG\.PY,Y=G>'5T:2+X*W!OR8?A7X
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ME-:[,_9=UUDR+_-X\NY&B3J2!>F[..8B6*:#\0R2]\Q8[["DY*UI8[;?@7*
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M)B)O<M_R_'PZZ:I67Q7&L;SF!AO&N;-,)^590,R$"CB/INA6;:'O0-E_-&8
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M!LX7/W_Z@),Y7J:OA2R4SHHA^9-$9ZR0M&/1>UX+6CN?VRPR*\"</D-VU<"
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M@2QK;U&D6,A=;^X K\9V^L096#\K*+1;A/;*%'\-X_S+=/8</GRHA3[/SDA
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MB8%D%KA,#(,&= ,8%AH3O61!4\6I!S[8YD8[;ED,ITTJ=\&89TY).#\$61P
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M4B##A:&&165\G1RN#<">F4UTJ8:U!=1KCD.N/BZ_@I_ /_[R?U!+ P04
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MK?5L/I=1D_?CHZ&?>2(7C"V=AHVO_\ZS,^*5L:87</KBPG?57?\SZDO;3CZ
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ML,I2/$9==4,*(9R7<_<$>A:&/$D!<GRS43,Y8/*Q^D@RTVK^4C?.T-Q\< 9
M+%@"C)' Y0,,QDTT1%C#*'5@S9H48.[^\C1!\PMDQ]29=@)=7D$!MO&1Y#UF
MR$_%U"@@<O<4E )D\J+6^W)_*KYXGL6(^O>P%,5SC%GE%SY[:7V.UNY DZZ:
M@-'-D5_L(+F@G%PHP#<L:&^'\Z<BEQ(G#8C@DTD!M$Y0@.ELO1_*ETQ.'Z
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M<34L1&#;!E@R#RXO)!23E/M1/KP=G#3-'0B:,SNV_C6/Y$"1664K@B5&IS[
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MI<"=Q"G>Q[?=/ ZQE;;0=)ZVZ:.M"%QGLE^^%7%,K5%$1Z*2'^6:$XBJVS^
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MP9"@?5C'D8AN%@+AR;'BD?4>L]&'K3N@#>ZH&V7Y@:>O-F^(/!BOC_,8,^R
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MF30_.**),-^L@!U=A<;8,G%O%T]S/XNT?>-X/>'&X*#X *>LI=O)JIL9' .
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MI6_E[KP'??>:UZD/,RM5:G_9 A8$)+.]O0<COE846_48*8; 6 '9T_'7(2<
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M>!W;)/AF.(5?\;[I_4R' ?CMI@^?0FCG:-;(Y39 F:;E?4DYRHY-Y<7]H<>
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MTQNPR^]X]>,G3RJ^)":*U<:_*3AA3>>S)J#C@V7#8#2WL$#*=FN=F0P?=X#
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M$I2VVQT-+?O% L58!>VLLZG\H5/,LM9(6M:AY\I0#Q(<[S!HO6G4WO8#0UY
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M0@W-VJNCI%'G+W*>X0*J6M8?07E/A# AP7BN!=,J6,E8UUUY1EA/$B8GU%(
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M P-&KQ]S/^_QYR:_EM>J%]6MTU&-2T!F/NI[!>V"S_K\*INT.3:Y[:QULY?
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M!EDSZ1Q=8/(C9&\:_M):FY:B"B_^Z?6?QW!RTEK/V?@>-[A@P0(AFH?R6:!
M,>@APS3>3[D4$]A\ .-,&YMA-9V_O832C*U70+3=[L%'A'NV'=P]S8'NQK+'
MM@SZK>[8LQ06Z$AA;MA,'4WGA\M2V)"3PX1@#D2$L'MW?K=<6FG=GLV[O^6$
M '%.Y_+QKS3GL7.FO705 I97)O4M(K2UY?(W.ZWK+UR8>_8YOH^FYO?G&HI]
M-E#JN'Y/ZGWADVC9@K],9_M/UD;_+ZU/_3^W#?J?>$T9GSH[DM%>\%Q+6O"!
MP:)(\7JX\/1DU/D^;7J;:I-;4M+21+66GIRC6:IG,99L9-5GG X595/1[*DX
M;][G4&YU,&!0^S!?/UU12)@QD0;>0=3<"11P.3GUTB[^T6H. *9=0N_QX:>;
M Q@LJM&8.&&L@BHVP=647V.!E*AY>J=?>(B![$;$LUVF(K_!N.B\O1Y/]1/"
M]6\/N&Y4X(]Y*]:OF;Y>=_@U\_S'A<MWU'XEP (=(Q14FISNK#?,#M\*-<GN
ML]3&U<#*0QYV5;F!H0=3I@,1+XAW%2X6.1G[G$"B)O,G'RJ^3:AYI2M@_2C\
MW\;?"5$SG=JD'+G@1IEO=N"^;GG<?7 +X?=( E?K9&@6:SE><F_1H@AB&^A'
M-5R9>%^KW HGFP< ,FN/->,>4FO)ZA'0^C2KRM05WH^*84T8[ZD9=DSJ83:/
MU<9Q-7;@Q(#URRW7D;Q >%ZW31U7NL ?3$2QW-R#8$TOJSC:707&>-;6$;[I
MC)L7%Z>\OVQ3@TS9LS^M:CK<23<L)IP=YZX"F85RT,.HJ73HB6(.%LA2.?8>
M#<[;RHP,;BYZKH/.<5H"5RG3!<R;+YX KZ22"QJNU!,1'42=(AK'2/E]SCN[
MP>(*T;AC;B*H^)QZV$8%CM_@3I:7/F/ZGA<JODX$1]\W,$=['UZD&R8>3BE@
M'C*8-K-NQE?,?X/MYUJHYR'?+RKX_O0S"V3H4(C_&/[I,^!',P&(&''VI(5!
ME)9C9&[72]#/EO>BIF07$X$LGPZ,J*NA_>?\XU"Y?MQ$3Q<@4EL@^9X%0J4[
M]9/ /NS^S21EH-9=P[=N.RH!.>0.PN[QL <4X:N]@GHV%>&.HG]P8==$K)NO
M44% ^/0D\B2<.<!F1B%L/ @3HU])$<&/^SX\CWW;LZ<J[!0[Q+0S7H=IG$QM
M@I-OD@Z/WS<>CJ;[2>_<7[6128&1V5[*3M(<L,A1OF&5RGREBZ6_5FQ0K]=V
M\T8S,PF;OSV-I08+]$BBGZ@,R%71^;>_I;?6T1P1)ZZ!\<8*=D94KGZA>J>>
MBCM!J 8V5G#V<]1[2G##QX<]..G\'LI%APQXG)U\VA5]#J5M;3G5,YIN079L
M(A.I%H X00<33*J]%'-RN_,8#^:NPR]'7D:N4O9M=Z" ,*$BX&1M_%/[9_;/
M@P>R:0$7"NC:.OJ+AO@XPW(62  \9B^N#R#.&ELSELJG<&2P*YYI@CX.)IMA
M8B<5B01A.C\O,2N[AF&1)=^GN"F+_[F:IM^(@1MRD3C9<\:?@J5'8\B_+W(C
M+L(9]O6J0(X@E<NYP_D1.M>TKRZ;*3#?TK&V<X39%UK[9IF!^6 WQB:Z%[.9
MQRO[UC)#B,+Q:QN#TI2#%G1!"V=T8:"T7YX%?#KS  NT".EEGF*6S&[^?ALD
MU+%"WC*1+I_'MFDAQ9T,I0N%M,JZ4I3;<(^17'%?,=P(9Q;(#!&)&[\M!_WH
M,R\>0O6@P)K 8]:M8'[F!?H?E4 BL<MN);"+>&#S@/JLD6O9<R$1$L']QN?]
MC>U!!($,OE$: >K*7E)!YQ*M?@8$"W-IK57$1%[<(GS#'F040SC'Z9I#I%KS
MJ3KN[S_]W]W^<#M$==SD0A.? 4?$ :GUD(?6WX#D9],7R<VYEPRNJL8D%YAD
MSP[Z")L<,R0Y?!S;]%U76U7H\7$3O#/@999M\MX44_K,148TMWWN?6[[F+4]
M2<O[#5&C>X3Y'7\0J8WLA?!34N/" O.!2\;:#FWY"'33+I[J-O[-[\RQM]7@
M.U%AM?R#1E@*SSU+$JZDJ@$%&&O#-./HE@3 _YZ1K*-L=GVES>GJS(AS@H]Y
M!/@,5NXSP3%D*]%S+8&0$R(7)NU_U$S^*K"Y:[<RCFJR _,WV10')+J3FV<K
MQ.1M6I=W7-,2D%:H\*S%XU8L$-EX;;3=%Q+%MC@W0.#$[/BX46K]_Q=[WQX/
M==?N/27G-"&$F'*L'.;.L2)3R2E)4HXQ"2$AE9 Q(^?3F"@4,8JHQ.0<89R%
M-#DS8DZ5G&<JXY<YO=/>[_OYW,^^[^?9[[/W_KS[>=_W^6,^6K_56K^U?FM=
MU_7]KL-UJ8ZL*)MP96Z3N*)H\O.(7[Z/G^)K!YNPS3DPA=RMT:>#!J/50^D0
M<LLX@I! W$Y@?Q_QMN=L$7L<RM)#"#?Q0*YT8A=JPC@3]D-6AF/'R>=39Z^O
M,%;*61C+!S."FO T6/2 N2-?^<67L:7F/,_W8/DM., I0SQ>-R6EI&@AM8-^
M/N6!D@(0[DGK.2BZXRIF<2^K%"4Y_1:?^B 2%X":TB)+>JOC8Y6%8;U"Y3?+
M>"#+2_E\8(^C]T-_"I,"F0_FF4&W0S'O\LS*'_4B9&"L<$G'M6))5.5'#^93
M83[.'$$5J/; *#/P6M^&PR%L&2A-17J=.\8\E$06V_K+QXX@"^[.7>GDBM4P
MU+T7TS#;YK_5HV9W(\\O_=II5S"%?P,#-;0!>_L:(#L19FB ZH0M?D#U)BT+
MT+)[[6NOI$"_'[/2\%:B2_$9<R /E)_,?[D=\[$=#_11VX0]7WB _Y)#K-M\
MXZ6,HCMA9'4):YZH3K3N*>_2I8;!U44K]@$\>\<+TGH>BBTSR_&9S\?$NAF4
M8]9/Q6%O,U& (TQF-P^$ 1.MW.$;P,C%W)]4#."$K=7!&^%K\_I-U'OC@_ /
MKO+IP &@FFW%>>,&87]X@*K\N4[L'$:MZ\2C"O3Y7^ ^BOQ\O/D8?P1\:MX(
M/V\")$LLG>>K/5$*,$H^BOSR&G*!K]F<$S4=AEVY$E-:QJ/:#R )43"V"KQV
MK6$#DW9;\#UL;N[H%)9%'F)"B./3',M&LLFCFRR[.J(?%RA>O *3E=Z!7UZ'
M<C1JXSCA@\AQ60Q7R@MUTB\=U9'!%\V6=M9;?'!(DG[UCXR0Q&/G6Y_"5>G%
M7!DX6_;XQ)<X9CEPY*:]8'"SQ/4[T>V6?3@_[A#G905^(N)&V\3!16;40 F!
MP_Q%.#J9^?4\D ?]QHE&'@B'VA[/ WWHAA /'F2?8]AR/U9 .9H/8!,7[(D=
M_!'N<$.5@'?R2ZERQ6T"6:_-#K(%FI00 ]BM"_Z=TR*3O<#0+U]4@DUQG]-Z
M4#4&%+-%^[+ %SZ]Z_6%^B297].@AH]>Q%$ FY/G&L,U0<D2ZU$2C<5<.?NN
M:=1/$>1[A8T-3AY3%)\I7\QRW^=.D(2XN23\' &OC<'2A/D#+[K\4RVB]]?L
M[VW@+(W#JBOZ,3]]0Z IDACJQU_A:R!LV?Z1-$PBJ29A=B5QPF6\>'IM]A#[
MB-84#T0I6DO[]18"U_1"&,LLHYH'TI0OYBIX'TOCPKARP)>1B65EA5!,'QHR
M[2I%DC^X\1W*V;^)VTB!=,=V\J6Z$=IOS<  +A"ZZR)JQHYEAA!_[37N8NKZ
M3 5;Y,L'\:]AY%=TQ#=N+URL3'P]"YQ\]CGJL4\;._#7VU^TRG3S0!#&XBW\
M&N/Q:5A6'@)>5]8F"AE *4?:SUP>T<V%/(HHK9G=U8*O4VFYX@C/@VS0LF%I
M@@FL%]#^%Z;.7+EUMDS/Q!R6*\HB!Q9%B 8QW'9XK=CVIO.[+L&WJH(>=3_Y
MG##6ZZO<B6_*TS2GPM0CR1'?\]:C0HCN9+MQ4UR*6P2!_6,6NR&5VA+"&"$/
M\I^ENHGPGXVIV'-$4A?*'GPV1"4]+)L_#.6!@O:%>MI!?^9Z83DM\!]=JG,X
M(! #[#> J)'HUO=S0V9S()B\WR16=G1CVX;X3> ;?T&IN/5<?BXG]!(DHIUQ
MPSH;+R@Z&+TOA&%"J9@UZV. S7./F+:XR1(^C=TF=<TJON&+I/UVEP$>Z,+*
M$#ZSLA^1C4I"A_!K@O4+I257NZ+>X<#?"OG=RG-E<_D8R)L'"@"CL;7@Y:M,
MF(*9[!7E+=@.HGI%=FY<R)K+JL);VYVO TYE;E(T:+U4I5KP(C72T\P>-VT/
M[(,NI;%,V6<Y. ,\VFSWB*+#V$7ZJ--&:ZZ&PGOJB5O?U.^&A4MF/;7O/V=U
M]]J-=ZB.?920)11@A:<HC/#)%/,J"SPYTC<]7Z,8NIS*15)7]A7GA HBCA2X
M6KKUSR-JW2L*4S0?;W"@):AMURH=XP:NL_E<E2)C4-8G8KN\MW%_5F%#^#WW
M18T5Q)%?2 %(8#GX0^H&\1VK4_">V\KHEQ$TFZ;J9FP7\^S'R1(GQA%2WI#E
M,;UG"=FB;X7.@K?:(?FPL%,(.867:@TA@KEB*;3Z1/NUO/#.(T*$SM@],[(1
MG6]0S9V&GR#TTY@I1V8@8,QRNT)2NNJ%L1Q5IX_6;WC$O<V<G+;^!L7N]T%G
M#,4\MNK?T1>C=V!=XSECE=R*R8QBF%BJA;E <R[!1/H,-_R$OAS2-4ZBI71=
MVG'I$V?JW&>'NLJ\+[;1M[\.?3.]0:WWZ(JLU=^5L[WTZ>G]P4_WGRX[W#)A
M4*S1Z+S_M([G#$:$OLJ6[&3*UHZ.=,$D325QB*-C][B79LT802N/M6ZOV!^X
M=)7U-*JL$SY%(D/:GXW#XK%;V/LH!7&;?D#!TVY5&[7^HF:?/HV?P-:%MS<^
MZGZ\<#OC)9EV.;_XPB%"V5Y!3;:!<LTS!@47,VO81)C)6CWE[C+]]7TOIJ,U
M)R.RXQR$=<3:A@<:J7O/)W<6&H3W!]@>>9<S/W5[:YX]\NBS6O-]QP"H&L;F
M2?,T5U9N6>Y%: E[<VV5X[KOF*FM-#)@Y]MBON:JRRGG-CC0+;.2RC(EWGV#
M3H3W!Y9S+A7#R)1%>R[E-&PC])BR\?@3[LX^'FBZ GGKUW&M$. \7FGM=!B)
MJ.MR=RW.EOY#TOOKIQP^Z&O5XB)L&9B>C0SD#_O*R% (((:#%$"(C=WVE(L:
M^-[#H3S0L*\#=]-R><MS6+[MMZL_W,NG378VLZ9?/SXV]OGN7O;@Q2O8G<@=
M_HT*V"[T-@TE[\,E%CS0ZMTICE9!'><^5\@<2@Q!J*K_F/F"'ZU4UUP0I_VH
MX$#)O1UV<L)V0.#CGLZ2I%/H!ZBV!](;0\L1I96CST;6'LT!^V_R0+ '<'G=
M3+@1#W3"RY,[!M]<X<LRQ*,E/I$Z)3*PID];$QPA%7Q]+*'I'=V;V"H507+D
M?WJ)+25^"^\Z(=FWE0JQ7F46GP*8O[5A/R;N+OXF8PAQI)[$=W5WP,A/1EAS
M9U%98+^TJ$&H-=_0^^6C.L8!RG-&$?*]L75925,I?LO.C5)1@^@WS%=C>!K)
MG.Z4E80CK@1KWHTV0I1,E Q9,35TRQA58T\_M3R2X]J<AC*\UB+QJ278CWBU
MR ;V;GAM8OG[YPQBYVG']>)AMO$N;$S ::MQ#'!&><]H)!\O\T#R'_U6== ;
M;EI(L;+4'WE\<^BDUXB2&<4""V-9K$<_4:"- CF&QT:__9KI%,H7&F^\58TA
M6%E>_NK0S/-%QU9[7/^ ^V'X$H?N:-4[R=WY=<GY<6.M-.2]W=BD@]L0I56Y
M<R"O4"HO^J<JJJ6<JVXEFI#6%,O*M#U%)R7=/"J$+G)UV_3!C5@2P0.U'BVO
M=?#L/GQSWBI'5/WSXZ9_V=/9W_/_\B;B/XSSE$=F?)K5;HN41=SFO&D.8@D"
MCI0D],W!J#;DMKBNP_4U5+1$[734@[*\O53WB-*N%9%[H>'6O0,QBEEF&!P!
M=J<-#!S*I]T1P"WU4?BZ@MSN+[#  Q'?,'L %&L_-!YA_,+_,#8%$<"0ZU(]
M#D21@X3[6;<:HU[U[1'RLZ8T).[V+:1:BN[P-JU1,83%P.J#[S ":7ZI*%]L
M,G)+"]VX&R(\[]344TS1.;FA6((?UG7-4CK=0U6M7YCLQXAG/6.<3%"2NZ[/
M#F4=NT+$I:'("ZB80I'QS[>&FR$L_4 W9MS6)"VEM>7QQWXW5&[KFV\]&441
MOA*^G$^5L&U'T6_8+]V!)0R\G-4&;&E*BEVVHNVO7\4.,YD[26-.7PQ#"_5:
M:S?]F.#3'O*3#PM82:0*(,V\RBE$V#'.0N*&Q5$I;KBD.G&3B HH&WOD1[ED
MJ$J!^9F,7:9W*[N.S\O?MYX6KD(24)!6:>XH2=#4D&6.V,JX>G@UGNW^M!?U
MY,JUS4]<\G>7:WEEG;CX]FN;WF&]5X+6N!@\>33(\1PCERW%.@<T4J,2L7 &
MH0<N'3BKUGCOH08^SS_+ZGJD]HG 1]]/\T!Q%]:6+6G,P\ @>?O*3;@0=]13
M=X@-E46%"R9.:V5*;;MSHD':>)<OH06$S!FR\ $6"#W&7$E\#8!ZZ1:P,7I7
MLLR3Y/[0*_%4NGX1JU.>&F-8_L<U053'+[J_A0=ZPL^R9ZO_.CA;+LT5I7G3
MN@'%Y]H;RVG6I@$O4ES<'AG$7CVTBRX>O/O6EC/"0S^<8)/-?%1S[ V4+02C
M6?T^<51QQW]/KK(@RQLYI*P^S+8FB; %*@;*TJR+[UUHK<DL?JUW.,DV+#1.
M(=XG\^%I]]N5Y[3*V6.<@K+E:>;.4#S2]/%Z30'IPCKN%.=E+7S[/$0Y["';
M?%=4G4A0<)!&&L@./#6L,[EDWJU"_O[-[[',G"$[C*H<E$>+J)&VES;*WO>Z
MP_A6NN.Z&WS6*7OC(Y ^(9F<8^1P+\#B*QY>./<"\1OPD#%"77N/91W"I%F=
M&JF+?&JLL-1A$^8@9ND397U9;>YV^:OPGW>U0%U!Z='[*&,<+.HR3'@:T !+
M1T1U;$17?T+;.R7.?+XNY)-9<M&#(.^]=!BD]0D22Q*9H(5TF=@+>+JE:&_5
MOW EXQ9W8<=Q 5!;W$,W]1[1SGN3F3\\DUA;V7OH;!5%B+C+S<_Q]TJCWZ)'
MD=FLLJ3F\[WR6"''CA?7"@Z>MCD9MFM714VNSJ'&US,]>B$G7E:4(UMM$Y\>
MBK[]<M<"_M:*4^WYVK0K%YZW++5\J9S^\'$<'X2?LCVQ!8/>,"JQH@.1)6.B
M9C&N+TNP5VAU>& ?:HGAG4DA@(%5CXO79'O;Y6XUPMP_-T R0E<]WA>PC"(@
MMF+ULUOIM*!Y9H'^>S:[8ZIB$$9Y$K"3VS_4?"@P ^LWI'H*>=1Y[& H&MYP
M'-M?P@.Y(*U&.NIV+BZ%?<\/I,?#J1@0GD\4\H RIQN03M1D3:_<W$'SBD W
MCP<A"/>/%UY!SA/J?&:YDS#Z69B<+@^41*KR2ZB]J2FV04@V/'(4<WUW50)*
M@@="1Y_+0Z%5C^VZW9WZ[&OYE:,[5JLB2-RX6W!@*ZJG)M)^QWFNQJ5<8&\/
M+/VIT<W. Y_&O)Z5S8[!*?N',61$0MAS5+L?(EH\4GD/'1I?T$H>:A:Y/#W_
M'4Y:XX%BN#)'D7T0^CFH\O$^AC&3QKBI/8<%K!1/#L5BCC'= T0VY@R9?G]U
M@I\!W"6=@:D,%<^39U)9]Z% @23AN[^68_9!'B@Q4<EP'NHSQP/=@TBW\^%X
M+(,'2I7I[4$1X3V%>JZBVJT:0&;Y!7K4)=7--&)=LQ+__YAQ'K!U0IFU]/6D
MJ339FRT?2D8;I*[;&-<,L,N7H+_K..9W_[X?H:H6O.9AT[I2P4=H)?WJYZB>
MFL_EA#&53S8L7U(@;*%M!]A@*7HX6SJ$;!_K"N\<IP=HEYDT&U-8$@9S$[^U
MYZT4<[*Y2F]C=?P\&+HE1=Y!S)9]?"8>LUQ)6/(TYH&*9G*Y A!&\>\3E6^O
M8;8=<Z6,XKL^PSC[:CIQX I"_O:/I$AC/IFZ9W2=":F>:+,S74VCS#2C9RJ#
M2W,U25%YTR-<";;Z\*NK9O)?'5[]VJ!SD&7W?ZGDI/7P0#\4^;:US9MK$/W[
ME.&T^>ZWK_#M'2.8$A6\FN\N(P7(5JF?*IS$M.* H[H/2Z;=00>W'WW.3G!]
MB?HK'ZG%NF,[^LE+=):M]Z747I8<F@?Z:NS+[V(OV_\O4E<2_R5 _"4&GB.T
MA*?SOP(:\OL$Z-_+/N?,E#W\]%'>K3)?F>[FMT[^FNF'#Q<6Q;7+/&1"%7F@
M#\%\+KH) PS]16KXOO?>VK$1H7M6$I7<0;S LJE%Z>PT^TBM4R$]Q5MJX/.K
MGM#/*].8J\ZE+BZ_3E/,$WWO.S'I12X78W]+3CT,$@8YZU>Z 4_#E R#ZVS]
M;C6J"+F(B$W?QKJ-_$7_ I.$LS\_O%E"O[_';@#ITF.\5NVL7V:)UOBIDOND
MJLK"^V\-Q*S_?_+C_ -G._HFRD_X,+1PQ946/G_C(QCDV5T1S,>*17A^AP72
M9^(;%[^X%J,.G-/E [P#S00B=Y>_WASN87';%'N\]&],M,"\4F%!9]I3N<4=
M/-!QI</79U1U:618>]3+GUCQVCW8GW.E/=@-$9GC-*8/  [CUE#JDGF@RA 5
MU%=MK>*_57%J&?B3(=)477/Q-/2'?L15_5GQ%:M>?)U]QPR,$M[UI8:^DLD\
MHK(Q?*@6&)NZ[W7\[9L'6:?)-O*T"";.$-?$54.HYE+KXW@@/G!-K]0N2W%'
M2*L)^M[A@9K1T_,?UH6:P\]PXI=_<)S&A8'X98E1EHQ@S,=FO]7@WGEX#",\
M0?Y3S8OL;WFAV0J8AVJT;;8K+XD7GB\/1!O4)PUZ5U\P[SITQJ9[0VL7="F;
M3AVA0KHC)MR'O%N&?[!<+[>F4H\,5>T_:VC&>O ;9 ER<F/.%O"CTTZT#[$%
MGA SAXI&5!Q_)@QZ(0X"5M". F&N) \D]-'UF+31SR]9FX?Y/'SVUNJ/KR:;
M/,"_5];PEW28T!G*HSR#T /IBT:?][F:&/OVYSM7VR!6-@K'/6(RI+<5&SQJ
MN-P<VBLE0CWZHGC3N8MB;G]+5P2N&AU1_=OJQ%_@G_E_,Q_T%R'2[]?5,6P8
M=J.A"SD=9'=+G[MMM[+[VC;7<KMIJ V)*13Y  ^D )I\4O47#\S^F?L?S?T=
M2_XW<UMO?*);L]O8H?>%N_B=(/DL\TU$9TV0&&CAZU\ULC%&>_^9]_?FB?]N
MF:+1UAV^ [MCQDKY^55=P=K+-EN% RX\ FG9_QYX%4FD:D'^*BS[A\FMB.A,
M'CW95C_T^DZ[ :CV?QUOH</:\7&HNM)?.SECP#W6Q8A[3'/&Z0(ZH1LO4HL3
MF4=JYG<5*E_/S9EPZ/]N$R1;.B$N- RH&*'NK5S76DW=*_ ),MW A '9T2P_
M!)A/,G*1!&7)$$F@G&)RY3 D':$4%"[80DAF'WC6P>BO'[Y@&JJ8[WKAH\6.
M+,NLX$S;N%H%K#C,%YJ"K=5DR^S!DTM1NY"[X!'ZEG18IR,9'S^[?4(WJ&2T
M-"?R<QX/Y-KH[NJ;,7W;ANE_Z;O\NZA9B_1L-Y9&*@C08IX&Q%G6/%#[?ACE
M)D(0T&'I+<*DV#+45642,$+NGKU3'L"'VO>N'.B=\V_*):YX1;D$K:C.YDJ^
M;"=G8C;&)(VK4.T:/-#%/A3Y$0]4Y9S$ _F1M@,YI L,C\&UV1;:S*TAZZ0S
MXZN^>A^;HV(T#'[NL=QCJ[:_:[,UQ&;H7T\O1<#9TB2N=6$%#^0]6\,#/=5H
M&?X3OR9'E>?_Q(N$L#HCBEQVAVOH?W?>3+<^6Z/V.E,!G;_E=;T.FN(2*_8*
MI/=J_[4RQ6Q7A*HC)S;DQV*^B3W@_J'Q3=,^/%>R8S/4$QOPB9;.+2A?./G[
M@\VXO/<'88DU[.,X3.>^P;#F)S]6J&,3%>^O *:Z&B?/[\ZW=.Z Q!8* UI/
M[$H 2Z)SWG(G:<$X79GZJ?*6T$606-'=%T5[!W8%7[Z\Z/^D94E73B*VLR=1
M66Q[:K6-J_HG-&UGQ_X#3M9[GZ1^+/K?#2/T'PTS]>?KB_]'PQS]/2N6?[%
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MD\?G(+"I.2<&(7D-(^W?0%D.6U;I&!_7,@$J?;Y[<K\)?732WFN!=/';-=&
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MYIN=.8.$L6- IS6B1K$'R7K1$K4.*VYO->.H\8D$C>-<[+\=\Y=/^.0IB97
M/60D5#ZDKPKC].=^B*52=H!![0HC8F6Z,[:$X0A3L<24HQJV<=U/K35OT9%!
MR'B@OA1RG+1ZTB8D]"M"A'<$[5&R"MZ Y9]LB)7$98QU$E23WAL_$=/0$V[M
M+MVUJE13R7CW4HA5$;=/""X0JZ93TZ@["/J"7J"1>EN@LC2CR_)_2TF)<B9)
M&V+%%WYXSK@%1K$Z0M:RIKK%3NL.':VMDQ+O=90/TR,";8X AA2_#JL?X\F8
M"439)8+WDRNEE8M][*9@#Z/G/!,@4'2PR-YIY/S12J]TWZU?3/YY[G8%]>C@
M,60919:@$820"#<<J<,FD+78L<O+?9@BT'5T:[Z3T!%]]W[QG?&?#&N>SK?B
MY[D&@DZ$M/D%KB\&P;J F'+CF@CD-"9%6:L=R,T+)D!0-0@\SO7#=7Z[Z+YH
M(OR@]/6E[4_R%?IL?AX2&?V?3A7#?X9L]SX,4IZ]4%@3)_Y]2H;\RS#^<QE$
M(@<&#8E2T"T=P']U!R[>X>Z/CK-\4HMV<(S_]=M%A8J&9I=P$RAA%[LM45N?
M0)*K *5GX=UP4(O21;F-W"38L4@V9*.(YD(O0,!FN*X?Y5AWN;2I'G?>I832
MU&B5)O]^_X?Q7=JE@C9CI))@.]!F0E8&11BHY06&KEGW.FP'0290264U[N'E
MP6]O1E;K^ >W*>J&[";'>-3T25Z>"7RZ*TYP>>X61.5!G>4!!F(<V;4.JRF]
MQ3,(?HD;GG7*1MXB(T!LP&:WON^N6DUJF]7C>JG]K5GG#RNY9O])B?=G '<C
ML.,V M'TQX*/:&'>20VRYF"+_&.>(7BSK/>?+(>KWX+K8I0;SD9KU.A^N(7(
M/5)\=),=XA#>G/\4H#5:JH)/JO Q8"HT5[+-;.>TW[+Y':>:@$EL>T-#T];T
MN42B8UVJOD+C_0S[!^_]7^?(-(PS&N\B2O";H'@WQKD%)K*TNA#U0+L;<GL?
MW<+ E4U)#8_5.YNR,G"&O:7MI6&!VIF,ODC.J,G8ZH$^;D/A-I]C0ON.P<-8
MB;=^H2=F:1"-FJ5KW0XQ4M83QGF.V;)F$@/-)1UT6^NTQ0\E[_5))UP>T_QG
MA\%[!GDS)" 7PH@DKD^PO8=K@S?C5U!\IK%T!%.6T:KG,'I@.4+"3\*Z'9+W
M9+1F0?Z$>_L3E9RO@9J^!S5O*@N?4KT(H 6?@;I&IA9+J,<37@/:<T7 <L9J
M0@2IKBKE]\!67.F91C*+^VQ 0S>=]TJL6LU?,]=']!OM:TW*K*44H7_&#*1
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M2A&4^BA&DEM0.I;E.WS>3T?A9OM-S??GQ8.^C8'W?9S+_H<-TO\?KG.>5)?
MAJK8YS-6V"WV37;/[NU1^ZW!VN_ZA &(!Z@:?#K8HLLH.*@S;<G1.[@R%'H_
MQP+^S1DUT91:R&L<G9JJ:!B;LT(%E%'\0S"!L55#W(4?^X'V=V#4.NSD2NHZ
M+-X6 %\@Z3YXLW78DS]6$/\N1O(NA0*L;D3-&%]25UK -UF'R=KP#B<NUZ_#
M3MF?6H=1'-9A7<[URZ"_@#"Z#GN[>QW6!X=/AJ)X:T70+VJMPWH_#@OD;#HH
M:XAP-$_IY,;'!P#6.6#R(LZ KED:+U $FR:J6NS#-$RBHH,7FSN"4L13MDM=
M?!/NO@Z+BJ(O(OY;^Y[:W#!!)UF\ 3Q3J ]*LAB3O>LPJ]<&04[YUQS(<Y\J
M=]W.?OUD^SBB@TQ.O4-OQR2Q/E:<3@\+/G+<FO,G9&3FT>C"TI.?CSPL]?!&
M*1?+AE%Y.,<0IZ:Y;XYBGFZ_/5U)VYT?"SY0=N%/LN",F0>S$CIG,P_XO,E0
M"?F$?!\6]$&H?,>=6_;:RV]CQDC.CPD?J$+FQ]E<QL<'M&D]5.:R%'WOZ$I[
M0>[H[=LW>JK59,]-)_WI^343RB?Q<]!+HQSSJGRN*Y6$-7.[\#=,4S H&'WR
M6XP;XML7O KT4>P]UQ!E:%:-I<HZ[!-WX_3/(81@/Q%T0>Q8AWV/'018@1#(
ME75'_XL4SJW#Q+VXNL"@U"!R=1A@7^(E_#_%LHP-[$+^7"0*Q$GK,!TSU'__
MS?,3N-4VI9RARPLS^D.56CD-/>*F:8XKL3");'>3?VGNTJHX 9KXVH%X(RY:
M!G2C&V=[/W>QGW/U:%,625[S"5N]<)ZT8S\VJ\03$X@[,;8 S%A86@V7=58^
MY=S__H/JYAC5Z$9@8GY:;&ZQ%VP791=U4T0 OZ4E^!WY?:2=O(@R5]",_CRT
M('^F6'#*1",JX[-X8\T.9)B_-M-S"KT9@Y8$_/3 _28\F08NK2=Q'1;8/XE>
M7J)WDAP;08 M\6N)NPZ362PWC#+9V>^KWZ<1:8K7#?F07F=9'JK\4U&HTZ*C
MET)+C&SJX4EG<^; /Q#?.,V>3XF0L+$;JLQFF+1Y.+ODA:]E)$>KV[_^<T^H
MY<8_MR>W+C@Q63"CWP!/!BW8[DIBH5!2>(TA(\@C=0H.#)/W\QP'>8KPI/#R
MI8B&X1!LJ4[\=L60%:W+1;F7[IK%UES;INET#1X'T%ZOPR0(2D#;/H*AX".%
M=0E()"F;7WH!-K^E[BP:-+=[C)ME6,Q4/5\BRS5G>$5)O*">64T:^7"(M _3
MS^S=_@L%'L0R4[G:/ >6_[(-6_XMH@X5'Q$LM\IYS])+OCIR@&<5\MTPR7)4
MJQ4@'>Z0S)2SOK+E6F3#MCVW+,8Z*2QG2@JP#7F-*"YXCZR+XDGW=,_(/V3X
MI9;-X%7)@RT72I><"9IOJM/LC.YP1K]:E7Y4]_&+>I.UK:/<;K]:H'PY/X="
M*X%HB"YALE"'?QL92)F06X?133H=E-]6X\8Z<HNZG9J^5;8^KO]4ATDHW#9[
MV=?E75IGU(U=B;MO$#9VSQ00/JW#8+^HH"Z5)STG6(?-^M^A-PY^ Q/"RMWM
M&,I>*O=-[\;[Y>J?[F(KN9M(&ERQXQTMBUB'92"W2@MVU S6#;.].T@!Z/$5
MU YS]-39$ ]O@=1-?\%']2AY3^>!KWS^:[/K 4+?J>,/!=OA=-1D%">#_U0@
MC1;T-P+B6($81LFA*J4>M7,Q%Q[VHK6KHC/5?!WFHV^E9"/<)(NML[]_S]_O
M@ZH68X G!^]6%>9G/X.ZG8*#<RS(;.>W.L'6:C-JC6RO^,Z\R0N>%21.U[.T
M:_E'=<5>99I/O=,, *('GX[UDZHCW[!^<HKYC13:<\HF@13/A_5UC=KYT$''
MGE4\FO]%CY.'A:,G[,PU%1Z<5_Q'Q.?=R;19=6/(]#/1+%?*1#G->=F91AW7
MXSP:PE^B5TW*TXU2P+WSM"^J.UM?CQHUE[MW^#78[[(^JA30>2PO_&+PRG)U
M<,XMR_<;6" 6K\7%\93Y:?7P>'W[4MX-UL>R"M"D.W)M5ONNF)C0S?T>$_:0
M&MR1.?MD:O7KO>/GGK#Z.%P*.X\G$],-L!RQ<GA%P;O/+3HL#D+1%5<XT'GB
MQ]BYX;EF^X#LOH ].-^^K-ZH_??5##8K\(K^;0VU^IG@PT8Q&<KX24X'_^7J
M-7-ENI@$O#M?*ZWE]%!+OE/R2\_O@R^=?K@'_SWW[>#S99B.<O5;:W43#I;_
MG"R)WSAE.;?%>Q:Q+<CT_II)*N";?G"@/;K\>Y[.CE?.E^W,00/5U=J:EVG9
M1RY_O9Q_2E?1Y@J\V%P4:MP(+&#'TP82*!AX'*F&D\< [A3JL9F)B;_Z0P88
MVAY!,T/S;@YJBU%*4>/BYSJS#N<\=2O-\9YJW?DW#EE5SJJZW CZLI#TQ@1H
M^LN@09S0FWP!P,'X'L&AP8&T=9@WFR$S4K>Z<S'OS_6.FZ4G2Z4TZYN3WNLT
M[_>ZDOSM3H=2Y>KT:1AO'E(4'D^));+\>QVVE<6[#.JPFJWL)<0Z"G=].K"\
M^^*QC_(>PU'VNZW._G@W51SU]N#*AYM[R26@/,N9/M^-GA"BN8%+)U+F9MMG
M5%B5%#J7KG23(S\ZFKM2)5V3]7 ,CTJ32W&15X^TV9CJ<%0G-=$3XEUQA_!H
MEG.*>43Q98SEGH;!)Y\,4UM/'%FIUY9W'YX>W9:*S0M2;PX6"2H__';+V CI
M%;P+=1>0 KS687<M#X&Q;"&KT;IF;&*^H4GTW;RR+G/C'\\*0H9LU-4EE1^K
MU31LG[^W3^CG*D<(7&!/T<:88=R8"<$'H$:U@HWI@G-/VMWD$^%)%>$ZVZ[*
M/?K;^.=X=G_D.]LBNUV/:I/&Q GM?"CTT"K0FS;V8[29&NJ!^U)QSNY#=<R@
MA?!_>+(-1^N=QZ;."OJ)MG>DD@V'9F0RC#5E7J:L?JMD4@R@KT N)A ^L2R8
M !HK7U)W\=1RLW@W@\\KEYG;7*NVN]HPM[?)2>_N'=N7SXY%?O4V8A.7UV%/
M<?&S5)XR4;61:Q)@ZMQ9 = &F$9:1-Y)%F.PJ#7/:5@WHJQ2:=+MK$++C>-Z
M!=7WD]63.8E(;1C_/+N4)[.TL7F1R/1GU7+\^?5(OV!DFRG0W?<WG)+H:<BB
M0!"W,3CC)=ESVN1L\G*PZI"_?G?2H'+2@^EC-X1J_LYMI*%7@/1*WC7P-]<$
M#VEIG!OO.#N1:+FU8(<]1=PD]5=?8+TR!GSV8#[0VZ!MQ[O<Z:<I1P]JO>8>
MWVRXL]<YCY]."5F'@7L2F9F,=9A0(/H5<OD!+1;+\%TI]7KN&1 )M< 87FF1
MQ<JP6S_SF:OCG7+](2]F+MCH*(:8WT\KX(Z9"41OL[FTJ&0*K171V)U*IZ3.
M*%&:V&<H.Z8ZSDY@KI^.0+\*<);TY),PB"-MZL+W]D8B6M.48&M;?PJV.[##
MH#E0(.S#B_$?('T"6FP8R#BRS& $.HE#,&0/?FIY..W8M?IXZ*6KLO+GEM>7
MO:^L="N<S$$?BKL<BI0':$U4"9X(%%^S6.LPGFS'6W2M39JY,UTW<E I5E7%
ML7NP+B8>X#_R;LYUL5_F7@FX<^_DT2/B[U+"/-U>$F8\8> T-$0E_F/(_M9A
M4_X]GFJL+ZJ;8RT[Z/"VV,TS:XKX*'$.4:/I?KD/)6#49>J*FT/WY!''^>1W
M@1?H2]ADP0XVEJ=H5($_\JDJ1/-SBR* "638HE'Y1Y97_,!;_K;F8\>5>W?C
MOOI8^UGE[VF+JCR&M",?@13NNODE[D'\==:E*B8$/K?PV0-QEB+X$VP-4_D$
M\I%%LEJMK\D%__=9JZ?3%'^![D)[^$^&L-HN:;LS9]%%Y+V"SX7&V;..M5PC
M0A])-+Q*!:1VJ*K6C^(ODW>S,=_S'=.%I\XTG'6(DBWX^FQQ=OEGTZG<9;DC
MJ>_8B4EV;"I/CMI%%0%H)9"-HR# U8VLZ>E4@7<7'@%[9O7@6@G7PLV^KU0:
MEE_&[GE-_GSPZ0G/43%,>([?S<W+-[?XSU\I?0\9S&HRNJ:4)UTE$/-FHQEP
MGJP.;6OJ2[PJ_W&+ ?TA,1&0YJ%HAF/7?JF@[(:=VF=1-Z[D,/27]<EO;3L/
M]-5/C @M6)@(Q/*>+J&KG;OU)K-1_'R]*VR;93;#OA\^BVIGHKHRNV**W:?L
MOYFYNI>TW)OIMKU1B2]HUS[\;E,KG-.T4;7<GJN] 1C% ,R"8//[*M";8?F$
MOJ23:FM^IN%/TYG))O5C4TK36;CAR+$KWR>Z9>).@WK,8^NP34 0%51/9"(9
M>J 6>KFMY+M@VQA!U9$L/]IB0CO^]/VL2_#5+$QJ:LQQK$SM5#<R0OSEFURK
MU]M*3IB3]($V:X#V!%&3QQ2"Q&<+2CS&P\',=9BH!S6!AV)-MWBK)I?VZX.1
M]EY2=L)+PE,2;>&^MOJ^V1A]]3VUST7&$0V-S'3N-=! (*;-M13T(L7),M]-
MR!*?PQ%2N+BACR@EB_L"C3>-PYIW^"4)=:G!$J\+)M0[R1CZ0Z]3/56X5 Z_
M%L(YM.=(.'"%)$?HE>=XJK&=;]5;W.A@J' JKK).!F]>R1<[+O_ /&6H^_D,
M=H+86U%]5V=N%=SGW$--0$#RKT=6 TP4&]FY^A1O.=(B-NNA/]PEOQ;1?FPL
M3RZ47[A9/*8S*^]8DG-8GL?CN8=<.\$GA/ ZC*$Q,%&H<I+AF>YU@[0%;X6)
M\BY;E)SZXC+M(1(3XS*;&7_2+"&X^L@.VVZ#8P@GL(HS#Z;.HA$\6S"4*T\8
MF 0ZRP?N9.F6IO^6P'97/!DON/RV4<NF.M=,I[N);.MIG.FRYZYQOH9!R$'U
M67.H0>&[H O;GW,</,ZU!X7HA/+ "GPP>X0@Q@+BS0-QAB1UC^GPO2DK2WWW
M;3:+Z<1I9AQU/?GM:;>G0_Q7XOBL8+L0*T:PC<F]+ABA5L]# *33N7!S-9C,
M[G$!2UG-W6NYQ(A0+X:8RN4>\I;<;=0_F0<.59W!2N_>_^X%]1B!"DA3O :F
M$)SS8"P=!>[KZ6@>$.49@%ULW;IU6*)@-UMV.7_O$_K?HE<M)(=1S4 9HSN-
M"/^\/I?(Y0R.3,&F0&\8PH&W"5R'L4L9(MU8%?Q.D,JU= $-SK(BB4\7G:(;
MB(RY44/^#0FKU4]&+<1 S)Z;#E?>+6D$3?U#C[QSTX) ,4#2'@"REA:$[G78
M+C*2\)&B0+F&@5 KM;:G;36Q@;S_D^!@$(5]:,0<^</AP)IF_XAR_S)[LG-8
M1GCZ[(D3W7LO)TY2JD68_=PC0-LIR\TN@B%D#37-;Q1O% %8I*5'>6E6=%6,
M:(BJY6O#]M'T3:Y?^GQ;+?X8 @&TC4M"K;).525]^"Z*VHD+?Z*^0F)BO#)!
M*:02!SLU)MA^7(0GK<4)!"/8!]=AG% V/.U7!> T:&X:\BOVQ.3,U)G<A4L[
M>]]D??OX^6J91,OMI.TN]N(\_CI,)(CG"(;1H4"D_B=-H(PAF [IFI^LPDR*
M#M;II%L;M;1>_GW$-S)%:FKZTI[,5-BQ;;$Z#R'#!P7#I%I2"D#[!RG<<IQ.
MRB!+CES[C4@KW-9<_;J:+5'79[@3^= \M?JCD^'?1[^.62_[G!49/@RT7;3<
M@S.#B%D$5Y,P"%2+)%NJ@,"LVLA3T&6V%=65:Y(5)!]Y5O1K8^NKAB^3,>;7
M2H3LU:467[XX58A^@BOG#+/'TLC&X"PGFI]!WAZ(WMERDO5Q:+#E9BP#J60<
M7W)Y9OJ$?^/PGC<9O>SYUD,,9Y3VU60?(KZW_Q4^&=)E/+\(Z<\%0&V39>&R
M/G9S.]JO 2QXB7;_4I54D7;==:"T0\9D1QLKTW;E1:6MDU8<)AD4YN+PVM"@
M+:#0@4(&P6^36&?[HY?:"%+@X.PJ>)FZW5+=8R'*1,FO2K9S>YY<X37)-\Y)
M!\ZEI3_N4M.,LIJ#$6Y#7S5'AJ!$@;:3@)^N 8?(JNH@2N(L[7XKMQJXL"@I
MNN;EK09GZ^]WA8H>$=N?B#B0FA8?)QF_AYN.'V,00>V!M^NP.]3JRHWL2R'P
M3RF&+ TZ!Y>?("N-Z.'-HOA%98&U]EA,<#1G+])4N'#.3DDSPHE[]*[--O<7
M?$DZ/^8TVS'>FQ&[_6N_[_.)K@C_P^GWWLLDJ2AC8'TY:K1;-M?W;?[V'\O3
MNV8JV$2Z7/SS_J(EDJRYB6]4"%>KOGE,=S;+^)>OOS"J^@6DD&3R5F P@$42
MR$12>![7$3L!VB/*J]4NK%(04I*P1]#OJ?SY=ZLG;: LR/GZT2S&"=B!SD/S
M,"<3GBE1(#J\#K/.I"-Y(MGKL-1*47N#.7QU J5+3W!J[?3%U\>'B/45'J=[
M.:4.Y;]K(RX$<0-:X9?780F_60:"5)L[4/-%]9 O_(Y4%0C?SF87M5_942J0
M,D,+CGJBUF$[BC9J$:W#!HMQT*M-7S<^"?F*<QOX%/@^9*ZU#KOU V"'OZE%
M?TT4"$.-#H^ST#Q!)T![ ?!>\_;Q6RB8 17")+KN+H6-[7+M[VSRG_)M9#7D
M_T#H. Y?>G=7P_-VRJV/-C.15Z-IN#''G&5*(W$Y898T7LLACI$EP5+KUZEG
MY&N^X-S.AUMZ%CVKS19_/JT8=Z]2/[+IE65I=].OJJ[#%)>U+X)J]O0,?^"7
MB)J@5]#9L0[SFUKD97YM^-(P/$^M6(U%34'6N9O"_(OH&I@@<.D#3"$V$D5T
M8^TM4DG/**E<'.PR6BG0\'W\9>B5OJ&O!C$*N;^G\ 9JDO+?)$0@ &V[ 5HF
M1;02\+,&'W)]>"*O/M=39:FI_<J.8X]##Q8\N[-9M^_>N6^:7]5^UO4\VG7[
M-_I?A54U>N.FO\Z!D@&%1FS=9.0"$/'K)S+E]2)IDWTJ.R/!]87YZNGPA==A
M@?V]T[;38>BG'G752XC_UIG__OHF\E\;*A*HV$#Q?6$=5F0+?4X(@CU=8R7]
M^>LP#21+&_BA]9ZK*K8.(XT3>;*0F/-4_Q8OKCFVEIY\&1!=T,HL:<?&+0Y%
M9!V5_^QB)V[1A8=8FW#\4'@%1B!JP[5S65+R;?VBS3+IDBYV/O0RI::KY(N]
MS*U#:OJV28O3EW)LVV!C37A+,)9&2; 4&R:KX$U93'+FTT YAH2)0]UY]<8T
MJ1//-=A9F'DLJ*L'<37T1DFP'$K==OPQ]FCF4W(]"],YZ9>1_ZQHET3L3<L\
M\[-3[2JWLVRR3IU-S;+?H=-D_J7\8=C<XHO3+UNS0TPBR1G3![,#S;#EORT/
M\>/(AW@.D!;+"T;74#PI(H?,3I\K9\DS+*:^"#Y09.H3_X:_+[D^0.=.'+FT
MQPYVX:USI@(L;],5+D +KJ\#6!<IDTIS1R1]LNE1'<3#[;?<I,%'XH6_")^!
MFL9E""P)W^;?#2%+@'F=3:AD<UV&\K9*_%'&Z@[/DY%KUH\SY\267,ZE)'OK
M]7X5L<%-?8L4^88$=Y?T,+-94;-C3!T6%':<JUR!=GM64;NGZ"?YGL9AA0K>
M\<>N)DF^=:.JC/.RGY_<+S_3N:M])D33)2AMH'@#,$WN+>*>!MW:J2P'K!@N
M]\_I)G ^(@*>5N^@>^OU$$_E2K)QA6G6MJU^60..BEO\+PRP\ME$T 0^.T \
M2/%%RVYD[)(M9N89SLOULSHDH:709I4QI?-VNX=#G)$_WG5GM2GN4F">>S.=
M'<8Y'\\)@V:P!@HTT/>N4<0)PYYJN7#XDM9;5>%ZT)]MN7HZGWK\U>ZYYM=N
MHH/CGHM2[GW*1SJFV@)Z4=@'E "J/&\CXWXWT!9#EL?[I<[R/Y!W\)^T($+I
MQ+3K8$>/5%#3W9RH$):8A.</MS*ERW2SEPP7#;/S^PXF'7GW&+YQ*M0[W@7^
M8PJ-!+#.$>,W%E 6*/Y\-(/8AMJ&-QOA:<U:F)U(<[A)6UA9N5.S=*@(7UT'
MX9\'CB,Z0IT_K.:Z>[[K37@SJ#SI*<'VV^S:MU36.6!"C)%QNQ*7UV:ZM>C)
M4KEL8^;+X]Z$S%>UY-N<?D2>X>ZB@]MW]7^KWF$W 4+16M@"W,3RYGRLX9/(
MQKSC@W6DS6 'W>D! [$=]X-CI:3LT0\ 6W+_*-UU:#G!4* %B*<]%YQYH5"[
MGY2,I?B2)MR.0P-9PXN#?9 Y$CZ'[PL)N6;45S7IU$<OX(6!-WIL F3<C#XU
M>&.#0R-T3"N::,T=,@+7'/U#(L6+KTZ06)$?'^XY]83$,?6[*I]%G=)/(^%A
MEG%-5/#(0\X!%K*3,I[8A6B8[T@%0"M+(Y[$<&*JN21;'6K6:H0YU'\G>\J<
M3?^:_%B*::VAD^#539N19XMP>OE9&^M#(A?=(.[6PSQ*4U'N&$74C'&$5R@O
MP*:/,]T2Y^KMM.10H1IQ1H^Z>V=<KHRKI_S6 W6BF&7RS"6N,8;$<@1 S3@;
M-K$'(3M+M!IK\:"+F! 46!E$C920E=7? ?&N90'QG=4:Z5H?>T)HR6HBHR36
M&>QDLS._;J, (!7J0!!5H4.XH9PQL-5M&HSO/;=KSYK%IVG3'<F*^=HN-KYJ
M_FEC<R),=;8;HVKY)_<:7GX=%I]B1)1=%*$G=@))\@ <?[SD=,_R&KJCN:!A
M35?P25_] 7,E(E)C-O9SC?BN^-]Z3)-*P@# @AP"J$5M@_YJ6).XMM\M5=AZ
MQ&MUQ,1[BW_61N2<G28]VG0J, D>;8W3FV>2W.\]761LD<A?1%[;0'@]R^5L
M XX4.Z]-!<-)!%.+0#?!SH;XDP^[*$H1=K\D]MBJ.PW/YRH_S X)IN4?V:4C
M\=CZ<(8$+&:5)Q//*1X!O/7&U1D4YCEZ\^60>CT1W)X?Z["3&5Y-6F3MFC&<
M8!]O/NG5RILNG#]/>8QU8ZH=P7) ;B5\LCQ(SG,#4]DOCD*\ =$=G7VS<6V:
M^;7&?&\@ZH.33IA, "DBLOJL6 ,>+A UX)[&ZT'J!D6]MAWUV'%[ADU7A;%>
M<@,:7F4.9Z3:8;/LO]^1W%;']W\_3<8UQ.9,GC6N&^QMKO5\ FGG>?XS0^($
MP+']!- *@$9"<PG^$-C*NF%6(!6KWM7TR.D0+M$N(PICX6R??[4L-L@K/+UP
M3Y?JWAGI&W&;YC;L$Z&$!MJ.(&FUZ)H!)L#R@0+R93R!+80W!8>+)C>I-#3#
M)W7WU) +#W?F'8JMG_#CTH.SS._[75A[4+$DIZHZ6/F;[X0].-H]:I_ZX'!!
M]=-<;^)CH[\/N ZXS0,0WX3L$04*/<?#7SOXTZ*6.RK=P:IN0.H:$%.\5+C'
MP,WB&;'T"SSK-SWFR&144EWHRX]I[<>> PZ_52S[(/$,U>M$Y,_,R:7@2$5%
MFQ51U5M28#PRI%'8^@H4YWLU"&F'<"SX$S9"5L-;@:DQCW&N]@,S1''<U8]'
M7*EG:@?6DGCOO_[<[-U_6)T\IT%JI@12)H3H -.D"F_.IB;_*K^,/\?JZ,F/
M2FY19R!J[KZN#?!#U[N57Y_QZ*(\E#X8N7+XC?A55QX-DI(5WI;5R-M9U(/8
M"5E#+J)Q+%E]HS *0<T#3*6ANXC2)A-U"*F%O,.=Z0%C_4FZ*[,[U>O.ZQ<,
MO3.XK9C]R]N:7T_>CK_$#DZ$D,]$?(\IO)/IA/EN76]RQ^A=U35#9=VV9Z];
MFQOUK83^WOP1_/ZG?^;]_4F=M:<V]2TA&B#.LIN'9\\OT[DJ>(4A?$PE3S?N
M VX==HEMDD8],70-6\DP./[LI+F3<XV[Y\UC=GN2G/;%/PX\F16?"/I"$T5@
MR7>A)I0AI9:D4R9^=NO-PF_GN18D=@%WK%?:+=#'6ZM3[+2VNI1F*#)[3S%W
M#1HH7G)\UU=N;1D-C3X2;[^Q"E! 8EVHFISE^/%K6[Q+02."+L^!Q(AJ)\J"
M3]?,=)&=T1%3MB&ZC]_\\S+8Z'& >D 4]J^/6O"90A1$O!+P1^E5$D#;&8!6
MM%:5_+(.=1>I6'>TCI1H^JSH1L-HT]I"OO"WNJ;TVJ.;<2$A*RIJF6'SUR(=
MZ"/WX!YL"D_>GY%W!^E%% ':;'4IM(<SVF30IBS0-.3);'HX;NZC<H&4\ILL
M*4YD5N?>D:(,.TDE:S??JU/WZJ[T>8QU;^RZ^Y-&WH0_!@8S@"0$1,B6"5OQ
MCNQG!?18:<;OU63FGJ:4E748TOM-GM5DB%==7F#PCY8;+\3K]G=Y8U,)NO@P
M4!>*LEO#Q[^_PKNPIF;>L^)M!KUK/$*$#(+.45V3#W3&_%$<V_(/^_4.VQZC
M+T#;-2!@X!;D UFG41-Y%X;)QKCS<V)5*51X%;-PJE/NQ\V&AEZ'SK[ZC^?5
M2F/"3QSJ5(*M-7,2H/FNPR"V(+'*J'&AX_SDEE@&178) :]L<: '_IJ^X&C[
M>R@/X9^Q#\"_QTI&W']O,3NUS6E/I.57<>JXM&#[E G3F6N%/\Y/109B)V)<
M0$5V'GTF/Y]<1.L/ZW1:JVCEW/LFSQP=^[3'1E\[5W?<X_&9! \6UUR/DP+R
M66[T5=ZN A:R1V  DIXLS*BR19;KRUP#/7>_&2ER$RTA.3V #,).]YMPMM_(
MU;=F3?NS/CXN1(*;]'@RR@(Q6;;-+&7Y&P/CQ"(E #ZID.#_4'<:OK^3:V*I
M,U(9\M7^<BE1^WIP\+S+7I\#5\-V!=^EP6+J**R+V!15<_Y#H]6I5(XWGTCM
M@>;ZE[:1Z)//%+J)G-*?),,ET>*4U7-#O[IKLX[2MBKF:Q:NS+CDZCL=;CK$
MMRZ'E-P!5&1400Q4V%*/\+'"G_$7"' @6"#HZ<_*H=L^D^\C.#')\VY3\3+]
MF*^I+D]];)_=&ZC1M-;-W$C8ED1#=%V8N[%0?[""XHN<TNIR=;Y%T.0)$R^P
MYHD$%5SNRA&CHQSW =U:5]<W4FC-#_J=U0J7.H>DRIK5+:VXYH1.:DW56RJH
MCEJ>AEPT#Y(D>>$">$Z@@2N_^-DP/7+57=#WAK6W]? ;<O6YZQURM?]H'":9
M?)5^=S4\^ N,<)]GP"\E6"R1M< <%D3E_)<SPTK!Q+=*D7DQSP(%,NSTAA+Y
ME*NM\F:JO3'C+R5E72=FO9'WHU[&*UP*M'2#B%\-SP:$*.$60S:))Y/-.<1_
M$([=C@Z,]%3/0['F6BNLJP-W3KA[V!Q\O"3QVF5N6O'A\EO8D.5HGF(8G"=U
M@6'#A',M\-= -E<7?Y-?ZP7VLT[2K4E%TZ#)+)!BM.U44\RT!M&2&/-<_O"7
MOLW;)AX4^Z7IRXWOM<V>PX)[NQN?\M"0BSYK:8@_ J++W3 SNU^Q\HA=*PDE
M9VIGCOF])K].\)31_%R<.G_,VCWVRR>1:4J-,_/A;-4="NL,]0Y2#@@$$L,L
MRRMQ9FU-)G'7?A%E#I:5@6,71PY4%#6@J3:;V\R'#D7]5,DR^NES<W-WO^N&
MO,[P EE8S@P8RY4B3")J"PMH]M14CG,5J[D+ E!3F$F_LJB YS_'W?\V&)^?
M=!?.,O?23,^_>&ZW;D\[LFZ^LT*94P )2XG0AZX36:;0(L">8D%_]$8--RDH
M1OB8JG^96C2.)A U"TM+[^?J9_>+%'"_;NJT[1J_LGW-F;.?7X^DI9$:$)U5
M(BY04*7XZ0F!\=W]H5M+RK\$4K<.G\Y^RPG,RUW\P9IX<?S0?J^$/9F3+@7&
MV3MO7A3Z=>(_DG*W1-E^>J^><$G1S_N62(4_T.Y+AZ\IU5%Y.XB\('Y_G7SN
MD,OT*57ML\5)TXJV;8B<4!*K?QTFA/S^8('TATGI;ED.KPUXS7?<F;4TH&TS
M]*4Z![J[/Z.IL=9^COK7 .(E=_K:$;^, BF@"@(<7(>)0A[U>] PP#)%LBNQ
M D4*S9\O;6$@X#=NW!6GL@P$R84/UF&$*1XF?C+4^;_R8CY4I0LN\U=Y"> ;
M-G""9=(1Z]:E9-SL%78S&)-ZQ+O)9J_SE:3(^'?B;S._2^ /OUALRGU3ABI?
M_%/S9=K]G4_AS4>U9JK%V6@__"E^+EE^B;!MY-? -MS>]IZ+62,/Q9ZWG:\A
M/K .>ZL1K/4I'QRX-%2O"S]/LOV\7-+0U'"OQUQZMY.URO&M%&'V7??C!T*4
MEZK/E?3^O;FK1!5#QC0J<$<;'1IB2":%+1?*X %U#;FM57]T;0*:1BOH_:Y4
MCT^K7^N;Z^_;8<UU[UJKK,/6II=6*'?1<KRCLVA8H.6^D?H^,4QYLQ'FN2I3
MIKCH6VC<C:VT4&8*>,%J, (KN3BZ)I?HI?EY>N2I&6ZW>VTU<QTVQD3[@PB.
M&WCN*7C2<8CG0"NPY)Z[.RC\>ZILKUUHKD6TSSV+6^6L:/>3NQRU%L^EE;F@
M"WH/SY%S@_3_5,0LU%=R5$^Q3X=Q,-,_H<X:O/E?$M8?(+ +_9_9,I89(/4;
M<68=]F[A0I= .K,S%"QR]/-.N-2:EA5K.IH>FDNI[6DST_EG59>P*_#] 4=5
MDXM'G434?O^N_-BZ2[S63COVQJ'4A??:]J.\P72*M&M(+:7._NL47_(O'_*V
M/Z 89;&Q5_H3X%\U\6P=UB6-PUQDRW=[G%"!=XWNC(\HGCY)6Y5$3S4U2GSC
MO^@>++;R/5@M+GOE90W0I@@!BV*2'.' (GEC*T\(9,['*YQ/\)\1=J@UC!6]
MOB[=;>HJO'/)J>*6YH%T9;LZKY;.G&-2,L2-YS(I!&CH,$L%P1BZQOFNY1Y>
M$*LA\?D4#TMI::K^'+&$TXR;00F#68-[,SW:;"<9*Y-J_;<\P\_>:'\#@ ><
M>=*H;F1]PVTZ,!7%46%K6"KS2RQW;GJ!-V);W']>7N5:N8"P>1/VPUZ\]Z,Z
M]9^VG,'J73_R5XTL, )1(TRP/U=V8LK5K?A<56<5(MAV!(9DU(S&; =[!&(=
MK*+9,>;4,_R),8H?43'(-9Q2_2RO%.PYY7'H:Q#9>'I'B<:1-JIF1KK2>Z5*
MT3QGJ_E V44J"X6:*FI#UE3Q=J[:\&LHUY)?\A3_K_:^-![J[^]["LEDWQ(Q
M92F%2%E")B&$$&4WRKZ,+64PC.QK,K*7*4LHDZP3AC'VE&S9Q8PI6_S,J,9H
M%O=XW?__?5_W?3V['ET/K@?GP<R#F>\YGW,^[_?[?,]Y?Q[RK6;^@0;W8,:9
MR(A)5&]4[W;%?-^5Q>DCKF/R)JHY(]<#7C/9M,%]*0DG!O:VE")YU]&M&=<G
M&084-?/E$9D-$+_^9?]'<RJ+F&J4/L4]?>C[==DLU.8&8*3@\&'UB]= AK%X
M<#,[!P?A9DC$I2T? NZ<"AQ*K%8-0I^.Z1[Z[:W;[K*KME Q)K+T:3C6C_:
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M$ %"OHGC8YBQ\X 5>RZZ'%B:<8[0?E#4=WO_6@UL'W5BW"3[I#_46K6E6(1
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M[AD\D-7 CHM9MXR;UJSHID :N@#NP/_?IN=_VO^T_YY-8'_V?P%02P,$%
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MMGO\ME[>(O,3Q#&CT.=9")&0G)F&@9#VI*!9AN/ ]ZU"U8^.,C<J;(_8B[*
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M?:^S]_0>ZKNZ7G%V6^]4@UV@@$<9BC#$B2<M)N(', LSE6,L6())*'AF5(K
M<MRY.?<;R97ETNY,MI%$N98>X'I(@6O;R3B_IHP(\<@KPA;=CVMTM=R@%1S<
MUKL%K,=!UZ*5TS@H3]2NR1G:=MV8[#$[VW')XG;3=56RUW&G<]* RP>P_SHT
MO8UFORW8^A<JHJBH^7YY*)2QU%?E9U(11W()0)E< D(!/19A%C ?A8'Y$F Y
M^-S6@4TJ2I>PHK(Y-[_K5+!@)]NI,%@ 1@1XY%7 !%NK6ES7XVVQ)(R(^U1M
M_/*:+DMEM"H/&U.JVK I+^NQA5R=P.;K^<BW<[3Y'6\U==7.?""B9U<-VWM.
MMW0,U'9G_1AZCX%5*E1;/Y%3U2+\@WC-'\LZ;W[A.M,F20.&TYA#'/I(.@O(
M@R0,0ABAD 4!R^+4;,TP&&MN2T1/5/4>L596R](.9Z UVUAR!-C(E-^74H'5
MR0F^MI(ZC#(TP,-M^8$SXTU;*^"RX@>)_0:7#(RFHW(E4S%ZG.F":NI(JN+W
MDIOR)[[-PGS/FP_B"_ZV2;%.4*KJ9L<PQLB'2&0J2,Y+89I2YGD1#SG-K(+D
MALDQ-ZKIJ0%*71R0]A4!=WHS5.?26^;-#YTHPS"W\>$?.WJMAWQ;EG%'A[4)
MVVY$WP!5$TC2F]1EE!SV*_%T&Y0V4)9I8\VN ^P@A.S*VPVL'5O=X2+_9QO[
MO#DJ4X?[!?LH'_:UQ_!!=*V\\')[B+9Y8Z/0XYGG9Y"%W(.(8RI9U0\@BCQ&
M_#!./8JM:LVZD&IN1-M7Z@;LJ*5=H+YBZD7?J-8_MC1X\T><9S-FGGSV1N;I
MJ2;.OM*N2Z#=5N9U(MFTE7Q=@GE0^=?IS8=1O3I1U(-\X?2^R/^QXJ]+U=UA
M$66AX'[(5:L9!A%A F+,0Q@+WQ=^EE!F9QB?&FANA+R1$]P^/E8EIFUAO8W4
MX&LKMR75GL39C#U=H#<R(5X/G#7574+%*7N='&Q20KJD\C['7/S\@&.>4Y9H
MNPEXL-.-LRRD:0!CJN+<PK:F$(=>&&28>QSCS,@,M!]Z;M1RT9VS.&^PFP.#
MTYW1D!W;#CL-ZH F*U<_[.;'.J,!/J-#G6-;1^WYCJNCG$$HGCW(L;OC=,<X
M@S3=.<09=H>A=F65JX@TW2),95<N1)"FF'H$AE$40N2''B04)3!*J4]$G(D$
M6V6"'8PP-[I?"]BU(J121%N;<1]#4V/Q"F1&MQ([4+H6@J_.H3+ (#RAN6-+
M<'^4B4W $TH>VGZG/CCPC$7R.\N7JT8RQV<55:IK*KSYU@:0M@4N'QY7:Z=U
M'4_ZD5<Z#^CV0:T0BP0'1'"$H1=D!*(LQ##S4 "C)$QXFGBI".W*$KB0:F[<
MT5<*U!NM ._4:@O?TJUB^D!872#_QCL55?I#VP%[>"]L-W-N>'@S]4R.?933
MG\2M0N#-SB2^VIW$M58JC;/-_;P!K68.3W5< NWVC,>)9-.>^+@$\^#\Q^G-
M1^A2K;P -8:J$"='I=+O6/@ACE,49A#A+)'_Q-+C%R&#-,!"J(A/%*?.NE0?
M$6!N9'[0I9IU,H/J7"%(-Y-A>#HS(L1C;P!<[$J]EE_7W=1M4)0*$_6E/@/>
M='VICPDQG[[49R"RZDM][C[7]E%\5SS)VY75<]O(M='-N+;[/EF2)M**3:'T
M:!%$$?8A]E ,>1S[#(<ASC*CPNFV \^-ZOK=\]:2*Y-';0:IQ-LVT7]H5\,+
MDV!&=6- .S+%'4/U^:;K-=UT/0;':2)MB]9(W00O#/Y"S0+-(#G="]#P^F'<
M]8G7TA&DJE?2:_[$E^6CVA3NXK6[B%\<LTQ$40!31*6E%H=4?I?&,$QCX@4L
M#'P>V="6P9AS8ZRUR/JPDFV%7N<<V'&5">AF-.48RI$9:@?%GKS;[!KG<=<6
M #DE)9-Q)^4C"R#VJ<CFTH$6U(K4TH/%U?-GK-N?JL3#VV]YO4BYCQ(A*,2I
MV@<,N/R.)3'T/,X]7_@BHE;END^.-#?&4>+I[L(Z-?:K$M&VS_-)4 U-(!=0
MC6WSV*!D;]9<0L"M'7-RM&D-ETM*'U@J%R\81@H?J_Q)^6A+.?6*<+J%,<-1
MQC(OAH0J)XI%,<0TXC 0ZO]I@#&Q2NTZ/LS<Z*"3$FS$M.."$UB:$<'U"(W,
M @?@C&!(G ?!*1&<&&I2%CBO[CX%7/CTL/?_IU6=%[RN;VE;YE:%O*K5RT]3
M3N. 0Q9D&**,)S!+10*])(W]P L9#JQV44Z,,S<&6(L)>G(.L@M.X6I&!@[0
M&ID-A@!E30<78'#*!Z?&FI00+BB\SPB7/CYQ,6K5^;EY?E?43:6CWFH=Y?3E
M'A==F=&_RELTFQJC>UO&^H^O)<%MJFLMHDQ@CY $QHRGJB>>@)D4&7(A0C^,
MO2SVTH6\FI2CUZQVK9O-J]S7<+PW6LO(F8Y/8.5RB:M>U()EJ,)L8!Z[WO5+
M/A9C>WW7%\5NT0$]>+H\VD8"M"V9W6+4KY=]<&ZH/P(45+WN?C,HHSW6_,^C
MUK9S[?X8!;G'FE1G5;M'$W"8P?":DZ8GS"8;U4LSQ@66CR0-?8A2%5Z8AC$,
M>,!QG%*"N6?C0YP89VX^A!*SSWEV2^<I,,T6,@<0C;RL[*,S2N+M!1B<LNNI
ML2;EN@L*[S//I8\/R$3[Q)]RS632<B1E6\#P]J[B_9TP+Z)ABK$'$0DBB'#D
MP]1G'&*?T)#Z*IV5&>>?&0PX-V;H1 8;,2V2GTSP/<\18Z V^EEF"]B.N%OX
M+N] #L/1(G7,,9X3)8Q]XH]M4GNM0X%^SJD^&58GQJ>@YKK*G"X$6"JS7UTG
M?Z?L>_FY]^63UA7XV0T(/#]TE51F@>_95#*3^TR70&:AU4[:F,UU R.,SY2V
MN7W"^5+%Q;PM*W4*M8V"_H*_+4)"4I'XDM=9S*2UETAR3X,0"B\4'D,!Y\CJ
M$'FP)'-C_8VP4)05K-5AZC:-Y 8T^-LZP 5\3WC!1=Y8;K<,GS0SJW*2J1AY
M*?GPZMT-T,;GYQ[XNW.CY-_I+G$#L)"/"-BV#[Q1];T<QBM?BZS;P.7!TDP;
MP7PM: >AS%??\/J89NDIYT7>\)_EZ*JDJWQV<SGJ;5WSIMX/<6992)A $-%4
M4BWV!,11F$$OP5BPB'A98G4Z/U".N1%M/S:WUX_HW<=/?\(/C__V>GBLL\WD
M&.XXCP_YV/O#.Y'0:QV@5@)LM0"M&I-%1@\ <[1 :1M97BQN>@!@Y\*HA]QN
MI'/*^M3^J?[GBQQ55?>2#_5[^9AW-:"P+WA"H@#BE&*(!**0!!F'!(F >42$
M(G7;)'> D'/C72TI4*(.K,@URDPZ.OD;>7Y&)FF;J7%_:G8%=M,>@ T1=%YG
M65= ;7TL=<U8 [L0E,63JE<N5P_EPNU97(E(D]B+"8RX%T(4<A]F7(20T B+
M( P2E%G51SP[VMS(MV^&;3K*Z0/[LN!=(\VNS^9:*?"^;+CEL=3Y&3#C6F>X
MCDR:?:CTCL&8MJL1*&Z[%IP=<=J^!2;*'W0N,+K(CF@8SQ<_R[E:?KR7K\W[
ME3X&2"-&4\13F*4XDKP2$$A2'L @(T)2#0T"@DQXY=C-YT8C6CZ@!02MA&;\
M<!2X\W1P+1PCO_T62!B_[.=4/O)NUYS^<%<^_2@OTZ_U/Y#Z%K;?ZG?YZ TG
M>77/J;)^4\]^9J %4'&6-V\QU>M;9^+'<JV/@X##,)+_((PBN>:G7%6T2U+B
M\2#V?:N%_\@@<WM16QG!6LB!'M=1. U7\2M!&GOQML7'?L4^ X#;A?K80-.N
MSV=4/5B6SWWVVOWQ(Y'NT@OI_22- E6+1%J\.RTTMR8J247*PCB$,1<4HB0A
M,$V9@ 2+-,,^3C =6!;D:MGF1C$G]M&W:NRVCE51O\H&&[J]?OW<VFZY3SIC
M$V[#'TO*J56P1N_GF]/S.,T6O3/P1]JVOUZ^%]K*=P;LZ>U]=T,,+'NJ3Q$V
M,;$BC*A/20(]$JOJ=@F"69)A&#+":$"S-$3$JG[ISNWG1LNM=)8U0W<!,R/*
MX3",O9O='26.T5WMJ,YN"VKN#C%M9<RCZAV4N#S^J0'1P*^YX)4T"+_@;^M-
MR9S7G\IGO&R>.WMA(8TP#Z51 D,<A!#%/(%I%$B3C L<HC@+L.<M"GZG6JZ=
M?X&-QS1ZF+/V8>Z//-XSW<D''FV,*'.,S[_Q;G&;*H&@%5<W6NP)? /64%K9
MH^906D0%NX9THK#@MD9MV]"X UE%)RXWQPJX::J<K!IM)S:E^FO[+7]X+"M<
M/0.6"WDEEZ14MS65*\/GVRXLV ;@LW'!1C>:+C#81J^=R&"K"R?."^^2TFX9
MTS8B7F[[E6Q-DU0:;-P+/1@E7@911 -(5!P&\9.,ICCV@LBJ4O&HTL[--'20
MJ[O)QMTJ#GJ:#VYL.>Y38^CYS^59&'LO8!:/P739US;3,X^,:B.)YQ59X@)\
M9YG/5H->6V._K.M7N*J>15FIL>N?\X*_DZ9.O?"2+ T"E$"1J5;U)/$@SOP$
M1BCU&2)AA$.K8JT&8\YMR>G5>I<R@QVAP5<E-M!RV_9!-D#?C/0=8SHR=5\/
MYQ6U\B\"-%)Y_-/COE!%_(M G"Z"?_G2E[&ZWWSC%<UK9?]WT1E1E(190$(8
M(Q&I;9<88@^'D"09BJ,XC'DPJ:5](.'<J*XGH/2 N\Q7M@ZL>]0U-H:W=7(_
MP=,8Q5=-VQ_($.[I>>,L(&CT29B5N7LHY1_*Q#T)LFNS]O1 P]:.GW'!U@5]
M8QJR5/@0QP)#I+K\817:B%&4HCB-?"RL2'][Z[FQM9+,CH%[,)E1YS#E1^8\
M)=0()7D/=75*+;W;3\H)AVKMO\Q'/O$R%MS?>*V*=Q5,-0.@\MLOI?K5AU53
M-U)&:7SN%?CJ:(1_K'+*%SC ?AQB#N-0^:H4,X@3%D&>!M)E9<2WK,+ULNK,
MC6U:;73EE%7QU/[ .\74"8GZ%<";+(SC=N.+E=MT\X1-8V].]]S\@8S3WN/W
MIO?4J5_+3VVA.5)2<PT/T/C,QZ1U,\^SLG^O5.D/92R[F3[7EK4CJ889 '\M
M2_9[OES*X?<3XC^6RYP^;R-9.8DI350PF^=SB +F0Q(@!B/!.,%)*H(4VRS6
MYD//;6$]K""A2&ZMC]WZ:#$!9FO9.+".O.ZLA=9 'L![ UK)P=?NZRAAP/;
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M&^IA'FM:HL95>0G;K:]ZD1(6Q$$FJ9)(OD19%$),/:JL3^(IZDSBP"(-P%J
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MKY9->_(O+;/\J?>W.UYP776_W$RWE*I\X*X:Y0V=JK,'!M8WG>YH8*B^.X<
M@V\RL'**2LKX('ZMV_JU'TA;F^%=L3YO>%M6>YDVW=C/BP!G@H>1@$&6"(@X
M4>TN< ")E_D1#],X]*P*+%PAR]Q6,:T*+ 7<Y+K4H.ST4>_RYNA<E'*QX[_W
MWL&EI@7KE<[%A)I9\!--T\BKX&:&I!YMEC7XT)N@-_T)VDLZW*R*SPXKQEP/
MJMNR,E?(,VWMF>N!.RA0X^"6 _R&P46U]#]_X[421\M>_U(6S?WR>5M#>,$(
M%8C&F6I(I*)EL6I2%!(8B5BZ'B*)DRPV]C'&E'1N3-X)")Y:J:TKC(\_M0;>
MREPF;.RCZNNK(>HOH-,8M"K?@/5#8% H?>KWVMQSFLM#,)&7-8>'P<Y?FF*"
MSOI6HPHPG1\V!8X[/MLD UZ;=--+-F[KRMP6K.='ZK#L7K^D./;#- U@)FBL
M^B4A2!*$H/3I?!%PS*4],2R[QDJ.N5D#_7R+S_E=D8N<JN+VK]9IC_4Z[W$G
M4_]VNX5IO:-V[4R:.743S,_8BW]O:@S [])<QFD\<"6:(Z6VV,GR0CDL@P [
MG:PR[':.&ZW\+-W'=PU_J!<,13Z/F"_)U \@XMB#.!$)#%*?^2S"-+-K0W=Y
MR+DQZ*C-5;9 F[&>6_A&)KBS#57 5R4RT#)/T4'E *!I>J=LAYU'UY0#&(S[
MI1Q>:4<ZC.>+-T63-\]_Y\OE_UN4OQ>?.:Y+M5&E\KNK!<($8R1B*#*40$2B
M%!(?)Q!'+)!DPQ'C1@7\+HXT-XIIA05*6OB;$A>LY6V+(YQN:V")\'F2<8K;
MR-PR'#)C2C&&XPB3U)S^<%<^_2COH4GD'TA]"]MO-7-<OOLDA&&LY)HGS"^X
MHI$2N>R:DLNN:6_7*?5Q%$=Q @G+&$1I0"#!$8:IEWB^%W@LI/'BB5>D-/8/
MQY#3Y@7K2SO>>_:W@;O(XTZGH8OXTE/T1]T]'J.]YJB3X;ZGCG-)I^^K,Q;8
M1WOKC#;8L%7D;5ZHIF#ZK/-CE1<T?\3+;NQZD4E+,HB#&,8B]""B(8(9200D
M&8M]Z=72.$WM\L?.CF=$&=.6TN]8H!1 M)*W41R6.WSG438CZ>N1FX9L.SG7
M59PWHJX9U6$5,B-(G%+>^1$GI2XCY?<IR.RB8532]OOZ(#8!%)_Y7?N AUX8
M1]RC,.4>@2@B2+7J""!//1)B$A)"L,W>V,F1YN:OMH(J]B"K.B]X78.Z$]6.
M0$YC:T8>3A ;F3BV8&VCLCY?0LN:,RXBX90O3H\V*5=<5'J?)RY?,(PC]DM&
M_83KG"Z0YR5!ZH4P2IF R%,YHY0*Z(4!1CPC/,96#2F.CC([;N -6):2$7#3
M5#E9-?K0JBEUYPGIF]2JH.-]N93@ULJKW/Q>EW*#@"BE=,]65BZ7N/N0_JME
M^];CDV)&+%=#/?;VUT$5O!N@973'*&<A<,HFQT>:E$G.*KO/(N<_/(Q!?NH6
M4NE"$6G,* ]*]8&0P[25=>J<:<HJBTWHYJLVQG[AD2#Q1)3 T(NE-Y-);P;S
M-((XC4*/H8R'<6)#,\-%F1L7;<5659VW<H-'_&Q?+..**3(CG6F 'YF9UDJ
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M//[;:\N*.]?,C!DY387WR-RU54,=66\5 >LJB%M=H%9&]<WMU %K?1S&5;N
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M1B#7(;Y^D]2"U'N3"LM@NI/H\B@( R\.8!82:1N@(( XE6X-C8,HQ+$T#8+
MHN#8]2!/7U%L,JP-%G07S^?(B[42$7ROA/PS^%#L<+WE,GP2*(LEU@5@$RV?
M0X&S6Q@O 7)VT3MY\70+VB7Y=Q:KBQ\>V >,4M5'756>52E8TJL[75LKH"2A
M../02QF%" <,IHBG, @%13BB84*X3:E8B[&M%JT)JL:N*W+Q;RK8H]O+*'4,
M$VTE!LNM$I9=Q"RF)&%4A#1-(8U(I,+ON5S=P@P2'&'.PS 6L547DK&F9(JV
MMS.9$K.MNY& 'GE!7$L-.K$UQM-4IQL F-L6<1;C3]LTSAZ8@S9R VXQL%(P
MKE020OV15SH>[@O_UOPDM?EMP0*1AEA$JIB=@"AE&<Q\$L,DX3P(O8!GJ;>0
MABHIC2L!GQK+YH7JCSC>>_43KG.J7Z;7^7*ETA55DS-MK:M$UU?EPX.TVK46
MEO6 3^)M1E-.,!R9E-8RJIS/%B/P5<D)M* .#Q0N@N&V,N_)T:8MOWM)Z8,:
MNQ<ON+(QRYMN@=\<EC'"/"]%"40!9M*Q5^5/ LQA1.*0\T1PZ>$/ZL*R/]+<
M3)YM$:*UT?.7@6U7#C UHP<G2(U,#UN0UD*.VS+E%!3C]$<Y&.UEFJ&<4OID
MYY.3%PQMMO:ND&^<;K3*7^,&KZUQ%-$H1<B#R,LD-]#4ASC!%#(>^AG/ B_#
M1MEEEP::&S6TLH*>L$!)>]$NMT/W/$NXQ&QL&V(@7 .:M)W'XLIN;2=N/G';
MMO,J'O9ON_#Y@?FL*CKA75U+-^;UJI*4TQ9,T(VR]=_V2BJP1<10$J9>#'V<
M26,BQ0*2@ 60QBBEH9?$/K$JHV8MP=Q(1 L)RE9*:6-T8MZ @ALRR/#),#-
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MA*\;RELN"JYGT7!1>,&Y&7M1Z*EV W:4T\M!7STU;QL%P5;#7@&AD0X'QYH
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M#PE>;>VD,[V2TEW>7W](2LI4.F^DDI(UB_?=:9<MB1$/I6 $&?$$(@1ITID
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M8NPN=:/.W@2M[\:1?P;]]$:=&+LF?>.*,&R%_%W4>@/I:[EY+KCFYOM[I2L
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MTQ;Z# ?JJ"#HAD<-,Y&_J2'4QZT_X,_KIVV]I]>C.F4CURF)+%%V,$PA9D$
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MP!E",LFD;11W9HRY&;!&3-#*N0 FQ-F40,MJ']Z= _1ZI.<!II&-SB"$G$+
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M/0FF2Q] L6:E*675>11:>, +Y3G7JQ= ZKHLZ+8V_F&] 00\E9NGC6;BVY1
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MV"^U'VDR?]59^;X?ZW[SW-))=D]J;GJ=3KU,,1&8ZEYA@5 V+B$2$AQQB'%
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M;!5Q;35(_JST1)NFZX1QD&M*BK*\Z[X ^OUJHQ_-Z:*)JIYSR7F,J 14IAF
M--$_B5 !Q"3#%,DDPE:7?L.2.361O"-PWU<@>&ZR#+;/Q@'5ZD*NI;:6OQM
MFY8@QE%N)$11EYU^ZM<B9*AOHEN 3V>EA[YT;/-X4#7\[G!Q#9_!77MQ2U:#
MDM=V6Y']9].P.XGU=FHZ,H%U?]5P\W(S-\OH9<_[:T@R\-I<:5(RU.QC-BX9
M&,&C9B9#S^:GUN:1LE.Y:TQ=^6*C*<F+.0VC*"%I F)N*E,DF0)8:?.-1AE%
M1$7:<(M<HM1="7#2#D8(/3>$G:WWZ*O4X]45L3/!AL1Y"N;7CH/ L#!<*4A;
MW 8M"7F5B%<M#6D+T;42D=;CN!<"^QO]K]7Z[5;+U"=M091!)J85>::$ @J:
M[H?85*G RAA'*DM@1+FVCFPK?IT./S6CIB'.*6;G G+= NAV/(96_2VA<"K+
M=9GCF^MOG1EZM$);E]EJ5]3J>*J?EO)'(3^K]\4F?Z(;6<RAB)2480@DE;$)
M7D: PE0 E5$I(Y0)IJRN>\X//[6MJJDS%L:./C=UX@@Z.V6A/R #[]5C+&;:
MS%[D_"7X7O\Y2"#P>3B\GO!'4XQZ?I]G[_ATOO!4S[Z*_%&*[<*,2->FSV=Q
M+]=-CZJ<:^/G7;[8FC+%1A]HI2V$0L8J(H";[0\)2P F>N=G61*3,"8I@58M
MBF^D8VHBHF'#[(W#NJKF7XQ#X]/VR>2TK=:E;^*=7*Z>\F7Y]S^,@R)?EFWS
MMF5%N)+UZKF*^>"3W-27&OJ8U \^Z8%+E!Q[)_9<=3NA-<):#BS=VLO8\%!"
M7G(Q.[,PWTM>AI%Z-^+IMY=@3UK&;0AX&V G7?UN'.YU.M[^KA\T+:$TK?E*
M5*5*9)BE7"9*KZ[* &3$^(Q$"A*B_PY%F KE=-$_ (U3D^B[;J0EK7JGO]$B
MNC!,%;^,V[#VW():"N377::AA;7'EK,5I^84KGB=7:D7-'I+V8ZEF%3/V'-T
M_DLUA>T VG?7UZZIW$,RW]7W='?+Y98NOLCGU7HSSVC"TB3B *I0_R>*J%;7
M$P&B,!-$LHPJB&SC,L]-,#6IW= 85$0&%97V(9IG0>P6MCZ@&=I_[X:*4\AF
M%^N]XS;/#CI:\&872^T(SL[G^BE_G[6IN#;29"T?M4#9M>PPMI^V 3^K;_3G
MO7'#:SG3*G/V;76OY<QR,T]#KG#*,4A))/5^IP0P4]$J9"*E(1)I#!.7R\$;
MZ9G:76')3L#;_ 1O%F4=I >:6X9R^UHK.QUNQ!486 I5X!^P$AS4HIJ5;@YM
M>FN6C%]Q76ES1^7\*K[\:6:> /:JA=U*TZ@:ER< C[4K7\/>[!]]>EZL7J3\
M*M<_<BXO*'V[>IB?E?'_/2S-16FEV)GKTE8%$9:D5$4D!!%*8B.BL5;)HA3@
MD/,LI'$FH-/=R6"43DVW.W#._7-K2GT>F'UUNI/C]<QP"^WL-'V]Y1O14M]9
MX'LS:=8LG2A=JV_I<[ZI(KK+J!(3!SB2FW68%1C*$>N9VM=RU0X#>H<S=Z )
M^QTT?S?=NY</91P'S^(8"I("AD)]-,B, 8*A-*U/)920<Y%:6>MGQIZ:,*])
MZU6QI@V9G9#M"<3 8M$2 V>!=H9;KR*H/?ZH0N,,8\?;_-PC[KZT.NCM)8K9
MMWRSD'.,.8]Y*(",1:J5-LP 9J$"A.,H,3??86K50>G<X%/;FB511LF*XC?L
MER;N\\7>B7:"WG4'VBV8#+Q+7>%P\IY=XKNWY^QDP-&\9I=8:7O,+C[3(TOO
MBRRD?N-Q5PFJ+B:+A Q3@2G(F+:J(%(Q("A6@$NH4I$RO9&MBJ-T33*U+=N0
M&<B&3H=4ITM =N]:7_ ,O'MWR.Q(O%Z%UQXBAUPN#U"]0B964QCON2Z_%FR-
ME:96ZV!=\^,KG^H*/IW94)?>'2^7Z0KU!YE(UY[M74632RG*0NH?BF)KZE%]
M5E6HV-=-&;K'HE@H%8*(A@1 2#B@+&: 9QG1_\P)B9TJ#E^=<6I2LB&XZGF0
MUR2;HYU7$76%H7K77F;W #?VGG-1S2NK@0CFF>2A7@,I@5X,T^$*"Y"E-*19
M&@F<Q/,?<LU6K[(>[9F'6Q'C[W\^6!43*GEI90*J]&?2M S2AM-VJ??'GR8[
M1?]%Y 4WOJ*Z99!^3X_C7H3C^LK9F9Q>5V/@0_)P8WQHP=^$FAJ"O19$M</&
M=SG4*[..70S5#H0SI5 M7^RA59<#F%&E>*=5]>5#Y?(JG63%/^BZ#%EY_U.N
M>:XU@7D6A@+*) 0)$Z&VBZ4 6,444*0(8_K R4*KNLP]YI[:Z=(0&,B&0O>0
MP3Y+8*&F#P?LT!<'I=BO* \JTG<!>A7ULV"'^XZ!X;!VT/>'PWPD,^#;8ZZ_
MY4451KG>VP35FN35FI0'1O/!FP/CSV8U6M^^+Q.A'Z2=EH/CD.,9%/UX/; S
M>@[1LXQ!61)W+F.*&,48$(F@J9)- *$0 R:IJ0.9A PKI^($Y;!3"R.JFK3>
M.?1D/8+)3H5T9WY@<7R%8_?4_@,&_2;L5T./FX9_P,Y)<OWA;WOU3F:;#\MB
MLR[%_\?\G]M<Y)N7MZL?<JGW\M_R9?ZT?:INS.<8QG&<8@C2!', 60H!XRD'
M+$)$AI)I\],J4<]YYJGI935QP:*A6MN&%=E.W8 =H+?0R(8"=& !4!8"V=,]
M"W:4!PWILZ !O*)^*)"=NB\/ _9(BIA/T%V;&KL#=Z6_L<. 8[8Z=N?SJ.MQ
MCP%Z]IK;V_F5)G>WW3RNUB8Z91ZE82Q2P4&J* &0LP304$O_%&EC'*M,(&)5
M0<5BKJE)^;<''MS*\ CHCMS^V7M=>-NI<9Y0'%BTMSU]C7$=["GUV-3M.AQ^
MF[=US#=ND[;KC)\T8[-XY;9>(_<T%Y_D9AY*E84D1D R;:[!!(> )82!$,$,
M"8Q#RM,^+47J\2<G+DQSPV=-6R JKY*Y=W@N[>/R=C._UM;:"E0[^7 #5 /+
MA%U/$$-:NQ5(*T1WUP%\UK0.-ZU"^";_T5UZKW>CD".8!ND'TLSQ*FT_CAB\
MU-WC^+%^<D"/L$^KN&-%V4]GCK@2&<):AY!1""#-$""9# &6,(I3%2$6.^4H
MG)UE:C)A5Z'EW]UV_7D([?;^S< ,+ ',!>U!CM:%=*S@>T.\QSC63G"\[OOS
M,XVZ^SN9/98!W0^[5V/\*A^,X?*[7#VLZ?-CSNGBW>J)YLMYEL4L4S(&$84,
MP"S) .6( 2T<,DXB'$MN793QXBQ3DP1M"H/O%8T.%1HOH]DM%+QA-+!0<(/'
MJ6KC5?9O+MYX>8;1:CA>9;)=RO'ZP_U+19C.J7.J.*($0R 01  R?<R34&G8
M5,J((I+KD]^U1(09>&J;>E<$P1#G7A&BQ*I[_]Z"P-".6ROF>Q5^:'-Z<\&'
M<K#1"SVT63A7X.'@]STN;GY?T)^KKT_YYO$_]2/R_N/;.GXX3-(X4AP#R:79
M>UD"<(PR$,:Q_H<D9C&UJLO5.<O4-N+O7__3X5+@(G86MRP^$!GZ+#4D!B6-
M04ED<!]\#-[V"5*_B)3#58D/Q%ZG84@%Y._KU?8Y^)AK#DSV,%T&5*FR%&<9
MG7+$7J#Y"][H[]%;B,HU_#IO1RZ^/-Y-R#7Z#VX]KC[<MY6A7EA>54^]6XJ#
M]KM2AIBB5  94@A@R@6@-&,@#3F!+%0\E4YNRHZYIB8VVZ26(<[4IA^O,\)V
M?@M/N VM];2H-/V,GQ=RAUZ;Y%GP:;5\7J_*N'*_#0.OPN2Y+^#E^49N_W>5
M\=,N?]=?N3EHI@J!RWE=A>+3ULBKSVK7G"OABD&I14LJ:&IN4!6@J4J!A$*;
M0D*$1,8]HV:N3#TU<5/15W;6<N^>Y@:ZA28W&)2#2Z"CV(V&]*8.RBRH@?ZL
M^K2I<P.Z=\R,1\!?*VCF)N!O"9NQQ,XA;N;:B*\5.&/):4?DC.T(_13+7[>%
M5E.+XNWJB9G:^_H#?+M:F@M+/;C^J<A%>8&Y6G[,*=-6P^9E+@5'*C0%%4.L
M3%.B%# 10H!2!HF2VD 73DF3/6B8VLFPIS?@;8+-06%NA=QTT3Z+8J>C#@SU
MP"='0WW0(G\6M+ _X, $!=8\^-->;P#0JU;;AXY1M=T;@#K6@F\9:N1^ Q\U
MH1\V\DEKS:& ,8XR$/+$:,U0 D8X,TF!A*$DRU 6N>4RWTZ4RU8>)]FY#.-Z
MU(>>EM'_NZY@.%(G@?U2<88QI)%6,DSY(BAX"G D.,!(PB1,L%XK-4HGB%X+
M-4J9R5O;"@3?#6]!R9QC93,/"VQW-HZ[; ,?E2.MV'@]'TY GD:+ASU9_QH=
M'4Y@]-; X73D'IZI"^>ZB>O[4)>:$!&),4P(0 )) %.A $$B 7$B0B5I!@6V
M<G=;SC<U4=QA:>1ER[0JHM_!7V*!N84WRB^2 TO'2R9#&=0;?+A6W*/?=VOO
M:/*+Y4C>I>;T* O47/A&%XU^7GZH9=+\2:RYKVM'>Q [W4P6PXSG6[+GZ<"A
MY/!:3WLI?UCF*N=4GP6\K#AD4NM-\]-<MJI_<\BX29X 7$EM$\4T BS*,I!)
M'D>AE'$JW,J\6TT[-0G^=?OT1-<O9J.T& CV' 0-"XZ*LMTB6"K#WJ$=6N'M
MAC+X/DR==">8_*JL=E./JY8ZP7&B>KJ]W3NYPR0ZW:]7/[0@%+^^F%:S'Y:[
M/)U]FLX\2F*A$-3("T$ 5#P!."$0)(S@2*-#8RQ="G?83^TDLD8H[F%2'KA)
M#]O6?7E7N[0F>CVMZ=9UL)-8PZ [L-0RP)9Y=PW9QB9_4W<__F7@[#%WQ'PG
MF-A./W;6B2,L9U)17$?H)\R^T9]OUU+D>KKU^D6MUL80KXM!9'KFC&$,> 0A
M@ )AP%"L?Z)0,)R%E%&KFL\6<TU-P]*D!KRD54NM/;$F.LRZ^H8-Q':"R1-P
M TLB@UE%9M"F<^:M>H8#'%[%3-=\H\H5"\:/!8G-*_TDQV\T7_^=+K:R*L%T
MMQ3-W9F62G^3M-CJ>3\OOYCB],9 UP]\6BW7S5]-L^^B[#\T9U%*51)A0$2F
MC3J5FO*]F #$%4M5%+*06A55\D[9U*2282PH.9L%.^K+N,LV_75;)\=+$G_+
M:2?37F61!I: GM;'62!ZQ]*K^/1'W:C"UCNHQZ+9_P0]!?EVO<PW>C(]P6_Y
M3_-34>>X<*4RPE,(0JRXU@!#!$@<29"F$<Y$&L$,.[7.NCS5Y$1M0VFY?55-
MJZ-(O0RLI8ST M?00N\ J8;,ZZE6[E+N*AI^Q=;EZ<:50U?9/A$LU]_H)RD^
M:J$D39^^4NSL'<*AC EAA(*8LL1$*L6 PC@!)$I4Q%&2*>%4(>W"/%.3$269
M@:'332Y<@M%.*'@ 9V")4%(X*X$9M,7H%22\2H-+<XTJ"JXP?"P'KCW>-Y&P
M'5M>J?R1H$B$VFXC,E( 9LI4Q-7* A(818)E*0R=++@S<TQM\[?[)G]<+1^
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M/U,HYNHK?=TR&_UUF*O8ZLI/#_O^IZE!DR\??E^MQ)_Y8C'G*!,PE!B0+$4
M2IX EH4*"$)5B$2*8NQ4B,]FTJF9>A^6X'F]XN9LU<-*#?3CO_VO* O_HTRF
M#H3\(1>KYZ>N+=)_ 51$,620 ,Q-H51J:O1(K,4\S)!4G))(JGG5Q?+KAJXW
MK[,,QP0,J*K+AWQI,CP"1A<F\F  S*&,D@@B!F0"3<TXA #-& (1C$,&88RA
M0C7F[Y=73*-A$6^F']#/4>6[#@>VK1/3+WR#NS4;<NO I.J ?;.C.6B(OAP5
MVL/7:8^19^^GQ<0C^T/MH3CUD#J\Z[4AY"Y:N]T0$F8A(DD(!,:FI1K4LBC!
M'!AM7[ LPS!E'AI"GIEZ:FK^KB'D<ZMOX2[KPW=3R'-K8>FR'03AH3VZW4TA
M=\2/V12R [$QFD*>FWX*32$[8+%L"MDUPK!%1^Y8L5GKG3H/21R%(LQ +%2F
MQ9I, 0FU<<&3A'&"C#-ZD+HC#0%3LS'>R>7J22^+WBC_/DPAD1WT=E)L2$ '
MEF6.Y43J#/'@>\.*Q_NLOBB^2GF1'1&3K#!R#%'?(B,GX_1M:E+Y?'?WZ2W/
MKXG-0%(P:IH79))* ",4 L9("BCBJ;8H0Q&ET*W!2>=\TY-G]3U%7KD9>P2\
M7$/83HYYQ&VL2[16#;F#&QZO@3&6N'CN=M(]Y\B=3ZP ..V"8O=:S[1:(ZU^
MI5I+,WY?N2S*Z\2[]5I_*&6)X%]?]H_<TQ?S3W>FR8(I$[YY:?7$*>MT?GND
MR\_/9HBV!#R2E%^DB?$K<X27I63<TL4WN7XJYMKLI(21$/ P5@!BA  .(01$
MI"%&@HN46N7F39*[J4E,$U/S0Q9&$]DN<^,Q^K/18YIR=.N&E^!%TK6C.)T4
M^+9)S%.B>4)'1<DT8(;KH(U,T(+&&/#MYVIX@KNJQ7J%T$$7K:HH\T:#%-0H
MS0XUY1/%>H=5T (K*-'RF+X]Q8_ ;\[XI#@<-U%]4JQ?./.G262/V, RP?]#
M6:/BW=:TA+ZO[NU*&\E,I/])DZE_*G)1YO*8,$%%*$FQ!&D&344/F@&L6 8$
M10EAC&6$6S4(Z$W!U$[J@U(?)IJ?[^@V/^X)=Z\.VW^5N@_44; ?^M K8:_H
M#RH&@HJ#QJVSYR$X8&)H[!UB#X=>@Y'"$ =8"[>0Q%MP[(Q.[#7P>(&*M_!]
M$+-XTT!]BVAV3ZD/OJ*L6E7]7%:)^"JY?K2\?:,A9#!)$H Q"@%$! ,:11AD
MDJ!(_S]&Q*F3WVWD3.U0JO5YKA64U=+LNI72JKPI8;XCWI0/T#NS=\GR&]?/
MTN0;;55>[;B:U3+2-#QO^#'+U>(HV+/DLR:H#V@]EPR]B:21*XKZ@.^TX*B7
M4?M)Y#,AZN6/:RGK#''%(\BD*<^EJ%;^I82 AHG^:Q02I,*8A3!V$;I79YR:
M7#V75C$+&II[9N%?Q]U.6'I%<V!Y>"N0SN+.&ARO$NWZK*,*+6L0CN62_8L]
ME4'^*,6VK#IH1!T[]JY\D<5FG?.-%*6$O%N*HW_YPSC)ZP"6E[(;_3?Y<_.K
M9OZ_YUCBC%,<@P@+K2JF(0-4IBF(8\1B3&,2*[>+BP&)G9K :W@U&HFYD_A[
M=2?QY>L?3>S72[!=BM)3+(-[_:ZC%CGDPEOJF!-9SA%O"7;>_[W3<A;LN:IJ
ML)9EGD_^T3 [VZ_]]Y+?P# <E!S[K%H_PL+XU5^')'A<[78$Z$]TWS'F[)MJ
MN3;%*3?25$/?Z]MU[0:LB$BBC "(0@6@@AE@&=6'3)C&4" 1L\@I>K%SMJD=
M$#MBJVK\Q75+M0?"=H+<&VX#2^(]9&5Q_3VE Y30L,+$<WIEUXPC)UA:,'^:
M8FGSTJUJKDT[R&,U-LXX0A$#C)C&95$: D)3!' J0\PD3QR[@-Q"S-2D4%M-
M/:2[\7R:5BY;O5=>=MU8JSX6YG?[AJV[W_758GNLJZN6.NQJ#:V%MA;*MD_N
M2$IF?UP'4B)[$/1*2F)_Z"XK@3>,V4\X_T;S]=_I8BM-5Y3%JMCJ[WZ_2T5(
MB**I  G/!("$$R.'%8B31+ PPRD73L7,.F>;FGBMR^F7_<KV :[!WR0U=(N
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M99Y:S#DUX6-1"KEVD3I*(!O\;;TY7E$=W(-S.Z">2TD?0#1B[>AJW@D5BSX
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MU/3.@F691>[4 =@._F[Y,!2HP]\0[KJ,!S6X%=$ENH;LNFJ1(7P 5!W*?@R
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M$:4+6A2?U3^H"2S;?%Z7M0#>_Y1KGA?R?IUSN?ME4?^VB.9I+".44 9HHE(
M91H"2@@%(H:2I3%%Q*WY9R\JIJ8B-?0&SX9@(Y?^K$D.WN1+;6XN%G1=!,_&
M#6=B@EW[-_1:*;NS:7#\AW:!&_H-XC61QG%94CD+=JMRWZQ*P\CN(8\VZ4U
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M6!F-^%'MF[&7Y-@D&GW^USDL6_3\0QJ[3M/\0Y_R#_+ _)LS'$4A01%@(DX
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M8[YQ;?+KC)\8Z1:O]!,>'Y8_M!A;K5^,)"H%7ET!HY@+&:5AK#B0B":F;)8
M-$D88"D648HB_5NG(.[+4TU-=#0%7DQ+T[RAVDU>=.!J)R[\H#6PM-@1&>RH
M;*KC>&RV<QT*KX*B8[I1Y<1UMH_%A,4;/=T!_%&*[4)^5I7G]E?3]GI_-?!.
M_U%L<J[%4]W[[%O9NDS^W)15D.9$29K%&0,*)9DI;1,!DD()8"1"$L8D5,I)
ME-Q(S]3D3<..L<3-M4# 2GY:UVFNB=ZW+IBE43W>,@QM&K=6H$;]9 UF0<-0
MJ1PUS2R_ETP-4_/+$\!^S=,;:1K7R/0#X(FIZ&G8WC4R3#A>V5'RP_)^O=)6
M9=&4<!")2".&"1!<FJO3C "*20I"+%B(& U9&#L6R+@XV=3D:)M6K;@%SS6U
MSD4R+L-K)QA]@3;XS<PA7@VAP]3&N(J([\(8ER<<NRK&5=;/E,2X_H['3K#E
M3:.0L4AE2@#3F&K1D<;:U@LE8!&5,86IB".WVCJ79IJ<W+C45M3I!O<ZP);"
MPP=L0TN.OHCYZ;1J>\GK+C4NSO;Z'5//7?_:O]!36-#BT?S?I '\H N3 *!-
MRLTZ-_YM\PNMXAS^0^O)>20PQ6F8 D49 1"A!. $:ZF"]1\1RD(E$O=./#?1
MY+*'QNNO8XB<!5S_MZPU6-,Z*^V,]8Z5ZH%+/7A>)+W<9FR Q>5AS(A4"L@8
M8P A58# 2 *"8II"RE"28M<&.B,O[?!M<7HL;*NJT=A+"D,J8!0*H$*6 DC3
M!- $<H SFJA,<))0.=_8!X2/MIR;$8+#79:R>%S]66K49A6-+K=:Y,)$L9?9
M[;+*6M2+;,8,?ENL_G0U46Y:9DLU9*S%&UI5*=>M1/I]>]WVM%>_-.MX_&^M
M%SQJ-#Z ]:OUW$31N)J1#_!.M"<O@_;(933E#O>YE6U!\47^D,NM?+OZ478L
MOGLR,7YS%<)8,L1 B&5B+#0%* Y#0' B$I1!+(E5B?@^DT_.:&N+U75%<<!K
MDK58+HEVR.MS78MN*3HTP@,+S;)8ZI[TV>$A5E,?O-VA?3<TV@ZYE0.B/E+&
MI6?TW?(Q>\+7F:7I.N9XN9L]N3W(Z.P[1C^3_!O]6=5,:Y=,,V'?[U:FMM\<
MFK(WBB4@0BP$D*%(Z^^$ 1;&H2 PS63LU![NRGQ3.Q8NU)2;U9D'%=&.'KUK
MD-LIU!Z!'%CZWXBALT9LB8Q7G??:G*-JM98 '.NMMJ^Y"1INA-3Z9?['U[E*
ML0B9:?W!D=8WN=8\:0(AB,T-8Q(QE4"K)B#[(:<F+O[XZ]>_V@F#%BS=^[T?
MLP-OZ3\^??CV_EWP]=O=M_=?;]^YISQVE-&K'Z[V9OV7<EN6&[(UU"A[[I3T
M9EN=^4W?"WK36K,L]'!/UY_7I=-'E+'>]W)=!I'/4R)B1E(.4LPD@ F- ,T4
M C*-4I%%II1-XG9/?W7.J>V]MZT.I+/@F:[K?"0?K<)MEL#V+M\KL(-?Z9>8
M?JTPU02;F[F*Y+K,F2:ZRO#Q>;EO#9'G._[K\XY\U6\-Q.F-O_VK_:32WR0U
M;<2,C?)A^;S=F,YB1N*9P@Y-\!#%62IHJHT%$0,84P0(BQ5088A(&">")DYQ
MFM>GG)I,:B@,UII$-Y%C@:^=Q/&+VL "IT5L4%(["W88EC5@_,<2V>/C5=I8
M3#NJL+&'X5C6.+S93]0<MO'Y(NDB_Q\I?M<V25F]!/)$HCCC0!$5:MTGH8!0
M)0&-6:CUGE *15W$3/=TDQ,QQKM7[,B=!>N:X.!!4QR\,1'@CMK.%;SMQ(X_
M%,=P3G]M =C0&OQ> OBQ$T!G<6.'BU=1<V7*4<6,'?O'(L;RK=XN4%G4.7%U
M)?,Y)P1"I$VI&"&MNJ01 BQ-$L A2V*5< 05<71['L\Q-4%2I@*:O'OW_)!S
M"%I[,6_!97C/I2R"FKQ9TUW JZ?R$O>^O9,G\XSMD;S$Z!DOY,5'>Z:;-4$R
M37[%W;+,R5_+1[DL=D7I=@G8:4PAH1$#-*(*0($PH"%1(%4ATR9+'"&>.J67
MN<T_-;FP([\,,6K3W60S]<V"=UT8.Y$R(-P#BQLO2+MGA?7#RV\6F",-XV9]
M]0/H),NKYS ]^[(7A=P4M0#=[:"$DH0(C7^6H@A !#/ .(U!%I(8HI"DB#F9
M2F=GF9H :YH"T9+8?W?LL7X61SM)=#,Z \N;BKZ=7C.(=.G$P&^+]+,SC=L1
MO8O9DP;HG0_WV_4?)355P)O/-,R$BB(:@E 1$U1OLJ\4)T#_C7*5I33.G+(W
M#X>?VCZOJ.NMC1QA9[?%^R,R\-ZV!\-Y2Y_GV>M>/IIBU$U\GKWCW7OAJ;YE
M<^I4[_O5(N<O^\()"I,TXD(!GFE[!"8X Y1!"E"6I Q&:2BX4\^Q2Q--;2OW
M+U5Q$4J[_>P#H(%W=KN$1$5E\+W^<Y"J$=<@\5PMY\)D(]?*Z6;YM%+.E>=[
MGN:KI3 )VWK',;K\[\]*R;44YEKEXX=?/W^I;P%5%H<,QP0(F9C"V$@!0I$$
M2<@5S(1(,FC5(=5IUJD)C)(TQ_/>"EU+-< W9D-K!R6]P8[@H*:XNF-]4Q+]
MRP!WK4XX^=4HK&8>5]%P >-$_W!ZN7^ZMG%2'&8H[3JPF7O>Q<I<_<XSE4*8
M" 0$YB:RDZ: A# %<<(54I@Q%KO5>K"=>6IRJ&P 6<:=U<F=C.K?<U<MQAYY
M._DT")X#RZA=&N5ILF6KS>:>=+\IE4YH>4^?M)M]]%1))U#.I46Z#="WE?R=
M$*:^S?VJV-#%_Y<_OUT).><\TOJ0S$"&L191DB0 TXP!1J,H23,D&;?RA71/
M,S5Y5%$:U*0:@\$0&VAJ T.N:QOYL\AVBR!_> TL;_I"U:.%?!<2-S:0/SOT
MR.WCN]@[;1[?^?2M!4;O>!F*UEPH-Q6/I?B84Y8ORG"2HV*5G"01AI0 FK+$
MM S) $8XU3\A17A,XPBYM0RY@9BIB9-V8<N&FR8^8E_C6U9=')9%_SJC/=;-
M\G9XI-48^JK8=B%:S(Q46[0_K@,5%NU!T"M5%>T/W>62HC>,V4_XUEG*OVD^
M38-'XQ[_1[YY?+LM-JLGN3[VRV*MF,$TPP"B, -04 6H5M$ BF0:99"K%%L5
MH>@W_=0$;).-;UJ=/BQS4QC 380ZHF\G-(?#=& QV<!I-EW0D![\J6D/&N*'
M=9[W0\ZK('0D8531UP^>8V'7<Y2^T81ZC ]%H27HN^TZ7S[<5W7]3$I54?ZR
M;N#3-.46<Y:1)(RE ))""J )O:$P3D$4"B%Y&(8H<M,HG4F8FIBKFL ?M8F3
M8A8LY:9,V"R3-%WS%GHLC82QP(I%().I5O%3B0!34 '%"(ICQH30RG[=,_Q5
M%^>P??G R[/KR[:C<=1%L=3D!]T%0^OO'IOG-?P59='M$@2?T:%]4?8<(.I,
MQL@QHGUA.@T3[3U2CY)QGU;+?V[I(E=Y58GNG512?X&+>_VU%M7!>:PR1B)B
MD!D?:BH8@))#0)5>-!G%64IH2$5JU02NY_Q3.\K:'%17%0T/@6'"H8A9C[7H
MEI0C(#RPF+P";M$G ,8+\ X%Y(9=@+%JR.UN9XS'B58^!5,N^KD"WO0V6[87
MJ[S\%,UB/9>+53R;8F8FS$"?;%5Q8N, _FOP[3$O K&?XHF^Z+.,+[9"!F^B
M7\IG']:K[7.A?Z0;4]QCD_/\N6H_'+S1DVOI6)9KK$;_)9"4/Y;3EMZP-_$O
M09%K@UKEW-27+W_QO%[]R LC2B_7['$K=M=_J3OKW?48=KR2=_UY/JAZ=\,P
M_>RX?TA3U%Z*._W-T ?Y:6L")CZK=_EBJ_^U.FX_;S?%1G\_^D.?8Y@)*4(.
M%!7Z[&.< Y();<E%L5XQ%LF4.16S<)Q_:L=>0SZ@%?UZ\U7E=TK"@]6>\@#H
MK5TRU=^(<%TL.PMBP"48^%QL* ]JTH.*=B.;*[*#%MVFA$;)D3^KH"=R7DT"
M5QI&M0=Z G1L#/0=YI8P=)-1W[C2\N56#_OY6<]>VAQ'G<EDT?0FFX=AICA.
M$(A)C+55(&-MM5(.*"=9DD8AHJI'I'HO6J8F*O]8YKM:_;VBV?NMB)T,' GG
M@>5A'1-?U>K8>_LK5H(]+^=:8>X;,?J.F;\)U0'"ZOO1\PJ1]S<!=SXX_[8A
M>ZJ85?\DTV>[[*!TH*)(+L-0R@RDH<BTP P30!+&@"DO0"3G4.N53OIDQV13
MDX@-K8Y*8!><EAJ?)Y"&5N]J,JLN(B6A;87.HQYG@8=?I:UKPG$U- O63]0Q
MFW=Z>&&;F\K/RZ:T7R8)XDI2D&0J I S!2@5# B10JBB1%N<PMK)>C+\U.3!
M[BY>4^C@MSN%S<(?>A,8 ^_[-@[7LV]L ''P4]X$S$AN2*L/Q<UG=Y'M3I?<
MZ5OC>=PN4GS@4+O\U(TYRGM7\-X=CA*$H%(AB"&, 20\ 4QB"KC@L<1(L"AT
M"N+JFFQJPLM#KO(Y2%W,M]N!&L<^,YT@6C<)WX?-5^Z 9)B<Y7,3OD[><@?K
M%W.7N][I)S(^_Y#KN\5BM2FK'I6WUO6Q)!$-.6<QD&EH2JRE,2 IY@ Q'"4X
M21(>.D5$79QI:L+"$ IH0VD=P^$F-2ZC:B<RO& UL+PH8;H[@FF ?.2K6'@5
M%)=G&U5*7&7Z6$1<?Z%W?8,'O>F>3'77;WJ(JFT\3F5&H@BD*BW+&3" 89(
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M*@^'90"N/]Z['H")8Y'O9/7GA^7GQJG[EC[G6K':73E$(C'7P0)0002 -(H
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M(^^O[D'G(],WX%X/5&_$C7K<^H;T^##V/GX/A\WYS-BF.G;9,F"N%(EB&4J
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MRHZ$S*AK@,%8<S,@W?WM^T<=B]3$[MZPX-HYC,V,BB/DQHY\=T!KY1QU?V<
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MIT#X(X85G6GYS6IU2H=:=)SK8!U86RC>R=:""TG64A#&7=;&^\-K:AXD83>
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MGN%96O,JOY,8O=%266!1\]J^T$ (]4+ %QME%A3/M0'K+M2-:V.[ ^K@"NT
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MT9?"C%4IM$^=W*1JW)?-(^+M(/5T,;QE]R+*.^0Y\4QIF4L$&\B2*TP)HJ<
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MO_'K:CT]H<AW-3&:O-V2"@1F).TS@HIWUH P68J8)2NJ3=KC.AWCYM,:8>H
M48^=B;VC1]IF8/WMT>"W? %OL@L4YV0A'*CZC" *G8$%ZW/)L<9:.Z5D]R9A
MW'39P%@ZHC8Z,$[D$B3B;MLCYL-T]<^71,-T7?\TH6!9*1DH;):*4Q2MJIT5
MQ(_ESG/&BTRMWF'<2]2X_3W;^66#**$#/-T[.?Z6NXG2Z>P*%([D<_KB(<C:
M4-<$+0W73O,V7O^N%([;B[,1TIJHIP/8?<!O.#_%S;2IQ7PCIW],UU]>GJ[6
MBQ-<WO(@1:'XAAR#6 J)T!1R#!(/((0PC%P&6W*KJZ>GT#EN^\U&$&RHJ@Z
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M/V%*.29E+9N/=58E9^"40Y#1"*:*(%^_37._AD.0TA?,IW4VY[T]0[>^2<+
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M)PE:&LNLYU++1CV-1]/>RUZ1,0.&$R.@BZ;S/Q8A3V>?;]4J$P=:EF+!QF!
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MGT-W(NU#[MG7O!YB%YVBX5R?7F]=;&P'V0W^YOK$9YSDL757'OMX914N<4G
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M\'APZOKN>KN.3-E8$U,MO>,D08G@K8M N6FA_Z8256>K*=^]M'VMQP0/)T;
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M#^L-[=/T(?Q8UQU=UOSG?=G\<3G)C()BE]8[ZPLH0Y+S*5"HXE1Q6:C A#G
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M]R8DW/"A T9I:L$E-^2>HT!PUD<H14H29:B[(D]P5W%#T6Z@._N7@$$5TP'
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M58QR'T6*Y*RQ2@\@JPJ)/<.4(_33^E[J0_HZ'4:E/G"$ZKIWW^_XL4J0Y+0
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M]Q<KR3ECX0/)[S$\J8V\<>%_! SJIZ;=?5#^Y]TJ_>=__!]02P$"% ,4
M" !F@EA49#-DOZ8#  "3)   $@              @ $     97AH:6)I=#(Q
M7S(P,C$N:'1M4$L! A0#%     @ 9H)85"+6G4-.!0  HR8  !,
M     ( !U@,  &5X:&EB:70R,S%?,C R,2YH=&U02P$"% ,4    " !F@EA4
MJ\]8O?('  !B(   $P              @ %5"0  97AH:6)I=#,Q,5\R,#(Q
M+FAT;5!+ 0(4 Q0    ( &:"6%2&WG58U <  )4@   3              "
M 7@1  !E>&AI8FET,S$R7S(P,C$N:'1M4$L! A0#%     @ 9H)85 ZSAI<^
M!   > P  !,              ( !?1D  &5X:&EB:70S,C%?,C R,2YH=&U0
M2P$"% ,4    " !F@EA4C#!E&S($  !6#   $P              @ 'L'0
M97AH:6)I=#,R,E\R,#(Q+FAT;5!+ 0(4 Q0    ( &:"6%1B+;/"JA   %Q?
M   8              "  4\B  !F;VQD+3$R,S$R,#(Q>&5X,3 R-2YH=&U0
M2P$"% ,4    " !F@EA4%$]O"]D,  #_7   &               @ $O,P
M9F]L9"TQ,C,Q,C R,7AE>#$P,C8N:'1M4$L! A0#%     @ 9H)85'-PQ8\U
M#   64L  !@              ( !/D   &9O;&0M,3(S,3(P,C%X97@Q,#(W
M+FAT;5!+ 0(4 Q0    ( &:"6%3%U@1TL@P  !U*   8              "
M :E,  !F;VQD+3$R,S$R,#(Q>&5X,3 R."YH=&U02P$"% ,4    " !F@EA4
M:[";W3,,  "^30  &               @ &160  9F]L9"TQ,C,Q,C R,7AE
M>#$P,CDN:'1M4$L! A0#%     @ 9H)85$_DT/:T#@  KE(  !@
M     ( !^F4  &9O;&0M,3(S,3(P,C%X97@Q,#,P+FAT;5!+ 0(4 Q0    (
M &:"6%01H#3BUA$$ +P\)P 1              "  >1T  !F;VQD+3(P,C$Q
M,C,Q+FAT;5!+ 0(4 Q0    ( &:"6%0PQ/<4XA0  #KG   1
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M &9O;&0M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( &:"6%1<?EJEI[(
M -I."  5              "  1AV!P!F;VQD+3(P,C$Q,C,Q7W!R92YX;6Q0
52P4&     !, $P#U!   \B@(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
